<SEC-DOCUMENT>0001698530-21-000091.txt : 20210812
<SEC-HEADER>0001698530-21-000091.hdr.sgml : 20210812
<ACCEPTANCE-DATETIME>20210812160822
ACCESSION NUMBER:		0001698530-21-000091
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210812
DATE AS OF CHANGE:		20210812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXICURE, INC.
		CENTRAL INDEX KEY:			0001698530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				815333008
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39011
		FILM NUMBER:		211167571

	BUSINESS ADDRESS:	
		STREET 1:		2430 N. HALSTED ST.
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60614
		BUSINESS PHONE:		847-673-1700

	MAIL ADDRESS:	
		STREET 1:		2430 N. HALSTED ST.
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Max-1 Acquisition Corp
		DATE OF NAME CHANGE:	20170221
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>xcur-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:5b54f0ec-bf0b-4618-8722-18f79640ae79,g:5933f058-0750-4e2c-9852-92fa9631b69d,d:a49112dadce14be6836937c1a8779dad--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xcur="http://www.exicuretx.com/20210630" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xcur-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80L2ZyYWc6NWUxY2E3MDc0YzBjNDg2OGIwYzdmNDZjZmI0MmM2N2IvdGFibGU6ZDEyYjA1ZWY5Y2FkNDFhZWE2Y2M3Y2U3NjgwNWUxNTgvdGFibGVyYW5nZTpkMTJiMDVlZjljYWQ0MWFlYTZjYzdjZTc2ODA1ZTE1OF8zLTEtMS0xLTA_0919ddf7-92fd-4719-9ae7-d9a9f1d70770">0001698530</ix:nonNumeric><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80L2ZyYWc6NWUxY2E3MDc0YzBjNDg2OGIwYzdmNDZjZmI0MmM2N2IvdGFibGU6ZDEyYjA1ZWY5Y2FkNDFhZWE2Y2M3Y2U3NjgwNWUxNTgvdGFibGVyYW5nZTpkMTJiMDVlZjljYWQ0MWFlYTZjYzdjZTc2ODA1ZTE1OF80LTEtMS0xLTA_5548950c-36f2-47f9-9695-6f75c0713321">12/31</ix:nonNumeric><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80L2ZyYWc6NWUxY2E3MDc0YzBjNDg2OGIwYzdmNDZjZmI0MmM2N2IvdGFibGU6ZDEyYjA1ZWY5Y2FkNDFhZWE2Y2M3Y2U3NjgwNWUxNTgvdGFibGVyYW5nZTpkMTJiMDVlZjljYWQ0MWFlYTZjYzdjZTc2ODA1ZTE1OF81LTEtMS0xLTA_0cb68908-e2cd-439b-ad74-4f371cbe18e5">2021</ix:nonNumeric><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80L2ZyYWc6NWUxY2E3MDc0YzBjNDg2OGIwYzdmNDZjZmI0MmM2N2IvdGFibGU6ZDEyYjA1ZWY5Y2FkNDFhZWE2Y2M3Y2U3NjgwNWUxNTgvdGFibGVyYW5nZTpkMTJiMDVlZjljYWQ0MWFlYTZjYzdjZTc2ODA1ZTE1OF82LTEtMS0xLTA_57dbc6b2-4689-4f01-a733-fd855e28d566">Q2</ix:nonNumeric><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80L2ZyYWc6NWUxY2E3MDc0YzBjNDg2OGIwYzdmNDZjZmI0MmM2N2IvdGFibGU6ZDEyYjA1ZWY5Y2FkNDFhZWE2Y2M3Y2U3NjgwNWUxNTgvdGFibGVyYW5nZTpkMTJiMDVlZjljYWQ0MWFlYTZjYzdjZTc2ODA1ZTE1OF83LTEtMS0xLTA_f3efe127-af08-4667-b48a-dd4cfe115596">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xcur-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i7e18a0d9b97a4e05b0e2b555178a79c3_I20210809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d06eb298aa3490d9159416638a3b58f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacfaf4956355489f844301e39562eb6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i279abc78769c4032be54ddfd0c7ffe6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c766de5b12643f4b84da4a3bfcd49bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a8e31b3400845b785f4078c29ad60c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i149a543a17ce4d93a6385033c1c76dab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2acf22eafee749ef879e689a5d4b7208_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07e140d0339e4a2c9fa363c5cc32a6e4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6ce674313764ae4915943fafa4cb5cd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bf9870e0c784838b0e84e18c5c665c7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i566e91ad0fa14f2d811d604abd6082cd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if46fbd1f2b5442348f674d9f2a9f0a54_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bde8e11b76e461896f96c566cc62872_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d493db55bc244c1818df293641b339b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a85ec43cc4f4214ba9bfbd44ce67a45_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b7b77f3ee3b4b51965fe742a7381fbd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96c703c4ce9440bea4222ca42e9f1f18_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb34f5fabfa643a7856aef0eb9f11e70_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i165b7f9261d44627b2f958e465d695e5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e3d4af8ea3748c6a09f9521da9ac2ca_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a543e3ada2340d0b5c1f3641c1d3468_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aa243ca27884648b86a0b1eb325cf57_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dde94d491614ea4bca5ec1bcd8d14b0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5073ecd4f57647949850dc29898c84dd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icddc4f4973ad446fbd01949b82185558_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0295336b38e40e498f9dd253711b758_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f137df29abc4c41a4815885b2a3d6b7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib010f58f2ede44548294dae32882407a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb13b835a182484c8f3fbf8f2b67cc67_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d226af906d44031be03e8c8a0a7ed41_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcec14fba6fa467990e368f7ad3ad3d6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6717e4937b164276903f7d7ad12330f9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27744bcce45d46b1a88c16b8b2198996_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8871fd9e9cd14336b5847fb59ece0447_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0cc9bb25cb645fbad03da89e50bc2e7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8cf7cd3ed49446ca5422f8857c95a70_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91f21e075fbf4956bcf55c01b1894a5c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3530849be0c2436a8869a0a68de58c4e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0f5631296644c3aa22951553d3ab6cc_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6f410f5826241079802ef8f86c3de4f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79a078e9f90449658270fc31aa0b394c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82a9e001ccee4221ae70569a6c358e78_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d68452da3a640b7a96348aa84cfe852_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30e55b2f78ad495ba7a2baa00860f9d1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia77029b06c3e4a209202062d9c9b7340_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if93626e950d1452db9e553b3385f4ace_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6df76506288a4a9cb1f3b1ec2a60be16_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">xcur:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9df56e3024f4230a66f1aaeeb151149_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>xcur:agreement</xbrli:measure></xbrli:unit><xbrli:context id="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-13</xbrli:startDate><xbrli:endDate>2019-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i323854d9e19745dd9223744aaa4363ae_D20191113-20191113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xcur:DevelopmentandCommercializationLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-13</xbrli:startDate><xbrli:endDate>2019-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc5418ff3e7c4d5196e4b2c13c675901_D20191113-20191113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-13</xbrli:startDate><xbrli:endDate>2019-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab515d133a4549b18fbb6f4ad02e2cc6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b844762003d4f3b95be40b6168ead6d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cbe4aacf45245898bfff13da476b491_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17febbe492b545c0b97d0ae80370db3f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dede066e6c145098de6bc8ed6e91eb7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b4f20000a14fd2b555bd263b4cb305_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i916551a6aa1f4e67bc25b95d7119fc61_D20190217-20190217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-17</xbrli:startDate><xbrli:endDate>2019-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabf8a9f039204f5a9f174a27e912c223_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf8a680258f340a5b95f6fa0166cc962_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie74bdc37f6204d6dab0e778172766ea3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a937d2024224f2187dd03316b8a9e85_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5e3560a2c7c44468ecad7133174a9d2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i073135b508cc4068bc10b72d2b0d3170_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e62ef03a17479584641f2e340a929c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00c9b49c74324d46b41817978d7a5a2c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3b5c379005b46dfbb023e9e0339cb54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09baee4ff554479da4cfb04820c2c407_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i925dc62162064a6e8afe8a1541ec5f89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifed0bbb359d14d848c59c0cae236a4ab_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31b47b75b7d444be881f797effc35ea5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88343bfea9104524b13b58dd117fa4a0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fbe3f7a19a3407695cd3173dc3fa872_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf1b0681e7a64826a8f5b37064e1c69f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie654008c14bb45bebaddc4a5e9306fd2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb46a2e715654544969c6e914b1268af_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d73b584ce0741a88f6493e030684da2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49032d31daff47918154c5a0df3b9f9e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8ec51807b1e46109dd345b48f722f7d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9577091c72d34a4d87f0ec5ba0d9a62a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i645a0991058845f0b7026139817fe54a_I20200925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41901b1bd0c34219aebdd24b5355e642_D20200925-20200925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-25</xbrli:startDate><xbrli:endDate>2020-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i436ecc2736cd40ac821c16bdf401d6bc_I20210401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d3967c9df24458ca2996a7076c5be12_D20200925-20200925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-25</xbrli:startDate><xbrli:endDate>2020-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installmentpayment"><xbrli:measure>xcur:installmentPayment</xbrli:measure></xbrli:unit><xbrli:context id="ia063169c06cb4eb1b3257cbed4a76a5b_I20221001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad1abf0184e64b35a21316ccc6ae8ef7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9d9075e5dfe4e329a0d45099cfb1c9d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i925aaaddcacc4778b5d8b7f62145a333_D20200925-20200925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-25</xbrli:startDate><xbrli:endDate>2020-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i300147310fb342fa8729d20a235e6672_I20200925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d311891d17c4c9d82be715743cfa91f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecb1d260e2dd441b95189e9938852f30_I20200925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iead4e91610bb417ba4c9ce8e04fe7b87_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if20db32734cd4856a7b5ebfc55b07f6e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide2ab8bf32e5471fb89bc743cfb84ebb_D20200302-20200302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-02</xbrli:startDate><xbrli:endDate>2020-03-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ic8159ef26edf4cfab622048f57adfe21_D20200701-20200701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xcur:ChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54669006cc704c238aa705208cb442e6_I20200701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xcur:ChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="extensionperiod"><xbrli:measure>xcur:extensionPeriod</xbrli:measure></xbrli:unit><xbrli:unit id="votepershare"><xbrli:measure>xcur:votePerShare</xbrli:measure></xbrli:unit><xbrli:context id="i6ff17028d7f742fc86b80a80958beb1c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c221311f05b4f77be016eb7ea9c9657_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0645f4970e4a4657940a7c44e95adbf2_I20210327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1678fc9eed904b0ea7406fdd2c19c39e_I20210428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if012e2aa547c4f42b1c5e1a7b5509669_I20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f09592eb17452db7a906b8878473eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0beb38fa0e984be794221ee6085d5212_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11febcbb571642db9e1cddde4919a982_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99e8cbf713bb404290e76a87777df0be_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19701c73d57b47c1b8e1d54bc15798ff_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i647d7754868047e08ca0cedc232ce793_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib87f672fddff47ec9c64d6d8f41b94f9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if36427efb36c41dd9f56f8366f4269ba_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bd85f97f1394ba795ddb6a54771a121_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e2f75424b9847e8a73a5ae083e07f16_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1752c7647ce4804833ba83742c774f7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9193c9218d6942f0a9ab8196225ec04e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eade0caa9a9429fb165b07368701d49_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id06b85497bc74266852a0e2b7f0b8df0_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4945a8246284e3fba84dfd77ee17303_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1a36e8396524c158a00a6f20220e59b_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d5200a99a654e799a285ca1f6cfe325_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2b6abdfb80e4807aa0282b97634d068_D20210514-20210514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-14</xbrli:startDate><xbrli:endDate>2021-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia10057774add4610b1347d547800695d_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f12b5a69194c1f8a504c77fc7c66d5_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30c821c806ac422d901e22a3a99f78f2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb72bd4b57dc4ad591c2fe0e40fe9b13_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8428d3250e664f26b96cd9f611b3d8a4_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7e5df1d06e74bd185e7eb2efc4d0d60_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30e4b305e726408ea8e78580cff53469_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb6d556e4e7c410abd113137b073abea_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0140ea063a1a461d9b7efc35c2a7db94_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib97b67429c7447b8beb926618dc44e33_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bbc9b612e4f400ea42e7192d40fe224_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05ee07b9e1c84d11b1a2bce3808048f7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb18755d773345cab01251ee868b67a2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80b5550a693944ca96e17fa1695bde69_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i840e5fd58f7b4defa073941d94fdaf68_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2062e93925194437bbd0a3795bd3f03a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb7aa76093ce43189a28a20fdc93f774_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i536ad3a9715049e6b9540b91aeecaf96_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fac72b464ac47a9b5b8d5a1d1c209c9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70f3df893ec74c418b087f907936dff7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60644eaa534948f49f8d5b8f40af2943_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a7f1be445ab4577a3269d5dc2dd853c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18c9158c52b548ed815e6df50eef7fe9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09b723f0eb514cb19e68b68bef52570d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i203967655c0047368d301fad6b928214_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i862f9b0b1702466189729eff0d9d775a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75e9456e863e42c28b31cca8610e356b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e5643a3e14a4b2ca2f6576189dc8cce_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f67c529634343ec87c7f862a41ec733_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbfcd4dc60684a77a8e8fff3eb283e9a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81809ddc049e44b18b81bcffd7f27327_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id968e5bf12ce4186bceeb5caa282ec2b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a183f19fdd448bdbb48aafc81f24e29_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f3a6610c3c4fb7a8f3011378ea9e4a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd0c5a447ff34bbc8d7908d531b56cff_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dd5b1839e3a4048b28a43a4c4e685d7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib57710941d894ca1b67a1c5d13d6d090_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifefc3417f0d145cea19c531c9a0c8f9e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e05ee112bbd483d8bd21004c56c115f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe496263a9ad417fad626fd81108d45e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica03537b84e847e99bee1a3a67a888b8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if36f90f4916647c996df4392cf9a2961_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7425a3abf5aa493d95862d239425df58_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia84bea4dabf04dc0b6316097c19d0d55_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05d4fc50d3924eab98e6d7e3de7886c3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i815c1749dc334f5aa2f2b3d7ce7325b5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae63ab432b644385ad760c25e7bb81a4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1841aafb4eea4763a606cf71ee256faa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14e02bfdb4fe4d5c945ef80c6fe4fad3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42f50fb4ed2946899515880a08b3b57b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d7ee51b5b4f4652af15034a165fbf74_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib437b59ac25f4bc78adb0e03658f743d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfb4a947556c46d38903332f34ab5729_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9ab61d3d42a48659e6eb92b8ae28834_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c3ba902ba2c44f4a67a96f6f613cca1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7875848c586b4375a60e0586a91f2a0e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91a58f1716064afdb7cb38c53987eb36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5292d66c2a14337935384c3078fb0f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15097b5bf7ee4089861f0faff5870a28_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d0d3d621aa248ffb7a89d07e53fb661_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i264f629b27bd4da3a95c37beb796c031_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfeb9eea9dbf4b46996f9c206cb93ed9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7abd43cf3d894cffa0f7cb487206018b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4e3860c3a63420e9d7641f47962c9cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21aac650411b42b8a24485f95cec055b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib62061d67fb7462295481dacb0f4878f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bf7aa4a7c3949849940d3879f239db6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b4abd0dd9174b658c26e0a2fb538250_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dd9add5bb4c45a78909b926908a9321_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1da4f481fa0f4d07a5cf47234b82b9fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12a40373542a452085cc5d600a78424a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbc3e793a60d4e38acabd4ccbf7e7571_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3949b66929b4496bb22e8f8f15df1a0e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibce5fd94c3494f099a9ee39d5d778059_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13bc69c967ce4483838129c6d0a0b70b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67b1b75f0b614cad8c61db673b402bc1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4ad8ee44ca14f698e0bcfb629608444_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89a31a873b4345549a9b1b9489d5fcda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf6b894493654106958401b815661301_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i075d22f912e34ce8b799f56c4e6c8bff_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9894ed94822f44a1b4e2a85180b8d226_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0304e7ef793b4159a6bfef1cd8f203bf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i766b5dbdd23d432ebc0191ac53b18fac_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i902680175ed94d4c9937aba91e427308_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ExercisePeriodAxis">xcur:ExercisePeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3058801971a44b62b1abb284fe077eef_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ExercisePeriodAxis">xcur:ExercisePeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c4f363adac940e3bca3d807b358d686_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia49112dadce14be6836937c1a8779dad_1"></div><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.912%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">______________________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDA5_0542ea79-84fd-4e2e-b5e3-925325e87655">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">______________________________________</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDA1_b3a1ec0f-01b2-4edf-b557-5a18ea39d7dd">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDAw_78703b41-2894-4cfc-bd55-b0d6e6bcfc64">June 30, 2021</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:9pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzk2_76478832-e803-49bf-9251-ffe0f2a34a83">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDA2_80da0118-820a-4b1a-91fc-f6d2e0035ee3">001-39011</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">______________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDAx_112c7efc-59af-4210-8013-25cf752c73e6">EXICURE, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6MTc1OGNhNTQ4ODA2NDVkYWFjMDU3NjgxZmZhZjI3ZWYvdGFibGVyYW5nZToxNzU4Y2E1NDg4MDY0NWRhYWMwNTc2ODFmZmFmMjdlZl8wLTAtMS0xLTA_bb4a4def-a60a-4fe6-8f62-727f1e7e7486">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6MTc1OGNhNTQ4ODA2NDVkYWFjMDU3NjgxZmZhZjI3ZWYvdGFibGVyYW5nZToxNzU4Y2E1NDg4MDY0NWRhYWMwNTc2ODFmZmFmMjdlZl8wLTItMS0xLTA_f7986bd6-a857-4eb1-909c-43b6c5f69d39">81-5333008</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzk5_debfd99d-87f6-4c15-ba15-a6ef05d30117">2430 N. Halsted St.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDA3_33723133-8611-4243-94fa-e7d199f81a3b">Chicago</ix:nonNumeric>, <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDAy_0be3d526-fc24-4675-a7fc-149a0dea2479">IL</ix:nonNumeric> <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzk3_19811ccd-96da-43a0-80eb-d32b9bb4a5d1">60614</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzkx_13513c14-a5fb-4da2-87ac-2f2dfecfb4d8">(847)</ix:nonNumeric> <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzky_38b44512-dd99-4a20-a7e0-2ceda28b117e">673-1700</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.944%"><tr><td style="width:1.0%"></td><td style="width:36.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6NWI2ZmY5NzllOGQwNDQxMDliMzk4NzRiYjI0MzQyZTcvdGFibGVyYW5nZTo1YjZmZjk3OWU4ZDA0NDEwOWIzOTg3NGJiMjQzNDJlN18xLTAtMS0xLTA_f3b8bed3-1694-4ab3-934d-a27bda68c9a7">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6NWI2ZmY5NzllOGQwNDQxMDliMzk4NzRiYjI0MzQyZTcvdGFibGVyYW5nZTo1YjZmZjk3OWU4ZDA0NDEwOWIzOTg3NGJiMjQzNDJlN18xLTItMS0xLTA_0fe41eea-33ed-4948-942c-387907286c9b">XCUR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6NWI2ZmY5NzllOGQwNDQxMDliMzk4NzRiYjI0MzQyZTcvdGFibGVyYW5nZTo1YjZmZjk3OWU4ZDA0NDEwOWIzOTg3NGJiMjQzNDJlN18xLTQtMS0xLTA_2dc5f413-6195-4e4e-bbb1-eec69894ef1d">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzkz_6d9ed7cf-f00f-4540-9e23-15e4076aadbc">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzk0_3ffacdb3-429e-44b2-9bb4-e1f2ead54f14">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6M2FhMWUwYTk0MGRlNGE4ZWJkMWMwYzZmYjFjY2JiNGYvdGFibGVyYW5nZTozYWExZTBhOTQwZGU0YThlYmQxYzBjNmZiMWNjYmI0Zl8xLTAtMS0xLTA_9c20590a-949a-4645-a2b3-e2226916a987">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6M2FhMWUwYTk0MGRlNGE4ZWJkMWMwYzZmYjFjY2JiNGYvdGFibGVyYW5nZTozYWExZTBhOTQwZGU0YThlYmQxYzBjNmZiMWNjYmI0Zl8xLTQtMS0xLTA_5756e5d7-5dfe-40b9-827d-7a698e547da9">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6M2FhMWUwYTk0MGRlNGE4ZWJkMWMwYzZmYjFjY2JiNGYvdGFibGVyYW5nZTozYWExZTBhOTQwZGU0YThlYmQxYzBjNmZiMWNjYmI0Zl8yLTQtMS0xLTA_5e34f5c4-1dd7-42af-8f3d-64a00c886b41">&#9746;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDA4_b7698d3d-8890-440d-a9cf-c4fec2f281c0">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzk1_5c3dceaa-3ac9-4566-bf85-2e6c25ca90be">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August 9, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i7e18a0d9b97a4e05b0e2b555178a79c3_I20210809" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzA2_e3e3f6dd-a213-4a67-a280-431a3363d18a">88,108,543</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.912%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_7"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.314%"><tr><td style="width:1.0%"></td><td style="width:86.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.050%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_13">PART I - FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_16">Item 1. Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_19">Unaudited Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_22">Unaudited Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_22">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_25">Unaudited Condensed Consolidated Statements of Comprehensive (Loss) Income</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_25">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_28">Unaudited Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_28">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_31">Unaudited Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_31">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_34">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_37">14</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_79">Item 2. Management's Discussion and Analysis and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_79">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_109">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_109">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_112">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_112">53</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_115">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_118">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_118">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_118">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_121">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_121">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_124">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_124">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_127">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_127">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_130">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_130">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_133">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_133">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_136">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_136">94</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_139">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_139">96</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q, including the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains express or implied &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221;, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to such statements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors described in the &#8220;Risk Factor Summary&#8221; below and set forth in Part II, Item 1A &#8220;Risk Factors&#8221; below and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. These forward-looking statements include, but are not limited to, statements concerning the following:</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">our expectations regarding the impact of the ongoing COVID-19 pandemic including the expected duration of disruption and immediate and long-term delays, interruptions or other adverse effects to clinical trials, patient enrollment and clinical activation, delays in regulatory review, preclinical research and development, or R&amp;D, collaboration and partnership programs, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy overall, and the overall impact of the COVID-19  pandemic on our business, financial condition and results of operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of expenses, ongoing losses, future revenue and capital requirements, including our expectations relating to our needs for additional financing; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress and results of our current and future preclinical studies, clinical trials, collaboration and partnership programs, including our ongoing clinical trials and any planned clinical trials for XCUR-FXN, cavrotolimod (AST-008) or any of our product candidates, and the research and development programs we pursue;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to advance our product candidates into, and successfully complete, clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and likelihood of regulatory filings for our current and future product candidates including any Investigational New Drug, or IND, application, Investigational Medicinal Product Dossier, or IMPD, Clinical Trial Application, or CTA, New Drug Application, or NDA, or other regulatory submissions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our product candidates in the indications for which we plan to develop them, and any related restrictions, limitations or warnings in the label of an approved drug or therapy;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth potential of the markets for our product candidates, if approved, and the rate and degree of market acceptance of our product candidates, including reimbursement that may be received from payors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of healthcare resources away from the conduct of clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others or voluntarily adopted in connection with the ongoing COVID-19 pandemic;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on current and future collaborators for advancement of therapeutic candidates pursuant to the terms of such collaborations, including ability to obtain and maintain regulatory approval and commercialization, if approved; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the status of clinical trials, development timelines and discussions with regulatory authorities related to product candidates under development by us and our collaborators;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt and timing of any milestone payments or royalties under any current or future research collaboration and license agreements or arrangements; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify and develop therapeutic candidates for treatment of additional disease indications; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of any approved therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercialization of any approved therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our business model and strategic plans for our business, technologies and therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain additional funds for our operations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain intellectual property protection for our technologies and therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reliance on third parties to conduct our preclinical studies and clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reliance on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development, preclinical and clinical trial supplies; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to attract and retain qualified key management and technical personnel; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of government laws and regulations as well as developments relating to our competitors or our industry; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors that may impact our financial and clinical results.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed in Part II, Item 1A of this Quarterly Report on Form 10-Q under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed with the SEC as exhibits thereto completely and with the understanding that our actual future results may be materially different from </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any future results expressed or implied by these forward-looking statements. Except as required by law, we assume no, and specifically decline any, obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q also contains or may contain estimates, projections and other information concerning our industry, our business and the markets for certain therapeutics, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where the context otherwise requires, in this Quarterly Report on Form 10-Q, the &#8220;Company,&#8221; &#8220;Exicure,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refers to Exicure, Inc., a Delaware corporation, and, where appropriate, its subsidiary. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">SUMMARY RISK FACTORS</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in common stock involves numerous risks, including the risks described in &#8220;Item 1A. Risk Factors&#8221; of this Quarterly Report on Form 10-Q. Below are some of these risks, any one of which could materially adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical-stage biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our approach to the discovery and development of innovative therapeutic treatments based on our technology is unproven and may not result in marketable products.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our therapeutic candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funds to advance the development of our therapeutic candidates, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or future therapeutic candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be adversely affected by the effects of health epidemics, including the global COVID&#8209;19 pandemic, in regions where we or third parties on which we rely have business operations and at our clinical trial sites, as well as the business or operations of our CROs or other third parties with whom we conduct business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we continue to experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be further delayed or prevented.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expense and present significant distractions to our management.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If third parties on which we depend to conduct our preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements, or miss expected deadlines, our development program could be delayed with materially adverse effects on our business, financial condition, results of operations and prospects.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because we rely on third-party manufacturing and supply partners, our supply of research and development, preclinical studies and clinical trial materials may become limited or interrupted or may not be of satisfactory quantity or quality.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies, including delivery technologies, or therapeutic candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market may not be receptive to our therapeutic candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of therapeutic candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will continue to increase the size of our organization, and we may experience difficulties in managing growth.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently license patent rights from Northwestern University and may in the future license patent rights from third-party owners or licensees. If Northwestern University or such other owners or licensees do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive position and business prospects may be adversely affected. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="ia49112dadce14be6836937c1a8779dad_16"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="ia49112dadce14be6836937c1a8779dad_19"></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfNC0xLTEtMS0w_6daf5c3c-8139-4970-9806-433535195756">42,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfNC0zLTEtMS0w_739fbca1-5162-4ea6-bd48-6f630b746cfe">33,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfNS0xLTEtMS0w_3d108a5e-7413-4aff-9ffc-ef1fbe8faef6">13,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfNS0zLTEtMS0w_58ea21e6-b278-4c71-baa5-245986b97e73">48,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfNi0xLTEtMS0w_3f86faed-54dc-4436-be06-4cad329a3a65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfNi0zLTEtMS0w_4fe4e97e-b52e-46c9-b91b-5d642b25719c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfOC0xLTEtMS0w_04853c87-f655-4f22-aa35-faeb6c616037">4,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfOC0zLTEtMS0w_d67112eb-632e-46bb-bcd2-f4ffa5e1afb6">4,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfOS0xLTEtMS0w_b6a02302-198e-4405-8a4e-41d7e4e4d5c3">60,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfOS0zLTEtMS0w_b0ff3636-7821-4c2f-834c-734779ff9461">86,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTAtMS0xLTEtMA_699b50f7-b37e-489a-abae-411710617f2f">4,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTAtMy0xLTEtMA_ecd6dd16-1980-4af4-bc38-1a6d57de148e">4,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTEtMS0xLTEtMA_1fc16535-0ea8-4020-ba7a-2f732eaab091">8,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTEtMy0xLTEtMA_b7898a20-f443-4097-a662-053e1df82083">8,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTItMS0xLTEtMA_b58a027e-683d-41d1-8662-97626af6f1ec">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTItMy0xLTEtMA_82e1e4dd-047d-4c82-ab8c-7f6862d9986b">1,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTMtMS0xLTEtMA_738672a4-5d75-4d6e-bf4c-9b33f238677f">74,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTMtMy0xLTEtMA_536e2a06-e569-478f-a03b-bcc71257375e">100,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTctMS0xLTEtMA_1023b14e-df95-4e4c-8855-a8a1336020c0">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTctMy0xLTEtMA_31bede6c-b951-4c26-a543-6032407cfb48">1,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTgtMS0xLTEtMA_28ac3d89-fec1-4314-94d2-ced57e2d8b36">3,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTgtMy0xLTEtMA_572fd635-5925-4963-af12-616663c9ce8f">3,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTktMS0xLTEtMA_3b535fd0-2e86-44bd-9716-aca56b54a373">7,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTktMy0xLTEtMA_4380ae22-64c1-4568-9fa8-d763ed964f46">8,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjAtMS0xLTEtMA_aaa89be7-4643-4ade-8048-6923d10d7ef5">12,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjAtMy0xLTEtMA_998c9d3e-debf-47a5-95f6-95245bb1f866">13,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjEtMS0xLTEtMA_e956e6cd-32cd-4f8a-9a83-762ec697b7f0">16,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjEtMy0xLTEtMA_8807531e-50a8-4fa6-a84c-f8fbddd48b07">16,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjQtMS0xLTEtMA_8d040278-7d4b-42a1-a63e-1a3d62da3ba5">7,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjQtMy0xLTEtMA_0c0d21f4-07a9-4f4b-84e8-d4ea2a180597">7,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjUtMS0xLTEtMA_6d8c8bc2-53d5-4992-9376-a14254a87479">656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjUtMy0xLTEtMA_14be9dc8-e172-47fe-87d4-b134932a556b">656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjctMS0xLTEtMA_b252f6f9-7b64-4f1c-99fd-3e6794df582f">37,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjctMy0xLTEtMA_de367b3c-3fb5-48d2-834e-450cc5e29fbd">38,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzIx_22b020f6-19da-4595-9b82-fa2d9e4b859b"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzIx_58531308-7b21-4f97-a776-f763333f29dc">0.0001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzQ1_2dad900d-dd83-4388-99a8-9e9b9774c5ac"><ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzQ1_ce09655f-cf24-4559-adea-625950196c7c">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzY3_162f1f8d-6821-45a2-8270-d9c0d0f1652f"><ix:nonFraction unitRef="shares" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzY3_2d852053-2f2a-4edc-9601-348f5601cacf"><ix:nonFraction unitRef="shares" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzY3_8588ded3-7d9d-4c29-9b48-6c3cfd1050a2"><ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzY3_bf2b7b42-b715-46ee-921c-3c1a2e48e77f">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding, June&#160;30, 2021 and December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMS0xLTEtMA_a95659cd-7647-4ecc-a5b0-8316f56156d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMy0xLTEtMA_09ca06ad-af3a-434e-ac00-afefc59bc580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzE5_74883970-e030-4a1f-ab92-c92cec5b1567"><ix:nonFraction unitRef="usdPerShare" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzE5_b184fba2-e91a-4ed8-8b86-a5b2e98ffdaa">0.0001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzQz_523a5beb-491a-4b4a-8b0b-47517a31c766"><ix:nonFraction unitRef="shares" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzQz_b8e8aba7-4e43-4b6f-96ff-50139f5d30f1">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzY1_3680310d-6d6d-480a-bee8-aef61f3b0bd4"><ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzY1_a09c422e-85ae-46e4-b8c5-3c53882127b5">88,096,694</ix:nonFraction></ix:nonFraction> issued and outstanding, June&#160;30, 2021; <ix:nonFraction unitRef="shares" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzk2_00720d85-5264-437e-8063-6a04d2340326"><ix:nonFraction unitRef="shares" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzk2_11448e58-1a10-4eeb-b81c-237918b721ff">87,651,352</ix:nonFraction></ix:nonFraction> issued and outstanding, December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMS0xLTEtMA_31b829a5-ffb4-4b89-bcc0-b6300f898ecc">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMy0xLTEtMA_730211b5-d5f0-46e3-a2f8-da51e731fa79">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzItMS0xLTEtMA_d89ee00d-862a-4403-a72a-a83fcfcf483c">169,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzItMy0xLTEtMA_e8ebb0ee-7b32-4543-ab6d-68864090f0aa">167,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzMtMS0xLTEtMA_ec35d524-a11e-41cc-adab-5371d860cf28">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzMtMy0xLTEtMA_c20c7077-efc4-4bcb-ac06-ec34721d5dd6">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzQtMS0xLTEtMA_815a90bf-f601-47c4-9532-f06834b239a1">132,711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzQtMy0xLTEtMA_e41ef82a-f619-431d-bc5b-7aa4ab748d7c">105,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzUtMS0xLTEtMA_a3cb882a-f527-4990-8b11-07397fb80efe">36,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzUtMy0xLTEtMA_21a52ee1-a042-4338-ae6b-630c25e62d41">61,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzYtMS0xLTEtMA_3d58ed84-e3c4-4b84-89b6-26d3c1ee1cd6">74,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzYtMy0xLTEtMA_2f1442d5-665e-4d17-8d6c-592035f212be">100,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_22"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMy0xLTEtMS0w_fb32d3fa-6c2c-45fe-9dab-8660408745da">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMy0zLTEtMS0w_e38dd50d-4bca-4bf5-8f25-d2ab22a01cbd">4,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMy01LTEtMS0w_00472f65-2e0f-4b2d-ae8c-cb671946797d">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMy03LTEtMS0w_61e9b4bb-dbc3-4959-b558-1fa34a843f35">14,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNC0xLTEtMS0w_7972ee1f-992f-4061-bbf0-50fe8f68e204">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNC0zLTEtMS0w_d4078106-d893-4104-9728-eebae7c27fa4">4,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNC01LTEtMS0w_171752ff-dc9d-4cf1-93dd-44754cd3c911">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNC03LTEtMS0w_050887ef-616a-4933-8d9f-abfffec4c655">14,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNi0xLTEtMS0w_43eee5e6-d7d2-4f47-863d-d8612899e50f">10,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNi0zLTEtMS0w_26d8160d-d8a9-4fa0-bb76-95b6f21cd0b7">7,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNi01LTEtMS0w_0cbb8331-cc34-44f3-89a0-3359ae6b91a2">21,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNi03LTEtMS0w_0ddb0f88-c952-457c-a889-3220b6378c22">13,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNy0xLTEtMS0w_ca493ff7-fec6-4869-92ad-84c68bcb7ae0">3,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNy0zLTEtMS0w_0aed8929-80b8-45a2-a6ac-72d9b15e6723">2,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNy01LTEtMS0w_f2e9e71d-3953-476a-baf0-a74aa6a8cf04">5,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNy03LTEtMS0w_17f1584a-0e6e-4771-b08c-5f27d64e06f7">4,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOC0xLTEtMS0w_d7b2af60-d26d-49e4-94d6-d743b1ea376c">13,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOC0zLTEtMS0w_f484b606-4aa0-4dec-b867-bb9ed333a2c9">9,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOC01LTEtMS0w_bee2cf80-36df-4230-a4e0-a7e4775ca090">27,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOC03LTEtMS0w_42380232-634c-45e7-8def-5e418ddebdeb">17,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOS0xLTEtMS0w_709ffe9d-f751-41e3-9468-7d157a0caa70">13,862</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOS0zLTEtMS0w_35c97985-9673-4a22-bd58-943129175edf">4,390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOS01LTEtMS0w_0154b3a0-f2c3-4c06-b780-855f69758966">26,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOS03LTEtMS0w_85a1086c-2332-42fa-9d7a-db31c433a7ab">3,856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Dividend income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTEtMS0xLTEtMA_dbeccaee-8cbe-4703-83e0-74615df01e18">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:InvestmentIncomeDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTEtMy0xLTEtMA_5af6e15b-fcf7-41ba-bd2b-7f61ad6fc31f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTEtNS0xLTEtMA_5ce07088-cec9-4e08-864e-a3e133578306">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:InvestmentIncomeDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTEtNy0xLTEtMA_c8b2d234-ae1b-4c98-a431-a98ed8b63ae6">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTItMS0xLTEtMA_5c01632b-d750-4f02-8d6f-b50fb5daa90e">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTItMy0xLTEtMA_d74d94e3-0ae5-4f80-8e7e-8bd94d7c06b6">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTItNS0xLTEtMA_af892e0a-d113-4b4f-8a45-e6f972086615">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTItNy0xLTEtMA_d99bda89-703c-45fb-a477-2041eaeb7eea">627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTMtMS0xLTEtMA_ba08e4d0-dc4f-4bb2-a93a-5d29d7875ab8">450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTMtMy0xLTEtMA_0c77ea5b-b2f0-49c4-92d5-cdd4109076ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTMtNS0xLTEtMA_89df4341-af2e-4be2-b201-fb980f5b6007">859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTMtNy0xLTEtMA_df287486-3863-4bc1-9563-eaea32df0190">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTQtMS0xLTEtMA_48778883-20e7-4b4a-8403-78cfdf171ba9">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTQtMy0xLTEtMA_4d05ee9f-edd8-4602-96f9-260feb98a6c0">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTQtNS0xLTEtMA_db73ad24-52d2-415b-a962-6b0627f38943">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTQtNy0xLTEtMA_edb8b8f6-cb9e-482a-87b4-68ca4ba96916">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTUtMS0xLTEtMA_5ee624c0-4b56-452d-ba99-0f4da56f3bcc">407</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTUtMy0xLTEtMA_377cf298-0e12-4bc4-91b0-f8888801def2">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTUtNS0xLTEtMA_6e00ebea-765c-4fbc-9b7d-2bc27a93a16f">727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTUtNy0xLTEtMA_dd298fee-1f2a-40e7-9b5a-561ebb34d199">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTYtMS0xLTEtNjA_08918ac0-bfab-4af2-8fab-e557d855030b">14,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTYtMy0xLTEtNjY_f23b48ea-edcd-4e25-876a-3136bcfdf074">4,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTYtNS0xLTEtMA_fe403e57-48e5-4d2e-80c5-ac6309480203">26,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTYtNy0xLTEtMA_5ab07550-ee33-49bd-97ba-95e96ffc44ac">3,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTctMS0xLTEtNzQ_58288d5c-f1dd-4c82-a978-7c4c5575e210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTctMy0xLTEtNzg_76110308-4fa3-4a47-b6c8-b6bb22321bba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTctNS0xLTEtMA_a1eefeda-0cb9-4749-81cd-fe8ddd31d562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTctNy0xLTEtMA_7a85145b-c0fc-4fc9-aeba-6b22a7825f11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTgtMS0xLTEtMA_8c2ddffc-4b8b-45d4-93da-313d341d8fb4">14,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTgtMy0xLTEtMA_5dbd4791-4b6a-4036-ad90-e27a0199ea33">4,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTgtNS0xLTEtMA_39a1b8d1-64d1-412e-873a-d8c7e5cdbb59">26,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTgtNy0xLTEtMA_a59b435d-8fcb-4cff-8e0a-929ee5c7bffb">3,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtMS0xLTEtMA_c0d5220b-dd7f-4906-b060-a5ec7e005c07"><ix:nonFraction unitRef="usdPerShare" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtMS0xLTEtMA_e18ff0cb-4647-4acb-9c7b-c2185a2a449e">0.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtMy0xLTEtMA_d87720f6-a79f-4bea-ad3e-e44ba94da0e9"><ix:nonFraction unitRef="usdPerShare" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtMy0xLTEtMA_eb67c1ac-fb88-433e-baa6-b0594e0eaea7">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtNS0xLTEtMA_82957923-196a-4f72-9290-beefa5bb8215"><ix:nonFraction unitRef="usdPerShare" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtNS0xLTEtMA_ccfd2cfc-6f59-42af-8df3-f08994cf6ddc">0.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtNy0xLTEtMA_db6e4c83-c068-4252-96e5-7b0d260bb5fc"><ix:nonFraction unitRef="usdPerShare" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtNy0xLTEtMA_f8f5df60-81a8-48f0-b060-a4a3379e712d">0.04</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtMS0xLTEtMA_2f6db7a2-1507-41df-98f0-a894c549efd7"><ix:nonFraction unitRef="shares" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtMS0xLTEtMA_b629d769-b9e0-4d45-8f7e-19830c791fb7">88,043,447</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtMy0xLTEtMA_02c6a5a0-0d6a-46db-82c2-361145b846e9"><ix:nonFraction unitRef="shares" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtMy0xLTEtMA_ccf69255-ef43-4f20-bc1d-fc0926a0c226">87,174,533</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtNS0xLTEtMA_39ffb032-32f1-4fea-9780-49d79d966739"><ix:nonFraction unitRef="shares" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtNS0xLTEtMA_8db20d9d-03f8-4013-b238-d1274bb918ba">87,948,440</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtNy0xLTEtMA_2d93a7c4-6f50-4728-aed0-63ec3ded246a"><ix:nonFraction unitRef="shares" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtNy0xLTEtMA_9bbc93a0-8e2b-417f-87bb-d2e55df9e214">87,126,847</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_25"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfMi0xLTEtMS0w_991d2189-c678-4920-9c20-f4c998ec6379">14,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfMi0zLTEtMS0w_ae678ab1-4da8-4660-9965-37c29323c671">4,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfMi01LTEtMS0w_8c4fb240-385a-49f0-b9a8-2fdd49c9a40c">26,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfMi03LTEtMS0w_aa495621-4c3b-443f-89a1-e4d2007d1258">3,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Unrealized (losses) gains on available for sale securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNC0xLTEtMS0w_7efb1152-c35a-4e16-a7a7-73fad736eae4">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNC0zLTEtMS0w_1fe79af9-6aa5-470c-baef-37a45b005c7c">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNC01LTEtMS0w_ae222c5f-a5da-43fb-ac83-31cc3fbe0ef6">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNC03LTEtMS0w_701c790e-807d-4158-aac6-c7e8393edc13">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNS0xLTEtMS0w_cc954297-3454-4704-bc6d-8d21879d69f5">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNS0zLTEtMS0w_c0d11e66-a619-418f-b61d-e345acf30790">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNS01LTEtMS0w_352ddb87-6738-4763-96da-da852ee91499">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNS03LTEtMS0w_3625d351-f219-4a69-bc90-ce99e7894c92">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNi0xLTEtMS0w_8542fd36-2096-4426-afcf-eda6e3739c34">14,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNi0zLTEtMS0w_40909898-ee17-44e4-8682-3398a830c6c8">3,956</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNi01LTEtMS0w_7e6971c3-cec0-49b3-9b5b-59a298fd28f3">26,824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNi03LTEtMS0w_d3f63256-abbc-4e0f-9e8c-aea0323d891e">2,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:49.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_28"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-in- Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacfaf4956355489f844301e39562eb6f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMi0xLTEtMS0w_b59753ab-70fa-4f3f-b8e4-88f3f60b117a">87,651,352</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacfaf4956355489f844301e39562eb6f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMi0zLTEtMS0w_0e9b149f-66ca-4c8d-9b25-aac89b91935b">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279abc78769c4032be54ddfd0c7ffe6b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMi01LTEtMS0w_b6fb9925-ac40-45df-b1d7-151c7a9b5e4c">167,379</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c766de5b12643f4b84da4a3bfcd49bc_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMi03LTEtMS0w_501fb1ff-8dac-4116-b808-5a0c1df8d754">105,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8e31b3400845b785f4078c29ad60c3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMi05LTEtMS0w_06f42acd-a62f-4308-be93-cb9fb72a5499">83</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMi0xMS0xLTEtMA_158fd074-8aae-4c5f-b044-cafdcaac853f">61,506</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i149a543a17ce4d93a6385033c1c76dab_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMy0xLTEtMS0w_fc543cb6-8131-41d8-8f92-e19baf5432ca">342,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2acf22eafee749ef879e689a5d4b7208_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMy01LTEtMS0w_1d45fc37-9193-48e0-ba45-7c76cfa5a5fa">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e140d0339e4a2c9fa363c5cc32a6e4_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMy0xMS0xLTEtMA_f84e252a-3ba5-4f4d-bc34-855d574db845">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2acf22eafee749ef879e689a5d4b7208_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfNC01LTEtMS0w_aecb4e37-ca3d-4cc9-8636-bb5df7635b2f">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e140d0339e4a2c9fa363c5cc32a6e4_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfNC0xMS0xLTEtMA_d505fa28-038b-4de8-8363-aebfea3bc0ea">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6ce674313764ae4915943fafa4cb5cd_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfNi05LTEtMS0w_38740e54-02a4-4ccc-a6f1-46fc99e7379e">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07e140d0339e4a2c9fa363c5cc32a6e4_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfNi0xMS0xLTEtMA_ea47009b-39eb-43e4-ace8-333a053eac4a">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf9870e0c784838b0e84e18c5c665c7_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfNy03LTEtMS0w_f42ed82c-ba31-42e4-bd7c-4717b78d250b">12,477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07e140d0339e4a2c9fa363c5cc32a6e4_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfNy0xMS0xLTEtMA_25a0151c-d314-4524-aed5-1cdd9e359a82">12,477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i566e91ad0fa14f2d811d604abd6082cd_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfOC0xLTEtMS0w_ffaa233f-9619-4b66-ac6a-57a1cf94ecff">87,993,598</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i566e91ad0fa14f2d811d604abd6082cd_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfOC0zLTEtMS0w_968e3b38-6868-4f31-84d5-29ecf2ee763b">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if46fbd1f2b5442348f674d9f2a9f0a54_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfOC01LTEtMS0w_dbfed997-810a-4c7c-a617-763a2ea17dde">168,442</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bde8e11b76e461896f96c566cc62872_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfOC03LTEtMS0w_910c2a7a-96ad-4af9-a586-c4f503d829d4">118,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d493db55bc244c1818df293641b339b_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfOC05LTEtMS0w_ec60cc30-bffd-4668-89ad-5ae98e82dd4f">32</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a85ec43cc4f4214ba9bfbd44ce67a45_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfOC0xMS0xLTEtMA_67062a28-fbd0-4b3f-a0d8-19d09cb615d6">50,041</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b7b77f3ee3b4b51965fe742a7381fbd_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTAtNS0xLTEtMTIz_c58d75c4-df94-4095-8e5f-cf554a8006f4">764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTAtMTEtMS0xLTEyMw_9cf89be6-9a2e-431b-9e56-4cd338bbaf1b">764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock-ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96c703c4ce9440bea4222ca42e9f1f18_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTEtMS0xLTEtMTIz_a7a9a287-ee28-4937-a571-b9a83e0772ee">103,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b7b77f3ee3b4b51965fe742a7381fbd_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTEtNS0xLTEtMTIz_db45524b-bb3b-4826-b391-a89d06390f03">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTEtMTEtMS0xLTEyMw_c6810d56-6aee-4109-8770-a47fa27aa1a2">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb34f5fabfa643a7856aef0eb9f11e70_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTItOS0xLTEtMTIz_39acc08f-2871-46a6-b61c-b870a19514c0">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTItMTEtMS0xLTEyMw_8a0186e2-8a4f-4697-9109-5a2f6292068d">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i165b7f9261d44627b2f958e465d695e5_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTMtNy0xLTEtMTIz_3d290f81-72ab-4551-94bd-efb6c834c7f1">14,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTMtMTEtMS0xLTEyMw_dd2bc56e-fed9-41d1-9272-e84de8f07fbf">14,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e3d4af8ea3748c6a09f9521da9ac2ca_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTQtMS0xLTEtMTI5_12a3a2f7-d494-497b-8969-13fb257863b2">88,096,694</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e3d4af8ea3748c6a09f9521da9ac2ca_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTQtMy0xLTEtMTI5_e0ea1d97-b136-447b-ab8c-08ee575f3b80">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a543e3ada2340d0b5c1f3641c1d3468_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTQtNS0xLTEtMTI5_0da8cca6-7cd8-4c36-b0b6-560429a5395e">169,337</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aa243ca27884648b86a0b1eb325cf57_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTQtNy0xLTEtMTI5_a161ed0e-3c82-4c9c-9364-969bd3c9bd36">132,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dde94d491614ea4bca5ec1bcd8d14b0_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTQtOS0xLTEtMTI5_9ff92ac3-5dce-4f33-99ae-3d18320d0022">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTQtMTEtMS0xLTEyOQ_18133df8-8de9-440a-bd7b-4db4ba2505de">36,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-in- Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5073ecd4f57647949850dc29898c84dd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMi0xLTEtMS0w_942dc7b4-c98c-4024-ad83-cdf13c76e31f">86,069,263</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5073ecd4f57647949850dc29898c84dd_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMi0zLTEtMS0w_60f29752-55f7-4ef9-ac93-296d68250004">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddc4f4973ad446fbd01949b82185558_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMi01LTEtMS0w_ba56c8d7-ce78-4114-b52f-bad08c01ef8a">162,062</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0295336b38e40e498f9dd253711b758_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMi03LTEtMS0w_0d6a03d5-8a78-468e-a08f-0f92f79b3456">81,297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f137df29abc4c41a4815885b2a3d6b7_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMi05LTEtMS0w_fe019e5e-53db-469f-99e4-05003973d177">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib010f58f2ede44548294dae32882407a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMi0xMS0xLTEtMA_d035b55a-cbed-47b6-b0ae-e7224a5db69c">80,747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb13b835a182484c8f3fbf8f2b67cc67_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNC01LTEtMS0w_43d1ba5c-fad8-493f-a36f-3af2bddd659d">441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNC0xMS0xLTEtMA_c7687830-e034-4a64-835b-212fbed49184">441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d226af906d44031be03e8c8a0a7ed41_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNS0xLTEtMS0w_c6528691-9692-4775-a610-79a50ec9bb52">1,081,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb13b835a182484c8f3fbf8f2b67cc67_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNS01LTEtMS0w_bb1934ef-c65f-4a22-8e75-64457c5266ea">2,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNS0xMS0xLTEtMA_76a94969-842e-48e3-8e38-40382c15e701">2,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcec14fba6fa467990e368f7ad3ad3d6_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNi05LTEtMS0w_d6b09fb6-3c42-4588-934e-ed75d7d30b08">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNi0xMS0xLTEtMA_2f7faac0-9dd9-481b-a4cc-18e3a81201b3">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6717e4937b164276903f7d7ad12330f9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNy03LTEtMS0w_d9df7393-ae9a-45cb-a634-1cf45562b281">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNy0xMS0xLTEtMA_68ad7a8d-1514-4a93-a1bb-79ba8e60221e">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27744bcce45d46b1a88c16b8b2198996_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOC0xLTEtMS0w_38dc408a-50fb-4799-b73e-e8e5e81c3260">87,150,447</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27744bcce45d46b1a88c16b8b2198996_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOC0zLTEtMS0w_c6565ee2-c749-4dce-acbe-1dd50bad8af6">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8871fd9e9cd14336b5847fb59ece0447_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOC01LTEtMS0w_b715ea15-705a-48db-880d-b1d5c12ea007">165,269</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0cc9bb25cb645fbad03da89e50bc2e7_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOC03LTEtMS0w_64a64a97-aac5-42c7-8f0a-6c2b79a1db55">80,147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8cf7cd3ed49446ca5422f8857c95a70_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOC05LTEtMS0w_879e04fe-e715-4804-b08c-2da853b31699">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91f21e075fbf4956bcf55c01b1894a5c_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOC0xMS0xLTEtMA_a6c2578c-e649-4c54-910d-36691a6cfdc9">85,114</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3530849be0c2436a8869a0a68de58c4e_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOS0xLTEtMS0xNDg_1291fa77-c19f-4b1f-8f66-971d90f59d45">55,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0f5631296644c3aa22951553d3ab6cc_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOS01LTEtMS0xNDg_70b5cb58-4af5-4b59-a440-98f5a2960011">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOS0xMS0xLTEtMTQ4_caf67701-a408-48a1-ab85-05f47acbaa87">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0f5631296644c3aa22951553d3ab6cc_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTAtNS0xLTEtMTQ4_70d2d5f8-17e9-4d8c-b801-c4b5b08d0d7d">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTAtMTEtMS0xLTE0OA_0ea2f0c0-4a9a-4e13-8333-e4ec23258d81">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6f410f5826241079802ef8f86c3de4f_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTEtOS0xLTEtMTQ4_65062006-c91d-442a-bdfd-aba2ecdf871f">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTEtMTEtMS0xLTE0OA_0240e613-f2b6-48f0-bc20-97e5bcc422a8">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79a078e9f90449658270fc31aa0b394c_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTItNy0xLTEtMTQ4_0416e73c-8e82-4115-9e53-38c8662e609e">4,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTItMTEtMS0xLTE0OA_d9ac845b-c521-4c37-a4cc-09485058cb05">4,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82a9e001ccee4221ae70569a6c358e78_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTMtMS0xLTEtMTQ4_3a6f506f-c086-4e6d-8542-7a6900911192">87,206,346</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a9e001ccee4221ae70569a6c358e78_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTMtMy0xLTEtMTQ4_cda743c7-3abb-42b9-824a-1d9bb46c0cf0">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d68452da3a640b7a96348aa84cfe852_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTMtNS0xLTEtMTQ4_4db9a887-53e7-488e-b6fe-8b50c82d7648">165,863</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30e55b2f78ad495ba7a2baa00860f9d1_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTMtNy0xLTEtMTQ4_dc64c45e-74ea-4de0-8f2b-b47b7ee3f5ce">84,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77029b06c3e4a209202062d9c9b7340_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTMtOS0xLTEtMTQ4_94bc33fe-f659-4d38-9c79-eb12916f4905">338</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93626e950d1452db9e553b3385f4ace_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTMtMTEtMS0xLTE0OA_15b357a4-c805-49f2-87d1-2578e24d7dd0">81,752</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_31"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMy0xLTEtMS0w_df861657-9c66-468c-bf71-76f9f1670af6">26,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMy0zLTEtMS0w_ae715c22-ad3e-4600-8635-ceeeb871b48b">3,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfNS0xLTEtMS0w_9525c243-3d13-4d8b-8112-5346e2a9fbce">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfNS0zLTEtMS0w_a523d5be-9ce4-4017-b854-b984f8d399d7">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfNy0xLTEtMS0w_114d0e22-1839-40b6-8efb-d3c9623787f5">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfNy0zLTEtMS0w_55751224-bc7f-42b5-942f-76d83fe12b8c">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfOC0xLTEtMS0w_d669e074-8e71-46f2-abce-5e754f651e48">1,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfOC0zLTEtMS0w_9575c283-ee19-4553-b78a-30d342e06ba7">985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of long-term debt issuance costs and fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfOS0xLTEtMS0w_8da120e8-436b-4ae8-9f90-672da01b247b">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfOS0zLTEtMS0w_3c1560fa-c5a1-4949-8dd2-fe9f7e0edc81">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTAtMS0xLTEtMA_02d3dc75-dc84-49b5-af22-b30ef47c0437">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTAtMy0xLTEtMA_0d10f635-1b5a-4a55-a65c-a6dbc6e2f2e1">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTEtMS0xLTEtMA_fd56247c-ba19-4600-b53c-3fd107a0d2ef">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTEtMy0xLTEtMA_056e48a3-6e1e-4b18-acc1-20eab859c539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTItMS0xLTEtMA_fd630bc3-0024-47c0-a756-eb015331516e">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTItMy0xLTEtMA_9404fa10-6f54-4892-bd37-e7cd5a21c163">157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTQtMS0xLTEtMA_d2afb301-825b-4c83-ae30-34e104604e64">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTQtMy0xLTEtMA_c267b633-e555-4ae4-8c33-120bb64e5d1a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTUtMS0xLTEtMA_7405aeea-20a5-45e1-b709-d91f8952d58e">357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTUtMy0xLTEtMA_ebe23dab-f5cb-4f85-ac40-44b7f0916176">1,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTYtMS0xLTEtMA_b3d81569-7eca-4817-ae1c-5d9c4036168c">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTYtMy0xLTEtMA_24ef7de0-053a-4f10-86e8-c41380ac0b98">1,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTctMS0xLTEtMA_8f555b08-1728-4a1e-8412-d5627510242b">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTctMy0xLTEtMA_a048dba5-0bc1-4579-9a68-6e28ebeeb972">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTgtMS0xLTEtMA_a76c5df7-5a51-4032-8fcc-6738be29d790">280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTgtMy0xLTEtMA_a4706f6e-daa8-437d-8fb6-f97866df342c">647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTktMS0xLTEtMA_5db1bb06-93ad-49ae-a3c9-f11b345e2c71">1,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTktMy0xLTEtMA_8a2012ce-bddb-40c5-9a95-aa7f944419b1">13,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjAtMS0xLTEtMA_5dd47e65-a53a-427e-a89a-18a0b699ba23">263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjAtMy0xLTEtMA_1b5434fe-b40a-4968-b1f9-959244e9b742">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjEtMS0xLTEtMA_51bc7937-a144-441a-9753-e7c6d72e46f7">25,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjEtMy0xLTEtMA_582d5730-05bf-4695-9ef4-fafde5c22486">18,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of available for sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjMtMS0xLTEtMA_0a61c7ab-69dd-4329-ab18-faf58e37e0dd">2,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjMtMy0xLTEtMA_dbb41a38-ed98-4bac-8299-fdc001817c2f">38,072</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of available for sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjQtMS0xLTEtMA_77146c78-6262-44c3-8b22-5a4eff282fc6">37,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjQtMy0xLTEtMA_1865f845-efce-4f68-8306-d6419d58cb5f">32,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjUtMS0xLTEtMA_0ab7e778-de9a-49e5-905b-576fbf57c6ea">564</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjUtMy0xLTEtMA_67a548c1-2b58-48b5-9aa0-9ad4984b3783">2,996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjYtMS0xLTEtMA_c3d769f2-f580-4f15-abaa-18450e327eac">34,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjYtMy0xLTEtMA_c9896699-dd24-49df-b1be-3d25f64ecc01">8,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from common stock offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjgtMS0xLTEtMA_6e769334-94ff-43b0-8fec-73c032f626dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjgtMy0xLTEtMA_bb52fa82-677a-4d52-95a6-773fc3a8159b">2,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of common stock financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="xcur:PaymentsOfCommonStockFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjktMS0xLTEtMA_5d5845fe-0276-4c4e-aa2b-8211084bf6b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="xcur:PaymentsOfCommonStockFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjktMy0xLTEtMA_bca09185-80c9-4b08-a1dd-061c083eb201"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="xcur:PaymentsOfCommonStockFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjktMy0xLTEtMA_f0465f00-b857-4c34-9efb-09baf12161a6">207</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of long-term debt fees and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzEtMS0xLTEtMA_dc527412-76f5-4f77-9535-2fdcdab485a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzEtMy0xLTEtMA_f4424801-90d0-4424-a602-a7bb9e79a22e">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzItMS0xLTEtMA_a0042afd-0eb7-45e8-a2e8-8311b95ccd72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzItMy0xLTEtMA_e6353f11-7df4-4862-bab3-23c8b6627a1d">4,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzMtMS0xLTEtOTQy_10ed17cc-0bcb-474c-b495-b6c00300be77">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzMtMy0xLTEtOTQ2_979982c6-4587-4835-b7d9-5f7e217133d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzMtMS0xLTEtMA_991dd094-0344-4d45-81e5-0a5b88c7c1bc">546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzMtMy0xLTEtMA_b8cbe7a3-c1f5-4526-a9af-a7a25ac034b9">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzQtMS0xLTEtMA_ee2afca2-f2ed-45e3-bfec-b722f31ad063">677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzQtMy0xLTEtMA_7486ded6-87fa-4f58-bab6-ef4ee6a47997">2,283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzYtMS0xLTEtMA_13ef1477-b227-4cf4-8d6c-cd7470cfc1e2">9,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzYtMy0xLTEtMA_fbb32296-3ab4-4b1d-9abe-d42b9c4c6ddf">30,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash - beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzctMS0xLTEtMA_8fbd472b-ca49-4b46-ba4c-a97418b655a2">34,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib010f58f2ede44548294dae32882407a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzctMy0xLTEtMA_61804ba0-8674-4f78-8d80-86206a26a728">48,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash - end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzgtMS0xLTEtMA_43b19f1d-f636-4a88-9957-566e8c401288">43,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93626e950d1452db9e553b3385f4ace_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzgtMy0xLTEtMA_57c6fca6-be86-4e0b-bdc4-06fbf939551d">18,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures (accounts payable and accrued expenses)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjQ5ZmNiNGQzOTc5NTRjZjJiMTA5ODhhNGM5MWQ4YmU3L3RhYmxlcmFuZ2U6NDlmY2I0ZDM5Nzk1NGNmMmIxMDk4OGE0YzkxZDhiZTdfNi0xLTEtMS0w_490aa9c9-6bdc-4e87-b791-679f43309949">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjQ5ZmNiNGQzOTc5NTRjZjJiMTA5ODhhNGM5MWQ4YmU3L3RhYmxlcmFuZ2U6NDlmY2I0ZDM5Nzk1NGNmMmIxMDk4OGE0YzkxZDhiZTdfNi0zLTEtMS0w_7cc4a42a-20c2-41ae-80c0-ad1e1aba5c53">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the amounts shown in the unaudited condensed consolidated statements of cash flows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjRkMmQzZjA4MTZmZjRlYTZhMWNmYWY3MzI5OWFjNjQ4L3RhYmxlcmFuZ2U6NGQyZDNmMDgxNmZmNGVhNmExY2ZhZjczMjk5YWM2NDhfMS0xLTEtMS0w_6daf5c3c-8139-4970-9806-433535195756">42,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjRkMmQzZjA4MTZmZjRlYTZhMWNmYWY3MzI5OWFjNjQ4L3RhYmxlcmFuZ2U6NGQyZDNmMDgxNmZmNGVhNmExY2ZhZjczMjk5YWM2NDhfMS0zLTEtMS0w_739fbca1-5162-4ea6-bd48-6f630b746cfe">33,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjRkMmQzZjA4MTZmZjRlYTZhMWNmYWY3MzI5OWFjNjQ4L3RhYmxlcmFuZ2U6NGQyZDNmMDgxNmZmNGVhNmExY2ZhZjczMjk5YWM2NDhfMi0xLTEtMS0w_8346128d-f34f-4971-8ebe-620fda5b26ca">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjRkMmQzZjA4MTZmZjRlYTZhMWNmYWY3MzI5OWFjNjQ4L3RhYmxlcmFuZ2U6NGQyZDNmMDgxNmZmNGVhNmExY2ZhZjczMjk5YWM2NDhfMi0zLTEtMS0w_55323044-74d4-44bc-afe4-990cc8f56cd9">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjRkMmQzZjA4MTZmZjRlYTZhMWNmYWY3MzI5OWFjNjQ4L3RhYmxlcmFuZ2U6NGQyZDNmMDgxNmZmNGVhNmExY2ZhZjczMjk5YWM2NDhfMy0xLTEtMS0w_64e598f3-492a-4ce2-9c24-f6025c74ad0f">43,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjRkMmQzZjA4MTZmZjRlYTZhMWNmYWY3MzI5OWFjNjQ4L3RhYmxlcmFuZ2U6NGQyZDNmMDgxNmZmNGVhNmExY2ZhZjczMjk5YWM2NDhfMy0zLTEtMS0w_154570a2-4261-4e6c-9a17-f3e7f14b3679">34,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_34"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="ia49112dadce14be6836937c1a8779dad_37"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfMTA2Nzg_af756d37-b0e9-4c86-85c7-19a91b02df9b" continuedAt="ib5d8d0972b1f4dc992855ab830ddfd9c" escape="true">Description of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="ib5d8d0972b1f4dc992855ab830ddfd9c" continuedAt="i1a2d8affcf754ec3a7b86869dabbd081"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exicure, Inc. (the &#8220;Company&#8221;) is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases, and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA&#8482;, technology. The Company believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. The Company is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNA-based therapeutic candidate, for the intrathecal treatment of Friedreich&#8217;s ataxia (FA).  The Company&#8217;s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes one of the key strengths of its proprietary SNAs is that they have the potential for increased cellular uptake compared to conventional linear oligonucleotides and as a result the potential to achieve higher efficacy at the same doses of oligonucleotide administered. The Company has shown in clinical and preclinical studies that SNAs may have therapeutic potential in immuno-oncology and dermatology.  In addition, the Company has shown in preclinical studies that SNAs may have therapeutic potential in neurology, ophthalmology, pulmonology, and gastroenterology. Accordingly, the Company has expanded its pipeline into neurology, for which IND-enabling activities are ongoing for XCUR-FXN, and is concluding early stage research activities in ophthalmology, pulmonology, and gastroenterology. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout these unaudited condensed consolidated financial statements, the terms the &#8220;Company&#8221; and &#8220;Exicure&#8221; refer to Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets and conducts all business activities and operations of Exicure, Inc.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfMTA2Njk_070fc573-cafb-4698-b8b7-82569669ea42" continuedAt="i594ad91b95274072840bfe2b110699dd" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i594ad91b95274072840bfe2b110699dd">The accompanying unaudited condensed consolidated financial statements as of June&#160;30, 2021 and December 31, 2020, and for the six months ended June&#160;30, 2021 and 2020, have been presented in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).</ix:continuation>  </span></div><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfMTA2Nzk_1e8aef6f-bb9c-4532-a07b-78af443b3f00" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, revenue for the three and six months ended June 30, 2021 reflects events and conditions that occurred during that period that increased the number of hours estimated to be required to complete the services under the AbbVie Collaboration Agreement. These increased estimated efforts resulted in less progress occurring relative to the increased estimate of total projected hours to complete the research services (and thus limited revenue recognized) during the three and six months ended June 30, 2021 and compared to the amount of revenue recognized in the comparable periods.  Due to uncertainties inherent in the estimation process, it is at least reasonably possible that estimated efforts required to complete the research services under the AbbVie Collaboration Agreement will be further revised in the near-term.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i1a2d8affcf754ec3a7b86869dabbd081" continuedAt="i1f808f69325c46728ea22996f0c1375c"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Risks and Uncertainties</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the ongoing COVID-19 pandemic, the Company has taken and continues to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on its business, such as remote working policies, facilitating management&#8217;s routine communication to address employee and business concerns and providing frequent updates to the Company&#8217;s board of directors (the &#8220;Board&#8221;).  During the second quarter of 2021 and through the date of this report, the Company continues to operate under COVID-19 social distancing guidelines and has generally operated with approximately <ix:nonFraction unitRef="number" contextRef="i6df76506288a4a9cb1f3b1ec2a60be16_D20210401-20210630" decimals="2" name="xcur:ResearchAndDevelopmentStaffOnSitePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfMzE2Nw_5cea2abe-eaa5-4cad-ae4e-c38f550a219e">100</ix:nonFraction>% of its R&amp;D staff on-site.  The Company&#8217;s office and general and administrative team is also working on-site approximately <ix:nonFraction unitRef="number" contextRef="i6df76506288a4a9cb1f3b1ec2a60be16_D20210401-20210630" decimals="2" name="xcur:OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfMzI5Mg_85e197ae-85ab-4e96-9cdf-43cf8c5e8388">50</ix:nonFraction>% of the time. The Company&#8217;s preclinical development program in Friedreich&#8217;s ataxia (&#8220;FA&#8221;) is ongoing and it began IND-enabling studies for XCUR-FXN in late 2020.  The Company also continues to progress its collaborations with AbbVie Inc. (&#8220;AbbVie&#8221;).  However, if the COVID-19 pandemic continues to persist for an extended period of time, the Company could experience further significant disruptions to its clinical and preclinical development timelines, which would adversely affect its business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company believes that the effects of the COVID-19 pandemic or its impact contributed to delays during the second half of 2020 and the first half of 2021 in its enrollment plans and clinical trial site start-ups for the Phase 2 dose expansion phase of the Phase 1b/2 clinical trial for its cavrotolimod (AST-008) clinical program.  The Company has taken additional measures to increase the enrollment of patients, including frequent interaction with its clinical trial sites currently open as well as increasing the number of clinical trial sites that potentially are activated for this trial so that the Company may continue to enroll patients as initially planned.  However, any additional delays may require the Company to further lengthen its clinical development timeline for cavrotolimod (AST-008).  Pending further enrollment delays or any unanticipated effects of the COVID-19 pandemic on our clinical development plans, the Company expects to report overall response rate, or ORR, results in the first half of 2022. The extent to which the COVID-19 pandemic or its impact or effects may continue to impact the Company&#8217;s business, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration or spread of the pandemic, its impact and effects, the possibility of additional periods of increases or spikes in the number of COVID-19 cases, travel restrictions, quarantines, social distancing, phased re-openings and business closure requirements in the United States and other countries, and the effectiveness of actions taken globally to contain and treat the disease including, without limitation, the effectiveness and timing of vaccination initiatives in the United States and worldwide.  The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biotechnology industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and the challenges of complying with applicable regulatory requirements.  In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company has generated an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfNzE1Nw_2fa6b475-8ffb-43d7-ada9-4e4bdcb512d0">151,548</ix:nonFraction> since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&#8217;s current operating plans, it believes that existing working capital at June&#160;30, 2021, including the $<ix:nonFraction unitRef="usd" contextRef="ia9df56e3024f4230a66f1aaeeb151149_D20210801-20210831" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfMTA5OTUxMTYzOTU3OQ_9af92333-979d-438f-abde-dbf81e850c63">20,000</ix:nonFraction> upfront payment received in August 2021 in connection with the Ipsen Collaboration Agreement (see Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i1f808f69325c46728ea22996f0c1375c"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and amounts borrowed and available under the MidCap Credit Facility (see Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), is sufficient to fund the Company&#8217;s current plans for at least the next 12 months from the date these financial statements were issued.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, such as its &#8220;at the market offering&#8221; program pursuant to its equity distribution agreement with BMO Capital Markets Corp., to fund its current operations and business strategy. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company.  The Company has historically principally raised capital through the sale of its securities.  However, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  If the disruption continues to persist and deepens, the Company could experience an inability to access additional capital, which could in the future negatively affect its ability to raise capital and ultimately, its operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated balance sheet as of June&#160;30, 2021, the interim condensed consolidated statements of operations for the three and six months ended June&#160;30, 2021 and 2020, the interim condensed consolidated statements of comprehensive (loss) income for the three and six months ended June&#160;30, 2021 and 2020, the interim condensed consolidated statements of changes in stockholders&#8217; equity for the three and six months ended June&#160;30, 2021 and 2020, and the interim condensed consolidated statements of cash flows for the six months ended June&#160;30, 2021 and 2020, are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&#8217;s financial position as of June&#160;30, 2021, the results of its operations for the three and six months ended June&#160;30, 2021 and 2020, and the results of its cash flows for the six months ended June&#160;30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and six months ended June&#160;30, 2021 and 2020 are unaudited. The results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2021, or any other interim periods, or any future year or period.</span></div><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfMTA2NzQ_bddb9d41-2c40-4f4b-a159-4e3b2c3ff0b9" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.</span></div></ix:nonNumeric></ix:continuation><div id="ia49112dadce14be6836937c1a8779dad_40"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80MC9mcmFnOjM1MmY2ZjFkNDI3MTQ1ZjhhNzM2N2I0NzdiMjE4ZDViL3RleHRyZWdpb246MzUyZjZmMWQ0MjcxNDVmOGE3MzY3YjQ3N2IyMThkNWJfMTk3NQ_fd3bfd49-33c1-49d2-878f-5cabf4d1213c" continuedAt="i12ffed5701c84e2fa0e01af7020b8708" escape="true">Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i12ffed5701c84e2fa0e01af7020b8708" continuedAt="ib6d67980360b44b89dcd1519cd310fe7"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 11, 2021. Since the date of those audited consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80MC9mcmFnOjM1MmY2ZjFkNDI3MTQ1ZjhhNzM2N2I0NzdiMjE4ZDViL3RleHRyZWdpb246MzUyZjZmMWQ0MjcxNDVmOGE3MzY3YjQ3N2IyMThkNWJfMTk3MQ_22c745e4-5e4a-4297-9414-92f935d8172b" continuedAt="ie342f67a272e43e4ba062e5819de53f5" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ib6d67980360b44b89dcd1519cd310fe7"><ix:continuation id="ie342f67a272e43e4ba062e5819de53f5"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#8212;Effective Dates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#8220;smaller reporting companies&#8221; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="ia49112dadce14be6836937c1a8779dad_43"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTQ2MDY_6dd4f288-3628-471b-98cc-1d9a6dca3c6e" continuedAt="i42c527b9a84749fd995e4cd1b15984e3" escape="true">Collaborative Research and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i42c527b9a84749fd995e4cd1b15984e3" continuedAt="i65a98966b27c4bf9a640e873b0e12dbb"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Collaboration Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2019 (the &#8220;Effective Date&#8221;), the Company entered into a Collaboration, Option and License Agreement (the &#8220;AbbVie Collaboration Agreement&#8221;), with a wholly-owned subsidiary of Allergan plc, Allergan. On May 8, 2020, Allergan plc, including Allergan was acquired by AbbVie. Pursuant to the AbbVie Collaboration Agreement, the Company granted to AbbVie exclusive access and options to license SNA based therapeutics arising from <ix:nonFraction unitRef="agreement" contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113" decimals="INF" format="ixt-sec:numwordsen" name="xcur:NumberofCollaborationPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNTQ4_6dd63839-d0d9-440f-8161-f0b968bca80e">two</ix:nonFraction> collaboration programs related to the treatment of hair loss disorders (each, a &#8220;Collaboration Program&#8221;). Under each such license (obtained in connection with the exercise of an Option, as defined and discussed further below), the Company would grant to AbbVie exclusive, royalty-bearing, sublicensable, nontransferable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Under the AbbVie Collaboration Agreement, the Company will use commercially reasonable efforts to conduct <ix:nonFraction unitRef="agreement" contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113" decimals="INF" format="ixt-sec:numwordsen" name="xcur:NumberofCollaborationPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTA2Ng_824ad938-e87c-488f-990e-a1854d7369a7">two</ix:nonFraction> Collaboration Programs, each focused on one or more hair loss disorders to discover one or more SNA products that are directed to, bind to or inhibit one or more specific Collaboration Program targets (each, a &#8220;Program Target&#8221;).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Effective Date, the Company and AbbVie have agreed upon a development plan for each Collaboration Program that describes the development activities and timelines required to advance such Collaboration Program through first IND filing (each, a &#8220;Development Plan&#8221;).  The activities described in the Development Plan are conducted under the supervision of the Joint Development Committee (the &#8220;JDC&#8221;) consisting of three members from each of the Company and AbbVie. The Company is primarily responsible for performing early stage discovery and preclinical activities (the &#8220;Initial Development Activities&#8221;) set forth in the Development Plan for each Collaboration Program and will be solely responsible for all costs and expenses related to the Initial Development Activities. AbbVie may elect, in its sole discretion and at its sole cost and expense, to conduct formulation assessment and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing as set forth in a Development Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of all Initial Development Activities, the Company is required to deliver to AbbVie a report that describes the results of the Initial Development Activities and identifies at least one SNA-based compound that satisfies certain criteria for such Collaboration Program as determined by the JDC (the &#8220;Initial Development Report&#8221;).  Following the delivery of the Initial Development Report for a Collaboration Program, AbbVie will have the ability for a defined period of time (the &#8220;Initial Option Exercise Period&#8221;) to exercise an option (each an &#8220;Option&#8221;) to obtain worldwide rights and license to the Company&#8217;s SNA technology and the Company&#8217;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any product (each a </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i65a98966b27c4bf9a640e873b0e12dbb" continuedAt="i62276076e0464affb4ffc45830e9114d"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Licensed Product&#8221;) that results from such Collaboration Program during the term of the AbbVie Collaboration Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At AbbVie&#8217;s sole option, AbbVie may extend the Initial Option Exercise Period (the &#8220;Option Extension&#8221;) and require the Company to perform IND-enabling activities described in the Development Plan (the &#8220;IND-Enabling Activities&#8221;), subject to the payment of additional consideration (&#8220;Extension Exercise&#8221;). If AbbVie exercises the Option Extension, the Company would be responsible for conducting the IND-Enabling Activities and would be solely responsible for all costs and expenses associated with such activities.  Upon completion of the IND-Enabling Activities, the Company is required to deliver a report that describes the results of the IND-Enabling Activities (the &#8220;IND-Enabling Activities Data Package&#8221;) to AbbVie. Following the delivery of IND-Enabling Activities Data Package, AbbVie will have the ability for a defined period of time (the &#8220;Extended Option Exercise Period&#8221;) to exercise an Option with respect to such Collaboration Program. After the exercise of an Option with respect to a Collaboration Program, AbbVie will be responsible for all development, manufacturing, and commercialization activities, and costs and expense associated with such activities in connection with Licensed Products arising from such Collaboration Program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligation to conduct the activities defined in the Development Plan under the AbbVie Collaboration Agreement commenced on November 13, 2019 and continues until the earlier of (i) the date AbbVie exercises an Option, (ii) the date AbbVie abandons a Collaboration Program and foregoes its Option to that Collaboration Program, or (iii) the fifth anniversary of the Effective Date (the &#8220;Research Term&#8221;). If the Initial Option Exercise Period or Extended Option Exercise Period is still in effect for a Collaboration Program or if the Company has not delivered a complete Initial Development Report or, if AbbVie made an Extension Exercise for a Collaboration Program, a complete IND-Enabling Activities Data Package for such Collaboration Program, as determined by the JDC, then the Research Term will automatically extend by one-year increments until such obligation is satisfied, but in no event past the seventh anniversary of the Effective Date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the AbbVie Collaboration Agreement, the Company received a $<ix:nonFraction unitRef="usd" contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNTQ0Mw_9fbac6b8-607a-48be-85ad-2e02c1fab4ae">25,000</ix:nonFraction> upfront, non-refundable, non-creditable cash payment (the &#8220;AbbVie Upfront Payment&#8221;) related to the Company&#8217;s research and development costs for conducting the Development Plan for <ix:nonFraction unitRef="agreement" contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113" decimals="INF" format="ixt-sec:numwordsen" name="xcur:NumberofCollaborationPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTA5OTUxMTY0MjY1Ng_824ad938-e87c-488f-990e-a1854d7369a7">two</ix:nonFraction> Collaboration Programs, each focused on one or more targets, and certain options to obtain exclusive, worldwide licenses under certain intellectual property rights owned or controlled by the Company to develop, manufacture and commercialize certain products resulting from each such Collaboration Programs.  The option exercise fee during the Initial Option Exercise Period is $<ix:nonFraction unitRef="usd" contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementOptionExerciseFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNjAwNw_dce918aa-abde-431f-9dc7-b98288a5841c">10,000</ix:nonFraction> per Collaboration Program.  If AbbVie elects to extend the Initial Option Exercise Period, AbbVie is required to pay an additional fee of $<ix:nonFraction unitRef="usd" contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementExtendedOptionAdditionalExerciseFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNjE0OA_b702da28-3084-4596-97a7-3e90a2987abd">10,000</ix:nonFraction>.  If AbbVie elects to exercise its option during the Extended Option Exercise Period, AbbVie must pay the Company the option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i323854d9e19745dd9223744aaa4363ae_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementOptionExerciseFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNjI5Mg_117b2c8a-77a4-44f2-b33d-7879c64037d7">15,000</ix:nonFraction>.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the exercise by AbbVie of an Option with respect to a Collaboration Program, AbbVie would be required to make certain milestone payments to the Company upon the achievement of specified development, product approval and launch, and commercial events, on a Licensed Product by Licensed Product basis. On a Licensed Product by Licensed Product basis, for the first Licensed Product to achieve the associated milestone event, the Company is eligible to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="icc5418ff3e7c4d5196e4b2c13c675901_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNjc4Ng_d6953925-01b6-4045-a6bf-ed6a275ef581">55,000</ix:nonFraction> for development milestone payments and $<ix:nonFraction unitRef="usd" contextRef="icc5418ff3e7c4d5196e4b2c13c675901_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNjgyOA_75f52a2c-e223-4578-97d2-31d8eae7ca5a">132,500</ix:nonFraction> for product approval and launch milestone payments. The Company is also eligible for up to $<ix:nonFraction unitRef="usd" contextRef="icc5418ff3e7c4d5196e4b2c13c675901_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNjkyMg_035da278-689a-4ac9-b9bd-241b9996b520">175,000</ix:nonFraction> in sales milestone payments on a Collaboration Program by Collaboration Program basis, associated with aggregate worldwide sales. Certain product approval milestones are subject to certain reductions under specified circumstances, including for payments required to be made by AbbVie to obtain certain third-party intellectual property rights.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, to the extent there is any Licensed Product, the Company would be entitled to receive tiered royalty payments of mid-single digits to the mid-teens percentage on future net worldwide product sales of such Licensed Products, subject to certain reductions under specified circumstances. Royalties are due on a Licensed Product by Licensed Product and country by country basis from the date of the first commercial sale of each Licensed Product in a country until the latest to occur of: (i) the expiration date in such country of the last to expire valid claim within the licensed intellectual property covering the manufacture, use or sale of such Licensed Product in such country, (ii) </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i62276076e0464affb4ffc45830e9114d" continuedAt="i2fc49ba557244d1893427ad1a1bd22a0"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the tenth anniversary of the first commercial sale of such Licensed Product in such country, and (iii) the expiration of regulatory exclusivity for such Licensed Product in such country.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie may terminate the AbbVie Collaboration Agreement for any reason or no reason, either in its entirety or on a Collaboration Program by Collaboration Program basis, at any time on <ix:nonNumeric contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113" format="ixt-sec:durday" name="xcur:CollaborationAgreementTerminationPeriodUponWrittenNotice" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfODM0MA_095ca829-9e6f-4da8-b5f8-4a3fdc6d3727">90</ix:nonNumeric> days&#8217; prior written notice to the Company. Unless earlier terminated, the term of the AbbVie Collaboration Agreement shall continue until (i) if both Option Exercise Periods expire without AbbVie exercising either Option, the expiration of the later to expire Option Exercise Period, and (ii) if either or both Options are exercised on a Licensed Product-by-Licensed Product and country-by-country basis, the expiration of the royalty term for such Licensed Product in such country. Either party may terminate the AbbVie Collaboration Agreement if the other party has materially breached or defaulted in the performance of any of its material obligations and such breach or default continues after the specified cure period. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the AbbVie Collaboration Agreement for any reason will not release either party from any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination. In addition, termination of the AbbVie Collaboration Agreement will not preclude either party from pursuing any rights and remedies it may have under the agreement or at law or in equity with respect to any breach of the AbbVie Collaboration Agreement. If either party terminates the AbbVie Collaboration Agreement, the license and rights granted to AbbVie with respect to the terminated Collaboration Program or License Product shall terminate. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Analysis</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that AbbVie is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance. Under the AbbVie Collaboration Agreement, the Company has identified a single performance obligation that includes (i) the research and development activities during the Research Term (the &#8220;AbbVie R&amp;D Services&#8221;), and (ii) Joint Development Committee services during the Research Term (the &#8220;AbbVie JDC Services&#8221;). The Company has concluded that the AbbVie R&amp;D Services is not distinct from the AbbVie JDC Services during the Research Term. The JDC provides oversight and management of the overall AbbVie Collaboration Agreement, and the members of the JDC from the Company have specialized industry knowledge, particularly as it relates to SNA technology. The JDC is meant to facilitate the early stage research being performed and coordinate the activities of both the Company and AbbVie. Further, the JDC services are critical to the ongoing evaluation of a Collaboration Program and the drafting and evaluation of the Initial Development Report and the IND-Enabling Data Package. Accordingly, the Company&#8217;s participation on the JDC is essential to AbbVie receiving value from the AbbVie R&amp;D Services and as such, the AbbVie JDC Services along with the AbbVie R&amp;D Services are considered one performance obligation (the &#8220;Collaboration Program Services&#8221;).  In addition, the Company has concluded that the option to purchase two development and commercialization licenses is considered a marketing offer as the options did not provide any discounts or other rights that would be considered a material right in the arrangement, and thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for these options will be accounted for when they are exercised.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Effective Date of the AbbVie Collaboration Agreement, the total transaction price was determined to be $<ix:nonFraction unitRef="usd" contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTE3NDM_03662a04-5ffc-4e21-9fa1-90a9b5791773">25,000</ix:nonFraction>, consisting solely of the AbbVie Upfront Payment. The Company also utilized the most likely amount method to estimate any development and regulatory milestone payments to be received. As of the Effective Date of the AbbVie Collaboration Agreement, there were no milestones included in the transaction price.&#160;The milestones were fully constrained due to the significant uncertainties surrounding such payments.&#160;The Company considered the stage of development and the risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or AbbVie.  The Company has determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur.  As of June&#160;30, 2021, the Company determined that any development, regulatory, or commercial milestones continue to be constrained and therefore the related milestone payments continue to be excluded from the transaction price at June 30, 2021.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i2fc49ba557244d1893427ad1a1bd22a0" continuedAt="iaf6db152cc074778bd88b980ef338d1b"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize revenue related to the Collaboration Program Services as the performance obligation is satisfied using an input method to measure progress. The Company believes the input method that most accurately depicts the measure of progress is the actual hours incurred to date relative to projected hours to complete the research service.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021, the Company recognized revenue under the AbbVie Collaboration Agreement of approximately $<ix:nonFraction unitRef="usd" contextRef="iab515d133a4549b18fbb6f4ad02e2cc6_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMjc0ODc3OTA4NDI3Mg_64dad4a2-ac72-4183-aa74-e69b6059ae9b">79</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6b844762003d4f3b95be40b6168ead6d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMjc0ODc3OTA4NDI4Mg_c8f6983c-743b-4925-9659-bca11e9c6d1e">1,076</ix:nonFraction>, respectively.  Revenue for the three and six months ended June 30, 2021 reflects events and conditions that occurred during that period that increased the number of hours estimated to be required to complete the services under the AbbVie Collaboration Agreement. These increased estimated efforts resulted in less progress occurring relative to the increased estimate of total projected hours to complete the research services (and thus limited revenue recognized) during the three and six months ended June 30, 2021 and compared to the amount of revenue recognized in the comparable periods.  During the three and six months ended June&#160;30, 2020, the Company recognized revenue under the AbbVie Collaboration Agreement of approximately $<ix:nonFraction unitRef="usd" contextRef="i0cbe4aacf45245898bfff13da476b491_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMjc0ODc3OTA4NDI4OA_9b6b574d-b72d-49d5-a040-5afab2a74fc5">4,833</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i17febbe492b545c0b97d0ae80370db3f_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTM0ODY_33462755-5679-4c60-a0f3-356f67460ff8">13,949</ix:nonFraction>, respectively.  As of June&#160;30, 2021 and December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i2dede066e6c145098de6bc8ed6e91eb7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTM1MzI_b0f1c64b-faea-4788-a93b-78578a272533">7,267</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib3b4f20000a14fd2b555bd263b4cb305_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTM1Mzk_fc9d9d0c-015b-4310-91d1-126d8d71bfde">8,343</ix:nonFraction> of deferred revenue related to the AbbVie Collaboration Agreement, which is classified as current on the unaudited condensed consolidated balance sheet.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dermelix Collaboration Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2019, Exicure entered into a License and Development Agreement with Dermelix (the &#8220;Dermelix Collaboration Agreement.&#8221;)  Under the terms of the Dermelix Collaboration Agreement, Exicure received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i916551a6aa1f4e67bc25b95d7119fc61_D20190217-20190217" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTM5NjA_00f9213c-69ea-48b7-99b0-e2f6705e3cbb">1,000</ix:nonFraction>, to be applied against the initial $<ix:nonFraction unitRef="usd" contextRef="i916551a6aa1f4e67bc25b95d7119fc61_D20190217-20190217" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationDevelopmentExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTM5OTg_03504f59-7b03-4430-8a06-fdda496b567f">1,000</ix:nonFraction> of the Company&#8217;s development expenses.  </span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaf6db152cc074778bd88b980ef338d1b">The Company initially recorded the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i916551a6aa1f4e67bc25b95d7119fc61_D20190217-20190217" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTQwOTY_de246798-f97c-4289-b2ae-fbeb600fca08">1,000</ix:nonFraction> as deferred revenue related to its wholly unsatisfied performance obligation and reduced this balance to <ix:nonFraction unitRef="usd" contextRef="iabf8a9f039204f5a9f174a27e912c223_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTA5OTUxMTY0MjY2NA_1e5d2c63-fdfb-41e9-b1f3-e79d7678fa0b">zero</ix:nonFraction> during 2019 by recognizing revenue as services were provided.  The Company recognized <ix:nonFraction unitRef="usd" contextRef="idf8a680258f340a5b95f6fa0166cc962_D20210101-20210630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTQyOTU_3406d6ed-64d0-4f69-a2be-be6efc2d09ee"><ix:nonFraction unitRef="usd" contextRef="ie74bdc37f6204d6dab0e778172766ea3_D20210401-20210630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTQyOTU_9e2dd762-7ecf-4886-abdf-b0e3d9a8719c">no</ix:nonFraction></ix:nonFraction> revenue under the Dermelix Collaboration Agreement during the three and six months ended June&#160;30, 2021. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i9a937d2024224f2187dd03316b8a9e85_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTQ0MDM_43c3b565-fd70-43cb-8a51-c1170c89189d">14</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia5e3560a2c7c44468ecad7133174a9d2_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMjc0ODc3OTA4NDMxMA_16ad3666-673d-4b4c-abff-c983ce40ace5">81</ix:nonFraction> of revenue during the three months ended June&#160;30, 2020 which reflected reimbursement by Dermelix for additional costs incurred by Exicure for early stage development costs beyond the initial $<ix:nonFraction unitRef="usd" contextRef="i916551a6aa1f4e67bc25b95d7119fc61_D20190217-20190217" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTQ1ODY_39cf702a-375d-4e71-aa40-f80c84f3e6be">1,000</ix:nonFraction> upfront payment.</ix:continuation>  </span></div><div id="ia49112dadce14be6836937c1a8779dad_46"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMjg1_770a4753-25ab-4aaa-be1d-5b9d0b7d487a" continuedAt="ic409886b13484acd8e81e947189c7351" escape="true">Supplemental Balance Sheet Information</ix:nonNumeric></span></div><ix:continuation id="ic409886b13484acd8e81e947189c7351" continuedAt="i947f45fa1e224a8095f4317c1b4787e2"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMjc5_8c7708b0-280c-4f14-9405-89674484b98a" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.948%"><tr><td style="width:1.0%"></td><td style="width:73.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.106%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical, contract research and manufacturing costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfMS0xLTEtMS0w_3675e0c6-bb40-4277-b1d0-093a96c81d7b">3,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfMS0zLTEtMS0w_6305e6b8-8914-4efc-a5d6-bcdaac390bb1">2,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfMi0xLTEtMS0w_d8d5292c-041b-4e97-9462-729495c0ef5e">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfMi0zLTEtMS0w_c34065e6-3be2-4299-8618-4cb02fa48034">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfMy0xLTEtMS0w_fbafc8e8-59ea-4cfd-b49e-bdd714ec515a">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfMy0zLTEtMS0w_b719c9fc-3cba-4947-9080-1d15e1bbf3ec">694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfNC0xLTEtMS0w_36bdaabe-550e-4b55-adfb-5e3003094241">902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfNC0zLTEtMS0w_3e41701c-28e7-410e-8b3c-e74489dcc23e">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfNS0xLTEtMS0w_f8425284-41b9-480b-98e9-32929c360de9">4,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfNS0zLTEtMS0w_6290b1f5-4a1f-43f5-b747-15f948f85324">4,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><ix:continuation id="i947f45fa1e224a8095f4317c1b4787e2"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMjc3_827ba965-d343-43d0-a05d-0ef1d0234c04" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment, net</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.628%"><tr><td style="width:1.0%"></td><td style="width:73.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.799%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i073135b508cc4068bc10b72d2b0d3170_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfMS0xLTEtMS0w_610cdf2e-1504-4f92-a05b-5bcbae8dd0fb">5,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e62ef03a17479584641f2e340a929c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfMS0zLTEtMS0w_febe4cad-3525-4796-b44c-1e8416b5f9c6">5,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c9b49c74324d46b41817978d7a5a2c_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfMi0xLTEtMS0w_f4ead12e-8ede-41ed-b883-a877f291deed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3b5c379005b46dfbb023e9e0339cb54_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfMi0zLTEtMS0w_3c43d155-73fb-4554-8270-c24237b998b9">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09baee4ff554479da4cfb04820c2c407_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfMy0xLTEtMS0w_e2c04515-a866-480e-8997-d4c3d35834e9">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925dc62162064a6e8afe8a1541ec5f89_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfMy0zLTEtMS0w_13f9b3c4-1c3e-4234-b6b7-ff079ef1dc75">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed0bbb359d14d848c59c0cae236a4ab_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNC0xLTEtMS0w_0b82285e-2bdf-4894-a1db-5eec5f975601">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31b47b75b7d444be881f797effc35ea5_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNC0zLTEtMS0w_e422a6df-0268-4a80-bb02-ff5368dcfcb0">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88343bfea9104524b13b58dd117fa4a0_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNS0xLTEtMS0w_d416915c-0963-40a1-814f-601362a8866e">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fbe3f7a19a3407695cd3173dc3fa872_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNS0zLTEtMS0w_bbc9ac22-9487-496e-bb11-7f60d7596d37">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNi0xLTEtMS0w_e3aa6822-d07d-4da6-90dd-a4bc366242db">6,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNi0zLTEtMS0w_4691fd8f-886c-44f4-b1cf-dff208d0e2a4">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNy0xLTEtMS0w_fc5bf497-2524-4ec4-9b2c-045b46283617">2,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNy0zLTEtMS0w_2a59e6e2-c193-4bb0-aa81-df4717907a0c">1,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfOC0xLTEtMS0w_c70aad87-e073-431c-8d7f-a0fa971513bd">4,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfOC0zLTEtMS0w_cc612006-5a2c-4af6-9991-6eb38a12ca4b">4,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMjE5OTAyMzI1NTk0Nw_da3198a1-9aa5-4604-a6d7-71a0c177bfac">283</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMjE5OTAyMzI1NTk1Nw_1abf5656-1438-467e-b321-d538f6bdbec6">187</ix:nonFraction> for the three months ended June 30, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMTYz_6597c630-1115-413c-8279-b2c49f07fc88">546</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMTcw_2a5eca35-8a60-4910-835f-28675eaed21d">335</ix:nonFraction> for the six months ended June 30, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMjg0_e8c8f742-bdd4-4989-a410-295b78d256a2" escape="true"><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued expenses and other current liabilities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.108%"><tr><td style="width:1.0%"></td><td style="width:73.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical, contract research and manufacturing costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfMS0xLTEtMS0w_9a9be009-5103-4d01-a819-0860fc97c02f">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfMS0zLTEtMS0w_2a470152-c665-4cc2-a30b-9c3a99182f98">1,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfMi0xLTEtMS0w_cd1dab77-62e3-418a-8ca7-14b8b998391f">1,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfMi0zLTEtMS0w_c6cd4a58-f9bc-445a-a746-6d971dcbeb08">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfNS0xLTEtMS0w_a9f97655-0971-40ec-8b95-cafa00288c15">420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfNS0zLTEtMS0w_af57d745-d083-4c2d-a20f-38b7aad2b4d3">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfNi0xLTEtMS0w_6a67e001-29b8-4266-8d7e-f5d7b5e54ee5">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfNi0zLTEtMS0w_f10c5cab-cfca-4c82-86b6-400b566d00ee">772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfNy0xLTEtMS0w_a12b586f-b4e5-4fb5-bb1c-0402ea17815a">3,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfNy0zLTEtMS0w_071a26e0-1623-4d93-89f1-69e62d11efc7">3,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;margin-top:1pt;text-align:center;text-indent:18pt"><span><br/></span></div><div id="ia49112dadce14be6836937c1a8779dad_49"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RleHRyZWdpb246NjMxYmIyNjdlNDIzNDBjMThlNTM2MmQ5NjczMDcxZDdfMTIzNw_539dd7b7-f26b-446e-be4e-078f70c038b4" continuedAt="ia535fafbb250443d9c3f8e9e75cc0b9a" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="ia535fafbb250443d9c3f8e9e75cc0b9a" continuedAt="if5e7daa09b3a426cab7d557512c9359a"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020, the Company primarily invested its excess cash in debt instruments of corporations, the U.S. Treasury, financial institutions, and U.S. government agencies with strong credit ratings and an investment grade rating at or above a long-term rating of Aa3/AA- and a short-term rating of P1/A1. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</span></div><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:InvestmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RleHRyZWdpb246NjMxYmIyNjdlNDIzNDBjMThlNTM2MmQ5NjczMDcxZDdfMTIzNQ_d4f78712-71a7-4bf0-af12-3048e4448eed" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contract maturity of the available-for-sale securities the Company held as of June&#160;30, 2021:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:282.75pt"><tr><td style="width:1.0pt"></td><td style="width:211.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year or less</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="2" name="xcur:DebtSecuritiesAvailableForSaleCurrentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjRlNWMzMTFiYTRkNzQ0ZDI5OWY1NDRiMmE2ZGUyZmNkL3RhYmxlcmFuZ2U6NGU1YzMxMWJhNGQ3NDRkMjk5ZjU0NGIyYTZkZTJmY2RfMC0xLTEtMS0w_8489c9df-2b49-4f16-b772-d4abc911a68d">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year but within two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="2" format="ixt:zerodash" name="xcur:DebtSecuritiesAvailableForSaleNoncurrentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjRlNWMzMTFiYTRkNzQ0ZDI5OWY1NDRiMmE2ZGUyZmNkL3RhYmxlcmFuZ2U6NGU1YzMxMWJhNGQ3NDRkMjk5ZjU0NGIyYTZkZTJmY2RfMS0xLTEtMS0w_a4410834-2885-4e02-8ffb-acccef006d0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="2" name="xcur:DebtSecuritiesAvailableforSalePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjRlNWMzMTFiYTRkNzQ0ZDI5OWY1NDRiMmE2ZGUyZmNkL3RhYmxlcmFuZ2U6NGU1YzMxMWJhNGQ3NDRkMjk5ZjU0NGIyYTZkZTJmY2RfMi0xLTEtMS0w_57f5dd66-42e4-467d-9f68-c2a4c24d1692">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s available-for-sale securities are available to the Company for use in its current operations. As a result, the Company categorizes all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="if5e7daa09b3a426cab7d557512c9359a"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RleHRyZWdpb246NjMxYmIyNjdlNDIzNDBjMThlNTM2MmQ5NjczMDcxZDdfMTIzNg_0244bbb2-008e-4849-9a01-a5db910bc413" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;June&#160;30, 2021&#160;and December&#160;31, 2020 were as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.826%"><tr><td style="width:1.0%"></td><td style="width:45.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1b0681e7a64826a8f5b37064e1c69f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMi0xLTEtMS0w_0d15e265-c6eb-4f87-b34f-ae725b975289">5,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1b0681e7a64826a8f5b37064e1c69f_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMi0zLTEtMS0w_78d0c521-1473-4cba-8e11-d4cf444e434c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1b0681e7a64826a8f5b37064e1c69f_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMi01LTEtMS0w_3d50bb38-d847-411b-a9c5-90843ea1bcbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1b0681e7a64826a8f5b37064e1c69f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMi03LTEtMS0w_b67036a8-fca3-460a-982f-8add792ae624">5,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie654008c14bb45bebaddc4a5e9306fd2_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMy0xLTEtMS0w_9d56cc81-0257-4011-8398-3bfd9b4f75d4">6,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie654008c14bb45bebaddc4a5e9306fd2_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMy0zLTEtMS0w_4e8a4eef-e058-4ad9-a981-9fecd39c0da5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie654008c14bb45bebaddc4a5e9306fd2_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMy01LTEtMS0w_0b2f3a67-82fd-49c5-9dac-8de7ffd54ab6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie654008c14bb45bebaddc4a5e9306fd2_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMy03LTEtMS0w_a31669db-b3a5-4e6c-bc93-8e51688a989e">6,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb46a2e715654544969c6e914b1268af_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNS0xLTEtMS0w_5e039f35-ebee-4001-8761-58da51a42072">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb46a2e715654544969c6e914b1268af_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNS0zLTEtMS0w_a9f8874a-3179-4c7a-b817-38e3692aeb91">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb46a2e715654544969c6e914b1268af_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNS01LTEtMS0w_f5dc7ca0-b50e-4ffd-846d-033284e5afd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb46a2e715654544969c6e914b1268af_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNS03LTEtMS0w_93611347-8836-4060-ba87-949b34da6159">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNi0xLTEtMS0w_04d5aca7-52c2-4aa4-af61-c6a1439939eb">13,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNi0zLTEtMS0w_d7261bea-0080-44fb-b1ac-058c3cf0ca78">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNi01LTEtMS0w_90dc5eb2-a313-4423-b1f8-2b7eb26f642d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNi03LTEtMS0w_1c991872-68ea-4b4b-9d8f-945e928a4b5d">13,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.025%"><tr><td style="width:1.0%"></td><td style="width:44.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73b584ce0741a88f6493e030684da2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMi0xLTEtMS0w_9adc77b1-0972-4534-ae23-10541b4945ae">15,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73b584ce0741a88f6493e030684da2_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMi0zLTEtMS0w_234c7156-0a7b-477d-ad80-ffe9a5a7e84a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d73b584ce0741a88f6493e030684da2_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMi01LTEtMS0w_ff16e58c-39b7-41a6-9269-94675aa83617">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d73b584ce0741a88f6493e030684da2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMi03LTEtMS0w_0825a0a8-dd6d-4d86-b6e5-3a8d5bd50db6">15,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49032d31daff47918154c5a0df3b9f9e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMy0xLTEtMS0w_e7e3b70d-ffb6-4562-8787-e4e204c2752d">29,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49032d31daff47918154c5a0df3b9f9e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMy0zLTEtMS0w_2e042695-e83d-4ca5-b31e-fecbb63cfd57">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49032d31daff47918154c5a0df3b9f9e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMy01LTEtMS0w_5361597d-328b-43b6-824a-fcda7e778ea4">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49032d31daff47918154c5a0df3b9f9e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMy03LTEtMS0w_eaed9a24-c195-4bbe-a6ea-7b48b2f2fe73">29,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8ec51807b1e46109dd345b48f722f7d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNC0xLTEtMS0w_ced881e0-d80d-49a5-b7db-d706bc259072">2,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8ec51807b1e46109dd345b48f722f7d_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNC0zLTEtMS0w_aef6c7e7-97c4-49da-872d-7f323b7b964c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8ec51807b1e46109dd345b48f722f7d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNC01LTEtMS0w_bd4338ab-b9c1-4eac-8642-164c0fe3f10c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8ec51807b1e46109dd345b48f722f7d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNC03LTEtMS0w_b44adcf7-d9e8-48e8-bc50-ed1c0df330dc">2,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9577091c72d34a4d87f0ec5ba0d9a62a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNS0xLTEtMS0w_95b422e6-fbf0-4aab-baa4-2a6c9d18545f">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9577091c72d34a4d87f0ec5ba0d9a62a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNS0zLTEtMS0w_0fd402b9-5070-4221-9a2c-d24ac1dfcbbc">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9577091c72d34a4d87f0ec5ba0d9a62a_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNS01LTEtMS0w_974c9b8a-d764-4f4b-89ee-b4b470480328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9577091c72d34a4d87f0ec5ba0d9a62a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNS03LTEtMS0w_39331fa5-34b6-4b1b-b034-26fa62a08003">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNi0xLTEtMS0w_bd697e8a-fdf3-4b92-af3e-fe9a2c075768">48,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNi0zLTEtMS0w_9fc226b5-82d1-4d0e-acae-6c997f965ed4">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNi01LTEtMS0w_355d8c82-70a7-439a-91e2-b91386bc41d9">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNi03LTEtMS0w_a3f8dab6-4458-401a-bb43-eaf26a6cd8de">48,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia49112dadce14be6836937c1a8779dad_52"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNTI1Nw_8f040513-0278-4632-a0c7-342b812b6da5" continuedAt="i15282c5a790d45a3a33396718c039046" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i15282c5a790d45a3a33396718c039046" continuedAt="i0dd301e0ab2c48bca1911f868e75a07f"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MidCap Credit Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2020, the Company entered into a Credit and Security Agreement, as amended on October 21, 2020, (the &#8220;MidCap Credit Agreement&#8221;), with MidCap Financial Trust (&#8220;MidCap&#8221;), as agent, and the lenders party thereto from time to time.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement provides for a secured term loan facility in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i645a0991058845f0b7026139817fe54a_I20200925" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMzk0_7a905ec5-ab66-47fb-ba98-72c93123d27a">25,000</ix:nonFraction> (the &#8220;MidCap Credit Facility&#8221;). The Company borrowed the first advance of $<ix:nonFraction unitRef="usd" contextRef="i41901b1bd0c34219aebdd24b5355e642_D20200925-20200925" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNDcx_7d31e76f-b4da-477d-8851-743a800155e8">17,500</ix:nonFraction> (&#8220;Tranche 1&#8221;) on September 25, 2020 (the &#8220;Closing Date&#8221;). Under the terms of the MidCap Credit Agreement, the second advance of $<ix:nonFraction unitRef="usd" contextRef="i436ecc2736cd40ac821c16bdf401d6bc_I20210401" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNjAy_7c475db9-8688-4218-aa03-c795f31c4fc7">7,500</ix:nonFraction> (&#8220;Tranche 2&#8221;) is available to the Company from April 1, 2021 to September 30, 2021, subject to the Company&#8217;s satisfaction of certain conditions described in the MidCap Credit Agreement. The Company believes the conditions to access the available Tranche 2 amount are satisfied as of June 30, 2021. The proceeds from the MidCap Credit Facility are expected to be used for working capital and general corporate purposes.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tranche 1, and if borrowed Tranche 2, each bear interest at a floating rate equal to <ix:nonFraction unitRef="number" contextRef="i645a0991058845f0b7026139817fe54a_I20200925" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTExNQ_3db61533-8f6a-45f7-a7b3-f1ad7f939a74">6.25</ix:nonFraction>% per annum, plus the greater of (i) <ix:nonFraction unitRef="number" contextRef="i7d3967c9df24458ca2996a7076c5be12_D20200925-20200925" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTE1Mw_6bd8507a-83ac-42d1-8980-c13deef7ddea">1.50</ix:nonFraction>% or (ii) one-month LIBOR. Interest on each loan advance is due and payable monthly in arrears. Principal on each loan advance is payable in <ix:nonFraction unitRef="installmentpayment" contextRef="ia063169c06cb4eb1b3257cbed4a76a5b_I20221001" decimals="INF" name="xcur:DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTI5NQ_62ab8e5b-ee3a-45eb-8635-db461e01f4de">36</ix:nonFraction> equal monthly installments beginning October 1, 2022 until paid in full on October 1, 2025 (the &#8220;Maturity Date&#8221;). Prepayments of the loans under the MidCap Credit Agreement, in whole or in part, will be subject to early termination fees in an amount equal to <ix:nonFraction unitRef="number" contextRef="iad1abf0184e64b35a21316ccc6ae8ef7_I20210630" decimals="INF" name="xcur:DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTU1Nw_63e2704a-7ea5-4b03-b0d7-5611113e71ab">3.0</ix:nonFraction>% of principal prepaid if prepayment occurs on or prior to the first anniversary of the Closing Date and <ix:nonFraction unitRef="number" contextRef="if9d9075e5dfe4e329a0d45099cfb1c9d_I20210630" decimals="INF" name="xcur:DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTY2Mw_4a5a8856-e88a-420b-9687-ab61661da30d">1.0</ix:nonFraction>% of principal prepaid if prepayment occurs after the first anniversary of the Closing Date and prior to the maturity date.  In connection with execution of the Midcap Credit Agreement, the Company paid MidCap a $<ix:nonFraction unitRef="usd" contextRef="i925aaaddcacc4778b5d8b7f62145a333_D20200925-20200925" decimals="-3" name="us-gaap:LoanProcessingFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTg3Ng_cd849445-3189-42cf-86b6-894cd1fa2ea2">125</ix:nonFraction> origination fee.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Maturity Date or on any earlier date on which all amounts advanced to the Company become due and payable in full, or are otherwise paid in full, the Company is required to pay an exit fee equal to <ix:nonFraction unitRef="number" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" name="xcur:DebtInstrumentExitFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMjEwMQ_0d52d5e2-7db9-429e-8832-cddb38b393e4">3.75</ix:nonFraction>% of the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i0dd301e0ab2c48bca1911f868e75a07f" continuedAt="i09a019411b2c4696a7b7a82d0219acca"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">principal amount of all loans advanced to the Company under the MidCap Credit Agreement. Upon the advance of Tranche 1, the Company accrued $<ix:nonFraction unitRef="usd" contextRef="i300147310fb342fa8729d20a235e6672_I20200925" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMjI1MQ_2898bc7c-212e-4f94-934f-f525d923f48c">656</ix:nonFraction> for the related exit fee.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the MidCap Credit Agreement are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge). Additionally, the Company&#8217;s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the MidCap Credit Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement contains customary affirmative covenants and customary negative covenants limiting the Company&#8217;s ability and the ability of the Company&#8217;s subsidiaries, if any, to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, delisting of the Company&#8217;s common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, the agent and the lenders may declare all or a portion of the Company&#8217;s outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the agreement. During the existence of an event of default, interest on the obligations could be increased by <ix:nonFraction unitRef="number" contextRef="i5d311891d17c4c9d82be715743cfa91f_D20210101-20210630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMzc2MQ_f5a3aafd-2fcb-4da3-96a3-994e2eccc321">2.0</ix:nonFraction>%.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total proceeds, net of fees and issuance costs, borrowed under Tranche 1 were $<ix:nonFraction unitRef="usd" contextRef="i41901b1bd0c34219aebdd24b5355e642_D20200925-20200925" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMzg0Mw_62e7af6b-248c-41ef-bed0-047db4e52a78">16,512</ix:nonFraction>.  Fees and issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i300147310fb342fa8729d20a235e6672_I20200925" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMzg3NQ_ab6b9942-c4c6-4db0-8187-f0b4b27cd53b">332</ix:nonFraction>, as well as fees of $<ix:nonFraction unitRef="usd" contextRef="i300147310fb342fa8729d20a235e6672_I20200925" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMzg5OA_2898bc7c-212e-4f94-934f-f525d923f48c">656</ix:nonFraction> that are payable to MidCap at maturity of Tranche 1, are recorded as a reduction to the carrying amount of long-term debt on the Company&#8217;s balance sheet and will be amortized to interest expense through the maturity date of October 1, 2025 using the effective interest method. Fees and issuance costs of $<ix:nonFraction unitRef="usd" contextRef="iecb1d260e2dd441b95189e9938852f30_I20200925" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNDIwNQ_40d2f1b8-3904-4de3-a2e6-f907231260a5">73</ix:nonFraction> attributed to the amount available to be borrowed under Tranche 2 were paid and recorded as deferred financing costs (other assets) and will be (i) recorded as a reduction in the carrying amount of long-term debt in future periods if amounts are borrowed under Tranche 2 or (ii) will be amortized and recorded to interest expense if amounts are not borrowed under Tranche 2. For the three and six months ended June 30, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="iead4e91610bb417ba4c9ce8e04fe7b87_D20210401-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTA5OTUxMTYzMzc1OA_ed5b57ee-1ff1-49d8-a424-9c74e9e78d89">37</ix:nonFraction> as interest expense and the remaining balance of the deferred financing costs is $<ix:nonFraction unitRef="usd" contextRef="if20db32734cd4856a7b5ebfc55b07f6e_I20210630" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTA5OTUxMTYzMzc1Mw_c41c3ffe-ea75-45e9-b63b-634a5dd48621">36</ix:nonFraction> as of June 30, 2021.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the aggregate carrying value of the Company&#8217;s long-term debt is $<ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNDk2NQ_258d639d-db23-4a71-a6a0-a4d7bfe7855b">16,730</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNTI1OA_bb901faf-1987-4b0d-bdf2-37a2c99606bc" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the principal maturities of the Company&#8217;s long-term debt were as follows:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:76.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining six months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfMS0yLTEtMS0w_04b651db-4257-4404-b909-ad8f6cfa8667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfMi0yLTEtMS0w_109c7fc0-474f-4324-9587-5bbfd7f516bb">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfMy0yLTEtMS0w_403a61f3-75dc-4bda-bdc6-8425b17f9fc8">5,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfNC0yLTEtMS0w_ecf4e4e1-8647-4ba4-945c-ef7d186a14f7">5,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfNS0yLTEtMS0w_f93d6b8d-e88a-4d3c-8e63-ce07fd9144ce">4,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal balance outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfNi0yLTEtMS0w_5b643af1-ab0a-47bc-abd4-9c90777f397e">17,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less: unamortized discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfNy0yLTEtMS0w_59e758bc-a556-47e6-b198-6085364db1ea">770</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfOC0yLTEtMS0w_980ff173-645a-45ed-b0fa-f01e03c94310">16,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfOS0yLTEtMS0w_047bf8c5-a2c0-46e5-b57b-9d13bea9c024">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfMTAtMi0xLTEtMA_64d45799-a6f5-4a62-8503-ab44fae2744e">16,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid interest on the MidCap Credit Agreement of $<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNTExNQ_6aac3bc0-4d84-4e41-a125-00a15c251feb">347</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMjc0ODc3OTA3NDczNA_eccdda8f-94f0-4232-82d8-2f7449828d35">686</ix:nonFraction> during the three and six months ended June 30, 2021, respectively. The Company paid interest on the Hercules Loan Agreement (as discussed below) of $<ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMjc0ODc3OTA3NDc1Nw_350996fb-8dd8-4fcc-81b9-5a65502b9bb6">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMjc0ODc3OTA3NDc1MQ_6bf9b4ff-1c7b-4045-a459-32d81c281460">142</ix:nonFraction> during the three and six months ended June 30, 2020, respectively.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i09a019411b2c4696a7b7a82d0219acca"><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hercules Loan Agreement</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 2, 2020, pursuant to the terms of the loan agreement with Hercules Technology Growth Capital (&#8220;Hercules&#8221;) and subsequent amendments thereto  (the &#8220;Hercules Loan Agreement&#8221;), the Company repaid all remaining outstanding obligations under the Hercules Loan Agreement as of the maturity date, including the outstanding principal balance of $<ix:nonFraction unitRef="usd" contextRef="ide2ab8bf32e5471fb89bc743cfb84ebb_D20200302-20200302" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNjA0NzMxMzk1OTUzNw_8b010dab-12d6-4bce-8f42-d7163f81b691">4,999</ix:nonFraction> and the end of term fee of $<ix:nonFraction unitRef="usd" contextRef="ide2ab8bf32e5471fb89bc743cfb84ebb_D20200302-20200302" decimals="-3" name="xcur:PaymentsForDebtEndTermFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNjA0NzMxMzk1OTU2OA_c4c1ef0c-95b8-4ced-a085-d10a325a7d6d">100</ix:nonFraction>.</span></div></ix:continuation><div id="ia49112dadce14be6836937c1a8779dad_55"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfNDU1Mg_ddc55fcd-1f4d-4752-81bb-7a146987bd8e" continuedAt="i87e66b55857247608416ab93a5a154f8" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i87e66b55857247608416ab93a5a154f8" continuedAt="i051af1fe03a246bea06459c0bc4b1ca1"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease arrangements at June 30, 2021 consist of (i) a lease for office and laboratory space at its headquarters in Chicago, Illinois that commenced in July 2020 (the &#8220;Chicago Lease&#8221;), (ii) a lease for office space at a multi-tenant facility in Cambridge, MA that commenced in March 2019 and is cancelable at any time (the &#8220;Cambridge Lease&#8221;), and (iii) leases for office equipment (the &#8220;Office Equipment Leases&#8221;). Each of these leases are classified as operating leases.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the Cambridge Lease, the Company determined that this lease represented a short-term lease with an initial term of less than twelve months and, as such, the Cambridge Lease is not recorded on the balance sheet and related lease costs are recognized in the statement of operations as they are incurred. The Company has also elected to not record the Office Equipment Leases on the balance sheet since related payment amounts and lease costs are insignificant. Lease costs for the Office Equipment Leases are recognized in the statement of operations on a straight-line basis over the lease term.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease arrangement for office and laboratory space at its former headquarters in Skokie, Illinois ended in February 2021 in accordance with the terms of that lease arrangement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chicago Lease</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately <ix:nonFraction unitRef="sqft" contextRef="ic8159ef26edf4cfab622048f57adfe21_D20200701-20200701" decimals="-3" format="ixt-sec:numwordsen" name="xcur:LesseeOperatingLeaseLeaseArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMTM1NA_41055250-3a29-4406-8d4f-bbf97416284f">thirty thousand</ix:nonFraction> square feet of office and laboratory space in Chicago, Illinois (the &#8220;Chicago Lease&#8221;). The original term (the &#8220;Original Term&#8221;) of the Chicago Lease is <ix:nonNumeric contextRef="i54669006cc704c238aa705208cb442e6_I20200701" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMTUwOA_a422e500-9f4f-4230-8ccb-6337e631a3e3">10</ix:nonNumeric> years, commencing on July 1, 2020 (the &#8220;Commencement Date&#8221;), which is the date the premises were ready for occupancy under the terms of the Chicago Lease.  The Company has options to extend the term of the Chicago Lease for&#160;<ix:nonFraction unitRef="extensionperiod" contextRef="ic8159ef26edf4cfab622048f57adfe21_D20200701-20200701" decimals="INF" format="ixt-sec:numwordsen" name="xcur:LesseeOperatingLeaseNumberOfExtensions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMTcyOQ_d3398332-64c8-44c6-83fb-b6a091417a90">two</ix:nonFraction>&#160;additional successive periods of <ix:nonNumeric contextRef="i54669006cc704c238aa705208cb442e6_I20200701" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMTc2NQ_71d484cf-ade0-465b-9d33-95d48c9b6e69">five years</ix:nonNumeric> each (the &#8220;Extension Periods&#8221;) at the then prevailing effective market rental rate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial annual base rent during the Original Term is approximately $<ix:nonFraction unitRef="usd" contextRef="i54669006cc704c238aa705208cb442e6_I20200701" decimals="-3" format="ixt:numdotdecimal" name="xcur:LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMTkyMw_4d666c74-e6e4-4c8e-a56a-f5d2a3332fb0">1,113</ix:nonFraction> for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of <ix:nonFraction unitRef="number" contextRef="i54669006cc704c238aa705208cb442e6_I20200701" decimals="2" name="xcur:LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMjEwMQ_94c6fb01-a12c-4e9a-93e7-5e61a0f45118">3</ix:nonFraction>%, for an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i54669006cc704c238aa705208cb442e6_I20200701" decimals="-3" format="ixt:numdotdecimal" name="xcur:LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMjEzMg_2cc500a1-c687-4b3e-8820-6b2286879a2a">12,761</ix:nonFraction> over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term.  During the first 12-month period of the Original Term, the base rent and the Company's proportionate share of operating expenses and taxes are subject to certain abatements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Chicago Lease, the Company will maintain a letter of credit for the benefit of the landlord in an initial amount of $<ix:nonFraction unitRef="usd" contextRef="i54669006cc704c238aa705208cb442e6_I20200701" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMjYwNA_ae68de9b-699e-4f11-b90f-aee9d7829db0">1,200</ix:nonFraction>, which amount is subject to reduction over time.  Upon execution of the Chicago Lease, the Company paid to the landlord the first installment of base rent and the estimated monthly amount of its pro rata share of taxes and its pro rata share of operating expenses in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="ic8159ef26edf4cfab622048f57adfe21_D20200701-20200701" decimals="-3" name="xcur:LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMjg5OA_280e02c7-b7f0-491d-a47a-62a90261746a">87</ix:nonFraction> which amount had been adjusted for the abatement as set forth in the lease agreement. The Company also paid the landlord a net amount of $<ix:nonFraction unitRef="usd" contextRef="ic8159ef26edf4cfab622048f57adfe21_D20200701-20200701" decimals="-3" name="us-gaap:PaymentsForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMzAzOA_8a614518-7b43-4c39-80e1-42a9255b449d">697</ix:nonFraction> toward tenant improvements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement for the Chicago Lease, the Company is required to maintain a&#160;standby letter of credit during the term of the lease, currently in the amount of $<ix:nonFraction unitRef="usd" contextRef="i54669006cc704c238aa705208cb442e6_I20200701" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMzIzNw_03f1a1d7-9052-4054-a9e3-d235f148eb78">1,200</ix:nonFraction> and subject to reduction over time, which is secured by a restricted certificate of deposit account and presented within other noncurrent assets on the Company&#8217;s unaudited condensed consolidated balance sheet at June&#160;30, 2021.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a right of use asset of $<ix:nonFraction unitRef="usd" contextRef="i54669006cc704c238aa705208cb442e6_I20200701" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMzUwNA_bdf1d694-2da0-47a7-ad8a-4e6f9199b540">8,931</ix:nonFraction> and a lease liability of $<ix:nonFraction unitRef="usd" contextRef="i54669006cc704c238aa705208cb442e6_I20200701" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMzUzMg_7981e93b-4d91-49bb-b777-2e9064d1babd">8,147</ix:nonFraction> on the Commencement Date. Because the rate implicit in the Chicago Lease is not readily determinable, the Company used its incremental </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i051af1fe03a246bea06459c0bc4b1ca1"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrowing rate of <ix:nonFraction unitRef="number" contextRef="i54669006cc704c238aa705208cb442e6_I20200701" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMzY4OA_e90f0f42-7317-4228-ad73-6aaa90ec727e">8.3</ix:nonFraction>% on the Commencement Date to determine the present value of the lease payments over the Original Term. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. As of June&#160;30, 2021, the Company determined it is not reasonably certain that the renewal option would be exercised.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="xcur:ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfNDU1OQ_f133d460-980d-4563-ba83-e5670d1aa76c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the Company&#8217;s operating lease asset and related operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:76.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjQ2YjYzMTJhMDc4MTQ1NGU5ZGNiNjlkMTI3MGZmOTQ2L3RhYmxlcmFuZ2U6NDZiNjMxMmEwNzgxNDU0ZTlkY2I2OWQxMjcwZmY5NDZfMS0yLTEtMS0w_a5c56e5f-1084-45e1-bace-24018587339b">9.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjQ2YjYzMTJhMDc4MTQ1NGU5ZGNiNjlkMTI3MGZmOTQ2L3RhYmxlcmFuZ2U6NDZiNjMxMmEwNzgxNDU0ZTlkY2I2OWQxMjcwZmY5NDZfMi0yLTEtMS0w_f9f27bd7-d899-4abe-9970-91a7511fbff2">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfNDU1Ng_10ac986e-5d90-4d7e-a198-c19f2c5c0804" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes lease costs in the Company&#8217;s unaudited condensed consolidated statement of operations:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMi0xLTEtMS0w_460e89cd-6dc4-4b31-af5c-9503ee2b678a">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMi0zLTEtMS0w_9c8781dc-28e7-4c49-8d3c-7c0323df552a">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMi01LTEtMS0w_ad7c0c81-f93e-4ff9-9877-35959347de61">653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMi03LTEtMS0w_acb9adc3-6e0c-4c04-bdbc-9cfcb5027ed2">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMy0xLTEtMS0w_95166975-30e8-47dd-9459-47c44267c8f5">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMy0zLTEtMS0w_e2d44d27-59d5-425d-b0d1-ed3712c3457f">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMy01LTEtMS0w_66abc61e-a58a-4092-81ba-a021fe5a5b43">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMy03LTEtMS0w_3af55928-1038-49ef-9f4c-316da90282e4">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNC0xLTEtMS0w_9f349f7a-5b19-4f5d-b549-f02d5b1a94c5">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNC0zLTEtMS0w_e774a3ac-7958-49d7-84b8-f28c0b99863d">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNC01LTEtMS0w_5afec312-cfaf-47d8-b861-610096de5e2c">572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNC03LTEtMS0w_3ebaaf49-2467-4ea0-b915-9e5f8fd2f94d">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNS0xLTEtMS0w_7a207632-ab4f-48cb-87ce-f46a24328efd">552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNS0zLTEtMS0w_38e4d2d4-fffa-4774-9624-5c5a6bead4d0">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNS01LTEtMS0w_b96e1046-c059-44c0-b4e0-263a0bd31bcb">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNS03LTEtMS0w_204f9a5b-8ea2-4c52-ba13-272217c697b1">596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made cash payments for operating leases of $<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfNDQxMg_9d8f72bc-418e-4935-a2fc-18e3818d9cff">1,106</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfNDQxOQ_db14debe-aa77-40db-a2f7-55e85a82bb35">1,227</ix:nonFraction> during the six months ended June 30, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfNDU1MQ_f9ffbd50-106b-44de-b1ac-8a20bca67ca2" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the Company&#8217;s lease liability as of June&#160;30, 2021 were as follows:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:76.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining six months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfMS0yLTEtMS0w_5e7805da-39a4-4aa1-a593-3a057dee2dd0">478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfMi0yLTEtMS0w_0a21f6f6-e5c6-41f8-bdaf-b9cf009ed570">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfMy0yLTEtMS0w_a5f48a53-f292-4b39-8a44-deafcd8b21ac">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfNC0yLTEtMS0w_bf47802a-ec47-4bbb-bf36-e25ae65aa5f9">1,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfNS0yLTEtMS0w_bb1d4a08-c785-4977-879f-ec58887e7994">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfNi0yLTEtMS0w_10f91318-075f-4bd6-9fb9-e64e88c17707">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfNy0yLTEtMS0w_732e547c-f6bf-4dce-b651-720358319c60">4,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfOC0yLTEtMS0w_12fd2854-0857-49de-bad2-a061270fd342">11,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfOS0yLTEtMS0w_7c48f256-b312-42f6-b0aa-982f17754c42">3,437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfMTAtMi0xLTEtMA_1328b8d1-0af4-41a3-b87e-6c2ccae56916">8,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfMTItMi0xLTEtMA_bf2a8010-aec9-497d-bf71-d5f9fef2c506">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfMTMtMi0xLTEtMA_f47e241c-e521-45f1-a061-5e429f657781">7,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfMTQtMi0xLTEtMA_9cbcec0f-cf58-4bbb-beb0-5d88f7e8e1b4">8,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_58"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjIyMQ_9733e468-c267-4d17-a8cb-8eeb2433f90c" continuedAt="ic3e3a01a04754a3e9d1a729f51baf7d2" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="ic3e3a01a04754a3e9d1a729f51baf7d2" continuedAt="ic310baf041ed41fcb2579c8c43956eba"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfNzg_b3371a5f-16d9-4de8-a7d8-643547dbed9f"><ix:nonFraction unitRef="shares" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfNzg_bde8fc37-1fc9-4abd-886a-b0250fa60247">10,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTE4_09e6849b-ad13-4146-8071-56ada0c2c11d"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTE4_27ae4e9a-13a4-481b-b1c6-a12df02dcec4">0.0001</ix:nonFraction></ix:nonFraction> authorized and <ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTM2_6a4292ae-8931-41ef-95c7-a9a03cb99a14"><ix:nonFraction unitRef="shares" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTM2_6d7c7d38-4a77-423a-986d-f7a7457da5c3"><ix:nonFraction unitRef="shares" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTM2_cbcac11a-1533-43d9-ba28-cb837b59ddc9"><ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTM2_cd707a5b-bc56-4de6-897f-7a14f12dc6b3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020, the Company had authorized <ix:nonFraction unitRef="shares" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjI3_bf9d015d-bb8e-41d7-9e86-367112e21eae"><ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjI3_c2d2d2f1-c58f-461c-b98a-77c2199fe3f9">200,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjY0_09098f34-096e-4211-9f64-bcdb3c7a221c"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjY0_41536ebb-126c-4c3e-ad01-48cd0854d8a7">0.0001</ix:nonFraction></ix:nonFraction>.  As of June&#160;30, 2021 and December&#160;31, 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMzAy_8088e5a6-b687-48e7-87e4-4c73793759f2"><ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMzAy_cfdac1c5-a03f-4d2f-80b7-4282668f310c">88,096,694</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjE5OTAyMzI1Nzc3OA_00720d85-5264-437e-8063-6a04d2340326"><ix:nonFraction unitRef="shares" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjE5OTAyMzI1Nzc3OA_11448e58-1a10-4eeb-b81c-237918b721ff">87,651,352</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of shares of the Company&#8217;s common stock are entitled to <ix:nonFraction unitRef="votepershare" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="xcur:CommonStockVotingRightsForEachShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfNDM1_83d49486-3018-4fff-9c70-75e83f5c6287">one</ix:nonFraction> vote per share on all matters to be voted upon by the Company&#8217;s stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&#8217;s common stock are entitled to receive ratably any dividends that may be declared from time to time by the Board out of funds legally available for that purpose. In the event of the Company&#8217;s liquidation, dissolution or winding up, the holders of shares of the Company&#8217;s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company&#8217;s common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company&#8217;s common stock. The outstanding shares of the Company&#8217;s common stock are fully paid and&#160;non-assessable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of June&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i6ff17028d7f742fc86b80a80958beb1c_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjE5OTAyMzI1Nzg0Mw_55b9f407-7da0-40f3-990f-a03fe699245b">no</ix:nonFraction> warrants were outstanding. As of December 31, 2020, warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i7c221311f05b4f77be016eb7ea9c9657_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTQ4Mg_bfd80c4d-b1a0-4baa-b241-733db4965a92">413,320</ix:nonFraction> shares of common stock at a price of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i7c221311f05b4f77be016eb7ea9c9657_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTUyMg_9c9596d1-51e6-469f-89b8-2efd8e2b8805">3.00</ix:nonFraction>&#160;per share were outstanding.  The warrants expired unexercised as follows: <ix:nonFraction unitRef="shares" contextRef="i0645f4970e4a4657940a7c44e95adbf2_I20210327" decimals="INF" format="ixt:numdotdecimal" name="xcur:ClassofWarrantorRightExpired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTU5OQ_58bd4d04-618f-4101-824c-a61d755acc2b">163,174</ix:nonFraction> warrants expired on March 27, 2021, <ix:nonFraction unitRef="shares" contextRef="i1678fc9eed904b0ea7406fdd2c19c39e_I20210428" decimals="INF" format="ixt:numdotdecimal" name="xcur:ClassofWarrantorRightExpired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTYzOA_d5f581e7-6f2e-4888-983b-92f6f87b51e3">132,884</ix:nonFraction> expired on April 28, 2021, and <ix:nonFraction unitRef="shares" contextRef="if012e2aa547c4f42b1c5e1a7b5509669_I20210503" decimals="INF" format="ixt:numdotdecimal" name="xcur:ClassofWarrantorRightExpired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTY3Mg_f54db714-c65d-4878-82a8-71262adc9702">117,262</ix:nonFraction> expired on May 3, 2021.  The warrants were classified as a liability which was remeasured each period at fair value. See Note 12,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for more information on the fair value of the common stock warrant liability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjIyMw_6a2c7519-f43b-4daa-9e59-46848e300cef" continuedAt="i32ec2ea2ded14df9b0cafaa3c0d40b60" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2021:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"></td><td style="width:57.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f09592eb17452db7a906b8878473eb_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfMS0yLTEtMS0w_7693375b-2718-4f08-8784-54a927e12a54">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8e31b3400845b785f4078c29ad60c3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfMS00LTEtMS0w_2a42e341-411d-47b2-9be1-34f4c521e406">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0beb38fa0e984be794221ee6085d5212_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfMi0yLTEtMS0w_5c7615e4-fc95-4ffc-93b5-35b9d5e64f44">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07e140d0339e4a2c9fa363c5cc32a6e4_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfMi00LTEtMS0w_2c5d39c9-c5c3-4619-b9c4-387ad543ae4d">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0beb38fa0e984be794221ee6085d5212_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfMy0yLTEtMS0w_a7f3cb40-5a0c-4eb0-957a-53da823e6fec">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07e140d0339e4a2c9fa363c5cc32a6e4_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfMy00LTEtMS0w_45e9d19b-18ec-4c93-972b-ee66df3f6018">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11febcbb571642db9e1cddde4919a982_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfNC0yLTEtMS0w_62fe7df5-9935-41bc-82a9-d562e4d11be4">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d493db55bc244c1818df293641b339b_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfNC00LTEtMS0w_7aedebda-555e-4a48-8428-75901f976471">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99e8cbf713bb404290e76a87777df0be_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfNS0yLTEtMS0w_fd1f0956-7be3-4503-88aa-71b48abba274">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfNS00LTEtMS0w_467f2a6a-3eff-4302-aa9d-893d7584aa49">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99e8cbf713bb404290e76a87777df0be_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfNy0yLTEtMS0w_54f081c9-d84a-4a4d-b029-29cbb84ffb58">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfNy00LTEtMS0w_8e564a4a-410e-4cee-a729-3f3c33837a4c">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19701c73d57b47c1b8e1d54bc15798ff_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfOC0yLTEtMS0w_53d63ac3-536c-43e9-8c81-6850a6d74f72">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dde94d491614ea4bca5ec1bcd8d14b0_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfOC00LTEtMS0w_05557f1a-f9d9-40a4-b653-762bd868ae55">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ic310baf041ed41fcb2579c8c43956eba"><ix:continuation id="i32ec2ea2ded14df9b0cafaa3c0d40b60"><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"></td><td style="width:57.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i647d7754868047e08ca0cedc232ce793_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfMS0yLTEtMS0w_9bc0fc1d-7d98-4eb2-9ed0-d1c348acfa31">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f137df29abc4c41a4815885b2a3d6b7_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfMS00LTEtMS0w_32955e9c-a6bc-482f-9d00-3aa147f13e44">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87f672fddff47ec9c64d6d8f41b94f9_D20200101-20200331" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfMi0yLTEtMS0w_ef2c5124-9f0b-4fc4-9515-2ef1a9a7975b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfMi00LTEtMS0w_b4b703a6-db66-44eb-adcc-8d991ec55dd3">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87f672fddff47ec9c64d6d8f41b94f9_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfMy0yLTEtMS0w_b82386f0-26ba-499b-814f-fdf89104ac98">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfMy00LTEtMS0w_5a601651-66e0-41f1-812a-2bd55694b741">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if36427efb36c41dd9f56f8366f4269ba_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNC0yLTEtMS0w_196b2c7f-3b66-4b28-8b86-9023150435ec">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8cf7cd3ed49446ca5422f8857c95a70_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNC00LTEtMS0w_e86f150f-6c9e-42d2-a60f-d99f7fcd5d95">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bd85f97f1394ba795ddb6a54771a121_D20200401-20200630" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNS0yLTEtMS0w_ebc14571-71a4-4fcc-a428-466802b8ebfc">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNS00LTEtMS0w_d022b78c-1d24-49ba-98ea-e2bca61a857b">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bd85f97f1394ba795ddb6a54771a121_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNi0yLTEtMS0w_34ab6e90-7eb0-4f6b-8045-afefe2bafbb1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNi00LTEtMS0w_6dec6f09-8db5-4322-9aff-d3799d1837ca">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bd85f97f1394ba795ddb6a54771a121_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNy0yLTEtMS0w_e5289747-e50d-4978-9097-e246c779cfdf">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNy00LTEtMS0w_66d1d077-b903-47a6-be74-73bb8d443d26">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2f75424b9847e8a73a5ae083e07f16_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfOC0yLTEtMS0w_7eca0d1c-cf28-43d7-935f-4ea8272811f2">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77029b06c3e4a209202062d9c9b7340_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfOC00LTEtMS0w_2a92859e-a76e-4fcd-9473-20e8b953ce87">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net loss reclassified from accumulated other comprehensive loss during the three months ended June 30, 2020 resulted from sales of available-for-sale securities prior to maturity. The gross realized gains and gross realized losses of these sales were $<ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjE5OTAyMzI1ODI4Mg_b15b6209-70b3-4c27-abba-c38ab64008f8">23</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjE5OTAyMzI1ODI5OA_487f4493-d37c-41a1-802e-377fdd6c0482">6</ix:nonFraction>, respectively, for the three and six months ended June 30, 2020. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $<ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjE5OTAyMzI1ODMwNQ_84ce768c-1bb5-43cb-87a2-143c4be21f2c">9,404</ix:nonFraction>.</span></div></ix:continuation><div id="ia49112dadce14be6836937c1a8779dad_61"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMzEyMQ_a9d2d7fe-1636-46be-b601-a2f5a73aa29e" continuedAt="i6e880a03e5b447cdaede9b4a92ad193d" escape="true">Equity-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i6e880a03e5b447cdaede9b4a92ad193d" continuedAt="i67de7ae54b6c4cccae5e0786152448f2"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards that may be awarded under the 2017 Equity Incentive Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) <ix:nonFraction unitRef="shares" contextRef="id1752c7647ce4804833ba83742c774f7_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMjMy_582c6f50-e91a-4c11-a076-24c7dd686192">4,600,000</ix:nonFraction> shares, (ii) <ix:nonFraction unitRef="number" contextRef="i9193c9218d6942f0a9ab8196225ec04e_I20210630" decimals="2" name="xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMjQ4_1b9dba33-7c4e-4683-8979-47ba219543d6">5</ix:nonFraction>% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board. The Compensation Committee made the determination to increase the share reserve for the 2017 Equity Incentive Plan by <ix:nonFraction unitRef="shares" contextRef="i3eade0caa9a9429fb165b07368701d49_D20210101-20210101" decimals="INF" format="ixt:numdotdecimal" name="xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfNTc5_a4df7d54-1d8a-4ac4-82fb-b1488b4796c6">4,382,567</ix:nonFraction> shares, effective January 1, 2021. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the aggregate number of equity awards available for grant under the 2017 Equity Incentive Plan was <ix:nonFraction unitRef="shares" contextRef="i9193c9218d6942f0a9ab8196225ec04e_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfNzMz_7316af51-f784-44af-ad5f-5130fcee7a51">2,831,213</ix:nonFraction>.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Grant</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company granted stock options to purchase up to <ix:nonFraction unitRef="shares" contextRef="id06b85497bc74266852a0e2b7f0b8df0_D20210501-20210531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0NDcwMg_7004e28c-6589-4438-987f-c8f0a169b814">600,000</ix:nonFraction> shares of common stock as a material inducement to Brian C. Bock, the Company&#8217;s Chief Financial Officer, to enter into employment with the Company (the &#8220;Inducement Grant&#8221;).  The Inducement Grant, which was made pursuant to a stand-alone nonstatutory stock option agreement (the &#8220;Inducement Award Agreement&#8221;), was approved by the Compensation Committee of the Board, was awarded in accordance with Nasdaq Listing Rule 5635(c)(4) and outside of the Company&#8217;s 2017 Equity Incentive Plan and is subject to the terms and conditions of the Inducement Award Agreement.  As such, any shares underlying the Inducement Grant are not, upon forfeiture, cancellation or expiration, returned to a pool of shares reserved for future issuance.  As of June 30, 2021, stock options to purchase up to <ix:nonFraction unitRef="shares" contextRef="if4945a8246284e3fba84dfd77ee17303_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0NDcxMQ_429bb0c9-5184-4240-92e6-738ab9daa86d">600,000</ix:nonFraction> shares of common stock remained outstanding under the Inducement Grant.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i67de7ae54b6c4cccae5e0786152448f2" continuedAt="i65c5fe702b1d4118b099c56f3d11bdf5"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Employee Stock Purchase Plan (the "ESPP") was adopted by the Board in September 2017 and approved by the Company's stockholders in September 2017. Through the ESPP, eligible employees may authorize payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="ia1a36e8396524c158a00a6f20220e59b_I20170930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDYzNw_d904e614-4940-432a-90d1-a975ff2f6727">15</ix:nonFraction>% of their compensation to purchase common stock. The maximum number of shares that an employee may purchase on any exercise date in an offer period will be the smaller of (i) <ix:nonFraction unitRef="shares" contextRef="i7d5200a99a654e799a285ca1f6cfe325_D20170901-20170930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDY0Mg_e6f74473-13e5-47f6-a1b4-ce22aa4475dd">7,500</ix:nonFraction> shares or (ii) such number of shares as has a fair market value (determined as of the offering date for such offer period) equal to $<ix:nonFraction unitRef="usd" contextRef="i7d5200a99a654e799a285ca1f6cfe325_D20170901-20170930" decimals="INF" format="ixt:numdotdecimal" name="xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDY0OQ_2a21dec1-c66b-4536-a17b-afef67ca473c">25,000</ix:nonFraction> within one calendar year minus the fair market value of any other shares of common stock that are attributed to such calendar year. The purchase price per share at each purchase date is equal to <ix:nonFraction unitRef="number" contextRef="i7d5200a99a654e799a285ca1f6cfe325_D20170901-20170930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDY1OA_02f75def-729b-44c4-a6f8-0dd0546cf519">85</ix:nonFraction>% of the lower of (i) the closing market price per share of Exicure common stock on the employee&#8217;s offering date or (ii) the closing market price per share of Exicure common stock on the exercise date. Each offering period is approximately <ix:nonNumeric contextRef="i7d5200a99a654e799a285ca1f6cfe325_D20170901-20170930" format="ixt-sec:durwordsen" name="xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDY3NA_528fcb4d-9254-4f93-984e-5e9728881c9c">six-months</ix:nonNumeric> in duration and the first offering period began on November 16, 2020 and ended on May 14, 2021.  In connection with the end of the first offering period on May 14, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="ib2b6abdfb80e4807aa0282b97634d068_D20210514-20210514" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0Mjc3Mg_841aadb5-1775-4618-9d88-8b6aba570b13">103,096</ix:nonFraction> shares of common stock that were purchased under the ESPP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2018 and each January 1 thereafter through January 1, 2027, by the least of (i) <ix:nonFraction unitRef="shares" contextRef="ia1a36e8396524c158a00a6f20220e59b_I20170930" decimals="INF" format="ixt:numdotdecimal" name="xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDY3Ng_d233d44d-d8ae-4246-bf75-dc8c222fd799">300,000</ix:nonFraction> shares; (ii) <ix:nonFraction unitRef="number" contextRef="i7d5200a99a654e799a285ca1f6cfe325_D20170901-20170930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDY4NQ_622f0f21-7b3a-40c7-8bf0-3a9dfabc1dd5">0.3</ix:nonFraction>% of the outstanding shares of common stock on the last day of the immediately preceding calendar year; or (iii) a lesser number of shares determined by the Board. On January 1, 2021 and 2020, the number of shares of common stock available for issuance under the ESPP increased by <ix:nonFraction unitRef="shares" contextRef="ia10057774add4610b1347d547800695d_D20210101-20210101" decimals="INF" format="ixt:numdotdecimal" name="xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDY5MQ_41b9377b-570c-4b23-9f7e-8f77392a0a5f">258,207</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="ib0f12b5a69194c1f8a504c77fc7c66d5_D20200101-20200101" decimals="INF" format="ixt:numdotdecimal" name="xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDcwMg_2a44b1c6-19e4-4bc5-9e1a-30a21462dd79">262,954</ix:nonFraction> shares, respectively. As of June 30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i30c821c806ac422d901e22a3a99f78f2_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDcxMQ_197433cc-18cc-43ef-b954-b2cdfbdebd6b">1,100,791</ix:nonFraction> shares available for issuance under the ESPP.</span></div><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMzExNA_4505f3ae-3ddb-419f-9d9e-900a00da5913" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-based compensation expense is classified in the statements of operations as follows:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb72bd4b57dc4ad591c2fe0e40fe9b13_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMi0xLTEtMS0w_2f63c566-0b6e-4782-b640-cd233aaf202f">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8428d3250e664f26b96cd9f611b3d8a4_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMi0zLTEtMS0w_f5f2cdb8-a8f1-4306-89f4-129ea0e5415a">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e5df1d06e74bd185e7eb2efc4d0d60_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMi01LTEtMS0w_d339225b-0181-4c1d-8681-8f507a90df66">618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e4b305e726408ea8e78580cff53469_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMi03LTEtMS0w_332880cf-1399-4a83-b23b-98ec26778241">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb6d556e4e7c410abd113137b073abea_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMy0xLTEtMS0w_dc065304-7c53-45d3-9084-608792f963d4">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0140ea063a1a461d9b7efc35c2a7db94_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMy0zLTEtMS0w_7dd48e27-6302-4d0b-8173-c93424067afd">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97b67429c7447b8beb926618dc44e33_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMy01LTEtMS0w_52a4a9cc-4bd8-4d45-b168-fb8ce615245b">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bbc9b612e4f400ea42e7192d40fe224_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMy03LTEtMS0w_0306bab2-746d-4b20-bf0a-6657c154b4a8">625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfNC0xLTEtMS0w_56f43608-c2f6-4328-9b8f-f3b7998ec6f6">764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfNC0zLTEtMS0w_bc91ba2e-36ee-41d2-a7cf-d382d1c29b00">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfNC01LTEtMS0w_20514040-0b66-41d5-af9f-df2c4b384738">1,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfNC03LTEtMS0w_af7ed6f4-5039-4857-a491-66478e172388">985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized equity-based compensation expense at June&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfODg4_216c035d-2cd1-4522-9881-07f0dd41d98f">8,350</ix:nonFraction>, which is expected to be amortized over a weighted-average period of <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfOTYw_c93d9ce8-986d-48e3-b499-da7670428921">3.2</ix:nonNumeric> years. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMzEyMw_d874e100-01cb-424c-b2de-6822b8867fea" continuedAt="i6c3910fec4c5445f9ae124c105cdfa30" escape="true">In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i65c5fe702b1d4118b099c56f3d11bdf5" continuedAt="i9bdf19d736b24610b528f3cd58439306"><div style="margin-top:5pt;text-align:center;text-indent:18pt"><ix:continuation id="i6c3910fec4c5445f9ae124c105cdfa30" continuedAt="iba0ef78bac694d8e90614dc4079b43f2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i05ee07b9e1c84d11b1a2bce3808048f7_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMi0xLTEtMS0wL3RleHRyZWdpb246OTM4OGQ4MzczNDQ5NDg1Zjk4NzBkOGU1YjU4OTQwMTBfNA_82187e25-9b69-4a4e-9d66-8a545db6772d">5.0</ix:nonNumeric> to <ix:nonNumeric contextRef="ibb18755d773345cab01251ee868b67a2_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMi0xLTEtMS0wL3RleHRyZWdpb246OTM4OGQ4MzczNDQ5NDg1Zjk4NzBkOGU1YjU4OTQwMTBfMTA_4677758e-7af9-42e8-b167-9b05f86951ce">6.1</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i80b5550a693944ca96e17fa1695bde69_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMi0zLTEtMS0wL3RleHRyZWdpb246YzEzMjllMmNkNGNhNGE5NWFlMTEwMzAyY2RkZGFlNGRfNA_588dedc2-b5c6-49c7-a5a3-46c749de1c88">5.2</ix:nonNumeric> to <ix:nonNumeric contextRef="i840e5fd58f7b4defa073941d94fdaf68_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMi0zLTEtMS0wL3RleHRyZWdpb246YzEzMjllMmNkNGNhNGE5NWFlMTEwMzAyY2RkZGFlNGRfMTA_bd439953-5e43-4b23-8b66-a0c619dfca2e">6.1</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMy0xLTEtMS0wL3RleHRyZWdpb246YTE5MTJmY2FlM2U5NDY4M2FkNDUyM2M3ZjNmYzM0YmNfNA_1f460247-085d-4bfe-bd41-6c5e9aa74063">0.36</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMy0xLTEtMS0wL3RleHRyZWdpb246YTE5MTJmY2FlM2U5NDY4M2FkNDUyM2M3ZjNmYzM0YmNfMTA_2b9c845f-0317-4eb2-98d3-31b5bc43e7f6">1.12</ix:nonFraction>%; weighted avg. <ix:nonFraction unitRef="number" contextRef="i2062e93925194437bbd0a3795bd3f03a_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMy0xLTEtMS0wL3RleHRyZWdpb246YTE5MTJmY2FlM2U5NDY4M2FkNDUyM2M3ZjNmYzM0YmNfMjg_09629459-41fd-4073-9c93-af49947fdf54">1.05</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMy0zLTEtMS0wL3RleHRyZWdpb246YmFmMDk4ZjRlZjg3NDA4MDg4N2U0ZDFjMjg3ZDVkODBfNA_973b4960-435b-4f4b-bfcc-6d0b66ba0eb0">0.41</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMy0zLTEtMS0wL3RleHRyZWdpb246YmFmMDk4ZjRlZjg3NDA4MDg4N2U0ZDFjMjg3ZDVkODBfMTA_96df73ef-4636-4861-9c08-db5e4fcee1c7">1.68</ix:nonFraction>%; weighted avg. <ix:nonFraction unitRef="number" contextRef="ibb7aa76093ce43189a28a20fdc93f774_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMy0zLTEtMS0wL3RleHRyZWdpb246YmFmMDk4ZjRlZjg3NDA4MDg4N2U0ZDFjMjg3ZDVkODBfMjg_e43386ec-53fc-4346-92c6-ef98092f794c">0.67</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNC0xLTEtMS0wL3RleHRyZWdpb246OTZjYmRiMzA0NzAxNDE0ODhiYzYyNmExY2E0OTExMzNfNA_b1ff64c7-a591-48c6-a2a2-f399f8e9a07f">81.7</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNC0xLTEtMS0wL3RleHRyZWdpb246OTZjYmRiMzA0NzAxNDE0ODhiYzYyNmExY2E0OTExMzNfMTA_ccb88e2c-acfd-49f8-bc91-92e62f7504c5">83.6</ix:nonFraction>%; weighted avg. <ix:nonFraction unitRef="number" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNC0xLTEtMS0wL3RleHRyZWdpb246OTZjYmRiMzA0NzAxNDE0ODhiYzYyNmExY2E0OTExMzNfMjg_9ef10085-f724-47f9-94f9-a12047b26d3c">82.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNC0zLTEtMS0wL3RleHRyZWdpb246YzYwOTAxYWU0ZWJiNGU2ZGEyNTIyZGViMTk0MjNlN2ZfNA_50091ec0-d665-4c42-97df-9a0cb4a84039">81.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNC0zLTEtMS0wL3RleHRyZWdpb246YzYwOTAxYWU0ZWJiNGU2ZGEyNTIyZGViMTk0MjNlN2ZfMTA_9936c3ea-e200-4f8a-b438-ba60c67a332f">85.8</ix:nonFraction>%; weighted avg. <ix:nonFraction unitRef="number" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNC0zLTEtMS0wL3RleHRyZWdpb246YzYwOTAxYWU0ZWJiNGU2ZGEyNTIyZGViMTk0MjNlN2ZfMjg_7fc2b12f-4520-465f-ac67-e6e9211a139e">83.8</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="2" name="xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNS0xLTEtMS0w_c39cf3ea-2370-4823-a11d-4a638e064683">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="2" name="xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNS0zLTEtMS0w_59566fd5-5558-46ed-80cd-a275e2e52724">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNi0xLTEtMS0w_0946b66e-62e9-4061-9b50-a15952711fae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNi0zLTEtMS0w_8980808d-54f9-47a8-b07a-c7360aae310a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term is based upon the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#8220;simplified method&#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.</span></div><ix:continuation id="iba0ef78bac694d8e90614dc4079b43f2"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the underlying common stock and the exercise price for the common stock options granted during the six months ended June 30, 2021 and 2020 are summarized in the table below:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:55.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Options Granted During Period Ended:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of Underlying Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price of Common Stock Option</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six months ended June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i536ad3a9715049e6b9540b91aeecaf96_I20210630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMS0xLTEtMS0wL3RleHRyZWdpb246MTZlMmU1Y2I0MmE3NDRkZGI0ZThjZDAwZTc2YjI1ZTZfNA_f21dd200-a020-4a0f-9a23-169c0bfe069b">1.54</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i9fac72b464ac47a9b5b8d5a1d1c209c9_I20210630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMS0xLTEtMS0wL3RleHRyZWdpb246MTZlMmU1Y2I0MmE3NDRkZGI0ZThjZDAwZTc2YjI1ZTZfMTA_01161126-f2b1-471d-8e69-9f3f16e794a5">2.57</ix:nonFraction>; weighted avg. $<ix:nonFraction unitRef="usdPerShare" contextRef="i70f3df893ec74c418b087f907936dff7_I20210630" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMS0xLTEtMS0wL3RleHRyZWdpb246MTZlMmU1Y2I0MmE3NDRkZGI0ZThjZDAwZTc2YjI1ZTZfMjk_f5d9c010-08b6-414e-ac7e-8ebfea04b61a">1.88</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i536ad3a9715049e6b9540b91aeecaf96_I20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMS0zLTEtMS0wL3RleHRyZWdpb246NTdiMzVjZjBlMzJmNDRmMDkwMDIwYjc4MmFjYmMzOGVfNA_268e3aa1-332a-47e8-a220-46f0297435a0">1.54</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i9fac72b464ac47a9b5b8d5a1d1c209c9_I20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMS0zLTEtMS0wL3RleHRyZWdpb246NTdiMzVjZjBlMzJmNDRmMDkwMDIwYjc4MmFjYmMzOGVfMTA_79c73393-c570-411f-8789-5b5f314a2ae5">2.57</ix:nonFraction>; weighted avg. $<ix:nonFraction unitRef="usdPerShare" contextRef="i70f3df893ec74c418b087f907936dff7_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMS0zLTEtMS0wL3RleHRyZWdpb246NTdiMzVjZjBlMzJmNDRmMDkwMDIwYjc4MmFjYmMzOGVfMjk_225419c0-71e5-42b4-9553-fdf2535b8c2c">1.88</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six months ended June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i60644eaa534948f49f8d5b8f40af2943_I20200630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMi0xLTEtMS0wL3RleHRyZWdpb246MzY1ZmQ5NWI4YjY2NDNhOTliYWJjY2VhMGQwOGYyNGVfNA_9770b231-5ce5-47c4-8945-0d2894bd043f">1.19</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i0a7f1be445ab4577a3269d5dc2dd853c_I20200630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMi0xLTEtMS0wL3RleHRyZWdpb246MzY1ZmQ5NWI4YjY2NDNhOTliYWJjY2VhMGQwOGYyNGVfMTA_23df3b72-99c5-4f8c-94fc-e597850b25f5">2.80</ix:nonFraction>:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $<ix:nonFraction unitRef="usdPerShare" contextRef="i18c9158c52b548ed815e6df50eef7fe9_I20200630" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMi0xLTEtMS0wL3RleHRyZWdpb246MzY1ZmQ5NWI4YjY2NDNhOTliYWJjY2VhMGQwOGYyNGVfMjg_ef14b66d-e825-4187-b58a-cb47c1bda590">1.85</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i60644eaa534948f49f8d5b8f40af2943_I20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMi0zLTEtMS0wL3RleHRyZWdpb246OGUzMTVhMjg4NTA0NGNiMGExNDJiODFkMTU3YWUwNzdfNA_0c772b47-86a6-488b-983e-196a7e14c862">1.19</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i0a7f1be445ab4577a3269d5dc2dd853c_I20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMi0zLTEtMS0wL3RleHRyZWdpb246OGUzMTVhMjg4NTA0NGNiMGExNDJiODFkMTU3YWUwNzdfMTA_85451fa0-fa9d-4b1f-80dd-2a3b18c066df">2.80</ix:nonFraction>:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $<ix:nonFraction unitRef="usdPerShare" contextRef="i18c9158c52b548ed815e6df50eef7fe9_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMi0zLTEtMS0wL3RleHRyZWdpb246OGUzMTVhMjg4NTA0NGNiMGExNDJiODFkMTU3YWUwNzdfMjg_91faf8a8-9148-4800-96d1-e07d37356171">1.85</ix:nonFraction></span></div></td></tr></table></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of common stock options granted in the six months ended June 30, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMjc4Mg_8776db63-f930-469d-b8bd-f3e75e2e4ee4">1.31</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMjc4OQ_5b036048-ea30-4bf8-9c33-45fbeea46519">1.29</ix:nonFraction> per common stock option, respectively.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i9bdf19d736b24610b528f3cd58439306"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMzExOQ_de2403bc-0c7b-4414-ac2c-d61bfed15127" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock option activity as of the periods indicated is as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMS0xLTEtMS0w_c261b086-6cf6-407b-b67a-0da879d986de">7,227,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMS0zLTEtMS0w_6f35b940-9080-4fc5-972f-1e67018353d2">2.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i09b723f0eb514cb19e68b68bef52570d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMS01LTEtMS0w_e8f5b22f-68aa-4c4f-b83e-209fca405ab9">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMS03LTEtMS0w_73c25c5b-ded9-44e1-abe1-d14f444c6662">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMi0xLTEtMS0w_102d480a-fbfb-4ee3-a2f9-0d311c1dd1b0">4,270,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMi0zLTEtMS0w_436039a4-3424-4cb4-85f6-90803acec3e1">1.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMy0xLTEtMS0w_d508c086-98cc-4d29-9514-b2d719a21bd9">342,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMy0zLTEtMS0w_68fef877-6d70-424e-8261-9e72f25addd9">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNC0xLTEtMS0w_74fde8ed-52f1-4c4f-b13a-1bcdddb0b8a2">95,702</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNC0zLTEtMS0w_08e76162-386c-4a62-8add-0fcc6c225f6a">2.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNS0xLTEtMS0w_b87e40b3-9eba-42c4-94d1-1b087d037542">11,059,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNS0zLTEtMS0w_461cf2c4-471d-432b-a544-89c141fd2d41">2.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNS01LTEtMS0w_ccf655f9-8434-4822-bc3e-ffc2e948c540">7.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNS03LTEtMS0w_63197066-9dc5-4f83-983d-946e9b7e31de">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable - June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNi0xLTEtMS0w_dfb86d3a-86e3-4b9b-8d56-96fef6163c69">4,580,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNi0zLTEtMS0w_8a33e1fa-25cd-47df-82b5-e94e9b2db5fe">2.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNi01LTEtMS0w_baa414d0-4bd4-48f6-8748-3f721d4bcf28">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNi03LTEtMS0w_ad4d90c6-9056-4b3f-8505-e66fc0007d70">832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Expected to Vest -<br/>June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNy0xLTEtMS0w_fb49454d-fe0b-4f20-b08a-8e32271534dd">10,559,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNy0zLTEtMS0w_0979e54c-d2d1-411a-bbaa-fdda0ab80332">2.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNy01LTEtMS0w_2ebd4bcb-54bf-4e47-aeff-a7bd31d419aa">7.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNy03LTEtMS0w_ac0f0c8a-4f0e-4f78-aa6d-0d457bf37c66">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of common stock options exercised during the six months ended June 30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMzAyMg_cfb95faf-aed5-4669-bbfc-390a0ad7ccc5">77</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMzAyOQ_a9257b43-c7cc-4d9e-a55b-9170ef1b620f">89</ix:nonFraction>, respectively.</span></div><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDUxNQ_b9adaafa-66d7-455c-8862-348e650b0200" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit activity of the periods indicated is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.512%"><tr><td style="width:1.0%"></td><td style="width:58.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.674%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i203967655c0047368d301fad6b928214_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjY1NWI1ZTUwNDBlYzQ5NzZhOWMyOGRjZGI3OWIwYTk0L3RhYmxlcmFuZ2U6NjU1YjVlNTA0MGVjNDk3NmE5YzI4ZGNkYjc5YjBhOTRfMS0xLTEtMS03NTM_89c69275-c414-415c-a398-8174c55a31b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i203967655c0047368d301fad6b928214_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjY1NWI1ZTUwNDBlYzQ5NzZhOWMyOGRjZGI3OWIwYTk0L3RhYmxlcmFuZ2U6NjU1YjVlNTA0MGVjNDk3NmE5YzI4ZGNkYjc5YjBhOTRfMS0zLTEtMS03NTM_99252ad7-3816-442d-b1fa-a4c80ff91346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i862f9b0b1702466189729eff0d9d775a_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjY1NWI1ZTUwNDBlYzQ5NzZhOWMyOGRjZGI3OWIwYTk0L3RhYmxlcmFuZ2U6NjU1YjVlNTA0MGVjNDk3NmE5YzI4ZGNkYjc5YjBhOTRfMi0xLTEtMS03NTM_901694d5-6e79-4c3a-bef8-efdb4721c57e">286,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i862f9b0b1702466189729eff0d9d775a_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjY1NWI1ZTUwNDBlYzQ5NzZhOWMyOGRjZGI3OWIwYTk0L3RhYmxlcmFuZ2U6NjU1YjVlNTA0MGVjNDk3NmE5YzI4ZGNkYjc5YjBhOTRfMi0zLTEtMS03NTM_ef5ba06e-032c-42b9-b1f2-5b0e229dac89">1.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75e9456e863e42c28b31cca8610e356b_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjY1NWI1ZTUwNDBlYzQ5NzZhOWMyOGRjZGI3OWIwYTk0L3RhYmxlcmFuZ2U6NjU1YjVlNTA0MGVjNDk3NmE5YzI4ZGNkYjc5YjBhOTRfNS0xLTEtMS03NTM_e32ddf48-04fe-41b0-b7f7-af3254e274ad">286,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i75e9456e863e42c28b31cca8610e356b_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjY1NWI1ZTUwNDBlYzQ5NzZhOWMyOGRjZGI3OWIwYTk0L3RhYmxlcmFuZ2U6NjU1YjVlNTA0MGVjNDk3NmE5YzI4ZGNkYjc5YjBhOTRfNS0zLTEtMS03NTM_f5e57458-14e0-4f69-97ac-dda482ae35e9">1.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of restricted stock units is based on the Company&#8217;s closing stock price at the date of grant. At vesting, each outstanding restricted stock unit will be exchanged for <ix:nonFraction unitRef="shares" contextRef="i75e9456e863e42c28b31cca8610e356b_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0NDcyNA_a693a4f9-46e1-4301-b5cb-67e903fe964f">one</ix:nonFraction> share of the Company&#8217;s common stock. The restricted stock units granted during the 2021 period generally vest evenly on a quarterly basis over a period of <ix:nonNumeric contextRef="i862f9b0b1702466189729eff0d9d775a_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0Mjc2Ng_998ad910-0e60-4127-ab96-b7c8e0caad02">4</ix:nonNumeric> years in exchange for continued service provided by the restricted stock unit recipient during that vesting period.</span></div></ix:continuation><div id="ia49112dadce14be6836937c1a8779dad_64"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfNjkx_693b64d1-c20e-4fd9-abe3-cad33eef8a4d" continuedAt="i5f428aba10114d9592448aa40ee01775" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5f428aba10114d9592448aa40ee01775">The Company incurred a pretax loss in each of the three and six months ended June 30, 2021 and 2020, which consists entirely of loss in the United States and resulted in <ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMTA5OTUxMTYyODgzNQ_14da7ea9-3b78-4e12-889f-936b10a48d37"><ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMTA5OTUxMTYyODgzNQ_50abfae5-6d7b-49e7-9c73-a81ce1702aa3"><ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMTA5OTUxMTYyODgzNQ_8bec2b82-294e-4db3-af8f-07c0e8cf0f3a"><ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMTA5OTUxMTYyODgzNQ_d77575d9-3b4b-4aec-82a3-2b77de84375b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> provision for income tax expense during the periods then ended.  The effective tax rate is <ix:nonFraction unitRef="number" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMjUy_20801442-374c-4019-805d-787a0c0378ee"><ix:nonFraction unitRef="number" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMjUy_30acd878-a6e7-4a76-8bc7-5a4019164468"><ix:nonFraction unitRef="number" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMjUy_36f805d0-e78d-44eb-83e5-e4a9042bcd04"><ix:nonFraction unitRef="number" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMjUy_913fdada-889b-40eb-abb8-d1ed6dea86f5">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% in each of the three and six months ended June 30, 2021 and 2020 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.</ix:continuation> </span></div><div id="ia49112dadce14be6836937c1a8779dad_67"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RleHRyZWdpb246NmMxYTlhMGE5NWI0NDNkZjg0Y2E5OTkwNjBmMThmN2NfMTE4NA_f35b693f-b919-41dc-9799-ecc91217159b" continuedAt="i8c804627cc984fc287e053741d280b80" escape="true">Loss Per Common Share</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8c804627cc984fc287e053741d280b80" continuedAt="i11ff796e77a64539823e7ba08ede50a9"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RleHRyZWdpb246NmMxYTlhMGE5NWI0NDNkZjg0Y2E5OTkwNjBmMThmN2NfMTE4Ng_37d18f17-da7d-46d9-bd14-a80197267f70" escape="true">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options, restricted stock units, and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods.</ix:nonNumeric>  Therefore, basic and diluted loss per common share is the same for each of the three and six months ended June 30, 2021 and 2020.</ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i11ff796e77a64539823e7ba08ede50a9"><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RleHRyZWdpb246NmMxYTlhMGE5NWI0NDNkZjg0Y2E5OTkwNjBmMThmN2NfMTE5Nw_73899094-b517-4af6-bf2c-d6084e18b526" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the computation of loss per common share for the three and six months ended June 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"></td><td style="width:37.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfMi0xLTEtMS0w_926d2483-7834-45e6-969c-fc0366fd80cb">14,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfMi0zLTEtMS0w_49729fed-d4ca-45f9-ad2e-1d11464b4967">4,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfMi01LTEtMS0w_4d61a480-03cf-498e-9b8b-ed7ca6549d96">26,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfMi03LTEtMS0w_dcc6919a-b911-412b-8fc7-71a4c34da26b">3,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC0xLTEtMS0w_2f6db7a2-1507-41df-98f0-a894c549efd7"><ix:nonFraction unitRef="shares" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC0xLTEtMS0w_b629d769-b9e0-4d45-8f7e-19830c791fb7">88,043,447</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC0zLTEtMS0w_02c6a5a0-0d6a-46db-82c2-361145b846e9"><ix:nonFraction unitRef="shares" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC0zLTEtMS0w_ccf69255-ef43-4f20-bc1d-fc0926a0c226">87,174,533</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC01LTEtMS0w_39ffb032-32f1-4fea-9780-49d79d966739"><ix:nonFraction unitRef="shares" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC01LTEtMS0w_8db20d9d-03f8-4013-b238-d1274bb918ba">87,948,440</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC03LTEtMS0w_2d93a7c4-6f50-4728-aed0-63ec3ded246a"><ix:nonFraction unitRef="shares" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC03LTEtMS0w_9bbc93a0-8e2b-417f-87bb-d2e55df9e214">87,126,847</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC0xLTEtMS0w_c0d5220b-dd7f-4906-b060-a5ec7e005c07"><ix:nonFraction unitRef="usdPerShare" contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC0xLTEtMS0w_e18ff0cb-4647-4acb-9c7b-c2185a2a449e">0.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC0zLTEtMS0w_d87720f6-a79f-4bea-ad3e-e44ba94da0e9"><ix:nonFraction unitRef="usdPerShare" contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC0zLTEtMS0w_eb67c1ac-fb88-433e-baa6-b0594e0eaea7">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC01LTEtMS0w_82957923-196a-4f72-9290-beefa5bb8215"><ix:nonFraction unitRef="usdPerShare" contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC01LTEtMS0w_ccfd2cfc-6f59-42af-8df3-f08994cf6ddc">0.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC03LTEtMS0w_db6e4c83-c068-4252-96e5-7b0d260bb5fc"><ix:nonFraction unitRef="usdPerShare" contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC03LTEtMS0w_f8f5df60-81a8-48f0-b060-a4a3379e712d">0.04</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RleHRyZWdpb246NmMxYTlhMGE5NWI0NDNkZjg0Y2E5OTkwNjBmMThmN2NfMTE5MQ_b6cc26d9-65ac-4a1f-bdc6-986354a33262" escape="true"><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company&#8217;s loss per share during that period:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:69.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e5643a3e14a4b2ca2f6576189dc8cce_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOjc4MjZlYjA1ZjcxYjQ0NzhiODc4OTNjOGE3MGFjZmJlL3RhYmxlcmFuZ2U6NzgyNmViMDVmNzFiNDQ3OGI4Nzg5M2M4YTcwYWNmYmVfMi0xLTEtMS0w_e220ed72-f6aa-4735-8e9e-fdd113cc3563">11,059,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f67c529634343ec87c7f862a41ec733_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOjc4MjZlYjA1ZjcxYjQ0NzhiODc4OTNjOGE3MGFjZmJlL3RhYmxlcmFuZ2U6NzgyNmViMDVmNzFiNDQ3OGI4Nzg5M2M4YTcwYWNmYmVfMi0zLTEtMS0w_a15c43ee-5e5e-41f5-84d3-d838811a6053">7,698,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbfcd4dc60684a77a8e8fff3eb283e9a_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOjc4MjZlYjA1ZjcxYjQ0NzhiODc4OTNjOGE3MGFjZmJlL3RhYmxlcmFuZ2U6NzgyNmViMDVmNzFiNDQ3OGI4Nzg5M2M4YTcwYWNmYmVfMy0xLTEtMS0xMzk0_5f32a8ba-c8ac-4c93-b6e9-d00cfa6a3bab">286,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81809ddc049e44b18b81bcffd7f27327_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOjc4MjZlYjA1ZjcxYjQ0NzhiODc4OTNjOGE3MGFjZmJlL3RhYmxlcmFuZ2U6NzgyNmViMDVmNzFiNDQ3OGI4Nzg5M2M4YTcwYWNmYmVfMy0zLTEtMS0xNTM1_b8a6392c-81d1-484e-b834-048e7845e93f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id968e5bf12ce4186bceeb5caa282ec2b_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOjc4MjZlYjA1ZjcxYjQ0NzhiODc4OTNjOGE3MGFjZmJlL3RhYmxlcmFuZ2U6NzgyNmViMDVmNzFiNDQ3OGI4Nzg5M2M4YTcwYWNmYmVfMy0xLTEtMS0w_434edc78-b44c-416c-9a3e-443421b67492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a183f19fdd448bdbb48aafc81f24e29_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOjc4MjZlYjA1ZjcxYjQ0NzhiODc4OTNjOGE3MGFjZmJlL3RhYmxlcmFuZ2U6NzgyNmViMDVmNzFiNDQ3OGI4Nzg5M2M4YTcwYWNmYmVfMy0zLTEtMS0w_511c9c92-23c6-4800-8f1a-d8925daa128d">413,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia49112dadce14be6836937c1a8779dad_70"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RleHRyZWdpb246NTg4NWVkMGI5ZTc0NGNjZmE1Yjc5NmRkYzc3YWJjMDZfMjc2Nw_ba2cf63a-b938-4071-b28b-095cebcb1112" continuedAt="i13b6a637674b4f63b163005f8a6f9c71" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i13b6a637674b4f63b163005f8a6f9c71" continuedAt="id51f8769a5b14051afc7d9f8378c2f36"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </span></div><ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RleHRyZWdpb246NTg4NWVkMGI5ZTc0NGNjZmE1Yjc5NmRkYzc3YWJjMDZfMjc2Mw_e2bacfe4-247c-4483-9891-72ba0373360d" continuedAt="icd7a5045ac7f4ddf8c78c2ffb0cfc831" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of June&#160;30, 2021 are as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:46.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f3a6610c3c4fb7a8f3011378ea9e4a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMy0xLTEtMS0w_a5def78b-e376-4f94-81d9-0d29fb13cf83">30,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd0c5a447ff34bbc8d7908d531b56cff_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMy0zLTEtMS0w_3c3aec92-b09b-413b-ab59-7a337ea71f89">30,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd5b1839e3a4048b28a43a4c4e685d7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMy01LTEtMS0w_82a3eaef-fb51-4e5a-ad9f-771c26251350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57710941d894ca1b67a1c5d13d6d090_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMy03LTEtMS0w_96f5ae34-291c-451f-95e9-08af0976d3f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifefc3417f0d145cea19c531c9a0c8f9e_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNi0xLTEtMS0w_b8a9b207-9e81-436c-a04e-644492681c75">5,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e05ee112bbd483d8bd21004c56c115f_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNi0zLTEtMS0w_323263df-c0f4-449a-bfd3-f48a655bbb3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe496263a9ad417fad626fd81108d45e_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNi01LTEtMS0w_482bc5e4-bb7f-4374-b83c-5017745f2179">5,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03537b84e847e99bee1a3a67a888b8_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNi03LTEtMS0w_ad5bb282-5df6-4cb3-aab6-12734402b847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36f90f4916647c996df4392cf9a2961_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNy0xLTEtMS0w_5431e7d7-e466-4e03-852d-46137876b18e">6,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7425a3abf5aa493d95862d239425df58_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNy0zLTEtMS0w_9f86b45e-c105-42a4-8a8c-551b1f97d266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia84bea4dabf04dc0b6316097c19d0d55_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNy01LTEtMS0w_91396fef-cf00-4819-9c13-9da67aed0b66">6,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d4fc50d3924eab98e6d7e3de7886c3_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNy03LTEtMS0w_9868b76c-602a-4192-991d-931730a7eac2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i815c1749dc334f5aa2f2b3d7ce7325b5_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfOS0xLTEtMS0w_f23366df-1900-42d1-93ea-99df4842e1f4">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae63ab432b644385ad760c25e7bb81a4_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfOS0zLTEtMS0w_9cfc7d8b-f256-4900-a8f0-edfad04aa3ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1841aafb4eea4763a606cf71ee256faa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfOS01LTEtMS0w_4c8ddad3-2fe6-4d7d-8cd2-1978a5182b06">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e02bfdb4fe4d5c945ef80c6fe4fad3_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfOS03LTEtMS0w_581db0e7-cc2d-4657-9daf-504813d7359c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f50fb4ed2946899515880a08b3b57b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMTAtMS0xLTEtMA_9cd0e9f2-3e10-4f78-adce-33449d9d1fb3">43,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d7ee51b5b4f4652af15034a165fbf74_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMTAtMy0xLTEtMA_87ed3748-56f5-4f76-a860-7434e64738b9">30,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib437b59ac25f4bc78adb0e03658f743d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMTAtNS0xLTEtMA_dadef432-92f2-4c8e-a626-76aedfb5d5fe">13,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb4a947556c46d38903332f34ab5729_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMTAtNy0xLTEtMA_8b7f3f45-9ed3-4be7-955a-aa8ef0ef0584">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="id51f8769a5b14051afc7d9f8378c2f36"><ix:continuation id="icd7a5045ac7f4ddf8c78c2ffb0cfc831"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 are as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:46.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ab61d3d42a48659e6eb92b8ae28834_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMy0xLTEtMS0w_8a6aba92-ead0-4cd9-ba49-214a6d61ba11">24,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3ba902ba2c44f4a67a96f6f613cca1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMy0zLTEtMS0w_16dcfb65-08b8-4445-8d69-a547dff6a10b">24,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875848c586b4375a60e0586a91f2a0e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMy01LTEtMS0w_de348248-59cc-43ad-974f-8f2af76e9585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a58f1716064afdb7cb38c53987eb36_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMy03LTEtMS0w_c42a9cac-4239-416b-a8d7-fb1a3b9bcbef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5292d66c2a14337935384c3078fb0f2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNS0xLTEtMS0w_dad6c466-eafa-4ac9-8254-6e817f04135d">15,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15097b5bf7ee4089861f0faff5870a28_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNS0zLTEtMS0w_fdab328b-aeb5-4b6f-9691-de978b11ae4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d0d3d621aa248ffb7a89d07e53fb661_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNS01LTEtMS0w_de74149d-1a76-4091-89bb-b3ec6626b18f">15,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264f629b27bd4da3a95c37beb796c031_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNS03LTEtMS0w_5d4e6a9c-321d-49e3-98cb-86d3b36a9b2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfeb9eea9dbf4b46996f9c206cb93ed9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNi0xLTEtMS0w_d088a853-ad02-428c-ba16-b11e76563eb0">29,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7abd43cf3d894cffa0f7cb487206018b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNi0zLTEtMS0w_6f1e4c44-8a11-4379-9221-dd55e0d9a240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e3860c3a63420e9d7641f47962c9cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNi01LTEtMS0w_40ad45f3-59c6-46d2-876d-beb9d683b005">29,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21aac650411b42b8a24485f95cec055b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNi03LTEtMS0w_4d15a6fe-ec20-4ac6-b1e6-d49e332a3cb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib62061d67fb7462295481dacb0f4878f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNy0xLTEtMS0w_4e5eaa40-89c6-4742-b4af-483feb92df5e">2,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf7aa4a7c3949849940d3879f239db6_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNy0zLTEtMS0w_542e2b4a-bce8-458a-9a82-4ea0a630eaac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b4abd0dd9174b658c26e0a2fb538250_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNy01LTEtMS0w_2b64f407-727e-4c00-a3e7-326f31bc7580">2,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd9add5bb4c45a78909b926908a9321_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNy03LTEtMS0w_da9ed9c0-8ea3-41fe-b16e-55ae95b34964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1da4f481fa0f4d07a5cf47234b82b9fe_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOC0xLTEtMS0w_5488a9b1-2ff7-4767-874b-06ed161e9bb5">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a40373542a452085cc5d600a78424a_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOC0zLTEtMS0w_1f96723a-ca95-4393-b173-ed0718d629b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc3e793a60d4e38acabd4ccbf7e7571_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOC01LTEtMS0w_1ce4515e-ae89-4ba9-b287-853d62e6606a">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3949b66929b4496bb22e8f8f15df1a0e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOC03LTEtMS0w_0f55a004-d050-4923-a50d-bcc9cfcf1534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce5fd94c3494f099a9ee39d5d778059_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOS0xLTEtMS0w_70a27d18-fb52-47f9-932d-bb04b2ea9fff">73,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13bc69c967ce4483838129c6d0a0b70b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOS0zLTEtMS0w_1383a220-dbac-4758-adbc-9d002aa9dad1">24,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b1b75f0b614cad8c61db673b402bc1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOS01LTEtMS0w_3982ed8e-6f37-46aa-a3f6-a601c4ee8130">48,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4ad8ee44ca14f698e0bcfb629608444_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOS03LTEtMS0w_1c002051-c5e8-4a28-8797-119951dec8d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce5fd94c3494f099a9ee39d5d778059_I20201231" decimals="-3" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTItMS0xLTEtMA_9ee60193-ff3a-4c87-a128-45e75ff1ee1c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13bc69c967ce4483838129c6d0a0b70b_I20201231" decimals="-3" format="ixt:zerodash" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTItMy0xLTEtMA_d6b835a6-ba5a-4a99-b992-999a368e3cea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b1b75f0b614cad8c61db673b402bc1_I20201231" decimals="-3" format="ixt:zerodash" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTItNS0xLTEtMA_a9f26ad2-01db-40ef-bf70-970fddb4af5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4ad8ee44ca14f698e0bcfb629608444_I20201231" decimals="-3" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTItNy0xLTEtMA_3dcf27f8-bcee-4e65-aee3-af25da788901">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce5fd94c3494f099a9ee39d5d778059_I20201231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTMtMS0xLTEtMA_fd67aec9-1d22-4ffa-b19c-e0bccab7b3d7">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13bc69c967ce4483838129c6d0a0b70b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTMtMy0xLTEtMA_049c3524-b469-4cee-b617-096c3f3fb53a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b1b75f0b614cad8c61db673b402bc1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTMtNS0xLTEtMA_240d057d-b347-4caf-b29a-86e8e96c6ee4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4ad8ee44ca14f698e0bcfb629608444_I20201231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTMtNy0xLTEtMA_fb88e1d9-cab4-4860-b332-82f6a1b3e5e8">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments.  The Company&#8217;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level 2 of the fair value hierarchy.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company&#8217;s common stock warrant liability was $<ix:nonFraction unitRef="usd" contextRef="i6ff17028d7f742fc86b80a80958beb1c_I20210630" decimals="INF" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RleHRyZWdpb246NTg4NWVkMGI5ZTc0NGNjZmE1Yjc5NmRkYzc3YWJjMDZfMjc0ODc3OTA3MzYxNQ_024b5121-1500-4f7d-8ef0-7adffe7f6171">0</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6ff17028d7f742fc86b80a80958beb1c_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RleHRyZWdpb246NTg4NWVkMGI5ZTc0NGNjZmE1Yjc5NmRkYzc3YWJjMDZfMjc0ODc3OTA3MzI1OQ_55b9f407-7da0-40f3-990f-a03fe699245b">no</ix:nonFraction> warrants were outstanding  (refer to Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information). <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RleHRyZWdpb246NTg4NWVkMGI5ZTc0NGNjZmE1Yjc5NmRkYzc3YWJjMDZfMjc3MQ_5d59377d-32b6-4ffa-b191-bef98e79162d" continuedAt="i3b6a77187b944acfa76d173aaedb397b" escape="true">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended June&#160;30, 2021:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i3b6a77187b944acfa76d173aaedb397b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.237%"><tr><td style="width:1.0%"></td><td style="width:72.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89a31a873b4345549a9b1b9489d5fcda_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU4ZTczZjgyYmI1ZjRmYmQ5MGZlODU4ZjcwMTA0ZDFhL3RhYmxlcmFuZ2U6ZThlNzNmODJiYjVmNGZiZDkwZmU4NThmNzAxMDRkMWFfMi0xLTEtMS0w_bcee3c76-e557-47f8-8bc1-1dfcdf50cd1d">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf6b894493654106958401b815661301_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU4ZTczZjgyYmI1ZjRmYmQ5MGZlODU4ZjcwMTA0ZDFhL3RhYmxlcmFuZ2U6ZThlNzNmODJiYjVmNGZiZDkwZmU4NThmNzAxMDRkMWFfMy0xLTEtMS0w_d482a326-44b2-4412-8591-abb8fbfdbb7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain included in other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf6b894493654106958401b815661301_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU4ZTczZjgyYmI1ZjRmYmQ5MGZlODU4ZjcwMTA0ZDFhL3RhYmxlcmFuZ2U6ZThlNzNmODJiYjVmNGZiZDkwZmU4NThmNzAxMDRkMWFfNC0xLTEtMS0w_be5d6382-f9cf-43ac-a4ec-f9934543bef8">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i075d22f912e34ce8b799f56c4e6c8bff_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU4ZTczZjgyYmI1ZjRmYmQ5MGZlODU4ZjcwMTA0ZDFhL3RhYmxlcmFuZ2U6ZThlNzNmODJiYjVmNGZiZDkwZmU4NThmNzAxMDRkMWFfNS0xLTEtMS0w_dc289c9b-74fe-476e-a9f3-ed7c4cb99d8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="ia49112dadce14be6836937c1a8779dad_73"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83My9mcmFnOjE4ODk0YzdiMzA0MDQxYzU4YTAwNjJmZmIxMzhjNjBiL3RleHRyZWdpb246MTg4OTRjN2IzMDQwNDFjNThhMDA2MmZmYjEzOGM2MGJfMjgyNg_030ed432-03c7-496f-a346-04b8602c1e18" continuedAt="i9f11c5bed04b4c52b56dbf616b931781" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i9f11c5bed04b4c52b56dbf616b931781" continuedAt="i4ae7316c3bc54e16b691313475f28539"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 7,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a discussion of the commitments associated with the Company&#8217;s lease agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Northwestern University License Agreements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2011, (1) AuraSense, LLC, the Company&#8217;s former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#8217;s 2009 license agreement with Northwestern University (&#8220;NU&#8221;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4ae7316c3bc54e16b691313475f28539">as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;assigned field&#8221;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#8217;s sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company.  In August 2015, the Company entered into a restated license agreement with NU (the &#8220;Restated License Agreement&#8221;). In February 2016, the Company obtained exclusive license as to NU&#8217;s rights in certain SNA technology it jointly owns with NU (the &#8220;Co-owned Technology License&#8221;). The Company&#8217;s license to NU&#8217;s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. In June 2016, the Company entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#8220;Wound Healing License&#8221;). The Company&#8217;s rights and obligations in the Co-owned Technology License and the Wound Healing License agreements&#160;are substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as &#8220;the Northwestern University License Agreements&#8221;).  All pending patent applications under the Wound Healing License have been abandoned and the Wound Healing License has been terminated.  As of June&#160;30, 2021, the Company has paid to NU an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="xcur:AggregatePaymentsMadeToDateForLicenseAgreements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83My9mcmFnOjE4ODk0YzdiMzA0MDQxYzU4YTAwNjJmZmIxMzhjNjBiL3RleHRyZWdpb246MTg4OTRjN2IzMDQwNDFjNThhMDA2MmZmYjEzOGM2MGJfMjc2Mw_484c6c95-abc3-4119-920e-8a50b993ec41">8,361</ix:nonFraction> in consideration of each of the obligations described above.</ix:continuation> </span></div><div id="ia49112dadce14be6836937c1a8779dad_76"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83Ni9mcmFnOjEyNjBjYjYyMGI0ODRjMTZhMWNmOTRkZmMyMjRjYWNiL3RleHRyZWdpb246MTI2MGNiNjIwYjQ4NGMxNmExY2Y5NGRmYzIyNGNhY2JfNDQz_e0daaa15-052f-46c4-b209-7cedb0e9b47b" continuedAt="ic60bacea2fbd4a90817cc56a5cb10145" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic60bacea2fbd4a90817cc56a5cb10145">The Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but, through April 30, 2021, served as a member of the Board. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i9894ed94822f44a1b4e2a85180b8d226_D20200101-20200630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83Ni9mcmFnOjEyNjBjYjYyMGI0ODRjMTZhMWNmOTRkZmMyMjRjYWNiL3RleHRyZWdpb246MTI2MGNiNjIwYjQ4NGMxNmExY2Y5NGRmYzIyNGNhY2JfMjE5OTAyMzI1NjAxMw_8ed428af-b6ae-425d-823c-63a54e7d21c2"><ix:nonFraction unitRef="usd" contextRef="i0304e7ef793b4159a6bfef1cd8f203bf_D20210101-20210630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83Ni9mcmFnOjEyNjBjYjYyMGI0ODRjMTZhMWNmOTRkZmMyMjRjYWNiL3RleHRyZWdpb246MTI2MGNiNjIwYjQ4NGMxNmExY2Y5NGRmYzIyNGNhY2JfMjE5OTAyMzI1NjAxMw_df9442a8-eaab-4cb0-a690-07b79a2663fe">50</ix:nonFraction></ix:nonFraction> as an expense in each of the six months ended June&#160;30, 2021 and 2020 in connection with these consulting services in the accompanying unaudited condensed consolidated statement of operations.</ix:continuation></span></div><div id="ia49112dadce14be6836937c1a8779dad_1214"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8xMDk5NTExNjQxNzQw_bf86206c-e2fc-4416-b68c-5d6ac162d393" continuedAt="ia784d0c3c9f04b6e90e641b03ff8c5cd" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="ia784d0c3c9f04b6e90e641b03ff8c5cd" continuedAt="i7d711b4ba53947a1bc3c2daccc9b1c7e"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events which may require adjustment to or disclosure in the accompanying unaudited condensed consolidated financial statements and has concluded that there are no subsequent events or transactions that occurred subsequent to the balance sheet date that would require recognition or disclosure in the accompanying unaudited condensed consolidated financial statements, except as noted below.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration, License, and Option Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021, the Company entered into a Collaboration, Option and License Agreement (the &#8220;Ipsen Collaboration Agreement&#8221;) with IPSEN BIOPHARM LIMITED (&#8220;Ipsen&#8221;). Pursuant to the Ipsen Collaboration Agreement, the Company granted to Ipsen exclusive access and options to license SNA based therapeutics arising from <ix:nonFraction unitRef="agreement" contextRef="i766b5dbdd23d432ebc0191ac53b18fac_D20210730-20210730" decimals="INF" format="ixt-sec:numwordsen" name="xcur:NumberofCollaborationPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8xMDk5NTExNjQ0MzQz_a3b7fa66-1b07-4223-87a8-14dd041b137d">two</ix:nonFraction> collaboration programs related to the treatment of Huntington&#8217;s disease and Angelman syndrome, respectively. Each such license would grant to Ipsen exclusive, royalty-bearing, sublicensable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Upon written notice to the Company, Ipsen may exercise its option during the corresponding collaboration program&#8217;s applicable option exercise period, (each, an &#8220;Option Exercise Period&#8221;).</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Ipsen Collaboration Agreement, the Company will conduct discovery and development in <ix:nonFraction unitRef="agreement" contextRef="i766b5dbdd23d432ebc0191ac53b18fac_D20210730-20210730" decimals="INF" format="ixt-sec:numwordsen" name="xcur:NumberofCollaborationPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8xMDk5NTExNjQ0MzUx_a3b7fa66-1b07-4223-87a8-14dd041b137d">two</ix:nonFraction> collaboration programs for Huntington&#8217;s disease and Angelman syndrome. The Company shall be solely responsible for all costs and expenses of conducting each collaboration program through the selection of SNA therapeutic candidates for further development (&#8220;Selection&#8221;), and Ipsen shall be responsible for all costs and expenses of all additional activities that are necessary to enable the first filing of an investigational new drug application (&#8220;IND&#8221;) for each proposed product candidate. In the event that Ipsen exercises an option, Ipsen will be </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i7d711b4ba53947a1bc3c2daccc9b1c7e" continuedAt="i7bf2a3c729294d84826544de10df4b7d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">responsible for further development from the license effective date and commercialization of the corresponding licensed product. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Ipsen Collaboration Agreement, the Company will receive an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i766b5dbdd23d432ebc0191ac53b18fac_D20210730-20210730" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8yMTk5MDIzMjY5NDE1_3f9f74ba-46eb-4909-aa4b-e572aac7284d">20,000</ix:nonFraction> (the &#8220;Ipsen Upfront Payment&#8221;), and, depending on the timing when Ipsen exercises its option right in a collaboration program, Ipsen will pay to the Company an option exercise fee equal to $<ix:nonFraction unitRef="usd" contextRef="i902680175ed94d4c9937aba91e427308_D20210730-20210730" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementOptionExerciseFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8yMTk5MDIzMjY5NDMy_5713e262-13a8-421d-a4d6-8be07e6696d5">10,000</ix:nonFraction> (if exercised within the Option Exercise Period after the Selection) or $<ix:nonFraction unitRef="usd" contextRef="i3058801971a44b62b1abb284fe077eef_D20210730-20210730" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementOptionExerciseFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8yMTk5MDIzMjY5NDYz_a72d782d-4110-4c24-ab12-210264b5627c">25,000</ix:nonFraction> (if exercised within the Option Exercise Period that begins after the first Option Exercise Period and ends after IND filing) for each collaboration program. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ipsen will pay a pre-clinical milestone of $<ix:nonFraction unitRef="usd" contextRef="i3c4f363adac940e3bca3d807b358d686_I20210730" decimals="-3" format="ixt:numdotdecimal" name="xcur:RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8yMTk5MDIzMjY5NDQ4_10d9a16e-6e62-4192-8df1-8fc29d12d79b">5,000</ix:nonFraction> for each collaboration program upon achievement of such milestone regardless of whether an option is exercised.  In addition to the option exercise fees and the pre-clinical milestones described above, if Ipsen exercises an option for a program, development and regulatory milestones will be payable for that program upon the initiation of certain clinical trials, and the filing for processing by the FDA in the United States and by 2 additional regulators outside the United States of a marketing application for review, per program, with an aggregate total of up to $<ix:nonFraction unitRef="usd" contextRef="i3c4f363adac940e3bca3d807b358d686_I20210730" decimals="-3" format="ixt:numdotdecimal" name="xcur:RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8yMTk5MDIzMjY5NDc5_474795d9-a795-4174-83df-2dcb2ff2db8b">180,000</ix:nonFraction> if both options are exercised. Commercial milestones will be payable for that program upon first commercial sale of a licensed product in certain jurisdictions and the achievement of specified aggregate sales thresholds for all licensed products from that program, with an aggregate total of up to $<ix:nonFraction unitRef="usd" contextRef="i3c4f363adac940e3bca3d807b358d686_I20210730" decimals="-3" format="ixt:numdotdecimal" name="xcur:RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8yMTk5MDIzMjY5NDk2_646fb6e3-b117-4665-a4f1-71a30e02b514">762,000</ix:nonFraction> if both options are exercised. In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company is eligible to receive tiered royalties at percentages ranging from the mid-single digits to the mid-teens on future net product sales of such commercialized therapeutic candidates. A percentage of the aforementioned payments will be due to NU upon receipt, pursuant to the terms of the Company&#8217;s existing license agreements with NU (see Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitment and Contingencies,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on the Northwestern University License Agreements).  In connection with the receipt of the Ipsen Upfront Payment, the Company will incur $<ix:nonFraction unitRef="usd" contextRef="i766b5dbdd23d432ebc0191ac53b18fac_D20210730-20210730" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementLicensingFeesIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8xNjQ5MjY3NDU2MDEx_e95d0ff6-de12-4210-b012-0191c4d26f8d">3,000</ix:nonFraction> in license fees payable to NU under the terms of the Northwestern License Agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ipsen Collaboration Agreement will remain in effect, unless earlier terminated, until (a) the expiration of the later-to-expire option exercise period, if Ipsen does not exercise either option, or (b) the expiration of the last-to-expire royalty term for any licensed product in such country on a licensed product-by-licensed product and country-by-country basis, if Ipsen exercises one or both options. Upon expiration of the royalty term with respect to a particular licensed product in a country, the license for such product in such country will convert to a fully-paid, irrevocable and perpetual license. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ipsen Collaboration Agreement also contains customary provisions for termination by either party, including in the event of breach of the Ipsen Collaboration Agreement, subject to cure, and by the Company upon a challenge of the licensed patents, subject, in certain cases, to customary reversion rights. Upon termination of the Ipsen Collaboration Agreement by the Company for Ipsen&#8217;s breach or bankruptcy, all licenses granted by the Company to Ipsen will terminate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ipsen Collaboration Agreement includes customary representations and warranties on behalf of both the Company and Ipsen. The Ipsen Collaboration Agreement also provides for customary mutual indemnities.  In addition, the Ipsen Collaboration Agreement imposes certain exclusivity obligations on Ipsen and the Company, respectively, with respect to the development, use, manufacture and commercialization of oligonucleotide-based therapeutic targeting the same targets in the collaboration programs and/or certain other specific targets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either party may assign the Ipsen Collaboration Agreement or delegate its obligations to an affiliate or to a successor to substantially all of the business to which the Ipsen Collaboration Agreement relates without the consent of the other party.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the entry into the Ipsen Collaboration Agreement, the Company, Ipsen and NU entered into a side letter to the Northwestern University License Agreements (the &#8220;Side Letter&#8221;). Pursuant to the Side Letter, the parties thereto clarified certain provisions of the Northwestern University License Agreements as they apply to the sublicenses granted to Ipsen pursuant to the Ipsen Collaboration Agreement, including providing for the survival of Ipsen&#8217;s sublicense to the applicable NU intellectual property rights should the Northwestern University License </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7bf2a3c729294d84826544de10df4b7d">Agreements terminate or if the Company&#8217;s licenses to such intellectual property rights are rendered non-exclusive in accordance with the Northwestern University License Agreements (other than as a result of an act or omission on the part of Ipsen or any of its Affiliates or sublicensees). Additionally, the Side Letter clarified Ipsen&#8217;s rights to grant further sublicenses under such intellectual property rights granted to the Company pursuant to the Northwestern University License Agreements.</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following information should be read in conjunction with our unaudited condensed consolidated financial statements and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission, or SEC, on March 11, 2021. This discussion and analysis contains forward-looking statements that involve significant risks and uncertainties. Our actual results, performance or experience could differ materially from what is indicated by any forward-looking statement due to various important factors, risks and uncertainties, including, but not limited to, those set forth under the section titled &#8220;Risk Factors&#8221; in Part II, Item 1A.  Such factors may be amplified by the COVID-19 pandemic and its current or future impact on our business and the global economy.</span></div><div id="ia49112dadce14be6836937c1a8779dad_82"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases, and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA&#8482;, technology. We believe that our proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics.  We are in preclinical development of XCUR-FXN, a lipid-nanoparticle SNA-based therapeutic candidate, for the intrathecal treatment of Friedreich&#8217;s ataxia, or FA.  Our therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe one of the key strengths of our proprietary SNAs is that they have the potential for increased cellular uptake compared to conventional linear oligonucleotides and as a result the potential to achieve higher efficacy at the same doses of oligonucleotide administered.  We have shown in clinical and preclinical studies that SNAs may have therapeutic potential in immuno-oncology and dermatology. In addition, we have shown in preclinical studies that SNAs may have therapeutic potential in neurology, ophthalmology, pulmonology, and gastroenterology. As a consequence, we have expanded our pipeline into neurology, for which IND-enabling activities are ongoing for XCUR-FXN, and are conducting early stage research activities in ophthalmology, pulmonology, and gastroenterology.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below sets forth the current status of development of our SNA therapeutic candidates.</span></div><div style="text-align:center;text-indent:18pt"><img src="xcur-20210630_g1.jpg" alt="xcur-20210630_g1.jpg" style="height:283px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  Cavrotolimod is a TLR9 agonist.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)  In combination with checkpoint inhibitors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating, financing, and cash flow considerations</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2011, we have devoted substantial resources to the research and development of SNAs and the protection and enhancement of our intellectual property. We have no products approved for sale and have primarily funded our operations through sales of our securities and collaborations. Through June 30, 2021, we have raised gross proceeds of $190.1 million from the sale of common stock and preferred stock. We have also received $36.0 million in upfront payments from collaborations, including an upfront payment of $25.0 million we received in November 2019 in connection with the AbbVie Collaboration Agreement and an upfront payment of $1.0 million we received in February 2019 in connection with the Dermelix Collaboration Agreement.  On September 25, 2020, we also borrowed $17.5 million under the terms of a credit and security agreement with MidCap Financial Trust (as described further below). As of June 30, 2021, our cash, cash equivalents, short-term investments, and restricted cash were $57.3 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses.  As of June 30, 2021, we have generated an accumulated deficit of $151.5 million. Substantially all of our operating losses resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue research and development of XCUR-FXN and other neurological therapeutic candidates and advance preclinical product candidates into clinical development;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to advance the ongoing Phase 1b/2 clinical development for cavrotolimod (AST-008) for immuno-oncology applications;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our SNA platform in dermatological indications with suitable collaboration partners;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate research and development, preclinical studies and clinical trials for any additional therapeutic candidates that we may pursue in the future;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance other therapeutic candidates through preclinical and clinical development;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our research and development activities to enhance our technology platform;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to manufacture increasing quantities of drug substance and drug product material for use in preclinical studies and clinical trials;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approval for our therapeutic candidates that successfully complete clinical trials;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other approved drugs, drug candidates or technologies; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional costs associated with operating as a public company.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated any revenue from commercial drug sales nor do we expect to generate substantial revenue from product sales unless or until we successfully complete development and obtain regulatory approval of and commercialize one or more of our therapeutic candidates. We do not anticipate generating revenue from drug sales for the next several years, if ever. If we obtain regulatory approval for any of our therapeutic candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Other sources of revenue could include a combination of research and development payments, license fees and other upfront payments, milestone payments, and royalties in connection with our current and any future collaborations and licenses. Until such time, if ever, that we generate revenue from whatever source, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings and research </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration and license agreements. We may be unable to raise capital or enter into such other arrangements when needed or on favorable terms. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our therapeutic candidates.</span></div><div id="ia49112dadce14be6836937c1a8779dad_85"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Therapeutic Development Program Updates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XCUR-FXN, Friedreich&#8217;s ataxia</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing XCUR-FXN, an SNA-based therapeutic candidate for the treatment of FA. FA is an autosomal recessive, neurodegenerative disease characterized by progressively impaired muscle coordination caused by the degeneration of neurons in the cerebellum, dorsal root ganglia, and spinal cord. FA patients may also experience impairment of visual, auditory and speech functions. FA patients also commonly suffer from life-threatening heart conditions, including cardiomyopathy and heart failure. The typical age of onset for FA is between 5 and 15 years.  We estimate that approximately 13,500 patients across the United States, Europe, Canada and Australia are affected by FA. There are currently no FDA-approved treatments for FA.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted extensive preclinical research evaluating the suitability of our SNA technology for genetically defined neurological diseases, including efficacy studies in animal models, and biodistribution in rodent and non-human primates. Based on the results, we believe we can target the underlying molecular cause of FA and meet an important unmet medical need for FA patients. FA is driven by expansion of guanine-adenine-adenine bases of the DNA sequence, or GAA, triplet repeats in the first intron of the frataxin, or FXN, gene.  The expanded repeat of FXN is believed to form an intramolecular triple-helix, which impairs transcription and reduces levels of frataxin protein. Our strategy is to use a genetically-targeted SNA therapy to increase frataxin protein.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have designed XCUR-FXN to take advantage of a key attribute of our SNA technology, the ability to incorporate more than one kind of active oligonucleotide in a single SNA molecule. Specifically, XCUR-FXN is a bi-specific SNA designed to increase the levels of frataxin protein by two distinct mechanisms: (i) degrade the natural antisense transcript that we believe normally lowers FXN mRNA levels; and (ii) increase the half-life of the existing pool of FXN mRNA. These two mechanisms are addressed by two different oligonucleotides, both of which are incorporated into a single SNA molecule at a defined ratio in XCUR-FXN.  In preclinical experiments, we observed that XCUR-FXN increased frataxin protein levels in fibroblasts and neurons derived from FA patients to near normal levels. Importantly, we observed near normal levels of frataxin protein in mitochondrion, the target cellular compartment, and 70-80% of near normal mitochondrial activity in neurons derived from FA patients.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have tested SNAs consisting of the two individual oligonucleotide components of XCUR-FXN in a Pook800J mouse model.  This model contains a hemizygous insertion of the human disease allele with approximately 800 GAA repeats, and lacks endogenous mouse FXN. For reference, in humans, 800 GAA repeats would represent classic FA disease manifestation with an early disease onset. The mice were administered one of the two XCUR-FXN oligonucleotide components at one of two dose levels via a single intra-cisterna magna injection.  After 14 days, key regions of the brain and spinal cord were harvested and analyzed for frataxin protein levels. As illustrated in the figure below, the components of XCUR-FXN increased frataxin protein levels by 2-3 fold in the cerebellum, cortex, and dorsal root ganglia neurons; these regions we believe are critical for addressing neurological manifestations of FA. We also found similar increases in frataxin protein levels in the brainstem, the midbrain and throughout the spinal cord.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><img src="xcur-20210630_g2.jpg" alt="xcur-20210630_g2.jpg" style="height:179px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> experiments, we have observed synergistic upregulation of FXN mRNA in cells treated with XCUR-FXN compared to its individual components alone at the same total oligonucleotide dose. We believe this effect, if recapitulated in FA patients, could represent a functional cure for patients with similar level of GAA repeat expansion. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated IND-enabling studies for XCUR-FXN in late 2020. As discussed during our R&amp;D day presentation in July 2021, in a completed non-GLP dose range finding study of XCUR-FXN in rats, designed to evaluate the safety profile of XCUR-FXN following intrathecal dosing, we have not observed any test article-related adverse findings and the highest dose level in this study (three repeat intrathecal (IT) injections of 782 &#181;g each) was the no-observed-adverse-effect level (NOAEL) in this study. We expect to complete our GLP toxicology program and file an IND for XCUR-FXN in FA in the fourth quarter of 2021, and expect to initiate a first-in-patient Phase 1b clinical trial for XCUR-FXN in FA in the first half of 2022. We are collaborating closely with the Friedreich&#8217;s Ataxia Research Alliance (FARA), the non-profit, charitable organization dedicated to accelerating research leading to treatments and a cure for FA, in the design and site selection of the Phase 1b clinical trial. The Phase 1b clinical trial is designed to demonstrate safety and characterize pharmacokinetic properties of multiple ascending doses of XCUR-FXN in FA patients and inform Phase 2/3 dose selection. We are also planning to examine multiple biomarkers, including brain imaging and measurements of FXN levels in patient cerebrospinal fluid (CSF), to provide rapid read-out for target engagement and pharmacodynamic (PD) effects. We may include one or more exploratory endpoints, such as the modified Friedreich&#8217;s Ataxia Rating Scale (mFARS), to prepare for a subsequent pivotal clinical trial.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other neurological indications</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are building on our proof-of-concept work generated to date and our therapeutic candidate XCUR-FXN to further explore new therapeutic applications of our SNA technology in neurology. On July 15, 2021, we presented preclinical data during a virtual research and development investor presentation related to programs targeting sodium voltage-gated channel alpha subunit 9 (SCN9A, or Na</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">v</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7) for neuropathic pain, CLN3 for Batten disease and SCA3 for spinocerebellar ataxia 3, which is summarized below.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our SCN9A-targeting program, we have identified a number of compounds that reduce target mRNA levels by up to 95% in induced pluripotent stem cell (iPSC)-derived human sensory neurons. Our SNA compounds appear highly selective for SCN9A and have minimal measurable effect on other SCN family members. We believe the selectivity of our SNA compounds for SCN9A over other members of the SCN family is a key differentiator for our program over SCN9A-targeting small molecules which have been historically plagued by off target effects on other SCN family members. We are currently further characterizing a number of promising SNC9A-targeting SNAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our CLN3 targeted program, we have identified compounds that correct the splicing of CLN3 mRNA and produce a truncated but stable mRNA transcript. Based on published literature, we believe this truncated mRNA transcript will be translated into a shortened, but functional protein. We have identified SNA compounds that splice convert up to 95% of mutant CLN3 mRNA into this splice-corrected form and increase overall CLN3 mRNA levels by an average of 242% compared to untreated cells (set to 100%) in CLN3 homozygous mutant fibroblasts. In a proof-of-concept </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> experiment, CLN3&#916;ex7/8 homologous mice were dosed intravitreally with a select CLN3 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">targeted SNA or vehicle. Eight days after the treatment, mice retinae were examined for total CLN3 mRNA levels. We observed that the SNA treated mice had nearly three times the total CLN3 mRNA levels compared to vehicle-treated mice, meaning the SNA treatment normalized the total CLN3 mRNA levels in the CLN3&#916;ex7/8 homologous mice to those measured in wildtype mice. We believe this initial </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proof-of-concept in mice provides evidence supporting the potential of SNAs to treat the ocular manifestations of CLN3 Batten disease.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently exploring additional neurological conditions, including other spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), Huntington&#8217;s disease, and Angelman syndrome.  Refer to Note 15,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the accompanying unaudited condensed consolidated financial statements for details surrounding the Company&#8217;s collaboration agreement with Ipsen for Huntington&#8217;s disease and Angelman syndrome. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cavrotolimod (AST-008)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August 4, 2021, we had 21 clinical trial sites open for enrollment and 8 additional sites pending activation.  We expect to open up to 30 sites for the Phase 2 stage of the clinical trial.  We anticipate all sites will be activated by the end of 2021. As of August 4, 2021, we had dosed 31 patients with 32 mg of cavrotolimod (AST-008) in the Phase 2 portion of the clinical trial, including the primary and exploratory cohorts.  Including the six patients dosed with 32 mg of cavrotolimod (AST-008) in the Phase 1b portion of the clinical trial, a total of 37 patients have been dosed with 32 mg of cavrotolimod (AST-008) through August 4, 2021.  As of August 4, 2021, 2 of the 37 patients dosed with 32 mg of cavrotolimod (AST-008) have experienced serious adverse events, or SAEs, assessed as related to cavrotolimod by clinical trial investigators.  Both of these patients were dosed in the Phase 2 stage of the clinical trial. Treatment-related hypotension and flu-like symptoms were reported in one patient. In a second patient, a treatment-related infusion-related reaction was reported.  None of the 14 patients dosed in the Phase 1b portion of the clinical trial with doses of cavrotolimod (AST-008) less than 32 mg experienced a treatment related SAE. Thus, as of August 4, 2021, in total, 2 of 51 patients treated with cavrotolimod (AST-008) have experienced a treatment-related SAE.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we announced that the U.S. Food and Drug Administration, or FDA, has granted Fast Track designations for cavrotolimod (AST-008), for two development programs: (i) cavrotolimod in combination with anti-programmed death (PD)-1 or anti-PD ligand 1 (PD-L1) therapy for the treatment of patients with locally advanced or metastatic Merkel cell carcinoma, or MCC, refractory to prior anti-PD-(L)1 blockade and (ii) cavrotolimod in combination with anti-PD-1 therapy for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma, or CSCC, refractory to prior anti-PD-1 blockade.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we announced that the FDA has granted Orphan Drug Designation for cavrotolimod (AST-008) for the treatment of patients with MCC.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, we presented our interim findings from the Phase 2 portion of the Phase 1b/2 clinical trial for cavrotolimod (AST-008). The Phase 2 stage of the clinical trial is evaluating cavrotolimod in combination with pembrolizumab (KEYTRUDA&#174;) or cemiplimab (LIBTAYO&#174;) in patients with locally advanced or metastatic solid tumors refractory to anti-PD-(L)1 therapy in two primary dose-expansion cohorts, one in MCC and one in CSCC, and three exploratory cohorts.  The response rate threshold was achieved to continue advancing patient enrollment in the Phase 2 MCC dose-expansion cohort. The confirmed overall response rate, or ORR, is 21% in all evaluable MCC patients enrolled to date in the Phase 1b/2 clinical trial.  The median duration of four Phase 1b stage responders is 14 months with the longest response to date of 17 months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key results from the Phase 2 stage include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">As of the data cut-off date of July 1, 2021, 26 patients, all with documented progression on anti-PD-(L)1 therapy, have been dosed in the Phase 2 stage, of whom 17 patients were evaluable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Nine of the 17 evaluable patients were in the MCC cohort and, per RECIST v1.1, best overall response was a complete response, or CR), in one MCC patient and stable disease in one MCC patient. </span></div><div style="padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Injected and non-injected tumor lesions completely resolved in the MCC patient with a CR, supporting systemic (abscopal) effects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">The CR in one MCC patient met the pre-specified Phase 2 stage threshold to continue advancing patient enrollment in the MCC dose-expansion cohort.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The remaining 8 evaluable patients were enrolled in either the CSCC dose-expansion cohort, in which enrollment and data accrual is continuing, or in the exploratory cohorts.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The majority (93%) of treatment-related adverse events (TRAEs) were grade 1 or grade 2. The most common TRAEs were injection-site reactions and flu-like symptoms.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Two patients experienced serious adverse events assessed as related to cavrotolimod by clinical trial investigators. Treatment-related hypotension and flu-like symptoms were reported in one melanoma patient and a treatment-related injection reaction was reported in one MCC patient.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The confirmed ORR in all evaluable MCC patients enrolled in total in the Phase 1b/2 clinical trial was 21% (three of 14) as of the July 1, 2021 data cutoff date.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The three patients were comprised of two CRs and one partial response, or PR.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Biopsy of individual tumor lesions of the MCC patient assessed as PR by RECIST v1.1 revealed no evidence of residual tumor.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pending further enrollment delays or any unanticipated effects of the COVID-19 pandemic on our clinical development plans, we expect to report ORR results of cavrotolimod in the first half of 2022. We will also continue to seek opportunities to advance this program through strategic collaborations or partnerships with the goal of maximizing stockholder value of the program and the full potential of our pipeline. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration, License, and Option Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021, we entered into a Collaboration, Option and License Agreement, or Ipsen Collaboration Agreement, with IPSEN BIOPHARM LIMITED, or Ipsen. Pursuant to the Ipsen Collaboration Agreement, we granted to Ipsen exclusive access and options to license SNA based therapeutics arising from two collaboration programs related to the treatment of Huntington&#8217;s disease and Angelman syndrome, respectively. Refer to Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the accompanying unaudited condensed consolidated financial statements for more information regarding the Ipsen Collaboration Agreement.</span></div><div id="ia49112dadce14be6836937c1a8779dad_88"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Business Update</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the global spread of the COVID-19 pandemic during 2020 and into 2021, we continue to monitor closely the developments and continue to take active measures to protect the health of our employees and their families, our communities, as well as our clinical trial investigators, patients, and caregivers.  On June 11, 2021, Illinois moved into &#8220;Phase 5&#8221; of the Restore Illinois Plan, which is intended to permit businesses to operate at full capacity and permits fully vaccinated individuals to resume activities without wearing a mask except where required by federal, state, local, tribal, or territorial laws, rules and regulations, including local business and workplace guidance.  As of August 9, 2021, Illinois remains in &#8220;Phase 5&#8221; of the Restore Illinois Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business and R&amp;D operations</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the COVID-19 pandemic&#8217;s impact on our business and R&amp;D operations from those which were discussed in our Annual Report on Form 10-K for the year ended December 31, 2020 and our Quarterly Report on Form 10-Q for the three months ended March 31, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply chain </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been no significant changes to the COVID-19 pandemic&#8217;s impact on our supply chain from those which were discussed in our Annual Report on Form 10-K for the year ended December 31, 2020 and our Quarterly Report on Form 10-Q for the three months ended March 31, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical operations</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the effects of the COVID-19 pandemic or its impact contributed to delays during the second half of 2020 and the first half of 2021 in our enrollment plans and clinical trial site start-ups for the Phase 2 dose expansion phase of the Phase 1b/2 clinical trial of cavrotolimod (AST-008) in patients with advanced or metastatic Merkel cell carcinoma, or cutaneous squamous cell carcinoma. As a result, we have taken additional measures to increase the enrollment of patients, including frequent interaction with our clinical trial sites currently open as well as increasing the number of clinical trial sites that potentially are activated for this trial so that we may continue to enroll patients as initially planned. However, any additional delays may require us to further lengthen our clinical development timeline for cavrotolimod (AST-008) and could potentially delay our proposed clinical development timeline for XCUR-FXN.  Pending further enrollment delays or any unanticipated effects of the COVID-19 pandemic on our clinical development plans, we expect to report ORR results of cavrotolimod in the first half of 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We remain committed to maintaining our development plans for cavrotolimod (AST-008) and XCUR-FXN and continue to monitor and manage the rapidly evolving situation of the effects of the pandemic. We have taken and continue to take measures to implement remote and virtual approaches, including remote patient monitoring where possible, to maintain patient safety and trial continuity and to preserve study integrity. Should the COVID-19 pandemic or its impact or effects continue, our ability to maintain patient enrollment and our clinical development timeline could continue to be negatively impacted. We could also see an impact on our ability to supply study drug, report trial results, or interact with regulators, ethics committees or other important agencies due to limitations in regulatory authority employee resources or otherwise. In addition, we rely on contract research organizations or other third parties to assist us with clinical trials, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the COVID-19 pandemic. As the COVID-19 pandemic continues to persist for an extended period of time, we continue to be impacted and could experience additional delays in patient enrollment for our Phase 2 stage of the Phase 1b/2 clinical trial of cavrotolimod (AST-008). Any significant disruptions to our clinical development timelines would further delay our anticipated timeline for results and adversely affect our business, financial condition, results of operations and growth prospects. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="ia49112dadce14be6836937c1a8779dad_91"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the revenue and expenses incurred during the reported periods. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ from these estimates under different assumptions or conditions, including uncertainty in the current economic environment due to the outbreak of COVID-19.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies require the most significant judgments and estimates in the preparation of our consolidated financial statements. There have been no significant changes to our critical accounting policies from those which were discussed in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements not yet adopted</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the accompanying unaudited condensed consolidated financial statements for a description of recently accounting pronouncements not yet updated.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Three Months Ended June 30, 2021 and 2020</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the three months ended June 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.429%"><tr><td style="width:1.0%"></td><td style="width:41.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.392%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,862)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,390)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,472)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Dividend income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(407)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,269)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,311)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,958)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,269)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,311)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,958)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue earned during the periods indicated:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.224%"><tr><td style="width:1.0%"></td><td style="width:45.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie Collaboration Agreement</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermelix Collaboration Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,847&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,847&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was $0.1 million during the three months ended June 30, 2021, reflecting a decrease of $4.8 million, or 98%, from collaboration revenue of $4.8 million for the three months ended June 30, 2020.  Collaboration revenue in both the three months ended June 30, 2021 and 2020 primarily related to activities performed under the AbbVie Collaboration Agreement.  The decrease in collaboration revenue of $4.8 million  reflects less progress occurring in the three months ended June 30, 2021 relative to the estimate of total projected hours to complete the research services under the AbbVie Collaboration Agreement.  Revenue for the three months ended June 30, 2021 reflects events and conditions that occurred during that period that increased the number of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hours estimated to be required to complete the services under the AbbVie Collaboration Agreement. These increased estimated efforts resulted in less progress occurring relative to the increased estimate of total projected hours to complete the research services (and thus limited revenue recognized) during the three months ended June 30, 2021 and compared to the amount of revenue recognized in the comparable period. In November 2019, we received an upfront payment of $25.0 million in connection with the AbbVie Collaboration Agreement for which revenue has been deferred and will be recognized as revenue in future periods as we satisfy our obligations under the AbbVie Collaboration Agreement.  At June 30, 2021, deferred revenue under the AbbVie Collaboration Agreement was $7.3 million and is expected to be recognized as revenue over the next twelve months as we satisfy our obligations under the AbbVie Collaboration Agreement.  Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the accompanying unaudited condensed consolidated financial statements for more information regarding revenue recognition for the AbbVie Collaboration Agreement.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate any product revenue for the foreseeable future. However, future revenue may include amounts attributable to partnership activities including, a combination of research and development payments, license fees and other upfront payments, milestone payments, product sales and royalties, and reimbursement of certain research and development expenses, in connection with the AbbVie Collaboration Agreement, the Ipsen Collaboration Agreement, or the Dermelix License Agreement or any future collaboration and licenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses incurred during the periods indicated:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars&#160;in&#160;thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development programs expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and discovery-related expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities, depreciation, and other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full time employees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense was $10.8 million for the three months ended June 30, 2021, reflecting an increase of $3.8 million, or 55%, from research and development expense of $7.0 million for the three months ended June 30, 2020.  Since June 30, 2020, we have increased our headcount in research and development from 41 to 66 at June 30, 2021. The increase in research and development expense for the three months ended June 30, 2021 of $3.8 million reflects this increased headcount and the related increase in research and development activities, to include increased clinical trial activities.  More specifically, the increase in research and development expense for the three months ended June 30, 2021 of $3.8 million was primarily due to a net increase in costs related to our clinical development programs of $2.5 million, higher employee-related expenses of $1.4 million and higher facilities, depreciation, and other expenses of $0.3 million, partially offset by lower platform and discovery-related expense of $0.4 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net increase in clinical development programs expense for the three months ended June 30, 2021 of $2.5 million was primarily due to manufacturing costs in connection with the preparation of IND-enabling and Phase 1 clinical trial activities for XCUR-FXN, in addition to higher clinical trial costs in connection with our Phase 1b/2 clinical trial for cavrotolimod (AST-008), partially offset by lower manufacturing costs for cavrotolimod (AST-008).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in employee-related expense for the three months ended June 30, 2021 of $1.4 million was due to higher compensation and related costs in connection with the net increase in headcount during the period presented as well as certain salary increases in 2021 for existing employees. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in facilities, depreciation, and other expenses for the three months ended June 30, 2021 of $0.3 million was mostly due to higher lease costs related to our Chicago Lease that commenced on July 1, 2020 as well as higher depreciation expense in connection with the acquisition of additional scientific equipment that were placed in service since the prior-year period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in platform and discovery-related expense of $0.4 million is mostly due to lower costs for materials and reagents mostly in connection with the absence of material-intensive discovery efforts associated with the AbbVie Collaboration Agreement that occurred during the three months ended June 30, 2020, as well as lower intellectual property costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to continue to increase during 2021 as compared to 2020 as we broaden our pipeline of SNA-based therapeutic candidates, continue investment into our clinical development programs, and further develop our SNA technology platform.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expense</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars&#160;in&#160;thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,098&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full time employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense was $3.1 million for the three months ended June 30, 2021, representing an increase of $0.9 million, or 39%, from $2.2 million for the three months ended June 30, 2020.  The increase for the three months ended June 30, 2021 is mostly due to higher compensation and related costs in connection with salary increases in 2021 and an increase in headcount, as well as higher costs for consulting services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest income of $0.2 million for the three months ended June 30, 2021 was primarily the result of lower average balances invested in available for sale securities during the three months ended June 30, 2021 as compared to the prior-year period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in interest expense of $0.5 million for the three months ended June 30, 2021 was the result of a higher average debt balance during the three months ended June 30, 2021 as compared to the prior-year period.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Six Months Ended June 30, 2021 and 2020</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the six months ended June 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.429%"><tr><td style="width:1.0%"></td><td style="width:41.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.392%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,954)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,954)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,019)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,856)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,163)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Dividend income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(731)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(727)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,422)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,746)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,161)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,585)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,746)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,161)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,585)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue earned during the periods indicated:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.224%"><tr><td style="width:1.0%"></td><td style="width:45.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie Collaboration Agreement</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,873)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermelix Collaboration Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,030&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,954)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,030&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,954)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was $1.1 million during the six months ended June 30, 2021, reflecting a decrease of $13.0 million, or 92%, from collaboration revenue of $14.0 million for the six months ended June 30, 2020.  Collaboration revenue in both the six months ended June 30, 2021 and 2020 primarily related to activities performed under the AbbVie Collaboration Agreement.  The decrease in collaboration revenue of $13.0 million reflects less progress occurring in the six months ended June 30, 2021 relative to the estimate of total projected hours to complete the research services under the AbbVie Collaboration Agreement.  In November 2019, we received an upfront payment of $25.0 million in connection with the AbbVie Collaboration Agreement for which revenue has been deferred and will be recognized as revenue in future periods as we satisfy our obligations under the AbbVie Collaboration Agreement.  At June 30, 2021, deferred revenue under the AbbVie Collaboration Agreement was $7.3 million and is expected to be recognized as revenue over the next twelve months as we satisfy our obligations under </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the AbbVie Collaboration Agreement.  Revenue for the six months ended June 30, 2021 reflects events and conditions that occurred during that period that increased the number of hours estimated to be required to complete the services under the AbbVie Collaboration Agreement. These increased estimated efforts resulted in less progress occurring relative to the increased estimate of total projected hours to complete the research services (and thus limited revenue recognized) during the six months ended June 30, 2021 and compared to the amount of revenue recognized in the comparable period.  Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the accompanying unaudited condensed consolidated financial statements for more information regarding revenue recognition for the AbbVie Collaboration Agreement.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate any product revenue for the foreseeable future. However, future revenue may include amounts attributable to partnership activities including, a combination of research and development payments, license fees and other upfront payments, milestone payments, product sales and royalties, and reimbursement of certain research and development expenses, in connection with the AbbVie Collaboration Agreement, the Ipsen Collaboration Agreement, or the Dermelix License Agreement or any future collaboration and licenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses incurred during the periods indicated:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars&#160;in&#160;thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development programs expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and discovery-related expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities, depreciation, and other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full time employees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense was $21.1 million for the six months ended June 30, 2021, reflecting an increase of $8.0 million, or 61%, from research and development expense of $13.1 million for the six months ended June 30, 2020.  Since June 30, 2020, we have increased our headcount in research and development from 41 to 66 at June 30, 2021. The increase in research and development expense for the six months ended June 30, 2021 of $8.0 million reflects this increased headcount and the related increase in research and development activities, to include increased clinical trial activities.  More specifically, the increase in research and development expense for the six months ended June 30, 2021 of $8.0 million was primarily due to a net increase in costs related to our clinical development programs of $3.5 million, higher employee-related expenses of $2.7 million, higher facilities, depreciation, and other expenses of $1.1 million and higher platform and discovery-related expense of $0.7 million .</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net increase in clinical development programs expense for the six months ended June 30, 2021 of $3.5 million was primarily due to manufacturing costs in connection with the preparation of IND-enabling and Phase 1 clinical trial activities for XCUR-FXN, in addition to higher clinical trial costs in connection with our Phase 1b/2 clinical trial for cavrotolimod (AST-008), partially offset by lower manufacturing costs for cavrotolimod (AST-008).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in employee-related expense for the six months ended June 30, 2021 of $2.7 million was due to higher compensation and related costs in connection with the net increase in headcount during the period presented as well as certain salary increases in 2021 for existing employees. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in facilities, depreciation, and other expenses for the six months ended June 30, 2021 of $1.1 million was mostly due to higher lease costs related to our Chicago Lease that commenced on July 1, 2020 as well as </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">higher depreciation expense in connection with the acquisition of additional scientific equipment that were placed in service since the prior-year period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in platform and discovery-related expense of $0.7 million is mostly due to higher costs for materials, reagents, supplies and contract research organizations, all in connection with increased research and development activities related to our FA program, XCUR-FXN, our discovery efforts for other therapeutic candidates for neurology and ophthalmology, and the AbbVie Collaboration Agreement, partially offset by lower intellectual property costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to continue to increase during 2021 as compared to 2020 as we broaden our pipeline of SNA-based therapeutic candidates, continue investment into our clinical development programs, and further develop our SNA technology platform.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expense</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars&#160;in&#160;thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full time employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense was $6.0 million for the six months ended June 30, 2021, representing an increase of $1.2 million, or 25%, from $4.8 million for the six months ended June 30, 2020.  The increase for the six months ended June 30, 2021 is mostly due to higher compensation and related costs mostly due to salary increases in 2021 and an increase in headcount, recruiting costs, particularly for certain executive and senior vice president positions, higher costs for consulting services, and higher D&amp;O insurance premium costs.  This increase was partially offset by lower accounting, legal, and investor relations costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest income of $0.5 million for the six months ended June 30, 2021 was primarily the result of lower average balances invested in available for sale securities during the six months ended June 30, 2021 as compared to the prior-year period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in interest expense of $0.7 million for the six months ended June 30, 2021 was the result of a higher average debt balance during the six months ended June 30, 2021 as compared to the prior-year period.</span></div><div id="ia49112dadce14be6836937c1a8779dad_97"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, our cash, cash equivalents, short-term investments, and restricted cash were $57.3 million.  As of June&#160;30, 2021, we have generated an accumulated deficit of $151.5 million since inception and expect to incur significant expenses and negative cash flows for the foreseeable future.  Based on our current operating plans, we believe that existing working capital at June 30, 2021, including the $20.0 million upfront payment received in August 2021 in connection with the Ipsen Collaboration Agreement and amounts borrowed and available under the MidCap Credit Facility (see below), is sufficient to fund our operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q.  Management believes that we will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, such as our &#8220;at the market offering&#8221; program pursuant to our equity distribution agreement with BMO Capital Markets Corp., to fund our current operations and business strategy. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to us.  We have historically principally raised capital through the sale of our securities.  However, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  If the disruption continues to persist and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our ability to raise capital and ultimately, our operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2020, we borrowed the first advance of $17.5 million (Tranche 1) under the terms of the MidCap Credit Agreement.  The second advance of $7.5 million (Tranche 2) will be available to us from April 1, 2021 to September 30, 2021, subject to our satisfaction of certain conditions described in the MidCap Credit Agreement.  We believe the conditions to access the available Tranche 2 amount are satisfied as of June 30, 2021.  See &#8220;&#8212;MidCap Credit Agreement&#8221; below for additional information.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into an equity distribution agreement with BMO under which we may offer and sell in &#8220;at the market offerings&#8221; (as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended) from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $50.0 million through BMO acting as our distribution agent, or the ATM Offering, pursuant to a prospectus supplement and a shelf registration statement on Form S-3 that was declared effective by the SEC on January 7, 2021.  This shelf registration statement allows us to sell from time-to-time up to $150.0 million of common stock, preferred stock, debt securities, warrants, or units comprised of any combination of these securities, for our own account in one or more offerings; the remaining amount available under this shelf registration is approximately $150.0 million. Through June 30, 2021, we have not sold any shares under the equity distribution agreement. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we filed a shelf registration statement on Form S-3 with the SEC, which was declared effective by the SEC on July 24, 2019. This shelf registration statement allows us to sell from time-to-time up to $125.0 million of common stock, preferred stock, debt securities, warrants, or units comprised of any combination of these securities, for our own account in one or more offerings; the remaining amount available under this shelf registration is approximately $31.3 million. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to other development stage biotechnology companies, we have not generated any revenue since inception.  We have incurred losses and experienced negative operating cash flows since our inception and anticipate that we will continue to incur losses for at least the next several years. As of June 30, 2021, we have generated an accumulated deficit of $151.5 million. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See &#8220;&#8212;Funding Requirements&#8221; below for additional information on our future capital needs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the six months ended June 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,885)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,062)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $25.9 million and $18.8 million for the six months ended June 30, 2021 and 2020, respectively. The increase in cash used in operating activities for the six months ended June 30, 2021 of $7.1 million was primarily due to higher cash used for working capital.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities was $34.5 million and $(9.0) million for the six months ended June 30, 2021 and 2020, respectively. The increase in cash provided by investing activities of $43.5 million was primarily due to lower purchases, net of maturities, of available-for-sale securities, as well as a decrease in the purchase of scientific equipment of $2.4 million. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities of $0.7 million&#160;for six months ended June 30, 2021 is due to the proceeds received from the exercise of stock options and the issuance of common stock in connection with our employee stock purchase plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities of $2.3 million for the six months ended June 30, 2020 is mostly due to the repayment of the loan with Hercules Technology Growth Capital in the amount of $5.0 million upon the loan&#8217;s maturity, partially offset by the net proceeds received from the sale of shares of our common stock in the amount of $2.8 million pursuant to the partial exercise of the option to purchase additional shares by the underwriters from our December 2019 financing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MidCap Credit and Security Agreement</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 25, 2020, we and our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">wholly owned subsidiary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Exicure Operating Company, entered into the MidCap Credit Agreement, with MidCap , as agent, and the lenders party thereto from time to time.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement provides for a secured term loan facility in an aggregate principal amount of up to $25.0 million, or the MidCap Credit Facility. We borrowed the first advance of $17.5 million, or Tranche 1, on September 25, 2020, or the Closing Date. Under the terms of the MidCap Credit Agreement, the second advance of $7.5 million, or Tranche 2, will be available to us from April 1, 2021 to September 30, 2021, subject to our satisfaction of certain conditions described in the MidCap Credit Agreement. We believe the conditions to access the available Tranche 2 amount are satisfied as of June 30, 2021.  The proceeds from the MidCap Credit Facility are expected to be used for working capital and general corporate purposes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tranche 1, and if borrowed Tranche 2, each bear interest at a floating rate equal to 6.25% per annum, plus the greater of (i) 1.50% or (ii) one-month LIBOR. Interest on each loan advance is due and payable monthly in arrears. Principal on each loan advance is payable in 36 equal monthly installments beginning October 1, 2022 until paid in full on October 1, 2025, or Maturity Date. Prepayments of the loans under the MidCap Credit Agreement, in whole or in part, will be subject to early termination fees in an amount equal to 3.0% of principal prepaid if prepayment occurs on or prior to the first anniversary of the Closing Date and 1.0% of principal prepaid if prepayment occurs after the first anniversary of the Closing Date and prior to the maturity date. In connection with execution of the MidCap Credit Agreement, we paid MidCap a $125,000 origination fee.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Maturity Date or on any earlier date on which all amounts advanced to us become due and payable in full, or are otherwise paid in full, we are required to pay an exit fee equal to 3.75% of the principal amount of all loans advanced to us under the MidCap Credit Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the MidCap Credit Agreement are secured by a security interest in substantially all of our assets, excluding intellectual property (which is subject to a negative pledge). Additionally, our future subsidiaries, if any, may be required to become co-borrowers or guarantors under the MidCap Credit Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement contains customary affirmative covenants and customary negative covenants limiting our ability and the ability of our subsidiaries, if any, to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, delisting of our common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, the agent and the lenders may declare all or a portion of our outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the agreement. During the existence of an event of default, interest on the obligations could be increased by 2.0%.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our primary uses of capital will continue to be third-party clinical and research and development services, compensation and related expenses, laboratory and related supplies, legal and other regulatory expenses and general overhead costs. Because of the numerous risks and uncertainties associated with research, development and commercialization of therapeutic candidates, we are unable to estimate the exact amount of our working capital requirements. Our future capital requirements are difficult to forecast and will depend on many factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the terms and timing of any other collaboration, licensing and other arrangements that we may establish;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing and completion of preclinical studies and clinical trials for our potential therapeutic candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of health epidemics, including the ongoing COVID-19 pandemic, on our operations or the business or operations of our CROs or other third parties with whom we conduct business;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the number and characteristics of therapeutic candidates that we pursue;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the progress, costs and results of our preclinical studies and clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the outcome, timing and cost of regulatory approvals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">delays that may be caused by changing regulatory requirements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the cost and timing of hiring new employees to support our continued growth;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">unknown legal, administrative, regulatory, accounting, and information technology costs as well as additional costs associated with operating as a public company;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing and prosecuting intellectual property rights and enforcing and defending any intellectual property-related claims;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the costs and timing of procuring clinical and commercial supplies of our therapeutic candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the extent to which we acquire or in-license other therapeutic candidates and technologies; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the extent to which we acquire or invest in other businesses, therapeutic candidates or technologies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our current operating plans, we believe that our existing working capital at June 30, 2021, including the $20.0 million upfront payment received in August 2021 in connection with the Ipsen Collaboration Agreement and amounts borrowed and available under the MidCap Credit Facility is sufficient to fund our operations for at least 12 months from the date of this Quarterly Report on Form 10-Q.  We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we expect. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. The COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  If the disruption continues to persist and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through future equity financings, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, reduce or eliminate our product development efforts or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="ia49112dadce14be6836937c1a8779dad_100"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our contractual obligations and commitments from those described in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="ia49112dadce14be6836937c1a8779dad_103"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-balance Sheet Arrangements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="ia49112dadce14be6836937c1a8779dad_106"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as an emerging growth company, we will not be required to provide an auditor&#8217;s attestation report on our internal control over financial reporting in future annual reports on Form 10-K as otherwise required by Section&#160;404(b) of the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act.  Our compliance with Section 404 of the Sarbanes-Oxley Act first became subject to management&#8217;s assessment regarding internal control over financial reporting in connection with the filing of our Annual Report on Form 10-K for the fiscal year ending December 31, 2018, and we will not be required to have an independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting until the filing of our first Annual Report on Form 10-K after we lose emerging growth company status, which may not be until the 2023 Annual Report on Form 10-K.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we are also a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended, or Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="ia49112dadce14be6836937c1a8779dad_109"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="ia49112dadce14be6836937c1a8779dad_112"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.  Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective. Accordingly, management believes that the financial statements included in this report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously seek to improve the efficiency and effectiveness of our internal controls. There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act during the fiscal quarter ended June 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="ia49112dadce14be6836937c1a8779dad_118"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to other information contained in this Quarterly Report on Form 10-Q, the following risks should be considered in evaluating our business and future prospects and an investment in our common stock. The risks and uncertainties described below are not the only ones we face. If any of the following risks and uncertainties develops into actual events, our business, financial condition, results of operations and cash flows could be materially adversely affected. In that case, the price of our common stock could decline and you may lose all or part of your investment. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a clinical-stage biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company developing therapeutics for immuno-oncology, genetic disorders and other indications based on our proprietary SNA technology.  Since our inception in June 2011, we have devoted our resources to the development of SNA technology.  We have had significant operating losses since our inception.  As of June 30, 2021, we have generated an accumulated deficit of $151.5 million. For the six months ended June 30, 2021 and 2020, our net loss was $26.7 million and $3.2 million, respectively. Substantially all of our losses have resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations. Our technology and therapeutic candidates are in early stages of development, and we are subject to the risks of failure inherent in the development of therapeutic candidates based on novel technologies. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated, and do not expect to generate, any product revenue for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies, clinical trials, and the regulatory approval process for therapeutic candidates. The amount of future losses is uncertain. Our ability to achieve profitability, if ever, will depend on, among other things, us, or any current or future collaborators, successfully developing therapeutic candidates, obtaining regulatory approvals to market and commercialize therapeutic candidates, manufacturing any approved products on commercially reasonable terms, establishing a sales and marketing organization or suitable third-party alternatives for any approved product and raising sufficient funds to finance business activities. If we, or any current or future collaborators, are unable to develop and commercialize one or more of our therapeutic candidates or if sales revenue from any therapeutic candidate that receives approval is insufficient, we will not achieve profitability, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approach to the discovery and development of innovative therapeutic treatments based on our technology is unproven and may not result in marketable products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to develop a pipeline of therapeutic candidates based on our proprietary SNA technology. We believe that therapeutic candidates identified with our therapeutic discovery technology may offer an improved therapeutic approach compared to small molecules and antibodies, as well as several advantages over linear oligonucleotide-based therapeutics. However, the scientific research that forms the basis of our efforts to develop therapeutic candidates based on our SNA technology and the identification and optimization of SNA-based therapeutic candidates is relatively new. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on SNA technology is both preliminary and limited. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutic candidates based on SNA technology have not been extensively tested in humans, and a number of clinical trials conducted by other companies using oligonucleotide technologies have not been successful. We may discover that the SNA-based therapeutic candidates do not possess certain properties required for therapeutic treatment to be effective, such as the ability to remain stable in the human body for the period of time required for the therapeutic candidate to reach the target tissue or the ability to cross the cell membrane and enter into cells within the target tissue for effective delivery. We currently have only limited data, and no conclusive evidence, to suggest that we can introduce these necessary drug-like properties into SNA-based therapeutic candidate. We may spend substantial funds attempting to introduce these properties and may never succeed in doing so. In addition, therapeutic candidates based on SNA technology may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. Even if therapeutic candidates have successful results in animal studies, they may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result, we may never succeed in developing a marketable therapeutic, we may not become profitable and the value of our common stock would decline. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the U.S. Food and Drug Administration, or FDA, and equivalent foreign regulatory authorities have limited experience with SNA-based therapeutics. No regulatory authority has granted approval to any person or entity, including us, to market and commercialize SNA-based therapeutics, which may increase the complexity, uncertainty and length of the regulatory approval process for our therapeutic candidates. We and any current or future collaborators may never receive approval to market and commercialize any therapeutic candidate. Even if we or a future collaborator obtain regulatory approval, the approval may be for disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or a future collaborator may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If our SNA technology proves to be ineffective, unsafe or commercially unviable, our technology and pipeline would have little, if any, value, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our therapeutic candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no therapeutics on the market and all of our therapeutic candidates are in early stages of development. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals, including an institutional review board, or IRB, approval to conduct clinical trials at particular sites for, and successfully commercializing, our therapeutic candidates, either alone or with third parties. Before obtaining regulatory approval for the commercial distribution of our therapeutic candidates, we or an existing or a future collaborator must conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy in humans of our therapeutic candidates. Preclinical studies and clinical trials are expensive, difficult to design and implement, can take many years to complete and are uncertain as to outcome. The start or end of a clinical trial is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparative therapeutic or required prior therapy, clinical outcomes or financial constraints. For instance, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development times or termination of a clinical trial. Clinical trials of a new therapeutic candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the therapeutic candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease, and COVID-19-related developments including the extent to which they may interact with any of the foregoing factors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A therapeutic candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for therapeutic candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical studies or early clinical trials of a therapeutic candidate may not predict the results that will be obtained in later phase clinical trials of the therapeutic candidate. We, the FDA, an IRB, an independent ethics committee, or other applicable regulatory authorities may suspend clinical trials of a therapeutic candidate at any time for various reasons, including a finding that subjects participating in such trials are being exposed to unreasonable and significant risk of illness or injury. Similarly, an IRB or ethics committee may suspend a clinical trial at a particular trial site. We may not have the financial resources to continue development of, or to enter into collaborations for, a therapeutic candidate if we experience any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, therapeutic candidates, including: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or inconclusive results from our clinical trials or the clinical trials of others for therapeutic candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">therapeutic-related side effects experienced by participants in our clinical trials or by individuals using therapeutics similar to our therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in submitting INDs or CTAs, or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators or IRBs or ethics committees to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions imposed by the FDA or comparable foreign authorities, such as the European Medicines Agency, or EMA, or European Union national competent authorities, regarding the scope or design of our clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further delays in enrolling research subjects in clinical trials; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">high drop-out rates of research subjects; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate supply or quality of therapeutic candidate components or materials or other supplies necessary for the conduct of our clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater than anticipated clinical trial costs; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">poor effectiveness of our therapeutic candidates during clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular, especially in light of the novelty of our therapeutic candidates;  </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">varying interpretations of data by the FDA and similar foreign regulatory agencies; or</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to accept data from clinical trials conducted outside the United States, or acceptance of these data subject to certain conditions by the FDA. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and generally takes many years to complete, and the outcome is inherently uncertain. Failure can occur at any time and at any stage during the clinical trial process. The results of preclinical studies and early clinical trials of our therapeutic candidates may not be predictive of the result of any subsequent clinical trials. Therapeutic candidates that have shown promising results in early stage clinical trials may still suffer significant setbacks in subsequent clinical trials. We will have to conduct trials in our proposed indications to verify the results obtained to date and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in clinical trials due to&#160;lack of efficacy or adverse safety profiles despite promising results in earlier clinical trials. Moreover, clinical data is often susceptible to varying interpretations and analyses. We do not know whether Phase 1, Phase 2, Phase 3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to receive regulatory approval or market our therapeutic candidates. &#160;If we experience delays in the completion of, or termination of, any clinical trial of our therapeutic candidates, the commercial prospects of our therapeutic candidates may be harmed, and our ability to generate product revenues from any of these therapeutic candidates will be delayed.&#160; In addition, any delays in completing clinical trials will increase our costs, slow down our therapeutic candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.&#160; Any of these occurrences could materially and adversely affect our business, financial condition, results of operations or prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of the clinical trials we conduct may be open-label in study design and may be conducted at a limited number of clinical sites on a limited number of patients. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Moreover, patients selected for early clinical studies often include the most severe sufferers and their symptoms may have been bound to improve notwithstanding the new treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. Given that our planned open-label Phase 1b/2 clinical trial of cavrotolimod (AST-008) includes an open-label dosing design, the results from this clinical trial may not be predictive of future clinical trial results with this or other product candidates for which we conduct an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A Fast Track Designation by the FDA may not actually lead to a faster development or regulatory review or approval process and does not increase the likelihood that our therapeutic candidates will receive marketing approval.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA fast track designation. The FDA has broad discretion whether to grant this designation. We have obtained fast track designations from the FDA for (i) cavrotolimod in combination with anti-PD-1 or anti-PD-L1 therapy for the treatment of patients with locally advanced or metastatic MCC, refractory to prior anti-PD-(L)1 blockade and (ii) cavrotolimod in combination with anti-PD-1 therapy for the treatment of patients with locally advanced or metastatic CSCC, refractory to prior anti-PD-1 blockade. However, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw our fast track designation if the FDA believes that the designation is no longer supported by data from our clinical development program. Our fast track designation does not guarantee that we will qualify for or be able to take advantage of the FDA&#8217;s expedited review procedures. Many drugs that have received Fast Track Designation have failed to obtain marketing approval. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funds to advance the development of our therapeutic candidates, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or future therapeutic candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our existing therapeutic candidates or our future therapeutic candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing, marketing, and sales capabilities or contract with other organizations to provide these capabilities for us. We have used substantial funds to develop our therapeutic candidates and will require significant funds to conduct further research and development and preclinical studies and clinical trials of our therapeutic candidates, to seek regulatory approvals for our therapeutic candidates and to manufacture and market products, if any, that are approved for commercial sale.  As of June 30, 2021, we had $43.8 million in cash, cash equivalents, and restricted cash and $13.5 million in short-term investments. Based on our current operating plans, we believe that existing working capital at June 30, 2021, including the $20.0 million upfront payment received in August 2021 in connection with the Ipsen Collaboration Agreement and amounts borrowed and available under the MidCap Credit Facility, is sufficient to fund our operations for at least 12 months from the date of this Quarterly Report on Form 10-Q.  Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing development and corporate activities. Since the length of time and activities associated with successful development of our therapeutic candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. To execute our business plan, we will need, among other things: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to obtain the human and financial resources necessary to develop, test, obtain regulatory approval for, manufacture and market our therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to build and maintain a strong intellectual property portfolio and avoid infringing the intellectual property of third parties; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to establish and maintain successful licenses, collaborations and alliances; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to satisfy the requirements of clinical trial protocols, including patient enrollment; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to establish and demonstrate the clinical efficacy and safety of our therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to obtain regulatory approvals; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to manage our spending as costs and expenses increase due to preclinical studies and clinical trials, regulatory approvals, and commercialization; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to obtain additional capital to support and expand our operations; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to market our products to achieve acceptance and use by the medical community in general. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, if any, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technology or therapeutic candidates that we would otherwise pursue on our own. We do not expect to realize revenue </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">from product sales, milestone payments or royalties in the foreseeable future, if at all. Our revenue sources are, and will remain, extremely limited unless and until our therapeutic candidates are clinically tested, approved for commercialization and successfully marketed. To date, we have primarily financed our operations through the sale of equity securities, payments received in connection with our collaboration, option, and license agreement with AbbVie Inc., or AbbVie, our research collaboration, license, and option agreement with Purdue Pharma L.P., or Purdue, our license and development agreement with Dermelix LLC, or Dermelix, or as a primary contractor or as a subcontractor on government grants, proceeds from our credit and security agreement with MidCap Financial Trust, or MidCap, and proceeds from our loan agreement with Hercules Technology Growth Capital, or Hercules. We will be required to seek additional funding in the future and intend to do so through either collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms, or at all, and our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. If we raise additional funds by issuing equity securities or by sales pursuant to our &#8220;at the market&#8221; program, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of equity securities received any distribution of corporate assets. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the global COVID&#8209;19 pandemic, in regions where we or third parties on which we rely have business operations and at our clinical trial sites, as well as the business or operations of our CROs or other third parties with whom we conduct business. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the novel strain of coronavirus, SARS-CoV-2, which causes coronavirus disease 2019, or COVID-19, continues to negatively impact the global economy. Our business and operations could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic, on our business activities performed by us or by third parties with whom we conduct business, including our third party manufacturers, contract research organizations, or CROs, shippers and others. Such effects could be more pronounced in regions where we have concentrations of clinical trial sites or other business operations. Our company headquarters is located in Chicago, Illinois, our CROs are located globally, and our substance and drug product manufacturers are located in the United States and Europe.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2021, Illinois moved into &#8220;Phase 5&#8221; of the Restore Illinois Plan, which is intended to permit businesses to operate at full capacity and permits fully vaccinated individuals to resume activities without wearing a mask except where required by federal, state, local, tribal, or territorial laws, rules and regulations, including local business and workplace guidance.  As of August 9, 2021, Illinois remains in &#8220;Phase 5&#8221; of the Restore Illinois Plan.  Certain jurisdictions have begun re-opening only to return to restrictions in the face of increases in new COVID-19 cases. The extent of and timing for lifting of government restrictions remains uncertain as the COVID-19 pandemic continues to evolve. There is no guarantee that prior or new restrictions will not be reinstated in response to the continued spread of COVID-19.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to current and prior public health directives and orders and to ensure the safety and wellbeing of our employees, we have implemented work-from-home policies to support the community efforts to reduce the transmission of COVID-19 and protect employees, complying with guidance from federal, state/provincial or municipal government and health authorities. We implemented a number of measures to ensure employee safety and business continuity.  Under social distancing guidelines for COVID-19, we were typically operating with less than 50% of our R&amp;D staff on-site at any one time through June 30, 2020. As of July 1, 2020, we took occupancy of approximately 30,000 square feet of laboratory and office space in our new headquarters in Chicago, Illinois.  Since then, we have operated under COVID-19 social distancing guidelines and have generally operated with approximately 100% of our R&amp;D staff on-site.  Our office and general and administrative team continues to generally work on site approximately 50% of the time.  We are managing laboratory staffing and taking other appropriate managerial actions to maintain progress on our preclinical and collaboration programs. Business travel has been restricted and we continue to take measures to secure our research and development project activities, while work in laboratories and facilities has been organized to reduce risk of COVID-19 transmission.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regions in which we operate are currently being affected by COVID-19 and have become subject to additional government-imposed mitigation measures to prevent the ongoing spread of COVID-19.  Further, timely enrollment in our clinical trials is dependent upon clinical trial sites which may be adversely affected by the COVID-19 pandemic or its impact or effects. During the third quarter of 2020 and through June 30, 2021, we have observed delays in our enrollment plans for the Phase 2 dose expansion phase of the Phase 1b/2 clinical trial for cavrotolimod (AST-008). We believe the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effects of the COVID-19 pandemic or its impact have contributed to such delays. As a result, we lengthened our clinical development timeline for cavrotolimod (AST-008) and, pending further enrollment delays or any unanticipated effects of the COVID-19 pandemic on our clinical development plans, expect to report ORR results in the first half of 2022 rather than by year end 2021 as previously guided in September 2020. Quarantines, shelter-in-place, safer-at-home, social distancing requirements and similar government orders, business shutdowns and closures, phased re-openings or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could continue to occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities and CROs in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. Additionally, our clinical trials may involve immunocompromised patients who are at higher risk for COVID-19 and who are therefore more likely to avoid hospitals or other high risk areas.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the executive orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines (for example, our timelines for any of our product candidates), the magnitude of which will continue to depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 outbreak, or similar pandemics, we may experience further disruptions that could severely impact our business, clinical trials and preclinical studies, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further delays or difficulties in enrolling or maintaining patients in our clinical trials, including patients who may not be able to comply with clinical trial protocols if quarantines, shelter-in-place or safer-at-home restrictions, or social distancing practices or requirements, business shutdowns and closures, among other similar requirements or government orders, continue to impede patient movement or interrupt healthcare services;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19, being forced to quarantine, or being unable to visit clinical trial locations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff who may have heightened exposure to COVID-19 or experience additional restrictions by their institutions, city, or state;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or disruptions in non-clinical experiments and investigational new drug application-enabling good laboratory practice standard toxicology studies due to unforeseen circumstances in supply chain;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion or prioritization of healthcare resources away from the conduct of clinical trials and towards the COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials, and because, who, as healthcare providers, may have heightened exposure to COVID-19 and adversely impact our clinical trial operations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of our key clinical trial activities , such as clinical assessments at pre-specified time points during the trial and clinical trial site data monitoring, due to limitations on travel imposed or recommended by governmental entities, employers and others or interruption of clinical trial subject visits and study procedures (particularly any procedures that may be deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption or delays in the operations of the FDA, European Medicines Agency and comparable foreign regulatory agencies or their refusal to accept data from clinical trials in affected geographies, which may impact approval timelines;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our clinical trials that we might conduct at sites outside the United States, in addition to the risks listed above, we may also experience the following adverse impacts, particularly in countries which are experiencing heightened impact from the COVID-19 pandemic:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption in global shipping that may affect the transport of clinical trial materials, such as investigational drug product and comparator drugs used in our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in local regulations as part of a response to the COVID-19 outbreak which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the refusal of the FDA to accept data from clinical trials in these affected geographies.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which continues to cause broad global impact, may materially affect us economically. The trading price for our shares as well as the trading prices of other biopharmaceutical companies, as well as the broader equity and debt markets overall, have been highly volatile as a result of the COVID-19 pandemic and the resulting impact on U.S. economic activities. Although the potential economic impact brought by, and the duration or subsequent reoccurrence of, the COVID-19 pandemic may be difficult to assess or predict, a widespread pandemic could continue to result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, even after the COVID-19 pandemic has subsided, a recession or market correction that has occurred or may occur in the future because of the COVID-19 could materially affect our business and the value of our common stock. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global outbreak of COVID-19 continues to rapidly evolve. The extent to which the COVID-19 pandemic or a similar pandemic will impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration and severity of the outbreak, the possibility of additional periods of increases or spikes in the number of COVID-19 cases, limitations on our ability to conduct our business in the ordinary course, any reopening plans and additional closures, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions for us, our third party contractors and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, including, without limitation, the effectiveness and timing of vaccination initiatives in the United States and worldwide. The ultimate impact of the COVID-19 pandemic or a similar health pandemic is highly uncertain and subject to change; we continue to monitor the COVID-19 situation closely.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we continue to experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be further delayed or prevented.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue conducting clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment is affected by other factors including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and nature of the patient population;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity of the disease under investigation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the eligibility criteria for, and design of, the trial in question;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived risks and benefits of the product candidate under study;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition in recruiting and enrolling patients in clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties due to the COVID-19 pandemic or its impact or effects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. We may encounter further difficulties and/or delays in completing our planned enrollments. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, or the inability to complete development of our product candidates, which would cause the value of our company to decline, limit our ability to obtain additional financing, and materially impair our ability to generate revenues.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expense related to our therapeutic candidates or future development programs; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials, or the addition or termination of clinical trials or funding support by us, or a future collaborator or licensing partner; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaboration, licensing or similar arrangement, and the timing of payments we may make or receive under such existing or future arrangements or the termination or modification of any such existing or future arrangements; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions and departures of key personnel; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or not any of our therapeutic candidates receives regulatory approval, market acceptance and demand for such therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our therapeutic candidates or those of our competitors; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in general economic, industry, political and market conditions, including, but not limited to, the ongoing impact of the COVID-19 pandemic. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expense and present significant distractions to our management.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases and&#160;out-&#160;or&#160;in-licensing&#160;of product candidates or technologies. In particular, in addition to our current arrangements with AbbVie, which began in November 2019, and Dermelix, which began in February 2019, and Purdue, with which there no active therapeutic candidates in development and which has not indicated any further interest in development, we will evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or pharmaceutical companies. For example, on July 30, 2021, we entered into a collaboration, option, and licensing agreement with IPSEN BIOPHARM LIMITED. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may be unable to maintain any new or existing collaboration if, for example, development or approval of a therapeutic candidate is delayed, sales of an approved product do not meet expectations or the collaborator terminates the collaboration. Any such collaboration, or other strategic transaction, may require us to incur&#160;non-recurring&#160;or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disrupt our management or business. These transactions entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material adverse effect on our business, results of operations, financial condition and prospects. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties on which we depend to conduct our preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements, or miss expected deadlines, our development program could be delayed with materially adverse effects on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party clinical investigators, CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor preclinical studies and clinical trials for our therapeutic candidates. Because we rely on third parties and do not have the ability to conduct preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources away from our programs. The third parties with which we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. The FDA requires preclinical studies to be conducted in accordance with applicable GLPs, and clinical trials to be conducted in accordance with applicable FDA regulations and GCPs, including requirements for conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Any adverse development or delay in our preclinical studies or clinical trials could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the operations of our CROs may be constrained or disrupted by the COVID-19 pandemic. Clinical site closure and other activities that require visits to clinical sites, have been and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic or concerns among patients about participating in clinical trials during a pandemic. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays could occur, which could compromise our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we rely on third-party manufacturing and supply partners, our supply of research and development, preclinical studies and clinical trial materials may become limited or interrupted or may not be of satisfactory quantity or quality. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party partners to manufacture and supply the materials and components for our research and development, preclinical study and clinical trial supplies. We do not own manufacturing facilities or supply sources for such components and materials. Our manufacturing requirements include oligonucleotides and lipids. We procure our nonclinical toxicology and clinical development materials from a limited number of suppliers on a purchase order basis. There can be no assurance that our supply of research and development, preclinical study and clinical trial therapeutic candidates and other materials will not be limited, interrupted, restricted in certain geographic regions or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our drug product manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for a therapeutic candidate is subject to oversight by the FDA and foreign regulatory authorities. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory requirements, such as cGMPs. In the event that any of our suppliers or manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our therapeutic candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to another third-party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our therapeutic candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop therapeutic candidates in a timely manner or within budget. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any therapeutic candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for therapeutic candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our therapeutic candidates successfully. Our or a third-party&#8217;s failure to execute on our manufacturing requirements and comply with cGMPs could adversely affect our business in a number of ways, including: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to initiate or continue preclinical studies or clinical trials of our therapeutic candidates under development; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in submitting regulatory applications, or receiving regulatory approvals, for therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of the cooperation of a future collaborator; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjecting manufacturing facilities of our therapeutic candidates to additional inspections by regulatory authorities; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to cease distribution or to recall batches of our therapeutic candidates; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the event of approval to market and commercialize a therapeutic candidate, an inability to meet commercial demands for our therapeutics. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our relationships with our manufacturers, suppliers or other vendors are terminated or scaled back as a result of the COVID-19 pandemic or other health epidemics, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Further, if the COVID-19 pandemic continues to persist for an extended period of time and impacts essential distribution systems such as FedEx and postal delivery, we could experience disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of our product candidates. Switching or adding additional suppliers or vendors involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new supplier or vendor commences work. As a result, delays may occur, which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. Although we carefully manage our relationships with our suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not harm our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies, including delivery technologies, or therapeutic candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of therapeutic candidates is highly competitive. We compete with a number of multinational pharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing or will develop therapeutic candidates and processes competitive with our therapeutic candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that enter the market. We believe that a significant number of therapeutics are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop therapeutic candidates. There is intense and rapidly evolving competition in the biotechnology, pharmaceutical and oligonucleotide therapeutics fields. While we believe that our SNA technology, its associated intellectual property and our scientific and technical know-how give us a competitive advantage in this space, competition from many sources remains. Our competitors include larger and better funded pharmaceutical, biotechnology and oligonucleotide therapeutics companies. Moreover, we also compete with current and future therapeutics developed at universities and other research institutions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several companies that are developing oligonucleotide delivery platforms and oligonucleotide-based therapeutics. These competitors include Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Arbutus Biopharma Corp., Wave Life Sciences Ltd., Arrowhead Pharmaceuticals, Inc., ProQR Therapeutics N.V., Stoke Therapeutics, Inc., Neubase Therapeutics, Inc., Idera Pharmaceuticals, Inc., Avidity Biosciences, Checkmate Pharmaceuticals, Inc., Dyne Therapeutics, Inc., Atalanta Therapeutics, Inc., PepGen, Inc. and others. These and other competitors compete with us in recruiting scientific and managerial talent, and for funding from pharmaceutical companies. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will partially depend on our ability to develop and protect therapeutics that are safer and more effective than competing therapeutics. Our commercial opportunity and success will be reduced or eliminated if competing therapeutics are safer, more effective, or less expensive than the therapeutics we develop. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our therapeutic candidates are approved for the indications we are currently pursuing, they will compete with a range of therapeutic treatments that are either in development or currently marketed. A number of therapeutics for treating psoriasis and cancers are on the market or in clinical development. For the treatment of psoriasis, marketed therapies range from small molecules like topical steroids to biologics, such as AbbVie Inc.&#8217;s adalimumab. In addition, numerous compounds are in clinical development for psoriasis treatment. With respect to immunogenic cancers such as melanoma, the most common treatments are chemotherapeutic compounds, radiation therapy and now immunotherapeutic antibodies such as ipilimumab, atezolizumab, pembrolizumab and others. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any therapeutic candidate, we will face competition based on many different factors, including the safety and effectiveness of our therapeutics, the ease with which our therapeutics can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these therapeutics, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing therapeutics could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any therapeutics we may develop. Competitive therapeutics may make any therapeutics we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our therapeutic candidates. Such </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market may not be receptive to our therapeutic candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of therapeutic candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if approval is obtained for a therapeutic candidate, we may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and otherwise accepted in the market. The therapeutic candidates that we are developing are based on our SNA technology. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors, may not adopt a treatment based on SNA technology, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for any therapeutic candidates developed by us or any current or future collaborators. Market acceptance of our therapeutic candidates will depend on, among other factors: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of our receipt of any marketing and commercialization approvals; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of any approvals and the countries in which approvals are obtained; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of our therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse side effects associated with our therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration of our therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to accept any new methods of administration; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our physician education programs; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate government and third-party payor reimbursement; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing of our products, particularly as compared to alternative treatments; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative effective treatments for indications our therapeutic candidates are intended to treat and the relative risks, benefits and costs of those treatments. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our focus on SNAs, these risks may increase to the extent the space becomes more competitive or less favored in the commercial marketplace. Additional risks apply in relation to any disease indications we may pursue which are classified as rare diseases and allow for orphan drug designation by regulatory agencies in major commercial markets, such as the U.S., Europe and Japan. Because of the small patient population for a rare disease, if pricing is not approved or accepted in the market at an appropriate level for an approved product with orphan drug designation, such therapeutic may not generate enough revenue to offset costs of development, manufacturing, marketing and commercialization despite any benefits received from the orphan drug designation, such as market exclusivity, assistance in clinical trial design or a reduction in user fees or tax credits related to development expense. Market size is also a variable in disease indications not classified as rare. Our estimates regarding potential market size for any indication may be materially different from what we discover to exist at the time we commence commercialization, if any, for a therapeutic, which could result in significant changes in our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a therapeutic candidate that has orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the therapeutic candidate is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same therapeutic candidate for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same therapeutic candidate as defined by the FDA or if our therapeutic candidate is determined to be contained within the competitor&#8217;s therapeutic candidate for the same indication or disease. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the U.S., we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made.  Sponsors of orphan drugs in the European Union can enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication.  During such period, marketing applications for similar medicinal products will not be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accepted, unless certain exceptions apply.  In the EU, a &#8220;similar medicinal product&#8221; is a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we, or any future collaborators, obtain orphan drug designation for a therapeutic candidate, such as we obtained in March 2021 for cavrotolimod for the treatment of patients with Merkel cell carcinoma, that designation may not effectively protect the therapeutic candidate from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective, or makes a major contribution to patient care.  </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued service of key management and other specialized personnel, including David A. Giljohann, Ph.D., our Chief Executive Officer, Brian C. Bock, our Chief Financial Officer, Matthias G. Schroff, Ph.D., our Chief Operating Officer,  Douglas E. Feltner, M.D., our Chief Medical Officer, and Elias D. Papadimas, our Chief Accounting Officer. The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs or clinical trials and materially harm our business, financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our therapeutic candidates and our technology and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. We do not maintain key person life insurance policies on any of our management team members or key employees. Our future success will depend in large part on our continued ability to attract and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to increase the size of our organization, and we may experience difficulties in managing growth.</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we had 78 employees. As our development and commercialization plans and strategies develop, and as we further develop as a public company, we expect to need additional managerial, operational, financial and other personnel, including personnel to support our product development and planned future commercialization efforts. Future growth will impose significant added responsibilities on members of management, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our internal development efforts effectively, including the clinical, FDA and EMA review processes for our product candidates; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring new employees, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our therapeutic candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future therapeutics. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no sales, marketing or distribution capabilities or experience. If any of our therapeutic candidates is approved, we will need to develop internal sales, marketing and distribution capabilities to appropriately commercialize such therapeutics, which would be expensive and time-consuming, or enter into collaborations with third parties to perform these services. If we decide to market our approved therapeutics directly, we will need to commit significant </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market our approved therapeutics or decide to co-promote therapeutics with collaborators, we will need to establish and maintain compliant marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and there can be no assurance that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved therapeutic. If we are not successful in commercializing any therapeutic approved in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects could be materially and adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with U.S. or foreign regulatory requirements, regulatory authorities could withhold marketing or commercialization approvals, limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our therapeutic candidates, as well as our suppliers, contract manufacturers, distributors, and contract testing laboratories are subject to extensive regulation by governmental authorities in the European Union, the U.S., and other countries, with the regulations differing from country to country. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or current or future collaborators, manufacturers or service providers fail to comply with applicable requirements, these regulatory authorities could refuse to issue necessary approvals for marketing and commercialization. Even if we receive marketing and commercialization approval of a therapeutic candidate, we and our third-party service providers will be subject to continuing regulatory requirements, including a broad array of regulations related to establishment registration and product listing, manufacturing processes, risk management measures, quality and pharmacovigilance systems, pre- and post-approval clinical data, labeling, advertising and promotional activities for such therapeutic, record keeping, distribution, and import and export of therapeutics for any therapeutic for which we obtain marketing approval. We are required to submit safety and other post market information and reports and are subject to continuing regulatory review, including in relation to adverse patient experiences with the therapeutic and clinical results that are reported after a therapeutic is made commercially available, both in the U.S. and any foreign jurisdiction in which we seek regulatory approval. The FDA and certain foreign regulatory authorities, such as the EMA, have significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a therapeutic or to require withdrawal of the therapeutic from the market. The FDA also has the authority to require a Risk Evaluation and Mitigation Strategies, or REMS, plan either before or after approval, which may impose further requirements or restrictions on the distribution or use of an approved therapeutic. The EMA now routinely requires risk management plans, or RMPs, as part of the marketing authorization application process, and such plans must be continually modified and updated throughout the lifetime of the product as new information becomes available. In addition, for nationally authorized medicinal products, the relevant governmental authority of any European Union member state can request an RMP whenever there is a concern about the risk/benefit balance of the product. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturer and manufacturing facilities we use to make a future therapeutic, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the therapeutic, manufacturer or facility, including withdrawal of the therapeutic from the market. If we rely on third-party manufacturers, we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. Although a physician may prescribe products for off-label use since the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. Companies may only share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. If we or our future collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our therapeutics, we or they may be subject to, among other things, fines, warning and untitled letters, clinical holds, delay or refusal by the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension, refusal to renew or withdrawal of regulatory approval, recalls, seizures or administrative detention of products, refusal to permit the import or export of therapeutics, operating restrictions, inability to participate in government programs including Medicare and Medicaid, and total or partial suspension of production or distribution, injunction, restitution, disgorgement, debarment, civil and criminal penalties and criminal prosecution. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Price controls imposed in foreign markets may adversely affect our future profitability. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control at the national level, and in some cases also at the regional level. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing and reimbursement negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our SNA therapeutic candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any therapeutic candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be adversely affected. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business entails a significant risk of product liability and our inability to obtain sufficient insurance coverage could have a material adverse effect on our business, financial condition, results of operations or prospects. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing therapeutics, such claims could result in an investigation by certain regulatory authorities, such as the FDA or foreign regulatory authorities, of the safety and effectiveness of our therapeutics, our manufacturing processes and facilities or our marketing programs and potentially a recall of our therapeutics or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our therapeutics, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels of product liability insurance prior to marketing any of our therapeutic candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material adverse effect on our business. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements which could have an adverse effect on our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include, but is not limited to, intentional failures to comply with FDA, the Centers for Medicare &amp; Medicaid Services, or CMS, the Department of Health and Human Services, or HHS, Office of Inspector General, or OIG, or other agency regulations, applicable laws, regulations, guidance or codes of conduct set by foreign governmental authorities or self-regulatory industry organizations, or provide accurate information to any governmental authorities, such as the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws, regulations, guidance and codes of conduct intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws, regulations, guidance and codes of conduct may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions, including, fines, debarment, or disqualification of those employees from participation in certain government-regulated activities, and serious harm to our reputation. This could include violations of the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including exclusion from participation in the U.S. federal healthcare programs, the imposition of significant fines or other sanctions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our technology. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Welfare Act, or AWA, is the federal law that covers the treatment of certain animals used in research. Currently, the AWA imposes a wide variety of specific regulations that govern the humane handling, care, treatment and transportation of certain animals by producers and users of research animals, most notably relating to personnel, facilities, sanitation, cage size, and feeding, watering and shipping conditions. Third parties with whom we contract are subject to registration, inspections and reporting requirements under the AWA. Furthermore, some states have their own regulations, including general anti-cruelty legislation, which establish certain standards in handling animals. Comparable rules, regulations, and or obligations exist in many foreign jurisdictions. If we or our contractors fail to comply with regulations concerning the treatment of animals used in research, we may be subject to fines and penalties and adverse publicity, and our operations could be adversely affected. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our therapeutic development programs. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruptions of our operations. For instance, the loss of preclinical study or clinical trial data involving our therapeutic candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, theft or other exposure of data may interfere with our ability to protect our intellectual property, trade secrets, and other information critical to our operations. We can provide no assurances that certain sensitive and proprietary information relating to one or more of our therapeutic candidates has not been, or will not in the future be, compromised. Although we have invested resources to enhance the security of our computer systems, there can be no assurances we will not experience additional unauthorized intrusions into our computer systems, or those of our CROs and other contractors and consultants, that we will successfully detect future unauthorized intrusions in a timely manner, or that future unauthorized intrusions will not result in material adverse effects on our financial condition, reputation, or business prospects. Payments related to the elimination of ransomware may materially affect our financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain data breaches must also be reported to affected individuals and the government, and in some cases to the media, under provisions of HIPAA, as amended by HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive.  Financial penalties may also apply in some data breaches where noncompliance with the applicable law is identified.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of our therapeutic candidates could be delayed. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research, development and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various flammable and toxic chemicals in our facilities in Chicago, Illinois that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our Chicago facilities comply with the relevant guidelines of Chicago, the state of Illinois, and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our information technology systems could face serious disruptions that could adversely affect our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions and delays in our research and development work. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing scrutiny and changing expectations from customers, regulators, investors, and other stakeholders with respect to our environmental, social and governance practices may impose additional costs on us or expose us to new or additional risks.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies are facing increasing scrutiny from customers, regulators, investors, and other stakeholders related to their environmental, social and governance practices. Investor advocacy groups, investment funds and influential investors are also increasingly focused on these practices, especially as they relate to the environment, health and safety, supply chain management, diversity and human rights. Failure to adapt to or comply with regulatory requirements or investor or stakeholder expectations and standards could negatively impact our reputation and the price of our ordinary shares.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the factors mentioned above, or the perception that we or our suppliers, or contract manufacturers or collaborators have not responded appropriately to the growing concern for such issues, regardless of whether we are legally required to do so, may damage our reputation and have a material adverse effect on our business, financial condition, results of operations cash flows and/or ordinary share price.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Natural disasters or other unexpected events may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of one or more unexpected events, including fires, tornadoes, tsunamis, hurricanes, earthquakes, floods, and other forms of severe hazards in the United States or in other countries in which we or our suppliers or manufacturers operate or are located could adversely affect our operations and financial performance.  These types of unexpected events could result in physical damage to and complete or partial closure of one or more of the manufacturing facilities operated by our contract manufacturers, or the temporary or long-term disruption in the supply of products, and/or disruption of our ability to deliver products to customers. Further, the long-term effects of climate change on general economic conditions and the pharmaceutical manufacturing and distribution industry in particular are unclear, and changes in the supply, demand or available sources of energy and the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses. Existing insurance arrangements may not provide protection for the costs that may arise from such events, particularly if such events are catastrophic in nature or occur in combination. Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations, our business, results of operations and stock price.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current operations are concentrated in one location and any events affecting this location may have material adverse consequences. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current operations are located in our facilities situated in Chicago, Illinois. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize the facilities, may have a material adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our therapeutic candidates or interruption of our business operations. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any business interruption may have a material adverse effect on our business, financial position, results of operations and prospects. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The investment of our cash, cash equivalents and fixed income marketable securities is subject to risks which may cause losses and affect the liquidity of these investments. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we had $43.8 million in cash, cash equivalents, and restricted cash and $13.5 million in short-term investments.  We historically have invested excess cash in certificates of deposit or money market mutual funds that invest in securities issued or guaranteed by the U.S.&#160;government or U.S.&#160;government agencies, floating rate and variable rate demand notes of U.S.&#160;and foreign corporations, and commercial paper.  During the fourth quarter of 2019, we have made direct purchases, and expect to continue to make direct purchases of, U.S.&#160;government or U.S.&#160;government agency securities, floating rate and variable rate demand notes of U.S.&#160;and foreign corporations, and commercial paper.  These investments are subject to general credit, liquidity, market and interest rate risks, including potential future impacts similar to the impact of U.S.&#160;sub-prime mortgage defaults that have affected various sectors of the financial markets and caused credit and liquidity issues.  We may realize losses in the fair value of these investments, an inability to access cash in these investments for a potentially meaningful period, or a complete loss of these investments, which would have a negative effect on our financial statements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act, and the rules&#160;and regulations of The Nasdaq Capital Market. Pursuant to Section&#160;404 of the Sarbanes-Oxley Act, or Section&#160;404, we are now required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. Further, we may in the future discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Moreover, our internal controls over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. Moreover, we are aware that the remote working arrangements implemented in connection with the COVID-19 pandemic potentially present new areas of risk, and we continue to monitor carefully any impact to our internal controls and procedures.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to assert that our internal control over financial reporting is effective, investors could lose confidence in the reliability of our financial statements, the market price of our stock could decline and we could be subject to sanctions or investigations by The Nasdaq Capital Market, the SEC or other regulatory authorities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain and enforce patent protection for our technology or therapeutic candidates, development and commercialization of our therapeutic candidates may be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our therapeutic candidates, methods used to manufacture our therapeutic candidates and methods for treating patients using our therapeutic candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. As of June 30, 2021, our patent portfolio consists of over 85 issued patents and allowed patent applications and over 105 pending patent applications.  We may not be able to apply for patents on certain aspects of our therapeutic candidates in a timely fashion or at all. Our existing issued and granted </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing therapeutics and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our issued or granted patents will not later be found to be invalid or unenforceable or that any issued or granted patents will include claims that are sufficiently broad to cover our therapeutic candidates or to provide meaningful protection from our competitors. Moreover, the patent position of pharmaceutical and biotechnology companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and therapeutic candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely impact our position in the market. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and pharmaceutical patents. As such, we do not know the degree of future protection that we will have on our proprietary therapeutics and technology. While we will endeavor to try to protect our therapeutic candidates with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive and sometimes unpredictable. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are numerous recent changes to the patent laws and proposed changes to the rules of the USPTO, which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, the Leahy-Smith America Invents Act enacted in 2011, involves significant changes in patent legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, some of which cases either narrow the scope of patent protection available in certain circumstances or weaken the rights of patent owners in certain situations. The 2013 decision by the Supreme Court in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Association for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> precludes a claim to a nucleic acid having a stated nucleotide sequence that is identical to a sequence found in nature and unmodified. We currently are not aware of an immediate impact of this decision on our patents or patent applications because we are developing oligonucleotide therapeutics which contain modifications that we believe are not found in nature. However, this decision has yet to be clearly interpreted by courts and by the USPTO. We cannot assure you that the interpretations of this decision or subsequent rulings will not adversely impact our patents or patent applications. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that may weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. In addition, there can be no assurance that: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others will not or may not be able to make, use or sell compounds that are the same as or similar to our therapeutic candidates but that are not covered by the claims of the patents that we own or license. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or our licensors, or any current or future collaborators, are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or our licensors, or any current or future collaborators, are the first to file patent applications covering certain aspects of our inventions. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others will not independently develop similar or alternative technologies or duplicate any of our technology without infringing our intellectual property rights. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A third-party will not challenge our patents and, if challenged, a court may not hold that our patents are valid, enforceable and infringed. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any issued patents that we own or have licensed will provide us with any competitive advantages, or will not be challenged by third parties. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will develop additional proprietary technologies that are patentable. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The patents of others will not have an adverse effect on our business. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our competitors will not conduct research and development activities in countries where we lack enforceable patent rights and then use the information learned from such activities to develop competitive therapeutics for sale in our major commercial markets. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent term may be inadequate to protect our competitive position on our future therapeutics for an adequate amount of time. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the amount of time required for the development, testing and regulatory review of new therapeutic candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the U.S. and, if available, in other countries where we have patents covering our product candidates. In the U.S., the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, the patent term extension or restoration cannot extend the remaining term of a patent beyond a total of 14 years from the approval date of the product candidate.&#160;Only one patent applicable to an approved product candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration dates. However, the applicable authorities, including the FDA and the USPTO in the U.S., and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently license patent rights from Northwestern University and may in the future license patent rights from third-party owners or licensees. If Northwestern University or such other owners or licensees do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive position and business prospects may be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do, and will continue to, rely on intellectual property rights licensed from third parties to protect our technology. We are a party to a number of licenses that give us rights to third-party intellectual property that is necessary or useful for our business. In particular, we have a license from Northwestern University, which provides us the exclusive worldwide right under certain patents and patent applications owned by Northwestern University to exploit therapeutics and processes using nanoparticles, nanotechnology, microtechnology and nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of administration. We may also license additional third-party intellectual property in the future. Our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, and in particular, for those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications licensed to us. Even if patents issue or are granted, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue litigation less aggressively than we would. Further, we may not obtain exclusive rights, which would allow for third parties to develop competing therapeutics. Without protection for, or exclusive rights to, the intellectual property we license, other companies might be able to offer substantially identical therapeutics for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, the U.S. government has certain rights to the inventions covered by the patent rights licensed to us by third parties and Northwestern University, as an academic research and medical center, has reserved the right to practice the patent rights it has licensed to us (i)&#160;for research, teaching and/or other educationally related purposes (including the right to distribute materials for such purposes) and (ii)&#160;for use in the field of diagnostics (including theradiagnostics) and in any field other than the field of use licensed to us. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other companies or organizations may challenge our or our licensors&#8217; patent rights or may assert patent rights that prevent us from developing and commercializing our therapeutic candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oligonucleotide and SNA-based therapeutics are a relatively new scientific field. We have obtained grants and issuances of SNA therapeutic patents and have licensed many of these patents from a third-party on an exclusive basis for therapeutics applications. The issued patents and pending patent applications in the U.S. and in key markets around the world that we own or license claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of SNA therapeutics. Specifically, we own and have licensed a portfolio of patents, patent applications and other intellectual property covering SNA compositions of matter as well as their methods of use. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the field of SNA therapeutics matures, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material adverse effect on our business and our ability to successfully compete. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many issued and pending patents that claim aspects of oligonucleotide chemistry and modifications that we may need to apply to our SNA therapeutic candidates. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for SNA therapeutics we wish to develop. Thus, it is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we may not be able to market therapeutics or perform research and development or other activities covered by these patents. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining a valid and enforceable issued or granted patent covering our technology in the U.S. and worldwide can be extremely costly. In jurisdictions where we have not obtained patent protection, competitors may use our technology to develop their own therapeutics and, further, may export otherwise infringing therapeutics to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the U.S. Competitor therapeutics may compete with our future therapeutics in jurisdictions where we do not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biotechnology and pharmaceuticals. This could make it difficult for us to prevent the infringement of our patents or marketing of competing therapeutics in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally file a provisional patent application first, also known as a priority filing, at the USPTO. An international application under the Patent Cooperation Treaty, or PCT, is usually filed within twelve months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in the U.S., European Union, Japan, Australia and Canada and, depending on the individual case, also in any or all of, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter alia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, China, India, South Korea, and Mexico. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant or after grant by nonpayment of maintenance fees for the resulting patent. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, various scopes of patent protection may be granted on the same therapeutic candidate or technology. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the U.S., and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our licensors, or any current or future strategic partners, may become subject to third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development and commercialization of our therapeutic candidates, or put our patents and other proprietary rights at risk. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors, or any current or future strategic partners, may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. We are generally obligated under our license agreements to indemnify and hold harmless our licensors for damages arising from intellectual property infringement by us. If we or our licensors, or any current or future strategic partners, are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we or our licensors, or any current or future strategic partners, may choose to seek, or be required to seek, a license from a third-party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we or any current or future collaborator may be unable to effectively market therapeutic candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to initiate legal proceedings against a third-party to enforce a patent covering one of our therapeutics or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our therapeutics or certain aspects of our technology. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also possible that we have failed to identify relevant third-party patents or applications. For example, U.S. applications filed before November&#160;29, 2000 and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our therapeutics or technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our SNA technology, our therapeutics or the use of our therapeutics. Third-party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our therapeutics. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our therapeutic candidates that are held to be infringing. We might, if possible, also be forced to redesign therapeutic candidates so that we no longer infringe the third-party intellectual </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our therapeutic candidates or we could lose certain rights to grant sublicenses. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell therapeutics that are covered by the licensed technology or could enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights in such unlicensed intellectual property. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future therapeutics, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in therapeutics that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize therapeutics, we may be unable to achieve or maintain profitability. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patent protection for certain aspects of our therapeutic candidates, we also consider trade secrets, including confidential and unpatented know-how important to the maintenance of our competitive position. We protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the U.S. and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Northwestern University License Agreements, Northwestern University could publish research findings relating to the patent rights licensed to us by Northwestern University, which could have a material adverse effect on our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject both in the U.S. and outside the U.S. to various regulatory schemes regarding requests for the information we provide to regulatory authorities, which may include, in whole or in part, trade secrets or confidential commercial information. While we are likely to be notified in advance of any disclosure of such information and would likely object to such disclosure, there can be no assurance that our challenge to the request would be successful. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees were previously employed at universities or pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">us from commercializing, our therapeutic candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may independently develop similar or superior technology. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that others will not independently develop, or have not already developed, similar or more advanced technologies than our technology; or that others will not design around, or have not already designed around, aspects of our technology and/or our trade secrets developed therefrom. If third parties develop technology similar or superior to our technology, or they successfully design around our current or future technology, our competitive position, business prospects, and results of operations could be materially and adversely affected. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The intellectual property which we have licensed from Northwestern University was discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed certain intellectual property from Northwestern University pursuant to the Northwestern University License Agreements. The Northwestern University License Agreements indicate that the rights licensed to us by Northwestern University are subject to the obligations to and the rights of the U.S. government, including those set&#160;forth in the Bayh-Dole Act of 1980, or Bayh-Dole Act. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future therapeutics based on the licensed Northwestern University intellectual property. These U.S. government rights&#160;in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide&#160;license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or nonexclusive licenses to any of these inventions to a third-party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, also referred to as&#160;&#8220;march-in rights.&#8221; While the U.S. government has sparingly used, and to our knowledge never successfully exercised, such march-in rights, any exercise of the march-in rights by the U.S. government could harm our competitive position, business, financial condition, results of operations, and prospects. If the U.S. government exercises such march-in rights, we may receive compensation that is deemed reasonable by the U.S. government in its sole discretion, which may be less than what we might be able to obtain in the open market. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government requires that any therapeutics embodying any invention generated through the use of U.S. government funding be manufactured substantially in the U.S. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. therapeutic manufacturers for therapeutics covered by such intellectual property. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our therapeutic candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our therapeutic candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing, sampling, and distribution of therapeutics. Rigorous preclinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new therapeutic can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that none of the therapeutic candidates we may develop will obtain the regulatory approvals necessary for us or any current or future collaborators to begin selling them. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA as well as foreign regulatory authorities, such as the EMA and European Union national competent authorities. The time required to obtain FDA and foreign regulatory approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the therapeutic candidate. The standards that the FDA and its foreign counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in the policy of the FDA or foreign regulatory authorities during the period of therapeutic development, clinical trials and regulatory review by the FDA or foreign regulatory authorities. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign laws, regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. In addition, unfavorable changes in our industry or the global economy, including as a result of the COVID-19 pandemic, could contribute to some of the events listed above and further impact our ability to progress our clinical trials, submit for marketing approval or commercialize our product candidates, if approved, as planned.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the therapeutics we are developing may represent a new class of therapeutic, the FDA and its foreign counterparts have not yet established any definitive policies, practices or guidelines in relation to these therapeutics. While we believe the therapeutic candidates that we are currently developing are regulated as new drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, the FDA could decide to regulate them or other therapeutics we may develop as biologics under the Public Health Service Act. The lack of policies, practices or guidelines may hinder or slow review by the FDA or foreign regulatory authorities of any regulatory filings that we may submit. Moreover, the FDA may respond to these submissions by defining requirements we may not have anticipated. Such responses could lead to significant delays in the clinical development of our therapeutic candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular therapeutic candidate for which we are seeking approval. Furthermore, any regulatory approval to market a therapeutic may be subject to limitations on the approved uses for which we may market the therapeutic or the labeling or other restrictions. Regulatory authorities also may impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the therapeutic. In addition, the FDA has the authority to require a REMS plan as part of a NDA or a Biologics License Application, or BLA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for the therapeutic and affect coverage and reimbursement by third-party payors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the U.S. and vice versa. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of our therapeutic candidates may require companion diagnostics in certain indications.  Failure to successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our therapeutic candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our therapeutic candidates may require companion diagnostics to identify appropriate patients for those therapeutic candidates in certain indications.  Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as a medical device and may require separate regulatory authorization prior to commercialization.  We may rely on third parties for the design, development, testing and manufacturing of these companion diagnostics, the application for and receipt of any required regulatory authorization, and the commercial supply of these companion diagnostics.  If these parties are unable to successfully develop companion diagnostics for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these therapeutic candidates, or experience delays in doing so, the development of our therapeutic candidates may be adversely affected and we may not be able to obtain marketing authorization for these therapeutic candidates.  Furthermore, our ability to market and sell, as well as the commercial success, of any of our therapeutic candidates that require a companion diagnostic will be tied to, and dependent upon, the receipt of required regulatory authorization and the continued ability of such third parties to make the companion diagnostic commercially available on reasonable terms in the relevant geographies.  Any failure to develop, validate, obtain and maintain marketing authorization for a companion diagnostic and supply such companion diagnostic will harm our business, results of operations and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or current or future collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our therapeutics and may harm our reputation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, our current and future business operations may subject us to additional healthcare statutory and regulatory requirements and enforcement by the federal, state and foreign governments of the jurisdictions in which we conduct our business. Healthcare providers, including physicians and third-party payors play a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain marketing approval. Our arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell or distribute our therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include, but are not limited to, the following:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from soliciting, receiving, offering or providing remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made, in whole or in part, under a federal healthcare program, such as Medicare or Medicaid. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers, among others, on the other. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S.&#160;federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the False Claims Act in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal health care programs for the product. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA includes a fraud and abuse provision sometimes referred to as the HIPAA All-Payor Fraud Law, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program (i.e., not just federal healthcare programs), or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the HITECH, and its implementing regulations, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses and their business associates that perform certain services involving the use or disclosure of individually identifiable health information as well as their covered </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subcontractors, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal Physician Payments Sunshine Act and the implementing regulations, also referred to as &#8220;Open Payments,&#8221; issued under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, which require that certain manufacturers of pharmaceutical and biological drugs reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program report to CMS all consulting fees, travel reimbursements, research grants, and other payments, transfers of value or gifts made to U.S.-licensed physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and U.S. teaching hospitals with limited exceptions, as well as ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations will extend to include transfers of value and payments made during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives; and </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state laws and regulations, such as, state anti-kickback and false claims laws potentially applicable to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures, state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of personal data (including personal health information) in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and state transparency laws that require the reporting of certain pricing information; among other state laws. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our future business arrangements with third-parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including significant administrative, civil and/or criminal penalties, monetary damages, disgorgement, fines, imprisonment, additional integrity reporting requirements and regulatory oversight, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect our financial results. Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or current or future collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to significant penalties and enforcement actions, which could affect our ability to develop, market and sell our therapeutics successfully and could harm our reputation and lead to reduced acceptance of our therapeutics by the market. These penalties and enforcement actions include, among others: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory inspection findings; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning or untitled letters; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary product recalls or public notification or medical product safety alerts to healthcare professionals; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on, or prohibitions against, marketing our therapeutics; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on, or prohibitions against, importation or exportation of our therapeutics; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of review or refusal to approve pending applications or supplements to approved applications; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exclusion from participation in government-funded healthcare programs; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exclusion from eligibility for the award of government contracts for our therapeutics; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integrity oversight and reporting obligations;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA debarment; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of therapeutic approvals; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seizures or administrative detention of therapeutics; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">civil and criminal penalties and fines. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any therapeutics we develop may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices or healthcare reform initiatives, thereby harming our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing and reimbursement for new therapeutics vary widely from country to country. Some countries require approval of the sale price of a therapeutic before it can be marketed. In many countries, the pricing review period begins after marketing or therapeutic licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. Although we intend to monitor these regulations, our programs are currently in the early stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result, we might obtain regulatory approval for a therapeutic in a particular country, but then be subject to price regulations that delay our commercial launch of the therapeutic and negatively impact the revenues we are able to generate from the sale of the therapeutic in that country.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are prescribed therapeutics for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved therapeutics. Our ability to commercialize any therapeutics successfully also will depend in part on the extent to which coverage and reimbursement for these therapeutics and related treatments will be available from government health administration authorities, private health insurers and other organizations. However, there may be significant delays in obtaining coverage for newly-approved therapeutics. Moreover, eligibility for coverage does not necessarily signify that a therapeutic will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution costs. Also, interim payments for new therapeutics, if applicable, may be insufficient to cover our costs and may not be made permanent. Thus, even if we succeed in bringing one or more therapeutics to the market, these therapeutics may not be considered cost-effective, and the amount reimbursed for any therapeutics may be insufficient to allow us to sell our therapeutics on a competitive basis. Because our programs are in the early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of reimbursement. Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are seeking greater upfront discounts, additional rebates and other concessions to reduce the prices for therapeutics. If the price we are able to charge for any therapeutics we develop, or the reimbursement provided for such therapeutics, is inadequate in light of our development and other costs, our return on investment could be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect that some therapeutics we develop may need to be administered under the supervision of a physician on an outpatient basis. Under currently applicable U.S. law, certain therapeutics that are not usually self-administered (including injectable therapeutics) may be eligible for coverage under Medicare through Medicare Part B. Medicare Part B is part of original Medicare, the federal health care program that provides health care benefits to the aged and disabled, and covers outpatient services and supplies, including certain pharmaceutical products that are medically necessary to treat a beneficiary&#8217;s health condition. Specifically, Medicare Part B coverage may be available for eligible beneficiaries when the following, among other requirements, have been satisfied:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product is reasonable and necessary for the diagnosis or treatment of the illness or injury for which the product is administered according to accepted standards of medical practice; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product is typically furnished incident to a physician&#8217;s services; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product has been approved by the FDA. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medicaid Drug Rebate Statute, a manufacturer must participate in the Medicaid Drug Rebate Program in order to receive payment for its covered outpatient drugs under Medicare Part B (the Medicare program that generally covers physician-administered, outpatient drugs).  In addition, manufacturers who participate in the Medicaid Drug Rebate Program are also required to (1) sign the Pharmaceutical Pricing Agreement and participate in the 340B Drug </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing Program, and (2) sign the VA Master Agreement for inclusion of the manufacturer&#8217;s drugs on the Federal Supply Schedule, or FSS. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of HHS as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities eligible to participate in the program. Average prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of therapeutics from countries where they may be sold at lower prices than in the U.S. Self-administered therapeutics are typically reimbursed under Medicare Part D, and therapeutics that are administered in an inpatient hospital setting are typically reimbursed under Medicare Part A under a bundled payment. On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap for single source and innovator multiple source drugs, beginning January 1, 2024.  It is difficult for us to predict how Medicare coverage and reimbursement policies will be applied to our therapeutics in the future and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial third-party payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement rates. Our inability to promptly obtain coverage, and adequate reimbursement from both government-funded and private payors for new therapeutics we develop and for which we obtain regulatory approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. Additionally, if any companion diagnostic provider is unable to obtain reimbursement or is inadequately reimbursed, that may limit the availability of such companion diagnostic, which would negatively impact prescriptions for our product candidates, if approved.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the efforts of governments and third-party payors to contain or reduce the cost of healthcare, and specifically, therapeutics, and legislative and regulatory proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biotechnology companies. A number of legislative and regulatory changes in the healthcare system in the U.S. and other major healthcare markets have been proposed. These developments could, directly or indirectly, affect our ability to sell our therapeutics, if approved, at a favorable price.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in the U.S., in 2010, the U.S. Congress passed the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of health spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional policy reforms.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of the ACA addressing coverage and reimbursement of pharmaceutical products that may be of importance to our potential therapeutic candidates include the following:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increases to pharmaceutical manufacturer rebate liability under the Medicaid Drug Rebate Program due to an increase in the minimum basic Medicaid rebate on most branded prescription drugs and the application of Medicaid rebate liability to drugs used in risk-based Medicaid managed care plans.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expansion of the 340B Drug Pricing Program to require discounts for &#8220;covered outpatient drugs&#8221; sold to certain children&#8217;s hospitals, critical access hospitals, freestanding cancer hospitals, rural referral centers, and sole community hospitals. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Requirements imposed on pharmaceutical companies to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly referred to as the &#8220;Donut Hole.&#8221; In February 2018, Congress passed the Bipartisan Budget Act of 2018, which, effective as of 2019, increased the discount to be paid by pharmaceutical companies from 50% to 70% of a brand-name drug&#8217;s negotiated price and added biosimilars to the coverage gap discount program.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Requirements imposed on pharmaceutical companies to pay an annual non-tax-deductible fee to the federal government based on each company&#8217;s market share of prior year total sales of branded drugs to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs, and Department of Defense. Since we currently expect our branded pharmaceutical sales to constitute a small portion of the total federal healthcare </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program pharmaceutical market, we do not currently expect this annual assessment to have a material impact on our financial condition. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For therapeutic candidates classified as biologics, marketing approval for a follow-on biologic therapeutic may not become effective until 12 years after the date on which the reference innovator biologic therapeutic was first licensed by the FDA, with a possible six-month extension for pediatric therapeutics. After this exclusivity ends, it may be possible for biosimilar manufacturers to enter the market, which is likely to reduce the pricing for such therapeutics and could affect our profitability if our therapeutics are classified as biologics. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, pursuant to certain health reform legislation and related initiatives, CMS is working with various healthcare providers to develop, refine, and implement Accountable Care Organizations, or ACOs, and other innovative models of care for Medicare and Medicaid beneficiaries, including the Bundled Payments for Care Improvement Initiative, the Financial Alignment Initiative Demonstration, and other models. The continued development and expansion of ACOs and other innovative models of care will have an uncertain impact on any future reimbursement we may receive for approved therapeutics administered by such organizations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and will remain open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future.  It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2023.  On November 20, 2020, CMS issued an interim final rule implementing the Trump administration&#8217;s Most Favored Nation, or MFN, executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the U.S. District Court for the Northern District of California issued a nationwide preliminary injunction against implementation of the interim final rule. On January 13, 2021, in a separate lawsuit brought by industry groups in the U.S. District of Maryland, the government defendants entered a joint motion to stay litigation on the condition that the government would not appeal the preliminary injunction granted in the U.S. District Court for the Northern District of California and that performance for any final regulation stemming from the MFN Model interim final rule shall not commence earlier than sixty (60) days after publication of that regulation in the Federal Register.  Based on a recent executive order, the Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, individual states have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our therapeutic candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our therapeutic candidates, restrict or regulate post-approval activities and affect our ability to commercialize our therapeutic candidates, if approved. In markets outside of the United States and European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our current or any future therapeutic candidates we may develop may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential liability related to the privacy and security of health information we obtain from clinical trials sponsored by us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the HITECH. We are not currently classified as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial penalties if we receive or use individually identifiable health information from a HIPAA-covered healthcare provider or research institution or business associate that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, certain health privacy laws, data security laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#8217; health information. Patients about whom we or our collaborators obtain health information, as well as the providers who share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time- consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or third-party manufacturers, CROs or other contractors or consultants fail to comply with applicable federal, state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217; ability to develop and commercialize our therapeutic candidates and could harm or prevent sales of any affected therapeutics that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our therapeutics. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security or reputational damage.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to obtain services, reimbursement or funding from the federal government may be impacted by possible reductions in federal spending. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal government agencies currently face potentially significant spending reductions. The Budget Control Act of 2011, or BCA, established a Joint Select Committee on Deficit Reduction, which was tasked with achieving a reduction in the federal debt level of at least $1.2 trillion. That committee did not draft a proposal by the BCA&#8217;s deadline. As a result, automatic cuts, referred to as sequestration, in various federal programs were scheduled to take place. This includes reductions to Medicare payments to providers of 2% per fiscal year, that began in April 2013, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. COVID-19 relief legislation, including the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, which was signed into law in March 2020 , among other things, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2021.  </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reductions may also impact the ability of relevant agencies to timely review and approve therapeutic research and development, manufacturing, and marketing activities, which may delay our ability to develop, market, and sell any therapeutics we may develop.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our therapeutic candidates receives marketing approval and we or others later identify undesirable side effects caused by the therapeutic candidate, our ability to market and derive revenue from the therapeutic candidates could be compromised. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any of our therapeutic candidates receive regulatory approval and we or others identify undesirable side effects, adverse events or other problems caused by one of our therapeutics, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the therapeutic or seize the therapeutic; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may need to recall the therapeutic or change the way the therapeutic is administered to patients; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular therapeutic or the manufacturing processes for the therapeutic or any component thereof; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to fines, restitution or disgorgement of profits or revenues, injunctions, or the imposition of civil penalties or criminal prosecution; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require us to implement a REMS, or to conduct post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the therapeutic; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic may become less competitive; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been, and is likely to continue to be, highly volatile, and you may not be able to resell your shares at or above the price you paid for them. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 31, 2019, our stock price has been volatile and it is likely that the trading price of our common stock will continue to be volatile. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for the shares. The market price for our common stock may be influenced by a variety of factors, including the other risks described in this section titled &#8220;Risk Factors&#8221; and the following:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive therapeutics or technologies; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of our preclinical studies and clinical trials of our therapeutic candidates, or those of our competitors, or any current or future collaborators; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our therapeutics; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introductions and announcements of new therapeutics by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions taken by regulatory agencies with respect to our therapeutics, clinical studies, manufacturing process or sales and marketing terms; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to acquire or in-license additional technologies, therapeutics or therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any current or future collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our therapeutics; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to raise additional capital and the terms on which we raise it; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement and expectation of additional financing efforts; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">speculation in the press or investment community; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock and overall fluctuations in U.S. equity markets, including as a result of the COVID-19 pandemic; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us or our stockholders; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the concentrated ownership of our common stock; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terrorist acts, acts of war or periods of widespread civil unrest; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters and other calamities; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry, political and market conditions, including, but not limited to, the ongoing impact of the COVID-19 pandemic. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock markets in general, and the markets for pharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market and industry factors, such as those related to the COVID-19 pandemic, may seriously harm the market price of our common stock, regardless of our operating performance. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional funds by issuing securities may cause dilution to existing stockholders and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, grants and license and development agreements in connection with any collaborations. We do not have any committed external source of funds. To the extent that we raise additional capital through the issuance of shares or other securities convertible into shares, our stockholders will be diluted.  Future issuances of our common stock or other equity securities, or the perception that such sales may occur, could adversely affect the prevailing market price of our common stock and impair our ability to raise capital through future offerings of equity or equity-linked securities.  For example, on December 23, 2019, we completed the sale of 10,000,000 shares of our common stock in the December 2019 Offering and on August 2, 2019 we completed the sale of 31,625,000 shares of our common stock in the August 2019 Offering.  The issuance of shares in both the December 2019 Offering and August 2019 Offering were pursuant to a shelf registration statement on Form S-3 that was declared effective by the SEC on July 24, 2019. The shelf registration statement allows us to sell from time-to-time up to $125.0 million of common stock, preferred stock, debt securities, warrants, or units comprised of any combination of these securities, for our own account in one or more offerings; the remaining amount available under this shelf registration after the December 2019 Offering (inclusive of the exercise of the underwriters&#8217; option in January 2020 to purchase additional shares at the public offering price in connection with the December 2019 Offering) is approximately $31.3 million. Further, in December 2020 we entered into an equity distribution agreement with BMO Capital Markets Corp. providing for the sale of up to $50.0 million of our common stock from time to time in &#8220;at the market offerings&#8221; (as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended) pursuant to a prospectus supplement and a shelf registration statement on Form S-3 that was declared effective by the SEC on January 7, 2021. The issuance of the shares pursuant to the December 2019 Offering and the August 2019 Offering and/or the resale of a substantial number of shares of our common stock in the public market or the sale of any shares of our common stock under the equity distribution agreement could adversely affect the market price for our common stock and make it more difficult for you to sell shares of our common stock at times and prices that you feel are appropriate. Adverse market and price pressures that may result from the December 2019 Offering or the August 2019 Offering or an offering pursuant to the shelf registration statement or such &#8216;at the market&#8217; offerings may continue for an extended period of time and continued negative pressure on the market price of our common stock could have a material adverse effect on our ability to raise additional equity capital.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. Any debt financing that we enter into may involve covenants that restrict our operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of our assets as well as prohibitions on our ability to create liens, pay dividends, redeem our stock or make investments. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (1)&#160;not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, (2)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (3)&#160;exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we are only required to provide two years of audited financial statements and two years of selected financial data. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our common stock held by non-affiliates exceeds $700.0&#160;million as of any June&#160;30 before that time or if we have total annual gross revenue of $1.07&#160;billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December&#160;31, or if we issue more than $1.0&#160;billion in non-convertible debt during </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any three-year period before that time, in which case we would no longer be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the beneficial ownership of our common stock as of June 30, 2021, our executive officers and directors, together with holders of five percent or more of our outstanding common stock and their respective affiliates, will beneficially own approximately&#160;37% of our outstanding common stock. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our Company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under the General Corporation Law of the State of Delaware could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and our bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders, and the ability of the Board to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, or DGCL, which prohibits stockholders owning in excess of 15% of the outstanding combined organization voting stock from merging or combining with the combined organization. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our Board, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then-current management by making it more difficult for stockholders to replace members of the Board, which is responsible for appointing the members of management. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents could discourage, delay or prevent a change in control of us and may affect the trading price of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate documents and the DGCL contain provisions that may enable our Board to resist a change in control of us even if a change in control were to be considered favorable by our stockholders. These provisions: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stagger the terms of our Board and require 66 and 2/3% stockholder voting to remove directors, who may only be removed for cause; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our Board to issue &#8220;blank check&#8221; preferred stock and to determine the rights and preferences of those shares, which may be senior to our common stock, without prior stockholder approval; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for nominating directors and proposing matters to be voted on by stockholders at stockholders&#8217; meetings; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit our stockholders from calling a special meeting and prohibit stockholders from acting by written consent; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require 66 and 2/3% stockholder voting to effect certain amendments to our certificate of incorporation and bylaws; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions could discourage, delay or prevent a transaction involving a change in control of us. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing and cause us to take other corporate actions our stockholders desire. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any of the following types of actions or proceedings under Delaware statutory or common law: derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. This provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or any other claims for which a court or forum other than the Court of Chancery has exclusive jurisdiction or for which the Court of Chancery does not have subject matter jurisdiction. Furthermore, Section 22 of the Securities Act of 1933, as amended, or the Securities Act, creates concurrent jurisdiction for federal and state courts over all Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. Our amended and restated certificate of incorporation also provides that any person purchasing or otherwise acquiring any interest in any shares of our common stock shall be deemed to have notice of and to have consented to this provision of our amended and restated certificate of incorporation.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. If a court were to find this exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in any action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could have a material adverse effect on our business, financial condition or results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition&#160;or results of operations.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Act, enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the CARES Act modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conform to the Tax Act, the CARES Act, or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. Our net operating loss, or NOL, carryforwards generated in tax years beginning on or before December 31, 2017, are only permitted to be carried forward for 20 years under applicable U.S. tax law. Under the Tax Act, as modified by the CARES Act, our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Act, or the CARES Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards, and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We have experienced ownership changes in the past. In addition, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside of our control. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to our Indebtedness</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:99%">Our indebtedness could adversely affect our business, financial condition and competitive position. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, we had $17.5 million of indebtedness outstanding, consisting of our borrowing under our MidCap Credit Facility. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to service this indebtedness and any additional indebtedness we may incur in the future, we need to generate cash. Our ability to generate cash is subject, to a certain extent, to our ability to successfully execute our business strategy, as well as general economic, financial, competitive, regulatory and other factors beyond our control. We cannot assure you that our business will be able to generate sufficient cash flow from operations or that future borrowings or other financing will be available to us in an amount sufficient to enable us to service our indebtedness and fund our other liquidity needs. To the extent we are required to use our cash flow from operations or the proceeds of any future financing to service our indebtedness instead of funding working capital, capital expenditures or other general corporate purposes, we will be less able to plan for, or react to, changes in our business, industry and in the economy generally. This will place us at a competitive disadvantage compared to our competitors that have less indebtedness.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the MidCap Credit Agreement contains, and any agreements evidencing or governing other future indebtedness may contain, certain restrictive covenants that limit our ability, among other things, to engage in certain activities that are in our long-term best interests, including our ability to:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional indebtedness;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create or incur liens;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in certain fundamental changes, including mergers or consolidations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make investments, loans, advances, guarantees and acquisitions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sell or transfer assets;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay dividends and distributions and repurchase capital stock;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in certain transactions with affiliates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into negative pledge clauses and clauses restricting subsidiary distributions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modify the terms of material documents.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> While we have not previously breached and are not in breach of any of these covenants, there can be no guarantee that we will not breach these covenants in the future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to comply with these covenants and restrictions may be affected by events and factors beyond our control. Our failure to comply with any of these covenants or restrictions could result in an event of default under our MidCap Credit Facility. This would permit the lending banks under such facilities to take certain actions, including terminating all outstanding commitments and declaring all amounts due under our credit agreement, such as outstanding principal and accrued and unpaid interest thereon, to be immediately due and payable. In addition, the lenders would have the right to proceed against the collateral we have granted to them, which includes substantially all of our assets. The occurrence of any of these events could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:99%">We may not be able to secure additional financing on favorable terms, or at all, to meet our future capital needs.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the future, we may require additional capital to respond to business opportunities, challenges, acquisitions or unforeseen circumstances, and may determine to engage in equity or debt financings or enter into credit facilities or refinance existing indebtedness for other reasons. We may not be able to timely secure additional debt or equity financing on favorable terms, or at all. As discussed above, the credit agreements governing the MidCap Credit Facility contain restrictive covenants that limit our ability to incur additional indebtedness and engage in other capital-raising activities. Any debt financing obtained by us in the future could involve covenants that further restrict our capital raising activities and other financial and operational matters, which may make it more difficult for us to operate our business, obtain additional capital and pursue business opportunities, including potential acquisitions. Furthermore, if we raise additional funds through the issuance of equity or convertible debt or other equity-linked securities or through the sale of our common stock pursuant to our &#8220;at the market&#8221; program, our existing stockholders could suffer significant dilution. If we are unable to obtain adequate financing or financing on terms satisfactory to us, when we require it, our ability to continue to grow or support our business and to respond to business challenges could be significantly limited.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General Risk Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">FINRA sales practice requirements may limit a stockholder&#8217;s ability to buy and sell our stock.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Industry Regulatory Authority, or FINRA, has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#8217;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our securities, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business.  Our research coverage by securities and industry analysts is currently limited.  In addition, because we did not become a reporting company by conducting an underwritten initial public offering of our common stock, security analysts of brokerage firms may not provide wider coverage of our Company.  In addition, investment banks may be less likely to agree to underwrite secondary offerings on our behalf than they might if we became a public reporting company by means of an underwritten initial public offering, because they may be less familiar with our Company as a result of more limited coverage by analysts and the media, and because we became public at an early stage in our development.  The failure to receive wider research coverage or support in the market for our shares will have an adverse effect on our ability to develop a liquid market for our common stock and the trading price for our stock would be negatively impacted.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we obtain wider securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our target studies and operating results fail to meet the expectations of analysts, our stock price would likely decline.  If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="ia49112dadce14be6836937c1a8779dad_127"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="ia49112dadce14be6836937c1a8779dad_130"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="ia49112dadce14be6836937c1a8779dad_133"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.024%"><tr><td style="width:1.0%"></td><td style="width:13.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex32.htm">Certificate of Amendment to Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on September 26, 2017.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/02/17</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;000-55764</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1698530/000169853021000031/exicureex33amendedandresta.htm">Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on November 15, 2017.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/11/21</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39011</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex34.htm">Amended and Restated Bylaws, as currently in effect.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/02/17</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;text-align:center;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-55764</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001698530/000169853021000060/exhibit101employmentagreem.htm">Employment Agreement between Exicure, Inc. and Brian Bock, dated April 16, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7.75pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/13/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39011</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001698530/000169853021000060/exhibit102noticeofgrantand.htm">Inducement Award Agreement between Exicure, Inc. and Brian Bock, dated May 13, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7.75pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/13/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39011 </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+ *</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exicureexhibit103-63021.htm">Amended and Restated Employment Agreement between Exicure, Inc. and Elias D. Papadimas, dated June 1, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exicureexhibit104-63021.htm">Amendment No. 2 dated as of July 30, 2021 to Credit and Security Agreement, dated as of September 25, 2020 by and among Exicure, Inc., Exicure Operating Company, the lenders party thereto from time to time and MidCap Financial Trust, as agent.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exicureexhibit311-63021.htm">Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exicureexhibit312-63021.htm">Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exicureexhibit321-63021.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.024%"><tr><td style="width:1.0%"></td><td style="width:13.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+ Indicates a management contract or compensatory plan.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*   Filed herewith.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**   The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exicure, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="ia49112dadce14be6836937c1a8779dad_139"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia49112dadce14be6836937c1a8779dad_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August 12, 2021</span></div><div style="margin-bottom:9pt;text-align:right;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.551%"><tr><td style="width:1.0%"></td><td style="width:11.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXICURE, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brian C. Bock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian C. Bock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">( Principal Financial Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Elias D. Papadimas</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elias D. Papadimas</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">( Principal Accounting Officer)</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>exicureexhibit103-63021.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="idb9f9dcfe10b48c295ffdb0713dddb9f_38"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div><font><br></font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MENDED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESTATED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MPLOYMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HIS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MENDED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESTATED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MPLOYMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XICURE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">, I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and Elias D. Papadimas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (each of the Executive and the Company, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Party,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), is entered into as of June 1, 2021.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company and the Executive previously entered into an employment agreement dated as of December 28, 2020 pursuant to which the Executive served as Vice President, Controller of the Company (the &#8220;Prior Agreement&#8221;)&#59;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company desires to employ the Executive as its Chief Accounting Officer and the Executive desires to accept such employment and to perform duties to the Company on the terms and conditions hereinafter set forth in this Agreement&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Parties wish to amend and restate the terms of the Prior Agreement as set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">, T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the mutual covenants contained herein and other valid consideration, the sufficiency of which is acknowledged, the Parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MPLOYMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive&#8217;s employment under this Agreement shall commence on 1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and shall continue until the termination of Executive&#8217;s at-will employment under this Agreement. The period from the Effective Date until the termination of Executive&#8217;s at-will employment under this Agreement is referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Employment Period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OSITION AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UTIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, Executive shall serve as the Chief Accounting Officer of the Company and shall have the duties, responsibilities and authority of an executive serving in such position, and such other duties as may be assigned and&#47;or prescribed from time to time by the Company&#8217;s Chief Financial Officer and&#47;or the Company&#8217;s Board of Directors. The Executive shall report to the Chief Financial Officer. The Executive&#8217;s assigned work office shall be Chicago, Illinois, and he will be expected to engage in business travel from time to time, as agreed upon with the Chief Financial Officer. Executive shall devote Executive&#8217;s full business time and efforts to the business and affairs of the Company and its subsidiaries. Executive shall not become a director of any for-profit entity without first receiving the written approval of the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ILL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MPLOYMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section 5 below, the parties agree that Executive's employment with the Company will be &#8220;at-will&#8221; employment and may be terminated at any time with or without cause or notice, for any reason or no reason.  Executive understands and agrees that neither Executive&#8217;s job performance nor promotions, commendations, bonuses or the like from the Company give rise to or in any way serve as the basis for modification, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">252092631 v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">amendment, or extension, by implication or otherwise, of Executive&#8217;s employment with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OMPENSATION AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ENEFITS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As compensation for Executive&#8217;s performance of Executive&#8217;s duties hereunder, Executive shall receive a base salary at the rate of three hundred thousand ($300,000) per year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), subject to standard payroll deductions and withholdings and payable in accordance with the Company&#8217;s regular payroll schedule. Executive&#8217;s Base Salary shall be reviewed by the Board for possible adjustment annually.  The Base Salary shall be reviewed for adjustments by the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in good faith, based upon Executive&#8217;s performance and the Company&#8217;s pay philosophy, not less often than annually, provided, that Executive&#8217;s Base Salary may only be decreased as part of an across-the-board reduction in base salaries of all Company executive officers, with the percentage reduction in Executive&#8217;s Base Salary being not greater than the percentage reduction applicable to other executive officers. The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall refer to the Base Salary as may be in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.85pt">Annual Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive will participate in the annual cash bonus program maintained for executive officers of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Annual Incentive Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Executive&#8217;s minimum target annual bonus shall be equal to at least 30% of Base Salary for each year during the Employment Period in which Executive participates in the Annual Incentive Program (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The actual amount of the annual bonus earned by and payable to Executive in any year shall be determined upon the satisfaction of goals and objectives established by the Compensation Committee and communicated to Executive , and shall be subject to such other terms and conditions of the Annual Incentive Program as in effect from time to time. Each bonus paid under the Annual Incentive Program shall be paid to Executive no later than March 15th of the calendar year following the calendar year in which the bonus is earned.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Executive will participate in the Company&#8217;s Equity Incentive Plan as determined by the Board or the Compensation Committee.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Other Benefits.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.19pt">Savings and Retirement Plans. Except as otherwise limited by applicable law, Executive shall be entitled to participate in all qualified and non-qualified savings and retirement plans applicable generally to other senior executive officers of the Company, in accordance with the terms of the plans, as may be amended from time to time.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.86pt">Welfare Benefit Plans. Except as otherwise limited by applicable law, Executive and&#47;or Executive&#8217;s eligible dependents shall be eligible to participate in and shall receive all benefits under the Company&#8217;s welfare benefit plans and programs applicable generally to other senior executive officers of the Company, in accordance with the terms of the plans, as may be amended from time to time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">252092631 v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.53pt">Perquisites. Except as otherwise limited by applicable law, Executive shall be entitled to such perquisites as may be available generally from time to time to other senior executive officers of the Company, but at levels commensurate with executive&#8217;s position as Chief Accounting Officer.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#222222;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(iv)</font><font style="background-color:#ffffff;color:#222222;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </font><font style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnification&#58;  Executive shall be entitled to indemnification to the maximum extent permitted by applicable law and the Company&#8217;s Bylaws with terms no less favorable than provided to any other Company executive officer or director.&#160; At all times during your employment, the Company shall maintain in effect a directors and officers liability insurance policy with the Executive as a covered officer.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Business Expenses. Subject to Section 15, Executive shall be reimbursed for reasonable travel and other expenses incurred in the performance of Executive&#8217;s duties on behalf of the Company in a manner consistent with the Company&#8217;s policies regarding such reimbursements, as may be in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ERMINATION OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MPLOYMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Executive&#8217;s employment under this Agreement shall terminate upon the earliest to occur of&#58; (i) Termination due to Disability (as defined below)&#59; (ii) termination of Executive&#8217;s employment by the Company for any reason other than Termination due to Disability&#59; (iii) Executive&#8217;s death&#59; or (iv) termination of Executive&#8217;s employment by Executive for any reason. Upon the termination of Executive&#8217;s employment with the Company for any reason, Executive shall be deemed to have resigned from all positions with the Company or any of its affiliates held by Executive as of the date immediately preceding Executive&#8217;s termination of employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">If Executive&#8217;s employment ends for any reason, except as otherwise contemplated in this Section 5, Executive shall cease to have any rights to salary, bonus (if any) or other benefits, other than (i) the earned but unpaid portion of Executive&#8217;s Base Salary through the date of termination or resignation, (ii) any annual, long-term, or other incentive award that relates to a completed fiscal year or performance period, as applicable, and is payable (but not yet paid) on or before the date of termination or resignation, which shall be paid in accordance with the terms of such award, (iii) a lump-sum payment in respect of accrued but unused vacation days at the Executive&#8217;s per-business-day Base Salary rate, (iv) any unpaid expense or other reimbursements due to Executive, and (v) any other amounts or benefits required to be paid or provided by law or under any plan, program, policy or practice of the Company, provided that Executive shall not be entitled to any payment or benefit under any severance plan maintained by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Termination without Cause or for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If Executive's employment hereunder shall be terminated by the Company without Cause, or by Executive for Good Reason, then in addition to the payments and benefits described in&#160;Section 5(b)&#160;and subject to Executive's execution and non-revocation of the release contemplated in Section 5(f) of this Agreement and Executive's continuing compliance with the Confidentiality and Work Product Assignment Agreement (as defined below)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">252092631 v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) the Company shall pay Executive continuation of six (6) months of Executive's annual Base Salary, as in effective immediately prior to Executive's termination of employment hereunder, payable during the 6-month period following Executive's termination of employment in the form of salary continuation in accordance with the Company's normal payroll practices&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) the Company shall pay Executive an annual cash bonus for the year of termination, payable at the same time as annual cash bonuses are paid to senior management, based on actual achievement of performance targets (as if Executive had remained employed through the end of the applicable performance period), subject, however, to proration based on the number of days in the applicable performance period that had elapsed prior to the date of termination&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) if the Executive timely elects to receive continued coverage under the Company's group health care plan pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;), the Company shall pay the employer portion of applicable COBRA premium payments for the Executive's and, as applicable, Executive's dependents', continued health coverage under such plan (as in effect or amended from time to time) (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">COBRA Subsidy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;) until the earlier of&#58; (1) twelve (12) months following the Executive's termination of employment, or (2) the date upon which the Executive obtains or becomes eligible for other health care coverage from a new employer or otherwise (such period referred to as the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">COBRA Subsidy Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;). The Executive shall promptly inform the Company in writing when Executive obtains or becomes eligible for any such other health care coverage. The Executive shall be responsible for paying a share of such COBRA premiums during the COBRA Subsidy Period at active employee rates as in effect from time to time, and shall be responsible for the full unsubsidized costs of such COBRA coverage thereafter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Termination without Cause or for Good Reason in Connection with a Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If Executive&#8217;s employment hereunder shall be terminated by the Company without Cause, or by Executive for Good Reason, in either case within 12 months following a Change in Control then, in addition to the payments and benefits described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and subject to Executive&#8217;s execution and non-revocation of the release contemplated in Section 5(f) of this Agreement and Executive&#8217;s continuing compliance with the Company's Confidential Information Agreement (as defined below)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">The Company shall pay Executive continuation of fifteen (15) months (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Benefit Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of Executive&#8217;s annual Base Salary, as in effect immediately prior to Executive&#8217;s termination of employment hereunder, payable during the 15-month period following Executive&#8217;s termination of employment in the form of salary continuation in accordance with the Company&#8217;s normal payroll practices.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">The Company shall pay Executive an annual cash bonus equal to Executive&#8217;s annual Target Bonus as set forth in Section 3(b) for the year in which the termination of employment occurs, payable by the later of (A) the same date as annual cash bonuses are paid to senior management for the calendar year in which Executive&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">252092631 v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">termination occurs&#59; or (B) 30 days after the effective date of the release contemplated in Section 5(f)&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">All equity awards, to the extent outstanding as of immediately prior to such termination, will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to the latter of&#58; (1) the date of termination and (2) the date of the Change in Control&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">If the Executive timely elects to receive continued coverage under the Company&#8217;s group health care plan pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Company shall pay the employer portion of applicable COBRA premium payments for the Executive&#8217;s and, as applicable, Executive&#8217;s dependents&#8217;, continued health coverage under such plan (as in effect or amended from time to time) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">COBRA Subsidy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) until the earlier of&#58; (1)  twelve (12) months following the Executive&#8217;s termination of employment, or (2) the date upon which the Executive obtains or becomes eligible for other health care coverage from a new employer or otherwise (such period referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">COBRA Subsidy Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Executive shall promptly inform the Company in writing when Executive obtains or becomes eligible for any such other health care coverage. The Executive shall be responsible for paying a share of such COBRA premiums during the COBRA Subsidy Period at active employee rates as in effect from time to time, and shall be responsible for the full unsubsidized costs of such COBRA coverage thereafter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Section 280G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in this Agreement, Executive expressly agrees that if the payments and benefits provided for in this Agreement or any other payments and benefits which Executive has the right to receive from the Company and its affiliates (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), would constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">parachute payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (as defined in Section 280G(b)(2) of the Code), then the Payments shall be either (a) reduced (but not below zero) so that the present value of the Payments will be one dollar ($1.00) less than three times Executive&#8217;s &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">base amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (as defined in Section 280G(b)(3) of the Code) and so that no portion of the Payments received by Executive shall be subject to the excise tax imposed by Section 4999 of the Code or (b) paid in full, whichever produces the better net after-tax position to Executive. The reduction of Payments, if any, shall be made by reducing first any Payments that are exempt from Section 409A of the Code and then reducing any Payments subject to Section 409A of the Code in the reverse order in which such Payments would be paid or provided (beginning with such payment or benefit that would be made last in time and continuing, to the extent necessary, through to such payment or benefit that would be made first in time). The determination as to whether any such reduction in the Payments is necessary shall be made by the Compensation Committee in good faith. If a reduced Payment is made or provided and, through error or otherwise, that Payment, when aggregated with other payments and benefits from Company (or its affiliates) used in determining if a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">parachute payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; exists, exceeds one dollar ($1.00) less than three times Executive&#8217;s base amount, then Executive shall immediately repay such excess to the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">252092631 v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.03pt">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive&#8217;s execution of a complete and general release of any and all of Executive&#8217;s potential claims (other than for benefits and payments described in this Agreement or any other vested benefits with the Company and&#47;or its affiliates) against the Company, any of its affiliated companies, and their respective successors and any officers, employees, agents, directors, attorneys, insurers, underwriters, and assigns of the Company or its affiliates and&#47;or successors, is an express condition of Executive&#8217;s right to receive the payments and benefits set forth in Section 5(c). Executive shall be required to execute within 45 days after Executive&#8217;s termination of employment a general waiver and release agreement in a form reasonably satisfactory to the Company, that will contain no greater post-employment restrictions than those set forth herein and in the Confidential Information Agreement, and will not waive require the Executive to waive any indemnification, advancement and liability insurance protection rights.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Certain Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the occurrence of any one of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.19pt">gross negligence or willful misconduct in the performance of, or Executive&#8217;s abuse of alcohol or drugs rendering Executive unable to perform the material duties and services required for Executive&#8217;s position with the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.86pt">Executive&#8217;s conviction or plea of nolo contendere for any crime involving moral turpitude or a felony&#59;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.53pt">Executive&#8217;s commission of an act of deceit or fraud intended to result in personal and unauthorized enrichment of Executive at the expense of the Company or any of its affiliates&#59; or</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.19pt">Executive&#8217;s material violation of the written policies of the Company or any of its affiliates (including ethics and compliance policies, as in effect from time to time), Executive&#8217;s material breach of a material obligation of Executive to the Company pursuant to Executive&#8217;s duties and obligations under the Company&#8217;s Bylaws, or Executive&#8217;s material breach of a material obligation of Executive to the Company or any of its affiliates pursuant to this Agreement or any award or other agreement between Executive and the Company or any of its affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be deemed to have occurred upon the occurrence of any of the following events&#58;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.19pt">The acquisition, other than from the Company, by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 50% or more of either the then outstanding shares of the Company or the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors, but excluding, for this purpose, any such acquisition by the Company or any of its subsidiaries, or any employee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">252092631 v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">benefit plan (or related trust) of the Company or its subsidiaries, or any corporation with respect to which, following such acquisition, more than 50% of, respectively, the then outstanding shares of such corporation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of all or substantially all directors is then beneficially owned, directly or indirectly, by the individuals and entities who were the beneficial owners, respectively, of shares and voting securities of the Company immediately prior to such acquisition in substantially the same proportion as their ownership, immediately prior to such acquisition, of the then outstanding shares of the Company or the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors, as the case may be&#59;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.86pt">The consummation of a reorganization, merger or consolidation of the Company, in each case, with respect to which all or substantially all of the individuals and entities who were the respective beneficial owners of shares and voting securities of the Company immediately prior to such reorganization, merger or consolidation do not, following such reorganization, merger or consolidation, beneficially own, directly or indirectly, more than 50% of, respectively, the then outstanding shares and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such reorganization, merger or consolidation&#59;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.53pt">During any twenty-four (24) month period, individuals who, as of the beginning of such period, constitute the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Incumbent Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to the beginning of such period whose election or nomination for election was approved by a vote of at least a majority of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without written objection to such nomination) shall be an Incumbent Director&#59; provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any person other than the Board shall be deemed to be an Incumbent Director&#59; or</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.19pt">a complete liquidation or dissolution of the Company or of the sale or other disposition of all or substantially all of the assets of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event shall a Change in Control include any bona fide primary or secondary public offering of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the existence of any of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.19pt">a material diminution in Executive&#8217;s authority, duties, or responsibilities from those applicable to Executive as of the Effective Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.86pt">a material diminution in Executive&#8217;s annual Base Salary, except to the extent contemplated by Section 3(b) of this Agreement&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">252092631 v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.53pt">a relocation of Executive&#8217;s principal place of employment by more than 50 miles from the location where Executive was assigned to work immediately prior to such relocation, which for purposes of this Agreement shall mean the Company requiring Executive to be permanently based in a location that is more than 50 miles from either (A) the Executive&#8217;s assigned Company office if such office is assigned, or (B) if Executive is assigned to work remotely, from the approved remote work location&#59; or</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.19pt">a material breach by the Company of any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing or any other provision in this Agreement to the contrary, any assertion by Executive of a Good Reason termination shall not be effective unless all of the following conditions are satisfied&#58;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.19pt">the conditions described in the preceding sentence giving rise to Executive&#8217;s termination of employment must have arisen without Executive&#8217;s written consent&#59;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.86pt">Executive must provide written notice to the Company of such condition and Executive&#8217;s intent to terminate employment within 90 days after the initial existence of the condition&#59;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.53pt">the condition specified in such notice must remain uncorrected for 30 days after receipt of such notice by the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.19pt">the date of Executive&#8217;s termination of employment must occur within 90 days after the notice provided by Executive pursuant to clause (ii).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Termination due to Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Executive&#8217;s termination of employment as a result of Executive becoming incapacitated for a period of at least 180 days by accident, sickness or other circumstance that renders Executive mentally or physically incapable of performing the material duties as Chief Accounting Officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONFIDENTIAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NFORMATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NVENTIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SSIGNMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BLIGATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As a condition of continued employment, Executive agrees to execute and abide by an Employee Confidentiality, Non-Hire, Non-Disparagement and Work Product Agreement attached as Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Confidential Information Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which may be amended by the parties from time to time without regard to this Agreement.  The Confidential Information Agreement contains provisions that are intended by the parties to survive and do survive termination of this Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">URVIVAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 6, 8, 9, 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereof shall survive and continue in full force and effect in accordance with their respective terms, notwithstanding any termination of the Employment Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTICES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notice provided for in this Agreement shall be in writing and shall be delivered (i) personally, (ii) by certified mail, postage prepaid, (iii) by Federal Express or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">252092631 v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">other reputable courier service regularly providing evidence of delivery (with charges paid by the party sending the notice), or (iv) by facsimile or a PDF or similar attachment to an email. Any such notice to a party shall be addressed at the address set forth below (subject to the right of a party to designate a different address for itself by notice similarly given)&#58;</font></div><div style="margin-bottom:6pt;padding-left:71.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">If to the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exicure, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Chief Executive Officer</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2430 N. Halsted St.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chicago, Illinois 60614</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58; davidg&#64;exicuretx.com</font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">If to Executive&#58;</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elias D. Papadimas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">At the most recent address on file with the Company.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NTIRE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement, including the Confidential Information Agreement, constitutes the entire agreement and understanding between the parties with respect to the subject matter hereof and supersedes and preempts any prior understandings, agreements or representations by or between the parties, written or oral, which may have related in any manner to the subject matter hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONFLICT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive represents and warrants that Executive is not bound by any employment contract, restrictive covenant, or other restriction preventing Executive from carrying out Executive&#8217;s responsibilities for the Company, or which is in any way inconsistent with the terms of this Agreement. Executive further represents and warrants that Executive shall not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UCCESSORS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SSIGNS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall inure to the benefit of and be enforceable by Executive and Executive&#8217;s heirs, executors and personal representatives, and the Company and its successors and assigns. Any successor or assignee of the Company shall assume the liabilities of the Company hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERNING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be governed by the internal laws (as opposed to the conflicts of law provisions) of the State of Illinois.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MENDMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AIVER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The provisions of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">252092631 v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITHHOLDING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All payments and benefits under this Agreement are subject to withholding of all applicable taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ODE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ECTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement is intended to comply with the requirements of Section 409A of the Code, and shall be interpreted and construed consistently with such intent. The payments to Executive pursuant to this Agreement are also intended to be exempt from Section 409A of the Code to the maximum extent possible, under either the separation pay exemption pursuant to Treasury regulation &#167;1.409A-1(b)(9)(iii) or as short-term deferrals pursuant to Treasury regulation &#167;1.409A-1(b)(4), and for such purposes, each payment to Executive under this Agreement shall be considered a separate payment. In the event the terms of this Agreement would subject Executive to taxes or penalties under Section 409A of the Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">409A Penalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Company and Executive shall cooperate diligently to amend the terms of the Agreement to avoid such 409A Penalties, to the extent possible. To the extent any amounts under this Agreement are payable by reference to Executive&#8217;s &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">termination of employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; such term and similar terms shall be deemed to refer to Executive&#8217;s &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">separation from service,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; within the meaning of Section 409A of the Code. Notwithstanding any other provision in this Agreement, to the extent any payments made or contemplated hereunder constitute nonqualified deferred compensation, within the meaning of Section 409A, then (i) each such payment which is conditioned upon Executive&#8217;s execution of a release and which is to be paid or provided during a designated period that begins in one taxable year and ends in a second taxable year, shall be paid or provided in the later of the two taxable years and (ii) if Executive is a specified employee (within the meaning of Section 409A of the Code) as of the date of Executive&#8217;s separation from service, each such payment that is payable upon Executive&#8217;s separation from service and would have been paid prior to the six-month anniversary of Executive&#8217;s separation from service, shall be delayed until the earlier to occur of (A) the first day of the seventh month following Executive&#8217;s separation from service or (B) the date of Executive&#8217;s death. Any reimbursement payable to Executive pursuant to this Agreement shall be conditioned on the submission by Executive of all expense reports reasonably required by Company under any applicable expense reimbursement policy, and shall be paid to Executive within 30 days following receipt of such expense reports, but in no event later than the last day of the calendar year following the calendar year in which Executive incurred the reimbursable expense. Any amount of expenses eligible for reimbursement, or in-kind benefit provided, during a calendar year shall not affect the amount of expenses eligible for reimbursement, or in-kind benefit to be provided, during any other calendar year. The right to any reimbursement or in-kind benefit pursuant to this Agreement shall not be subject to liquidation or exchange for any other benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LAWBACKS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The payments to Executive pursuant to this Agreement are subject to forfeiture or recovery by the Company or other action pursuant to any clawback or recoupment policy which the Company may adopt from time to time, including without limitation any such policy or provision that the Company has included in any of its existing compensation programs or plans or that it may be required to adopt under the Dodd-Frank Wall Street Reform and Consumer Protection Act and implementing rules and regulations thereunder, or as otherwise required by law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">252092631 v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OMPANY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OLICIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive shall be subject to additional Company policies as they may exist from time-to-time, including but not limited to the Confidential Information Agreement, the Company&#8217;s Code of Business Conduct and Ethics, Security Trading Policy (pursuant to which Executive is determined to be a Restricted Person), and other applicable policies with regard to stock ownership by senior executives and&#47;or regarding trading of securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Follow&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">252092631 v3</font></div></div></div><div id="idb9f9dcfe10b48c295ffdb0713dddb9f_41"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITNESS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the parties hereto have executed this Agreement as of the date first written above.</font></div><div style="margin-bottom:6pt;padding-left:216pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.839%"><tr><td style="width:1.0%"></td><td style="width:14.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">XICURE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; David A. Giljohann</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">David A. Giljohann</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Elias D. Papadimas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Elias D. Papadimas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Accounting Officer</font></td></tr></table></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">252092631 v3</font></div></div></div><div id="idb9f9dcfe10b48c295ffdb0713dddb9f_44"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">Confidentiality, Non-Hire, Non-Disparagement and Work Product Agreement</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">252092631 v3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>exicureexhibit104-63021.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="idfaea434cf3b4f399b38d9f915a8f9bc_255"></div><div style="min-height:64.8pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.4</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Execution Version</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is made as of this 30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> day of July, 2021, by and among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXICURE, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), as a Borrower,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> EXICURE OPERATING COMPANY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exicure Operating Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), as a Borrower, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MIDCAP FINANCIAL TRUST</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, as Agent (in such capacity, together with its successors and assigns, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and the financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.31pt">Agent, Lenders and Borrowers have entered into that certain Credit and Security Agreement, dated as of September 25, 2020 (as amended by that certain Amendment No. 1 to Credit and Security Agreement, dated as of October 21, 2020 and as further amended, supplemented or otherwise modified from time to time prior to the date hereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Original Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and, as the same is amended hereby and as it may be further amended, modified, supplemented and restated from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), pursuant to which the Lenders have agreed to make certain advances of money and to extend certain financial accommodations to Borrowers in the amounts and manner set forth in the Credit Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.92pt">Borrowers have informed Agent of its intention to enter into that certain Collaboration, Option and License Agreement, dated as of July 30, 2021, between Parent and Ipsen Biopharm Limited, a company organized under the laws of England, located at Ash Road, Wrexham Industrial Estate, Wrexham LL13 9UF, United Kingdom, pursuant to which Parent will grant Ipsen certain options and rights to license the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exicure SNA Technology and all Exicure Other Technology (each as defined in the Ipsen License Agreement on the date hereof)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.8pt">Borrowers have requested, and Agent and Lenders have agreed, on and subject to the terms and conditions set forth in this Agreement and the other Financing Documents, to among other things, amend certain provisions of the Original Credit Agreement relating to the foregoing. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing, the terms and conditions set forth in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Agent, Lenders and Borrowers hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Recitals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement shall constitute a Financing Document and the Recitals and each reference to the Credit Agreement, unless otherwise expressly noted, will be deemed to reference the Credit Agreement as amended hereby.  The Recitals set forth above shall be construed as part of this Agreement as if set forth fully in the body of this Agreement and capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Credit Agreement (including those capitalized terms used in the Recitals hereto).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Amendment to Original Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Agreement, including, without limitation, the conditions to effectiveness set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below, the Original Credit Agreement is hereby amended as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Excluded Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; in Article 15 of the Original Credit Agreement is amended by&#58; </font></div><div style="height:67.21pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MidCap &#47; Exicure &#47; Amendment No. 2 </font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;DC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#8211; 036639&#47;000119 - 16276544</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">deleting the &#8220;and&#8221; at the end of clause (b) thereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">adding an &#8220;and&#8221; at the end of clause (c) thereof&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.53pt">adding the following new clause (d) in appropriate alphabetical order therein&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;(d)  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">after the occurrence of a Springing IP Lien Event, all Intellectual Property that is exclusively licensed to Ipsen pursuant to the Ipsen License Agreement (as the same is in effect on the Second Amendment Effective Date), including all Exicure SNA Technology and all Exicure Other Technology (each as defined in the Ipsen License Agreement on the Second Amendment Effective Date) that is exclusively licensed to Ipsen (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ipsen Licensed IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">rovided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that (i) in no event shall (x) the Ipsen License Agreement, (y) any rights to payment of a Borrower under the Ipsen License Agreement or any proceeds received by or on behalf of a Borrower under the Ipsen License Agreement, or (z) any IP Proceeds of the Ipsen Licensed IP, constitute or be deemed to be &#8220;Excluded Property&#8221;, and (ii) upon termination of the Ipsen License Agreement or any exclusive license granted to Ipsen thereunder with respect to any Ipsen Licensed IP (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Terminated Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), such Terminated Licensed IP shall no longer constitute &#8220;Excluded Property&#8221; pursuant to this clause (d) and &#8220;Collateral&#8221; shall immediately include all such Terminated Licensed IP of each Credit Party (including, for the avoidance of doubt, all IP Proceeds thereof) automatically and without notice or any further action by Agent, any Lender or any Credit Party&#59;&#8221;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">The definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Material Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; in Article 15 of the Original Credit Agreement is amended by&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">adding the following as new clause (b) in the appropriate alphabetical order therein&#59; and</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;(b) the Ipsen License Agreement,&#8221;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">renumbering the existing clause (b) as clause (c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The following definitions are hereby added to Article 15 of the Original Credit Agreement in the appropriate alphabetical order therein.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ipsen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Ipsen Biopharm Limited a company organized under the laws of England, located at Ash Road, Wrexham Industrial Estate, Wrexham LL13 9UF, United Kingdom.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ipsen License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain Collaboration, Option and License Agreement, dated as of July 30, 2021, between Parent and Ipsen, as amended, restated, supplemented or otherwise modified from time to time in accordance with the terms thereof and the terms of this Agreement.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Second Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain Amendment No. 2 to Credit and Security Agreement, dated as of July 30, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Second Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) among Borrowers, Agent and Lenders.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Representations and Warranties&#59; Reaffirmation of Security Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="height:67.21pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MidCap &#47; Exicure &#47; Amendment No. 2 </font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;DC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#8211; 036639&#47;000119 - 16276544</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Each Borrower hereby confirms that all of the representations and warranties set forth in the Credit Agreement are true and correct in all material respects (without duplication of any materiality qualifier in the text of such representation or warranty) with respect to Borrowers as of the date hereof except to the extent that any such representation or warranty relates to a specific date in which case such representation or warranty shall be true and correct in all material respects as of such earlier date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in each case, such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof.  Each Borrower hereby represents and warrants that the Ipsen License Agreement is a &#8220;Permitted License&#8221; pursuant to, and satisfies all of the conditions of, clause (c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of the definition thereof.     </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Except as otherwise provided herein, nothing herein is intended to impair or limit the validity, priority or extent of Agent&#8217;s security interests in and Liens on the Collateral.  Each Borrower acknowledges and agrees that the Credit Agreement, the other Financing Documents and this Agreement constitute the legal, valid and binding obligation of such Borrower, and are enforceable against such Borrower in accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws relating to the enforcement of creditors&#8217; rights generally and by general equitable principles.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Conditions to Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement shall become effective as of the date on which each of the following conditions has been satisfied, as determined by Agent in its sole discretion&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Agent shall have received (including by way of facsimile or other electronic transmission) a duly authorized, executed and delivered counterpart of the signature page to this Amendment from Borrowers, Agent and the Lenders&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Agent shall have received a fully executed copy of the Ipsen License Agreement and all documents, agreements and instruments executed in connection therewith&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">all representations and warranties of Borrowers contained herein shall be true and correct in all material respects (without duplication of any materiality qualifier in the text of such representation or warranty) as of the date hereof except to the extent that any such representation or warranty relates to a specific date in which case such representation or warranty shall be true and correct in all material respects as of such earlier date&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in each case, such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof (and such parties&#8217; delivery of their respective signatures hereto shall be deemed to be its certification thereof)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">prior to and after giving effect to the agreements set forth herein, no Default or Event of Default shall exist under any of the Financing Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In consideration of the agreements of Agent and Lenders contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, each Borrower, voluntarily, knowingly, unconditionally and irrevocably, with specific and express intent, for and on behalf of itself and all of its respective parents, subsidiaries, affiliates, members, managers, predecessors, successors, and assigns, and each of its respective current and former directors, officers, shareholders, agents, and employees, and each of its respective predecessors, successors, heirs, and assigns (individually and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Releasing Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) does hereby fully and completely release, acquit and forever discharge each of Agent, Lenders, and each of their respective parents, subsidiaries, affiliates, members, managers, shareholders, directors, officers and employees, and each of their respective predecessors, successors, heirs, and assigns (individually and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Released </font></div><div style="height:67.21pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MidCap &#47; Exicure &#47; Amendment No. 2 </font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;DC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#8211; 036639&#47;000119 - 16276544</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), of and from any and all actions, causes of action, suits, debts, disputes, damages, claims, obligations, liabilities, costs, expenses and demands of any kind whatsoever, at law or in equity, whether matured or unmatured, liquidated or unliquidated, that the Releasing Parties (or any of them) has against the Released Parties or any of them (whether directly or indirectly), based in whole or in part on facts, now known or of which the Releasing Parties would reasonably be expected to know, existing on or before the date hereof, that relate to, arise out of or otherwise are in connection with&#58; (i) any or all of the Financing Documents or transactions contemplated thereby or any actions or omissions in connection therewith or (ii) any aspect of the dealings or relationships between or among any Borrower, on the one hand, and any or all of the Released Parties, on the other hand, relating to any or all of the documents, transactions, actions or omissions referenced in clause (i) hereof, in each case, based in whole or in part on facts now known to exist before the Second Amendment Effective Date.  Each Borrower acknowledges that the foregoing release is a material inducement to Agent&#8217;s and each Lender&#8217;s decision to enter into this Agreement and agree to the modifications contemplated hereunder, and has been relied upon by Agent and Lenders in connection therewith.  Without limiting the terms and conditions set forth in the Credit Agreement, the general release set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not extend to, and shall not include, any obligations of Agent and the Lenders to make the Credit Extensions after the date of this Agreement to Borrowers in accordance with the terms of the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">No Waiver or Novation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The execution, delivery and effectiveness of this Agreement shall not, except as expressly provided in this Agreement, operate as a waiver of any right, power or remedy of Agent, nor constitute a waiver of any provision of the Credit Agreement, the Financing Documents or any other documents, instruments and agreements executed or delivered in connection with any of the foregoing.  Nothing herein is intended or shall be construed as a waiver of any existing Defaults or Events of Default under the Credit Agreement or the other Financing Documents or any of Agent&#8217;s rights and remedies in respect of such Defaults or Events of Default.  This Agreement (together with any other document executed in connection herewith) is not intended to be, nor shall it be construed as, a novation of the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Affirmation and Collateral Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Except as specifically amended pursuant to the terms hereof, each Borrower hereby acknowledges and agrees that the Credit Agreement and all other Financing Documents (and all covenants, terms, conditions and agreements therein) shall remain in full force and effect, and are hereby ratified and confirmed in all respects by Borrowers.  Each Borrower covenants and agrees to comply with all of the terms, covenants and conditions of the Credit Agreement and the Financing Documents, notwithstanding any prior course of conduct, waivers, releases or other actions or inactions on Agent&#8217;s or any Lender&#8217;s part which might otherwise constitute or be construed as a waiver of or amendment to such terms, covenants and conditions.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Each Borrower (i) hereby grants to Agent, for the benefit of itself and Lenders, a first priority Lien on and security interest in, upon, and to such Borrower&#8217;s right, title and interest in and to the Ipsen License Agreement and all products and proceeds thereof and (ii) represents, warrants and covenants that the Ipsen License Agreement, each Borrower&#8217;s rights thereunder and the products and proceeds thereof shall in no event constitute Excluded Property.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Reference to the Effect on the Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Upon the effectiveness of this Agreement, each reference in the Credit Agreement to &#8220;this Agreement,&#8221; &#8220;hereunder,&#8221; &#8220;hereof,&#8221; &#8220;herein,&#8221; or words of similar import shall mean and be a reference to the Credit Agreement, as amended by this </font></div><div style="height:67.21pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MidCap &#47; Exicure &#47; Amendment No. 2 </font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;DC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#8211; 036639&#47;000119 - 16276544</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Agreement.  Except as specifically amended above, the Credit Agreement, and all other Financing Documents (and all covenants, terms, conditions and agreements therein), shall remain in full force and effect, and are hereby ratified and confirmed in all respects by Borrowers.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">GOVERNING LAW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  THIS AGREEMENT AND ALL DISPUTES AND OTHER MATTERS RELATING HERETO OR THERETO OR ARISING THEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES (OTHER THAN SECTION 5-1401 OF THE GENERAL OBLIGATIONS LAW). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">WAIVER OF JURY TRIAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.   BORROWERS, AGENT AND THE LENDERS PARTY HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY AND AGREES THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY.  EACH BORROWER, AGENT AND EACH LENDER ACKNOWLEDGES THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT, AND THAT EACH WILL CONTINUE TO RELY ON THIS WAIVER IN THEIR RELATED FUTURE DEALINGS.  EACH BORROWER, AGENT AND EACH LENDER WARRANTS AND REPRESENTS THAT IT HAS HAD THE OPPORTUNITY OF REVIEWING THIS JURY WAIVER WITH LEGAL COUNSEL, AND THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Incorporation of Credit Agreement Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The provisions contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (Choice of law&#59; venue and jury trial waiver) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (Indemnification) of the Credit Agreement are incorporated herein by reference to the same extent as if reproduced herein in their entirety.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Section headings in this Agreement are included for convenience of reference only and shall not constitute a part of this Agreement for any other purpose.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement may be signed in any number of counterparts, each of which shall be deemed an original and all of which when taken together shall constitute one and the same instrument.  Delivery of an executed counterpart of this Agreement by facsimile or by electronic mail delivery of an electronic version (e.g., .pdf or .tif file) of an executed signature page&#160;shall be effective as delivery of an original executed counterpart hereof and shall bind the parties hereto.  In furtherance of the foregoing, the words &#8220;execution&#8221;, &#8220;signed&#8221;, &#8220;signature&#8221;, &#8220;delivery&#8221; and words of like import in or relating to any document to be signed in connection with this Agreement and the transactions contemplated hereby or thereby shall be deemed to include Electronic Signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.&#160; As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Electronic Signature</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an electronic sound, symbol, or process attached to, or associated with, a contract or other record and adopted by a Person with the intent to sign, authenticate or accept such contract or other record.&#160;  </font></div><div style="height:67.21pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MidCap &#47; Exicure &#47; Amendment No. 2 </font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;DC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#8211; 036639&#47;000119 - 16276544</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement constitutes the entire agreement and understanding among the parties hereto and supersedes any and all prior agreements and understandings, oral or written, relating to the subject matter hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In case any provision of or obligation under this Agreement shall be invalid, illegal or unenforceable in any applicable jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt;text-decoration:underline"> Successors&#47;Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement shall bind, and the rights hereunder shall inure to, the respective successors and assigns of the parties hereto, subject to the provisions of the Credit Agreement and the other Financing Documents.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;SIGNATURES APPEAR ON FOLLOWING PAGES&#93;</font></div><div style="height:67.21pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MidCap &#47; Exicure &#47; Amendment No. 2 </font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#92;&#92;DC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#8211; 036639&#47;000119 - 16276544</font></div></div></div><div id="idfaea434cf3b4f399b38d9f915a8f9bc_258"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, intending to be legally bound, the undersigned have executed this Agreement as of the day and year first hereinabove set forth.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AGENT&#58;&#160;&#160;&#160;&#160; MIDCAP FINANCIAL TRUST, </font></div><div style="padding-left:216pt;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> By&#58; &#160;&#160;&#160;&#160;Apollo Capital Management, L.P.,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> its investment manager</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> By&#58;&#160;&#160;&#160;&#160;Apollo Capital Management GP, LLC,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> its general partner</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:36pt;text-indent:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.493%"><tr><td style="width:1.0%"></td><td style="width:11.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Maurice Amsellem</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maurice Amsellem</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Authorized Signatory</font></td></tr></table></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LENDERS&#58;&#160;&#160;&#160;&#160; MIDCAP FINANCIAL TRUST, </font></div><div style="padding-left:216pt;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> By&#58; &#160;&#160;&#160;&#160;Apollo Capital Management, L.P.,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> its investment manager</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> By&#58;&#160;&#160;&#160;&#160;Apollo Capital Management GP, LLC,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> its general partner</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:36pt;text-indent:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.493%"><tr><td style="width:1.0%"></td><td style="width:11.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Maurice Amsellem</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maurice Amsellem</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Authorized Signatory</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:74.41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MidCap &#47; Exicure &#47; Amendment No. 2 </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LENDERS&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ELM 2020-4 TRUST</font></div><div style="padding-left:216pt;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-indent:-216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> By&#58; MidCap Financial Services Capital Management,</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> LLC, as Servicer</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.493%"><tr><td style="width:1.0%"></td><td style="width:11.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; David Murphy</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">David Murphy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Authorized Signatory</font></td></tr></table></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ELM 2020-3 TRUST</font></div><div style="padding-left:216pt;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-indent:-216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> By&#58; MidCap Financial Services Capital Management,</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> LLC, as Servicer</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.493%"><tr><td style="width:1.0%"></td><td style="width:11.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; David Murphy</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">David Murphy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Authorized Signatory</font></td></tr></table></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div style="height:74.41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MidCap &#47; Exicure &#47; Amendment No. 2 </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LENDERS&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SILICON VALLEY BANK</font></div><div style="padding-left:216pt;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.493%"><tr><td style="width:1.0%"></td><td style="width:11.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Kristine Rohmer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Kristine Rohmer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vice President</font></td></tr></table></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt;text-indent:-216pt"><font><br></font></div><div style="height:74.41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MidCap &#47; Exicure &#47; Amendment No. 2 </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BORROWER&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EXICURE, INC.</font></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="margin-bottom:24pt;padding-left:216pt;text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.493%"><tr><td style="width:1.0%"></td><td style="width:11.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; David Giljohann</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">David Giljohann</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:24pt;padding-left:216pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EXICURE OPERATING COMPANY</font></div><div style="margin-bottom:24pt;padding-left:211.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.493%"><tr><td style="width:1.0%"></td><td style="width:11.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; David Giljohann</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">David Giljohann</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:18pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:74.41pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MidCap &#47; Exicure &#47; Amendment No. 2 </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exicureexhibit311-63021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i19f5f8568e0f4473adc6114840bc2ce8_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David A. Giljohann, Ph.D., certify that&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Exicure, Inc.&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August 12, 2021 </font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.470%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David A. Giljohann</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">David A. Giljohann, Ph.D.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exicureexhibit312-63021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia336a9cdd0704698b30386788c5e21da_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brian C. Bock, certify that&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Exicure, Inc.&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August 12, 2021 </font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.470%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian C. Bock</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brian C. Bock</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exicureexhibit321-63021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="idb6cd506cf1945c2ad3f51346e60a567_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350 CERTIFICATIONS* </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), David A. Giljohann, Ph. D., President and Chief Executive Officer of Exicure, Inc. (the &#8220;Company&#8221;), and Brian C. Bock, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Quarterly Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; August 12, 2021</font></div><div style="margin-top:5pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.910%"><tr><td style="width:1.0%"></td><td style="width:44.896%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.898%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David A. Giljohann</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian C. Bock</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">David A. Giljohann, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brian C. Bock</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.073%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies the Quarterly Report on Form 10-Q, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></td></tr></table></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>xcur-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:5b54f0ec-bf0b-4618-8722-18f79640ae79,g:5933f058-0750-4e2c-9852-92fa9631b69d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xcur="http://www.exicuretx.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exicuretx.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exicuretx.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME">
        <link:definition>1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical">
        <link:definition>1007008 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofPresentation" roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofPresentationDetails" roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Description of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchandLicenseAgreements" roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements">
        <link:definition>2105103 - Disclosure - Collaborative Research and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchandLicenseAgreementsDetails" roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails">
        <link:definition>2406402 - Disclosure - Collaborative Research and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformation" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation">
        <link:definition>2107104 - Disclosure - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationTables" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables">
        <link:definition>2308301 - Disclosure - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails">
        <link:definition>2409403 - Disclosure - Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails">
        <link:definition>2410404 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails">
        <link:definition>2411405 - Disclosure - Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.exicuretx.com/role/Investments">
        <link:definition>2112105 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.exicuretx.com/role/InvestmentsTables">
        <link:definition>2313302 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDetails" roleURI="http://www.exicuretx.com/role/InvestmentsDetails">
        <link:definition>2414406 - Disclosure - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforsaleSecuritiesDetails" roleURI="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails">
        <link:definition>2415407 - Disclosure - Investments - Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.exicuretx.com/role/Debt">
        <link:definition>2116106 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.exicuretx.com/role/DebtTables">
        <link:definition>2317303 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails">
        <link:definition>2418408 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtPrincipalMaturitiesofLongTermDebtDetails" roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails">
        <link:definition>2419409 - Disclosure - Debt - Principal Maturities of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtPrincipalMaturitiesofLongTermDebtDetails_1" roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1">
        <link:definition>2419409 - Disclosure - Debt - Principal Maturities of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.exicuretx.com/role/Leases">
        <link:definition>2120107 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.exicuretx.com/role/LeasesTables">
        <link:definition>2321304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.exicuretx.com/role/LeasesNarrativeDetails">
        <link:definition>2422410 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRightofUseAssetInformationDetails" roleURI="http://www.exicuretx.com/role/LeasesRightofUseAssetInformationDetails">
        <link:definition>2423411 - Disclosure - Leases - Right of Use Asset Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostsDetails" roleURI="http://www.exicuretx.com/role/LeasesLeaseCostsDetails">
        <link:definition>2424412 - Disclosure - Leases - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumRentalPaymentsDetails" roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails">
        <link:definition>2425413 - Disclosure - Leases - Schedule of Future Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1">
        <link:definition>2425413 - Disclosure - Leases - Schedule of Future Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.exicuretx.com/role/StockholdersEquity">
        <link:definition>2126108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.exicuretx.com/role/StockholdersEquityTables">
        <link:definition>2327305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCurrentCapitalizationDetails" roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails">
        <link:definition>2428414 - Disclosure - Stockholders' Equity - Current Capitalization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockWarrantsDetails" roleURI="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails">
        <link:definition>2429415 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails">
        <link:definition>2430416 - Disclosure - Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensation" roleURI="http://www.exicuretx.com/role/EquityBasedCompensation">
        <link:definition>2131109 - Disclosure - Equity-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationTables" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables">
        <link:definition>2332306 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationNarrativeDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails">
        <link:definition>2433417 - Disclosure - Equity-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationScheduleofCompensationExpenseDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails">
        <link:definition>2434418 - Disclosure - Equity-Based Compensation - Schedule of Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails">
        <link:definition>2435419 - Disclosure - Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails">
        <link:definition>2436420 - Disclosure - Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails">
        <link:definition>2437421 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationRSUActivityDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails">
        <link:definition>2438422 - Disclosure - Equity-Based Compensation - RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exicuretx.com/role/IncomeTaxes">
        <link:definition>2139110 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.exicuretx.com/role/IncomeTaxesDetails">
        <link:definition>2440423 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.exicuretx.com/role/LossPerCommonShare">
        <link:definition>2141111 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareTables" roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables">
        <link:definition>2342307 - Disclosure - Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareComputationofEarningsPerShareDetails" roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails">
        <link:definition>2443424 - Disclosure - Loss Per Common Share - Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>2444425 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exicuretx.com/role/FairValueMeasurements">
        <link:definition>2145112 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables">
        <link:definition>2346308 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>2447426 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2448427 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2449428 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.exicuretx.com/role/CommitmentandContingencies">
        <link:definition>2150113 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesDetails" roleURI="http://www.exicuretx.com/role/CommitmentandContingenciesDetails">
        <link:definition>2451429 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions">
        <link:definition>2152114 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2453430 - Disclosure - Related-Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.exicuretx.com/role/SubsequentEvents">
        <link:definition>2154115 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.exicuretx.com/role/SubsequentEventsDetails">
        <link:definition>2455431 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="xcur_DevelopmentandCommercializationLicenseMember" abstract="true" name="DevelopmentandCommercializationLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_ExercisePeriodAxis" abstract="true" name="ExercisePeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" abstract="false" name="DebtSecuritiesAvailableForSaleNoncurrentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" abstract="false" name="DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="xcur_MidCapCreditAgreementMember" abstract="true" name="MidCapCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_CollaborationDevelopmentExpenses" abstract="false" name="CollaborationDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_CollaborationAgreementLicensingFeesIncurred" abstract="false" name="CollaborationAgreementLicensingFeesIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" abstract="false" name="AccruedClinicalContractResearchAndManufacturingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" abstract="false" name="LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ExercisePeriodDomain" abstract="true" name="ExercisePeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ExercisePeriodOneMember" abstract="true" name="ExercisePeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_ConsultingServicesMember" abstract="true" name="ConsultingServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" abstract="false" name="OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_ClassofWarrantorRightExpired" abstract="false" name="ClassofWarrantorRightExpired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xcur_CollaborationAgreementUpfrontPayment" abstract="false" name="CollaborationAgreementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_MidCapCreditAgreementTranche2Member" abstract="true" name="MidCapCreditAgreementTranche2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" abstract="false" name="DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_MidCapCreditAgreementTranche1Member" abstract="true" name="MidCapCreditAgreementTranche1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_PaymentsForDebtEndTermFees" abstract="false" name="PaymentsForDebtEndTermFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_AggregatePaymentsMadeToDateForLicenseAgreements" abstract="false" name="AggregatePaymentsMadeToDateForLicenseAgreements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xcur_SupplementalBalanceSheetInformationAbstract" abstract="true" name="SupplementalBalanceSheetInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xcur_ResearchAndDevelopmentStaffOnSitePercentage" abstract="false" name="ResearchAndDevelopmentStaffOnSitePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_CommonStockWarrantLiabilityFairValueDisclosure" abstract="false" name="CommonStockWarrantLiabilityFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ExicureInc.2017EquityIncentivePlanMember" abstract="true" name="ExicureInc.2017EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_AbbVieCollaborationMember" abstract="true" name="AbbVieCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_NumberofCollaborationPrograms" abstract="false" name="NumberofCollaborationPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xcur_ArrangementNameAxis" abstract="true" name="ArrangementNameAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="xcur_CommonStockVotingRightsForEachShare" abstract="false" name="CommonStockVotingRightsForEachShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xcur_DebtInstrumentExitFeePercentage" abstract="false" name="DebtInstrumentExitFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" abstract="false" name="ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ExercisePeriodTwoMember" abstract="true" name="ExercisePeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" abstract="false" name="LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_IpsenCollaborationMember" abstract="true" name="IpsenCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" abstract="false" name="CollaborationAgreementTerminationPeriodUponWrittenNotice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xcur_PaymentsOfCommonStockFinancingCosts" abstract="false" name="PaymentsOfCommonStockFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ComputersandSoftwareMember" abstract="true" name="ComputersandSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_DermelixLicenseAgreementMember" abstract="true" name="DermelixLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseNumberOfExtensions" abstract="false" name="LesseeOperatingLeaseNumberOfExtensions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" abstract="false" name="LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_WarrantLiabilityMember" abstract="true" name="WarrantLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_DebtSecuritiesAvailableForSaleCurrentPercent" abstract="false" name="DebtSecuritiesAvailableForSaleCurrentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_ChicagoMember" abstract="true" name="ChicagoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_ArrangementNameDomain" abstract="true" name="ArrangementNameDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_HerculesTechnologyGrowthCapitalMember" abstract="true" name="HerculesTechnologyGrowthCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseLeaseArea" abstract="false" name="LesseeOperatingLeaseLeaseArea" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" abstract="false" name="CollaborationAgreementExtendedOptionAdditionalExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" abstract="false" name="RetainedEarningsAccumulatedDeficitInceptiontoDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_CollaborationAgreementOptionExerciseFee" abstract="false" name="CollaborationAgreementOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xcur_DebtSecuritiesAvailableforSalePercent" abstract="false" name="DebtSecuritiesAvailableforSalePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" abstract="false" name="LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>xcur-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:5b54f0ec-bf0b-4618-8722-18f79640ae79,g:5933f058-0750-4e2c-9852-92fa9631b69d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="xcur-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a126ce03-143d-4a89-b845-0869fb0dd289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b7430964-d0fd-4eee-8030-c9a78eb96da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a126ce03-143d-4a89-b845-0869fb0dd289" xlink:to="loc_us-gaap_Liabilities_b7430964-d0fd-4eee-8030-c9a78eb96da8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eae91e98-3fce-4efb-bbfe-2ba705db5d38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a126ce03-143d-4a89-b845-0869fb0dd289" xlink:to="loc_us-gaap_StockholdersEquity_eae91e98-3fce-4efb-bbfe-2ba705db5d38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1cae31d0-9d57-4534-8268-0de0cea7c09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fdeb5751-d00a-4e82-8cc8-35ccf7349850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1cae31d0-9d57-4534-8268-0de0cea7c09f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fdeb5751-d00a-4e82-8cc8-35ccf7349850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ef0f3cb3-a29d-4a00-b519-3e229f53fdea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1cae31d0-9d57-4534-8268-0de0cea7c09f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ef0f3cb3-a29d-4a00-b519-3e229f53fdea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_52018848-5e77-4009-a8be-035150a77523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1cae31d0-9d57-4534-8268-0de0cea7c09f" xlink:to="loc_us-gaap_LiabilitiesCurrent_52018848-5e77-4009-a8be-035150a77523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c3c2eb03-d482-4fb9-ad3e-eee1cce81324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1cae31d0-9d57-4534-8268-0de0cea7c09f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c3c2eb03-d482-4fb9-ad3e-eee1cce81324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_54a685b9-bba3-4eab-b86b-ee0f773c478f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_48ae5d06-2b36-457f-b93e-b33ffa1993cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_54a685b9-bba3-4eab-b86b-ee0f773c478f" xlink:to="loc_us-gaap_AssetsCurrent_48ae5d06-2b36-457f-b93e-b33ffa1993cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3485d89d-17c9-4f65-bcde-a6f4ed5eaa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_54a685b9-bba3-4eab-b86b-ee0f773c478f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3485d89d-17c9-4f65-bcde-a6f4ed5eaa4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ee41fd64-9237-4670-bb89-536089eb12d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_54a685b9-bba3-4eab-b86b-ee0f773c478f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ee41fd64-9237-4670-bb89-536089eb12d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0590b140-bee8-42d6-b258-3813f3969863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_54a685b9-bba3-4eab-b86b-ee0f773c478f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0590b140-bee8-42d6-b258-3813f3969863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b988dabe-a690-49c8-a6b9-f5c590fa0eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0bbbb9a4-0d5a-4194-8888-b121da0a8a36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b988dabe-a690-49c8-a6b9-f5c590fa0eaf" xlink:to="loc_us-gaap_AccountsPayableCurrent_0bbbb9a4-0d5a-4194-8888-b121da0a8a36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e59cc161-cc0d-4121-bb67-79a970908595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b988dabe-a690-49c8-a6b9-f5c590fa0eaf" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e59cc161-cc0d-4121-bb67-79a970908595" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_25c63e7a-e904-4f76-9c6d-d06bd235aaac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b988dabe-a690-49c8-a6b9-f5c590fa0eaf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_25c63e7a-e904-4f76-9c6d-d06bd235aaac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ac8ae3d-99e4-42e4-b324-5e4334795182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cd359f09-9d00-47c9-9578-5a2aa78323c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5ac8ae3d-99e4-42e4-b324-5e4334795182" xlink:to="loc_us-gaap_CommonStockValue_cd359f09-9d00-47c9-9578-5a2aa78323c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f670fbeb-9966-41be-9f90-d81f83ec1fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5ac8ae3d-99e4-42e4-b324-5e4334795182" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f670fbeb-9966-41be-9f90-d81f83ec1fc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f0970bad-e125-4713-804a-c63409222b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5ac8ae3d-99e4-42e4-b324-5e4334795182" xlink:to="loc_us-gaap_PreferredStockValue_f0970bad-e125-4713-804a-c63409222b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_86519aa7-e90d-4db0-bc49-60f824a0d8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5ac8ae3d-99e4-42e4-b324-5e4334795182" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_86519aa7-e90d-4db0-bc49-60f824a0d8e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_856fa42c-9fa7-481f-b753-14bb69f6ffaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5ac8ae3d-99e4-42e4-b324-5e4334795182" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_856fa42c-9fa7-481f-b753-14bb69f6ffaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_df1e8853-9cd4-49e0-8865-0b472517a4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_a9ba151c-a9ff-42df-8f05-7251d798c4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df1e8853-9cd4-49e0-8865-0b472517a4b1" xlink:to="loc_us-gaap_ShortTermInvestments_a9ba151c-a9ff-42df-8f05-7251d798c4a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a16876a3-43a3-481c-9901-ce51a8a07ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df1e8853-9cd4-49e0-8865-0b472517a4b1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a16876a3-43a3-481c-9901-ce51a8a07ee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1396120f-ddec-49f0-8ee4-4e6a937af620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df1e8853-9cd4-49e0-8865-0b472517a4b1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1396120f-ddec-49f0-8ee4-4e6a937af620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ca326d76-7f24-462e-8316-42a87b41d491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_df1e8853-9cd4-49e0-8865-0b472517a4b1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ca326d76-7f24-462e-8316-42a87b41d491" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="xcur-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_03285d94-1c05-4010-bb65-c55e235a0b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend_d6a56519-a4b2-4d31-a33b-a7b84d855b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_03285d94-1c05-4010-bb65-c55e235a0b16" xlink:to="loc_us-gaap_InvestmentIncomeDividend_d6a56519-a4b2-4d31-a33b-a7b84d855b71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_08f0524e-1a0f-4742-b100-faffdd70cdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_03285d94-1c05-4010-bb65-c55e235a0b16" xlink:to="loc_us-gaap_InvestmentIncomeInterest_08f0524e-1a0f-4742-b100-faffdd70cdb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_08faf993-e812-4d19-9932-10f8f21b2b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_03285d94-1c05-4010-bb65-c55e235a0b16" xlink:to="loc_us-gaap_InterestExpense_08faf993-e812-4d19-9932-10f8f21b2b26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_69a09151-b69b-4a32-adeb-05698f67ce4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_03285d94-1c05-4010-bb65-c55e235a0b16" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_69a09151-b69b-4a32-adeb-05698f67ce4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0783a184-3c11-4efd-9c15-bf45d57a3a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4736189f-f927-4fde-91e6-ddc4ece7759c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0783a184-3c11-4efd-9c15-bf45d57a3a47" xlink:to="loc_us-gaap_Revenues_4736189f-f927-4fde-91e6-ddc4ece7759c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f156d68a-3f67-4868-b5bd-0cc1f25d6285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0783a184-3c11-4efd-9c15-bf45d57a3a47" xlink:to="loc_us-gaap_OperatingExpenses_f156d68a-3f67-4868-b5bd-0cc1f25d6285" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_829a7e61-e2c1-46c7-b33d-cf00747ffa43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fcbb2946-c0d1-4b20-986f-a12a660b547d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_829a7e61-e2c1-46c7-b33d-cf00747ffa43" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fcbb2946-c0d1-4b20-986f-a12a660b547d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e0e485c9-6736-4ef6-9194-8df6df5199a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_829a7e61-e2c1-46c7-b33d-cf00747ffa43" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e0e485c9-6736-4ef6-9194-8df6df5199a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_41eda765-29ef-4d2c-9544-ca2b82747d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b563f4c-1858-494a-b5e3-c3a077c23a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_41eda765-29ef-4d2c-9544-ca2b82747d7e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b563f4c-1858-494a-b5e3-c3a077c23a32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_05f038dc-b4c6-42ad-a618-b8a359be491d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d6865a35-7c0b-47c5-b2cd-750e56556cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_05f038dc-b4c6-42ad-a618-b8a359be491d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d6865a35-7c0b-47c5-b2cd-750e56556cc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_9704dbc7-9028-45f7-a632-158a791cf0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_05f038dc-b4c6-42ad-a618-b8a359be491d" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_9704dbc7-9028-45f7-a632-158a791cf0f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="xcur-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_357ebffb-51dd-44e9-b3b6-bec8e50fb816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_93c608e0-2444-459c-9a9e-ed1ad29e2b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_357ebffb-51dd-44e9-b3b6-bec8e50fb816" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_93c608e0-2444-459c-9a9e-ed1ad29e2b62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6c7952f7-960b-41b1-bfa3-670d3eacd09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_03d09040-3ea0-4e56-a6ea-ef68bac09079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6c7952f7-960b-41b1-bfa3-670d3eacd09f" xlink:to="loc_us-gaap_NetIncomeLoss_03d09040-3ea0-4e56-a6ea-ef68bac09079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_05b64e0d-bc2e-41e8-8267-1844f925e4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6c7952f7-960b-41b1-bfa3-670d3eacd09f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_05b64e0d-bc2e-41e8-8267-1844f925e4d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="xcur-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e1965f93-af10-4415-9860-7a7273d8fe9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_bf7fd7e0-3ac6-4c7f-9b58-fa3f1429d96e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e1965f93-af10-4415-9860-7a7273d8fe9c" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_bf7fd7e0-3ac6-4c7f-9b58-fa3f1429d96e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_90cef8a4-b1f5-4ea0-a9f1-f865f81d617e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e1965f93-af10-4415-9860-7a7273d8fe9c" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_90cef8a4-b1f5-4ea0-a9f1-f865f81d617e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bb8c0741-e82d-4056-a67b-f607aade926d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e1965f93-af10-4415-9860-7a7273d8fe9c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bb8c0741-e82d-4056-a67b-f607aade926d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69877823-a8ea-4e4c-a051-54c1000c04bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74d44f2b-de37-43b1-b11d-d270b5682d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69877823-a8ea-4e4c-a051-54c1000c04bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74d44f2b-de37-43b1-b11d-d270b5682d18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a1b4ea02-b259-4604-9c6f-3d627b793ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69877823-a8ea-4e4c-a051-54c1000c04bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a1b4ea02-b259-4604-9c6f-3d627b793ea7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3d84ac4f-6620-4a13-9a10-1041f0740d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69877823-a8ea-4e4c-a051-54c1000c04bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3d84ac4f-6620-4a13-9a10-1041f0740d2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87a5fdee-d1a1-4e22-abb5-3d75b7ff292c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_NetIncomeLoss_87a5fdee-d1a1-4e22-abb5-3d75b7ff292c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ae0e4c74-3320-47c3-a82a-f9ccbc2ba08f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ae0e4c74-3320-47c3-a82a-f9ccbc2ba08f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_538208ce-1a12-4f92-9a7e-196a6b5d7876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_538208ce-1a12-4f92-9a7e-196a6b5d7876" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_88c10c56-0b04-4a94-9466-1c916f6c33b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_ShareBasedCompensation_88c10c56-0b04-4a94-9466-1c916f6c33b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ccfb9ec7-221c-4e2a-af28-800950a3d263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ccfb9ec7-221c-4e2a-af28-800950a3d263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_0a46cb27-e095-4432-bb7f-3e1a843211e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_0a46cb27-e095-4432-bb7f-3e1a843211e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2fde2650-0232-4713-a9ea-a6df07385baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2fde2650-0232-4713-a9ea-a6df07385baa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e6bfd14d-c416-4916-9200-94d00c9f77d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e6bfd14d-c416-4916-9200-94d00c9f77d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ad05906c-ab4e-43c4-9564-c225d3763c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ad05906c-ab4e-43c4-9564-c225d3763c38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_cf7eb306-a14f-4b49-903f-bec449501a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_cf7eb306-a14f-4b49-903f-bec449501a0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1cb20a91-7c3c-4103-b284-f9efb854f423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1cb20a91-7c3c-4103-b284-f9efb854f423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f945cf10-94d1-4a7f-9d87-fe631e04fa9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f945cf10-94d1-4a7f-9d87-fe631e04fa9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_657750d8-a6fb-4a1c-9af8-d7136b66afdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_657750d8-a6fb-4a1c-9af8-d7136b66afdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8740b406-09e6-4c08-9c14-357f69bca6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8740b406-09e6-4c08-9c14-357f69bca6f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_ae8d3087-96e2-4c66-881c-661c0aa57717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b58e885b-a31c-48ff-b6f3-75c04a7cf381" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_ae8d3087-96e2-4c66-881c-661c0aa57717" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_56747b66-c866-437f-8d02-bc5962aa8268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1ed07a8f-8544-433c-b069-0dad92d9a2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_56747b66-c866-437f-8d02-bc5962aa8268" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1ed07a8f-8544-433c-b069-0dad92d9a2ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c0d721e9-80f1-49fb-9084-8057f0b86a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_56747b66-c866-437f-8d02-bc5962aa8268" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c0d721e9-80f1-49fb-9084-8057f0b86a0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b7a48781-1a9d-462e-91d0-0cc33043328a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_56747b66-c866-437f-8d02-bc5962aa8268" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b7a48781-1a9d-462e-91d0-0cc33043328a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsOfCommonStockFinancingCosts_0d4883ab-35dd-40d0-ad5f-b6073141cd68" xlink:href="xcur-20210630.xsd#xcur_PaymentsOfCommonStockFinancingCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_56747b66-c866-437f-8d02-bc5962aa8268" xlink:to="loc_xcur_PaymentsOfCommonStockFinancingCosts_0d4883ab-35dd-40d0-ad5f-b6073141cd68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_bf4c136a-05e5-4e3c-b5b4-b1682fcfa9be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_56747b66-c866-437f-8d02-bc5962aa8268" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_bf4c136a-05e5-4e3c-b5b4-b1682fcfa9be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_b77c98db-3f07-451c-9eec-3a663d2d60d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_56747b66-c866-437f-8d02-bc5962aa8268" xlink:to="loc_us-gaap_ProceedsFromStockPlans_b77c98db-3f07-451c-9eec-3a663d2d60d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="xcur-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32af7c47-02f8-40f5-b323-d51ab23bcc40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_0cbca0fa-103b-4e21-9708-6e35f59959ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32af7c47-02f8-40f5-b323-d51ab23bcc40" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_0cbca0fa-103b-4e21-9708-6e35f59959ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0e4a8daf-9f17-4137-b295-720b6710035c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32af7c47-02f8-40f5-b323-d51ab23bcc40" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0e4a8daf-9f17-4137-b295-720b6710035c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f1341498-8a19-4b9e-9078-26e9c05f10e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_11630e0b-270b-41c5-abc3-b26303168622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f1341498-8a19-4b9e-9078-26e9c05f10e8" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_11630e0b-270b-41c5-abc3-b26303168622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_d739ecd6-5725-46f2-849f-97da4e5b66b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f1341498-8a19-4b9e-9078-26e9c05f10e8" xlink:to="loc_us-gaap_InterestReceivable_d739ecd6-5725-46f2-849f-97da4e5b66b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_c9c9d6e3-ace9-4228-8359-f237afca0f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f1341498-8a19-4b9e-9078-26e9c05f10e8" xlink:to="loc_us-gaap_PrepaidInsurance_c9c9d6e3-ace9-4228-8359-f237afca0f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_a903f7fa-0b06-4d5a-af70-149c21f9d22a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f1341498-8a19-4b9e-9078-26e9c05f10e8" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_a903f7fa-0b06-4d5a-af70-149c21f9d22a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_83bd43b8-1908-48e4-8db3-5b926c70dc93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8d4aeb20-1e64-4f2c-9b7b-5f9e4775e816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_83bd43b8-1908-48e4-8db3-5b926c70dc93" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8d4aeb20-1e64-4f2c-9b7b-5f9e4775e816" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8f10ac9f-7a54-4f8c-a720-5678a94320a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_83bd43b8-1908-48e4-8db3-5b926c70dc93" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8f10ac9f-7a54-4f8c-a720-5678a94320a6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7ea0468c-24c7-487e-a059-3cac11a2fa41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c2848d3e-75e3-4866-9450-da37b6be335c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7ea0468c-24c7-487e-a059-3cac11a2fa41" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c2848d3e-75e3-4866-9450-da37b6be335c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_f68d18d7-8470-44c1-8dee-4337e4daedf2" xlink:href="xcur-20210630.xsd#xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7ea0468c-24c7-487e-a059-3cac11a2fa41" xlink:to="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_f68d18d7-8470-44c1-8dee-4337e4daedf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_62b350d2-de12-4c54-bad7-cbbc7baed881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7ea0468c-24c7-487e-a059-3cac11a2fa41" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_62b350d2-de12-4c54-bad7-cbbc7baed881" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_86f43762-0173-412b-8c14-25f3bc7cd8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7ea0468c-24c7-487e-a059-3cac11a2fa41" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_86f43762-0173-412b-8c14-25f3bc7cd8a2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#InvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableforSalePercent_e2697cb5-dd27-407d-bbde-a922e05a4214" xlink:href="xcur-20210630.xsd#xcur_DebtSecuritiesAvailableforSalePercent"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_b45418f1-07b3-4eac-a2ff-b6777147ce13" xlink:href="xcur-20210630.xsd#xcur_DebtSecuritiesAvailableForSaleCurrentPercent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xcur_DebtSecuritiesAvailableforSalePercent_e2697cb5-dd27-407d-bbde-a922e05a4214" xlink:to="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_b45418f1-07b3-4eac-a2ff-b6777147ce13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_6bd6910c-7773-47ac-ab10-e7eb814d8a22" xlink:href="xcur-20210630.xsd#xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xcur_DebtSecuritiesAvailableforSalePercent_e2697cb5-dd27-407d-bbde-a922e05a4214" xlink:to="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_6bd6910c-7773-47ac-ab10-e7eb814d8a22" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#InvestmentsAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dc7c6025-fc70-44de-a63e-8bac8c049049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e039355c-a83a-4423-a2fe-22ce13c73f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dc7c6025-fc70-44de-a63e-8bac8c049049" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e039355c-a83a-4423-a2fe-22ce13c73f3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6bbd05dd-90a2-46d2-967d-e7fbcf347aad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dc7c6025-fc70-44de-a63e-8bac8c049049" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6bbd05dd-90a2-46d2-967d-e7fbcf347aad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_931743c6-3029-4d31-9913-103676d22224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dc7c6025-fc70-44de-a63e-8bac8c049049" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_931743c6-3029-4d31-9913-103676d22224" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#DebtPrincipalMaturitiesofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e2acb79e-cc6b-4108-bc91-39315f76526b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_daedf975-499c-4a06-89b8-6592f249afcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e2acb79e-cc6b-4108-bc91-39315f76526b" xlink:to="loc_us-gaap_LongTermDebtCurrent_daedf975-499c-4a06-89b8-6592f249afcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e756b5de-8742-4c2b-82bf-c716eecf6989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e2acb79e-cc6b-4108-bc91-39315f76526b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e756b5de-8742-4c2b-82bf-c716eecf6989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2170eec4-62de-459c-bec9-881dee5d4679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b729a516-b452-4bb8-a725-10958e684af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2170eec4-62de-459c-bec9-881dee5d4679" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b729a516-b452-4bb8-a725-10958e684af0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9688d259-79d3-4381-8646-e74a19ae3f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2170eec4-62de-459c-bec9-881dee5d4679" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9688d259-79d3-4381-8646-e74a19ae3f97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_7716067a-f42c-4c17-b49a-b85fac18d6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2170eec4-62de-459c-bec9-881dee5d4679" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_7716067a-f42c-4c17-b49a-b85fac18d6e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_95560d2d-1011-401c-9ae5-2a3bbe4d33bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2170eec4-62de-459c-bec9-881dee5d4679" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_95560d2d-1011-401c-9ae5-2a3bbe4d33bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_b75b916b-9938-4261-8969-57fdca7d59c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2170eec4-62de-459c-bec9-881dee5d4679" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_b75b916b-9938-4261-8969-57fdca7d59c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1" xlink:type="simple" xlink:href="xcur-20210630.xsd#DebtPrincipalMaturitiesofLongTermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3fb075cb-0329-4822-b1ef-f4411b82cfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_68955556-dd55-45ae-bf4e-de757f3058c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3fb075cb-0329-4822-b1ef-f4411b82cfcf" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_68955556-dd55-45ae-bf4e-de757f3058c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3f11d193-7bd7-4cd0-a27b-f6e05534265c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3fb075cb-0329-4822-b1ef-f4411b82cfcf" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3f11d193-7bd7-4cd0-a27b-f6e05534265c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesLeaseCostsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#LeasesLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b3fa6524-d0a3-4bf2-a1c2-be7e72981aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_dd015a5f-97e5-44fc-9d9a-7a7534f94276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b3fa6524-d0a3-4bf2-a1c2-be7e72981aea" xlink:to="loc_us-gaap_OperatingLeaseCost_dd015a5f-97e5-44fc-9d9a-7a7534f94276" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_46b67fd4-ea37-4345-a34d-c1012fa15667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b3fa6524-d0a3-4bf2-a1c2-be7e72981aea" xlink:to="loc_us-gaap_ShortTermLeaseCost_46b67fd4-ea37-4345-a34d-c1012fa15667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0b99eda7-f83c-4e98-848d-53282ede38b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b3fa6524-d0a3-4bf2-a1c2-be7e72981aea" xlink:to="loc_us-gaap_VariableLeaseCost_0b99eda7-f83c-4e98-848d-53282ede38b2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#LeasesScheduleofFutureMinimumRentalPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c094c22-92f4-4b97-863d-c273176f3d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3344701e-0a9e-4bc0-84a1-951b49fef32c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c094c22-92f4-4b97-863d-c273176f3d03" xlink:to="loc_us-gaap_OperatingLeaseLiability_3344701e-0a9e-4bc0-84a1-951b49fef32c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8672c592-429e-4262-8e9d-b31cf30f2600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c094c22-92f4-4b97-863d-c273176f3d03" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8672c592-429e-4262-8e9d-b31cf30f2600" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ee71069d-18cb-46a0-9e8b-1eb636031a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d5a6894f-8b80-420f-b4ed-c053f5439050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ee71069d-18cb-46a0-9e8b-1eb636031a7a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d5a6894f-8b80-420f-b4ed-c053f5439050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ec2d21bc-0954-46e0-ade2-53d5521565f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ee71069d-18cb-46a0-9e8b-1eb636031a7a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ec2d21bc-0954-46e0-ade2-53d5521565f3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" xlink:type="simple" xlink:href="xcur-20210630.xsd#LeasesScheduleofFutureMinimumRentalPaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9500a51-7b1a-414a-acc9-ac9839d8ae85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e33f31a8-5f62-47bd-9c77-7c69177847be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9500a51-7b1a-414a-acc9-ac9839d8ae85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e33f31a8-5f62-47bd-9c77-7c69177847be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9e1fdc84-d3c0-4caf-941f-fac9526ec4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9500a51-7b1a-414a-acc9-ac9839d8ae85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9e1fdc84-d3c0-4caf-941f-fac9526ec4a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5853c10e-29ef-45c7-b830-cc5f95fbb8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9500a51-7b1a-414a-acc9-ac9839d8ae85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5853c10e-29ef-45c7-b830-cc5f95fbb8fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_379d3e24-8647-4310-a27d-e2767aa32222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9500a51-7b1a-414a-acc9-ac9839d8ae85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_379d3e24-8647-4310-a27d-e2767aa32222" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cc2c2297-11dd-4640-be69-c473f3f4b969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9500a51-7b1a-414a-acc9-ac9839d8ae85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cc2c2297-11dd-4640-be69-c473f3f4b969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0c4e7a85-eff7-467d-82c0-d7b390648bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9500a51-7b1a-414a-acc9-ac9839d8ae85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0c4e7a85-eff7-467d-82c0-d7b390648bd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3bc85c19-87fb-44db-b98d-77ab0e28e0da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9500a51-7b1a-414a-acc9-ac9839d8ae85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3bc85c19-87fb-44db-b98d-77ab0e28e0da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0ed32bd0-1a20-4ea0-b103-85f50dab3ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_5abeac02-c160-41e0-b5c6-5163267f39ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0ed32bd0-1a20-4ea0-b103-85f50dab3ad3" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_5abeac02-c160-41e0-b5c6-5163267f39ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_34d4b6b7-f0c2-403e-92f0-5f59fdc15748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0ed32bd0-1a20-4ea0-b103-85f50dab3ad3" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_34d4b6b7-f0c2-403e-92f0-5f59fdc15748" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6c61e7a8-17e5-4a06-9f3a-1c99a5aebf68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4168ec67-8a5a-43f2-8d12-54b5faefe239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6c61e7a8-17e5-4a06-9f3a-1c99a5aebf68" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4168ec67-8a5a-43f2-8d12-54b5faefe239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_18f1d9e7-9018-47fb-8355-3e09184506ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6c61e7a8-17e5-4a06-9f3a-1c99a5aebf68" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_18f1d9e7-9018-47fb-8355-3e09184506ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_78f828ce-65a0-4fdd-a434-448e2a351e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_fc49067b-b14c-494d-b7b9-0fc840ec6d4b" xlink:href="xcur-20210630.xsd#xcur_CommonStockWarrantLiabilityFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_78f828ce-65a0-4fdd-a434-448e2a351e6f" xlink:to="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_fc49067b-b14c-494d-b7b9-0fc840ec6d4b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>xcur-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:5b54f0ec-bf0b-4618-8722-18f79640ae79,g:5933f058-0750-4e2c-9852-92fa9631b69d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="xcur-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="idb6e7adca746465f99d96afb201bd020_UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e94d3acf-aae5-4ce9-9b73-ebbbe1ccd8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e94d3acf-aae5-4ce9-9b73-ebbbe1ccd8a7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b66dc236-0425-451f-a33d-d3d2fb50f7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_SharesOutstanding_b66dc236-0425-451f-a33d-d3d2fb50f7bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7b7c3e10-38ec-42f4-91ab-7e1e2141cb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockholdersEquity_7b7c3e10-38ec-42f4-91ab-7e1e2141cb1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_058a7cde-3611-424e-b7b7-1f854d00bd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_058a7cde-3611-424e-b7b7-1f854d00bd2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1d449347-e595-457e-a5d2-df4521998ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1d449347-e595-457e-a5d2-df4521998ae8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_25953800-987d-4c1a-8c66-9fc3e986ff71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_25953800-987d-4c1a-8c66-9fc3e986ff71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d7a5f866-9f82-4a37-9aa4-ca1e4e7bf493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d7a5f866-9f82-4a37-9aa4-ca1e4e7bf493" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_837b71d9-a24e-436c-8578-aebc0493325e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_837b71d9-a24e-436c-8578-aebc0493325e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_65341b72-6387-4c35-8ded-875e2813948a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_65341b72-6387-4c35-8ded-875e2813948a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1c52daf1-ca7a-46b9-8fa8-984f4a4ecb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1c52daf1-ca7a-46b9-8fa8-984f4a4ecb5b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59bd9b14-5807-432a-a046-e9cdcd98f762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59bd9b14-5807-432a-a046-e9cdcd98f762" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3bd1ce67-8c0f-4c49-a50a-9ec9c3d6beb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_NetIncomeLoss_3bd1ce67-8c0f-4c49-a50a-9ec9c3d6beb4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_30829837-b9b4-46e5-b6b2-fc60637ef297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2f46afa8-2377-4322-bc9d-688f8dd9ea54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_63308901-5d74-4926-9259-6fc1b0d570af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e94d3acf-aae5-4ce9-9b73-ebbbe1ccd8a7" xlink:to="loc_us-gaap_StatementTable_63308901-5d74-4926-9259-6fc1b0d570af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4208b4e4-1534-49a9-acee-466df0836570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_63308901-5d74-4926-9259-6fc1b0d570af" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4208b4e4-1534-49a9-acee-466df0836570" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4208b4e4-1534-49a9-acee-466df0836570_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4208b4e4-1534-49a9-acee-466df0836570" xlink:to="loc_us-gaap_EquityComponentDomain_4208b4e4-1534-49a9-acee-466df0836570_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a51cdcff-2670-416d-a3bf-bbc3ea72fdff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4208b4e4-1534-49a9-acee-466df0836570" xlink:to="loc_us-gaap_EquityComponentDomain_a51cdcff-2670-416d-a3bf-bbc3ea72fdff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e312ebc9-0fd8-4818-b23e-88baae9f2f30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a51cdcff-2670-416d-a3bf-bbc3ea72fdff" xlink:to="loc_us-gaap_CommonStockMember_e312ebc9-0fd8-4818-b23e-88baae9f2f30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a7b90645-19b1-476f-8953-0d5e48c32bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a51cdcff-2670-416d-a3bf-bbc3ea72fdff" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a7b90645-19b1-476f-8953-0d5e48c32bd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_18049c94-e330-4dc3-872b-6e16501704f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a51cdcff-2670-416d-a3bf-bbc3ea72fdff" xlink:to="loc_us-gaap_RetainedEarningsMember_18049c94-e330-4dc3-872b-6e16501704f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8ce137bd-93f9-431e-b377-55b935fe72da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a51cdcff-2670-416d-a3bf-bbc3ea72fdff" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8ce137bd-93f9-431e-b377-55b935fe72da" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#DescriptionofBusinessandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="extended" id="iebde3a816ca3435281f28fda5d84d0fe_DescriptionofBusinessandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_855e2a5a-7efd-43d4-b23c-de53f31ba7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ResearchAndDevelopmentStaffOnSitePercentage_e1acb7b9-924f-43e8-910f-7ccf8e488983" xlink:href="xcur-20210630.xsd#xcur_ResearchAndDevelopmentStaffOnSitePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_855e2a5a-7efd-43d4-b23c-de53f31ba7fa" xlink:to="loc_xcur_ResearchAndDevelopmentStaffOnSitePercentage_e1acb7b9-924f-43e8-910f-7ccf8e488983" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage_f5dc86a1-ee61-4492-8a90-8310e73fa16a" xlink:href="xcur-20210630.xsd#xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_855e2a5a-7efd-43d4-b23c-de53f31ba7fa" xlink:to="loc_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage_f5dc86a1-ee61-4492-8a90-8310e73fa16a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_b7b20ffd-0fb0-4e02-a654-8e12fcac6e3c" xlink:href="xcur-20210630.xsd#xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_855e2a5a-7efd-43d4-b23c-de53f31ba7fa" xlink:to="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_b7b20ffd-0fb0-4e02-a654-8e12fcac6e3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_c918799e-f830-4863-b4a6-a62ecffc5099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_855e2a5a-7efd-43d4-b23c-de53f31ba7fa" xlink:to="loc_us-gaap_ProceedsFromCollaborators_c918799e-f830-4863-b4a6-a62ecffc5099" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyTable_09c254f3-5a6a-47a0-be39-ed110548e792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_855e2a5a-7efd-43d4-b23c-de53f31ba7fa" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyTable_09c254f3-5a6a-47a0-be39-ed110548e792" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_ca770aa5-c245-42af-9e7d-45a98bd14f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_09c254f3-5a6a-47a0-be39-ed110548e792" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_ca770aa5-c245-42af-9e7d-45a98bd14f97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_ca770aa5-c245-42af-9e7d-45a98bd14f97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_ca770aa5-c245-42af-9e7d-45a98bd14f97" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_ca770aa5-c245-42af-9e7d-45a98bd14f97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_09ce52ab-617f-4a9f-8319-fa2df784eacb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_ca770aa5-c245-42af-9e7d-45a98bd14f97" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_09ce52ab-617f-4a9f-8319-fa2df784eacb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_COVID19Member_6ba15778-3406-4b62-b08f-3f5400c7931b" xlink:href="xcur-20210630.xsd#xcur_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_09ce52ab-617f-4a9f-8319-fa2df784eacb" xlink:to="loc_xcur_COVID19Member_6ba15778-3406-4b62-b08f-3f5400c7931b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b6712cde-af26-42d6-a8d0-3d83682ef63f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_09c254f3-5a6a-47a0-be39-ed110548e792" xlink:to="loc_srt_StatementScenarioAxis_b6712cde-af26-42d6-a8d0-3d83682ef63f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b6712cde-af26-42d6-a8d0-3d83682ef63f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_b6712cde-af26-42d6-a8d0-3d83682ef63f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b6712cde-af26-42d6-a8d0-3d83682ef63f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bd2ee396-4f61-4f68-89ea-e8c5e66e2fa4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_b6712cde-af26-42d6-a8d0-3d83682ef63f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bd2ee396-4f61-4f68-89ea-e8c5e66e2fa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_29cb1c10-142e-43b1-b267-6b8e33336b25" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_bd2ee396-4f61-4f68-89ea-e8c5e66e2fa4" xlink:to="loc_srt_ScenarioForecastMember_29cb1c10-142e-43b1-b267-6b8e33336b25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_dc8ec8d4-8d48-4ea6-93f5-06b3d1a3db2f" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_09c254f3-5a6a-47a0-be39-ed110548e792" xlink:to="loc_xcur_ArrangementNameAxis_dc8ec8d4-8d48-4ea6-93f5-06b3d1a3db2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_dc8ec8d4-8d48-4ea6-93f5-06b3d1a3db2f_default" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xcur_ArrangementNameAxis_dc8ec8d4-8d48-4ea6-93f5-06b3d1a3db2f" xlink:to="loc_xcur_ArrangementNameDomain_dc8ec8d4-8d48-4ea6-93f5-06b3d1a3db2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_d98d0909-2c32-421a-92a4-a02aa624e5ca" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xcur_ArrangementNameAxis_dc8ec8d4-8d48-4ea6-93f5-06b3d1a3db2f" xlink:to="loc_xcur_ArrangementNameDomain_d98d0909-2c32-421a-92a4-a02aa624e5ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenCollaborationMember_62978031-61ce-4b07-8878-d374f330bf03" xlink:href="xcur-20210630.xsd#xcur_IpsenCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ArrangementNameDomain_d98d0909-2c32-421a-92a4-a02aa624e5ca" xlink:to="loc_xcur_IpsenCollaborationMember_62978031-61ce-4b07-8878-d374f330bf03" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#CollaborativeResearchandLicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails" xlink:type="extended" id="i60d8d3018ee24004a71b4b11ed8829e3_CollaborativeResearchandLicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_NumberofCollaborationPrograms_3cc3db3a-d863-42cc-b903-505755194e76" xlink:href="xcur-20210630.xsd#xcur_NumberofCollaborationPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_NumberofCollaborationPrograms_3cc3db3a-d863-42cc-b903-505755194e76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_0c7a8534-d79b-4563-b46b-7af921e8f968" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_CollaborationAgreementUpfrontPayment_0c7a8534-d79b-4563-b46b-7af921e8f968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionExerciseFee_7946d1f7-84b6-4c04-b8fe-b7807e3a717a" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_CollaborationAgreementOptionExerciseFee_7946d1f7-84b6-4c04-b8fe-b7807e3a717a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_002fa12b-73c9-458f-a033-f6a1fad1b5fa" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_002fa12b-73c9-458f-a033-f6a1fad1b5fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_8f8b17d6-8ee5-4a8d-bbbf-cba3d431747d" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_8f8b17d6-8ee5-4a8d-bbbf-cba3d431747d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_e5a9ab22-664e-4d1d-8e8b-fb9fdbdadba7" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_e5a9ab22-664e-4d1d-8e8b-fb9fdbdadba7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_f3898804-cc25-4185-901e-a3685b11857b" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_f3898804-cc25-4185-901e-a3685b11857b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_69828b1b-d927-4eba-bb8a-de2ee28f8523" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_69828b1b-d927-4eba-bb8a-de2ee28f8523" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4940a20a-eda5-4073-b069-d5562089fd28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4940a20a-eda5-4073-b069-d5562089fd28" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ae28cc8e-91ea-4eeb-94f3-4c504711ad9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ae28cc8e-91ea-4eeb-94f3-4c504711ad9f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationDevelopmentExpenses_3e44b941-649e-409e-b69c-efd962b9d8b0" xlink:href="xcur-20210630.xsd#xcur_CollaborationDevelopmentExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_CollaborationDevelopmentExpenses_3e44b941-649e-409e-b69c-efd962b9d8b0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_94201750-d89d-48af-b233-ab13420d3aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_us-gaap_ContractWithCustomerLiability_94201750-d89d-48af-b233-ab13420d3aac" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_143a8858-2395-4118-8f89-06ef907635b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_143a8858-2395-4118-8f89-06ef907635b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_89d5a81f-c195-46b3-b434-c9ec6d175ddb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_143a8858-2395-4118-8f89-06ef907635b9" xlink:to="loc_srt_RangeAxis_89d5a81f-c195-46b3-b434-c9ec6d175ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_89d5a81f-c195-46b3-b434-c9ec6d175ddb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_89d5a81f-c195-46b3-b434-c9ec6d175ddb" xlink:to="loc_srt_RangeMember_89d5a81f-c195-46b3-b434-c9ec6d175ddb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f2b58457-d64a-4188-b9b6-5817c88b4f05" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_89d5a81f-c195-46b3-b434-c9ec6d175ddb" xlink:to="loc_srt_RangeMember_f2b58457-d64a-4188-b9b6-5817c88b4f05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ca365958-52f6-489e-814b-0c9965ac8313" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f2b58457-d64a-4188-b9b6-5817c88b4f05" xlink:to="loc_srt_MaximumMember_ca365958-52f6-489e-814b-0c9965ac8313" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_44d84778-f660-4e3f-829d-628db3ddb081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_143a8858-2395-4118-8f89-06ef907635b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_44d84778-f660-4e3f-829d-628db3ddb081" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_44d84778-f660-4e3f-829d-628db3ddb081_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_44d84778-f660-4e3f-829d-628db3ddb081" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_44d84778-f660-4e3f-829d-628db3ddb081_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9df4e7cd-75bc-4863-b152-cee2628e7a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_44d84778-f660-4e3f-829d-628db3ddb081" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9df4e7cd-75bc-4863-b152-cee2628e7a38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DevelopmentandCommercializationLicenseMember_e5dcd28a-db63-46a4-bddf-8dced745161f" xlink:href="xcur-20210630.xsd#xcur_DevelopmentandCommercializationLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9df4e7cd-75bc-4863-b152-cee2628e7a38" xlink:to="loc_xcur_DevelopmentandCommercializationLicenseMember_e5dcd28a-db63-46a4-bddf-8dced745161f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_5bc7d7c1-5c65-4a96-b4d6-242c99fe8fa6" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_143a8858-2395-4118-8f89-06ef907635b9" xlink:to="loc_xcur_ArrangementNameAxis_5bc7d7c1-5c65-4a96-b4d6-242c99fe8fa6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_5bc7d7c1-5c65-4a96-b4d6-242c99fe8fa6_default" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xcur_ArrangementNameAxis_5bc7d7c1-5c65-4a96-b4d6-242c99fe8fa6" xlink:to="loc_xcur_ArrangementNameDomain_5bc7d7c1-5c65-4a96-b4d6-242c99fe8fa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_63e80c52-d2ea-4e22-b6a5-ef45a6bbd670" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xcur_ArrangementNameAxis_5bc7d7c1-5c65-4a96-b4d6-242c99fe8fa6" xlink:to="loc_xcur_ArrangementNameDomain_63e80c52-d2ea-4e22-b6a5-ef45a6bbd670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AbbVieCollaborationMember_288206ec-180a-4744-aa3d-b224c6fba899" xlink:href="xcur-20210630.xsd#xcur_AbbVieCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ArrangementNameDomain_63e80c52-d2ea-4e22-b6a5-ef45a6bbd670" xlink:to="loc_xcur_AbbVieCollaborationMember_288206ec-180a-4744-aa3d-b224c6fba899" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DermelixLicenseAgreementMember_fde6fee7-d50d-4110-a2a2-d4bc96bad50f" xlink:href="xcur-20210630.xsd#xcur_DermelixLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ArrangementNameDomain_63e80c52-d2ea-4e22-b6a5-ef45a6bbd670" xlink:to="loc_xcur_DermelixLicenseAgreementMember_fde6fee7-d50d-4110-a2a2-d4bc96bad50f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b7f40781-db5c-480a-8df3-843334c25d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_143a8858-2395-4118-8f89-06ef907635b9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b7f40781-db5c-480a-8df3-843334c25d1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7f40781-db5c-480a-8df3-843334c25d1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b7f40781-db5c-480a-8df3-843334c25d1e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7f40781-db5c-480a-8df3-843334c25d1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20060d35-ba51-4167-b1bb-57303d802c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b7f40781-db5c-480a-8df3-843334c25d1e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20060d35-ba51-4167-b1bb-57303d802c90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b8e0d5cf-38ee-4c8a-aa04-24af803f2cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20060d35-ba51-4167-b1bb-57303d802c90" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b8e0d5cf-38ee-4c8a-aa04-24af803f2cb8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="extended" id="i67a046d524ee41ad9d0319fa23abbc0c_SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9fa03f9-a107-41e6-9513-d2fcef5501d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_065408fc-1d84-4ee5-b5bd-04dddb7b4cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9fa03f9-a107-41e6-9513-d2fcef5501d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_065408fc-1d84-4ee5-b5bd-04dddb7b4cd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a535c7f7-b87b-46f4-8721-b9b5773187d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9fa03f9-a107-41e6-9513-d2fcef5501d5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a535c7f7-b87b-46f4-8721-b9b5773187d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c6a0a0ab-9916-4fe6-81ee-77cabf7e26c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9fa03f9-a107-41e6-9513-d2fcef5501d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c6a0a0ab-9916-4fe6-81ee-77cabf7e26c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_5c748e1e-ae8b-4a39-b01d-991fbfaabe30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9fa03f9-a107-41e6-9513-d2fcef5501d5" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_5c748e1e-ae8b-4a39-b01d-991fbfaabe30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_728ecc2b-530e-4cd6-94f7-08dee3ff4aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9fa03f9-a107-41e6-9513-d2fcef5501d5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_728ecc2b-530e-4cd6-94f7-08dee3ff4aa5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8a79efa-53e7-4614-917b-ac98cba5204f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_728ecc2b-530e-4cd6-94f7-08dee3ff4aa5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8a79efa-53e7-4614-917b-ac98cba5204f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8a79efa-53e7-4614-917b-ac98cba5204f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8a79efa-53e7-4614-917b-ac98cba5204f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8a79efa-53e7-4614-917b-ac98cba5204f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee624d2f-d5a7-4882-be93-262bcae41ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8a79efa-53e7-4614-917b-ac98cba5204f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee624d2f-d5a7-4882-be93-262bcae41ea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_1beaaf20-487f-478f-84f3-2b2dc4b12826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee624d2f-d5a7-4882-be93-262bcae41ea8" xlink:to="loc_us-gaap_EquipmentMember_1beaaf20-487f-478f-84f3-2b2dc4b12826" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ad29654f-bdca-4951-a5c0-75f17641e1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee624d2f-d5a7-4882-be93-262bcae41ea8" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ad29654f-bdca-4951-a5c0-75f17641e1c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ComputersandSoftwareMember_5201e940-4073-4aec-8581-9a0a791e4e3e" xlink:href="xcur-20210630.xsd#xcur_ComputersandSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee624d2f-d5a7-4882-be93-262bcae41ea8" xlink:to="loc_xcur_ComputersandSoftwareMember_5201e940-4073-4aec-8581-9a0a791e4e3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_47bc95ac-0d8e-41e9-8583-4388b26408b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee624d2f-d5a7-4882-be93-262bcae41ea8" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_47bc95ac-0d8e-41e9-8583-4388b26408b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_274e2df5-d759-4cf0-9aa8-b2c8f31de6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee624d2f-d5a7-4882-be93-262bcae41ea8" xlink:to="loc_us-gaap_ConstructionInProgressMember_274e2df5-d759-4cf0-9aa8-b2c8f31de6a9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#InvestmentsAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="extended" id="i7e25bc7c9b2f479cb0bb70af67209c1c_InvestmentsAvailableforsaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f13ba93-ea71-417a-889a-065eae539b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_48ca0979-c81f-4a58-bff7-3d6c39e90da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f13ba93-ea71-417a-889a-065eae539b90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_48ca0979-c81f-4a58-bff7-3d6c39e90da4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_893bc087-e8ec-40b8-ba6b-9717d25bc5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f13ba93-ea71-417a-889a-065eae539b90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_893bc087-e8ec-40b8-ba6b-9717d25bc5b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_feb9c758-fc98-4cf1-9268-9cb540341cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f13ba93-ea71-417a-889a-065eae539b90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_feb9c758-fc98-4cf1-9268-9cb540341cf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_96a05df1-d823-479c-a7cc-7bcfd72c632b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f13ba93-ea71-417a-889a-065eae539b90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_96a05df1-d823-479c-a7cc-7bcfd72c632b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cf948149-a721-4878-8d44-d25b9df62121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f13ba93-ea71-417a-889a-065eae539b90" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cf948149-a721-4878-8d44-d25b9df62121" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b2a07d0d-5734-4182-bc9f-77a5b8f10568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cf948149-a721-4878-8d44-d25b9df62121" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b2a07d0d-5734-4182-bc9f-77a5b8f10568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2a07d0d-5734-4182-bc9f-77a5b8f10568_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b2a07d0d-5734-4182-bc9f-77a5b8f10568" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2a07d0d-5734-4182-bc9f-77a5b8f10568_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bd20fa1-1705-4680-b4a1-98ba637fad2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b2a07d0d-5734-4182-bc9f-77a5b8f10568" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bd20fa1-1705-4680-b4a1-98ba637fad2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_1e1d078c-bc5d-432d-ab3b-40592d7a5f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bd20fa1-1705-4680-b4a1-98ba637fad2b" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_1e1d078c-bc5d-432d-ab3b-40592d7a5f51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_93f9c63c-2cb6-48d0-a304-c0864dc82d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bd20fa1-1705-4680-b4a1-98ba637fad2b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_93f9c63c-2cb6-48d0-a304-c0864dc82d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8924b6b7-9c37-4f56-b484-3353df16d3be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bd20fa1-1705-4680-b4a1-98ba637fad2b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8924b6b7-9c37-4f56-b484-3353df16d3be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a0895230-5d6c-4aaa-a855-795c9aad7f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bd20fa1-1705-4680-b4a1-98ba637fad2b" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a0895230-5d6c-4aaa-a855-795c9aad7f78" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="extended" id="idb259fb59c034242aeb36f65adb21602_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_13715373-6361-4b5d-a4b0-5f5e7df9efd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_13715373-6361-4b5d-a4b0-5f5e7df9efd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_657085eb-8f88-49e8-9966-153350183dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_657085eb-8f88-49e8-9966-153350183dbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_59da3957-7736-4c2d-a9e7-14eed1da73d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_59da3957-7736-4c2d-a9e7-14eed1da73d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_bf31d8bd-33d2-4419-ad3f-f383008c2448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_bf31d8bd-33d2-4419-ad3f-f383008c2448" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments_8d7db527-c9bb-4dae-9161-288a8760c302" xlink:href="xcur-20210630.xsd#xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments_8d7db527-c9bb-4dae-9161-288a8760c302" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal_73837546-6b76-47fd-a227-83d399e44358" xlink:href="xcur-20210630.xsd#xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal_73837546-6b76-47fd-a227-83d399e44358" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanProcessingFee_373c31b4-1c2f-4f4d-b308-ec47a95a2741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoanProcessingFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_LoanProcessingFee_373c31b4-1c2f-4f4d-b308-ec47a95a2741" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentExitFeePercentage_e85a5b63-02fe-4662-893b-4c6f2df9781b" xlink:href="xcur-20210630.xsd#xcur_DebtInstrumentExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_xcur_DebtInstrumentExitFeePercentage_e85a5b63-02fe-4662-893b-4c6f2df9781b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_00d8b5b7-1d9b-47fa-bbf7-b8a565235671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_00d8b5b7-1d9b-47fa-bbf7-b8a565235671" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_fb91cfcf-d16b-4a5a-ac32-17b50ba4cdac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_fb91cfcf-d16b-4a5a-ac32-17b50ba4cdac" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_9a52f272-a224-466c-80c9-1e10f8a000f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_9a52f272-a224-466c-80c9-1e10f8a000f1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_deab9372-aca0-47ba-ac33-667c4f3ca70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_deab9372-aca0-47ba-ac33-667c4f3ca70f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b5e941f5-11f2-462e-a11a-6a8e57f209a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b5e941f5-11f2-462e-a11a-6a8e57f209a5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3217f274-5514-4cdb-ab28-05f528aa74c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_LongTermDebt_3217f274-5514-4cdb-ab28-05f528aa74c3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_22232846-ff35-4b14-85cb-75be32ae6ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_InterestPaidNet_22232846-ff35-4b14-85cb-75be32ae6ef4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_17b25034-4a6e-4f20-af43-7b05072b392d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_17b25034-4a6e-4f20-af43-7b05072b392d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsForDebtEndTermFees_3bd4ec41-f7aa-4f8f-ba73-02554c7fe82c" xlink:href="xcur-20210630.xsd#xcur_PaymentsForDebtEndTermFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_xcur_PaymentsForDebtEndTermFees_3bd4ec41-f7aa-4f8f-ba73-02554c7fe82c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d302c6e5-501f-453a-9f3e-e96b2ccfe6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d302c6e5-501f-453a-9f3e-e96b2ccfe6bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d302c6e5-501f-453a-9f3e-e96b2ccfe6bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d302c6e5-501f-453a-9f3e-e96b2ccfe6bc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d302c6e5-501f-453a-9f3e-e96b2ccfe6bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6142c8d7-6b03-4960-9203-beca66b8739b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d302c6e5-501f-453a-9f3e-e96b2ccfe6bc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6142c8d7-6b03-4960-9203-beca66b8739b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_3a5c70f5-8cc1-421d-8c93-f6d4f818e6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6142c8d7-6b03-4960-9203-beca66b8739b" xlink:to="loc_us-gaap_SecuredDebtMember_3a5c70f5-8cc1-421d-8c93-f6d4f818e6c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_3c50f5a1-e040-4c67-935b-03f59f43a7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6142c8d7-6b03-4960-9203-beca66b8739b" xlink:to="loc_us-gaap_LoansPayableMember_3c50f5a1-e040-4c67-935b-03f59f43a7cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_06ce7623-aa77-431b-993b-d7247e6c7ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:to="loc_us-gaap_CreditFacilityAxis_06ce7623-aa77-431b-993b-d7247e6c7ee1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_06ce7623-aa77-431b-993b-d7247e6c7ee1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_06ce7623-aa77-431b-993b-d7247e6c7ee1" xlink:to="loc_us-gaap_CreditFacilityDomain_06ce7623-aa77-431b-993b-d7247e6c7ee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2deb6644-09f3-463a-9059-4cc0adacab93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_06ce7623-aa77-431b-993b-d7247e6c7ee1" xlink:to="loc_us-gaap_CreditFacilityDomain_2deb6644-09f3-463a-9059-4cc0adacab93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_09aca46c-dc58-45b6-8d93-76ff73c8e3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2deb6644-09f3-463a-9059-4cc0adacab93" xlink:to="loc_us-gaap_SecuredDebtMember_09aca46c-dc58-45b6-8d93-76ff73c8e3b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_7566a76d-b5bb-4851-af53-41a89e3f82b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_7566a76d-b5bb-4851-af53-41a89e3f82b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_7566a76d-b5bb-4851-af53-41a89e3f82b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_7566a76d-b5bb-4851-af53-41a89e3f82b2" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_7566a76d-b5bb-4851-af53-41a89e3f82b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_6ae41d1f-a4a3-4857-9dee-600208653ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_7566a76d-b5bb-4851-af53-41a89e3f82b2" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_6ae41d1f-a4a3-4857-9dee-600208653ff5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember_d6e75813-96e5-43f1-9426-12d317a5abc7" xlink:href="xcur-20210630.xsd#xcur_HerculesTechnologyGrowthCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_6ae41d1f-a4a3-4857-9dee-600208653ff5" xlink:to="loc_xcur_HerculesTechnologyGrowthCapitalMember_d6e75813-96e5-43f1-9426-12d317a5abc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2d307b59-f5e1-4c43-b8af-af42af755c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:to="loc_us-gaap_DebtInstrumentAxis_2d307b59-f5e1-4c43-b8af-af42af755c1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2d307b59-f5e1-4c43-b8af-af42af755c1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2d307b59-f5e1-4c43-b8af-af42af755c1c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2d307b59-f5e1-4c43-b8af-af42af755c1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26001037-08b4-4845-8207-c7f3d5dc7fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2d307b59-f5e1-4c43-b8af-af42af755c1c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26001037-08b4-4845-8207-c7f3d5dc7fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementMember_5427a20a-80ea-4be0-b995-ef65751e888e" xlink:href="xcur-20210630.xsd#xcur_MidCapCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26001037-08b4-4845-8207-c7f3d5dc7fb2" xlink:to="loc_xcur_MidCapCreditAgreementMember_5427a20a-80ea-4be0-b995-ef65751e888e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementTranche1Member_443f9117-d679-4610-8e55-6c9f217887d3" xlink:href="xcur-20210630.xsd#xcur_MidCapCreditAgreementTranche1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_MidCapCreditAgreementMember_5427a20a-80ea-4be0-b995-ef65751e888e" xlink:to="loc_xcur_MidCapCreditAgreementTranche1Member_443f9117-d679-4610-8e55-6c9f217887d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementTranche2Member_05611f22-00f4-43ef-b250-33c11df22d56" xlink:href="xcur-20210630.xsd#xcur_MidCapCreditAgreementTranche2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_MidCapCreditAgreementMember_5427a20a-80ea-4be0-b995-ef65751e888e" xlink:to="loc_xcur_MidCapCreditAgreementTranche2Member_05611f22-00f4-43ef-b250-33c11df22d56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_8c457a40-e893-41c5-bdf9-969d0ee556a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_8c457a40-e893-41c5-bdf9-969d0ee556a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8c457a40-e893-41c5-bdf9-969d0ee556a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_8c457a40-e893-41c5-bdf9-969d0ee556a2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8c457a40-e893-41c5-bdf9-969d0ee556a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_30c498fc-52f5-479b-a87f-e4c3d509c3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_8c457a40-e893-41c5-bdf9-969d0ee556a2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_30c498fc-52f5-479b-a87f-e4c3d509c3ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_8a30d129-80f7-47af-bad6-3b4ce4b22957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_30c498fc-52f5-479b-a87f-e4c3d509c3ac" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_8a30d129-80f7-47af-bad6-3b4ce4b22957" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_69858ec6-a96f-4ca8-8ca8-3b09626214ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_30c498fc-52f5-479b-a87f-e4c3d509c3ac" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_69858ec6-a96f-4ca8-8ca8-3b09626214ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c664f472-f52a-41ba-87ae-3ee1fa539e4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:to="loc_srt_StatementScenarioAxis_c664f472-f52a-41ba-87ae-3ee1fa539e4b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c664f472-f52a-41ba-87ae-3ee1fa539e4b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_c664f472-f52a-41ba-87ae-3ee1fa539e4b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c664f472-f52a-41ba-87ae-3ee1fa539e4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f68d82d5-f1af-49de-85ef-fb489785558e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_c664f472-f52a-41ba-87ae-3ee1fa539e4b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f68d82d5-f1af-49de-85ef-fb489785558e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_6f70fc37-926d-416a-88f8-914140e82304" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f68d82d5-f1af-49de-85ef-fb489785558e" xlink:to="loc_srt_ScenarioForecastMember_6f70fc37-926d-416a-88f8-914140e82304" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LeasesNarrativeDetails" xlink:type="extended" id="id92ec7e324e24d149c1a4e3344e3cb1e_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseArea_6df0aaf2-bec2-4528-a0fa-2a023707b03c" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_xcur_LesseeOperatingLeaseLeaseArea_6df0aaf2-bec2-4528-a0fa-2a023707b03c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_57915787-6eb9-4e27-8e2a-f84170e08d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_57915787-6eb9-4e27-8e2a-f84170e08d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseNumberOfExtensions_528e88c8-6a0c-4f48-846a-8668dde60eab" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseNumberOfExtensions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_xcur_LesseeOperatingLeaseNumberOfExtensions_528e88c8-6a0c-4f48-846a-8668dde60eab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ad2ef6ff-4ead-4bbb-87f7-d7195e5cc4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ad2ef6ff-4ead-4bbb-87f7-d7195e5cc4e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths_93eaaedd-336f-4c4a-b674-6007ca022e1c" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths_93eaaedd-336f-4c4a-b674-6007ca022e1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease_e5e4a787-aaed-4d6b-bcf4-068028ab7139" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease_e5e4a787-aaed-4d6b-bcf4-068028ab7139" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm_bd4e450f-bd28-4314-9413-b6001ecec005" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm_bd4e450f-bd28-4314-9413-b6001ecec005" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_2f0e3dd1-9a30-458f-89bd-fa024b93e477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_2f0e3dd1-9a30-458f-89bd-fa024b93e477" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement_f2994b11-8dbd-49e5-81bc-8b731ae9bf0a" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement_f2994b11-8dbd-49e5-81bc-8b731ae9bf0a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_ca8215fb-ca7c-43c6-b0cd-2b3651792659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_ca8215fb-ca7c-43c6-b0cd-2b3651792659" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_91b99642-275e-4454-9445-22a7b02ac188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_91b99642-275e-4454-9445-22a7b02ac188" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7f953563-ff5c-4766-a2c7-d04204085815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_OperatingLeaseLiability_7f953563-ff5c-4766-a2c7-d04204085815" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_283ab4c6-7054-4314-adfb-66f3f887b06f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_283ab4c6-7054-4314-adfb-66f3f887b06f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_2f1bf0bb-47b8-4c47-8a37-3149bbb3b3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_OperatingLeasePayments_2f1bf0bb-47b8-4c47-8a37-3149bbb3b3d7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_156917a0-8244-4152-bd95-c177c9e342cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_156917a0-8244-4152-bd95-c177c9e342cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c1ec6197-e073-4e01-90c7-c44244afc235" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_156917a0-8244-4152-bd95-c177c9e342cf" xlink:to="loc_srt_StatementGeographicalAxis_c1ec6197-e073-4e01-90c7-c44244afc235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c1ec6197-e073-4e01-90c7-c44244afc235_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c1ec6197-e073-4e01-90c7-c44244afc235" xlink:to="loc_srt_SegmentGeographicalDomain_c1ec6197-e073-4e01-90c7-c44244afc235_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dd0f5b6a-11ed-4c7e-8c3a-67aad4febc2c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c1ec6197-e073-4e01-90c7-c44244afc235" xlink:to="loc_srt_SegmentGeographicalDomain_dd0f5b6a-11ed-4c7e-8c3a-67aad4febc2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ChicagoMember_e17671fb-33d5-4c45-8947-81eea54124f5" xlink:href="xcur-20210630.xsd#xcur_ChicagoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_dd0f5b6a-11ed-4c7e-8c3a-67aad4febc2c" xlink:to="loc_xcur_ChicagoMember_e17671fb-33d5-4c45-8947-81eea54124f5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#StockholdersEquityCommonStockWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="extended" id="i482a1fc5cbbf4f88a2dc5039c1a55d21_StockholdersEquityCommonStockWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_a5994ef6-3f11-419b-8386-456a9651788b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ed7765b5-e3ca-4cfa-b23f-24c57cdf3ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_a5994ef6-3f11-419b-8386-456a9651788b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ed7765b5-e3ca-4cfa-b23f-24c57cdf3ceb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a550e1a4-91b7-4331-bf52-0a69f00f4ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_a5994ef6-3f11-419b-8386-456a9651788b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a550e1a4-91b7-4331-bf52-0a69f00f4ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ClassofWarrantorRightExpired_dc5e4f2d-9b7e-4c9e-82a2-f6f5dfbe45e4" xlink:href="xcur-20210630.xsd#xcur_ClassofWarrantorRightExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_a5994ef6-3f11-419b-8386-456a9651788b" xlink:to="loc_xcur_ClassofWarrantorRightExpired_dc5e4f2d-9b7e-4c9e-82a2-f6f5dfbe45e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_b1aafcb9-85c5-491a-8c13-f554049aaba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_a5994ef6-3f11-419b-8386-456a9651788b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_b1aafcb9-85c5-491a-8c13-f554049aaba3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f37f70d6-8274-4677-bc95-66164532b52c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_b1aafcb9-85c5-491a-8c13-f554049aaba3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f37f70d6-8274-4677-bc95-66164532b52c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f37f70d6-8274-4677-bc95-66164532b52c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f37f70d6-8274-4677-bc95-66164532b52c" xlink:to="loc_us-gaap_ClassOfStockDomain_f37f70d6-8274-4677-bc95-66164532b52c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5eb47a6a-8a1c-4954-8226-f41ec3971b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f37f70d6-8274-4677-bc95-66164532b52c" xlink:to="loc_us-gaap_ClassOfStockDomain_5eb47a6a-8a1c-4954-8226-f41ec3971b00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d384ba52-c605-4dfb-a7f8-34efd4c93967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5eb47a6a-8a1c-4954-8226-f41ec3971b00" xlink:to="loc_us-gaap_CommonStockMember_d384ba52-c605-4dfb-a7f8-34efd4c93967" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i92524b2c41b0486185a172daca7216a1_StockholdersEquityAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8de827dd-970d-4b82-8266-5e7126cdf352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_963d9592-e72f-4207-aac2-b506baf0197c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8de827dd-970d-4b82-8266-5e7126cdf352" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_963d9592-e72f-4207-aac2-b506baf0197c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_03168fb7-aee9-4da8-b96b-ffb72d86b23b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_963d9592-e72f-4207-aac2-b506baf0197c" xlink:to="loc_us-gaap_StockholdersEquity_03168fb7-aee9-4da8-b96b-ffb72d86b23b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_39f0527b-e45b-4bfa-8aa6-843a3d557471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_963d9592-e72f-4207-aac2-b506baf0197c" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_39f0527b-e45b-4bfa-8aa6-843a3d557471" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c4ad332b-256d-4ece-8ef5-4da8384ac9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_963d9592-e72f-4207-aac2-b506baf0197c" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c4ad332b-256d-4ece-8ef5-4da8384ac9a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_57646bdc-3d02-4f8c-9d91-9a92a5e4cd63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_963d9592-e72f-4207-aac2-b506baf0197c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_57646bdc-3d02-4f8c-9d91-9a92a5e4cd63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d3ca051f-4769-4512-b208-9a1126621b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_094c11d3-f671-4b9c-873d-28a16f6af29d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8de827dd-970d-4b82-8266-5e7126cdf352" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_094c11d3-f671-4b9c-873d-28a16f6af29d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_4b77e6f0-7f2e-4826-bca4-fe2cd1ede177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8de827dd-970d-4b82-8266-5e7126cdf352" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_4b77e6f0-7f2e-4826-bca4-fe2cd1ede177" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_8f8e9753-6740-4ac8-8ff0-4fe5f6cb76db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8de827dd-970d-4b82-8266-5e7126cdf352" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_8f8e9753-6740-4ac8-8ff0-4fe5f6cb76db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b875ca0-0aad-4fa7-832f-7d682e3f4087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8de827dd-970d-4b82-8266-5e7126cdf352" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b875ca0-0aad-4fa7-832f-7d682e3f4087" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_20c8a2ea-644b-4f49-a8fe-a9e340562efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b875ca0-0aad-4fa7-832f-7d682e3f4087" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_20c8a2ea-644b-4f49-a8fe-a9e340562efa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_20c8a2ea-644b-4f49-a8fe-a9e340562efa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20c8a2ea-644b-4f49-a8fe-a9e340562efa" xlink:to="loc_us-gaap_EquityComponentDomain_20c8a2ea-644b-4f49-a8fe-a9e340562efa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fe96a77e-f4a7-4dd4-b500-3d16859856be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20c8a2ea-644b-4f49-a8fe-a9e340562efa" xlink:to="loc_us-gaap_EquityComponentDomain_fe96a77e-f4a7-4dd4-b500-3d16859856be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_44fb6a04-e992-4c3e-9963-42f6e9cf37d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe96a77e-f4a7-4dd4-b500-3d16859856be" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_44fb6a04-e992-4c3e-9963-42f6e9cf37d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_48317a47-5d17-4517-8ff0-bbe55a6a77e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe96a77e-f4a7-4dd4-b500-3d16859856be" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_48317a47-5d17-4517-8ff0-bbe55a6a77e1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#EquityBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="extended" id="ic351b34669324eeda2400752cc2c5a0a_EquityBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_6617b695-d909-430f-8719-140b5244623e" xlink:href="xcur-20210630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_6617b695-d909-430f-8719-140b5244623e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_133f3e12-0901-4aa4-9ff7-d85d46a5053c" xlink:href="xcur-20210630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_133f3e12-0901-4aa4-9ff7-d85d46a5053c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_838ae9fb-de55-4323-afda-14f62754232b" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_838ae9fb-de55-4323-afda-14f62754232b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9a47e5f0-9449-41c4-acff-bfe90e4c594a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9a47e5f0-9449-41c4-acff-bfe90e4c594a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_541e12a9-652b-4ffe-986f-8a6e48d50c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_541e12a9-652b-4ffe-986f-8a6e48d50c2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23c28f07-d86c-451c-b1c0-287472ff03a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23c28f07-d86c-451c-b1c0-287472ff03a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_db3ce953-e33c-4d1b-a782-16536d89cc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_db3ce953-e33c-4d1b-a782-16536d89cc76" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_33094e38-9f9e-4975-b57c-4926abc82fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_33094e38-9f9e-4975-b57c-4926abc82fc6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_64f896c5-fbd8-4f6c-8de8-0423aa185557" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_64f896c5-fbd8-4f6c-8de8-0423aa185557" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_eb1ba4ca-8c53-4037-a7fe-8976384d447a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_eb1ba4ca-8c53-4037-a7fe-8976384d447a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_437d5045-6367-413a-9436-fcdc1226a363" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_437d5045-6367-413a-9436-fcdc1226a363" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a7d43603-bbbf-445a-b3a1-37db1d981e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a7d43603-bbbf-445a-b3a1-37db1d981e88" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_b73365b5-7efb-4974-b15d-aebfe31a27be" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_b73365b5-7efb-4974-b15d-aebfe31a27be" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_104c5542-9c73-4f68-939f-0fe4951d700d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_104c5542-9c73-4f68-939f-0fe4951d700d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23a3ea0e-8bf3-4eb7-87c5-f2c113d56a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23a3ea0e-8bf3-4eb7-87c5-f2c113d56a76" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3bf4acf6-4893-4b77-a933-41b1f83a9446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3bf4acf6-4893-4b77-a933-41b1f83a9446" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f4c70011-6ae8-4389-adf9-a9e26330e494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f4c70011-6ae8-4389-adf9-a9e26330e494" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3588f383-c146-4ef4-92a5-56f5d0d44f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3588f383-c146-4ef4-92a5-56f5d0d44f1d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting_17b358ec-dcb7-4ca0-a3fd-4aa73ea9c438" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting_17b358ec-dcb7-4ca0-a3fd-4aa73ea9c438" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51e3fda7-7ef0-4242-b4c4-52538f649eec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51e3fda7-7ef0-4242-b4c4-52538f649eec" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f77b466-1772-4e9f-9732-f8929317c7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f77b466-1772-4e9f-9732-f8929317c7e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_89e01d82-b0e4-413b-86e8-a9217cffc2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f77b466-1772-4e9f-9732-f8929317c7e5" xlink:to="loc_us-gaap_AwardTypeAxis_89e01d82-b0e4-413b-86e8-a9217cffc2fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89e01d82-b0e4-413b-86e8-a9217cffc2fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_89e01d82-b0e4-413b-86e8-a9217cffc2fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89e01d82-b0e4-413b-86e8-a9217cffc2fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81f18309-bc6b-4c4c-951f-9bb3002aa576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_89e01d82-b0e4-413b-86e8-a9217cffc2fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81f18309-bc6b-4c4c-951f-9bb3002aa576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d7d4fccc-69be-493b-bf02-9de309759115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81f18309-bc6b-4c4c-951f-9bb3002aa576" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d7d4fccc-69be-493b-bf02-9de309759115" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_74956bde-3cc7-4600-9361-d1d6c87f4fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81f18309-bc6b-4c4c-951f-9bb3002aa576" xlink:to="loc_us-gaap_EmployeeStockMember_74956bde-3cc7-4600-9361-d1d6c87f4fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4be8c6d3-b89e-4493-bb62-777d8f64734f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81f18309-bc6b-4c4c-951f-9bb3002aa576" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4be8c6d3-b89e-4493-bb62-777d8f64734f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bade395c-090f-4f60-b2de-adb5401479f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f77b466-1772-4e9f-9732-f8929317c7e5" xlink:to="loc_us-gaap_PlanNameAxis_bade395c-090f-4f60-b2de-adb5401479f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bade395c-090f-4f60-b2de-adb5401479f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_bade395c-090f-4f60-b2de-adb5401479f4" xlink:to="loc_us-gaap_PlanNameDomain_bade395c-090f-4f60-b2de-adb5401479f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_19c45760-5fd4-4835-a3e6-2fcd9be6f8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_bade395c-090f-4f60-b2de-adb5401479f4" xlink:to="loc_us-gaap_PlanNameDomain_19c45760-5fd4-4835-a3e6-2fcd9be6f8dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_08c5bf1c-3ff7-4f94-9e78-a9f67a5bb0b9" xlink:href="xcur-20210630.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_19c45760-5fd4-4835-a3e6-2fcd9be6f8dd" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_08c5bf1c-3ff7-4f94-9e78-a9f67a5bb0b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ab2f6b02-6549-4567-bbda-eb0ef685d199" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f77b466-1772-4e9f-9732-f8929317c7e5" xlink:to="loc_srt_TitleOfIndividualAxis_ab2f6b02-6549-4567-bbda-eb0ef685d199" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ab2f6b02-6549-4567-bbda-eb0ef685d199_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_ab2f6b02-6549-4567-bbda-eb0ef685d199" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ab2f6b02-6549-4567-bbda-eb0ef685d199_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13dfe576-767a-4571-acb4-355f778f4bff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_ab2f6b02-6549-4567-bbda-eb0ef685d199" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13dfe576-767a-4571-acb4-355f778f4bff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_2753704e-03bd-4d4b-a755-3d8b2b12187f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13dfe576-767a-4571-acb4-355f778f4bff" xlink:to="loc_srt_ChiefFinancialOfficerMember_2753704e-03bd-4d4b-a755-3d8b2b12187f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#EquityBasedCompensationScheduleofCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails" xlink:type="extended" id="i4f2f515dfad043b9aa05b09ab3c9eaa8_EquityBasedCompensationScheduleofCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5643ae79-461c-4794-9c94-8ce1529ddf13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ea1f467e-512e-4aba-b707-6cf3c5ca1b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5643ae79-461c-4794-9c94-8ce1529ddf13" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ea1f467e-512e-4aba-b707-6cf3c5ca1b51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8f52657-16aa-4116-b21b-a90d85ae6222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5643ae79-461c-4794-9c94-8ce1529ddf13" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8f52657-16aa-4116-b21b-a90d85ae6222" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c1c81e7c-3541-41dd-898f-85556eb476e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8f52657-16aa-4116-b21b-a90d85ae6222" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c1c81e7c-3541-41dd-898f-85556eb476e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c1c81e7c-3541-41dd-898f-85556eb476e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c1c81e7c-3541-41dd-898f-85556eb476e8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c1c81e7c-3541-41dd-898f-85556eb476e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4f788ad6-e398-43ad-988d-8fba7b4410d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c1c81e7c-3541-41dd-898f-85556eb476e8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4f788ad6-e398-43ad-988d-8fba7b4410d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e7ee3b1-56c8-4d8b-90a0-55dd7532ab6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4f788ad6-e398-43ad-988d-8fba7b4410d4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e7ee3b1-56c8-4d8b-90a0-55dd7532ab6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f5034052-9f95-4869-90ce-6109d5d99674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4f788ad6-e398-43ad-988d-8fba7b4410d4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f5034052-9f95-4869-90ce-6109d5d99674" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" xlink:type="extended" id="i3858ccda3a5f493ebacef38370741384_EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a3f6ba24-68f8-46f0-9666-627594b2740b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a3f6ba24-68f8-46f0-9666-627594b2740b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_25fbe92e-3145-4c7c-9271-5cee758fadaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_25fbe92e-3145-4c7c-9271-5cee758fadaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c34bd6ca-0b3e-46f9-aadf-3ffaa335414c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c34bd6ca-0b3e-46f9-aadf-3ffaa335414c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9f2b2433-c71c-48b2-a2bc-0e358c253fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9f2b2433-c71c-48b2-a2bc-0e358c253fc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6b4f5aeb-fada-4547-a53b-659e3830ab86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6b4f5aeb-fada-4547-a53b-659e3830ab86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6c4ba190-89fd-47ea-8caa-a02523b4a664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6c4ba190-89fd-47ea-8caa-a02523b4a664" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_b509c50d-2c70-4f29-886b-4d06bc6c23ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_b509c50d-2c70-4f29-886b-4d06bc6c23ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_691a8ad5-1e38-4778-b138-5fdb9d29d7b7" xlink:href="xcur-20210630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_691a8ad5-1e38-4778-b138-5fdb9d29d7b7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9ba50913-ca86-4696-9e27-27ed2e505268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9ba50913-ca86-4696-9e27-27ed2e505268" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b4daac3-8041-4df3-b39e-b7200cfbebb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b4daac3-8041-4df3-b39e-b7200cfbebb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6666700a-7d3c-49da-b54c-0902adfe56c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b4daac3-8041-4df3-b39e-b7200cfbebb3" xlink:to="loc_srt_RangeAxis_6666700a-7d3c-49da-b54c-0902adfe56c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6666700a-7d3c-49da-b54c-0902adfe56c6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6666700a-7d3c-49da-b54c-0902adfe56c6" xlink:to="loc_srt_RangeMember_6666700a-7d3c-49da-b54c-0902adfe56c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_64061a2e-c7e0-40a4-831f-5b6a8d526738" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6666700a-7d3c-49da-b54c-0902adfe56c6" xlink:to="loc_srt_RangeMember_64061a2e-c7e0-40a4-831f-5b6a8d526738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c3e0f804-4986-4692-b221-b712a7abc8cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_64061a2e-c7e0-40a4-831f-5b6a8d526738" xlink:to="loc_srt_MinimumMember_c3e0f804-4986-4692-b221-b712a7abc8cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9812995c-73a7-4711-97f8-3ecbb693b8d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_64061a2e-c7e0-40a4-831f-5b6a8d526738" xlink:to="loc_srt_MaximumMember_9812995c-73a7-4711-97f8-3ecbb693b8d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_627e0b26-24d4-4a3f-8f70-eb86c168db92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_64061a2e-c7e0-40a4-831f-5b6a8d526738" xlink:to="loc_srt_WeightedAverageMember_627e0b26-24d4-4a3f-8f70-eb86c168db92" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" xlink:type="extended" id="ic5d7728e15084c2fb7abbbaaaba944d5_EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a1f15c1-97a6-45c5-8e98-ecdcdf46f9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_9081681b-b889-44df-8f6d-f0f7b10e6e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a1f15c1-97a6-45c5-8e98-ecdcdf46f9fb" xlink:to="loc_us-gaap_SharePrice_9081681b-b889-44df-8f6d-f0f7b10e6e72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_b35fc388-8e52-4ad3-aac9-0b9647e68157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a1f15c1-97a6-45c5-8e98-ecdcdf46f9fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_b35fc388-8e52-4ad3-aac9-0b9647e68157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07efed41-8437-477d-b120-1bb20137f818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a1f15c1-97a6-45c5-8e98-ecdcdf46f9fb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07efed41-8437-477d-b120-1bb20137f818" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4776aac0-5758-4fdc-8e35-6581370f8edb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07efed41-8437-477d-b120-1bb20137f818" xlink:to="loc_srt_RangeAxis_4776aac0-5758-4fdc-8e35-6581370f8edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4776aac0-5758-4fdc-8e35-6581370f8edb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4776aac0-5758-4fdc-8e35-6581370f8edb" xlink:to="loc_srt_RangeMember_4776aac0-5758-4fdc-8e35-6581370f8edb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_582c30e8-6be8-4063-ad66-16244d38130f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4776aac0-5758-4fdc-8e35-6581370f8edb" xlink:to="loc_srt_RangeMember_582c30e8-6be8-4063-ad66-16244d38130f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3f9a71f3-63a2-4d36-8245-5e77280a8adb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_582c30e8-6be8-4063-ad66-16244d38130f" xlink:to="loc_srt_MinimumMember_3f9a71f3-63a2-4d36-8245-5e77280a8adb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_081f8478-2b08-413b-be33-c552e9c9b846" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_582c30e8-6be8-4063-ad66-16244d38130f" xlink:to="loc_srt_MaximumMember_081f8478-2b08-413b-be33-c552e9c9b846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_47cb65e1-e22c-455d-a631-f51d2b38a040" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_582c30e8-6be8-4063-ad66-16244d38130f" xlink:to="loc_srt_WeightedAverageMember_47cb65e1-e22c-455d-a631-f51d2b38a040" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#EquityBasedCompensationRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails" xlink:type="extended" id="ieb74f31dc2bd4ccc8ab8d0734171f931_EquityBasedCompensationRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7cccec45-bdf4-45ea-b2f5-6bd6913b469e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_66eda113-18b8-410c-8829-ec488774b5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7cccec45-bdf4-45ea-b2f5-6bd6913b469e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_66eda113-18b8-410c-8829-ec488774b5fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_749952a3-b3dd-4adb-aaa0-f4116c58aea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_66eda113-18b8-410c-8829-ec488774b5fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_749952a3-b3dd-4adb-aaa0-f4116c58aea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d2cdf93-7650-4e54-8ec7-ca2ed93f7452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_66eda113-18b8-410c-8829-ec488774b5fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d2cdf93-7650-4e54-8ec7-ca2ed93f7452" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9342bc1e-b431-4160-bbc5-3209e6d23fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f017e8f8-a81b-4a87-b733-3b07994a6bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7cccec45-bdf4-45ea-b2f5-6bd6913b469e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f017e8f8-a81b-4a87-b733-3b07994a6bb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6871a4df-c46f-4e9a-9399-9a06db765b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f017e8f8-a81b-4a87-b733-3b07994a6bb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6871a4df-c46f-4e9a-9399-9a06db765b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af546e5f-14c6-4b67-9959-8197db0fbb50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f017e8f8-a81b-4a87-b733-3b07994a6bb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af546e5f-14c6-4b67-9959-8197db0fbb50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3a7d4d53-30ec-4d32-bcd6-ac40bafbd5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a01ff70-e42b-40ed-97ce-b9f7697bb25d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7cccec45-bdf4-45ea-b2f5-6bd6913b469e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a01ff70-e42b-40ed-97ce-b9f7697bb25d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4059e1e2-6fcd-4a1f-9cd6-9f76ea9b5482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a01ff70-e42b-40ed-97ce-b9f7697bb25d" xlink:to="loc_us-gaap_AwardTypeAxis_4059e1e2-6fcd-4a1f-9cd6-9f76ea9b5482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4059e1e2-6fcd-4a1f-9cd6-9f76ea9b5482_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4059e1e2-6fcd-4a1f-9cd6-9f76ea9b5482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4059e1e2-6fcd-4a1f-9cd6-9f76ea9b5482_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_021e5e72-4a5b-46a4-95ce-df921de6dd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4059e1e2-6fcd-4a1f-9cd6-9f76ea9b5482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_021e5e72-4a5b-46a4-95ce-df921de6dd6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0f78412f-df5e-4b0d-a855-c393333bc0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_021e5e72-4a5b-46a4-95ce-df921de6dd6c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0f78412f-df5e-4b0d-a855-c393333bc0c1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="i07b34e3828b24c029babe47373d2f0e7_LossPerCommonShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_097e997d-ae63-4ab1-b070-27d26d4e1b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ca79b391-b7e9-48a3-91cb-f4ffc2358f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_097e997d-ae63-4ab1-b070-27d26d4e1b3e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ca79b391-b7e9-48a3-91cb-f4ffc2358f0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_59cb1c3d-0594-48ab-9d19-cf08ac497d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_097e997d-ae63-4ab1-b070-27d26d4e1b3e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_59cb1c3d-0594-48ab-9d19-cf08ac497d17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cae26c6-e49d-414a-8b49-ab2966a91a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_59cb1c3d-0594-48ab-9d19-cf08ac497d17" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cae26c6-e49d-414a-8b49-ab2966a91a27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8cae26c6-e49d-414a-8b49-ab2966a91a27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cae26c6-e49d-414a-8b49-ab2966a91a27" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8cae26c6-e49d-414a-8b49-ab2966a91a27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0fcd34f8-3c0a-458b-9e25-e312d03259f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cae26c6-e49d-414a-8b49-ab2966a91a27" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0fcd34f8-3c0a-458b-9e25-e312d03259f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_72076b3e-871e-4cce-b770-070a4a344d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0fcd34f8-3c0a-458b-9e25-e312d03259f9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_72076b3e-871e-4cce-b770-070a4a344d2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_49146bf7-283d-4da0-8f95-e44a949181c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0fcd34f8-3c0a-458b-9e25-e312d03259f9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_49146bf7-283d-4da0-8f95-e44a949181c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_747854db-0ec7-41b8-abd7-ca1ffbef50a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0fcd34f8-3c0a-458b-9e25-e312d03259f9" xlink:to="loc_us-gaap_WarrantMember_747854db-0ec7-41b8-abd7-ca1ffbef50a6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="i43256df56f0d48cdbcdb1a94fc176f12_FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8f741b3-4e92-4841-ba4f-e40b994988cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1451e703-1fc2-4ef4-9c28-4070f363105f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8f741b3-4e92-4841-ba4f-e40b994988cf" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1451e703-1fc2-4ef4-9c28-4070f363105f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ea66b875-ab59-4a80-8e25-f575b74b2d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8f741b3-4e92-4841-ba4f-e40b994988cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ea66b875-ab59-4a80-8e25-f575b74b2d71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5f6e1c61-8984-4bbe-994d-5243191a1db2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8f741b3-4e92-4841-ba4f-e40b994988cf" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5f6e1c61-8984-4bbe-994d-5243191a1db2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_1a23574a-6bcb-4b11-a11c-0173d2dff063" xlink:href="xcur-20210630.xsd#xcur_CommonStockWarrantLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8f741b3-4e92-4841-ba4f-e40b994988cf" xlink:to="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_1a23574a-6bcb-4b11-a11c-0173d2dff063" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_2094bbae-fe10-4b46-95ae-ff153f81af61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8f741b3-4e92-4841-ba4f-e40b994988cf" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_2094bbae-fe10-4b46-95ae-ff153f81af61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5126e4de-d954-4db7-be3a-2b6f83e89e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8f741b3-4e92-4841-ba4f-e40b994988cf" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5126e4de-d954-4db7-be3a-2b6f83e89e87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_814ecf24-52eb-4735-8767-f688869e75cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5126e4de-d954-4db7-be3a-2b6f83e89e87" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_814ecf24-52eb-4735-8767-f688869e75cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_814ecf24-52eb-4735-8767-f688869e75cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_814ecf24-52eb-4735-8767-f688869e75cb" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_814ecf24-52eb-4735-8767-f688869e75cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1a4e71e1-f17a-4fdd-ae95-28b0b01501aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_814ecf24-52eb-4735-8767-f688869e75cb" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1a4e71e1-f17a-4fdd-ae95-28b0b01501aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_24895bc7-ee3d-43e2-b9cd-b122cfe6fd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1a4e71e1-f17a-4fdd-ae95-28b0b01501aa" xlink:to="loc_us-gaap_MoneyMarketFundsMember_24895bc7-ee3d-43e2-b9cd-b122cfe6fd0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_670bee49-cef5-426b-afa6-a4f1881c1cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5126e4de-d954-4db7-be3a-2b6f83e89e87" xlink:to="loc_us-gaap_FinancialInstrumentAxis_670bee49-cef5-426b-afa6-a4f1881c1cc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_670bee49-cef5-426b-afa6-a4f1881c1cc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_670bee49-cef5-426b-afa6-a4f1881c1cc4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_670bee49-cef5-426b-afa6-a4f1881c1cc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7817d24b-6054-40e0-b4c0-50ab6ff0204e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_670bee49-cef5-426b-afa6-a4f1881c1cc4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7817d24b-6054-40e0-b4c0-50ab6ff0204e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0c6cc72f-4dbc-4b29-bfa0-4e4d74114ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7817d24b-6054-40e0-b4c0-50ab6ff0204e" xlink:to="loc_us-gaap_CommercialPaperMember_0c6cc72f-4dbc-4b29-bfa0-4e4d74114ec8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6f31ebb5-fe5a-4944-a1ba-915d6813ca77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7817d24b-6054-40e0-b4c0-50ab6ff0204e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6f31ebb5-fe5a-4944-a1ba-915d6813ca77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a0416c04-1a3a-4feb-8849-5255d1089566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7817d24b-6054-40e0-b4c0-50ab6ff0204e" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a0416c04-1a3a-4feb-8849-5255d1089566" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_243e0c00-e757-42fe-b5c1-827b7e7dacd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7817d24b-6054-40e0-b4c0-50ab6ff0204e" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_243e0c00-e757-42fe-b5c1-827b7e7dacd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5c6910a2-28ac-4d6d-894e-96e9aa245983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5126e4de-d954-4db7-be3a-2b6f83e89e87" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5c6910a2-28ac-4d6d-894e-96e9aa245983" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5c6910a2-28ac-4d6d-894e-96e9aa245983_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5c6910a2-28ac-4d6d-894e-96e9aa245983" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5c6910a2-28ac-4d6d-894e-96e9aa245983_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_25d002b9-22cf-4d28-9981-c8f6645a4970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5c6910a2-28ac-4d6d-894e-96e9aa245983" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_25d002b9-22cf-4d28-9981-c8f6645a4970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_36834c60-07a8-41d7-bb21-387634e999f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_25d002b9-22cf-4d28-9981-c8f6645a4970" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_36834c60-07a8-41d7-bb21-387634e999f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dcd61f76-1463-42f3-961b-7de7574ba8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5126e4de-d954-4db7-be3a-2b6f83e89e87" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dcd61f76-1463-42f3-961b-7de7574ba8e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dcd61f76-1463-42f3-961b-7de7574ba8e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dcd61f76-1463-42f3-961b-7de7574ba8e7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dcd61f76-1463-42f3-961b-7de7574ba8e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f68eb9a-27c2-4f35-8c62-0eff03e6d7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dcd61f76-1463-42f3-961b-7de7574ba8e7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f68eb9a-27c2-4f35-8c62-0eff03e6d7e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6d74bfc7-e92d-48ae-9cfd-b84962f0aa12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f68eb9a-27c2-4f35-8c62-0eff03e6d7e0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6d74bfc7-e92d-48ae-9cfd-b84962f0aa12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2c59e2b9-9232-42eb-8d7c-f8f40e0248fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f68eb9a-27c2-4f35-8c62-0eff03e6d7e0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2c59e2b9-9232-42eb-8d7c-f8f40e0248fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_11819059-2db1-462c-aea4-65e5cb0e5925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f68eb9a-27c2-4f35-8c62-0eff03e6d7e0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_11819059-2db1-462c-aea4-65e5cb0e5925" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="ic19282a0ee274a1098940dba22357327_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cd9ae48f-b395-491e-a617-852e99ed7d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_c009c53b-e383-4bb0-b7cc-0abf7af4e7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cd9ae48f-b395-491e-a617-852e99ed7d34" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_c009c53b-e383-4bb0-b7cc-0abf7af4e7f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d0efe1a1-d4d5-4252-a1a6-b1c97c7b619d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cd9ae48f-b395-491e-a617-852e99ed7d34" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d0efe1a1-d4d5-4252-a1a6-b1c97c7b619d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db23f112-e2d4-46fe-9713-a9481e16be72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cd9ae48f-b395-491e-a617-852e99ed7d34" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db23f112-e2d4-46fe-9713-a9481e16be72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_07127a4b-f85a-4871-8594-80e5cd73778c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db23f112-e2d4-46fe-9713-a9481e16be72" xlink:to="loc_us-gaap_StatementClassOfStockAxis_07127a4b-f85a-4871-8594-80e5cd73778c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_07127a4b-f85a-4871-8594-80e5cd73778c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_07127a4b-f85a-4871-8594-80e5cd73778c" xlink:to="loc_us-gaap_ClassOfStockDomain_07127a4b-f85a-4871-8594-80e5cd73778c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_47e108de-ef14-4880-b4bc-90b474a99b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_07127a4b-f85a-4871-8594-80e5cd73778c" xlink:to="loc_us-gaap_ClassOfStockDomain_47e108de-ef14-4880-b4bc-90b474a99b0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5af19303-95d1-4cb1-98b1-7aa983ecfbec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_47e108de-ef14-4880-b4bc-90b474a99b0b" xlink:to="loc_us-gaap_CommonStockMember_5af19303-95d1-4cb1-98b1-7aa983ecfbec" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="idab7a219489e49898c95a89c9ba571e8_FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_fd9b28f0-4b04-4588-b84e-a2be3a1bd43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e869e96a-87c4-4c48-808a-84241ee81df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_fd9b28f0-4b04-4588-b84e-a2be3a1bd43a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e869e96a-87c4-4c48-808a-84241ee81df7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_87bdfcda-1c6d-4748-b68f-220b08309223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e869e96a-87c4-4c48-808a-84241ee81df7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_87bdfcda-1c6d-4748-b68f-220b08309223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_6e7c590f-fe1c-423e-9dc7-c08d288b44b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e869e96a-87c4-4c48-808a-84241ee81df7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_6e7c590f-fe1c-423e-9dc7-c08d288b44b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f1ec4286-0a32-4802-a44c-b994aa9fca8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e869e96a-87c4-4c48-808a-84241ee81df7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f1ec4286-0a32-4802-a44c-b994aa9fca8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5024cd0f-9b96-4525-ad31-2a344906c5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6416c58c-2b12-4b3f-a27b-5dc6e90d6b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_fd9b28f0-4b04-4588-b84e-a2be3a1bd43a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6416c58c-2b12-4b3f-a27b-5dc6e90d6b42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_856d4cfb-4ff6-4308-8e53-794b1f73c476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6416c58c-2b12-4b3f-a27b-5dc6e90d6b42" xlink:to="loc_us-gaap_StatementClassOfStockAxis_856d4cfb-4ff6-4308-8e53-794b1f73c476" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_856d4cfb-4ff6-4308-8e53-794b1f73c476_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_856d4cfb-4ff6-4308-8e53-794b1f73c476" xlink:to="loc_us-gaap_ClassOfStockDomain_856d4cfb-4ff6-4308-8e53-794b1f73c476_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6300cf54-89fd-4ddc-8865-85b747a70bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_856d4cfb-4ff6-4308-8e53-794b1f73c476" xlink:to="loc_us-gaap_ClassOfStockDomain_6300cf54-89fd-4ddc-8865-85b747a70bf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fce17d95-1038-4f59-80e2-6e77db75205e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6300cf54-89fd-4ddc-8865-85b747a70bf4" xlink:to="loc_us-gaap_CommonStockMember_fce17d95-1038-4f59-80e2-6e77db75205e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_0d55fdfc-c060-4216-a149-e1097459030d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6416c58c-2b12-4b3f-a27b-5dc6e90d6b42" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_0d55fdfc-c060-4216-a149-e1097459030d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0d55fdfc-c060-4216-a149-e1097459030d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0d55fdfc-c060-4216-a149-e1097459030d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0d55fdfc-c060-4216-a149-e1097459030d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fb715d1d-224d-4538-9316-f80727925abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0d55fdfc-c060-4216-a149-e1097459030d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fb715d1d-224d-4538-9316-f80727925abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_WarrantLiabilityMember_9c50c2b5-2e52-41b4-bc55-34f572438131" xlink:href="xcur-20210630.xsd#xcur_WarrantLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fb715d1d-224d-4538-9316-f80727925abb" xlink:to="loc_xcur_WarrantLiabilityMember_9c50c2b5-2e52-41b4-bc55-34f572438131" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i60d6b949c9f84aee88656da056ede094_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d818e361-16a4-4d5a-9709-b33dcca3eac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_e15c0d74-1833-4722-babc-0305193e83d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d818e361-16a4-4d5a-9709-b33dcca3eac4" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_e15c0d74-1833-4722-babc-0305193e83d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a74af9c-3c36-490c-a03b-38078b868020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d818e361-16a4-4d5a-9709-b33dcca3eac4" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a74af9c-3c36-490c-a03b-38078b868020" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d6f0dfc-7b8f-4c53-828d-2e61d1f5b44e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a74af9c-3c36-490c-a03b-38078b868020" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d6f0dfc-7b8f-4c53-828d-2e61d1f5b44e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1d6f0dfc-7b8f-4c53-828d-2e61d1f5b44e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d6f0dfc-7b8f-4c53-828d-2e61d1f5b44e" xlink:to="loc_us-gaap_RelatedPartyDomain_1d6f0dfc-7b8f-4c53-828d-2e61d1f5b44e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_23009e04-b100-4a2c-b032-eb79863a1ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d6f0dfc-7b8f-4c53-828d-2e61d1f5b44e" xlink:to="loc_us-gaap_RelatedPartyDomain_23009e04-b100-4a2c-b032-eb79863a1ade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_99656aa5-6b7a-4bfc-858c-9ac5e8ce46bd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_23009e04-b100-4a2c-b032-eb79863a1ade" xlink:to="loc_srt_DirectorMember_99656aa5-6b7a-4bfc-858c-9ac5e8ce46bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2521f819-a178-4c38-8855-2c2714255b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a74af9c-3c36-490c-a03b-38078b868020" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2521f819-a178-4c38-8855-2c2714255b9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2521f819-a178-4c38-8855-2c2714255b9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2521f819-a178-4c38-8855-2c2714255b9d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2521f819-a178-4c38-8855-2c2714255b9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0dcfbf8d-8cd7-4964-b602-8a634863e30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2521f819-a178-4c38-8855-2c2714255b9d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0dcfbf8d-8cd7-4964-b602-8a634863e30d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ConsultingServicesMember_fd208671-7820-4179-85ab-f29dfa585391" xlink:href="xcur-20210630.xsd#xcur_ConsultingServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0dcfbf8d-8cd7-4964-b602-8a634863e30d" xlink:to="loc_xcur_ConsultingServicesMember_fd208671-7820-4179-85ab-f29dfa585391" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SubsequentEventsDetails" xlink:type="extended" id="ie6fe6086a528493d80bcb5b559e5ef27_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_NumberofCollaborationPrograms_c2eb3595-ae05-4e34-bd81-9bc4a4330774" xlink:href="xcur-20210630.xsd#xcur_NumberofCollaborationPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_xcur_NumberofCollaborationPrograms_c2eb3595-ae05-4e34-bd81-9bc4a4330774" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_e1463e04-547d-4203-a044-3089b7c92e50" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_xcur_CollaborationAgreementUpfrontPayment_e1463e04-547d-4203-a044-3089b7c92e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionExerciseFee_6261a925-6cbe-488d-88b3-47ca41c6a6cf" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_xcur_CollaborationAgreementOptionExerciseFee_6261a925-6cbe-488d-88b3-47ca41c6a6cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment_72a0c50a-c960-4ef2-bf6b-3caf019b00f2" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment_72a0c50a-c960-4ef2-bf6b-3caf019b00f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment_9841cf8f-a423-465d-b24f-11377f22eff3" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment_9841cf8f-a423-465d-b24f-11377f22eff3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment_2dd8c4d0-b8ff-4560-bd5f-1a834f5e60e7" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment_2dd8c4d0-b8ff-4560-bd5f-1a834f5e60e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementLicensingFeesIncurred_55030424-a48a-45cb-a728-087b1a7d5642" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementLicensingFeesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_xcur_CollaborationAgreementLicensingFeesIncurred_55030424-a48a-45cb-a728-087b1a7d5642" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_9e482ba0-7fea-44cd-a664-346aca573ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_us-gaap_SubsequentEventTable_9e482ba0-7fea-44cd-a664-346aca573ded" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_858d3c88-555c-478a-a307-1a1269a0a5c9" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9e482ba0-7fea-44cd-a664-346aca573ded" xlink:to="loc_xcur_ArrangementNameAxis_858d3c88-555c-478a-a307-1a1269a0a5c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_858d3c88-555c-478a-a307-1a1269a0a5c9_default" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xcur_ArrangementNameAxis_858d3c88-555c-478a-a307-1a1269a0a5c9" xlink:to="loc_xcur_ArrangementNameDomain_858d3c88-555c-478a-a307-1a1269a0a5c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_06df31c5-d6ab-491d-9895-c90f4b6b7dd1" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xcur_ArrangementNameAxis_858d3c88-555c-478a-a307-1a1269a0a5c9" xlink:to="loc_xcur_ArrangementNameDomain_06df31c5-d6ab-491d-9895-c90f4b6b7dd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenCollaborationMember_c7ec7957-2dff-4904-913f-0d2a477c559d" xlink:href="xcur-20210630.xsd#xcur_IpsenCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ArrangementNameDomain_06df31c5-d6ab-491d-9895-c90f4b6b7dd1" xlink:to="loc_xcur_IpsenCollaborationMember_c7ec7957-2dff-4904-913f-0d2a477c559d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3967c66f-2fab-4e9f-b5e2-d6c62205d024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9e482ba0-7fea-44cd-a664-346aca573ded" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3967c66f-2fab-4e9f-b5e2-d6c62205d024" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3967c66f-2fab-4e9f-b5e2-d6c62205d024_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3967c66f-2fab-4e9f-b5e2-d6c62205d024" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3967c66f-2fab-4e9f-b5e2-d6c62205d024_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67aca625-fd76-4686-ae01-a3a62f48a512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3967c66f-2fab-4e9f-b5e2-d6c62205d024" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67aca625-fd76-4686-ae01-a3a62f48a512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_7b1b4eb1-1857-403f-a3d4-eec9edf2093b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67aca625-fd76-4686-ae01-a3a62f48a512" xlink:to="loc_us-gaap_CollaborativeArrangementMember_7b1b4eb1-1857-403f-a3d4-eec9edf2093b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodAxis_66919cfc-f416-46ef-a100-7f7c1b458180" xlink:href="xcur-20210630.xsd#xcur_ExercisePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9e482ba0-7fea-44cd-a664-346aca573ded" xlink:to="loc_xcur_ExercisePeriodAxis_66919cfc-f416-46ef-a100-7f7c1b458180" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodDomain_66919cfc-f416-46ef-a100-7f7c1b458180_default" xlink:href="xcur-20210630.xsd#xcur_ExercisePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xcur_ExercisePeriodAxis_66919cfc-f416-46ef-a100-7f7c1b458180" xlink:to="loc_xcur_ExercisePeriodDomain_66919cfc-f416-46ef-a100-7f7c1b458180_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodDomain_910caee9-fc13-4c6f-bf49-02012dbe8182" xlink:href="xcur-20210630.xsd#xcur_ExercisePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xcur_ExercisePeriodAxis_66919cfc-f416-46ef-a100-7f7c1b458180" xlink:to="loc_xcur_ExercisePeriodDomain_910caee9-fc13-4c6f-bf49-02012dbe8182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodOneMember_0358dad5-6310-43e4-ac16-21eb8d6f3d79" xlink:href="xcur-20210630.xsd#xcur_ExercisePeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ExercisePeriodDomain_910caee9-fc13-4c6f-bf49-02012dbe8182" xlink:to="loc_xcur_ExercisePeriodOneMember_0358dad5-6310-43e4-ac16-21eb8d6f3d79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodTwoMember_c37fe673-025e-4c03-b0ef-4630d5acceca" xlink:href="xcur-20210630.xsd#xcur_ExercisePeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ExercisePeriodDomain_910caee9-fc13-4c6f-bf49-02012dbe8182" xlink:to="loc_xcur_ExercisePeriodTwoMember_c37fe673-025e-4c03-b0ef-4630d5acceca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_66b662d0-1b5d-4fa8-848d-bdc60371af9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9e482ba0-7fea-44cd-a664-346aca573ded" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_66b662d0-1b5d-4fa8-848d-bdc60371af9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_66b662d0-1b5d-4fa8-848d-bdc60371af9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_66b662d0-1b5d-4fa8-848d-bdc60371af9e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_66b662d0-1b5d-4fa8-848d-bdc60371af9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e371d8f8-a0f0-4791-a4cf-3132dc59b865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_66b662d0-1b5d-4fa8-848d-bdc60371af9e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e371d8f8-a0f0-4791-a4cf-3132dc59b865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c05521c9-11d2-490c-a5c7-af835c3a65bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e371d8f8-a0f0-4791-a4cf-3132dc59b865" xlink:to="loc_us-gaap_SubsequentEventMember_c05521c9-11d2-490c-a5c7-af835c3a65bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>xcur-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:5b54f0ec-bf0b-4618-8722-18f79640ae79,g:5933f058-0750-4e2c-9852-92fa9631b69d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0f52f518-74d4-4578-9daa-61c34b7ba2a4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on short-term investments</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8f1c26da-049f-406c-ab5b-6513d22857da_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) Earnings Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_204c045d-e321-4b5b-a4d7-af92ffa7820c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_737363d4-8d78-4876-8b63-a12b1b5198c0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5ddf9842-f24b-44d7-bceb-bd677a5bfdfe_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1214f276-6e04-4dcc-b8f1-15cda827bd7b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_286040ea-1850-4a8a-babd-bacf15f427a4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_68ccf9c9-5cf3-46a5-a0a6-e0593888a315_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_ea6e01ec-f95b-48c6-afb5-55cd552c919d_terseLabel_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution amount</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_label_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_documentation_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:to="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_78171c27-8487-4370-ad18-76272bb24400_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_75f465d0-26d2-4a46-a897-72adb41ab988_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll-related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_5b3a7891-d966-4aaa-b141-dc44ca0acd2b_terseLabel_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One year or less</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_label_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Current, Percent</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_documentation_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Current, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:href="xcur-20210630.xsd#xcur_DebtSecuritiesAvailableForSaleCurrentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:to="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_65e148a0-bb61-49d6-a403-2b1200fb9569_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4a0c072d-64a2-4a14-b0b6-dded2210b32c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a0a33e5a-8c8e-4d13-b4dc-462bcfdb199b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0c6aa9f6-72a1-4aa4-86ac-91b044ebcfeb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_25b80ca2-da77-466c-92e1-ceb55ec11991_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares per employee in purchase period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c3e3b223-d079-4f11-901d-e3fb0920b6f7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44c3f5bf-592d-4136-af65-1e3ed146ff41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bf5aaded-9696-406e-95b7-7c813098e5b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_00e1443b-44d3-4504-9b37-7d3662dc1f82_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f3bd438-3239-4626-90ad-90232a68b00f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c126adcd-0425-4025-bd14-b041fa2a3d81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_40789a96-b01f-457a-8b70-ad1cd4ed675b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0d09f2ab-541e-447b-8a12-44bbc15b0e6c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3b363dac-27f5-4b41-ae2c-1fcee36f58e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_844cc2c5-062e-4931-ae66-c64476b39e14_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_184621ed-30dd-49dc-9d3f-e2164551fc0b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_3442504e-52be-4c73-9fbc-02eeee5e6c00_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e29d8d9b-3b5e-4d31-a26a-291cfeb4ad30_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain included in other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4be64949-aaaf-4c5c-9d06-8fa1eb01f9ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, stock options, exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_b38215ba-9eea-4c77-b52e-ed1fc02c80b1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale or maturity of available for sale securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_7b8bd8b4-e70e-413c-a18d-21daa272832e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_f76f257e-ce6e-4757-be82-3911d2271458_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remaining six months)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5849177e-3582-4a45-ab85-b720cd88c5d0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_PaymentsForDebtEndTermFees_5c79c35d-a0b4-471f-9676-6c79a880e557_terseLabel_en-US" xlink:label="lab_xcur_PaymentsForDebtEndTermFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for debt end term fees</link:label>
    <link:label id="lab_xcur_PaymentsForDebtEndTermFees_label_en-US" xlink:label="lab_xcur_PaymentsForDebtEndTermFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Debt End Term Fees</link:label>
    <link:label id="lab_xcur_PaymentsForDebtEndTermFees_documentation_en-US" xlink:label="lab_xcur_PaymentsForDebtEndTermFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Debt End Term Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsForDebtEndTermFees" xlink:href="xcur-20210630.xsd#xcur_PaymentsForDebtEndTermFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PaymentsForDebtEndTermFees" xlink:to="lab_xcur_PaymentsForDebtEndTermFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_9c2e057d-6df9-4a21-8de2-ee65fc0d2def_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_36b3a2a2-4b0d-4de7-b7d8-157c7a42261c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_80e1be8d-57a2-4c87-90f7-05b8a12e2544_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80dea37d-8fbe-45dc-8fbc-68e0773546dc_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a751e05e-f156-4537-89e9-497fdc44a307_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_74477531-ceba-4b27-8ebf-85808b366df7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_3164ddcc-0364-48f2-9d71-aac20dcd57b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_c3858cc6-c01f-44c0-b1d2-90a3503c2a95_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_98b4aca9-1ca9-4ee3-bf8e-4ee4fb883ec0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_67e89346-5c69-4f9b-99ff-d376bf1f8b31_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_260c6433-b62e-4c0a-a635-d9f8df5247ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (losses) gains on available for sale securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac9a3a0c-263b-45fa-a2fe-6d2f71f94da1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_6f757c2c-09b9-49f9-8a93-d0fe76a89224_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_331a0a9c-001e-4315-bcfb-55009ac180cf_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_b79c4a7c-17da-42cd-8b4b-4f0f0f313da9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2824b777-b23c-4b94-b355-5e3a897e38cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7aa9db3a-9d93-48d8-bcc6-33cfa5741063_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ResearchAndDevelopmentStaffOnSitePercentage_ff4eb17f-faf8-49e7-8780-b79f3f8e897e_terseLabel_en-US" xlink:label="lab_xcur_ResearchAndDevelopmentStaffOnSitePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of R&amp;D staff on site</link:label>
    <link:label id="lab_xcur_ResearchAndDevelopmentStaffOnSitePercentage_label_en-US" xlink:label="lab_xcur_ResearchAndDevelopmentStaffOnSitePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Staff on Site, Percentage</link:label>
    <link:label id="lab_xcur_ResearchAndDevelopmentStaffOnSitePercentage_documentation_en-US" xlink:label="lab_xcur_ResearchAndDevelopmentStaffOnSitePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Staff on Site, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ResearchAndDevelopmentStaffOnSitePercentage" xlink:href="xcur-20210630.xsd#xcur_ResearchAndDevelopmentStaffOnSitePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ResearchAndDevelopmentStaffOnSitePercentage" xlink:to="lab_xcur_ResearchAndDevelopmentStaffOnSitePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8c595e10-730e-488c-a17f-02506ddc140d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_56d38b12-8323-4e04-9da0-fecc04bbd7b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8db449cf-fac3-4a2e-bb4f-54ba00442d60_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_6c2c859c-0905-4b3f-9478-366ba213303b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, June&#160;30, 2021 and December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9cda7372-5eef-47a7-bf0a-7f36ad072bb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_84b1f9ae-b7ff-4531-bb96-bf9864f51213_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f671f2e8-84c9-4ba2-b28a-8320a1e36864_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_06366ba8-4178-46a2-9070-9acedaae8b4e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9a22c5e0-ce46-41f0-9c64-dad1daca9883_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_40534191-147b-4ba1-b686-b96f3af4e48f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_844af0cd-0d20-4ab0-8d5a-48ac3413f385_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_76a6e5a9-04c8-4771-b1a1-ce0a0ad86253_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ed83123-d825-43d2-beed-d007744672ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_9a8a5268-63f1-45a0-8ebc-21aac339ecd8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8c8bf2df-c369-4c8a-aea4-389900480cac_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_81d25e10-b652-42b1-af1f-44b7ddf7f3a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_d22847fb-6c81-4052-9052-d24bf882fab1_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_22acaa09-e622-4eaf-bf2f-9a35995a3f4a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6d57758b-4271-4c69-9ff8-8b3fa128c28c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures (accounts payable and accrued expenses)</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_AbbVieCollaborationMember_9b72cd4e-095e-4837-9c3b-85002da0553a_terseLabel_en-US" xlink:label="lab_xcur_AbbVieCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Collaboration</link:label>
    <link:label id="lab_xcur_AbbVieCollaborationMember_label_en-US" xlink:label="lab_xcur_AbbVieCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Collaboration [Member]</link:label>
    <link:label id="lab_xcur_AbbVieCollaborationMember_documentation_en-US" xlink:label="lab_xcur_AbbVieCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allergan Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AbbVieCollaborationMember" xlink:href="xcur-20210630.xsd#xcur_AbbVieCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AbbVieCollaborationMember" xlink:to="lab_xcur_AbbVieCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement_761605fc-a4b3-4b6f-996a-ab57381a6d5d_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental payment adjusted for abatement</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rental Payment Adjusted For Abatement</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rental Payment Adjusted For Abatement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" xlink:to="lab_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f7f41bc4-2b93-4cb4-8ccb-985d2ede0160_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ESPP contribution rate as a percentage of compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_MidCapCreditAgreementMember_be9c8270-ddc4-46de-ac85-3a9a89d946e7_terseLabel_en-US" xlink:label="lab_xcur_MidCapCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement</link:label>
    <link:label id="lab_xcur_MidCapCreditAgreementMember_label_en-US" xlink:label="lab_xcur_MidCapCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement [Member]</link:label>
    <link:label id="lab_xcur_MidCapCreditAgreementMember_documentation_en-US" xlink:label="lab_xcur_MidCapCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementMember" xlink:href="xcur-20210630.xsd#xcur_MidCapCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_MidCapCreditAgreementMember" xlink:to="lab_xcur_MidCapCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_82ea2e21-80ef-482b-b976-eb9a3a96fcf1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0b79e268-cdb8-4d76-b471-1db5af635f7c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_dae39416-f871-431d-9e1f-7852400ad79d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bc3ce503-a5b4-421c-b1da-92952ac3998d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8abd7a52-2676-493f-aaf9-7e2e57b31dbb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (loss) earnings per common share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_915c57cf-02f0-49df-a27c-3b033ca5ce0a_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) earnings per basic common share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CommonStockVotingRightsForEachShare_995f82ff-6e3c-417a-822a-a0a88206307b_terseLabel_en-US" xlink:label="lab_xcur_CommonStockVotingRightsForEachShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, voting rights for each share</link:label>
    <link:label id="lab_xcur_CommonStockVotingRightsForEachShare_label_en-US" xlink:label="lab_xcur_CommonStockVotingRightsForEachShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights For Each Share</link:label>
    <link:label id="lab_xcur_CommonStockVotingRightsForEachShare_documentation_en-US" xlink:label="lab_xcur_CommonStockVotingRightsForEachShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights For Each Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockVotingRightsForEachShare" xlink:href="xcur-20210630.xsd#xcur_CommonStockVotingRightsForEachShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommonStockVotingRightsForEachShare" xlink:to="lab_xcur_CommonStockVotingRightsForEachShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b00f1e88-af38-4e78-9f47-04d7e59ad776_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyTable_7e61802c-067b-4c73-a6ba-4ef5dc7e731f_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Table]</link:label>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyTable_label_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable" xlink:to="lab_us-gaap_UnusualRiskOrUncertaintyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_f535f7d6-4aed-46d5-bd0a-da3e1c5c249b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeDividend" xlink:to="lab_us-gaap_InvestmentIncomeDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a9d3d516-13e8-4ec4-950d-8b40cec3013e_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4d70be5b-3b8d-4082-acec-d69fb1dd2df5_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at June&#160;30, 2021</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_36bdd000-f447-418e-aa42-b62b40ea57dc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance - beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1440b0c4-e812-4054-ba40-86bb7c73189f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance - end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6e9302ca-2ebe-4f9b-9215-867e3eda6795_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5b2ed493-5d9d-4f87-b9e8-54329d4714f1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_c695f12f-b94d-4435-859c-3e7489a0ad9d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical, contract research and manufacturing costs</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm_25f28944-8d10-46ea-b08f-d92c2f43410b_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated rental payment over original term</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Estimated Rental Payment Over Original Term</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Estimated Rental Payment Over Original Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" xlink:to="lab_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c3325648-6b4e-4619-8f9b-0fca5eb19fad_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_3b413e0d-78ff-4a5f-b737-384abbd5094a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_691bedda-1793-474f-8fc5-c431efa99988_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, cash payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_952673cb-c06a-49cd-bf8c-cd2929ec8a9a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_9c639f93-3cc5-478c-9c41-a0ea7d2692c9_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal balance outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_c2163d0a-43db-46d1-9fc9-8801bd15b8d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After first anniversary</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_29a91aa4-d9df-4815-959d-ebcf556a6dc4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_a0680488-3d94-43d9-b61f-01e46f9fe6b1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_2b43d16c-1839-4e4e-bdff-125f1132e950_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting_914e4c20-710c-43b4-a1da-664f64b07f44_terseLabel_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued for each vested restricted stock unit (in shares)</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting_label_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting_documentation_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" xlink:to="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_fd4e7502-af07-48ed-91db-982df0b901cf_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_91ff52ee-5e0c-45d7-be2f-f3ac5455d57c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_87736c56-3882-46e9-84ab-194ed367041d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ee356792-f54a-4ba8-a07a-af6f66dee4a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_5ac9c41a-4b99-4404-995d-a65531550d3b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1d09e498-ad5f-4838-bc46-bc6013a5323b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_607efb8d-79b1-4379-879f-0f38861ea102_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_bea59168-3193-4f7d-b8c5-297cccfb2601_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_56b11bfa-2a86-41a0-a77e-6f0ef9e3b193_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_004024b2-4344-4660-9ad0-cc8b01ea6a17_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_2dfcf750-8227-436d-9ffc-98a67f4c1259_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6948f81a-ecab-406d-b9dd-3a533aebd7e7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_975ca3ad-f74b-4393-9aa5-75aac2d6ef97_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_addc7c1f-cdeb-4809-b0a7-4f1863d64c36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_a4dd4a63-2894-4195-ac97-49ea92f65726_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0a7f1015-d9e7-479b-9dc9-475a42b8ef48_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_809e6a19-463c-4ed2-a168-8539fc23e010_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_f4911590-972a-403c-b749-bd88e3390bbb_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for tenant improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForTenantImprovements" xlink:to="lab_us-gaap_PaymentsForTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a9df85a2-9105-48c1-9c90-9f1c98375fee_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_cf466394-7c05-4876-8aee-d6249daaa97a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_5a3a0508-f664-4fdd-9a50-7c27ce4fbf9e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_fb4fb9b9-1d12-4925-8220-7d7a11215b3d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_f5ff11de-1924-4f50-97c2-af480326c54b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_329b88d0-9ab8-4d85-aeef-8c0903bccf06_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_05964425-2716-46a1-a4d0-f6e27c364982_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_c06b4a34-6618-444c-b30e-35ae2615c0c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized gains, available for sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d0b41ae2-671e-4159-a5df-504befc5d3b3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_b0532b7f-074c-4f5f-acf1-619e3e59c1d6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_6bcd009f-7468-4f6a-9c07-6d7ebd342589_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a72e7e7b-9359-4b44-bfc3-dabffd37b2cf_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_84d3ecf0-a19d-404c-aff7-623fcfce6765_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fb073d8d-af40-46d8-8723-39bd39bcdd39_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Holding Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementLicensingFeesIncurred_ac15ca0c-9d07-44b8-8ba5-64597ba8bd28_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementLicensingFeesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, licensing fees incurred</link:label>
    <link:label id="lab_xcur_CollaborationAgreementLicensingFeesIncurred_label_en-US" xlink:label="lab_xcur_CollaborationAgreementLicensingFeesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Licensing Fees Incurred</link:label>
    <link:label id="lab_xcur_CollaborationAgreementLicensingFeesIncurred_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementLicensingFeesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Licensing Fees Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementLicensingFeesIncurred" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementLicensingFeesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementLicensingFeesIncurred" xlink:to="lab_xcur_CollaborationAgreementLicensingFeesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_138209ba-f742-45dc-b229-269dd98e45fc_terseLabel_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares allowable annually under the plan (in shares)</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_label_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_documentation_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:to="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7e97fe35-45c7-4d20-839d-d450a7396375_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_42bae919-1557-4a00-a314-f24795c81e55_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_8f7ab5fd-537b-40e2-a9f7-28c3bfdfd047_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_a37afedf-ece4-4fcc-9c24-96a52ef26df4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_cc5beb8e-47ce-4724-b4e8-127b406e54e9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_bc7db4c0-688c-4286-b1fb-7b6436ccd720_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_13d8eba8-dfb7-4975-827d-2422e7c3f568_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_8efff1a7-3441-4a18-b987-9059d6ad47bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_9fd5d8c2-736e-4851-8f23-ff9195df3a44_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5bbb380d-57cd-458e-9abc-323f7d9b011b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a5c4334a-07cd-4b52-b654-c665c8863430_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_6f1326ad-b19b-4eb0-8596-e4a73cf21c10_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_a4cbc43c-ba5a-4ae7-89a3-8b8a0f147d13_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a19bbcc6-0b1f-4b43-b20a-39121e5abcdd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc2cf3b6-ee3f-46d4-ac1b-601709ca43b1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_84f90037-d4fd-4b54-b548-4ae847accb45_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment received for research agreement</link:label>
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_label_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementUpfrontPayment" xlink:to="lab_xcur_CollaborationAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f1720f5b-3700-4361-b83c-ab4474e5cb14_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c300d8f4-decf-4289-8534-48b549f2e845_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_85dd3162-a3b5-4701-8935-6b74c19c807d_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_b55f0a3f-7cfe-4351-862b-c700a993b5b9_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e22c703f-5bf5-49d9-8723-449b3de60764_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 88,096,694 issued and outstanding, June&#160;30, 2021; 87,651,352 issued and outstanding, December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_c8257985-2d41-4bae-9116-b3f6d0c3bb97_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6dff6e53-4ec5-4089-8f6e-3de3a3f91e9b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_303c1bbe-fac5-43c1-9643-075491adc064_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance - beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_130ed26d-419e-402e-a3fc-be4b3ba5ed14_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance - end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4c03a5d0-346d-4277-924c-96d277351493_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_cd3056ed-ffed-4107-ac61-38a23e33e933_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_2ce98c50-2a6b-41c6-9466-bbc25d5b185a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_35c50d06-9e50-42cb-a086-eee5aca534e1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_94fff6a0-93bc-4d54-9f39-886727a64a2f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt, net of fees and issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_576904c9-7c4c-4bfd-864f-dfad622c4fa6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remaining six months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_664713aa-cd12-4498-8db7-6af04a243cc0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of long-term debt fees and issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3bfcf587-cc49-475c-a93f-bb857e94a745_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used to Determine Fair Value of Common Stock Option Grants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_d4605ac1-6a27-401a-aa8b-a9c217000664_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_1655d09d-3b81-4eb0-97c2-dbfe1cd0a0e3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_025310c4-5d1f-4de7-a0cb-1d6028dbd863_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_4d6307e1-9ddf-4972-b0dd-0c3d3f3c023f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseNumberOfExtensions_1848ca13-44de-4d61-9639-4a7d9aade50d_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseNumberOfExtensions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of extensions</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseNumberOfExtensions_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseNumberOfExtensions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number of Extensions</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseNumberOfExtensions_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseNumberOfExtensions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number of Extensions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseNumberOfExtensions" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseNumberOfExtensions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseNumberOfExtensions" xlink:to="lab_xcur_LesseeOperatingLeaseNumberOfExtensions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_045f791f-1a12-4b72-bc97-f6986d221290_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_526e8f3a-be0e-47c0-8231-177794ed8c03_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_11c6dc07-5439-4b9d-b02d-9337127205e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_70ae8524-b62a-4c18-8c18-3ee1fbd3a40f_terseLabel_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Technology Growth Capital</link:label>
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_label_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Technology Growth Capital [Member]</link:label>
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_documentation_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Technology Growth Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember" xlink:href="xcur-20210630.xsd#xcur_HerculesTechnologyGrowthCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_HerculesTechnologyGrowthCapitalMember" xlink:to="lab_xcur_HerculesTechnologyGrowthCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_59cf5849-f05b-4969-a76c-36fa833d6bee_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_978bc019-43a0-49c8-8f64-192f320161e5_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_e0f95176-4d41-47b7-ba4a-f963c00add46_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyLineItems_8ed8a196-fa14-49d5-814a-2ec7ab0a6c22_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyLineItems_label_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:to="lab_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_04f12664-c840-4af2-a0af-ec1167e4753a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1a167f78-7991-4c4d-b051-f4efb7ecf0c7_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e086abc-d0cf-40de-b227-708b79e096d5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4f4218f4-4907-44b5-8e2e-1e7857d73e9d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_add3635f-0e7e-4ec1-b81d-3210097fd81f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_8c3b2b87-7a67-4902-b66b-7a2728db1432_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_d87af805-e1d5-470a-8089-f55f069a2f28_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c5da3932-b4fb-43db-872b-4b90685fb9e6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_59d2a552-8f17-4334-90d9-ea3f96c45719_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationDevelopmentExpenses_c88a64ae-95a6-40ed-9ff6-3cedac33428e_terseLabel_en-US" xlink:label="lab_xcur_CollaborationDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration development expenses</link:label>
    <link:label id="lab_xcur_CollaborationDevelopmentExpenses_label_en-US" xlink:label="lab_xcur_CollaborationDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Development Expenses</link:label>
    <link:label id="lab_xcur_CollaborationDevelopmentExpenses_documentation_en-US" xlink:label="lab_xcur_CollaborationDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationDevelopmentExpenses" xlink:href="xcur-20210630.xsd#xcur_CollaborationDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationDevelopmentExpenses" xlink:to="lab_xcur_CollaborationDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_d6d2e930-aad4-4607-b4e0-e011e23920d7_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6cf2cf0c-21f1-4f09-b86e-74a8d5d680e3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_685b5b3b-fe1f-4803-8445-4c4a9471d7df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a595eb4b-c869-429d-9f8d-ed7d1bdd34fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_906328fd-51db-426a-88c4-ec2164f2894f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_cb2a21dd-fe1e-47cf-bd3a-d8572be41d87_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_AggregatePaymentsMadeToDateForLicenseAgreements_26e766fa-2f94-425b-bc64-aca31edd9093_terseLabel_en-US" xlink:label="lab_xcur_AggregatePaymentsMadeToDateForLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate consideration paid to NU for agreement obligations</link:label>
    <link:label id="lab_xcur_AggregatePaymentsMadeToDateForLicenseAgreements_label_en-US" xlink:label="lab_xcur_AggregatePaymentsMadeToDateForLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Payments Made To Date For License Agreements</link:label>
    <link:label id="lab_xcur_AggregatePaymentsMadeToDateForLicenseAgreements_documentation_en-US" xlink:label="lab_xcur_AggregatePaymentsMadeToDateForLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Payments Made To Date For License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AggregatePaymentsMadeToDateForLicenseAgreements" xlink:href="xcur-20210630.xsd#xcur_AggregatePaymentsMadeToDateForLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AggregatePaymentsMadeToDateForLicenseAgreements" xlink:to="lab_xcur_AggregatePaymentsMadeToDateForLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b02e093e-e5c8-4055-ae2b-c980774bb565_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Holding Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_3a04522a-be2f-471f-8e69-7c8d2cefb250_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Research and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81186955-60f3-4e79-aba1-6771e137ca69_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e20b8edd-30b2-46b5-808a-cdabab14bb03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e7fc3a7a-9c99-4683-9371-8dd20de1b782_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ArrangementNameAxis_9bdcf84a-1624-401d-bd6e-7ba519330ea5_terseLabel_en-US" xlink:label="lab_xcur_ArrangementNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Axis]</link:label>
    <link:label id="lab_xcur_ArrangementNameAxis_label_en-US" xlink:label="lab_xcur_ArrangementNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Axis]</link:label>
    <link:label id="lab_xcur_ArrangementNameAxis_documentation_en-US" xlink:label="lab_xcur_ArrangementNameAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ArrangementNameAxis" xlink:to="lab_xcur_ArrangementNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_01032688-cd72-4b7b-a1cf-4bb2e6f928c7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in- Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b2f07f1d-7ece-42dc-b38e-4ddac25d8f5f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ChicagoMember_b16b252b-6a78-4b6b-8898-762421753968_terseLabel_en-US" xlink:label="lab_xcur_ChicagoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chicago</link:label>
    <link:label id="lab_xcur_ChicagoMember_label_en-US" xlink:label="lab_xcur_ChicagoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chicago [Member]</link:label>
    <link:label id="lab_xcur_ChicagoMember_documentation_en-US" xlink:label="lab_xcur_ChicagoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chicago</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ChicagoMember" xlink:href="xcur-20210630.xsd#xcur_ChicagoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ChicagoMember" xlink:to="lab_xcur_ChicagoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_b95fd31c-f8af-400d-90cd-ef55f9924b69_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_31792a78-02e1-461c-a475-7db13060185d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c3960167-ec5b-4515-b478-d69ce9db93cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available for sale securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa3a36eb-31b7-4992-b36b-575deb0b2662_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment_96082466-67db-4c96-8e63-927f4820f5d2_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestone payment amount</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Development And Regulatory Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Development And Regulatory Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_cc97e111-3962-4b15-8d0f-bf8e79f85892_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_bb9fe26a-575a-4b22-bf17-9d48cd1478c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8e015386-f7cd-4b39-9730-53f36a0b12de_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_23777a82-6c29-42f2-83a9-533a764c324d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_07bf1b1e-f836-46f2-aa4e-961fbabcebc9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_PaymentsOfCommonStockFinancingCosts_e5dc4782-6170-4f6d-8061-9b598f32d18e_negatedLabel_en-US" xlink:label="lab_xcur_PaymentsOfCommonStockFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of common stock financing costs</link:label>
    <link:label id="lab_xcur_PaymentsOfCommonStockFinancingCosts_label_en-US" xlink:label="lab_xcur_PaymentsOfCommonStockFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Common Stock Financing Costs</link:label>
    <link:label id="lab_xcur_PaymentsOfCommonStockFinancingCosts_documentation_en-US" xlink:label="lab_xcur_PaymentsOfCommonStockFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Common Stock Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsOfCommonStockFinancingCosts" xlink:href="xcur-20210630.xsd#xcur_PaymentsOfCommonStockFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PaymentsOfCommonStockFinancingCosts" xlink:to="lab_xcur_PaymentsOfCommonStockFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_583b6443-8223-4c90-82de-c49447080fe5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1cb1b440-d0fe-45e8-b143-2efb1de2bb75_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_b51b464a-831a-46f0-808e-245db65b8c29_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1ac0e19c-f6c4-4122-a0f7-88239382d8c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_506f7ada-e670-4716-bdd1-8e091d381887_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ExercisePeriodAxis_bcda5e90-f053-4a56-9045-971fb817343a_terseLabel_en-US" xlink:label="lab_xcur_ExercisePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period [Axis]</link:label>
    <link:label id="lab_xcur_ExercisePeriodAxis_label_en-US" xlink:label="lab_xcur_ExercisePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period [Axis]</link:label>
    <link:label id="lab_xcur_ExercisePeriodAxis_documentation_en-US" xlink:label="lab_xcur_ExercisePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodAxis" xlink:href="xcur-20210630.xsd#xcur_ExercisePeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExercisePeriodAxis" xlink:to="lab_xcur_ExercisePeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fffe85f3-1990-44bd-9e55-adecedc24f2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_40fda66d-5440-4725-838c-d2786337bb32_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized, potential maximum additional shares (in shares)</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:href="xcur-20210630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63f08b3a-5a56-4ae6-8d2a-88862a6bc6ba_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5bb1dc1e-8494-4d9b-bfdc-3f5396ae8141_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_33819f9c-41db-4b68-b160-8572f5e76479_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_078b64a7-961c-46f6-8542-7f7eea83578d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f268f863-19ec-44c0-9d31-0548953cd903_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_bc15421c-0236-41c8-bef8-f3f5cdfe1c68_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0e18e2a0-05b6-47ef-aead-fb42f2623c24_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0bf445e6-94c2-42d0-bd6b-195e4886a5d5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_284932dc-b287-4859-9f53-bb67cf67cea2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_COVID19Member_3f305172-b749-45e4-86db-1ada73dbc7ab_terseLabel_en-US" xlink:label="lab_xcur_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_xcur_COVID19Member_label_en-US" xlink:label="lab_xcur_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_xcur_COVID19Member_documentation_en-US" xlink:label="lab_xcur_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_COVID19Member" xlink:href="xcur-20210630.xsd#xcur_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_COVID19Member" xlink:to="lab_xcur_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_94bb3d08-4fd4-4993-8dca-747204f2a2c2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized losses, available for sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_367c3b6c-5178-4d9a-88c2-0021f3b664ff_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c13c4cfe-6d93-4bbc-bde6-f429e5ccef97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_43b397fc-237e-4079-b25f-ae2cb1719d6f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_IpsenCollaborationMember_8800b2cf-2fd1-48a6-a873-eba162588ef8_terseLabel_en-US" xlink:label="lab_xcur_IpsenCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Collaboration</link:label>
    <link:label id="lab_xcur_IpsenCollaborationMember_label_en-US" xlink:label="lab_xcur_IpsenCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Collaboration [Member]</link:label>
    <link:label id="lab_xcur_IpsenCollaborationMember_documentation_en-US" xlink:label="lab_xcur_IpsenCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenCollaborationMember" xlink:href="xcur-20210630.xsd#xcur_IpsenCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_IpsenCollaborationMember" xlink:to="lab_xcur_IpsenCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_72d38b27-d845-430c-ab7f-5b2c653ff2b6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9569f00b-5249-495d-b61a-8641d96e5a51_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_38b426ba-a2fc-4930-8177-e7de4478d862_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_66b4c762-ff55-483f-8c19-2bd3a0cc4cf7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_43967c46-7e2b-421f-a088-5252b795d301_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6b36fa1b-b10b-415d-8587-6daa8a99511a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_WarrantLiabilityMember_298eef0f-ddac-4e3a-bddd-7b62a9c143c1_terseLabel_en-US" xlink:label="lab_xcur_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_xcur_WarrantLiabilityMember_label_en-US" xlink:label="lab_xcur_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:label id="lab_xcur_WarrantLiabilityMember_documentation_en-US" xlink:label="lab_xcur_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_WarrantLiabilityMember" xlink:href="xcur-20210630.xsd#xcur_WarrantLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_WarrantLiabilityMember" xlink:to="lab_xcur_WarrantLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_846c0030-575f-4c67-9923-44173bc4224c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_cdeb51ee-f32d-4776-8014-075406f53bcf_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of underlying common stock (dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2d3683cd-9075-4fcb-8d29-429e340ab9e0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_260b759c-814c-4e4f-9d28-41b60f246a79_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment_cb5e005e-12da-4102-ac1d-f1902e5d054e_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payment amount</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Commercial Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Commercial Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_63ef91c9-64ea-4dc1-a572-c5f07a5c6c2d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_159a5002-6a4b-430e-a30c-05eee68932e0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c0375a4a-f579-4ede-bd3c-f885a6b963f8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock-ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_64aa4d88-f3a2-42e3-9429-54622b0f5d5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_ab525719-a4fd-49ac-9e7a-000cc942a851_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:href="xcur-20210630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_421158e4-1e0b-4a6d-935a-6989393a4ddf_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_85e61743-f88d-4b65-b00a-c1f5dbd092bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6ec872d7-c0b1-49ff-9cf1-b4e6438658d0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_cae009f0-1b57-4fdf-adbe-b34016274339_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_3f00f6b5-f9e1-456c-81dc-e8a8076b365e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoanProcessingFee_cb1d65f4-8697-4003-8048-cffacd0aebf5_terseLabel_en-US" xlink:label="lab_us-gaap_LoanProcessingFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Origination fee</link:label>
    <link:label id="lab_us-gaap_LoanProcessingFee_label_en-US" xlink:label="lab_us-gaap_LoanProcessingFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Processing Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanProcessingFee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoanProcessingFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoanProcessingFee" xlink:to="lab_us-gaap_LoanProcessingFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_cb82ab37-cb08-400e-99b5-a9822e658495_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_e1bd09b7-0f6e-467e-b0ea-0e0dbe48a231_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_a87dd6a2-6489-4cf3-a23d-9ff051d56c8c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1f808f21-84ad-4420-a89b-9336c720b58d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_30187f16-5a79-4881-9333-d835228d0cf3_terseLabel_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year but within two years</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_label_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Noncurrent, Percent</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_documentation_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Noncurrent, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:href="xcur-20210630.xsd#xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:to="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7d659336-3d82-4344-9ec0-ba786b941d08_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_79f6b5c6-8c0e-4573-8804-796a917d9138_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_09cfe3f3-2fd9-477b-b48b-34e20aa84cd2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term borrowing</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_645db286-6a98-4b5c-bada-a264b880762a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9e8db009-3be1-4083-bf7e-21390e8b8c50_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e898e80a-b3ae-44b6-b585-89e2a9231316_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c6b1e20c-45e1-4d91-895b-99b1b02d5e63_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b429d526-75e3-4258-87dc-53f351020cc9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f64ce9d7-26d7-4fbd-8f27-bf40b8b0e30b_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_985e6b03-50a2-46d9-8430-97ffb0b39b47_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f45c23a9-4a6c-4342-b4a3-c174fb65dbf7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_85bbf338-f6e0-4d3c-80fe-f3d6bbfe1895_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate increase</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f1375e11-1d9e-4696-93b6-6733406a48fe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_NumberofCollaborationPrograms_1f11b865-5f0e-440d-b3b4-463f1c40fcaa_terseLabel_en-US" xlink:label="lab_xcur_NumberofCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of collaboration programs</link:label>
    <link:label id="lab_xcur_NumberofCollaborationPrograms_label_en-US" xlink:label="lab_xcur_NumberofCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Collaboration Programs</link:label>
    <link:label id="lab_xcur_NumberofCollaborationPrograms_documentation_en-US" xlink:label="lab_xcur_NumberofCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Collaboration Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_NumberofCollaborationPrograms" xlink:href="xcur-20210630.xsd#xcur_NumberofCollaborationPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_NumberofCollaborationPrograms" xlink:to="lab_xcur_NumberofCollaborationPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4ab64b1f-9a69-4419-bff0-88ec91f7659e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_bf63ffe3-a6ec-4aec-b723-6ec1a7b2c88d_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_bfee7ef8-1809-4a6e-b422-b4ef3450bba7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b5ba7188-174e-44d7-b3d5-5d58bd455ac7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7f89af77-7ab6-46d3-a940-396bf7d557c8_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_db1edd04-f345-4832-a6a4-4fc145e20bd8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment_6f1339fb-4885-417e-aaf3-241d95a2f889_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-clinical milestone payment amount</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Collaboration Agreement, Pre-Clinical Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Collaboration Agreement, Pre-Clinical Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2fd040c4-dde4-45c5-bd8a-2e2c24350308_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_4c242549-97b9-4643-a825-be3ffdbb0772_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_35f72c9c-070d-4ad0-996d-825c33b65458_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term lease costs</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_306e2c8d-76ea-44db-b063-71275d2ba906_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ee2332b9-556e-45d2-89fe-02bf3c639fed_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_f6451a8d-8658-450e-8506-74892009821f_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAbstract_ba9b206d-5668-4cca-a7d4-780272042b68_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3e51f85f-f307-48bb-81ba-543f68c0825a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8ed483f9-c29c-456a-b643-f6a844c86fe1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b7d96ff1-9799-4ec2-b18b-3113de8551de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_0bf9c134-e63f-478c-b939-01a930b7a864_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_e14055c3-7039-4270-860e-075c1f7917a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Compensation Expense Classification in Statement of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cd04022f-8dba-4963-be6a-a86280e8bb0a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6ff69877-0b29-43c6-af28-e594a360d237_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_4570d5dc-c9ce-474c-ab9a-d78a5fd3f584_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a1a7d420-f0d7-4e09-9055-1456508bad97_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_ee7655e0-0fe0-435d-aec0-a29facfcd4ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_2f11493f-9a95-438d-bd5a-f879d31d9b3d_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_73e3acb0-d5e2-4dc9-8f92-8c0a1c330ac6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_a835b295-85be-4c02-b50d-5c2f476e4c1e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP purchase price as a percentage of market price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_bb44b342-8ded-4d77-88fc-705e78cbda15_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1b4abe19-6252-4070-8d8c-37b51929ef12_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ArrangementNameDomain_cd6fc518-3a8a-4f7f-a7d3-0462c7d91010_terseLabel_en-US" xlink:label="lab_xcur_ArrangementNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Domain]</link:label>
    <link:label id="lab_xcur_ArrangementNameDomain_label_en-US" xlink:label="lab_xcur_ArrangementNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Domain]</link:label>
    <link:label id="lab_xcur_ArrangementNameDomain_documentation_en-US" xlink:label="lab_xcur_ArrangementNameDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Arrangement, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ArrangementNameDomain" xlink:to="lab_xcur_ArrangementNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0666303f-3538-492c-baf0-92f3fbd723a4_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Costs</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_ec55c8c2-e6a7-48af-ac8a-2bdd57bc7a47_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3857cd93-7850-47c5-b6ef-dfc60641af49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of loss per common share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a87adc1c-37ec-4d2a-85e9-888e4073a7ec_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40caf5fb-884b-4449-b8cc-32a6d2df5c7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ce716612-1064-433c-86cb-4964dea201f5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_9f7a84c5-0350-4806-95ce-4c6f8df8ed15_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bb6111b0-9b9a-4072-be3e-5d5fdc60eb6f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ecaf1ab7-1d92-4cbc-afa5-2fc5bc4f0b20_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1eac24e6-2b13-4d49-9304-744f6d45f160_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_7273b2af-4be1-47cf-8b13-1cb8ec1e2c47_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseArea_238e84ab-0f80-48f0-9192-f637deae62fe_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease area</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseArea_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Area</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseArea_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseArea" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseLeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseLeaseArea" xlink:to="lab_xcur_LesseeOperatingLeaseLeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal_8c0f3779-08bd-4e9b-bf28-676d3f60f1cf_terseLabel_en-US" xlink:label="lab_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early termination fee</link:label>
    <link:label id="lab_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal_label_en-US" xlink:label="lab_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Early Termination Fee, Percentage of Principal</link:label>
    <link:label id="lab_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal_documentation_en-US" xlink:label="lab_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Early Termination Fee, Percentage of Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" xlink:href="xcur-20210630.xsd#xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" xlink:to="lab_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_56b75b5c-65db-485e-ad38-5fa21ed647fd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_33bd5b63-1e1a-4f3b-952a-f5e917bcd99e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_fe2d4e81-d1a7-41ef-8e90-4a18d42a64b0_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_4574acc8-07c0-4262-8747-25ddf80808a3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4827307f-d2cd-4e60-8128-a40930271345_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_451f2214-bcab-456b-ab56-0b6a6dc3bbd7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_01d274f9-0557-42ef-baa6-cc6341d09cec_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid on debt</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_da5bd9f4-a479-4ad4-aea9-735f384d5de7_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_da5d0aad-5161-45a2-be2c-9bdb1439b165_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c5adbfab-0cc0-4d2c-8fbf-29adf19df62a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_637df9a1-6912-4afe-955d-2fae411c4d6f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2f3a0b5d-f5a7-47c3-8bd5-8a060728d385_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_fcbe5520-f9cf-4145-87a7-6eb754e1fee1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_176e8b7b-0d95-4b3d-87b8-dce7ebccc61c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_acb61041-7016-415a-b033-397b23f0a6f1_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7a7cbac7-1550-4fdf-a0be-b0da71915a75_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e395ab2b-466e-41d8-a18e-4f050bae1fbc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e080e600-09de-4ace-8a0d-a00d3a621a3f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_fc4c1696-ce2e-4f43-956d-f3c55a993e44_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_0f0d318d-ec1c-4919-b8f5-d9e2a1360f87_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_24b38fe7-6753-47c3-8248-b84f77a995e4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b7bf9214-ee0f-4e57-ba27-1df42c4c56f9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_SupplementalBalanceSheetInformationAbstract_2458788d-f37a-41b6-a029-079f0299aff7_terseLabel_en-US" xlink:label="lab_xcur_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_xcur_SupplementalBalanceSheetInformationAbstract_label_en-US" xlink:label="lab_xcur_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_xcur_SupplementalBalanceSheetInformationAbstract_documentation_en-US" xlink:label="lab_xcur_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract" xlink:href="xcur-20210630.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract" xlink:to="lab_xcur_SupplementalBalanceSheetInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_7896b527-13b2-43e0-9aac-dd7f080d47f5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_4985ce10-c14c-4610-be5b-d4b9760e2654_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_cd78fd36-13d6-4ddf-a764-0fb3c3303c99_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7390a4ef-ece6-44e5-aa5d-85ad26cec515_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average basic common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f5a5e08b-4c78-4f44-b848-48e352be76c1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (loss) earnings per common share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_afaf40a9-355b-4f8a-b89b-40e4a61e6804_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) earnings per diluted common share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4d6762ce-81a1-4e7c-ae26-9fac0f4f9114_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_4f5a70c9-fb1d-4621-a272-7a9d981a95d8_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_300f448f-1c5c-4db0-9a67-e0996d8229fa_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized, percentage of common stock outstanding</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:href="xcur-20210630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_9382a355-0b16-4f4e-a75a-0df78f16ced2_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration option exercise fee</link:label>
    <link:label id="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_label_en-US" xlink:label="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Extended Option, Additional Exercise Fee</link:label>
    <link:label id="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Extended Option, Additional Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:to="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_e71c71fa-42e0-40b2-b7a2-7a401766b6b7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_02a5c358-710a-4cc9-88fb-0f49f5c0e68c_terseLabel_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares available for grant (in shares)</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_documentation_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:to="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b725191b-5f47-4b7f-a5ce-89d5b97da787_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_92d341b7-3468-4c70-a17b-1938465a2423_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa63f2ba-450c-444e-a152-b15e1928b9c3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c982216b-f838-4d68-85c5-9d0e2a04af0d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income, net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease_11f7d022-3c83-42f6-8ae4-4bb3c0ef62d3_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent annual percentage increase</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Base Rent Annual Percentage Increase</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Base Rent Annual Percentage Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" xlink:to="lab_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_874c3564-79b5-47c3-bc2b-cbff4c52b184_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_845c582c-3587-427c-bf81-c164197b6ac4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefFinancialOfficerMember_ac1e66da-421b-43fa-ac00-aefb1bd6a632_terseLabel_en-US" xlink:label="lab_srt_ChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Financial Officer</link:label>
    <link:label id="lab_srt_ChiefFinancialOfficerMember_label_en-US" xlink:label="lab_srt_ChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember" xlink:to="lab_srt_ChiefFinancialOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_c4e41ca9-8469-49bc-a0e3-e4fe7b2ff95c_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths_ac96f29a-7dcd-4472-9ad8-6b0f6dd5c0c9_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rent payment initial twelve months</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" xlink:to="lab_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_bcc5c0a4-0063-4307-aeb2-ac1f65040e10_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit Awards Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_c37a9865-db59-42fd-a04b-7a209eda80da_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes/bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_6e342b5d-97d3-4b4b-bb76-4264c54ad8bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_72e0d185-6405-4a91-9af3-6465c513a23a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_14e718c3-99ac-4536-a8b3-329b0b01eb4f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_3f995a9b-e974-445f-a3b2-312bd7465ca6_terseLabel_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period duration</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_eeb6830f-6d87-47bd-84b3-d5bad4e371e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_766d463a-38a0-44f2-ab2a-53276df4e277_terseLabel_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit generated, since inception</link:label>
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_label_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Inception to Date</link:label>
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_documentation_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Inception to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:href="xcur-20210630.xsd#xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:to="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_59292e25-2443-464d-b909-ff08df7fef9e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b95c494d-c3c7-4377-baeb-29ff0d2a4029_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_873b579c-da6d-4697-bdf1-92440196e99d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ca02ed5-31b7-4524-a272-41c04f053ccf_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtSecuritiesAvailableforSalePercent_ffee912f-3d23-4209-8bf9-13f13c6ba2e6_totalLabel_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableforSalePercent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableforSalePercent_label_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableforSalePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available for Sale, Percent</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableforSalePercent_documentation_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableforSalePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available for Sale, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableforSalePercent" xlink:href="xcur-20210630.xsd#xcur_DebtSecuritiesAvailableforSalePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtSecuritiesAvailableforSalePercent" xlink:to="lab_xcur_DebtSecuritiesAvailableforSalePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage_0e7606a0-f480-4121-9824-c7bf7a2f25b0_terseLabel_en-US" xlink:label="lab_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of time that office and general and administrative staff are on site</link:label>
    <link:label id="lab_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage_label_en-US" xlink:label="lab_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And General And Administrative Staff On Site, Percentage</link:label>
    <link:label id="lab_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage_documentation_en-US" xlink:label="lab_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And General And Administrative Staff On Site, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" xlink:href="xcur-20210630.xsd#xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" xlink:to="lab_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_20a6c72c-d4db-4b99-b17a-eebd03f12c7b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ExercisePeriodOneMember_869d94b9-a2c0-43ea-8e70-266f62277763_terseLabel_en-US" xlink:label="lab_xcur_ExercisePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Period after the Selection</link:label>
    <link:label id="lab_xcur_ExercisePeriodOneMember_label_en-US" xlink:label="lab_xcur_ExercisePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period One [Member]</link:label>
    <link:label id="lab_xcur_ExercisePeriodOneMember_documentation_en-US" xlink:label="lab_xcur_ExercisePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodOneMember" xlink:href="xcur-20210630.xsd#xcur_ExercisePeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExercisePeriodOneMember" xlink:to="lab_xcur_ExercisePeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_07ad5f2a-e6d0-4cb4-ab33-b7b206bff981_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product approval and launch milestone payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_a887f3f8-35e2-4677-a5b5-14a751120b93_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ClassofWarrantorRightExpired_f06e6594-83f6-4064-9390-75251f5123c8_terseLabel_en-US" xlink:label="lab_xcur_ClassofWarrantorRightExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expirations (in shares)</link:label>
    <link:label id="lab_xcur_ClassofWarrantorRightExpired_label_en-US" xlink:label="lab_xcur_ClassofWarrantorRightExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:label id="lab_xcur_ClassofWarrantorRightExpired_documentation_en-US" xlink:label="lab_xcur_ClassofWarrantorRightExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ClassofWarrantorRightExpired" xlink:href="xcur-20210630.xsd#xcur_ClassofWarrantorRightExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ClassofWarrantorRightExpired" xlink:to="lab_xcur_ClassofWarrantorRightExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4854ccfe-dc48-4441-afa2-924dc37c55e8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_19a1433a-2468-4fe7-8959-a115d240d17b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_ac9f4324-f89a-490e-bb05-47e71280a319_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ExercisePeriodDomain_04ff9bfe-112a-4445-ba2b-f5a2e80e39fa_terseLabel_en-US" xlink:label="lab_xcur_ExercisePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period [Domain]</link:label>
    <link:label id="lab_xcur_ExercisePeriodDomain_label_en-US" xlink:label="lab_xcur_ExercisePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period [Domain]</link:label>
    <link:label id="lab_xcur_ExercisePeriodDomain_documentation_en-US" xlink:label="lab_xcur_ExercisePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodDomain" xlink:href="xcur-20210630.xsd#xcur_ExercisePeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExercisePeriodDomain" xlink:to="lab_xcur_ExercisePeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22b5db4a-72e6-41b3-b019-048d8562beda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_2f64cc77-01e7-4f76-9c86-dbba577d7038_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e782d0cb-2871-4bf2-ac29-7df74adf44f3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b4edd124-a171-4d73-8fe6-526cad3437b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_0cf43f9c-d4f7-4254-a15a-94abe97eb040_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DevelopmentandCommercializationLicenseMember_abc8b990-8c2c-4c0a-baaa-aaf8e6071d1b_terseLabel_en-US" xlink:label="lab_xcur_DevelopmentandCommercializationLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercialization License</link:label>
    <link:label id="lab_xcur_DevelopmentandCommercializationLicenseMember_label_en-US" xlink:label="lab_xcur_DevelopmentandCommercializationLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercialization License [Member]</link:label>
    <link:label id="lab_xcur_DevelopmentandCommercializationLicenseMember_documentation_en-US" xlink:label="lab_xcur_DevelopmentandCommercializationLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercialization License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DevelopmentandCommercializationLicenseMember" xlink:href="xcur-20210630.xsd#xcur_DevelopmentandCommercializationLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DevelopmentandCommercializationLicenseMember" xlink:to="lab_xcur_DevelopmentandCommercializationLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_a3ef9c4c-4c3c-4573-812b-046dfbfd737f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_86c8e033-7ce3-4bdc-afe7-be84a2f70214_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_dab9f69d-9ff8-4950-b8de-3210399a029e_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_2d573ea6-8e6e-4542-9d70-b8a309082e8b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_08df939a-6b2c-4698-8135-a4763ca48adb_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_74413e4d-2c99-4265-9803-df4bae856011_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ExercisePeriodTwoMember_5e1db429-8d13-406a-891b-ea4440748097_terseLabel_en-US" xlink:label="lab_xcur_ExercisePeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Period that begins after the first Option Exercise Period</link:label>
    <link:label id="lab_xcur_ExercisePeriodTwoMember_label_en-US" xlink:label="lab_xcur_ExercisePeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period Two [Member]</link:label>
    <link:label id="lab_xcur_ExercisePeriodTwoMember_documentation_en-US" xlink:label="lab_xcur_ExercisePeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodTwoMember" xlink:href="xcur-20210630.xsd#xcur_ExercisePeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExercisePeriodTwoMember" xlink:to="lab_xcur_ExercisePeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_979bb61b-4238-4134-8327-480741852517_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_96ef49d6-a724-47ae-8692-2d2e3ec5137a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_88302ebf-784f-45db-9aa1-aa33661338ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_51ae0df9-80c1-4c08-b3f4-92d3ad4f70a9_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e21386d2-4279-4998-b830-7785e14e3838_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_2e13c8df-5807-4ebd-be39-249445cc6e1e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ae194aa4-1d79-40ec-8f69-752ff913cc2f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_2f26ed92-2269-4d1b-b7ff-c9522432c394_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_755344db-ba92-49be-a210-b6a062986570_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_4110f171-1337-44cf-bc28-078755023e4a_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ef6dbc84-acc2-4d50-ba91-15a88a54865b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_490e7c68-6d01-4d52-acdd-253fffb51c32_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtInstrumentExitFeePercentage_78e5b19b-7145-46de-b751-54daa65fa60d_terseLabel_en-US" xlink:label="lab_xcur_DebtInstrumentExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee percentage</link:label>
    <link:label id="lab_xcur_DebtInstrumentExitFeePercentage_label_en-US" xlink:label="lab_xcur_DebtInstrumentExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exit Fee, Percentage</link:label>
    <link:label id="lab_xcur_DebtInstrumentExitFeePercentage_documentation_en-US" xlink:label="lab_xcur_DebtInstrumentExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exit Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentExitFeePercentage" xlink:href="xcur-20210630.xsd#xcur_DebtInstrumentExitFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtInstrumentExitFeePercentage" xlink:to="lab_xcur_DebtInstrumentExitFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_01fc0889-dbb4-43ff-aa53-7d6eb4f538a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_02eb467f-0aad-438b-88df-ace56890b640_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_7fc4388d-49fd-4068-9909-75c8de8a13c8_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_681b05e3-669c-4f4f-b3ce-36bac6bde4c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_53202cc6-97a4-4095-a6aa-f4fb922875b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e85e6ae3-8406-4e55-ad7e-cf3229bad0ca_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_2dc1c15d-2324-47f5-b4c8-a246bb2a58b7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_227ff915-6347-43a8-8275-f069b1c7a028_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8af1c9e8-ed98-4e98-8a97-e278d4613d6c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_4675c18b-e974-4251-bef0-d97dc6b9f24f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of common stock option (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_951c30f3-16d7-49b1-b7bf-09cfc8623249_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ComputersandSoftwareMember_33332b13-04c0-4a59-807e-709cff8a87ce_terseLabel_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and software</link:label>
    <link:label id="lab_xcur_ComputersandSoftwareMember_label_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and Software [Member]</link:label>
    <link:label id="lab_xcur_ComputersandSoftwareMember_documentation_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ComputersandSoftwareMember" xlink:href="xcur-20210630.xsd#xcur_ComputersandSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ComputersandSoftwareMember" xlink:to="lab_xcur_ComputersandSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_e83ee54b-9254-4ae8-bd9c-1b180f3a8b0e_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c1259e08-c92b-4ced-8c9d-6df73539e2d9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementOptionExerciseFee_16b6f3ce-b962-43b4-8422-cc0b5bfc2dac_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration option exercise fee</link:label>
    <link:label id="lab_xcur_CollaborationAgreementOptionExerciseFee_label_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option, Exercise Fee</link:label>
    <link:label id="lab_xcur_CollaborationAgreementOptionExerciseFee_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option, Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionExerciseFee" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementOptionExerciseFee" xlink:to="lab_xcur_CollaborationAgreementOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1a3d2436-f8e5-47d7-96ea-6fbc784878cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c64d1875-0f16-4f11-9672-d5db3763d351_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e5cd6a22-7271-49f8-8120-9d9037c22ccc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_40290d3f-e2cf-4281-bef8-4dc46c824308_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure_ebbc084b-7cb3-4f31-9ae3-9453b178fc8d_terseLabel_en-US" xlink:label="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant Liability, Fair Value Disclosure</link:label>
    <link:label id="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure_documentation_en-US" xlink:label="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:href="xcur-20210630.xsd#xcur_CommonStockWarrantLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:to="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6ab7a244-3217-445b-9fcc-40d1d2651b37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_22092f66-284e-46cf-b276-51f5d29a57b7_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination period upon written notice</link:label>
    <link:label id="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_label_en-US" xlink:label="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Termination Period Upon Written Notice</link:label>
    <link:label id="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Termination Period Upon Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:to="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_9933a618-cadd-4e6a-8fdb-f549c3b7cc74_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of long-term debt issuance costs and fees</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2d504545-62e8-4af7-9329-5b5a7be80a38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_5363d87a-d597-44e9-bf16-6dfaba7604e4_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c92de4f9-2df4-4269-88f3-35fd05d04b35_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash - beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8c998f21-3232-494c-aba2-97b8bb1438d7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash - end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c781a965-7d7c-460c-8f08-3fb5d0c6683b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_dfecb54a-adbf-47e4-abfb-6263dbffaa7a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_b87805be-66fd-4f3b-a94c-433a7fa4ad74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b53c556a-836e-43f3-a574-2bbb3e0ebb49_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e0f6d7ed-44b5-42be-abde-b46727086ef6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_ec3a9f6b-4233-4eeb-b82e-abd0c1e5e1e5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to first anniversary</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_618e5126-5a6b-4d08-b113-9de0c97dc0e9_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6e19ce44-2131-499a-b32e-c17458cbf6b3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock_ecdd38d7-dc7a-4e79-964d-71e8c0da8d69_terseLabel_en-US" xlink:label="lab_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leases, Additional Information</link:label>
    <link:label id="lab_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock_label_en-US" xlink:label="lab_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leases, Additional Information [Table Text Block]</link:label>
    <link:label id="lab_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock_documentation_en-US" xlink:label="lab_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leases, Additional Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" xlink:href="xcur-20210630.xsd#xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" xlink:to="lab_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b7312f9c-5df9-4fc4-94f3-1c7b2e7283d1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_38b6105e-be14-4439-a40d-515b75b8d89b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c42728be-27c0-491d-bf3b-5d98d8302cda_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c4b3aa3f-6bc7-41b0-a13c-59fc5ced020b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net losses (gains) reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9bd56dc9-20ba-4da6-a3a7-1ddffbd4615e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e0040dab-e6e0-4238-b855-b41e7f90ae11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_098f9351-00d9-4c17-ac1a-14b7a121fb5c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_fd8d153c-e131-4c1e-8043-12c2319fce54_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_edc5882a-9be3-4f31-9faa-b63b073a2625_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7739a046-077e-4585-9b43-7a1e3db34cff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_7c45bc54-2a34-4066-b5e7-627a95e0ed66_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_d52e51eb-81b3-4fc4-9edc-dd9b7520b6eb_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_db69d218-4949-47ca-bed6-aed95e119f81_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_645aebdc-2a8a-4a2e-96d1-d8a5fb285b21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8ab2d5c4-2526-4372-a703-df5eb9c82161_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_be65c2d2-a962-4f68-b904-ddf57585460f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_7a477a6e-aec5-4520-a49f-68dcc93053b8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f84735c3-c724-4b22-951c-e563e553a6ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_36d67060-757d-432a-b188-a2d79432ac4b_terseLabel_en-US" xlink:label="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical, contract research and manufacturing costs</link:label>
    <link:label id="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_label_en-US" xlink:label="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical, Contract Research And Manufacturing Costs, Current</link:label>
    <link:label id="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_documentation_en-US" xlink:label="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical, Contract Research And Manufacturing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:href="xcur-20210630.xsd#xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:to="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_e61cc801-3c24-4779-86fe-a6d36f8ef4e2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_9de20647-0427-4820-88c8-3c31b8062a6f_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_a84ee6a5-d7f5-4462-a2d2-c74cdcd879e5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DermelixLicenseAgreementMember_5d093b99-7042-4614-9a75-edef3bfc2dcb_terseLabel_en-US" xlink:label="lab_xcur_DermelixLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermelix License Agreement</link:label>
    <link:label id="lab_xcur_DermelixLicenseAgreementMember_label_en-US" xlink:label="lab_xcur_DermelixLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermelix License Agreement [Member]</link:label>
    <link:label id="lab_xcur_DermelixLicenseAgreementMember_documentation_en-US" xlink:label="lab_xcur_DermelixLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermelix License Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DermelixLicenseAgreementMember" xlink:href="xcur-20210630.xsd#xcur_DermelixLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DermelixLicenseAgreementMember" xlink:to="lab_xcur_DermelixLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_04e5d5bd-b722-4218-8533-4f00cb7df858_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ca22391-4157-4170-927f-69ec5d4cfe7c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6a40681-5b62-4b8e-a411-b36eecf999c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4c42d75a-57d8-449d-a17d-a0c507d6e1f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e209f1bc-25f4-47b1-b759-f7c4b62585a9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock-ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_MidCapCreditAgreementTranche1Member_71785967-599a-4231-a293-cc3fb91a0d2e_terseLabel_en-US" xlink:label="lab_xcur_MidCapCreditAgreementTranche1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement - Tranche 1</link:label>
    <link:label id="lab_xcur_MidCapCreditAgreementTranche1Member_label_en-US" xlink:label="lab_xcur_MidCapCreditAgreementTranche1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement - Tranche 1 [Member]</link:label>
    <link:label id="lab_xcur_MidCapCreditAgreementTranche1Member_documentation_en-US" xlink:label="lab_xcur_MidCapCreditAgreementTranche1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement - Tranche 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementTranche1Member" xlink:href="xcur-20210630.xsd#xcur_MidCapCreditAgreementTranche1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_MidCapCreditAgreementTranche1Member" xlink:to="lab_xcur_MidCapCreditAgreementTranche1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_f320b34d-e56e-4059-bf59-272902e08243_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_80e35f14-8e34-4f0d-9266-dd79a675584d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_5ec86a7e-94f7-4e41-aec5-818f2f328a9d_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_d2e1fece-cb3e-48be-9f3d-961f908b0edd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_4f597970-050a-421f-b507-b093c7659898_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9319da9a-1686-4251-b4bb-7f83b48394f8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_63293078-f55a-42cb-a9fe-f7987a4a9206_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_63999f07-7179-4db2-b6c4-58e85d5c808a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_6ccc9b6b-3ccb-44f7-9bad-6824510fbf34_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ConsultingServicesMember_7953d9cf-5142-4d47-88fc-19789ec41cf4_terseLabel_en-US" xlink:label="lab_xcur_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting services</link:label>
    <link:label id="lab_xcur_ConsultingServicesMember_label_en-US" xlink:label="lab_xcur_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:label id="lab_xcur_ConsultingServicesMember_documentation_en-US" xlink:label="lab_xcur_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ConsultingServicesMember" xlink:href="xcur-20210630.xsd#xcur_ConsultingServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ConsultingServicesMember" xlink:to="lab_xcur_ConsultingServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_0a65f735-4a05-4f10-8c4b-4526c70cd733_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ee2e478e-5643-4507-999f-18658cfaf780_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3eef3d2e-d35a-4b4f-8142-2a9f5e9e4c8c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_5dff5d94-dfcf-4f7c-9049-ff47add3c125_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding shares allowable as annual increase</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ba320afb-7f25-4e7b-9f49-d38b0fc8a9b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less: unamortized discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments_22a309dd-61f7-42d2-9185-c2b2dacf2f4c_terseLabel_en-US" xlink:label="lab_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of monthly installment payments</link:label>
    <link:label id="lab_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments_label_en-US" xlink:label="lab_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Principal Payment, Number of Monthly Installment Payments</link:label>
    <link:label id="lab_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments_documentation_en-US" xlink:label="lab_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Principal Payment, Number of Monthly Installment Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" xlink:href="xcur-20210630.xsd#xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" xlink:to="lab_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_37350af3-12f2-45aa-9fb9-e4d6c8cbb878_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f8ae9298-a9ab-4c11-97b6-0ac56658020c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_5949c34b-8e47-46fd-a80f-99615cedbc70_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8808f880-de8e-49d6-b77f-5b360b3800f5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_af9ea75b-41b3-4ecd-83fe-2fe6d77b0dcb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1230236d-9881-484e-8ae0-6f246594984f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_MidCapCreditAgreementTranche2Member_5c074c32-261b-4138-adca-6a13f4e59e54_terseLabel_en-US" xlink:label="lab_xcur_MidCapCreditAgreementTranche2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement - Tranche 2</link:label>
    <link:label id="lab_xcur_MidCapCreditAgreementTranche2Member_label_en-US" xlink:label="lab_xcur_MidCapCreditAgreementTranche2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement - Tranche 2 [Member]</link:label>
    <link:label id="lab_xcur_MidCapCreditAgreementTranche2Member_documentation_en-US" xlink:label="lab_xcur_MidCapCreditAgreementTranche2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement - Tranche 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementTranche2Member" xlink:href="xcur-20210630.xsd#xcur_MidCapCreditAgreementTranche2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_MidCapCreditAgreementTranche2Member" xlink:to="lab_xcur_MidCapCreditAgreementTranche2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_6f2e7fd1-7593-48fd-91fc-650e798fcf44_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTableTextBlock" xlink:to="lab_us-gaap_InvestmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a1689d1d-c9c8-4c81-88c1-7af64d262380_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_025ebc0f-7570-470f-81f0-448514041add_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8ce51a18-013c-496d-b0be-695443d66f73_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_9b822b4a-e97a-4891-b899-4e1fe9f8ff0f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0ba02917-4182-400a-85c8-96bc6ecd4f78_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_26b4d5a1-4ec2-46fa-9222-28434a9510e4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_a566039f-abea-4d1c-9af1-c441c4259533_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_bf7fcf79-b5d3-467e-b373-977293747a44_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_2828241e-21fe-4d85-a513-e2dbe748eb40_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_89a6cc59-9089-44d9-bd9f-c77f1f16d35a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6c73a8ef-5858-4f3b-bd42-991d0f4a9eb1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_43f55e83-83c5-4b8d-aa5d-ddb4919c5a2d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_b78447b0-c222-4047-a476-ddc67064c6c3_terseLabel_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan</link:label>
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_label_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:href="xcur-20210630.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:to="lab_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_4bfdcfb5-396e-4ef5-a571-47a269c9c64c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_fa5efb69-1162-40b6-a055-10d20e116d0e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7017ecad-4552-4902-aaf4-0e4dda611568_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>xcur-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:5b54f0ec-bf0b-4618-8722-18f79640ae79,g:5933f058-0750-4e2c-9852-92fa9631b69d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exicuretx.com/role/CoverPage" xlink:type="simple" xlink:href="xcur-20210630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ad785125-4af2-4018-aae9-bc5e8db44ad5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_DocumentType_ad785125-4af2-4018-aae9-bc5e8db44ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0470ade9-7e23-449a-b05c-58b301bdf72a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_DocumentQuarterlyReport_0470ade9-7e23-449a-b05c-58b301bdf72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_00f92a9e-b7b6-4bef-804e-274948763862" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_DocumentPeriodEndDate_00f92a9e-b7b6-4bef-804e-274948763862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_52f3adfe-db9f-4948-a320-ebc9a161c497" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_DocumentTransitionReport_52f3adfe-db9f-4948-a320-ebc9a161c497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f563b430-dfd3-43fe-8b79-5f6f56c812d3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityFileNumber_f563b430-dfd3-43fe-8b79-5f6f56c812d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5928186d-cba9-46c3-8ddd-84e40de05c79" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityRegistrantName_5928186d-cba9-46c3-8ddd-84e40de05c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5f6769a0-da38-4037-a92d-48df8aab89da" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5f6769a0-da38-4037-a92d-48df8aab89da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_82572461-cbbf-4652-a7a1-e2500cfca034" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityTaxIdentificationNumber_82572461-cbbf-4652-a7a1-e2500cfca034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_eb303d24-02d7-4166-9bde-2fe0bc2f7461" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityAddressAddressLine1_eb303d24-02d7-4166-9bde-2fe0bc2f7461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_60aa4989-51ab-4416-81fa-5e1b9b040431" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityAddressCityOrTown_60aa4989-51ab-4416-81fa-5e1b9b040431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_709deec5-8b64-49bb-98b3-316b364ab61b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityAddressStateOrProvince_709deec5-8b64-49bb-98b3-316b364ab61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9903973b-bcc2-4483-8f2a-e33fbf9c4305" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityAddressPostalZipCode_9903973b-bcc2-4483-8f2a-e33fbf9c4305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_92db91e9-2143-46e9-a016-c6614d55e7ba" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_CityAreaCode_92db91e9-2143-46e9-a016-c6614d55e7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_123e62c6-1940-4481-86d1-5e39aee37321" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_LocalPhoneNumber_123e62c6-1940-4481-86d1-5e39aee37321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cf38cdda-9d67-408c-99fa-e5c5c71343dc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_Security12bTitle_cf38cdda-9d67-408c-99fa-e5c5c71343dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_62f865f9-3212-4846-b83b-4285801633c2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_TradingSymbol_62f865f9-3212-4846-b83b-4285801633c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_bbd1b236-386d-4f7d-97c7-283363f14023" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_SecurityExchangeName_bbd1b236-386d-4f7d-97c7-283363f14023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c6b90216-18cc-4d67-926e-9de142d20d4a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityCurrentReportingStatus_c6b90216-18cc-4d67-926e-9de142d20d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_dc290935-441d-4ed7-bf9b-32a59c58da8b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityInteractiveDataCurrent_dc290935-441d-4ed7-bf9b-32a59c58da8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3f82db5d-b272-4a38-91a1-001bd9795551" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityFilerCategory_3f82db5d-b272-4a38-91a1-001bd9795551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e1ad1848-7fba-4907-8a25-5dfc889d4288" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntitySmallBusiness_e1ad1848-7fba-4907-8a25-5dfc889d4288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9a5f049d-0080-425f-96aa-caccf40677ad" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityEmergingGrowthCompany_9a5f049d-0080-425f-96aa-caccf40677ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_b0bfb358-3406-4550-b09a-4904d932f7e6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityExTransitionPeriod_b0bfb358-3406-4550-b09a-4904d932f7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b2487bb9-15ce-4a6a-a2dd-7598c6ec9704" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityShellCompany_b2487bb9-15ce-4a6a-a2dd-7598c6ec9704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d70e0703-61d3-4142-9969-84904196caf9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d70e0703-61d3-4142-9969-84904196caf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d3fa1a66-d648-4dd0-9396-2b9e2905b53a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_EntityCentralIndexKey_d3fa1a66-d648-4dd0-9396-2b9e2905b53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ed65f468-2855-4c03-a4f9-2819d576dc28" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_CurrentFiscalYearEndDate_ed65f468-2855-4c03-a4f9-2819d576dc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0eee5d37-1519-4d52-bf90-ccfdfeae7326" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_DocumentFiscalYearFocus_0eee5d37-1519-4d52-bf90-ccfdfeae7326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1eee289a-5fed-4cea-95ef-a2cb2f31fd41" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1eee289a-5fed-4cea-95ef-a2cb2f31fd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_cf271d1a-bf0b-432f-a6e8-2966d2e1aca4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2cf65f8-87c1-44d0-a083-1614623f5b6b" xlink:to="loc_dei_AmendmentFlag_cf271d1a-bf0b-432f-a6e8-2966d2e1aca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="xcur-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_adedd46c-15ce-4299-943c-38edbd40d301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a5ed555f-5db1-443d-8a5e-9774944b0a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adedd46c-15ce-4299-943c-38edbd40d301" xlink:to="loc_us-gaap_AssetsAbstract_a5ed555f-5db1-443d-8a5e-9774944b0a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1fb30a86-f167-4c74-8e0f-64736a9a29fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a5ed555f-5db1-443d-8a5e-9774944b0a87" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1fb30a86-f167-4c74-8e0f-64736a9a29fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4f0647a5-28c7-4a19-b55a-8dabd20153ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fb30a86-f167-4c74-8e0f-64736a9a29fa" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4f0647a5-28c7-4a19-b55a-8dabd20153ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_d004457f-5f00-4cac-8c2a-887984d2dab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fb30a86-f167-4c74-8e0f-64736a9a29fa" xlink:to="loc_us-gaap_ShortTermInvestments_d004457f-5f00-4cac-8c2a-887984d2dab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8d423e5e-ed6b-4e68-a3cf-4e0f038fee74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fb30a86-f167-4c74-8e0f-64736a9a29fa" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8d423e5e-ed6b-4e68-a3cf-4e0f038fee74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_67052d28-ff1c-4b15-9344-b4dfce655b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fb30a86-f167-4c74-8e0f-64736a9a29fa" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_67052d28-ff1c-4b15-9344-b4dfce655b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a6fe36c4-8e1b-46fe-b9b3-df23069e93a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fb30a86-f167-4c74-8e0f-64736a9a29fa" xlink:to="loc_us-gaap_AssetsCurrent_a6fe36c4-8e1b-46fe-b9b3-df23069e93a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ce0382a6-8e44-491a-b801-08ef4ff0e3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a5ed555f-5db1-443d-8a5e-9774944b0a87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ce0382a6-8e44-491a-b801-08ef4ff0e3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b82ad17a-60ca-48eb-9713-64d06a39940e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a5ed555f-5db1-443d-8a5e-9774944b0a87" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b82ad17a-60ca-48eb-9713-64d06a39940e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e0837236-19ed-4f7b-ae54-8ac9d54fe62e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a5ed555f-5db1-443d-8a5e-9774944b0a87" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e0837236-19ed-4f7b-ae54-8ac9d54fe62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f44ce427-0989-491a-8fb5-812cfa18788d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a5ed555f-5db1-443d-8a5e-9774944b0a87" xlink:to="loc_us-gaap_Assets_f44ce427-0989-491a-8fb5-812cfa18788d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ee6f8315-83aa-471d-a043-343cfa4f8edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adedd46c-15ce-4299-943c-38edbd40d301" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ee6f8315-83aa-471d-a043-343cfa4f8edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_22c6c78c-c955-4e2b-bc06-a05b7b5d0d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ee6f8315-83aa-471d-a043-343cfa4f8edf" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_22c6c78c-c955-4e2b-bc06-a05b7b5d0d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_634f7502-27af-4ca2-9d2d-3e62d9fb8df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22c6c78c-c955-4e2b-bc06-a05b7b5d0d31" xlink:to="loc_us-gaap_AccountsPayableCurrent_634f7502-27af-4ca2-9d2d-3e62d9fb8df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bf261e26-c530-413c-8a36-6b2b0524101d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22c6c78c-c955-4e2b-bc06-a05b7b5d0d31" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bf261e26-c530-413c-8a36-6b2b0524101d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1eaa302c-f2bc-434f-96f7-cda93e1c95d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22c6c78c-c955-4e2b-bc06-a05b7b5d0d31" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1eaa302c-f2bc-434f-96f7-cda93e1c95d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_07ef6834-443a-4432-9d96-5aefb180cfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22c6c78c-c955-4e2b-bc06-a05b7b5d0d31" xlink:to="loc_us-gaap_LiabilitiesCurrent_07ef6834-443a-4432-9d96-5aefb180cfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_70888ab7-dfbe-4c01-abd2-f4616b88949c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ee6f8315-83aa-471d-a043-343cfa4f8edf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_70888ab7-dfbe-4c01-abd2-f4616b88949c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_223f19f0-feba-4c7f-b25d-e5a324f26e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ee6f8315-83aa-471d-a043-343cfa4f8edf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_223f19f0-feba-4c7f-b25d-e5a324f26e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ccc7e740-4fe5-4359-bed3-ef8908e974d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ee6f8315-83aa-471d-a043-343cfa4f8edf" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ccc7e740-4fe5-4359-bed3-ef8908e974d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f43be9ea-03da-4b32-92b6-ea1b87c0fd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ee6f8315-83aa-471d-a043-343cfa4f8edf" xlink:to="loc_us-gaap_Liabilities_f43be9ea-03da-4b32-92b6-ea1b87c0fd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_bdb9a29a-da39-41bd-8198-b8c3be94f6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ee6f8315-83aa-471d-a043-343cfa4f8edf" xlink:to="loc_us-gaap_StockholdersEquityAbstract_bdb9a29a-da39-41bd-8198-b8c3be94f6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_092f5f91-2daf-4046-b73b-31d006589071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bdb9a29a-da39-41bd-8198-b8c3be94f6ad" xlink:to="loc_us-gaap_PreferredStockValue_092f5f91-2daf-4046-b73b-31d006589071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_89388a89-559e-4de0-a0c6-ca3e999c4784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bdb9a29a-da39-41bd-8198-b8c3be94f6ad" xlink:to="loc_us-gaap_CommonStockValue_89388a89-559e-4de0-a0c6-ca3e999c4784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9fbbc5b4-6595-4b66-aa3b-c069c765f223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bdb9a29a-da39-41bd-8198-b8c3be94f6ad" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9fbbc5b4-6595-4b66-aa3b-c069c765f223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2d8754da-6e31-44a6-89d8-3224a40f79a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bdb9a29a-da39-41bd-8198-b8c3be94f6ad" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2d8754da-6e31-44a6-89d8-3224a40f79a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_03b0ec5b-2ca3-4c14-9029-876c3bc44e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bdb9a29a-da39-41bd-8198-b8c3be94f6ad" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_03b0ec5b-2ca3-4c14-9029-876c3bc44e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ff63446-0a5b-4d6d-9243-ab7be7989024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bdb9a29a-da39-41bd-8198-b8c3be94f6ad" xlink:to="loc_us-gaap_StockholdersEquity_5ff63446-0a5b-4d6d-9243-ab7be7989024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c66a1e96-0f60-441f-bf86-e2d16ad421da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ee6f8315-83aa-471d-a043-343cfa4f8edf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c66a1e96-0f60-441f-bf86-e2d16ad421da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="xcur-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fd1c82e2-9934-4615-bc54-4c97cc312421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_adc022f7-0eb8-4538-bb41-408afc171b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd1c82e2-9934-4615-bc54-4c97cc312421" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_adc022f7-0eb8-4538-bb41-408afc171b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0ecb9543-54e2-433b-acad-a9985c465bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd1c82e2-9934-4615-bc54-4c97cc312421" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0ecb9543-54e2-433b-acad-a9985c465bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_56f03c64-4165-405c-8d94-2e787b755832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd1c82e2-9934-4615-bc54-4c97cc312421" xlink:to="loc_us-gaap_PreferredStockSharesIssued_56f03c64-4165-405c-8d94-2e787b755832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_b8626c61-64cb-4d7b-856a-b35c02416165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd1c82e2-9934-4615-bc54-4c97cc312421" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_b8626c61-64cb-4d7b-856a-b35c02416165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_69f0dfd3-c652-437c-83b5-876a5c281137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd1c82e2-9934-4615-bc54-4c97cc312421" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_69f0dfd3-c652-437c-83b5-876a5c281137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0aab331a-f115-4882-8040-86d960f91ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd1c82e2-9934-4615-bc54-4c97cc312421" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0aab331a-f115-4882-8040-86d960f91ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4ba740fc-29a7-4c6a-a31e-e53dd4c4ceb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd1c82e2-9934-4615-bc54-4c97cc312421" xlink:to="loc_us-gaap_CommonStockSharesIssued_4ba740fc-29a7-4c6a-a31e-e53dd4c4ceb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_81ac4235-618d-46bf-a379-6b483484ab8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd1c82e2-9934-4615-bc54-4c97cc312421" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_81ac4235-618d-46bf-a379-6b483484ab8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="xcur-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_71519e5e-730d-4759-a522-c3f6e91a4ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_96b1c544-5139-4f48-879a-e9a3d08585e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71519e5e-730d-4759-a522-c3f6e91a4ea4" xlink:to="loc_us-gaap_RevenuesAbstract_96b1c544-5139-4f48-879a-e9a3d08585e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9fc0541b-df3c-4241-9dcb-07f5dc229614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_96b1c544-5139-4f48-879a-e9a3d08585e0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9fc0541b-df3c-4241-9dcb-07f5dc229614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7907c3b2-dd78-48c0-a349-d06533cad541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_96b1c544-5139-4f48-879a-e9a3d08585e0" xlink:to="loc_us-gaap_Revenues_7907c3b2-dd78-48c0-a349-d06533cad541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_cd2bc259-81d4-4a32-9fce-65a23e9ad25e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71519e5e-730d-4759-a522-c3f6e91a4ea4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_cd2bc259-81d4-4a32-9fce-65a23e9ad25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cb5c223a-cff8-46ab-8f8d-7de2c6cc6bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cd2bc259-81d4-4a32-9fce-65a23e9ad25e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cb5c223a-cff8-46ab-8f8d-7de2c6cc6bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7fd90a36-7e3e-4230-a436-bea15e066719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cd2bc259-81d4-4a32-9fce-65a23e9ad25e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7fd90a36-7e3e-4230-a436-bea15e066719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a6b02f22-7e22-42c4-a628-fd946e3f096e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cd2bc259-81d4-4a32-9fce-65a23e9ad25e" xlink:to="loc_us-gaap_OperatingExpenses_a6b02f22-7e22-42c4-a628-fd946e3f096e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5f7f117e-8e3a-4143-9d28-51a5a5194825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71519e5e-730d-4759-a522-c3f6e91a4ea4" xlink:to="loc_us-gaap_OperatingIncomeLoss_5f7f117e-8e3a-4143-9d28-51a5a5194825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2ee6ccee-cade-4b8a-a87f-d47c5b58abe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71519e5e-730d-4759-a522-c3f6e91a4ea4" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2ee6ccee-cade-4b8a-a87f-d47c5b58abe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend_926797b9-9475-4ecc-a066-46527ffa75c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2ee6ccee-cade-4b8a-a87f-d47c5b58abe0" xlink:to="loc_us-gaap_InvestmentIncomeDividend_926797b9-9475-4ecc-a066-46527ffa75c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5e3d6f25-c0c0-40c1-87cf-8f5d316473e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2ee6ccee-cade-4b8a-a87f-d47c5b58abe0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5e3d6f25-c0c0-40c1-87cf-8f5d316473e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0a4c2354-e0ce-47d7-b546-ee6764ab162c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2ee6ccee-cade-4b8a-a87f-d47c5b58abe0" xlink:to="loc_us-gaap_InterestExpense_0a4c2354-e0ce-47d7-b546-ee6764ab162c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a6b25dc2-2928-4510-956f-11ddbd414230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2ee6ccee-cade-4b8a-a87f-d47c5b58abe0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a6b25dc2-2928-4510-956f-11ddbd414230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_080b9aa4-07fd-4bfd-9956-1931103170a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2ee6ccee-cade-4b8a-a87f-d47c5b58abe0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_080b9aa4-07fd-4bfd-9956-1931103170a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_aeb93d6d-0c86-4fb2-8366-e814fc8037fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71519e5e-730d-4759-a522-c3f6e91a4ea4" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_aeb93d6d-0c86-4fb2-8366-e814fc8037fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1096ada4-5f47-4151-a3bc-6312354e189b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71519e5e-730d-4759-a522-c3f6e91a4ea4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1096ada4-5f47-4151-a3bc-6312354e189b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_230e37f0-94a8-4c3c-b59f-be6a78f8843b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71519e5e-730d-4759-a522-c3f6e91a4ea4" xlink:to="loc_us-gaap_NetIncomeLoss_230e37f0-94a8-4c3c-b59f-be6a78f8843b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_622863ba-2ccc-40bc-b1be-31078d99d86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71519e5e-730d-4759-a522-c3f6e91a4ea4" xlink:to="loc_us-gaap_EarningsPerShareBasic_622863ba-2ccc-40bc-b1be-31078d99d86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_29ea412f-846b-4ce9-87be-6aaa22d33f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71519e5e-730d-4759-a522-c3f6e91a4ea4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_29ea412f-846b-4ce9-87be-6aaa22d33f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d21562dc-ce4b-446d-b2be-6597c94ed276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71519e5e-730d-4759-a522-c3f6e91a4ea4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d21562dc-ce4b-446d-b2be-6597c94ed276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae5e01e3-f92a-4306-beff-484b217298f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_71519e5e-730d-4759-a522-c3f6e91a4ea4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae5e01e3-f92a-4306-beff-484b217298f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="xcur-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3eb866c3-e45f-4d79-acf5-cba1171b2b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8c0bfefe-f3e4-460e-b395-f2744839ced1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3eb866c3-e45f-4d79-acf5-cba1171b2b48" xlink:to="loc_us-gaap_NetIncomeLoss_8c0bfefe-f3e4-460e-b395-f2744839ced1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_722e2511-99b4-4675-b931-94a9f016679b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3eb866c3-e45f-4d79-acf5-cba1171b2b48" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_722e2511-99b4-4675-b931-94a9f016679b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b1e288ca-5290-40a8-b079-bd8136e2a1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_722e2511-99b4-4675-b931-94a9f016679b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b1e288ca-5290-40a8-b079-bd8136e2a1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_91636990-efe6-41b2-a32d-7255fb361fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_722e2511-99b4-4675-b931-94a9f016679b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_91636990-efe6-41b2-a32d-7255fb361fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7f12fdbc-a607-4c49-8468-98ada5d6d70e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3eb866c3-e45f-4d79-acf5-cba1171b2b48" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7f12fdbc-a607-4c49-8468-98ada5d6d70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="xcur-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8272a262-9075-46ad-9b1b-556243029d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_63308901-5d74-4926-9259-6fc1b0d570af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8272a262-9075-46ad-9b1b-556243029d3f" xlink:to="loc_us-gaap_StatementTable_63308901-5d74-4926-9259-6fc1b0d570af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4208b4e4-1534-49a9-acee-466df0836570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_63308901-5d74-4926-9259-6fc1b0d570af" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4208b4e4-1534-49a9-acee-466df0836570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a51cdcff-2670-416d-a3bf-bbc3ea72fdff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4208b4e4-1534-49a9-acee-466df0836570" xlink:to="loc_us-gaap_EquityComponentDomain_a51cdcff-2670-416d-a3bf-bbc3ea72fdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e312ebc9-0fd8-4818-b23e-88baae9f2f30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a51cdcff-2670-416d-a3bf-bbc3ea72fdff" xlink:to="loc_us-gaap_CommonStockMember_e312ebc9-0fd8-4818-b23e-88baae9f2f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a7b90645-19b1-476f-8953-0d5e48c32bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a51cdcff-2670-416d-a3bf-bbc3ea72fdff" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a7b90645-19b1-476f-8953-0d5e48c32bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_18049c94-e330-4dc3-872b-6e16501704f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a51cdcff-2670-416d-a3bf-bbc3ea72fdff" xlink:to="loc_us-gaap_RetainedEarningsMember_18049c94-e330-4dc3-872b-6e16501704f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8ce137bd-93f9-431e-b377-55b935fe72da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a51cdcff-2670-416d-a3bf-bbc3ea72fdff" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8ce137bd-93f9-431e-b377-55b935fe72da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e94d3acf-aae5-4ce9-9b73-ebbbe1ccd8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_63308901-5d74-4926-9259-6fc1b0d570af" xlink:to="loc_us-gaap_StatementLineItems_e94d3acf-aae5-4ce9-9b73-ebbbe1ccd8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e94d3acf-aae5-4ce9-9b73-ebbbe1ccd8a7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b66dc236-0425-451f-a33d-d3d2fb50f7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_SharesOutstanding_b66dc236-0425-451f-a33d-d3d2fb50f7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7b7c3e10-38ec-42f4-91ab-7e1e2141cb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockholdersEquity_7b7c3e10-38ec-42f4-91ab-7e1e2141cb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_058a7cde-3611-424e-b7b7-1f854d00bd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_058a7cde-3611-424e-b7b7-1f854d00bd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1d449347-e595-457e-a5d2-df4521998ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1d449347-e595-457e-a5d2-df4521998ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_25953800-987d-4c1a-8c66-9fc3e986ff71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_25953800-987d-4c1a-8c66-9fc3e986ff71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d7a5f866-9f82-4a37-9aa4-ca1e4e7bf493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d7a5f866-9f82-4a37-9aa4-ca1e4e7bf493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_837b71d9-a24e-436c-8578-aebc0493325e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_837b71d9-a24e-436c-8578-aebc0493325e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_65341b72-6387-4c35-8ded-875e2813948a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_65341b72-6387-4c35-8ded-875e2813948a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1c52daf1-ca7a-46b9-8fa8-984f4a4ecb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1c52daf1-ca7a-46b9-8fa8-984f4a4ecb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59bd9b14-5807-432a-a046-e9cdcd98f762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59bd9b14-5807-432a-a046-e9cdcd98f762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3bd1ce67-8c0f-4c49-a50a-9ec9c3d6beb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_NetIncomeLoss_3bd1ce67-8c0f-4c49-a50a-9ec9c3d6beb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_30829837-b9b4-46e5-b6b2-fc60637ef297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_SharesOutstanding_30829837-b9b4-46e5-b6b2-fc60637ef297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2f46afa8-2377-4322-bc9d-688f8dd9ea54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f3cf4667-e100-40c7-b514-5671579e5ab1" xlink:to="loc_us-gaap_StockholdersEquity_2f46afa8-2377-4322-bc9d-688f8dd9ea54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="xcur-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a67bdd9c-1713-4de5-9161-72e9c06137cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3c05090b-1b71-4401-b82f-31c1888aac4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a67bdd9c-1713-4de5-9161-72e9c06137cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3c05090b-1b71-4401-b82f-31c1888aac4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8378bb06-186b-4697-a7d4-f0857a8f2f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3c05090b-1b71-4401-b82f-31c1888aac4b" xlink:to="loc_us-gaap_NetIncomeLoss_8378bb06-186b-4697-a7d4-f0857a8f2f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_550bdf07-19dc-4d9b-a5bc-45e9f1131958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3c05090b-1b71-4401-b82f-31c1888aac4b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_550bdf07-19dc-4d9b-a5bc-45e9f1131958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_f1b664b2-cef6-4e29-aebc-720f29cbfb59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_550bdf07-19dc-4d9b-a5bc-45e9f1131958" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_f1b664b2-cef6-4e29-aebc-720f29cbfb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_fb4179c0-9fe6-4b5b-9e10-e84438701902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_550bdf07-19dc-4d9b-a5bc-45e9f1131958" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_fb4179c0-9fe6-4b5b-9e10-e84438701902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_440beb38-9f20-46b1-90b8-ebdcdc3a027e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_550bdf07-19dc-4d9b-a5bc-45e9f1131958" xlink:to="loc_us-gaap_ShareBasedCompensation_440beb38-9f20-46b1-90b8-ebdcdc3a027e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_0d2813b5-8a22-4be9-85bb-2615b0d0fcc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_550bdf07-19dc-4d9b-a5bc-45e9f1131958" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_0d2813b5-8a22-4be9-85bb-2615b0d0fcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2671cc03-ed5e-45ae-9830-930af30abf18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_550bdf07-19dc-4d9b-a5bc-45e9f1131958" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2671cc03-ed5e-45ae-9830-930af30abf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_a9d82c23-e300-49a2-89ed-206ca86329d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_550bdf07-19dc-4d9b-a5bc-45e9f1131958" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_a9d82c23-e300-49a2-89ed-206ca86329d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3b55d116-72ba-4ef7-8e66-ebb3692d8f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_550bdf07-19dc-4d9b-a5bc-45e9f1131958" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_3b55d116-72ba-4ef7-8e66-ebb3692d8f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96f499ce-f356-4364-960c-316dbe273189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_550bdf07-19dc-4d9b-a5bc-45e9f1131958" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96f499ce-f356-4364-960c-316dbe273189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_41e97134-1328-4530-ad7d-2b16efacfb81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96f499ce-f356-4364-960c-316dbe273189" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_41e97134-1328-4530-ad7d-2b16efacfb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7098e9cf-4f2e-4a20-bef7-d78af1566e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96f499ce-f356-4364-960c-316dbe273189" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7098e9cf-4f2e-4a20-bef7-d78af1566e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_bf4f4251-c999-46ee-ab32-574ddcb7efc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96f499ce-f356-4364-960c-316dbe273189" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_bf4f4251-c999-46ee-ab32-574ddcb7efc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8d7ff812-48a5-4f20-8bac-cecff8a63734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96f499ce-f356-4364-960c-316dbe273189" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8d7ff812-48a5-4f20-8bac-cecff8a63734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_529940ea-e99c-411f-834d-c8816a6c5d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96f499ce-f356-4364-960c-316dbe273189" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_529940ea-e99c-411f-834d-c8816a6c5d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_feea4aac-007e-4a5b-bf3c-f86e53a0494f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96f499ce-f356-4364-960c-316dbe273189" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_feea4aac-007e-4a5b-bf3c-f86e53a0494f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f167887f-7c48-43e5-8106-71d0b1e04bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96f499ce-f356-4364-960c-316dbe273189" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f167887f-7c48-43e5-8106-71d0b1e04bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3acdc2f-148e-41e6-be1e-bd02d40f0a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3c05090b-1b71-4401-b82f-31c1888aac4b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3acdc2f-148e-41e6-be1e-bd02d40f0a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7b07c95a-45b2-41c4-9cd5-6c9ab555b937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a67bdd9c-1713-4de5-9161-72e9c06137cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7b07c95a-45b2-41c4-9cd5-6c9ab555b937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_841b7a89-309f-4a43-b75b-9d8a8b474842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7b07c95a-45b2-41c4-9cd5-6c9ab555b937" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_841b7a89-309f-4a43-b75b-9d8a8b474842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_e561370f-8449-47e4-8a24-a252bfb92d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7b07c95a-45b2-41c4-9cd5-6c9ab555b937" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_e561370f-8449-47e4-8a24-a252bfb92d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b842000c-a4c5-4b13-9eed-8cd4b038d41c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7b07c95a-45b2-41c4-9cd5-6c9ab555b937" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b842000c-a4c5-4b13-9eed-8cd4b038d41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_971ec098-0163-4e64-abfa-b66677b0c8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7b07c95a-45b2-41c4-9cd5-6c9ab555b937" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_971ec098-0163-4e64-abfa-b66677b0c8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eabc2fe8-396b-4972-b738-6c0d69ac8b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a67bdd9c-1713-4de5-9161-72e9c06137cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eabc2fe8-396b-4972-b738-6c0d69ac8b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_46869308-947a-4d01-a35c-15a7af5e09b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eabc2fe8-396b-4972-b738-6c0d69ac8b3e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_46869308-947a-4d01-a35c-15a7af5e09b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsOfCommonStockFinancingCosts_b602702a-4be5-4470-aa58-47fa390d3b10" xlink:href="xcur-20210630.xsd#xcur_PaymentsOfCommonStockFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eabc2fe8-396b-4972-b738-6c0d69ac8b3e" xlink:to="loc_xcur_PaymentsOfCommonStockFinancingCosts_b602702a-4be5-4470-aa58-47fa390d3b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6df10102-3782-443a-a580-bdde3a387747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eabc2fe8-396b-4972-b738-6c0d69ac8b3e" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6df10102-3782-443a-a580-bdde3a387747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a5301129-346d-4cbb-b8d4-0fa4014d5157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eabc2fe8-396b-4972-b738-6c0d69ac8b3e" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a5301129-346d-4cbb-b8d4-0fa4014d5157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_69341ab9-6873-4c88-b48c-d073856a45cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eabc2fe8-396b-4972-b738-6c0d69ac8b3e" xlink:to="loc_us-gaap_ProceedsFromStockPlans_69341ab9-6873-4c88-b48c-d073856a45cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_047ee1b1-6f84-4a07-91f9-cfc04f136d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eabc2fe8-396b-4972-b738-6c0d69ac8b3e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_047ee1b1-6f84-4a07-91f9-cfc04f136d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a40b72d-eb8b-4929-ab9e-9b60ac4254ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eabc2fe8-396b-4972-b738-6c0d69ac8b3e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a40b72d-eb8b-4929-ab9e-9b60ac4254ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_48f4465b-0a13-4dd3-af93-50ec2d5d0595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a67bdd9c-1713-4de5-9161-72e9c06137cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_48f4465b-0a13-4dd3-af93-50ec2d5d0595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af752dbb-1208-4d26-a3bd-921ff0907b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a67bdd9c-1713-4de5-9161-72e9c06137cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af752dbb-1208-4d26-a3bd-921ff0907b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ffed505-b4db-4dad-96c7-88ef8d687407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a67bdd9c-1713-4de5-9161-72e9c06137cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ffed505-b4db-4dad-96c7-88ef8d687407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_3f16ea80-a828-4a7a-bbd9-5a2651f3c466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a67bdd9c-1713-4de5-9161-72e9c06137cb" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_3f16ea80-a828-4a7a-bbd9-5a2651f3c466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_16bc2f11-cd06-43b9-932c-187ef7e2783e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_3f16ea80-a828-4a7a-bbd9-5a2651f3c466" xlink:to="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_16bc2f11-cd06-43b9-932c-187ef7e2783e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d520b913-009a-43cf-b40d-e0383d3c6315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_16bc2f11-cd06-43b9-932c-187ef7e2783e" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d520b913-009a-43cf-b40d-e0383d3c6315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="xcur-20210630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_38dd15f7-a1c2-42ee-8bb8-59b64f03e41f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e98591e6-51a3-41f1-88da-63fd58dbaae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_38dd15f7-a1c2-42ee-8bb8-59b64f03e41f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e98591e6-51a3-41f1-88da-63fd58dbaae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_56f0fd56-6768-4639-a8e4-1b82ddb31a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_38dd15f7-a1c2-42ee-8bb8-59b64f03e41f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_56f0fd56-6768-4639-a8e4-1b82ddb31a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_103855b8-c040-48ee-bfa0-495205fc2caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_38dd15f7-a1c2-42ee-8bb8-59b64f03e41f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_103855b8-c040-48ee-bfa0-495205fc2caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="xcur-20210630.xsd#DescriptionofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_39cd74d8-911a-4c57-9cd8-644fd36791b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_4520bbf8-9550-4e20-adbe-d869d9bf8234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39cd74d8-911a-4c57-9cd8-644fd36791b8" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_4520bbf8-9550-4e20-adbe-d869d9bf8234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#DescriptionofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c45d889e-09aa-4e52-a250-47f647136e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyTable_09c254f3-5a6a-47a0-be39-ed110548e792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d889e-09aa-4e52-a250-47f647136e27" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyTable_09c254f3-5a6a-47a0-be39-ed110548e792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_ca770aa5-c245-42af-9e7d-45a98bd14f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_09c254f3-5a6a-47a0-be39-ed110548e792" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_ca770aa5-c245-42af-9e7d-45a98bd14f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_09ce52ab-617f-4a9f-8319-fa2df784eacb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_ca770aa5-c245-42af-9e7d-45a98bd14f97" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_09ce52ab-617f-4a9f-8319-fa2df784eacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_COVID19Member_6ba15778-3406-4b62-b08f-3f5400c7931b" xlink:href="xcur-20210630.xsd#xcur_COVID19Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_09ce52ab-617f-4a9f-8319-fa2df784eacb" xlink:to="loc_xcur_COVID19Member_6ba15778-3406-4b62-b08f-3f5400c7931b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b6712cde-af26-42d6-a8d0-3d83682ef63f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_09c254f3-5a6a-47a0-be39-ed110548e792" xlink:to="loc_srt_StatementScenarioAxis_b6712cde-af26-42d6-a8d0-3d83682ef63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bd2ee396-4f61-4f68-89ea-e8c5e66e2fa4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_b6712cde-af26-42d6-a8d0-3d83682ef63f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bd2ee396-4f61-4f68-89ea-e8c5e66e2fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_29cb1c10-142e-43b1-b267-6b8e33336b25" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_bd2ee396-4f61-4f68-89ea-e8c5e66e2fa4" xlink:to="loc_srt_ScenarioForecastMember_29cb1c10-142e-43b1-b267-6b8e33336b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_dc8ec8d4-8d48-4ea6-93f5-06b3d1a3db2f" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_09c254f3-5a6a-47a0-be39-ed110548e792" xlink:to="loc_xcur_ArrangementNameAxis_dc8ec8d4-8d48-4ea6-93f5-06b3d1a3db2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_d98d0909-2c32-421a-92a4-a02aa624e5ca" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameAxis_dc8ec8d4-8d48-4ea6-93f5-06b3d1a3db2f" xlink:to="loc_xcur_ArrangementNameDomain_d98d0909-2c32-421a-92a4-a02aa624e5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenCollaborationMember_62978031-61ce-4b07-8878-d374f330bf03" xlink:href="xcur-20210630.xsd#xcur_IpsenCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameDomain_d98d0909-2c32-421a-92a4-a02aa624e5ca" xlink:to="loc_xcur_IpsenCollaborationMember_62978031-61ce-4b07-8878-d374f330bf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_855e2a5a-7efd-43d4-b23c-de53f31ba7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_09c254f3-5a6a-47a0-be39-ed110548e792" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_855e2a5a-7efd-43d4-b23c-de53f31ba7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ResearchAndDevelopmentStaffOnSitePercentage_e1acb7b9-924f-43e8-910f-7ccf8e488983" xlink:href="xcur-20210630.xsd#xcur_ResearchAndDevelopmentStaffOnSitePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_855e2a5a-7efd-43d4-b23c-de53f31ba7fa" xlink:to="loc_xcur_ResearchAndDevelopmentStaffOnSitePercentage_e1acb7b9-924f-43e8-910f-7ccf8e488983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage_f5dc86a1-ee61-4492-8a90-8310e73fa16a" xlink:href="xcur-20210630.xsd#xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_855e2a5a-7efd-43d4-b23c-de53f31ba7fa" xlink:to="loc_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage_f5dc86a1-ee61-4492-8a90-8310e73fa16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_b7b20ffd-0fb0-4e02-a654-8e12fcac6e3c" xlink:href="xcur-20210630.xsd#xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_855e2a5a-7efd-43d4-b23c-de53f31ba7fa" xlink:to="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_b7b20ffd-0fb0-4e02-a654-8e12fcac6e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_c918799e-f830-4863-b4a6-a62ecffc5099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_855e2a5a-7efd-43d4-b23c-de53f31ba7fa" xlink:to="loc_us-gaap_ProceedsFromCollaborators_c918799e-f830-4863-b4a6-a62ecffc5099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="xcur-20210630.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f9c6aa00-01eb-40f1-815d-a7f072583f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_58bbe471-eff6-4a94-b283-e56d87aa175a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f9c6aa00-01eb-40f1-815d-a7f072583f15" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_58bbe471-eff6-4a94-b283-e56d87aa175a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="xcur-20210630.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_424ca7e2-d76e-4f19-a64d-7475615c1115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9b3f68f6-d520-4b2a-9d0b-0de0b2d03c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_424ca7e2-d76e-4f19-a64d-7475615c1115" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9b3f68f6-d520-4b2a-9d0b-0de0b2d03c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_f63d2703-832c-42c3-8678-58c2eabe7c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_424ca7e2-d76e-4f19-a64d-7475615c1115" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_f63d2703-832c-42c3-8678-58c2eabe7c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_6a66802a-f6f6-4492-b9a7-fac561c913ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_424ca7e2-d76e-4f19-a64d-7475615c1115" xlink:to="loc_us-gaap_UseOfEstimates_6a66802a-f6f6-4492-b9a7-fac561c913ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_100d06f2-5448-410e-afad-0436a4e9c930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_424ca7e2-d76e-4f19-a64d-7475615c1115" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_100d06f2-5448-410e-afad-0436a4e9c930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a3510551-a46e-4a02-9c49-0ede7ace0cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_424ca7e2-d76e-4f19-a64d-7475615c1115" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a3510551-a46e-4a02-9c49-0ede7ace0cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements" xlink:type="simple" xlink:href="xcur-20210630.xsd#CollaborativeResearchandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_54722e09-61fe-42c3-a786-7514db9897e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_07702239-2801-4947-8acb-e716af7096a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_54722e09-61fe-42c3-a786-7514db9897e8" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_07702239-2801-4947-8acb-e716af7096a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#CollaborativeResearchandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_bd847646-8270-4acf-a55d-23ee2a95c3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_143a8858-2395-4118-8f89-06ef907635b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_bd847646-8270-4acf-a55d-23ee2a95c3a4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_143a8858-2395-4118-8f89-06ef907635b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_89d5a81f-c195-46b3-b434-c9ec6d175ddb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_143a8858-2395-4118-8f89-06ef907635b9" xlink:to="loc_srt_RangeAxis_89d5a81f-c195-46b3-b434-c9ec6d175ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f2b58457-d64a-4188-b9b6-5817c88b4f05" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_89d5a81f-c195-46b3-b434-c9ec6d175ddb" xlink:to="loc_srt_RangeMember_f2b58457-d64a-4188-b9b6-5817c88b4f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ca365958-52f6-489e-814b-0c9965ac8313" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f2b58457-d64a-4188-b9b6-5817c88b4f05" xlink:to="loc_srt_MaximumMember_ca365958-52f6-489e-814b-0c9965ac8313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_44d84778-f660-4e3f-829d-628db3ddb081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_143a8858-2395-4118-8f89-06ef907635b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_44d84778-f660-4e3f-829d-628db3ddb081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9df4e7cd-75bc-4863-b152-cee2628e7a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_44d84778-f660-4e3f-829d-628db3ddb081" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9df4e7cd-75bc-4863-b152-cee2628e7a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DevelopmentandCommercializationLicenseMember_e5dcd28a-db63-46a4-bddf-8dced745161f" xlink:href="xcur-20210630.xsd#xcur_DevelopmentandCommercializationLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9df4e7cd-75bc-4863-b152-cee2628e7a38" xlink:to="loc_xcur_DevelopmentandCommercializationLicenseMember_e5dcd28a-db63-46a4-bddf-8dced745161f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_5bc7d7c1-5c65-4a96-b4d6-242c99fe8fa6" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_143a8858-2395-4118-8f89-06ef907635b9" xlink:to="loc_xcur_ArrangementNameAxis_5bc7d7c1-5c65-4a96-b4d6-242c99fe8fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_63e80c52-d2ea-4e22-b6a5-ef45a6bbd670" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameAxis_5bc7d7c1-5c65-4a96-b4d6-242c99fe8fa6" xlink:to="loc_xcur_ArrangementNameDomain_63e80c52-d2ea-4e22-b6a5-ef45a6bbd670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AbbVieCollaborationMember_288206ec-180a-4744-aa3d-b224c6fba899" xlink:href="xcur-20210630.xsd#xcur_AbbVieCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameDomain_63e80c52-d2ea-4e22-b6a5-ef45a6bbd670" xlink:to="loc_xcur_AbbVieCollaborationMember_288206ec-180a-4744-aa3d-b224c6fba899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DermelixLicenseAgreementMember_fde6fee7-d50d-4110-a2a2-d4bc96bad50f" xlink:href="xcur-20210630.xsd#xcur_DermelixLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameDomain_63e80c52-d2ea-4e22-b6a5-ef45a6bbd670" xlink:to="loc_xcur_DermelixLicenseAgreementMember_fde6fee7-d50d-4110-a2a2-d4bc96bad50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b7f40781-db5c-480a-8df3-843334c25d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_143a8858-2395-4118-8f89-06ef907635b9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b7f40781-db5c-480a-8df3-843334c25d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20060d35-ba51-4167-b1bb-57303d802c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b7f40781-db5c-480a-8df3-843334c25d1e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20060d35-ba51-4167-b1bb-57303d802c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b8e0d5cf-38ee-4c8a-aa04-24af803f2cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20060d35-ba51-4167-b1bb-57303d802c90" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b8e0d5cf-38ee-4c8a-aa04-24af803f2cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_143a8858-2395-4118-8f89-06ef907635b9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_NumberofCollaborationPrograms_3cc3db3a-d863-42cc-b903-505755194e76" xlink:href="xcur-20210630.xsd#xcur_NumberofCollaborationPrograms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_NumberofCollaborationPrograms_3cc3db3a-d863-42cc-b903-505755194e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_0c7a8534-d79b-4563-b46b-7af921e8f968" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementUpfrontPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_CollaborationAgreementUpfrontPayment_0c7a8534-d79b-4563-b46b-7af921e8f968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionExerciseFee_7946d1f7-84b6-4c04-b8fe-b7807e3a717a" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementOptionExerciseFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_CollaborationAgreementOptionExerciseFee_7946d1f7-84b6-4c04-b8fe-b7807e3a717a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_002fa12b-73c9-458f-a033-f6a1fad1b5fa" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_002fa12b-73c9-458f-a033-f6a1fad1b5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_8f8b17d6-8ee5-4a8d-bbbf-cba3d431747d" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_8f8b17d6-8ee5-4a8d-bbbf-cba3d431747d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_e5a9ab22-664e-4d1d-8e8b-fb9fdbdadba7" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_e5a9ab22-664e-4d1d-8e8b-fb9fdbdadba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_f3898804-cc25-4185-901e-a3685b11857b" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_f3898804-cc25-4185-901e-a3685b11857b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_69828b1b-d927-4eba-bb8a-de2ee28f8523" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_69828b1b-d927-4eba-bb8a-de2ee28f8523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4940a20a-eda5-4073-b069-d5562089fd28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4940a20a-eda5-4073-b069-d5562089fd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ae28cc8e-91ea-4eeb-94f3-4c504711ad9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ae28cc8e-91ea-4eeb-94f3-4c504711ad9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationDevelopmentExpenses_3e44b941-649e-409e-b69c-efd962b9d8b0" xlink:href="xcur-20210630.xsd#xcur_CollaborationDevelopmentExpenses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_xcur_CollaborationDevelopmentExpenses_3e44b941-649e-409e-b69c-efd962b9d8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_94201750-d89d-48af-b233-ab13420d3aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a11d7f89-3e25-4f6e-9ffc-39a722d5f52f" xlink:to="loc_us-gaap_ContractWithCustomerLiability_94201750-d89d-48af-b233-ab13420d3aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="simple" xlink:href="xcur-20210630.xsd#SupplementalBalanceSheetInformation"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_3de47543-2752-49a4-9b10-33589115771d" xlink:href="xcur-20210630.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_e31ecdd1-0e59-4958-8225-eebe65214576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_3de47543-2752-49a4-9b10-33589115771d" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_e31ecdd1-0e59-4958-8225-eebe65214576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="simple" xlink:href="xcur-20210630.xsd#SupplementalBalanceSheetInformationTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_d690d372-8185-4aa8-b7f0-1cee6c3fd876" xlink:href="xcur-20210630.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_8b683db1-900a-477b-bf9f-d235ff6beefe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_d690d372-8185-4aa8-b7f0-1cee6c3fd876" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_8b683db1-900a-477b-bf9f-d235ff6beefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e23af8c9-48f5-44e4-90cc-9bc6af80bc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_d690d372-8185-4aa8-b7f0-1cee6c3fd876" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e23af8c9-48f5-44e4-90cc-9bc6af80bc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_35d32078-44ba-42ef-a0bb-3f23dc02f65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_d690d372-8185-4aa8-b7f0-1cee6c3fd876" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_35d32078-44ba-42ef-a0bb-3f23dc02f65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_a1bd6f9e-27cb-4859-b7c7-b3735ddf429e" xlink:href="xcur-20210630.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_c4acaa93-88e1-44ec-9cb9-9cac9e382e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_a1bd6f9e-27cb-4859-b7c7-b3735ddf429e" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_c4acaa93-88e1-44ec-9cb9-9cac9e382e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_2e556187-fbd3-40a9-b781-df8bd89c0a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_a1bd6f9e-27cb-4859-b7c7-b3735ddf429e" xlink:to="loc_us-gaap_InterestReceivable_2e556187-fbd3-40a9-b781-df8bd89c0a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_abb02481-9b0a-4896-a90f-f2e41e1f83c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_a1bd6f9e-27cb-4859-b7c7-b3735ddf429e" xlink:to="loc_us-gaap_PrepaidInsurance_abb02481-9b0a-4896-a90f-f2e41e1f83c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_f6c014bd-15e2-4059-875e-4cda8d3c5a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_a1bd6f9e-27cb-4859-b7c7-b3735ddf429e" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_f6c014bd-15e2-4059-875e-4cda8d3c5a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7472b7ac-c5bd-4606-bec2-ef1d20e5dbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_a1bd6f9e-27cb-4859-b7c7-b3735ddf429e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7472b7ac-c5bd-4606-bec2-ef1d20e5dbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_a6ccf45f-3605-4061-ac13-9927cfe872d5" xlink:href="xcur-20210630.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_728ecc2b-530e-4cd6-94f7-08dee3ff4aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_a6ccf45f-3605-4061-ac13-9927cfe872d5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_728ecc2b-530e-4cd6-94f7-08dee3ff4aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8a79efa-53e7-4614-917b-ac98cba5204f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_728ecc2b-530e-4cd6-94f7-08dee3ff4aa5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8a79efa-53e7-4614-917b-ac98cba5204f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee624d2f-d5a7-4882-be93-262bcae41ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8a79efa-53e7-4614-917b-ac98cba5204f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee624d2f-d5a7-4882-be93-262bcae41ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_1beaaf20-487f-478f-84f3-2b2dc4b12826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee624d2f-d5a7-4882-be93-262bcae41ea8" xlink:to="loc_us-gaap_EquipmentMember_1beaaf20-487f-478f-84f3-2b2dc4b12826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ad29654f-bdca-4951-a5c0-75f17641e1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee624d2f-d5a7-4882-be93-262bcae41ea8" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ad29654f-bdca-4951-a5c0-75f17641e1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ComputersandSoftwareMember_5201e940-4073-4aec-8581-9a0a791e4e3e" xlink:href="xcur-20210630.xsd#xcur_ComputersandSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee624d2f-d5a7-4882-be93-262bcae41ea8" xlink:to="loc_xcur_ComputersandSoftwareMember_5201e940-4073-4aec-8581-9a0a791e4e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_47bc95ac-0d8e-41e9-8583-4388b26408b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee624d2f-d5a7-4882-be93-262bcae41ea8" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_47bc95ac-0d8e-41e9-8583-4388b26408b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_274e2df5-d759-4cf0-9aa8-b2c8f31de6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee624d2f-d5a7-4882-be93-262bcae41ea8" xlink:to="loc_us-gaap_ConstructionInProgressMember_274e2df5-d759-4cf0-9aa8-b2c8f31de6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9fa03f9-a107-41e6-9513-d2fcef5501d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_728ecc2b-530e-4cd6-94f7-08dee3ff4aa5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9fa03f9-a107-41e6-9513-d2fcef5501d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_065408fc-1d84-4ee5-b5bd-04dddb7b4cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9fa03f9-a107-41e6-9513-d2fcef5501d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_065408fc-1d84-4ee5-b5bd-04dddb7b4cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a535c7f7-b87b-46f4-8721-b9b5773187d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9fa03f9-a107-41e6-9513-d2fcef5501d5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a535c7f7-b87b-46f4-8721-b9b5773187d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c6a0a0ab-9916-4fe6-81ee-77cabf7e26c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9fa03f9-a107-41e6-9513-d2fcef5501d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c6a0a0ab-9916-4fe6-81ee-77cabf7e26c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_5c748e1e-ae8b-4a39-b01d-991fbfaabe30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9fa03f9-a107-41e6-9513-d2fcef5501d5" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_5c748e1e-ae8b-4a39-b01d-991fbfaabe30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_88db9d99-87fd-4388-8a9d-7ff3c6aa31ad" xlink:href="xcur-20210630.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_fd034d13-4340-4f45-be83-a3c7edb40704" xlink:href="xcur-20210630.xsd#xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_88db9d99-87fd-4388-8a9d-7ff3c6aa31ad" xlink:to="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_fd034d13-4340-4f45-be83-a3c7edb40704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_059730ab-3e75-4841-8dac-2ac9a9f1cb80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_88db9d99-87fd-4388-8a9d-7ff3c6aa31ad" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_059730ab-3e75-4841-8dac-2ac9a9f1cb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8f4e64f6-b9ef-41bf-a11d-42bdefab5e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_88db9d99-87fd-4388-8a9d-7ff3c6aa31ad" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8f4e64f6-b9ef-41bf-a11d-42bdefab5e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_394524b6-d5de-48e5-9cb9-57a0e279f7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_88db9d99-87fd-4388-8a9d-7ff3c6aa31ad" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_394524b6-d5de-48e5-9cb9-57a0e279f7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_deda18fe-0458-470d-a9bc-af8ed46a5e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_88db9d99-87fd-4388-8a9d-7ff3c6aa31ad" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_deda18fe-0458-470d-a9bc-af8ed46a5e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Investments" xlink:type="simple" xlink:href="xcur-20210630.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_41aae0b9-13aa-4685-890c-b3a6b8b87fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_44655eb3-6498-4df4-b7a2-bcf3fb8a04eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_41aae0b9-13aa-4685-890c-b3a6b8b87fbd" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_44655eb3-6498-4df4-b7a2-bcf3fb8a04eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsTables" xlink:type="simple" xlink:href="xcur-20210630.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_ebc4d50b-464f-43f2-9c45-cbe57269a568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock_35fd0f26-0212-4a3a-b420-bf8e12890f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_ebc4d50b-464f-43f2-9c45-cbe57269a568" xlink:to="loc_us-gaap_InvestmentTableTextBlock_35fd0f26-0212-4a3a-b420-bf8e12890f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_931cb543-08fe-4bab-b76e-9a5daa519d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_ebc4d50b-464f-43f2-9c45-cbe57269a568" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_931cb543-08fe-4bab-b76e-9a5daa519d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#InvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_83dbbc37-0d75-4890-ad0f-aae4c8d64427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_9104b4fc-f6cb-4afa-a571-a801b85ec427" xlink:href="xcur-20210630.xsd#xcur_DebtSecuritiesAvailableForSaleCurrentPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_83dbbc37-0d75-4890-ad0f-aae4c8d64427" xlink:to="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_9104b4fc-f6cb-4afa-a571-a801b85ec427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_63c1b1f8-715f-469e-b418-1e88a398ef55" xlink:href="xcur-20210630.xsd#xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_83dbbc37-0d75-4890-ad0f-aae4c8d64427" xlink:to="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_63c1b1f8-715f-469e-b418-1e88a398ef55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableforSalePercent_8e7bbba9-a569-4ef1-9835-dee49a4c2296" xlink:href="xcur-20210630.xsd#xcur_DebtSecuritiesAvailableforSalePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_83dbbc37-0d75-4890-ad0f-aae4c8d64427" xlink:to="loc_xcur_DebtSecuritiesAvailableforSalePercent_8e7bbba9-a569-4ef1-9835-dee49a4c2296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#InvestmentsAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_d5628e82-3e32-4c76-9262-25bc5215b568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cf948149-a721-4878-8d44-d25b9df62121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_d5628e82-3e32-4c76-9262-25bc5215b568" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cf948149-a721-4878-8d44-d25b9df62121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b2a07d0d-5734-4182-bc9f-77a5b8f10568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cf948149-a721-4878-8d44-d25b9df62121" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b2a07d0d-5734-4182-bc9f-77a5b8f10568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bd20fa1-1705-4680-b4a1-98ba637fad2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b2a07d0d-5734-4182-bc9f-77a5b8f10568" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bd20fa1-1705-4680-b4a1-98ba637fad2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_1e1d078c-bc5d-432d-ab3b-40592d7a5f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bd20fa1-1705-4680-b4a1-98ba637fad2b" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_1e1d078c-bc5d-432d-ab3b-40592d7a5f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_93f9c63c-2cb6-48d0-a304-c0864dc82d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bd20fa1-1705-4680-b4a1-98ba637fad2b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_93f9c63c-2cb6-48d0-a304-c0864dc82d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8924b6b7-9c37-4f56-b484-3353df16d3be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bd20fa1-1705-4680-b4a1-98ba637fad2b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8924b6b7-9c37-4f56-b484-3353df16d3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a0895230-5d6c-4aaa-a855-795c9aad7f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bd20fa1-1705-4680-b4a1-98ba637fad2b" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a0895230-5d6c-4aaa-a855-795c9aad7f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f13ba93-ea71-417a-889a-065eae539b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cf948149-a721-4878-8d44-d25b9df62121" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f13ba93-ea71-417a-889a-065eae539b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_48ca0979-c81f-4a58-bff7-3d6c39e90da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f13ba93-ea71-417a-889a-065eae539b90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_48ca0979-c81f-4a58-bff7-3d6c39e90da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_893bc087-e8ec-40b8-ba6b-9717d25bc5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f13ba93-ea71-417a-889a-065eae539b90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_893bc087-e8ec-40b8-ba6b-9717d25bc5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_feb9c758-fc98-4cf1-9268-9cb540341cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f13ba93-ea71-417a-889a-065eae539b90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_feb9c758-fc98-4cf1-9268-9cb540341cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_96a05df1-d823-479c-a7cc-7bcfd72c632b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f13ba93-ea71-417a-889a-065eae539b90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_96a05df1-d823-479c-a7cc-7bcfd72c632b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Debt" xlink:type="simple" xlink:href="xcur-20210630.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f694e82d-b7e1-48d8-9765-0748aea9bb43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_38a24d58-8d4d-4f90-ba16-6ce5232b53cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f694e82d-b7e1-48d8-9765-0748aea9bb43" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_38a24d58-8d4d-4f90-ba16-6ce5232b53cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtTables" xlink:type="simple" xlink:href="xcur-20210630.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cb77617c-4ec8-47fa-bc3e-b6a64825d58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_d03d9f85-f251-4be0-bdac-e7d3dcb0b6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cb77617c-4ec8-47fa-bc3e-b6a64825d58e" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_d03d9f85-f251-4be0-bdac-e7d3dcb0b6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0b76166d-d2ca-4654-8e08-ca25716e4118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0b76166d-d2ca-4654-8e08-ca25716e4118" xlink:to="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d302c6e5-501f-453a-9f3e-e96b2ccfe6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d302c6e5-501f-453a-9f3e-e96b2ccfe6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6142c8d7-6b03-4960-9203-beca66b8739b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d302c6e5-501f-453a-9f3e-e96b2ccfe6bc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6142c8d7-6b03-4960-9203-beca66b8739b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_3a5c70f5-8cc1-421d-8c93-f6d4f818e6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6142c8d7-6b03-4960-9203-beca66b8739b" xlink:to="loc_us-gaap_SecuredDebtMember_3a5c70f5-8cc1-421d-8c93-f6d4f818e6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_3c50f5a1-e040-4c67-935b-03f59f43a7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6142c8d7-6b03-4960-9203-beca66b8739b" xlink:to="loc_us-gaap_LoansPayableMember_3c50f5a1-e040-4c67-935b-03f59f43a7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_06ce7623-aa77-431b-993b-d7247e6c7ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:to="loc_us-gaap_CreditFacilityAxis_06ce7623-aa77-431b-993b-d7247e6c7ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2deb6644-09f3-463a-9059-4cc0adacab93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_06ce7623-aa77-431b-993b-d7247e6c7ee1" xlink:to="loc_us-gaap_CreditFacilityDomain_2deb6644-09f3-463a-9059-4cc0adacab93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_09aca46c-dc58-45b6-8d93-76ff73c8e3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2deb6644-09f3-463a-9059-4cc0adacab93" xlink:to="loc_us-gaap_SecuredDebtMember_09aca46c-dc58-45b6-8d93-76ff73c8e3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_7566a76d-b5bb-4851-af53-41a89e3f82b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_7566a76d-b5bb-4851-af53-41a89e3f82b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_6ae41d1f-a4a3-4857-9dee-600208653ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_7566a76d-b5bb-4851-af53-41a89e3f82b2" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_6ae41d1f-a4a3-4857-9dee-600208653ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember_d6e75813-96e5-43f1-9426-12d317a5abc7" xlink:href="xcur-20210630.xsd#xcur_HerculesTechnologyGrowthCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_6ae41d1f-a4a3-4857-9dee-600208653ff5" xlink:to="loc_xcur_HerculesTechnologyGrowthCapitalMember_d6e75813-96e5-43f1-9426-12d317a5abc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2d307b59-f5e1-4c43-b8af-af42af755c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:to="loc_us-gaap_DebtInstrumentAxis_2d307b59-f5e1-4c43-b8af-af42af755c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26001037-08b4-4845-8207-c7f3d5dc7fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2d307b59-f5e1-4c43-b8af-af42af755c1c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26001037-08b4-4845-8207-c7f3d5dc7fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementMember_5427a20a-80ea-4be0-b995-ef65751e888e" xlink:href="xcur-20210630.xsd#xcur_MidCapCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26001037-08b4-4845-8207-c7f3d5dc7fb2" xlink:to="loc_xcur_MidCapCreditAgreementMember_5427a20a-80ea-4be0-b995-ef65751e888e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementTranche1Member_443f9117-d679-4610-8e55-6c9f217887d3" xlink:href="xcur-20210630.xsd#xcur_MidCapCreditAgreementTranche1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_MidCapCreditAgreementMember_5427a20a-80ea-4be0-b995-ef65751e888e" xlink:to="loc_xcur_MidCapCreditAgreementTranche1Member_443f9117-d679-4610-8e55-6c9f217887d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementTranche2Member_05611f22-00f4-43ef-b250-33c11df22d56" xlink:href="xcur-20210630.xsd#xcur_MidCapCreditAgreementTranche2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_MidCapCreditAgreementMember_5427a20a-80ea-4be0-b995-ef65751e888e" xlink:to="loc_xcur_MidCapCreditAgreementTranche2Member_05611f22-00f4-43ef-b250-33c11df22d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_8c457a40-e893-41c5-bdf9-969d0ee556a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_8c457a40-e893-41c5-bdf9-969d0ee556a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_30c498fc-52f5-479b-a87f-e4c3d509c3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_8c457a40-e893-41c5-bdf9-969d0ee556a2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_30c498fc-52f5-479b-a87f-e4c3d509c3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_8a30d129-80f7-47af-bad6-3b4ce4b22957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_30c498fc-52f5-479b-a87f-e4c3d509c3ac" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_8a30d129-80f7-47af-bad6-3b4ce4b22957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_69858ec6-a96f-4ca8-8ca8-3b09626214ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_30c498fc-52f5-479b-a87f-e4c3d509c3ac" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_69858ec6-a96f-4ca8-8ca8-3b09626214ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c664f472-f52a-41ba-87ae-3ee1fa539e4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:to="loc_srt_StatementScenarioAxis_c664f472-f52a-41ba-87ae-3ee1fa539e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f68d82d5-f1af-49de-85ef-fb489785558e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_c664f472-f52a-41ba-87ae-3ee1fa539e4b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f68d82d5-f1af-49de-85ef-fb489785558e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_6f70fc37-926d-416a-88f8-914140e82304" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f68d82d5-f1af-49de-85ef-fb489785558e" xlink:to="loc_srt_ScenarioForecastMember_6f70fc37-926d-416a-88f8-914140e82304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a8bfeb11-35a2-410f-89f0-48d9cda68ef2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_13715373-6361-4b5d-a4b0-5f5e7df9efd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_13715373-6361-4b5d-a4b0-5f5e7df9efd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_657085eb-8f88-49e8-9966-153350183dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_657085eb-8f88-49e8-9966-153350183dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_59da3957-7736-4c2d-a9e7-14eed1da73d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_59da3957-7736-4c2d-a9e7-14eed1da73d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_bf31d8bd-33d2-4419-ad3f-f383008c2448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_bf31d8bd-33d2-4419-ad3f-f383008c2448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments_8d7db527-c9bb-4dae-9161-288a8760c302" xlink:href="xcur-20210630.xsd#xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments_8d7db527-c9bb-4dae-9161-288a8760c302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal_73837546-6b76-47fd-a227-83d399e44358" xlink:href="xcur-20210630.xsd#xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal_73837546-6b76-47fd-a227-83d399e44358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanProcessingFee_373c31b4-1c2f-4f4d-b308-ec47a95a2741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoanProcessingFee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_LoanProcessingFee_373c31b4-1c2f-4f4d-b308-ec47a95a2741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentExitFeePercentage_e85a5b63-02fe-4662-893b-4c6f2df9781b" xlink:href="xcur-20210630.xsd#xcur_DebtInstrumentExitFeePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_xcur_DebtInstrumentExitFeePercentage_e85a5b63-02fe-4662-893b-4c6f2df9781b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_00d8b5b7-1d9b-47fa-bbf7-b8a565235671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_00d8b5b7-1d9b-47fa-bbf7-b8a565235671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_fb91cfcf-d16b-4a5a-ac32-17b50ba4cdac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_fb91cfcf-d16b-4a5a-ac32-17b50ba4cdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_9a52f272-a224-466c-80c9-1e10f8a000f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_9a52f272-a224-466c-80c9-1e10f8a000f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_deab9372-aca0-47ba-ac33-667c4f3ca70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_deab9372-aca0-47ba-ac33-667c4f3ca70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b5e941f5-11f2-462e-a11a-6a8e57f209a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b5e941f5-11f2-462e-a11a-6a8e57f209a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3217f274-5514-4cdb-ab28-05f528aa74c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_LongTermDebt_3217f274-5514-4cdb-ab28-05f528aa74c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_22232846-ff35-4b14-85cb-75be32ae6ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_InterestPaidNet_22232846-ff35-4b14-85cb-75be32ae6ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_17b25034-4a6e-4f20-af43-7b05072b392d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_17b25034-4a6e-4f20-af43-7b05072b392d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsForDebtEndTermFees_3bd4ec41-f7aa-4f8f-ba73-02554c7fe82c" xlink:href="xcur-20210630.xsd#xcur_PaymentsForDebtEndTermFees"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a958fba-3a83-4b44-be7c-ca0fcb4ae70d" xlink:to="loc_xcur_PaymentsForDebtEndTermFees_3bd4ec41-f7aa-4f8f-ba73-02554c7fe82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#DebtPrincipalMaturitiesofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_041e61e0-c658-4155-b06c-4c290b92aef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b86358f4-5f1c-4e72-b77c-535752062d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_041e61e0-c658-4155-b06c-4c290b92aef4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b86358f4-5f1c-4e72-b77c-535752062d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_49544cd9-1455-413d-a540-5e4ce26a7428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_041e61e0-c658-4155-b06c-4c290b92aef4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_49544cd9-1455-413d-a540-5e4ce26a7428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_280e9075-a62c-43a9-89d3-a3c68d73cec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_041e61e0-c658-4155-b06c-4c290b92aef4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_280e9075-a62c-43a9-89d3-a3c68d73cec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_335a9c09-cf3a-48dd-821b-80987af742a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_041e61e0-c658-4155-b06c-4c290b92aef4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_335a9c09-cf3a-48dd-821b-80987af742a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_87975ba1-ebc7-4831-b01c-0bf5595dcfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_041e61e0-c658-4155-b06c-4c290b92aef4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_87975ba1-ebc7-4831-b01c-0bf5595dcfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_203e1ac4-32a3-47ed-bf26-3cecd4d41081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_041e61e0-c658-4155-b06c-4c290b92aef4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_203e1ac4-32a3-47ed-bf26-3cecd4d41081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_658736a8-64f8-4f95-9088-b6237dcf9077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_041e61e0-c658-4155-b06c-4c290b92aef4" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_658736a8-64f8-4f95-9088-b6237dcf9077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6a2ad2d2-e19b-4686-8349-718f8f67f86e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_041e61e0-c658-4155-b06c-4c290b92aef4" xlink:to="loc_us-gaap_LongTermDebt_6a2ad2d2-e19b-4686-8349-718f8f67f86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a7b299cf-ee01-4436-becf-6ca8f4097bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_041e61e0-c658-4155-b06c-4c290b92aef4" xlink:to="loc_us-gaap_LongTermDebtCurrent_a7b299cf-ee01-4436-becf-6ca8f4097bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_189a937b-4fa5-4e2c-90d1-544b56d2d8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_041e61e0-c658-4155-b06c-4c290b92aef4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_189a937b-4fa5-4e2c-90d1-544b56d2d8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1" xlink:type="simple" xlink:href="xcur-20210630.xsd#DebtPrincipalMaturitiesofLongTermDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Leases" xlink:type="simple" xlink:href="xcur-20210630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bd68dce3-7cad-4e50-860c-5a1013582f83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_bd5e8538-e01f-4a1e-bd0c-6784f5901815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd68dce3-7cad-4e50-860c-5a1013582f83" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_bd5e8538-e01f-4a1e-bd0c-6784f5901815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesTables" xlink:type="simple" xlink:href="xcur-20210630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7a02841c-5687-4c85-9f0a-b50189c477a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock_8340b867-b3d3-4490-8541-d5809433746f" xlink:href="xcur-20210630.xsd#xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a02841c-5687-4c85-9f0a-b50189c477a8" xlink:to="loc_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock_8340b867-b3d3-4490-8541-d5809433746f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_2dd592c9-f71d-4c2b-9332-2bf5742f5c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a02841c-5687-4c85-9f0a-b50189c477a8" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_2dd592c9-f71d-4c2b-9332-2bf5742f5c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a8616981-1d3e-442f-8d7e-38b304a0ae3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a02841c-5687-4c85-9f0a-b50189c477a8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a8616981-1d3e-442f-8d7e-38b304a0ae3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f6534b23-6dbe-4394-a0ab-e6313388ae47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_156917a0-8244-4152-bd95-c177c9e342cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6534b23-6dbe-4394-a0ab-e6313388ae47" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_156917a0-8244-4152-bd95-c177c9e342cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c1ec6197-e073-4e01-90c7-c44244afc235" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_156917a0-8244-4152-bd95-c177c9e342cf" xlink:to="loc_srt_StatementGeographicalAxis_c1ec6197-e073-4e01-90c7-c44244afc235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dd0f5b6a-11ed-4c7e-8c3a-67aad4febc2c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c1ec6197-e073-4e01-90c7-c44244afc235" xlink:to="loc_srt_SegmentGeographicalDomain_dd0f5b6a-11ed-4c7e-8c3a-67aad4febc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ChicagoMember_e17671fb-33d5-4c45-8947-81eea54124f5" xlink:href="xcur-20210630.xsd#xcur_ChicagoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_dd0f5b6a-11ed-4c7e-8c3a-67aad4febc2c" xlink:to="loc_xcur_ChicagoMember_e17671fb-33d5-4c45-8947-81eea54124f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_156917a0-8244-4152-bd95-c177c9e342cf" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseArea_6df0aaf2-bec2-4528-a0fa-2a023707b03c" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseLeaseArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_xcur_LesseeOperatingLeaseLeaseArea_6df0aaf2-bec2-4528-a0fa-2a023707b03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_57915787-6eb9-4e27-8e2a-f84170e08d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_57915787-6eb9-4e27-8e2a-f84170e08d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseNumberOfExtensions_528e88c8-6a0c-4f48-846a-8668dde60eab" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseNumberOfExtensions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_xcur_LesseeOperatingLeaseNumberOfExtensions_528e88c8-6a0c-4f48-846a-8668dde60eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ad2ef6ff-4ead-4bbb-87f7-d7195e5cc4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ad2ef6ff-4ead-4bbb-87f7-d7195e5cc4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths_93eaaedd-336f-4c4a-b674-6007ca022e1c" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths_93eaaedd-336f-4c4a-b674-6007ca022e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease_e5e4a787-aaed-4d6b-bcf4-068028ab7139" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease_e5e4a787-aaed-4d6b-bcf4-068028ab7139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm_bd4e450f-bd28-4314-9413-b6001ecec005" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm_bd4e450f-bd28-4314-9413-b6001ecec005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_2f0e3dd1-9a30-458f-89bd-fa024b93e477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_2f0e3dd1-9a30-458f-89bd-fa024b93e477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement_f2994b11-8dbd-49e5-81bc-8b731ae9bf0a" xlink:href="xcur-20210630.xsd#xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement_f2994b11-8dbd-49e5-81bc-8b731ae9bf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_ca8215fb-ca7c-43c6-b0cd-2b3651792659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_ca8215fb-ca7c-43c6-b0cd-2b3651792659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_91b99642-275e-4454-9445-22a7b02ac188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_91b99642-275e-4454-9445-22a7b02ac188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7f953563-ff5c-4766-a2c7-d04204085815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_OperatingLeaseLiability_7f953563-ff5c-4766-a2c7-d04204085815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_283ab4c6-7054-4314-adfb-66f3f887b06f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_283ab4c6-7054-4314-adfb-66f3f887b06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_2f1bf0bb-47b8-4c47-8a37-3149bbb3b3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2cda7be3-8485-4518-a60c-5c650c8e8509" xlink:to="loc_us-gaap_OperatingLeasePayments_2f1bf0bb-47b8-4c47-8a37-3149bbb3b3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesRightofUseAssetInformationDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#LeasesRightofUseAssetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesRightofUseAssetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_39be6081-aa71-4a61-a4bc-b4ab728746b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_be48309a-ec47-4289-8e01-4c4ed2c1e273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39be6081-aa71-4a61-a4bc-b4ab728746b1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_be48309a-ec47-4289-8e01-4c4ed2c1e273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1c3d1eac-0784-4428-b46c-89e71d77c966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39be6081-aa71-4a61-a4bc-b4ab728746b1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1c3d1eac-0784-4428-b46c-89e71d77c966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesLeaseCostsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#LeasesLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b8f09d8c-2a12-4168-88b6-6d637044643b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1851acf6-c5f5-4102-8a07-c6ad81d7a6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b8f09d8c-2a12-4168-88b6-6d637044643b" xlink:to="loc_us-gaap_OperatingLeaseCost_1851acf6-c5f5-4102-8a07-c6ad81d7a6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_04e639fb-728d-4022-a6ab-284a78e59da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b8f09d8c-2a12-4168-88b6-6d637044643b" xlink:to="loc_us-gaap_ShortTermLeaseCost_04e639fb-728d-4022-a6ab-284a78e59da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_b773f28a-2435-4db4-aa68-c7fd8b30eced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b8f09d8c-2a12-4168-88b6-6d637044643b" xlink:to="loc_us-gaap_VariableLeaseCost_b773f28a-2435-4db4-aa68-c7fd8b30eced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_dcdc03d9-1f06-48d2-83e3-c3952537fc48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b8f09d8c-2a12-4168-88b6-6d637044643b" xlink:to="loc_us-gaap_LeaseCost_dcdc03d9-1f06-48d2-83e3-c3952537fc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#LeasesScheduleofFutureMinimumRentalPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0cd60786-103e-4c86-9be9-0887eeaf01cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e82a47ca-96fc-4e66-9695-ccf449db5bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0cd60786-103e-4c86-9be9-0887eeaf01cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e82a47ca-96fc-4e66-9695-ccf449db5bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_784bd825-27bb-4e1f-a250-a0b8c7476fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0cd60786-103e-4c86-9be9-0887eeaf01cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_784bd825-27bb-4e1f-a250-a0b8c7476fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8224f7fb-9ffc-49a1-bc39-12c039fe3796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0cd60786-103e-4c86-9be9-0887eeaf01cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8224f7fb-9ffc-49a1-bc39-12c039fe3796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d752e412-dd62-454a-a53c-438546f78e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0cd60786-103e-4c86-9be9-0887eeaf01cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d752e412-dd62-454a-a53c-438546f78e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_98b2b534-859a-4e0b-8a70-1cf66ed72d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0cd60786-103e-4c86-9be9-0887eeaf01cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_98b2b534-859a-4e0b-8a70-1cf66ed72d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f8dd9ab6-8703-47f2-81a3-b085c6fd8a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0cd60786-103e-4c86-9be9-0887eeaf01cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f8dd9ab6-8703-47f2-81a3-b085c6fd8a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1e4f5e35-12b7-455f-a2cf-4e26e260960e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0cd60786-103e-4c86-9be9-0887eeaf01cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1e4f5e35-12b7-455f-a2cf-4e26e260960e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_efd006f0-0ee8-4a2f-acc9-38575f4b6dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0cd60786-103e-4c86-9be9-0887eeaf01cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_efd006f0-0ee8-4a2f-acc9-38575f4b6dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b2c2b0b2-e697-4e85-bab5-71a23d289bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0cd60786-103e-4c86-9be9-0887eeaf01cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b2c2b0b2-e697-4e85-bab5-71a23d289bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b62cd9c8-b5bf-43b0-8610-c7fd7b732116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0cd60786-103e-4c86-9be9-0887eeaf01cd" xlink:to="loc_us-gaap_OperatingLeaseLiability_b62cd9c8-b5bf-43b0-8610-c7fd7b732116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b33661e2-cdc6-45e3-b7d3-32aa0e5927b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0cd60786-103e-4c86-9be9-0887eeaf01cd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b33661e2-cdc6-45e3-b7d3-32aa0e5927b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e5546b88-65b5-4e8d-a7a9-d5e777a787a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0cd60786-103e-4c86-9be9-0887eeaf01cd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e5546b88-65b5-4e8d-a7a9-d5e777a787a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" xlink:type="simple" xlink:href="xcur-20210630.xsd#LeasesScheduleofFutureMinimumRentalPaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="xcur-20210630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3a7225c1-728d-4f63-b9aa-0d3d427a8200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_963d1596-9e90-401d-805c-4b2c802e5b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3a7225c1-728d-4f63-b9aa-0d3d427a8200" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_963d1596-9e90-401d-805c-4b2c802e5b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="xcur-20210630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_67b60fa1-c1d6-480b-9144-b02299d489c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_540d212a-aaae-4e5f-9657-eadeff0bb438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_67b60fa1-c1d6-480b-9144-b02299d489c7" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_540d212a-aaae-4e5f-9657-eadeff0bb438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#StockholdersEquityCurrentCapitalizationDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2025f0ba-2cde-4dc6-a880-276e84b4d8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_accbb41c-3393-4cac-933f-079a67594e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2025f0ba-2cde-4dc6-a880-276e84b4d8bc" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_accbb41c-3393-4cac-933f-079a67594e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4990bf81-7b0a-45fc-917b-4daf257913c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2025f0ba-2cde-4dc6-a880-276e84b4d8bc" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4990bf81-7b0a-45fc-917b-4daf257913c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_580c76d9-1176-472a-a462-a40cdcc23cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2025f0ba-2cde-4dc6-a880-276e84b4d8bc" xlink:to="loc_us-gaap_PreferredStockSharesIssued_580c76d9-1176-472a-a462-a40cdcc23cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_78802379-dc1b-498d-ba07-869f2712f924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2025f0ba-2cde-4dc6-a880-276e84b4d8bc" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_78802379-dc1b-498d-ba07-869f2712f924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d9b554e2-a767-40c3-b227-c14de3280118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2025f0ba-2cde-4dc6-a880-276e84b4d8bc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d9b554e2-a767-40c3-b227-c14de3280118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_06fd4752-1ea5-4896-a954-68d99c4acc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2025f0ba-2cde-4dc6-a880-276e84b4d8bc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_06fd4752-1ea5-4896-a954-68d99c4acc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ece7b0e3-1a7a-432c-8588-307e1067980d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2025f0ba-2cde-4dc6-a880-276e84b4d8bc" xlink:to="loc_us-gaap_CommonStockSharesIssued_ece7b0e3-1a7a-432c-8588-307e1067980d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1d3e0e4f-e5da-413f-b23e-3cd598098bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2025f0ba-2cde-4dc6-a880-276e84b4d8bc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1d3e0e4f-e5da-413f-b23e-3cd598098bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockVotingRightsForEachShare_3cca705a-7cc8-427a-b0b8-cf861d39e18f" xlink:href="xcur-20210630.xsd#xcur_CommonStockVotingRightsForEachShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2025f0ba-2cde-4dc6-a880-276e84b4d8bc" xlink:to="loc_xcur_CommonStockVotingRightsForEachShare_3cca705a-7cc8-427a-b0b8-cf861d39e18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#StockholdersEquityCommonStockWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0fac03b7-b5e4-47b3-9e3b-e65e5d577fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_b1aafcb9-85c5-491a-8c13-f554049aaba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0fac03b7-b5e4-47b3-9e3b-e65e5d577fe8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_b1aafcb9-85c5-491a-8c13-f554049aaba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f37f70d6-8274-4677-bc95-66164532b52c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_b1aafcb9-85c5-491a-8c13-f554049aaba3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f37f70d6-8274-4677-bc95-66164532b52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5eb47a6a-8a1c-4954-8226-f41ec3971b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f37f70d6-8274-4677-bc95-66164532b52c" xlink:to="loc_us-gaap_ClassOfStockDomain_5eb47a6a-8a1c-4954-8226-f41ec3971b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d384ba52-c605-4dfb-a7f8-34efd4c93967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5eb47a6a-8a1c-4954-8226-f41ec3971b00" xlink:to="loc_us-gaap_CommonStockMember_d384ba52-c605-4dfb-a7f8-34efd4c93967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_a5994ef6-3f11-419b-8386-456a9651788b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_b1aafcb9-85c5-491a-8c13-f554049aaba3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_a5994ef6-3f11-419b-8386-456a9651788b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ed7765b5-e3ca-4cfa-b23f-24c57cdf3ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_a5994ef6-3f11-419b-8386-456a9651788b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ed7765b5-e3ca-4cfa-b23f-24c57cdf3ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a550e1a4-91b7-4331-bf52-0a69f00f4ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_a5994ef6-3f11-419b-8386-456a9651788b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a550e1a4-91b7-4331-bf52-0a69f00f4ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ClassofWarrantorRightExpired_dc5e4f2d-9b7e-4c9e-82a2-f6f5dfbe45e4" xlink:href="xcur-20210630.xsd#xcur_ClassofWarrantorRightExpired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_a5994ef6-3f11-419b-8386-456a9651788b" xlink:to="loc_xcur_ClassofWarrantorRightExpired_dc5e4f2d-9b7e-4c9e-82a2-f6f5dfbe45e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3944dd1b-9d66-4f68-82bf-9bf43f8f135f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b875ca0-0aad-4fa7-832f-7d682e3f4087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3944dd1b-9d66-4f68-82bf-9bf43f8f135f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b875ca0-0aad-4fa7-832f-7d682e3f4087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_20c8a2ea-644b-4f49-a8fe-a9e340562efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b875ca0-0aad-4fa7-832f-7d682e3f4087" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_20c8a2ea-644b-4f49-a8fe-a9e340562efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fe96a77e-f4a7-4dd4-b500-3d16859856be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20c8a2ea-644b-4f49-a8fe-a9e340562efa" xlink:to="loc_us-gaap_EquityComponentDomain_fe96a77e-f4a7-4dd4-b500-3d16859856be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_44fb6a04-e992-4c3e-9963-42f6e9cf37d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe96a77e-f4a7-4dd4-b500-3d16859856be" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_44fb6a04-e992-4c3e-9963-42f6e9cf37d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_48317a47-5d17-4517-8ff0-bbe55a6a77e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe96a77e-f4a7-4dd4-b500-3d16859856be" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_48317a47-5d17-4517-8ff0-bbe55a6a77e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8de827dd-970d-4b82-8266-5e7126cdf352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0b875ca0-0aad-4fa7-832f-7d682e3f4087" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8de827dd-970d-4b82-8266-5e7126cdf352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_963d9592-e72f-4207-aac2-b506baf0197c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8de827dd-970d-4b82-8266-5e7126cdf352" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_963d9592-e72f-4207-aac2-b506baf0197c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_03168fb7-aee9-4da8-b96b-ffb72d86b23b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_963d9592-e72f-4207-aac2-b506baf0197c" xlink:to="loc_us-gaap_StockholdersEquity_03168fb7-aee9-4da8-b96b-ffb72d86b23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_39f0527b-e45b-4bfa-8aa6-843a3d557471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_963d9592-e72f-4207-aac2-b506baf0197c" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_39f0527b-e45b-4bfa-8aa6-843a3d557471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c4ad332b-256d-4ece-8ef5-4da8384ac9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_963d9592-e72f-4207-aac2-b506baf0197c" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c4ad332b-256d-4ece-8ef5-4da8384ac9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_57646bdc-3d02-4f8c-9d91-9a92a5e4cd63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_963d9592-e72f-4207-aac2-b506baf0197c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_57646bdc-3d02-4f8c-9d91-9a92a5e4cd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d3ca051f-4769-4512-b208-9a1126621b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_963d9592-e72f-4207-aac2-b506baf0197c" xlink:to="loc_us-gaap_StockholdersEquity_d3ca051f-4769-4512-b208-9a1126621b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_094c11d3-f671-4b9c-873d-28a16f6af29d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8de827dd-970d-4b82-8266-5e7126cdf352" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_094c11d3-f671-4b9c-873d-28a16f6af29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_4b77e6f0-7f2e-4826-bca4-fe2cd1ede177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8de827dd-970d-4b82-8266-5e7126cdf352" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_4b77e6f0-7f2e-4826-bca4-fe2cd1ede177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_8f8e9753-6740-4ac8-8ff0-4fe5f6cb76db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8de827dd-970d-4b82-8266-5e7126cdf352" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_8f8e9753-6740-4ac8-8ff0-4fe5f6cb76db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="simple" xlink:href="xcur-20210630.xsd#EquityBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d92cd1b6-ea6f-4edf-a6da-9b4ed6e35fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e547130e-86fc-4c41-91ef-0fa62f0a1ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d92cd1b6-ea6f-4edf-a6da-9b4ed6e35fe1" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e547130e-86fc-4c41-91ef-0fa62f0a1ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="simple" xlink:href="xcur-20210630.xsd#EquityBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_22482ec8-8092-4762-816d-8d9dd435ee49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_cef9308f-8671-4a39-ad40-2449b7c8c5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_22482ec8-8092-4762-816d-8d9dd435ee49" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_cef9308f-8671-4a39-ad40-2449b7c8c5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_63e12d59-2599-467d-8fda-3319a5f171c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_22482ec8-8092-4762-816d-8d9dd435ee49" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_63e12d59-2599-467d-8fda-3319a5f171c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8a8b4ecf-3cba-4411-9128-35ec14c9b4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_22482ec8-8092-4762-816d-8d9dd435ee49" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8a8b4ecf-3cba-4411-9128-35ec14c9b4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_7327fbb7-c3a4-4b84-a024-bb8e9a7c813b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_22482ec8-8092-4762-816d-8d9dd435ee49" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_7327fbb7-c3a4-4b84-a024-bb8e9a7c813b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#EquityBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b0cef89-b214-4b6f-9717-05bc03bbbb75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f77b466-1772-4e9f-9732-f8929317c7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b0cef89-b214-4b6f-9717-05bc03bbbb75" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f77b466-1772-4e9f-9732-f8929317c7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_89e01d82-b0e4-413b-86e8-a9217cffc2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f77b466-1772-4e9f-9732-f8929317c7e5" xlink:to="loc_us-gaap_AwardTypeAxis_89e01d82-b0e4-413b-86e8-a9217cffc2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81f18309-bc6b-4c4c-951f-9bb3002aa576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_89e01d82-b0e4-413b-86e8-a9217cffc2fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81f18309-bc6b-4c4c-951f-9bb3002aa576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d7d4fccc-69be-493b-bf02-9de309759115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81f18309-bc6b-4c4c-951f-9bb3002aa576" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d7d4fccc-69be-493b-bf02-9de309759115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_74956bde-3cc7-4600-9361-d1d6c87f4fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81f18309-bc6b-4c4c-951f-9bb3002aa576" xlink:to="loc_us-gaap_EmployeeStockMember_74956bde-3cc7-4600-9361-d1d6c87f4fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4be8c6d3-b89e-4493-bb62-777d8f64734f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81f18309-bc6b-4c4c-951f-9bb3002aa576" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4be8c6d3-b89e-4493-bb62-777d8f64734f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bade395c-090f-4f60-b2de-adb5401479f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f77b466-1772-4e9f-9732-f8929317c7e5" xlink:to="loc_us-gaap_PlanNameAxis_bade395c-090f-4f60-b2de-adb5401479f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_19c45760-5fd4-4835-a3e6-2fcd9be6f8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_bade395c-090f-4f60-b2de-adb5401479f4" xlink:to="loc_us-gaap_PlanNameDomain_19c45760-5fd4-4835-a3e6-2fcd9be6f8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_08c5bf1c-3ff7-4f94-9e78-a9f67a5bb0b9" xlink:href="xcur-20210630.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_19c45760-5fd4-4835-a3e6-2fcd9be6f8dd" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_08c5bf1c-3ff7-4f94-9e78-a9f67a5bb0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ab2f6b02-6549-4567-bbda-eb0ef685d199" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f77b466-1772-4e9f-9732-f8929317c7e5" xlink:to="loc_srt_TitleOfIndividualAxis_ab2f6b02-6549-4567-bbda-eb0ef685d199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13dfe576-767a-4571-acb4-355f778f4bff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_ab2f6b02-6549-4567-bbda-eb0ef685d199" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13dfe576-767a-4571-acb4-355f778f4bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_2753704e-03bd-4d4b-a755-3d8b2b12187f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13dfe576-767a-4571-acb4-355f778f4bff" xlink:to="loc_srt_ChiefFinancialOfficerMember_2753704e-03bd-4d4b-a755-3d8b2b12187f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f77b466-1772-4e9f-9732-f8929317c7e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_6617b695-d909-430f-8719-140b5244623e" xlink:href="xcur-20210630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_6617b695-d909-430f-8719-140b5244623e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_133f3e12-0901-4aa4-9ff7-d85d46a5053c" xlink:href="xcur-20210630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_133f3e12-0901-4aa4-9ff7-d85d46a5053c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_838ae9fb-de55-4323-afda-14f62754232b" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_838ae9fb-de55-4323-afda-14f62754232b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9a47e5f0-9449-41c4-acff-bfe90e4c594a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9a47e5f0-9449-41c4-acff-bfe90e4c594a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_541e12a9-652b-4ffe-986f-8a6e48d50c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_541e12a9-652b-4ffe-986f-8a6e48d50c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23c28f07-d86c-451c-b1c0-287472ff03a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23c28f07-d86c-451c-b1c0-287472ff03a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_db3ce953-e33c-4d1b-a782-16536d89cc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_db3ce953-e33c-4d1b-a782-16536d89cc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_33094e38-9f9e-4975-b57c-4926abc82fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_33094e38-9f9e-4975-b57c-4926abc82fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_64f896c5-fbd8-4f6c-8de8-0423aa185557" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_64f896c5-fbd8-4f6c-8de8-0423aa185557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_eb1ba4ca-8c53-4037-a7fe-8976384d447a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_eb1ba4ca-8c53-4037-a7fe-8976384d447a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_437d5045-6367-413a-9436-fcdc1226a363" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_437d5045-6367-413a-9436-fcdc1226a363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a7d43603-bbbf-445a-b3a1-37db1d981e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a7d43603-bbbf-445a-b3a1-37db1d981e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_b73365b5-7efb-4974-b15d-aebfe31a27be" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_b73365b5-7efb-4974-b15d-aebfe31a27be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_104c5542-9c73-4f68-939f-0fe4951d700d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_104c5542-9c73-4f68-939f-0fe4951d700d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23a3ea0e-8bf3-4eb7-87c5-f2c113d56a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_23a3ea0e-8bf3-4eb7-87c5-f2c113d56a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3bf4acf6-4893-4b77-a933-41b1f83a9446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3bf4acf6-4893-4b77-a933-41b1f83a9446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f4c70011-6ae8-4389-adf9-a9e26330e494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f4c70011-6ae8-4389-adf9-a9e26330e494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3588f383-c146-4ef4-92a5-56f5d0d44f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3588f383-c146-4ef4-92a5-56f5d0d44f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting_17b358ec-dcb7-4ca0-a3fd-4aa73ea9c438" xlink:href="xcur-20210630.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting_17b358ec-dcb7-4ca0-a3fd-4aa73ea9c438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51e3fda7-7ef0-4242-b4c4-52538f649eec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_defce424-b2ec-49d1-81c3-4cd5c00a1ef2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51e3fda7-7ef0-4242-b4c4-52538f649eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#EquityBasedCompensationScheduleofCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_573c3a75-d55e-46d9-adab-2895af6c4002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8f52657-16aa-4116-b21b-a90d85ae6222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_573c3a75-d55e-46d9-adab-2895af6c4002" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8f52657-16aa-4116-b21b-a90d85ae6222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c1c81e7c-3541-41dd-898f-85556eb476e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8f52657-16aa-4116-b21b-a90d85ae6222" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c1c81e7c-3541-41dd-898f-85556eb476e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4f788ad6-e398-43ad-988d-8fba7b4410d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c1c81e7c-3541-41dd-898f-85556eb476e8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4f788ad6-e398-43ad-988d-8fba7b4410d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e7ee3b1-56c8-4d8b-90a0-55dd7532ab6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4f788ad6-e398-43ad-988d-8fba7b4410d4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e7ee3b1-56c8-4d8b-90a0-55dd7532ab6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f5034052-9f95-4869-90ce-6109d5d99674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4f788ad6-e398-43ad-988d-8fba7b4410d4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f5034052-9f95-4869-90ce-6109d5d99674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5643ae79-461c-4794-9c94-8ce1529ddf13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f8f52657-16aa-4116-b21b-a90d85ae6222" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5643ae79-461c-4794-9c94-8ce1529ddf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ea1f467e-512e-4aba-b707-6cf3c5ca1b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5643ae79-461c-4794-9c94-8ce1529ddf13" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ea1f467e-512e-4aba-b707-6cf3c5ca1b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f0910733-1732-4df7-b8de-ff2f088d8415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b4daac3-8041-4df3-b39e-b7200cfbebb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f0910733-1732-4df7-b8de-ff2f088d8415" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b4daac3-8041-4df3-b39e-b7200cfbebb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6666700a-7d3c-49da-b54c-0902adfe56c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b4daac3-8041-4df3-b39e-b7200cfbebb3" xlink:to="loc_srt_RangeAxis_6666700a-7d3c-49da-b54c-0902adfe56c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_64061a2e-c7e0-40a4-831f-5b6a8d526738" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6666700a-7d3c-49da-b54c-0902adfe56c6" xlink:to="loc_srt_RangeMember_64061a2e-c7e0-40a4-831f-5b6a8d526738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c3e0f804-4986-4692-b221-b712a7abc8cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_64061a2e-c7e0-40a4-831f-5b6a8d526738" xlink:to="loc_srt_MinimumMember_c3e0f804-4986-4692-b221-b712a7abc8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9812995c-73a7-4711-97f8-3ecbb693b8d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_64061a2e-c7e0-40a4-831f-5b6a8d526738" xlink:to="loc_srt_MaximumMember_9812995c-73a7-4711-97f8-3ecbb693b8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_627e0b26-24d4-4a3f-8f70-eb86c168db92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_64061a2e-c7e0-40a4-831f-5b6a8d526738" xlink:to="loc_srt_WeightedAverageMember_627e0b26-24d4-4a3f-8f70-eb86c168db92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b4daac3-8041-4df3-b39e-b7200cfbebb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a3f6ba24-68f8-46f0-9666-627594b2740b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a3f6ba24-68f8-46f0-9666-627594b2740b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_25fbe92e-3145-4c7c-9271-5cee758fadaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_25fbe92e-3145-4c7c-9271-5cee758fadaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c34bd6ca-0b3e-46f9-aadf-3ffaa335414c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c34bd6ca-0b3e-46f9-aadf-3ffaa335414c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9f2b2433-c71c-48b2-a2bc-0e358c253fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9f2b2433-c71c-48b2-a2bc-0e358c253fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6b4f5aeb-fada-4547-a53b-659e3830ab86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6b4f5aeb-fada-4547-a53b-659e3830ab86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6c4ba190-89fd-47ea-8caa-a02523b4a664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6c4ba190-89fd-47ea-8caa-a02523b4a664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_b509c50d-2c70-4f29-886b-4d06bc6c23ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_b509c50d-2c70-4f29-886b-4d06bc6c23ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_691a8ad5-1e38-4778-b138-5fdb9d29d7b7" xlink:href="xcur-20210630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_691a8ad5-1e38-4778-b138-5fdb9d29d7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9ba50913-ca86-4696-9e27-27ed2e505268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61e4d4f4-3387-4205-ace0-a1227102b3ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9ba50913-ca86-4696-9e27-27ed2e505268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8c29056-6ca5-431e-a71f-a1dfe3ec070a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07efed41-8437-477d-b120-1bb20137f818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8c29056-6ca5-431e-a71f-a1dfe3ec070a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07efed41-8437-477d-b120-1bb20137f818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4776aac0-5758-4fdc-8e35-6581370f8edb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07efed41-8437-477d-b120-1bb20137f818" xlink:to="loc_srt_RangeAxis_4776aac0-5758-4fdc-8e35-6581370f8edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_582c30e8-6be8-4063-ad66-16244d38130f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4776aac0-5758-4fdc-8e35-6581370f8edb" xlink:to="loc_srt_RangeMember_582c30e8-6be8-4063-ad66-16244d38130f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3f9a71f3-63a2-4d36-8245-5e77280a8adb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_582c30e8-6be8-4063-ad66-16244d38130f" xlink:to="loc_srt_MinimumMember_3f9a71f3-63a2-4d36-8245-5e77280a8adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_081f8478-2b08-413b-be33-c552e9c9b846" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_582c30e8-6be8-4063-ad66-16244d38130f" xlink:to="loc_srt_MaximumMember_081f8478-2b08-413b-be33-c552e9c9b846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_47cb65e1-e22c-455d-a631-f51d2b38a040" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_582c30e8-6be8-4063-ad66-16244d38130f" xlink:to="loc_srt_WeightedAverageMember_47cb65e1-e22c-455d-a631-f51d2b38a040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a1f15c1-97a6-45c5-8e98-ecdcdf46f9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07efed41-8437-477d-b120-1bb20137f818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a1f15c1-97a6-45c5-8e98-ecdcdf46f9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_9081681b-b889-44df-8f6d-f0f7b10e6e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a1f15c1-97a6-45c5-8e98-ecdcdf46f9fb" xlink:to="loc_us-gaap_SharePrice_9081681b-b889-44df-8f6d-f0f7b10e6e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_b35fc388-8e52-4ad3-aac9-0b9647e68157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a1f15c1-97a6-45c5-8e98-ecdcdf46f9fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_b35fc388-8e52-4ad3-aac9-0b9647e68157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d071c599-9037-44d7-9b37-1257184ef4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32bffa41-336e-4fc4-8dc1-9fb3dec789d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d071c599-9037-44d7-9b37-1257184ef4c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32bffa41-336e-4fc4-8dc1-9fb3dec789d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75c4c9c0-2b28-4105-9581-c32fe3f74269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32bffa41-336e-4fc4-8dc1-9fb3dec789d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75c4c9c0-2b28-4105-9581-c32fe3f74269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4e4acfef-c53a-4fcb-ac2d-c0308260ae01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32bffa41-336e-4fc4-8dc1-9fb3dec789d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4e4acfef-c53a-4fcb-ac2d-c0308260ae01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_741de449-5cf6-446b-8fde-80fe6f9fab85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32bffa41-336e-4fc4-8dc1-9fb3dec789d9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_741de449-5cf6-446b-8fde-80fe6f9fab85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a6c0757a-4b66-4581-a6e8-d6a2c8a42844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32bffa41-336e-4fc4-8dc1-9fb3dec789d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a6c0757a-4b66-4581-a6e8-d6a2c8a42844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0244d259-ff07-4dd6-bc4c-a02f743fd308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32bffa41-336e-4fc4-8dc1-9fb3dec789d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0244d259-ff07-4dd6-bc4c-a02f743fd308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_68942e62-02d7-4649-8192-f7e227304633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d071c599-9037-44d7-9b37-1257184ef4c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_68942e62-02d7-4649-8192-f7e227304633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e5e0468c-e0ff-4c77-b945-3555e917c693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d071c599-9037-44d7-9b37-1257184ef4c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e5e0468c-e0ff-4c77-b945-3555e917c693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f75ee238-3277-4198-b684-37c7154577ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d071c599-9037-44d7-9b37-1257184ef4c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f75ee238-3277-4198-b684-37c7154577ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d84a83c1-e8ee-4886-bb9f-a4931353f6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f75ee238-3277-4198-b684-37c7154577ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d84a83c1-e8ee-4886-bb9f-a4931353f6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bb3f765d-39f2-418c-84ee-fd35da61d263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f75ee238-3277-4198-b684-37c7154577ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bb3f765d-39f2-418c-84ee-fd35da61d263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3ea6ddbd-93a7-4aba-bd1a-2cd6a42019d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f75ee238-3277-4198-b684-37c7154577ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3ea6ddbd-93a7-4aba-bd1a-2cd6a42019d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3030843c-2cd0-4ff4-9d13-989edeeee2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f75ee238-3277-4198-b684-37c7154577ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3030843c-2cd0-4ff4-9d13-989edeeee2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a49acc52-00ec-45d9-aabc-9d7e19e988df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f75ee238-3277-4198-b684-37c7154577ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a49acc52-00ec-45d9-aabc-9d7e19e988df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f8ea20b6-087c-4101-9097-f1b3ee9324d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d071c599-9037-44d7-9b37-1257184ef4c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f8ea20b6-087c-4101-9097-f1b3ee9324d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f1412ee2-ba93-465f-b63c-6bafe0e6c7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d071c599-9037-44d7-9b37-1257184ef4c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f1412ee2-ba93-465f-b63c-6bafe0e6c7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0a9482a0-2c93-48cb-9db6-c386fcb70e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d071c599-9037-44d7-9b37-1257184ef4c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0a9482a0-2c93-48cb-9db6-c386fcb70e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8f0b68b1-bebc-42a8-bef0-54e68f0de25d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0a9482a0-2c93-48cb-9db6-c386fcb70e0f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8f0b68b1-bebc-42a8-bef0-54e68f0de25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b3989a10-5285-4802-bc0a-24571247cba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0a9482a0-2c93-48cb-9db6-c386fcb70e0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b3989a10-5285-4802-bc0a-24571247cba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_efb5f3e0-6702-42d5-9fab-b921289cde7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0a9482a0-2c93-48cb-9db6-c386fcb70e0f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_efb5f3e0-6702-42d5-9fab-b921289cde7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_eba75de9-3e6f-4010-85c9-309846aba1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0a9482a0-2c93-48cb-9db6-c386fcb70e0f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_eba75de9-3e6f-4010-85c9-309846aba1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_0eeda602-e7d0-4cf6-8f8a-45802eb25341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0a9482a0-2c93-48cb-9db6-c386fcb70e0f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_0eeda602-e7d0-4cf6-8f8a-45802eb25341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_cd864654-ca99-4422-88cc-aea09787fd36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0a9482a0-2c93-48cb-9db6-c386fcb70e0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_cd864654-ca99-4422-88cc-aea09787fd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#EquityBasedCompensationRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e91e1969-7351-450c-bd07-58ebd70dc1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a01ff70-e42b-40ed-97ce-b9f7697bb25d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e91e1969-7351-450c-bd07-58ebd70dc1c8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a01ff70-e42b-40ed-97ce-b9f7697bb25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4059e1e2-6fcd-4a1f-9cd6-9f76ea9b5482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a01ff70-e42b-40ed-97ce-b9f7697bb25d" xlink:to="loc_us-gaap_AwardTypeAxis_4059e1e2-6fcd-4a1f-9cd6-9f76ea9b5482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_021e5e72-4a5b-46a4-95ce-df921de6dd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4059e1e2-6fcd-4a1f-9cd6-9f76ea9b5482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_021e5e72-4a5b-46a4-95ce-df921de6dd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0f78412f-df5e-4b0d-a855-c393333bc0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_021e5e72-4a5b-46a4-95ce-df921de6dd6c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0f78412f-df5e-4b0d-a855-c393333bc0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7cccec45-bdf4-45ea-b2f5-6bd6913b469e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a01ff70-e42b-40ed-97ce-b9f7697bb25d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7cccec45-bdf4-45ea-b2f5-6bd6913b469e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_66eda113-18b8-410c-8829-ec488774b5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7cccec45-bdf4-45ea-b2f5-6bd6913b469e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_66eda113-18b8-410c-8829-ec488774b5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_749952a3-b3dd-4adb-aaa0-f4116c58aea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_66eda113-18b8-410c-8829-ec488774b5fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_749952a3-b3dd-4adb-aaa0-f4116c58aea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d2cdf93-7650-4e54-8ec7-ca2ed93f7452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_66eda113-18b8-410c-8829-ec488774b5fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d2cdf93-7650-4e54-8ec7-ca2ed93f7452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9342bc1e-b431-4160-bbc5-3209e6d23fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_66eda113-18b8-410c-8829-ec488774b5fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9342bc1e-b431-4160-bbc5-3209e6d23fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f017e8f8-a81b-4a87-b733-3b07994a6bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7cccec45-bdf4-45ea-b2f5-6bd6913b469e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f017e8f8-a81b-4a87-b733-3b07994a6bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6871a4df-c46f-4e9a-9399-9a06db765b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f017e8f8-a81b-4a87-b733-3b07994a6bb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6871a4df-c46f-4e9a-9399-9a06db765b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af546e5f-14c6-4b67-9959-8197db0fbb50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f017e8f8-a81b-4a87-b733-3b07994a6bb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af546e5f-14c6-4b67-9959-8197db0fbb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3a7d4d53-30ec-4d32-bcd6-ac40bafbd5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f017e8f8-a81b-4a87-b733-3b07994a6bb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3a7d4d53-30ec-4d32-bcd6-ac40bafbd5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="xcur-20210630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d66a0b09-f0e9-4853-8deb-2df25d4e0b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_ecc8fa23-f164-41d8-bc8f-f109c2115774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d66a0b09-f0e9-4853-8deb-2df25d4e0b82" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_ecc8fa23-f164-41d8-bc8f-f109c2115774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2bf79986-28e4-44b2-8855-22159130bb54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4a6241a0-484e-4ec8-9372-b4b84e11e799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2bf79986-28e4-44b2-8855-22159130bb54" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4a6241a0-484e-4ec8-9372-b4b84e11e799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6646a0e8-9a8c-4085-8246-c93fbcc7e730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2bf79986-28e4-44b2-8855-22159130bb54" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6646a0e8-9a8c-4085-8246-c93fbcc7e730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="xcur-20210630.xsd#LossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f489419e-c9d4-41d5-a205-163f54728ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_586914e1-7650-4e21-8d1c-054a13ebd002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f489419e-c9d4-41d5-a205-163f54728ae4" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_586914e1-7650-4e21-8d1c-054a13ebd002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="simple" xlink:href="xcur-20210630.xsd#LossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_80f8c4c9-c215-4214-ad38-1eb3206e2c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c2dc3026-4e1c-4f6a-a900-67f0a9e9349b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_80f8c4c9-c215-4214-ad38-1eb3206e2c3d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c2dc3026-4e1c-4f6a-a900-67f0a9e9349b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_15c93206-2a3b-4163-b2d9-91ccd3def196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_80f8c4c9-c215-4214-ad38-1eb3206e2c3d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_15c93206-2a3b-4163-b2d9-91ccd3def196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#LossPerCommonShareComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b0b09e99-ab66-4c19-a6e7-b39751e57e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c39f0dd6-2db3-428c-84f2-6d19e6c0a24c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b0b09e99-ab66-4c19-a6e7-b39751e57e1f" xlink:to="loc_us-gaap_NetIncomeLoss_c39f0dd6-2db3-428c-84f2-6d19e6c0a24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3a30160b-4b00-4357-b6e5-7f2cced45cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b0b09e99-ab66-4c19-a6e7-b39751e57e1f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3a30160b-4b00-4357-b6e5-7f2cced45cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b6073e3-cddd-4cbd-9319-1111c0d88223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b0b09e99-ab66-4c19-a6e7-b39751e57e1f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b6073e3-cddd-4cbd-9319-1111c0d88223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8d3d4ea6-d4f4-4e1e-89cb-636973f709f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b0b09e99-ab66-4c19-a6e7-b39751e57e1f" xlink:to="loc_us-gaap_EarningsPerShareBasic_8d3d4ea6-d4f4-4e1e-89cb-636973f709f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_51dc2b11-eece-4067-9964-079d32235c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b0b09e99-ab66-4c19-a6e7-b39751e57e1f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_51dc2b11-eece-4067-9964-079d32235c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_48d7a077-1cba-42ee-9fc1-344e3b9272c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_59cb1c3d-0594-48ab-9d19-cf08ac497d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_48d7a077-1cba-42ee-9fc1-344e3b9272c6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_59cb1c3d-0594-48ab-9d19-cf08ac497d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cae26c6-e49d-414a-8b49-ab2966a91a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_59cb1c3d-0594-48ab-9d19-cf08ac497d17" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cae26c6-e49d-414a-8b49-ab2966a91a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0fcd34f8-3c0a-458b-9e25-e312d03259f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cae26c6-e49d-414a-8b49-ab2966a91a27" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0fcd34f8-3c0a-458b-9e25-e312d03259f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_72076b3e-871e-4cce-b770-070a4a344d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0fcd34f8-3c0a-458b-9e25-e312d03259f9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_72076b3e-871e-4cce-b770-070a4a344d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_49146bf7-283d-4da0-8f95-e44a949181c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0fcd34f8-3c0a-458b-9e25-e312d03259f9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_49146bf7-283d-4da0-8f95-e44a949181c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_747854db-0ec7-41b8-abd7-ca1ffbef50a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0fcd34f8-3c0a-458b-9e25-e312d03259f9" xlink:to="loc_us-gaap_WarrantMember_747854db-0ec7-41b8-abd7-ca1ffbef50a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_097e997d-ae63-4ab1-b070-27d26d4e1b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_59cb1c3d-0594-48ab-9d19-cf08ac497d17" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_097e997d-ae63-4ab1-b070-27d26d4e1b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ca79b391-b7e9-48a3-91cb-f4ffc2358f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_097e997d-ae63-4ab1-b070-27d26d4e1b3e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ca79b391-b7e9-48a3-91cb-f4ffc2358f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="xcur-20210630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_609069c5-e371-4ade-a8d0-8313da36b3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_9981b103-9e69-4731-860b-3cad423feba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_609069c5-e371-4ade-a8d0-8313da36b3e2" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_9981b103-9e69-4731-860b-3cad423feba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="xcur-20210630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d986c005-50b8-4b05-91b9-f965f8e0c0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_587a7626-ae82-4ee6-9a9a-376338aae37f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d986c005-50b8-4b05-91b9-f965f8e0c0ab" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_587a7626-ae82-4ee6-9a9a-376338aae37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b8002ab9-81fc-4f1a-a589-6fc6f149322f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d986c005-50b8-4b05-91b9-f965f8e0c0ab" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b8002ab9-81fc-4f1a-a589-6fc6f149322f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9d135c6c-9d0b-4423-88c5-114f90e28fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5126e4de-d954-4db7-be3a-2b6f83e89e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9d135c6c-9d0b-4423-88c5-114f90e28fcb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5126e4de-d954-4db7-be3a-2b6f83e89e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_814ecf24-52eb-4735-8767-f688869e75cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5126e4de-d954-4db7-be3a-2b6f83e89e87" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_814ecf24-52eb-4735-8767-f688869e75cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1a4e71e1-f17a-4fdd-ae95-28b0b01501aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_814ecf24-52eb-4735-8767-f688869e75cb" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1a4e71e1-f17a-4fdd-ae95-28b0b01501aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_24895bc7-ee3d-43e2-b9cd-b122cfe6fd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1a4e71e1-f17a-4fdd-ae95-28b0b01501aa" xlink:to="loc_us-gaap_MoneyMarketFundsMember_24895bc7-ee3d-43e2-b9cd-b122cfe6fd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_670bee49-cef5-426b-afa6-a4f1881c1cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5126e4de-d954-4db7-be3a-2b6f83e89e87" xlink:to="loc_us-gaap_FinancialInstrumentAxis_670bee49-cef5-426b-afa6-a4f1881c1cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7817d24b-6054-40e0-b4c0-50ab6ff0204e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_670bee49-cef5-426b-afa6-a4f1881c1cc4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7817d24b-6054-40e0-b4c0-50ab6ff0204e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0c6cc72f-4dbc-4b29-bfa0-4e4d74114ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7817d24b-6054-40e0-b4c0-50ab6ff0204e" xlink:to="loc_us-gaap_CommercialPaperMember_0c6cc72f-4dbc-4b29-bfa0-4e4d74114ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6f31ebb5-fe5a-4944-a1ba-915d6813ca77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7817d24b-6054-40e0-b4c0-50ab6ff0204e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6f31ebb5-fe5a-4944-a1ba-915d6813ca77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a0416c04-1a3a-4feb-8849-5255d1089566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7817d24b-6054-40e0-b4c0-50ab6ff0204e" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a0416c04-1a3a-4feb-8849-5255d1089566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_243e0c00-e757-42fe-b5c1-827b7e7dacd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7817d24b-6054-40e0-b4c0-50ab6ff0204e" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_243e0c00-e757-42fe-b5c1-827b7e7dacd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5c6910a2-28ac-4d6d-894e-96e9aa245983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5126e4de-d954-4db7-be3a-2b6f83e89e87" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5c6910a2-28ac-4d6d-894e-96e9aa245983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_25d002b9-22cf-4d28-9981-c8f6645a4970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5c6910a2-28ac-4d6d-894e-96e9aa245983" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_25d002b9-22cf-4d28-9981-c8f6645a4970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_36834c60-07a8-41d7-bb21-387634e999f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_25d002b9-22cf-4d28-9981-c8f6645a4970" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_36834c60-07a8-41d7-bb21-387634e999f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dcd61f76-1463-42f3-961b-7de7574ba8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5126e4de-d954-4db7-be3a-2b6f83e89e87" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dcd61f76-1463-42f3-961b-7de7574ba8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f68eb9a-27c2-4f35-8c62-0eff03e6d7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dcd61f76-1463-42f3-961b-7de7574ba8e7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f68eb9a-27c2-4f35-8c62-0eff03e6d7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6d74bfc7-e92d-48ae-9cfd-b84962f0aa12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f68eb9a-27c2-4f35-8c62-0eff03e6d7e0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6d74bfc7-e92d-48ae-9cfd-b84962f0aa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2c59e2b9-9232-42eb-8d7c-f8f40e0248fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f68eb9a-27c2-4f35-8c62-0eff03e6d7e0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2c59e2b9-9232-42eb-8d7c-f8f40e0248fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_11819059-2db1-462c-aea4-65e5cb0e5925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f68eb9a-27c2-4f35-8c62-0eff03e6d7e0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_11819059-2db1-462c-aea4-65e5cb0e5925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8f741b3-4e92-4841-ba4f-e40b994988cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5126e4de-d954-4db7-be3a-2b6f83e89e87" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8f741b3-4e92-4841-ba4f-e40b994988cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1451e703-1fc2-4ef4-9c28-4070f363105f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8f741b3-4e92-4841-ba4f-e40b994988cf" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1451e703-1fc2-4ef4-9c28-4070f363105f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ea66b875-ab59-4a80-8e25-f575b74b2d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8f741b3-4e92-4841-ba4f-e40b994988cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ea66b875-ab59-4a80-8e25-f575b74b2d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5f6e1c61-8984-4bbe-994d-5243191a1db2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8f741b3-4e92-4841-ba4f-e40b994988cf" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5f6e1c61-8984-4bbe-994d-5243191a1db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_1a23574a-6bcb-4b11-a11c-0173d2dff063" xlink:href="xcur-20210630.xsd#xcur_CommonStockWarrantLiabilityFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8f741b3-4e92-4841-ba4f-e40b994988cf" xlink:to="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_1a23574a-6bcb-4b11-a11c-0173d2dff063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_2094bbae-fe10-4b46-95ae-ff153f81af61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8f741b3-4e92-4841-ba4f-e40b994988cf" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_2094bbae-fe10-4b46-95ae-ff153f81af61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b690dbf6-41e6-4d6b-a172-add1f6ec5955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db23f112-e2d4-46fe-9713-a9481e16be72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b690dbf6-41e6-4d6b-a172-add1f6ec5955" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db23f112-e2d4-46fe-9713-a9481e16be72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_07127a4b-f85a-4871-8594-80e5cd73778c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db23f112-e2d4-46fe-9713-a9481e16be72" xlink:to="loc_us-gaap_StatementClassOfStockAxis_07127a4b-f85a-4871-8594-80e5cd73778c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_47e108de-ef14-4880-b4bc-90b474a99b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_07127a4b-f85a-4871-8594-80e5cd73778c" xlink:to="loc_us-gaap_ClassOfStockDomain_47e108de-ef14-4880-b4bc-90b474a99b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5af19303-95d1-4cb1-98b1-7aa983ecfbec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_47e108de-ef14-4880-b4bc-90b474a99b0b" xlink:to="loc_us-gaap_CommonStockMember_5af19303-95d1-4cb1-98b1-7aa983ecfbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cd9ae48f-b395-491e-a617-852e99ed7d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db23f112-e2d4-46fe-9713-a9481e16be72" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cd9ae48f-b395-491e-a617-852e99ed7d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_c009c53b-e383-4bb0-b7cc-0abf7af4e7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cd9ae48f-b395-491e-a617-852e99ed7d34" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_c009c53b-e383-4bb0-b7cc-0abf7af4e7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d0efe1a1-d4d5-4252-a1a6-b1c97c7b619d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cd9ae48f-b395-491e-a617-852e99ed7d34" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d0efe1a1-d4d5-4252-a1a6-b1c97c7b619d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_35a2f617-e929-499b-b050-f296a830cba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6416c58c-2b12-4b3f-a27b-5dc6e90d6b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_35a2f617-e929-499b-b050-f296a830cba2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6416c58c-2b12-4b3f-a27b-5dc6e90d6b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_856d4cfb-4ff6-4308-8e53-794b1f73c476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6416c58c-2b12-4b3f-a27b-5dc6e90d6b42" xlink:to="loc_us-gaap_StatementClassOfStockAxis_856d4cfb-4ff6-4308-8e53-794b1f73c476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6300cf54-89fd-4ddc-8865-85b747a70bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_856d4cfb-4ff6-4308-8e53-794b1f73c476" xlink:to="loc_us-gaap_ClassOfStockDomain_6300cf54-89fd-4ddc-8865-85b747a70bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fce17d95-1038-4f59-80e2-6e77db75205e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6300cf54-89fd-4ddc-8865-85b747a70bf4" xlink:to="loc_us-gaap_CommonStockMember_fce17d95-1038-4f59-80e2-6e77db75205e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_0d55fdfc-c060-4216-a149-e1097459030d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6416c58c-2b12-4b3f-a27b-5dc6e90d6b42" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_0d55fdfc-c060-4216-a149-e1097459030d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fb715d1d-224d-4538-9316-f80727925abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0d55fdfc-c060-4216-a149-e1097459030d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fb715d1d-224d-4538-9316-f80727925abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_WarrantLiabilityMember_9c50c2b5-2e52-41b4-bc55-34f572438131" xlink:href="xcur-20210630.xsd#xcur_WarrantLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fb715d1d-224d-4538-9316-f80727925abb" xlink:to="loc_xcur_WarrantLiabilityMember_9c50c2b5-2e52-41b4-bc55-34f572438131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_fd9b28f0-4b04-4588-b84e-a2be3a1bd43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6416c58c-2b12-4b3f-a27b-5dc6e90d6b42" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_fd9b28f0-4b04-4588-b84e-a2be3a1bd43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e869e96a-87c4-4c48-808a-84241ee81df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_fd9b28f0-4b04-4588-b84e-a2be3a1bd43a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e869e96a-87c4-4c48-808a-84241ee81df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_87bdfcda-1c6d-4748-b68f-220b08309223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e869e96a-87c4-4c48-808a-84241ee81df7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_87bdfcda-1c6d-4748-b68f-220b08309223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_6e7c590f-fe1c-423e-9dc7-c08d288b44b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e869e96a-87c4-4c48-808a-84241ee81df7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_6e7c590f-fe1c-423e-9dc7-c08d288b44b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f1ec4286-0a32-4802-a44c-b994aa9fca8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e869e96a-87c4-4c48-808a-84241ee81df7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f1ec4286-0a32-4802-a44c-b994aa9fca8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5024cd0f-9b96-4525-ad31-2a344906c5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e869e96a-87c4-4c48-808a-84241ee81df7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5024cd0f-9b96-4525-ad31-2a344906c5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="xcur-20210630.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fc0b6963-40df-4c9f-8530-27e435ce6fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6aae51ac-3276-49fb-93b7-be30d1401696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fc0b6963-40df-4c9f-8530-27e435ce6fbf" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6aae51ac-3276-49fb-93b7-be30d1401696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#CommitmentandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_083b1fac-6a2e-408d-b6cc-7edaecc949a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AggregatePaymentsMadeToDateForLicenseAgreements_1bf2ae60-6f02-4d8b-a8dc-05c061432b1d" xlink:href="xcur-20210630.xsd#xcur_AggregatePaymentsMadeToDateForLicenseAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_083b1fac-6a2e-408d-b6cc-7edaecc949a8" xlink:to="loc_xcur_AggregatePaymentsMadeToDateForLicenseAgreements_1bf2ae60-6f02-4d8b-a8dc-05c061432b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="xcur-20210630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_45a78717-3fec-4afc-b01c-0dfb1c2fc7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1063df08-8e97-4edf-894c-52f2a367667a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_45a78717-3fec-4afc-b01c-0dfb1c2fc7bb" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1063df08-8e97-4edf-894c-52f2a367667a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_60c59857-b546-47b4-9e2a-2cf4572957ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a74af9c-3c36-490c-a03b-38078b868020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_60c59857-b546-47b4-9e2a-2cf4572957ad" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a74af9c-3c36-490c-a03b-38078b868020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d6f0dfc-7b8f-4c53-828d-2e61d1f5b44e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a74af9c-3c36-490c-a03b-38078b868020" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d6f0dfc-7b8f-4c53-828d-2e61d1f5b44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_23009e04-b100-4a2c-b032-eb79863a1ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d6f0dfc-7b8f-4c53-828d-2e61d1f5b44e" xlink:to="loc_us-gaap_RelatedPartyDomain_23009e04-b100-4a2c-b032-eb79863a1ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_99656aa5-6b7a-4bfc-858c-9ac5e8ce46bd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_23009e04-b100-4a2c-b032-eb79863a1ade" xlink:to="loc_srt_DirectorMember_99656aa5-6b7a-4bfc-858c-9ac5e8ce46bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2521f819-a178-4c38-8855-2c2714255b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a74af9c-3c36-490c-a03b-38078b868020" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2521f819-a178-4c38-8855-2c2714255b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0dcfbf8d-8cd7-4964-b602-8a634863e30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2521f819-a178-4c38-8855-2c2714255b9d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0dcfbf8d-8cd7-4964-b602-8a634863e30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ConsultingServicesMember_fd208671-7820-4179-85ab-f29dfa585391" xlink:href="xcur-20210630.xsd#xcur_ConsultingServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0dcfbf8d-8cd7-4964-b602-8a634863e30d" xlink:to="loc_xcur_ConsultingServicesMember_fd208671-7820-4179-85ab-f29dfa585391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d818e361-16a4-4d5a-9709-b33dcca3eac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7a74af9c-3c36-490c-a03b-38078b868020" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_d818e361-16a4-4d5a-9709-b33dcca3eac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_e15c0d74-1833-4722-babc-0305193e83d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d818e361-16a4-4d5a-9709-b33dcca3eac4" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_e15c0d74-1833-4722-babc-0305193e83d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="xcur-20210630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_17a09f14-1e70-4337-ba6a-1b8d0eb24c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_9102d930-7056-4a40-8100-b4ab0cbf0873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_17a09f14-1e70-4337-ba6a-1b8d0eb24c11" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_9102d930-7056-4a40-8100-b4ab0cbf0873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="xcur-20210630.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_eecf3bbf-d52c-4c06-ad3b-0f36241c8a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_9e482ba0-7fea-44cd-a664-346aca573ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_eecf3bbf-d52c-4c06-ad3b-0f36241c8a7c" xlink:to="loc_us-gaap_SubsequentEventTable_9e482ba0-7fea-44cd-a664-346aca573ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_858d3c88-555c-478a-a307-1a1269a0a5c9" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9e482ba0-7fea-44cd-a664-346aca573ded" xlink:to="loc_xcur_ArrangementNameAxis_858d3c88-555c-478a-a307-1a1269a0a5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_06df31c5-d6ab-491d-9895-c90f4b6b7dd1" xlink:href="xcur-20210630.xsd#xcur_ArrangementNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameAxis_858d3c88-555c-478a-a307-1a1269a0a5c9" xlink:to="loc_xcur_ArrangementNameDomain_06df31c5-d6ab-491d-9895-c90f4b6b7dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenCollaborationMember_c7ec7957-2dff-4904-913f-0d2a477c559d" xlink:href="xcur-20210630.xsd#xcur_IpsenCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameDomain_06df31c5-d6ab-491d-9895-c90f4b6b7dd1" xlink:to="loc_xcur_IpsenCollaborationMember_c7ec7957-2dff-4904-913f-0d2a477c559d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3967c66f-2fab-4e9f-b5e2-d6c62205d024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9e482ba0-7fea-44cd-a664-346aca573ded" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3967c66f-2fab-4e9f-b5e2-d6c62205d024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67aca625-fd76-4686-ae01-a3a62f48a512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3967c66f-2fab-4e9f-b5e2-d6c62205d024" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67aca625-fd76-4686-ae01-a3a62f48a512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_7b1b4eb1-1857-403f-a3d4-eec9edf2093b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67aca625-fd76-4686-ae01-a3a62f48a512" xlink:to="loc_us-gaap_CollaborativeArrangementMember_7b1b4eb1-1857-403f-a3d4-eec9edf2093b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodAxis_66919cfc-f416-46ef-a100-7f7c1b458180" xlink:href="xcur-20210630.xsd#xcur_ExercisePeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9e482ba0-7fea-44cd-a664-346aca573ded" xlink:to="loc_xcur_ExercisePeriodAxis_66919cfc-f416-46ef-a100-7f7c1b458180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodDomain_910caee9-fc13-4c6f-bf49-02012dbe8182" xlink:href="xcur-20210630.xsd#xcur_ExercisePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ExercisePeriodAxis_66919cfc-f416-46ef-a100-7f7c1b458180" xlink:to="loc_xcur_ExercisePeriodDomain_910caee9-fc13-4c6f-bf49-02012dbe8182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodOneMember_0358dad5-6310-43e4-ac16-21eb8d6f3d79" xlink:href="xcur-20210630.xsd#xcur_ExercisePeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ExercisePeriodDomain_910caee9-fc13-4c6f-bf49-02012dbe8182" xlink:to="loc_xcur_ExercisePeriodOneMember_0358dad5-6310-43e4-ac16-21eb8d6f3d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodTwoMember_c37fe673-025e-4c03-b0ef-4630d5acceca" xlink:href="xcur-20210630.xsd#xcur_ExercisePeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ExercisePeriodDomain_910caee9-fc13-4c6f-bf49-02012dbe8182" xlink:to="loc_xcur_ExercisePeriodTwoMember_c37fe673-025e-4c03-b0ef-4630d5acceca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_66b662d0-1b5d-4fa8-848d-bdc60371af9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9e482ba0-7fea-44cd-a664-346aca573ded" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_66b662d0-1b5d-4fa8-848d-bdc60371af9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e371d8f8-a0f0-4791-a4cf-3132dc59b865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_66b662d0-1b5d-4fa8-848d-bdc60371af9e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e371d8f8-a0f0-4791-a4cf-3132dc59b865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c05521c9-11d2-490c-a5c7-af835c3a65bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e371d8f8-a0f0-4791-a4cf-3132dc59b865" xlink:to="loc_us-gaap_SubsequentEventMember_c05521c9-11d2-490c-a5c7-af835c3a65bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9e482ba0-7fea-44cd-a664-346aca573ded" xlink:to="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_NumberofCollaborationPrograms_c2eb3595-ae05-4e34-bd81-9bc4a4330774" xlink:href="xcur-20210630.xsd#xcur_NumberofCollaborationPrograms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_xcur_NumberofCollaborationPrograms_c2eb3595-ae05-4e34-bd81-9bc4a4330774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_e1463e04-547d-4203-a044-3089b7c92e50" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementUpfrontPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_xcur_CollaborationAgreementUpfrontPayment_e1463e04-547d-4203-a044-3089b7c92e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionExerciseFee_6261a925-6cbe-488d-88b3-47ca41c6a6cf" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementOptionExerciseFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_xcur_CollaborationAgreementOptionExerciseFee_6261a925-6cbe-488d-88b3-47ca41c6a6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment_72a0c50a-c960-4ef2-bf6b-3caf019b00f2" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment_72a0c50a-c960-4ef2-bf6b-3caf019b00f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment_9841cf8f-a423-465d-b24f-11377f22eff3" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment_9841cf8f-a423-465d-b24f-11377f22eff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment_2dd8c4d0-b8ff-4560-bd5f-1a834f5e60e7" xlink:href="xcur-20210630.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment_2dd8c4d0-b8ff-4560-bd5f-1a834f5e60e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementLicensingFeesIncurred_55030424-a48a-45cb-a728-087b1a7d5642" xlink:href="xcur-20210630.xsd#xcur_CollaborationAgreementLicensingFeesIncurred"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8bf42c71-7003-4ecd-979a-09e466fb8061" xlink:to="loc_xcur_CollaborationAgreementLicensingFeesIncurred_55030424-a48a-45cb-a728-087b1a7d5642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>xcur-20210630_g1.jpg
<TEXT>
begin 644 xcur-20210630_g1.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@I024-#7U!23T9)3$4  0$   I 041"
M10)   !M;G1R4D="(%A96B 'WP ) !4 #@ $ "!A8W-P35-&5     !$14Q,
M                        ]M8  0    #3+41%3$QM':Y$VU;J;O9-['O4
M\BCC                                          ID97-C    _
M (1C<')T   !@    #AW='!T   !N    !1R6%E:   !S    !1G6%E:   !
MX    !1B6%E:   !]    !1R5%)#   ""   " QG5%)#   ""   " QB5%)#
M   ""   " QC:&%D   *%    "QD97-C         "I$14Q,(%4R-S$W1"!#
M;VQO<B!0<F]F:6QE+$0V-3 P
M
M                      !T97AT     $-O<'ER:6=H=" H8RD@,C Q-2!$
M96QL($EN8RX                          %A96B        #VU@ !
M -,M6%E:(        'PN  ! "   !=)865H@        65(  +*B   =QEA9
M6B         A5P  #58  *^58W5R=@        0     !0 *  \ %  9 !X
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M_DO^W/]M__]S9C,R       !#$0   7?___S)@  !Y0  /V/___[H?___:(
M  /;  # =?_N  Y!9&]B90!D      '_VP!#  P("!L*&R(1%R0J)!P;("0K
M*"@@)"DE)3$O)2DN*BLK.2LJ+B\T-34U-"\[.SL[.SL[.SL[.SL[.SL[.SL[
M.SO_VP!# 0T+"Q .$!L4&R0R*"$H,CLT,C(R.SL[.SL[.SL[.SL[.SL[.SM
M0$! 0#M 0$! 0$! 0$! 0$! 0$! 0$! 0$#_VP!# @T+"Q .$!L4&R0R*"$H
M,CLT,C(R.SL[.SL[.SL[.SL[.SL[.SM 0$! 0#M 0$! 0$! 0$! 0$! 0$!
M0$! 0$#_P  1" 1R"<L# "(  1$! A$"_\0 'P   04! 0$! 0$
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M?VLGH?T_QH O451_M9/0_I_C1_:R>A_3_&@"]15'^UD]#^G^-']K)Z']/\:
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M?VLGH?T_QH O451_M9/0_I_C1_:R>A_3_&@"]15'^UD]#^G^-']K)Z']/\:
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MC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4
M1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/
MR%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1
M]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D
M_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T
M4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^
MZ/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\
MA1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?
M9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%
M2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F
M3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_N
MC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4
M1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/
MR%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1
M]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D
M_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T
M4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^
MZ/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\
MA1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?
M9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%
M2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F
M3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_N
MC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4
M1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/
MR%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 9>JQ!-N !U
MZ#'I5_[,G]T?D*I:Q_#^/]*TJ (OLR?W1^0H^S)_='Y"I:* (OLR?W1^0H^S
M)_='Y"I:* (OLR?W1^0H^S)_='Y"I:* (OLR?W1^0H^S)_='Y"I:* (OLR?W
M1^0H^S)_='Y"I:* (OLR?W1^0H^S)_='Y"I:* (OLR?W1^0H^S)_='Y"I:*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH S=8_A_'^E:59NL?P_C_2M*@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S;W_
M %J?\!_G6E6;>_ZU/^ _SK2H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K-_Y;_Y_NUI5F_\ +?\ S_=H TJ*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH S='_B_#^M:59NC_P 7X?UK2H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *S='_ (OP_K6E6;H_\7X?UH TJ*** "J.K?<'^]_0U>JC
MJWW!_O?T- %FV^XO^Z/Y5+45M]Q?]T?RJ6@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0'4@JP!!!R"#T(-8/A_QK#KLA@B5PRJ6^<*!@$#LQ]:2387.@HHK%\1^*XM
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M?-M&S"_Q=<@'H,@<D XKHJ&FMP3N%9O_ "W_ ,_W:TJS?^6_^?[M(9I4444
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MNPZ GDCIZX%)*XS1HJEHVJKJT2W,8(5\X#8!X)7L3Z>M7:&K %%%% !1110
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MQ'\,1;1^;:%G9<ED;!)'^S@#D>G?MSP:LG&-W86MV9D4:2:JHLL;/.4C8<#
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M=ZSK*V]H]XC8!BW(V.[#Y#@CN2.H^M9'Q,T\7%H9N-T+*0<9.&.TC/;J"?7
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M -:IJ* (?[8_V?U_^M1_;'^S^O\ ]:IJ* (?[8_V?U_^M1_;'^S^O_UJFHH
MA_MC_9_7_P"M1_;'^S^O_P!:IJ* (?[8_P!G]?\ ZU']L?[/Z_\ UJFHH A_
MMC_9_7_ZU']L?[/Z_P#UJFHH A_MC_9_7_ZU']L?[/Z__6J:B@"'^V/]G]?_
M *U']L?[/Z__ %JFHH A_MC_ &?U_P#K4?VQ_L_K_P#6J:B@"'^V/]G]?_K4
M?VQ_L_K_ /6J:B@"'^V/]G]?_K4?VQ_L_K_]:IJ* (?[8_V?U_\ K4?VQ_L_
MK_\ 6J:B@"'^V/\ 9_7_ .M1_;'^S^O_ -:IJ* (?[8_V?U_^M1_;'^S^O\
M]:IJ* (?[8_V?U_^M1_;'^S^O_UJFHH A_MC_9_7_P"M1_;'^S^O_P!:IJ*
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MO_UJFHH A_MC_9_7_P"M1_;'^S^O_P!:IJ* (?[8_P!G]?\ ZU']L?[/Z_\
MUJFHH A_MC_9_7_ZU']L?[/Z_P#UJFHH A_MC_9_7_ZU']L?[/Z__6J:B@"'
M^V/]G]?_ *U']L?[/Z__ %JFHH A_MC_ &?U_P#K4?VQ_L_K_P#6J:B@"'^V
M/]G]?_K4?VQ_L_K_ /6J:B@"'^V/]G]?_K4?VQ_L_K_]:IJ* (?[8_V?U_\
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MV?U_^M4U% $/]L?[/Z__ %J/[8_V?U_^M4U% $/]L?[/Z_\ UJ/[8_V?U_\
MK5-10!#_ &Q_L_K_ /6H_MC_ &?U_P#K5-10!#_;'^S^O_UJ/[8_V?U_^M4U
M% $/]L?[/Z__ %J/[8_V?U_^M4U% $/]L?[/Z_\ UJ/[8_V?U_\ K5-10!0F
MO/-<28Z8XSZ'-6?[8_V?U_\ K5-10!#_ &Q_L_K_ /6H_MC_ &?U_P#K5-10
M!#_;'^S^O_UJ/[8_V?U_^M4U% $/]L?[/Z__ %J/[8_V?U_^M4U% $/]L?[/
MZ_\ UJ/[8_V?U_\ K5-10!#_ &Q_L_K_ /6H_MC_ &?U_P#K5-10!#_;'^S^
MO_UJ/[8_V?U_^M4U% $/]L?[/Z__ %J/[8_V?U_^M4U% $/]L?[/Z_\ UJ/[
M8_V?U_\ K5-10!#_ &Q_L_K_ /6H_MC_ &?U_P#K5-10!#_;'^S^O_UJ/[8_
MV?U_^M4U% $/]L?[/Z__ %J/[8_V?U_^M4U% $/]L?[/Z_\ UJ/[8_V?U_\
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MU344 0_VQ_L_K_\ 6H_MC_9_7_ZU344 0_VQ_L_K_P#6H_MC_9_7_P"M4U%
M$/\ ;'^S^O\ ]:C^V/\ 9_7_ .M4U% $/]L?[/Z__6H_MC_9_7_ZU344 0_V
MQ_L_K_\ 6H_MC_9_7_ZU344 0_VQ_L_K_P#6H_MC_9_7_P"M4U% $/\ ;'^S
M^O\ ]:C^V/\ 9_7_ .M4U% $/]L?[/Z__6H_MC_9_7_ZU344 0_VQ_L_K_\
M6H_MC_9_7_ZU344 0_VQ_L_K_P#6H_MC_9_7_P"M4U% %"SO/LV>,YQWQTJS
M_;'^S^O_ -:IJ* (?[8_V?U_^M1_;'^S^O\ ]:IJ* (?[8_V?U_^M1_;'^S^
MO_UJFHH A_MC_9_7_P"M1_;'^S^O_P!:IJ* (?[8_P!G]?\ ZU']L?[/Z_\
MUJFHH A_MC_9_7_ZU']L?[/Z_P#UJFHH A_MC_9_7_ZU']L?[/Z__6J:B@"'
M^V/]G]?_ *U']L?[/Z__ %JFHH A_MC_ &?U_P#K4?VQ_L_K_P#6J:B@"'^V
M/]G]?_K4?VQ_L_K_ /6J:B@"'^V/]G]?_K4?VQ_L_K_]:IJ* (?[8_V?U_\
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M7,CN**KW]\MA&T[_ '4!)Z?D,XY/0>IK@U\67VNN19J%"#) VGKCJS\=<X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)C52R*S;3O0 ]MVTMQD >_3TKU62,2 JP!!!!!&00>HQ3J*J<W(%%(X&_P#
M]QITAN+!L#C"[L-U&5Y^5E[_ #'D<')'->ZT75-7Q%.<)SG+(%]>1'R>0,<'
M!].:]&HI^U8N1&1X:\.+H<9C!W,QRS8 SZ#OP/J>23WKE/$GAJ[GO&NX$R 4
M*MN3JJKV8]B.XKT*BDIM.XW%-6.!_P")S_GR*L:?_:WF)YO^KWKO_P!3]W(W
M=.>GIS7;44>T\D+E\PHHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_0U>JCJWW!_O?T- %FV^XO\ NC^52U%;?<7_ '1_*I: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *HZM]P?[W]#5ZJ.K?<'^]_0T 6;;[B_[H_E4M16WW%_W1_*I: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML',CLZ*XS_A:MK_<E_[Y3_XNC_A:MK_<E_[Y3_XNCV<NP<R.SHKC/^%JVO\
M<E_[Y3_XNC_A:MK_ ')?^^4_^+H]G+L',CLZ*XS_ (6K:_W)?^^4_P#BZ/\
MA:MK_<E_[Y3_ .+H]G+L',CLZ*XS_A:MK_<E_P"^4_\ BZ/^%JVO]R7_ +Y3
M_P"+H]G+L',CLZ*XS_A:MK_<E_[Y3_XNC_A:MK_<E_[Y3_XNCV<NP<R.SHKD
MK+XFVMRZQD.FXXW.%"CZD,<?7H.^!S76U+BUN--,****0PHHHH **** "BBB
M@ HHHH **** "J7_ "U_SZ5=JE_RU_SZ4 7:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH I:;W_  _K5VJ6F]_P_K5V@ HHHH **** "BBB@ HHHH ****
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MBBN@\%>'X]=F:"4L%6,M\A .0RCN#ZTF[*X)7.?HK6\+:4NK7*6TA(5]V2N
M>%+=P?3TJQXQ\-_V#-Y:Y,;J"A;D^C G &0?3L1ZTN97L.VES!HKH/!7A^/7
M9F@E+!5C+?(0#D,H[@^M5?"VE+JUREM(2%?=DK@'A2W<'T]*.9:^06,FBNXN
M=#TFV9HGGE#(Q4C!."#@CB*H-4\%12P&^L)3)&@.Y7P&^7)8YPN,#!VD D<@
MG(!7M$'*SCJ***L04444 %%%% !1110 445T'C7P_'H4RP1%BK1AOG()R68=
M@/2E?6P6.?HHKH++P_'/82Z@2WF1R!0 1MP2G48S_$>_I0W8$KG/T5J7%O;+
M;)(CL;DL=Z$?*%^;!!V_[O\ $>IX],NA.X!1113 **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *[SP+XZ^RXLKD_N^B.?X?12?[OH?X>A^
M7[O!T5,HJ2LQIV/HFBO,O OCK[+BRN3^[Z(Y_A]%)_N^A_AZ'Y?N^FUR3@XN
MQM&5PHHHJ1A1110 4444 %%%% !1110 52_Y:_Y]*NU2_P"6O^?2@"[1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% %+3>_X?UJ[5+3>_P"']:NT %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %9NC_Q?A_6M*LW1_P"+\/ZT :5%%% !
M5'5ON#_>_H:O51U;[@_WOZ&@"S;?<7_='\JEJ*V^XO\ NC^52T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\*O^/I_^N+?^AI757'Q*M$C,B,6?;D)M8')[$XVC'<Y/MGC/._"BP8RR7/\
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M]WL\O;_%NSNW?[(QC%7_ !+I\5];R)-@*%9MQ!.TJ"=X YX]!U&1T-:=>?\
MQ+UYG*Z9#R7P7 &XG)&Q!C)SD9(QG[N#@D5G%<TM-"GHM3A_#MFEY<10RG".
MX!X)SZ+Q@C<>,]LY[5[M'&(@$4 *H   P !T %>7>(/ 9L+2.=%)E0$S8YX;
MG/WB/DZ':.1\QP!79^"?$1UN ,Y'FH=KXP/HV >X^@R#@8%75?,KK8F&FAYS
MX=T'^U[>YVC,D7ELF!R<;]R]">1T ZL%KJO#NN?VCIL\+??@A=3_ +NQMAZ
M=!CN>,GK5?X1?\O'_;+_ -GK)\36K>&+F0QC]U<Q2  <#$@(*_=P-K8( _AV
M@GFKE[TG'[A+1)G3_"K_ (]7_P"NS?\ H"5TNK?<'^]_0US7PJ_X]7_Z[-_Z
M E=+JWW!_O?T-8U/B9<=D6;;[B_[H_E4M16WW%_W1_*I:@H**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH XSXJ_\>J?]=E_] >N=\/?$7^QX$M?*W;-
MW/F;<[F+=-I]?6NB^*O_ !ZI_P!=E_\ 0'K1^'W_ !XQ?\#_ /1C5LFE3U5]
M2'?F#PCXN_X2+S/W>SR]O\6[.[=_LC&,5YZ8);N_FM86*F>:5&(Q]S>6;J1V
M7)&1D#'?%>R5Y5H/_(8;_KM<?R>BFU[S78)+8U]6\,CP_IL\6\N79#G!4??0
M8V[B/J>IX!Z"I/AO=BSL9IVSMCDD8XZX6-2<5L?$'_CQE_X!_P"C%K#\ 6AO
M-/G@7&Z1I5&>F6C4#-%[P;?<+6D8.ENOBF5Y=0G"(H^4>8$P6/10V1@!>>^<
M$D\FKOAC5SHU[]@64/;,VU?FWK\V2F". <D!L#&2<] 1F>#K:T:1[>_&&XVE
MV9 "N=RD@C!Z=?3'7 /2:6-*:Z$$,;>8C HX,C(64@\88].N2-N 3G'6Y6U6
MMB5W,SQ%>2>*;X::K;8T=E (XR@.]B >3P=O3C'3)--\:^%3H,*B*1C \@RC
MX)#[6PP( '*Y!Z=NO&V*20>']5,T^0AD=L@$_+*&P>V<;N<9Y! SBM3XF>((
M+N)+:)P[;PY*$,H ##D@]3GI^>.,BNG%+8-+/N:.@_\ (';_ *XW'\WKCO">
M@R^(@UKYA2&,[SP&&]L*.,J3D*<'G&#TSSV.@_\ (';_ *XW'\WK.^$7_+Q_
MVR_]GJ;V4GYCM=H9XUU>30(H=,@=@5C!9P2&(!P #N)&2#D=A@ XR*S-5T*#
M28%N;:Y!N$V[@DRGJ-K;-H#=3W/W<YJ[\5[!A+'<_P !39GG@J2W/&.0>.><
M'TJS-'HT4(N=N=V/D61S)D]05W\8]2<>A.1EQ=HIB>[)K_6SK&D/,Y!D!57P
M,<B1<>W*D$XXR>W02?#>[%G8S3MG;')(QQUPL:DXINJK;?V5*]FI6-V0X;=G
M=O0'[Q.<8QP2,@X/6F^ +0WFGSP+C=(TJC/3+1J!FI=N5^H^J]#(T+3Y/&\S
MRW,A"1\[5/3?D *#D*/EY/).!G).1M^'_"]WHEV5B)-IDGYW #!@/X1N^8>N
M%SMQD XK(^&^KQZ3)+;W!\MGVX+_ "@%-V5)/0\]_3'7 /46GCR.[N_L,:%U
M)PLB,""0,L<'' YY!.<< YISYKM+8(VM?J<9XK1WU0K$0)#)#M)Z!MJ8)X/0
M^Q^E6?&7A$:%&EXDKM*9 &9CR6(+;P1R.0>I)YZ\<MU[_D,+_P!=K?\ DE=%
M\5?^/5/^NR_^@/3YFG%>0K;FSX6U!]6M$FD.'=6!90 <ABN[!!&>,],9[8XJ
MSHFBKI:XR7D;!>1SEV(&!DG/ Z 9X'ODG.^'W_'C%_P/_P!&-7022",%CG !
M/ )/'H!DGZ#FL9:-HT6R/&[74%\1W&=0F*(<XQ]T$X 49R$'<DCMR<G-=GX9
M\*R:;*)K:X#VK9./O \X(P#MR /O@YR,;<9%9TITKQ%(Y),+[MQ<L(P_8D;B
M5YX)R QZ_P!ZL/P]*VE7ZV]M(94,BJQ4$*PQACM!YVY)!Y'&[I6[U3MIY&:T
M9[!7-_$'4S8VC@9W2D1C !^]DMG/JH(]<D?4=)7F'Q*NSJ-U'8QX+( ,=#OE
M(XR>.FW'U.3Z8TE>1<W9$VD>'UETF60XW/OD!V@D>42 N??:>>VX\=<Z?PLU
M,W$#VQSF%N.!C:^2!ZGY@Q.?4<^F='X(U.(!%N0%4  ":4  = !MK,\);O#N
MH?9IL MF,GDCYL,A&/4[>HX!Y [:NTE+6_4E:-%#4_#\=K?C3U+>69(ER2-V
M'"YYQCOQQ7I<^@26=I]ALGVL,@-)UPS$M\RC@\\'!_ _,.%\12"+5P[$!5F@
M)).   F236Q\3]1:6&'R6W02,^XH<H2N-H+#_@7&>HSU'!*\N5 K*YA^(?#=
MEI\'F0W DF!48#(P;UP%Y7UR21QCJ0:[/X<ZI)J%KF4EF21EW$DL1@-R23G[
MV/H!7'7UO8VU@KQ8:YD5 ?FRZG<&?Y21M VE00.A')!)/3_"K_CU?_KLW_H"
M4IZP^81^(YV\C;P->^:@W12*VT<@%2?N;B&Y4@'C)(QG&<5I_#C13=N^JS9+
M%FV'IDMG>V  #UP,<9W<9 K.\17+^,;L6EOC9$' )Y7C[SY4' . !U'3IG%:
M_P ./$;-G3)\[X\[-QP<+@&/!P<KR0.>,C@**<K\GGU!6YO(QOBK_P ?2?\
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MB@ HHHH **** "BBB@ HHHH **** "NT^%7_ !]/_P!<6_\ 0TKBZ[3X5?\
M'T__ %Q;_P!#2HJ?"QQW1G?#[_C^B_X'_P"BVK?$@UXW.CN0)%GE>%F/&0Y)
M7 P3U;^]P2<?*,X'P^_X_HO^!_\ HMJJ:O>O97LTT1*NL\A!'^^?\D=".#4R
M5Y?(:=D;WPNC,5W(C AEA8$$8((=,@BLSX??\?T7_ __ $6U=WX<MX[V<:K
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M98TG6['79$MI+98F+J4*[,$KD[6.U>&QMQ@YSV.#7.^.;9;:\ECC4*HV8"@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "LW1_XOP_K6E6;H_P#%^']:
M -*BBB@ JCJWW!_O?T-7JHZM]P?[W]#0!9MON+_NC^52U%;?<7_='\JEH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *R=5\+6VK,)9TW,%V@[F' )./E(]36M133:"PV.,1
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MM]P?[W]#5ZJ.K?<'^]_0TF[@6;;[B_[H_E4M16WW%_W1_*I: "BBB@ HHHH
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MYB3C@<9QWK1HHYG:PK(I:IHT.JKLG0.!TSU'0\,,$9P,X//>J47@VTB1H%B
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MHHH **** "BBB@ HHHH **** "M3P_X@DT*0SQ!2S*5^<$C!(/8CTK+HI-7
MNZ-JK:3*MS& 63. V2.05[$>OK4-[=F\D>=L;I&9CCIECDXJ"BBVMP-SP[XO
MFT$,D04JY!P^X@$=P PZ]_7 ]*H:-JK:3*MS& 63. V2.05[$>OK5*BCE6OF
M%V=I_P +5NO[D7_?+_\ Q=8^M^,KG6 8Y& C)!V(,+Q[\L>><$D9^@QAT4E"
M*Z#<FPHHHJA'2Z/\0+K2T$(*NJ@!1("=H&> 00?SS@  8%4M>\53ZX0)B-H.
M0BC"@XQGN3^).,G& :QZ*GD5[V'=FI;^()(+9]/ 7RY&#$D'=D;>ASC^$=O6
MH-&U5M)E6YC +)G ;)'(*]B/7UJE13LA7-:R\3364[7L9 >1F+#&5(9MQ7!R
M<9'8Y]ZU;[XE7=TH0;8\,#F,'/'./F+<>OKT/!(/*44G"+Z#YF7];UAM8E-R
MZJK,!G9G!P, \D]L#CCCIG-;C?$J[,GG#:!M *8.PXSS@DD'GL1G SG%<I10
MXIA=FQKWBJ?7"!,1M!R$484'&,]R?Q)QDXP#4=OX@D@MGT\!?+D8,20=V1MZ
M'./X1V]:RZ*?*K6%=FI<>())[9-/(7RXV+ @'=D[NISC^(]O2C5?$$FIQPP.
M%"VZ[5V@@D84<Y)_NCIBLNBCE07-32O$$FF1S0(%*W"[6W D@88<8(_O'KFM
M?PCHL\L;WMG)B>-MOE@+DAL<DLV,=2,@\KQSTY2K-AJ,FGL)86*,.ZGW!P?4
M<=#P>]*4=-!IGHFFZSJ6KRQQ/%Y48=6=MCIE5()7+$]>F!R>_P N:XSQE?K?
MW<LL?*E@ >,':H7(()X.,CVHO_&5W?J8I)25/4*%7/!!!V@9'/0\5BU,(6=Q
MN5PHHHK0D**** "BBB@ HHHH **** "BBB@ HHHH **** "GQQF4A%!+,0
M,DD] !1'&92$4$LQ   R23T %>L^"?!(T<"XF ,[#ZA >P]_4_@.,EHG-10X
MQN'@GP2-' N)@#.P^H0'L/?U/X#C);K:**Y)2<G=FR5@HHHI#"BBB@ HHHH
M**** "BBB@ JE_RU_P ^E7:I?\M?\^E %VBBB@ HHHH **** "BBB@ HHHH
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MKZG]/\*M44 5?[/7U/Z?X4?V>OJ?T_PJU10!5_L]?4_I_A1_9Z^I_3_"K5%
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M3^G^%6J* *O]GKZG]/\ "C^SU]3^G^%6J* *O]GKZG]/\*/[/7U/Z?X5:HH
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M_9Z^I_3_  JU10!5_L]?4_I_A1_9Z^I_3_"K5% %7^SU]3^G^%']GKZG]/\
M"K5% %7^SU]3^G^%5_LXW^7V_P#K9K2JE_RU_P ^E #_ .SU]3^G^%']GKZG
M]/\ "K5% %7^SU]3^G^%']GKZG]/\*M44 5?[/7U/Z?X4?V>OJ?T_P *M44
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M_9Z^I_3_  JU10!5_L]?4_I_A1_9Z^I_3_"K5% %7^SU]3^G^%']GKZG]/\
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MH **** "BBB@ HHHH **** "BBB@#G?'-Z]C;M-&<.N,' /5E!X.1T->=_\
M"P;[_GK_ ..1_P#Q-=[\1_\ CT?_ (#_ .AK7C]=%&*<3.HVF='_ ,+!OO\
MGK_XY'_\31_PL&^_YZ_^.1__ !-<Y16O)'L1S,Z/_A8-]_SU_P#'(_\ XFC_
M (6#??\ /7_QR/\ ^)KG**.2/8.9G1_\+!OO^>O_ (Y'_P#$T?\ "P;[_GK_
M ..1_P#Q-<Y11R1[!S,Z/_A8-]_SU_\ '(__ (FC_A8-]_SU_P#'(_\ XFN<
MHHY(]@YF='_PL&^_YZ_^.1__ !-'_"P;[_GK_P".1_\ Q-<Y11R1[!S,Z/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6;H_P#%^']:TJS='_B_#^M &E11
M10 51U;[@_WOZ&KU4=6^X/\ >_H: +-M]Q?]T?RJ6HK;[B_[H_E4M !1110
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M[B_[H_E4M16WW%_W1_*I:D84444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 =!X1\7/H+X.6A8_,O_LP]_P!".#V(]BLKU+U%FB(9&&01_G\Q
MU!X-?/M=3X UZ6QG6V0%HYF 9>>,_P 8],#D]B!ST!&-6G?7J7"5M#V"BBBN
M8U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *I?\M?\^E7:I?\ +7_/I0!=HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"EIO?\/ZU=JEIO?\ #^M7: "BBB@ HHHH **** "BBB@
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MBA<XZ9P!ZTV3289'\]HT,F0=Q12V1T.<9XQQ5>T7,WW%RZ)'FOQ5_P"/I/\
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M,-F=\4:(Q&,HBJ<>F0*TE4337<E1=T>:Z#_R&&_Z[7'\GHU[_D,+_P!=K?\
MDE>E1Z3#&_GK&@DR3N"*&R>ISC/.>:)-)AD?SVC0R9!W%%+9'0YQGC'%'M5>
M_E8.30Y?XJ_\>J?]=E_] >M'X??\>,7_  /_ -&-6W=V4=X-DJ*Z@YPZAAGU
MP:=;VRVRB.-0JCH%  &>>@J>;W;%6UN<W\1_^/1_^ _^AK7C]>P?$?\ X]'_
M . _^AK7C];4/A,ZFX4445L0%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !114]E9/>NL,0+.QP /\_F>@')H +*R>]=88@6=C@ ?Y_,] .37L7A'
MPBF@IDX:9A\S?^RCV_4GD]@#PCX1304R<-,P^9O_ &4>WZD\GL!T%<M6KS:+
M8UA"VH4445D6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 52_Y:_P"?2KM4O^6O^?2@"[1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% %+3>_X?UJ[5+3>_X?UJ[0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5FZ/_ !?A_6M*LW1_XOP_K0!I4444 %4=6^X/
M][^AJ]5'5ON#_>_H: +-M]Q?]T?RJ6HK;[B_[H_E4M !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %4=6^X/][^AJ]5'5ON#_>_H: +-M]Q?]T?RJ6HK;[B_P"Z/Y5+0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_?M/\*/^$<M?^>$7_?M/\*/K"[![-G@]%>\?\(Y:_P#/"+_OVG^%'_".6O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ JE_RU_P ^E7:I?\M?\^E %VBBB@ HHHH **** "BBB@ HHHH
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M_L]?4_I_A1_9Z^I_3_"@ _M!?0_I_C1_:"^A_3_&C^SU]3^G^%']GKZG]/\
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M7U/Z?X4?V>OJ?T_PH /[07T/Z?XT?V@OH?T_QH_L]?4_I_A1_9Z^I_3_  H
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M_L]?4_I_A1_9Z^I_3_"@ _M!?0_I_C1_:"^A_3_&C^SU]3^G^%']GKZG]/\
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M?4_I_A1_9Z^I_3_"@ _M!?0_I_C1_:"^A_3_ !H_L]?4_I_A1_9Z^I_3_"@
M_M!?0_I_C1_:"^A_3_&C^SU]3^G^%']GKZG]/\* #^T%]#^G^-']H+Z']/\
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M7U/Z?X4?V>OJ?T_PH /[07T/Z?XT?V@OH?T_QH_L]?4_I_A1_9Z^I_3_  H
M/[07T/Z?XT?V@OH?T_QH_L]?4_I_A1_9Z^I_3_"@ _M!?0_I_C1_:"^A_3_&
MC^SU]3^G^%']GKZG]/\ "@ _M!?0_I_C1_:"^A_3_&C^SU]3^G^%']GKZG]/
M\* #^T%]#^G^-']H+Z']/\:/[/7U/Z?X4?V>OJ?T_P * #^T%]#^G^-']H+Z
M']/\:/[/7U/Z?X4?V>OJ?T_PH /[07T/Z?XT?V@OH?T_QH_L]?4_I_A1_9Z^
MI_3_  H /[07T/Z?XT?V@OH?T_QH_L]?4_I_A1_9Z^I_3_"@ _M!?0_I_C1_
M:"^A_3_&C^SU]3^G^%']GKZG]/\ "@"O:7 ASGOCI5C^T%]#^G^-5[2W$V<]
ML=*L?V>OJ?T_PH /[07T/Z?XT?V@OH?T_P :/[/7U/Z?X4?V>OJ?T_PH /[0
M7T/Z?XT?V@OH?T_QH_L]?4_I_A1_9Z^I_3_"@ _M!?0_I_C1_:"^A_3_ !H_
ML]?4_I_A1_9Z^I_3_"@ _M!?0_I_C1_:"^A_3_&C^SU]3^G^%']GKZG]/\*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M17@__"1W7_/>7_OX_P#C1_PD=U_SWE_[^/\ XT?5WW#VB/>**\'_ .$CNO\
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MWE_[^/\ XT?\)'=?\]Y?^_C_ .-'U=]P]HCWBBO!_P#A([K_ )[R_P#?Q_\
M&C_A([K_ )[R_P#?Q_\ &CZN^X>T1[Q17@__  D=U_SWE_[^/_C1_P )'=?\
M]Y?^_C_XT?5WW#VB/>**\.LO%MU:NLHE=MIZ.[,I]B"?_K]P0>:];\.>(X]=
MC\V/AA@.A/*G^H/8]_8@@3.DXE1FF:U%%%9E!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+_
M ):_Y]*NU2_Y:_Y]* +M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4M-[_
M (?UJ[5+3>_X?UJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5FZ/\
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MD1X# $ JS%AU."...W SDFHP<G8')(]3HKA_&7CA$MU%I)\\W0[6!"992P)
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M (?UJ[5+3>_X?UJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5FZ/\
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M*".G.<]QG..1G1@NM*UYEWIY#C;D<(C8R2N1\N/<A6/ ![5K>)/%L^DS>7-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !72^ +2>:Z5X,A4(\P_P[">5/KNQP/7GC&10\.>')-=D
M\J/A1@NY'"C^I/8=_8 D>S:1I$>DQBWA&%'4]R>[$]R?_K#  %95:B2L7"-]
M2[1117*:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %4O\ EK_GTJ[5+_EK_GTH NT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!2TWO\ A_6KM4M-[_A_6KM !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#EOB/_P >C_\  ?\ T-:\?KV?QS9/
M?6[0QC+MC R!T92>3@=!7G?_  KZ^_YY?^/Q_P#Q5=%&243.HFV<Y171_P#"
MOK[_ )Y?^/Q__%4?\*^OO^>7_C\?_P 56O/'N1RLYRBNC_X5]??\\O\ Q^/_
M .*H_P"%?7W_ #R_\?C_ /BJ.>/<.5G.45T?_"OK[_GE_P"/Q_\ Q5'_  KZ
M^_YY?^/Q_P#Q5'/'N'*SG**Z/_A7U]_SR_\ 'X__ (JC_A7U]_SR_P#'X_\
MXJCGCW#E9SE%='_PKZ^_YY?^/Q__ !5'_"OK[_GE_P"/Q_\ Q5'/'N'*SG**
MZ/\ X5]??\\O_'X__BJ/^%?7W_/+_P ?C_\ BJ.>/<.5G.45T?\ PKZ^_P">
M7_C\?_Q5'_"OK[_GE_X_'_\ %4<\>X<K.<HKH_\ A7U]_P \O_'X_P#XJC_A
M7U]_SR_\?C_^*HYX]PY6<Y171_\ "OK[_GE_X_'_ /%4?\*^OO\ GE_X_'_\
M51SQ[ARLYRBNC_X5]??\\O\ Q^/_ .*H_P"%?7W_ #R_\?C_ /BJ.>/<.5G.
M45T?_"OK[_GE_P"/Q_\ Q5'_  KZ^_YY?^/Q_P#Q5'/'N'*SG**Z/_A7U]_S
MR_\ 'X__ (JC_A7U]_SR_P#'X_\ XJCGCW#E9SE%='_PKZ^_YY?^/Q__ !5'
M_"OK[_GE_P"/Q_\ Q5'/'N'*SG**Z/\ X5]??\\O_'X__BJ/^%?7W_/+_P ?
MC_\ BJ.>/<.5G.45T?\ PKZ^_P">7_C\?_Q5'_"OK[_GE_X_'_\ %4<\>X<K
M.<HKH_\ A7U]_P \O_'X_P#XJC_A7U]_SR_\?C_^*HYX]PY6<Y16^W@2]4[3
M%R?]M/\ XJI/^%?7W_/+_P ?C_\ BJ.>/<.5G.45T?\ PKZ^_P">7_C\?_Q5
M'_"OK[_GE_X_'_\ %4<\>X<K.<HKH_\ A7U]_P \O_'X_P#XJC_A7U]_SR_\
M?C_^*HYX]PY6<Y171_\ "OK[_GE_X_'_ /%4?\*^OO\ GE_X_'_\51SQ[ARL
MYRM;PYX<DUV3RH^%&"[D<*/ZD]AW]@"1IV7PXO)G5)$"*3RQ9&P/HK$GV'KU
M('->IZ1I$>DQBWA&%'4]R>[$]R?_ *PP !45*J2T*C"X:1I$>DQBWA&%'4]R
M>[$]R?\ ZPP !5VBBN5NYJ%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4O^6O^?2KM4O^6O\
MGTH NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!2TWO^']:NU2TWO^']:N
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %9NC_Q?A_6M*LW1_XOP_K0
M!I4444 %4=6^X/\ >_H:O51U;[@_WOZ&@"S;?<7_ '1_*I:I07RJH'/ '\J?
M_:"^A_3_ !H M455_M!?0_I_C1_:"^A_3_&@"U157^T%]#^G^-']H+Z']/\
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MC0!:HJK_ &@OH?T_QH_M!?0_I_C0!:HJK_:"^A_3_&C^T%]#^G^- %JBJO\
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MT%]#^G^- %JBJO\ :"^A_3_&C^T%]#^G^- %JBJO]H+Z']/\:/[07T/Z?XT
M,NO]8OX?SJ[6;-<!V#CH,?SJQ_:"^A_3_&@"U157^T%]#^G^-']H+Z']/\:
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M4 0?8T]/U-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T_4T?8T]/U-3T4
M0?8T]/U-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T_4T?8T]/U-3T4 0?
M8T]/U-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T_4T?8T]/U-3T4 0?8T
M]/U-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T_4T?8T]/U-3T4 0?8T]/
MU-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T_4T?8T]/U-3T4 0?8T]/U-
M5=1A$*@KP<_T-:-4=6^X/][^AH D@M5902.2!W/I3_L:>GZFG6WW%_W1_*I:
M (/L:>GZFC[&GI^IJ>B@"#[&GI^IH^QIZ?J:GHH @^QIZ?J:/L:>GZFIZ* (
M/L:>GZFC[&GI^IJ>B@"#[&GI^IH^QIZ?J:GHH QKQ CD#IQ_*H*MZDNU\^H'
M^%5*Z([(R>YP6GW T&]D$O"/N /8!B&4_3L:[N.02#<I!![BJ&LZ%'JJX<?,
M.C#J*YH^%+O3SFWDR.>^./H>*O1BV);[7;ZW=B(_D5C_  YX[<UF1S2>+)U1
M\*B#) [#(SCW-7-(U2YANUMKASW!!Z<J2/Z5/#I[6VI;D4A"">.F"G/_ (]3
MV$=B!C@55U+34U%##)T..G7BK5<G?^,Y+*1XVB^56(!YY'8_C4I#-ZRTZ'2$
M.P!5'4GK^)JZCB0!@<@]Q7 W5Y<^)R(57;&",]<?4G^E=OIUD+&-85Z(,<T-
M C)\9PRSP^5$I;<PW8ZX'/\ /%6M,MQHML __+-"S8]>6-:E(Z!P5/(/6BX&
M59WT7B*%E['AE/4=ZL6,,6F*MJI ZX!/)SS7$^)M)_L)UDA8@2;L =1C'Z<U
ML:/X-:.1;BX?<RD$ >HYY)]Z=D!5^(,?DO%.O#_,,_[I!'\S7;5Q/Q ?SY(;
M=>6P?_'R /U%=M0]D")[- [@'IS_ "K2^QIZ?J:HZ:N6^@-:M<]3<TAL0?8T
M]/U-'V-/3]34]%040?8T]/U-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T
M_4T?8T]/U-3T4 0?8T]/U-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T_4
MT?8T]/U-3T4 0?8T]/U-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T_4T?
M8T]/U-3T4 0?8T]/U-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T_4T?8T
M]/U-3T4 0?8T]/U-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T_4T?8T]/
MU-3T4 0?8T]/U-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T_4T?8T]/U-
M3T4 0?8T]/U-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T_4T?8T]/U-3T
M4 0?8T]/U-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T_4T?8T]/U-3T4
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MH @^QIZ?J:/L:>GZFIZ* (/L:>GZFC[&GI^IJ>B@"#[&GI^IH^QIZ?J:GHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P">O_CD?_Q-<Y11R1[!S,Z/_A8-]_SU_P#'(_\ XFC_ (6#??\ /7_QR/\
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MF_\ BJ] T_56N;1;P@;C$6P,XSC-5.C*&XH58SV-6BO*O^%LW'_/./\ )O\
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MEIO?\/ZU=JEIO?\ #^M7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
MW1_XOP_K6E6;H_\ %^']: -*BBB@ JCJWW!_O?T-7JHZM]P?[W]#0!9MON+_
M +H_E4M16WW%_P!T?RJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /*M!_P"0PW_7:X_D]>B>(_\
MCUG_ .N,G_H!KSO0?^0PW_7:X_D]>B>(_P#CUG_ZXR?^@&M:GQ(B.S.,^$7_
M "\?]LO_ &>NNC\56TCO#Y@#19W[@5 PP4_,P ZD#K]*Y'X1?\O'_;+_ -GK
M#M=,34]4>WESL:>;(!QG:6;&??'/?'0BJE%2G*XD[)'HEEXVL[UUACE!9S@
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M-@Y=SQ_Q'J%KK12.QMV67/.U0,@ G 1"0>N2<9 '<=.MN_"<UWIJ6;G,\7S
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M94]M:&?V'K5JWTW'+_D*O 8XK.53L4HC8HA$-HI]%%9%A1110 4444 %%%%
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MZ/Y5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !5'5ON#_>_H:O51U;[@_P![^AH LVWW%_W1
M_*I:BMON+_NC^52T %%%% !1110 4444 %%%% !1110 4444 %%%% !2$9XI
M:* *\EBC]L?3_.*B;2P>A/X\_P"%7:*I2:%9&?\ V5_M?I_]>GKI8'4G\./\
M:NT4<\@Y45X[%$[9^O\ G%3@8XI:*3;8[!1112 **** "BBB@ HHHH ****
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MQ3R?K]WT]:O^'?#4>C*=N6D?[[MRQ/\ A_D\ULT53FVK$J"3N%%%%24%%%%
M!144EP$(0]34M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %4O^6O^?2KM4O\ EK_GTH NT444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M2TWO^']:NU2TWO\ A_6KM !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M;H_\7X?UK2K-T?\ B_#^M &E1110 51U;[@_WOZ&KU4=6^X/][^AH ;#?[5
MQT [_P#UJ?\ VE[?K_\ 6J6WA4JIP/NCM[5)Y"^@_(4 5O[2]OU_^M1_:7M^
MO_UJL^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@_(4
M5O[2]OU_^M1_:7M^O_UJL^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K
M/D+Z#\A1Y"^@_(4 5O[2]OU_^M1_:7M^O_UJL^0OH/R%'D+Z#\A0!6_M+V_7
M_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@_(4 5O[2]OU_^M1_:7M^O_UJL^0OH/R%
M'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@_(4 5O[2]OU_^M1_
M:7M^O_UJL^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@
M_(4 5O[2]OU_^M1_:7M^O_UJL^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_
M -:K/D+Z#\A1Y"^@_(4 5O[2]OU_^M1_:7M^O_UJL^0OH/R%'D+Z#\A0!6_M
M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@_(4 5O[2]OU_^M1_:7M^O_UJL^0O
MH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@_(4 5O[2]OU_
M^M1_:7M^O_UJL^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1
MY"^@_(4 5O[2]OU_^M1_:7M^O_UJL^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7
MM^O_ -:K/D+Z#\A1Y"^@_(4 5O[2]OU_^M1_:7M^O_UJL^0OH/R%'D+Z#\A0
M!6_M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@_(4 5O[2]OU_^M1_:7M^O_UJ
ML^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@_(4 5O[2
M]OU_^M1_:7M^O_UJL^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K/D+Z
M#\A1Y"^@_(4 5O[2]OU_^M4%W<_:!MQCG/K6AY"^@_(54U- B@@8Y[?0T )%
M?[ %QT '7T_"G_VE[?K_ /6J:WA4JI('0=O:G^0OH/R% %;^TO;]?_K4?VE[
M?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R%
M %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6
MJSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]O
MU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\
MA1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4
M?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0O
MH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K
M_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O
M[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D
M+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]
M?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(
M4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?V
ME[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(
M4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]
M:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^
MTO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"
M^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\
MK4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"
M^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[
M?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R%
M %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6
MJSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]O
MU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\
MA1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4
M?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0O
MH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K
M_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O
M[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D
M+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]
M?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(
M4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 9]S<^=CC&*G_M+
MV_7_ .M3;] N,#'7I^%6_(7T'Y"@"M_:7M^O_P!:C^TO;]?_ *U6?(7T'Y"C
MR%]!^0H K?VE[?K_ /6H_M+V_7_ZU6?(7T'Y"CR%]!^0H K?VE[?K_\ 6H_M
M+V_7_P"M5GR%]!^0H\A?0?D* *W]I>WZ_P#UJ/[2]OU_^M5GR%]!^0H\A?0?
MD* *W]I>WZ__ %J/[2]OU_\ K59\A?0?D*/(7T'Y"@"M_:7M^O\ ]:C^TO;]
M?_K59\A?0?D*/(7T'Y"@"M_:7M^O_P!:C^TO;]?_ *U6?(7T'Y"CR%]!^0H
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M@_(4>0OH/R% %;^TO;]?_K4?VE[?K_\ 6JSY"^@_(4>0OH/R% %;^TO;]?\
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M 5O[2]OU_P#K4?VE[?K_ /6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_\
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M?0?D*/(7T'Y"@"M_:7M^O_UJ/[2]OU_^M5GR%]!^0H\A?0?D* *W]I>WZ_\
MUJBT?^+\/ZU>\A?0?D*HZ/\ Q?A_6@#2HHHH *HZM]P?[W]#5ZJ.K?<'^]_0
MT 6;;[B_[H_E4M16WW%_W1_*I: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZM]P?[W]#5ZJ
M.K?<'^]_0T 6;;[B_P"Z/Y5+45M]Q?\ ='\JEH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M84444 02VV]@^>F/T-3T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\LQ_(5T6LZJNDQ-<R E4QD+@GDA>Y'KZT.#073+M%<I+\2K2-%E^8E_X  7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EIO?\/ZU=JEIO?\/ZU=H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *S='_B_#^M:59NC_ ,7X?UH
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MT\H=RC')"Y/09.<=C1=)FCU4SM&XC\Z<[BC!<$/@YQCG/%/1.3[H.B)/BY&
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MTYZ4GM'U!=2I\*;)!#)<8'F&0KN[[0JG'MR>?7C/05@^'8Q%JY10 JS3@ #
M  ?  KJ_AI926=LZ2HR,9F.'4J<;4YP:P=%TF:/53.T;B/SISN*,%P0^#G&.
M<\47UF%M$>EUA^*(+6_3[+=2*G(89D5&&,C(W?B.01U[UN5RGCSPDVMJLD./
M-CSU.-RXSMSCKG[N2 ,G/6LH6N7+8Y^?X?7FE@M9S$@@9"L8F)SZ9VG .<EA
MWX];_@?QG->3-97?+G=M)7:P*]4(  Z GG&,$<Y&*$?B/5;1/LYA9F4%=YB=
MFXXSN!VMCL<$'J<][O@KPC,LQU.ZRKDLP7C)+@Y8@=/O'C@YZXQ@ZR^%\UB%
MOH-^*VD%UCO5'W?D<\YP>5]@ <C/') Y[4O'^O?;[:V7*DRKYCA3D@A=N.IP
M,EASW&,\&N^U[3!JD$EMQEU.,D@;ARI..>& /]#7EW@FT.L7,*-@+:KNXX)"
MR%QZ_P ;\]/E]Z*;3C?L$EKZEWQ_I@TN"SMN,HLF<$D;CL+$9YY8D_T%=1#I
MT<.E%548:U+GC.6,>[=SWSR/3 QC K.^*.FRWOD>4C/M\S.Q2V,[,9P#Z5O?
M9F_L[RMIW_9-NW!W9\K&,=<YXQ2<O=CZC2U9S/PB_P"7C_ME_P"SUE_#N,:E
M>M-, S!6DR1_&77YL#CN<>AY'(%;GPNTV6R\_P U&3=Y>-ZE<XWYQD#UJA)H
M-UX4NC=6L9DA8D84%CM8YV$<L,8X;D=,]2M4VN:2[B2T0?%BR2)XIE #R!PQ
M'?;MVY^F>O7&!V%3^,O^07:_]L?_ $4U4/%D%]KP6Y:!DC4[4C +/\V=S$ ;
MNJ]P!]W .23K^+--EGTZVB1&9U\G*JI+#$3 Y &1@\4+110=RW\/-#A^RQW#
M(K2,S-N95)!5BHP<9&-N?KDUS8_XGFK>7/RJRNH'48B#$#!SP=OS#OD],UV_
M@:V:VLXHY%*L-^0P((R['H:Y_P 4>%9[:Y_M2R )!#,H.#N&=W QD,!R 2S$
MGCFI4O>D-K1&G\2K!;BT:5OO1,I4\9^9@I&<=#G/'<#TKC+N_:[TI%?GRKK8
M#SG C9AU/;=@>@ %;6M7E[XI5;-+=H5W L7+ $#@9)5>!G)&&)P"!Q4GB?PP
MUEI\5I"A=UE5GV*6))5MQX .,G )'3 -.'NI)]Q/6[-7X>:=&+)6VC,V_?D9
MW89E .>V.,=.OJ:X[X9627-T2X!\N,LN>S!E /X9X]#SU KOO ULUM9Q1R*5
M8;\A@01EV/0UR7PTTF:SN7>6-T4PL,NC*,[DXR123^,+?"4OBG&$NE( !:%2
M<#J=S#)]> !] *G^*]PS3QQ$_*L6X#W9B"?QVC\JF^)>DS7ERCQ1NZB%1E$9
MAG<_&0*VO'_A!]8"W$ !E0;2I.-RYR,$G VDGTR">> #49)<H-/4P]=U*;5+
M<60LI4";=A_>-MV\#C8,_+D<GOGK73?#Q)8K413(4,;L%#*5)!PV<'W8C\*Q
M&\4ZE/$L"6[K,2 92AP>>NUEVKGC))QUX'&.ST,3B)?M17S<<[!C''?D@GU(
MP,\ 8&3$](V''<Q?B/\ \>C_ / ?_0UKQ^O8/B/_ ,>C_P# ?_0UKQ^M*'PD
MU-PHHHK8@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J>RLGO76
M&(%G8X '^?S/0#DT65D]ZZPQ L['  _S^9Z <FO8O"/A%-!3)PTS#YF_]E'M
M^I/)[ 14J*"*C&YIZ-:R6L*13/OD5<,WK_CCID\G&3R:NT45QO4V"D)Q2TA&
M: *TMX>D:ES^2_\ ?1_ID^U8E_I2QJ9[IP$SGRUR(\_3.6)_#Z5TM<DL?]N7
MC"3_ %5OT7L3G'ZG/X#%;T.KV2U;ZG-B':RW;=DNGS+EI>R7VU5'D0G&WCYF
M]AQA?;N>U;5M9K;?=')ZD\D_4GDU))")048 J>H/2L2/43I<ZV4IS',"8F/)
M!'5">_L>O8Y/-0Y<VVGD:QAR;ZON;U<1\6?^/:/_ *[#_P!!:NWKB/BS_P >
MT?\ UV'_ *"U%#^(@K? SRJO:M$_Y!R?]>Y_]!->*U[5HG_(.3_KW/\ Z":Z
ML7LO4Y\-N_0\5KH_"&OW&D^9]GB\S?MW?*S8QG'W?7-<Y7H_PAZ3_P#;/_V:
MM:[2@VU<SHIN:Z#?^$]U#_GV_P#(<G^-8_B36+[7E6*2%E53G"QOR<8[Y]:]
M?HKC5:,7=11UNE)JSD>#VOA>ZNB$6%^?52H_,X%>N1^&$ELUTZ7D! "1ZCG(
M_&MRBE4KRG;I8*=%0N>9R_"-P?EF7'NI!_0FG1?"V>'A9P/H&'\C74GQ_9#C
MS1_WR_\ \32?\+ L?^>H_P"^7_\ B:OVE?\ I$^SI?TSEYOAM=J"5N,D#@9<
M9_'-<-_:$J'[[Y'^T?\ &O7YOB'9("PDR0.@5LGVY KQB1MQ)]36U!SE?F7X
M&-91C;E9Z=\,?$4M]YEM,Q?8 RECDXS@C/?MBO-[_P#UC_[[?S-=M\)(2997
M[! ,^Y.?Z5Q-_P#ZQ_\ ?;^9JJ:2J2MY"FVZ<;FIX3T*3696BB?RR$)SSTR!
MCCZUU7_"M+G_ )^/_0_\:Y_P#KL>CW!DF.$9"N0"<'(/0<]J]$_X6#8_\]?_
M !Q__B:SK2J*6BT]"Z,:;CKOZE#P[X#?3Y1/-,7V]%&0,^IR>?I6IXZ_X\IO
M]T?^A"HO^%@V/_/7_P <?_XFHO$^IQZGI\LT)W(1C.".C#/4"L/?<TVNIM[J
MBTCG_A#UG^D?_L];WCCP>-:3S8QB=!Q_M#^Z?Z&L'X0]9_I'_P"SUZ13K2<:
MK:%2BI4DF?.LD9C)5A@@X(/4$5Z%\//&FW%A.?:-C_Z ?Z?EZ5>^('@O[<#>
MP#]X!\RC^(#N/]H?J/?KY;TKJ3C7@<[4J,CL_BM_Q]+_ -<5_P#0GKTO0_\
MCWA_ZY)_Z"*\/U76)-4*/*<LB!,]R 203[\U[AH?_'O#_P!<D_\ 016&(BXP
MBC:C)2G)EZBBBN4Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ JE_RU_SZ5=JE_RU_P ^E %VBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** *6F]_P_K5VJ6F]_P_K5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K-T?^+\/ZUI5FZ/_%^']: -*BBB@ JCJWW!_O?T-7JHZM]P?[W]#0!9MON+
M_NC^52U%;?<7_='\JEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCJWW!_O?T-7JHZM]P?[W
M]#0!9MON+_NC^52U%;?<7_='\JEH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *S/$6ER:E$8X9&BD!RK*Q7) /!QS@Y_ X/.,'3HIIV X<W6LQ*8
MO+C<C<!)E,GKA@-ZCZ97ZCK5GP'X.;1-T\V/,=0 %).T=2">A)..F<8X)S77
MT53F[6)Y0HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ3-?Y,
M5G&K1O'@ON"N&.0<'>N,#!!QUIG@7PLVA1LTA_>2[2P'1=N<#/<\G)Z=ATR>
MGHJN=VL*VMPHHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110!RWQ'_X
M]'_X#_Z&M>/U[/XYLGOK=H8QEVQ@9 Z,I/)P.@KSO_A7U]_SR_\ 'X__ (JN
MBC)*)G43;.<HKH_^%?7W_/+_ ,?C_P#BJ/\ A7U]_P \O_'X_P#XJM>>/<CE
M9SE%='_PKZ^_YY?^/Q__ !5'_"OK[_GE_P"/Q_\ Q5'/'N'*SG**Z/\ X5]?
M?\\O_'X__BJ/^%?7W_/+_P ?C_\ BJ.>/<.5G.45T?\ PKZ^_P">7_C\?_Q5
M'_"OK[_GE_X_'_\ %4<\>X<K.<HKH_\ A7U]_P \O_'X_P#XJC_A7U]_SR_\
M?C_^*HYX]PY6<Y171_\ "OK[_GE_X_'_ /%4?\*^OO\ GE_X_'_\51SQ[ARL
MYRBNC_X5]??\\O\ Q^/_ .*H_P"%?7W_ #R_\?C_ /BJ.>/<.5G.45T?_"OK
M[_GE_P"/Q_\ Q5'_  KZ^_YY?^/Q_P#Q5'/'N'*SG*GLK)[UUAB!9V. !_G\
MST Y-;G_  KZ^_YY?^/Q_P#Q5>C>$?"*:"F3AIF'S-_[*/;]2>3V F=5)#C!
ML/"/A%-!3)PTS#YF_P#91[?J3R>P'0445RMMNYLE8****0!1110 5AM;?V9<
M-<C_ %4P ?\ V6'1OH>_H>>E;E17$ZP*7D(51U+' _,U4).-_,B<%*W=:HD!
MS7">++K^U+ZVLH>6A?<Y';D'] /U K4FNI[_ #%8J4C/66084?[BGD_7[OIZ
MU?\ #OAJ/1E.W+2/]]VY8G_#_)YJXVAKUZ"=YZ&S5#6-#BUA1%.NY5;(&2.<
M$=B/6K]%9IM:FC5SF?\ A7%C_P \S_WV_P#C6Y!IR01"V48C"[<9/3&,9ZU:
MHIN<I;L2C%;(YG_A7%C_ ,\S_P!]O_C6GHWAR#1MWD+MWXS\Q/3..I/K6G10
MZDFK-L2A%= HHHJ2@HHHH YH_#JR//EG_OM_\:3_ (5Q8_\ /,_]]O\ XUTU
M%7[6?=D^SCV1S/\ PKBQ_P">9_[[?_&E7X=6(Y\L_P#?;_\ Q5=+11[6?=A[
M./9%:PTV/3U\J%0J^@'Z^]8LGP]LI"6,?).3\[]_^!5T=%)3DMF-Q3Z'-?\
M"NK'_GG_ ./O_P#%4?\ "NK'_GG_ ./O_P#%5TM%/VL^[%[./9'-?\*ZL?\
MGG_X^_\ \56E'X;@C@-B%_<MG*[CW.>N<]?>M.BDZDGU8*$5T,O1O#<&C;C
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M\/ZU=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S='_ (OP_K6E6;H_
M\7X?UH TJ*** "J.K?<'^]_0U>JCJWW!_O?T- %FV^XO^Z/Y5+69%?,H XX
MIW]H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]?\ &@#1HK._M!O0?K_C1_:#>@_7
M_&@#1HK._M!O0?K_ (T?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO
M[0;T'Z_XT?V@WH/U_P : -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O\
MC1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_
M !H T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO[0;T'Z_P"-']H-Z#]?\: -&BL[
M^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]?\ &@#1HK._M!O0?K_C
M1_:#>@_7_&@#1HK._M!O0?K_ (T?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U_
MQH T:*SO[0;T'Z_XT?V@WH/U_P : -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^
MT&]!^O\ C1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_&@#1HK._M!O0?K_C1
M_:#>@_7_ !H T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO[0;T'Z_P"-']H-Z#]?
M\: -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]?\ &@#1HK._
MM!O0?K_C1_:#>@_7_&@#1JCJWW!_O?T-,_M!O0?K_C45Q<&<;3ZYXH T;;[B
M_P"Z/Y5+6:E\R *,<#%+_:#>@_7_ !H T:*SO[0;T'Z_XT?V@WH/U_QH T:*
MSO[0;T'Z_P"-']H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O
M^-']H-Z#]?\ &@#1HK._M!O0?K_C1_:#>@_7_&@#1HK._M!O0?K_ (T?V@WH
M/U_QH T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U_P : -&B
ML[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O\ C1_:#>@_7_&@#1HK._M!O0?K
M_C1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_ !H T:*SO[0;T'Z_XT?V@WH/
MU_QH T:*SO[0;T'Z_P"-']H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]?\: -&BL
M[^T&]!^O^-']H-Z#]?\ &@#1HK._M!O0?K_C1_:#>@_7_&@#1HK._M!O0?K_
M (T?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U
M_P : -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O\ C1_:#>@_7_&@#1HK
M._M!O0?K_C1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_ !H T:*SO[0;T'Z_
MXT?V@WH/U_QH T:*SO[0;T'Z_P"-']H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]
M?\: -&BL[^T&]!^O^-']H-Z#]?\ &@#1HK._M!O0?K_C1_:#>@_7_&@#1HK.
M_M!O0?K_ (T?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO[0;T'Z_X
MT?V@WH/U_P : -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O\ C1_:#>@_
M7_&@#1HK._M!O0?K_C1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_ !H T:*S
MO[0;T'Z_XT?V@WH/U_QH T:*SO[0;T'Z_P"-']H-Z#]?\: -&BL[^T&]!^O^
M-']H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]?\ &@#1HK._M!O0?K_C1_:#>@_7
M_&@#1HK._M!O0?K_ (T?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO
M[0;T'Z_XT?V@WH/U_P : -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O\
MC1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_
M !H T:*SO[0;T'Z_XT?V@WH/U_QH DU+M^/]*NUE3W!FQGMZ5)_:#>@_7_&@
M#1HK._M!O0?K_C1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_ !H T:*SO[0;
MT'Z_XT?V@WH/U_QH T:*SO[0;T'Z_P"-']H-Z#]?\: -&BL[^T&]!^O^-']H
M-Z#]?\: -&BL[^T&]!^O^-']H-Z#]?\ &@#1HK._M!O0?K_C1_:#>@_7_&@#
M1HK._M!O0?K_ (T?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO[0;T
M'Z_XT?V@WH/U_P : -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O\ C1_:
M#>@_7_&@"^PSP.*KC3D)#L-S#H6YQ],\#\ *@_M!O0?K_C1_:#>@_7_&@#1H
MK._M!O0?K_C1_:#>@_7_ !H T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO[0;T'Z
M_P"-']H-Z#]?\: +DEP$(0]34M94EP7(<]14G]H-Z#]?\: -&BL[^T&]!^O^
M-']H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]?\ &@#1HK._M!O0?K_C1_:#>@_7
M_&@#1HK._M!O0?K_ (T?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO
M[0;T'Z_XT?V@WH/U_P : -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O\
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M* (_(7T'Y"CR%]!^0J2B@"/R%]!^0H\A?0?D*DHH C\A?0?D*/(7T'Y"I**
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M% $?D+Z#\A1Y"^@_(5)10!'Y"^@_(4>0OH/R%244 1^0OH/R%'D+Z#\A4E%
M$?D+Z#\A1Y"^@_(5)10!'Y"^@_(4>0OH/R%244 1^0OH/R%'D+Z#\A4E% $?
MD+Z#\A1Y"^@_(5)10!'Y"^@_(4>0OH/R%244 1^0OH/R%'D+Z#\A4E% $?D+
MZ#\A1Y"^@_(5)10!'Y"^@_(4>0OH/R%244 4+A '4 <<?SJWY"^@_(56NO\
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M4 1^0OH/R%'D+Z#\A4E% $?D+Z#\A1Y"^@_(5)10!'Y"^@_(4>0OH/R%244
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M* (_(7T'Y"CR%]!^0J2B@"/R%]!^0H\A?0?D*DHH C\A?0?D*/(7T'Y"I**
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M%17-PMLK2N<*BEB>N !DGB@"6J.K?<'^]_0TS2/$,&L;O(?=LQGY67&[./O
M>AI^K?<'^]_0T-6 LVWW%_W1_*I:BMON+_NC^52T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1_\ @/\ Z&M>/UTT/A,JFX4445L0%%%% !1110 4444 %%%% !1110 4444
M%%%% !7>>!?'7V7%E<G]WT1S_#Z*3_=]#_#T/R_=X.BIE%25F-.Q]$T5YEX%
M\=?9<65R?W?1'/\ #Z*3_=]#_#T/R_=]-KDG!Q=C:,KA1114C"BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 51U;[@_P![^AJ]5'5ON#_>_H: (HKYE '' %._M!O0?K_C4L'W1]!_*GT
M5_[0;T'Z_P"-']H-Z#]?\:L44 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z
M_P"-']H-Z#]?\:L44 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-']H-
MZ#]?\:L44 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-']H-Z#]?\:L4
M4 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-']H-Z#]?\:L44 5_[0;T
M'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-']H-Z#]?\:L44 5_[0;T'Z_XT?V@
MWH/U_P :L44 5_[0;T'Z_P"-']H-Z#]?\:L44 5_[0;T'Z_XT?V@WH/U_P :
ML44 5_[0;T'Z_P"-']H-Z#]?\:L44 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0
M;T'Z_P"-']H-Z#]?\:L44 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-
M']H-Z#]?\:L44 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-']H-Z#]?
M\:L44 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-']H-Z#]?\:L44 5_
M[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-']H-Z#]?\:L44 5_[0;T'Z_X
MT?V@WH/U_P :L44 5_[0;T'Z_P"-17%P9QM/KGBKM% %9+YD 48X&*7^T&]!
M^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB
M@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@W
MH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M
M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5
MBB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#
M>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^
MT&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\
MC5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_
M &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_
MQH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?
MK_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"
MO_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7
M_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!
M^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB
M@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@W
MH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M
M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5
MBB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#
M>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^
MT&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\
MC5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_
M &@WH/U_QH_M!O0?K_C5BB@"G/<&;&>WI4G]H-Z#]?\ &K%% %?^T&]!^O\
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MH-Z#]?\ &C^T&]!^O^-6** *_P#:#>@_7_&C^T&]!^O^-6** *_]H-Z#]?\
M&H_M!W>9W_\ K8JY10!7_M!O0?K_ (T?V@WH/U_QJQ10!7_M!O0?K_C1_:#>
M@_7_ !JQ10!7_M!O0?K_ (T?V@WH/U_QJQ10!7_M!O0?K_C1_:#>@_7_ !JQ
M10!7_M!O0?K_ (T?V@WH/U_QJQ10!7_M!O0?K_C1_:#>@_7_ !JQ10!7_M!O
M0?K_ (T?V@WH/U_QJQ10!7_M!O0?K_C1_:#>@_7_ !JQ10!7_M!O0?K_ (T?
MV@WH/U_QJQ10!7_M!O0?K_C1_:#>@_7_ !JQ10!7_M!O0?K_ (T?V@WH/U_Q
MJQ10!7_M!O0?K_C1_:#>@_7_ !JQ10!7_M!O0?K_ (T?V@WH/U_QJQ10!7_M
M!O0?K_C1_:#>@_7_ !JQ10!7_M!O0?K_ (T?V@WH/U_QJQ10!7_M!O0?K_C1
M_:#>@_7_ !JQ10!7_M!O0?K_ (T?V@WH/U_QJQ10!7_M!O0?K_C1_:#>@_7_
M !JQ10!3@N##G'?UJ3^T&]!^O^-6** *_P#:#>@_7_&C^T&]!^O^-6** *_]
MH-Z#]?\ &C^T&]!^O^-6** *_P#:#>@_7_&C^T&]!^O^-6** *_]H-Z#]?\
M&C^T&]!^O^-6** *_P#:#>@_7_&C^T&]!^O^-6** *_]H-Z#]?\ &C^T&]!^
MO^-6** *_P#:#>@_7_&C^T&]!^O^-6** *_]H-Z#]?\ &C^T&]!^O^-6** *
M_P#:#>@_7_&C^T&]!^O^-6** *_]H-Z#]?\ &C^T&]!^O^-6** *_P#:#>@_
M7_&C^T&]!^O^-6** *_]H-Z#]?\ &C^T&]!^O^-6** *_P#:#>@_7_&C^T&]
M!^O^-6** *_]H-Z#]?\ &C^T&]!^O^-6** *_P#:#>@_7_&C^T&]!^O^-6**
M *_]H-Z#]?\ &C^T&]!^O^-6** *_P#:#>@_7_&C^T&]!^O^-6** *_]H-Z#
M]?\ &C^T&]!^O^-6** *_P#:#>@_7_&DT?\ B_#^M6:K:/\ Q?A_6@#2HHHH
M *HZM]P?[W]#5ZJ.K?<'^]_0T .@^Z/H/Y4^F0?='T'\JY7Q=?202JJ.RC8#
MA6('5O2M*5-U)<I,Y<JN=;15;4W*12,#@A&((Z]#7%Z7J\L<B.[L4+8.]CM[
M ]3C@'/MQ54J#J1;704ZBBTCO:*1W" L3@#DD]*\[FU>>0F3>X#$]&8+ZD#G
MMGI]**-!U;A4J*!Z+117G4.KSQD2;W(4CJS%?4 \]\=/K11H.K>SV"=10L>B
MT4B.' 8'(/((Z5P>J:O+)([H[! V!L8[>X'0XY S[\TJ-%U&T$ZB@CO:*S?-
M;[)OR=WD9SGG.S.<^M9O@Z[>X\S>Q;&S&XD_WO6E[)\LI=@Y]4NYTE%%<EX1
MOI)Y65W9AL)PS$CJOK1"FY1E+L.4K-+N=;17)^*[N6.94C9AE!PI(R2Q'0=Z
MT_"^J&]CVL<O'P2>I!Z'^GKQD]:J5!JFIB51.7*;-%8GBZX:")61BIW@94D'
MHWI6EICEXHV)R2BDD]>@J'"T%+N-2]ZQ9HKD[S7IM2D\FTSMP>1@$^IR?NCT
MZ'\2 %;1KV'YQ)N(QP'8Y_[Z 'YUI]7MNTGV)]K?97.KHKG_  _X@:X;[--_
MK.<'&,XZ@CL1_GGKT%9U*;@[,J,E)70445FZYK(TQ,XR[9VCMQU)]AG\?U$Q
MBY.RW&VDKFE17(6]K>ZD!+O*@@8RQ3(YYPH_4CGC&1227=WHA!D.]">YW \=
M-Q^8>WN.AYK?ZMK925^Q'M>MG8["BH;*\6\02I]UO7KZ$?G7$7^IS1S2;7?"
M.W<D !L#CICH/3M44J#J-K:PYU%%)G>T57L+P7L:S#HP_(]".W0UAZW=O'=Q
M(K$*=F0"0#ER#Q2A3<I./8<II*YTE%0WMXMFAE?[J^G7T _.N5CN[O6R3&=B
M ]CM XZ;A\Q]_<]!Q13I.:;V2ZL4IJ.G4["BN.N5O-'_ 'K,67C)W%UY/0@\
MCIU]\9YKH]%U/^T8Q+T;HP'3(^OMS^.*=2BXKF3NO((U+NVS+U%<_P"(/$#6
M[?9H?]9QDXSC/0 =R?\ //2HNC7LWSF3:3G@NPQ_WR"/RIQH>ZFVE<3J:V2N
M=717)V>O3:;)Y-WG;@<G!(]#D?>'KU/X@@]'J;E(I&!P0C$$=>AJ9T7!I=]F
M5&::+-%<WX.NWN/,WL6QLQN)/][UKI*52'LY.(0ES*X445R=YKTVI2>3:9VX
M/(P"?4Y/W1Z=#^) #ITG4?ZA*:B=917*-HU[#\XDW$8X#L<_]] #\ZM^'_$#
M7#?9IO\ 6<X.,9QU!'8C_//6I4/=;33L2JFMFK'045#>WBV:&5_NKZ=?0#\Z
MY9+RZUP_NOD0'J#M ZXRW4GUQQT.!4TZ3FF]EW*E-1TZG7T5Q]U97NG#SMY8
M+DG#%@/J&Z_D<=>*V?#^N_VF"K !U].A![@$YX[_ (>N*J=!J/,FFA1J7=GH
MS7HKCKNXFT:<;G=H\Y&XDY!Z\9QD9_/!Q@UUT4HF4.O(8 CZ'D5-2DX)/=,<
M9\UT/HKCKG49=7N/+@9@G RI(X'5B,CU]NPZUUT4?EJ%R3@ 9/)..Y/K14I.
M"5]WT",^:X^BBBLR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *K:/\ Q?A_6K-5M'_B_#^M &E1
M110 51U;[@_WOZ&KU4=6^X/][^AH =!]T?0?RKCO&G^N7_KF/_0FKL8/NCZ#
M^5<=XT_UR_\ 7,?^A-71@_XAE7^$ZK5O]3)_US?_ -!-<6MKYEH9 .4F/.>@
M95!_7'^<UVFK?ZF3_KF__H)K#\,6HNK:2(_Q,PY&<?*N#CV/-50GR0;\T*I'
MFE;R+FIZENM/.R,R(![9;A@.>HY^F.:YO4K7[/!!Q@MYC'GUVX/Y8_\ UTR&
MX-W'%9[N/-/;H#@ ^_);O_2M;QL@01*!@#> !T_AK:G'V<XQ[MO\")/FBWY(
MZNN!TVU^T03\9*^6PY]-V3^6?_UUWU<IX)0.)5(R#L!!Z?Q5A0ERPF^UOS-*
MBO**]31TS4MMIYV1F-"/;*\*#SU/'USQ7-M:^7:"0CEYASGJ%5@/US_G%,FN
M#:1RV>[CS1VZ@9!/MR%[_P!:V_$]J+6VCB'\+*.!C/RMDX]SS6Z7LY6_F?X&
M;?,O1&C_ ,N?_;O_ .R5E>!O^6O_  #_ -FK8BB,UH$7DM  /J4P*Q/!-PJ,
M\9.&;;@>N,Y_G6*UI5/7]2W\<3K:XOP7_KF_ZYG_ -"6NQEE$*EVX"@D_0<F
MN/\ !2$RLV. A&>W)&/Y4J/\*I\AU/CB6=?_ ./R'_MG_P"AFHIQ_85T)!Q%
M)[<8/4=/X3S@=L#O4NO_ /'Y#_VS_P#0S6KXDTW[=$<#YTY7U]QT)Y';N<5:
MFDH)[-69+C?F:W3*OC3_ %*_]=!_Z"U.OI3%8@CKY48_ [0?T-8=UJ/VJT6,
M_>CD4?AM;;V_#\,GK71269O+-8EZF),?4 $#MUQBDX^SC%/I($^9MKL4_!,
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MXC-&XMUN%,;C*MU!J.SL([(;8U"CVZGZD\GK46KZD-.C,AZ]%&,Y)''X>O\
MC4>B:O\ VFI?;MP<=<@\9]C^G_UL5&?)?H7>/-;J<WX57[5<&5C\P#-]23@_
M^A&NUKA]+D_L6Z,;]/ND^QP0W7 [$^@SWKN*VQ?QI]+:$4=K'.>-H 8TD[JV
M/;YAD_\ H-36,IEL23U\J0?@-P'Z"J/C34 VVV';YF]NP'7T))_"M2.S-G9M
M$W41/GZD$D=^F<56U*"?<6\Y>AF>!O\ EK_P#_V:NJKE? W_ "U_X!_[-755
MGBOXK_KH51^!&;XCE,5O(1UP!^!(!_0UG>"8 (WD[LV/;Y1D?^A5K:S9F\A>
M)>I''U!! [=<8K!\%Z@%W6Q[_,OOV(Z^@!'XU4-:$DNXI:5$=77%>*E^RW E
M4_,0K?0@X'_H(KM:X?5)/[:NA&G3[H/L,DMUP>Y'J,=Z,)\;?2VH5MK&EXWG
M(6./LQ)]_E  _P#0JV-"@$,$:CNH//\ M?,?U-9OC.S\V-91_P LSSZ8;C/Y
M@5:\,Z@+N$+_ !1X4CZ=#U[C]<T2UP\;='J"_B,?<>(+="T3MTR""K$>A'3%
M1Z++:[BEOC=@D\-G''=ATZ<9IUUH-MS+(H&3DDNP&2?KCK6!X+_US?\ 7,_^
MA+1&$)4Y-7T^X'*2DD['2:UI0U*,IQN'*D]C_@>A_/'%<C'K<EM"UH>#G'(Y
M .=P^N?;N?;'?5Q>I?\ '^/^ND7\EJL+*]XO5+4596LUZ&WX:T?["F]A^\?D
M\<@=EY_7W^@K9HHKFG-SDVS6,5%6"BBBI&%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5;1_XOP_
MK5FJVC_Q?A_6@#2HHHH *HZM]P?[W]#5ZJ.K?<'^]_0T .@^Z/H/Y5A>(?#T
MFHR"1"H 4#YB<]2>P/K6[!]T?0?RI]73J.#NB914E9D-] 9XWC'5E8#/3D8J
MEX>TMM.C,;D$EB?ESCH!W ]*TZ*2FU%QZ#Y5>YB6OAXPW+76?E.X@9YRW7/&
M,<G'/I2^(]%?4]FP@;=V=Q/?'H#Z5M457MI<REU0O9JS05B^'-%?3-^\@[MN
M-I/;/J!ZUM45*FU%Q[C<4VGV,2Z\/&:Y6ZS\HVDC/.5Z8XQC@9Y]:L>(=+;4
M8Q&A (8'YLXZ$=@?6M.BJ]K*Z?;87(K/S(;& P1I&>JJH..G Q6%J/A'>QE@
M;8>"%Z '/4$<CVXZ^@Z='12A5E!W02@FK,Y.3PQ<W&%DE!7/=F;\<$=:W]*T
MI--38O)/WF[D_P"'H/ZY-7:*J=><U9["C347<Q=3T5[JXCN%(VIMSDG/RL2>
MU;5%%1*;DDNQ2BE<Y._\'O)(S1%0A.0"2,9ZC 7&,]/:NFL8#!&D9ZJJ@XZ<
M#%3454ZTII)]!1@HNZ,'6/"JWK&6,[6.<C'!/K[>_7UQG.:3>&KJ;Y))<J<9
MR[M^A&#75T54<1-*PG2BV9NC:&FF X^9SU8C''H!S@?S_+&E1164I.3N]RDD
ME9!5>^L4OD,3C(/Y@^H]_P#/2K%%";3N-JYR@\*3VQ_<RX!QGED/Y#-26WA!
MI&\RX?<<\@9.0!Q\QP?TZ=_3IZ*V>*J&?LHB(@0!0, < #I6-IFBO:W$EPQ&
MU]V,$Y^9@1VK:HK*,W%-=RW%.Q%=6RW2&)NC#'_U^>X[5R]CX1E@D20E,*RD
MX)SP<_W:ZVBJIUI032ZBE!2=Q'0."I&0>"#TKF;GP@T;>9;OM.> <C (Y^89
M/Z=._KT]%*G5E#8)04MSE$\)2W#!IY,@=P2S=>GS 8[^OTKI;*S6S01)]U?7
MKZD_G4U%.I6E/1[!&"B9NLZ&FI@9^5QT8#/'H1QD?R_/.,OAJZA^2.7"C.,.
MZ_H!@5U=%.%><5;H*5.+=S!T?PJMDPED.YAC QP#Z^_MT]<9QC8OH#/&\8ZL
MK 9Z<C%345,JDI2YGN-025D<A!X6N;?.R0+GKM9A_(5+_8%Y_P ]O_(C_P"%
M=516CQ4WV^XGV,3/T6TEM4*S-N8L3G);C XR:HZQX56]8RQG:QSD8X)]?;WZ
M^N,YSO45"JR4N9;E.":L<HWAJZF^227*G&<N[?H1@ULZ-H::8#CYG/5B,<>@
M'.!_/\L:5%.=><E;H*-.*=Q'0."I&0>"#TKFKOPB8V\RV?:?0DC&<]&'/MC]
M:Z:BIIU90V'*"EN<FWA6XN2/-D! SR2S$?0''\ZVM)T&/3?F7)<C!8_AD8Z8
MR/<^]:5%5.O.2MT%&G%.X5S]WX>DFN1= KM#(<$G/RXSVQV]:Z"BIA4<&VAR
MBI!1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %5M'_ (OP_K5FJVC_ ,7X?UH TJ**
M* "J.K?<'^]_0U>JCJWW!_O?T- "0S*% R.@[T_SU]1^8H@L$902.2!W/I]:
M?_9T?I^I_P : &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4
M>>OJ/S%/_LZ/T_4_XT?V='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T
M?I^I_P : &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ
M/S%/_LZ/T_4_XT?V='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I
M_P : &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/
M_LZ/T_4_XT?V='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P :
M &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/
MT_4_XT?V='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P : &>>
MOJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_
MXT?V='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P : &>>OJ/S
M%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V
M='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P : &>>OJ/S%'GK
MZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?
MJ?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P : &>>OJ/S%'GKZC\Q
M3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\
M&@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P : &>>OJ/S%'GKZC\Q3_[.
MC]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\ &@!G
MGKZC\Q1YZ^H_,4_^SH_3]3_C574;185!48.?4^AH G\]?4?F*//7U'YBB"P1
ME!(Y('<^GUI_]G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\
M&@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P : &>>OJ/S%'GKZC\Q3_[.
MC]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\ &@!G
MGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P : &>>OJ/S%'GKZC\Q3_[.C]/U
M/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\ &@!GGKZC
M\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P : &>>OJ/S%'GKZC\Q3_[.C]/U/^-'
M]G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\ &@!GGKZC\Q1Y
MZ^H_,4_^SH_3]3_C1_9T?I^I_P : &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^
MGZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\ &@!GGKZC\Q1YZ^H_
M,4_^SH_3]3_C1_9T?I^I_P : &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_
M !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^
MSH_3]3_C1_9T?I^I_P : &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H
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M3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\
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MQH 9YZ^H_,4>>OJ/S%/_ +.C]/U/^-']G1^GZG_&@!GGKZC\Q1YZ^H_,4_\
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MSH_3]3_C1_9T?I^I_P : &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H
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M3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\
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MH *HZM]P?[W]#5ZJ.K?<'^]_0T 6;;[B_P"Z/Y5+45M]Q?\ ='\JEH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1_QH^JON'MD=O17$?VA+_?;_ +Z/^-']H2_WV_[Z/^-'U5]P]LCMZI?\M?\
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M10 4444 %%%% !1110 4444 %%%% !6;H_\ %^']:TJS='_B_#^M &E1110
M51U;[@_WOZ&KU4=6^X/][^AH LVWW%_W1_*I:BMON+_NC^52T %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 51U;[@_WOZ&KU4=6^X/][^AH LVWW%_W1_*I:BMON+_ +H_E4M
M!1110 4444 %%%% !1110 4444 %%%,DD$8R: $GG$(R:S)93(<FDDD,AR:;
M0 4444 %%,>94X) ^IQ6;<:P<X0<>IH U:*Q$U9UZX/U'^&*T[2]6YZ<$=C0
M!8HHHH *?%*8SD4RB@#6@G$PR*DK'CD,9R*UHY!(-P[T .HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(\6?\>TG_
M  '_ -#6M>LCQ9_Q[2?\!_\ 0UJZ/\2/JB9_"_0YN6 Q6MO>*/FB<YXS_&2,
MD=@1C\:U-6 U.[AA&&1%WD@;ASS@\XP0!CZ]\BGZ99?;;#RAU*OC&!R') Y]
MQ5;P3 TS/<MV54'3' '&/8!?_KUU2EI*76+:^_\ IF26R[V_ KZ9.;>YNI!U
M1)B,].&!K-T34(;=FDN%+EAQPK#DY).X]??ZUJ:- +B[N8ST=90<=>7 J#2[
MM_#4C),AVOW'?;T*DX!'//<>Q&*TNO>76R([/I=D&F7ZQ7@DA!".^-IP/O\
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M[) P&3SQ\P) X)P,?B:75/\ D(#_ *Z1?R6MW0-:FU)B6C C[-R/7CG[Q^F
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MN;**,F5@PR ""&."Q.1C .,GC@9..*L> 7 ,JYY(0X[\;L_S%;U5:G->??\
M$S@[SBS*\+Z8NH3;).5522.>>@QD$8ZY_"M?Q@!811VL0Q&2Q(R>Q!QR>F6S
MSWQ5/P+_ *]O^N9_]"6MSQ=I#7\8=!EHR>/4'K@=SP/UZG%%2=JZ3>@1C^[=
MMQNG^'(9;95VC=(@.XC+ L <@\<#T_/J:O:'HW]E(8PQ;)R<@ 9]AUZ8ZD].
MU<]!XO\ LL'D%2)47:.F!C@$YYR.XP<D=L\;_AZ:>:/=<#!SQE=K8]3_ "'
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M9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %*JEC@<D^E"J6.!R3Z5U.C:,+0>8_+G]/;Z^I_ >\5*B
M@BHQ<F7;!'2-1(<L!SW^GZ58HHK@;N[G2@HHHI %%%% !1110 4444 %%%%
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M[_X\O^-']@S?W?\ QY?\:/:0[H.5]C/HK0_L&;^[_P"/+_C1_8,W]W_QY?\
M&CVD.Z#E?8SZ*T/[!F_N_P#CR_XT?V#-_=_\>7_&CVD.Z#E?8SZ*T/[!F_N_
M^/+_ (T?V#-_=_\ 'E_QH]I#N@Y7V,^BM#^P9O[O_CR_XT?V#-_=_P#'E_QH
M]I#N@Y7V,^BM#^P9O[O_ (\O^-']@S?W?_'E_P :/:0[H.5]C/HK0_L&;^[_
M ./+_C1_8,W]W_QY?\:/:0[H.5]C/HK0_L&;^[_X\O\ C1_8,W]W_P >7_&C
MVD.Z#E?8SZ*T/[!F_N_^/+_C1_8,W]W_ ,>7_&CVD.Z#E?8SZ*T/[!F_N_\
MCR_XT?V#-_=_\>7_ !H]I#N@Y7V,^BM#^P9O[O\ X\O^-,_L>7.S;S]1_C1[
M2'=!ROL4J*T/[!F_N_\ CR_XT?V#-_=_\>7_ !H]I#N@Y7V,^BM#^P9O[O\
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MH.5]C/HK0_L&;^[_ ./+_C1_8,W]W_QY?\:/:0[H.5]C/HK0_L&;^[_X\O\
MC1_8,W]W_P >7_&CVD.Z#E?8SZ*T/[!F_N_^/+_C1_8,W]W_ ,>7_&CVD.Z#
ME?8SZ*T/[!F_N_\ CR_XT?V#-_=_\>7_ !H]I#N@Y7V,^BM#^P9O[O\ X\O^
M-']@S?W?_'E_QH]I#N@Y7V,^BM#^P9O[O_CR_P"-']@S?W?_ !Y?\:/:0[H.
M5]C/HK0_L&;^[_X\O^-']@S?W?\ QY?\:/:0[H.5]C/HK0_L&;^[_P"/+_C1
M_8,W]W_QY?\ &CVD.Z#E?8SZ*T/[!F_N_P#CR_XT?V#-_=_\>7_&CVD.Z#E?
M8SZ*NQZ/++T7I[C_ !I_]@S?W?\ QY?\:/:0[H.5]C/HK0_L&;^[_P"/+_C1
M_8,W]W_QY?\ &CVD.Z#E?8SZ*T/[!F_N_P#CR_XT?V#-_=_\>7_&CVD.Z#E?
M8SZ55+' Y)]*O_V#-_=_\>7_ !K:T;1A:#S'Y<_I[?7U/X#WF=:,5>]QQ@VP
MT;1A:#S'Y<_I[?7U/X#WU:**XI2<G=FZ22L%%%%2,**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LW1_XOP_K
M6E6;H_\ %^']: -*BBB@ JCJWW!_O?T-7JHZM]P?[W]#0!9MON+_ +H_E4M1
M6WW%_P!T?RJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"EJ^JKID9E;GG  [D]!GMTZ_P#ZJYBU6]UL>:'V*"<<
ME ?7&T9('3G\\YJ?Q\Y B7/!+G';C;C^9KH-%0)!$ ,?NU/'N 3^9KIC:G24
MK:LR?O3:Z(Y6'6+C0I?*N"74\D$[C@G&X$\]NAQ] 3FNU1PX# Y!&01R.:9+
M;+*0S*"5.02 2/IZ=*JZW;_:(F0R>6#C+<8QGH<XX/U'Y<'.<XU&M+/J5&+B
MGU'_ -L0?\]4_P"^U_QJT[A 6)P ,DG@<5P>K+9+%B DR C!^;GU)W8'Y=\=
MLUM^#_\ 2K9HGY7<RXZ<$ D<?4U=2@HPYM=^I,:C;L;MO>)<Y\ME;'7:P.,_
M2DGOX[<[7=5.,X9@#^IKE?"K?V=<R6C=\@$@@DIDCZ J2?RY]67T8UF^\KJB
M<' /1<E@>G\1*Y^GXGU=<[5]+7N'M'R^=['7?;$W>5N7?_=W#=TSTZ].:+>\
M2YSY;*V.NU@<9^E<-XAC:6\:-#@N44'./O*H[=N>?:NA_LZ/PY')<)EFV@#=
M@]\#H!QDC/THE0BHQUU=K(:J-M]D;%Q>);8\QE7/3<P&<?6GPS+,-Z$$'H0<
MC\Q7'>&-&75=]Q<9?G:,L<Y &23UZ8 Y]>.E0W?_ !3ET-A/EMAMN2?E.001
MQDCG;GVR>M/ZO%MQ3]Y"]H[7MH7_ !7XC:!O(A8#@[F4@G/(V^Q'Y].G?IH+
ME;@;D8,,XRI!'Z5POC&T6VG^08WKN/).26;)YKH=8*:%;LL(V[VP,$G!8<G)
M.1P./?%.=.+A!+=BC)J4K]#7GOX[<[7=5.,X9@#^IJ5'#@,#D$9!'(YKE/#?
MAV.]C^T3C>TC$CYF['!SC').?7M[U5TR9M%NS:Y)C9MN,Y^_C:<<#/3)QTSB
MI="+YDGJA^T>C:T9)XROY+>951V4>6#A6('WF]#6YK\'F[/W_DXW=\;NG^TO
M3^M<YXZ_UZ_]<Q_Z$U7/'W_++_@?_LM:QC?V2VW);MSG11W26B())%^Z,,S
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M7L-S=W;H=/5:;4HH3L=U!'4%@#^1-<UI7B)Q:RL<F2+&&)R?G. <G.2#GMC
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MK_\ 6H OT50_M3_9_7_ZU']J?[/Z_P#UJ +]%4/[4_V?U_\ K4?VI_L_K_\
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MG]?_ *U %^BJ']J?[/Z__6H_M3_9_7_ZU %^BJ']J?[/Z_\ UJ/[4_V?U_\
MK4 7Z*H?VI_L_K_]:C^U/]G]?_K4 7Z*H?VI_L_K_P#6H_M3_9_7_P"M0!?H
MJA_:G^S^O_UJ/[4_V?U_^M0!?HJA_:G^S^O_ -:C^U/]G]?_ *U %^BJ']J?
M[/Z__6H_M3_9_7_ZU %^BJ']J?[/Z_\ UJ/[4_V?U_\ K4 7Z*H?VI_L_K_]
M:C^U/]G]?_K4 7Z*H?VI_L_K_P#6H_M3_9_7_P"M0!?HJA_:G^S^O_UJ/[4_
MV?U_^M0!?HJA_:G^S^O_ -:C^U/]G]?_ *U %^BJ']J?[/Z__6H_M3_9_7_Z
MU %^BJ']J?[/Z_\ UJ/[4_V?U_\ K4 7Z*H?VI_L_K_]:C^U/]G]?_K4 7Z*
MH?VI_L_K_P#6H_M3_9_7_P"M0!?HJA_:G^S^O_UJ/[4_V?U_^M0!?HJA_:G^
MS^O_ -:C^U/]G]?_ *U %^BJ']J?[/Z__6H_M3_9_7_ZU %^BJ']J?[/Z_\
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M7M^O_P!:@"[15+^TO;]?_K4?VE[?K_\ 6H NT52_M+V_7_ZU']I>WZ__ %J
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M40PK^]90&^4[OE^9CG!R,KTSP/3&*V/ O^H;_KH?_05K<BL(X@55% 88("@
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MK 37;=FA.[8V1@$9*CD8(R>#Q[XK9GMEN!M=0PSG# $?K1!;+;C:BA1G.%
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M HHHH **** "BBB@ HHHH **** "J.K?<'^]_0U>JCJWW!_O?T- %FV^XO\
MNC^52U%;?<7_ '1_*I: "BBB@ HHHH **** "BBB@ HHHH H:BO(/J/Y?_KK
M+O;P6PSW/2MR\CWJ?;FL"]T_[20V<8&.F: ,620R'<>2:T;9!9+YKCYCT'?_
M .M[_P"15FVTQ8?F/)'K_A4EY9BY&.A'0T 8MS=-<'+?D.E1J2GS#(]Q6S!I
MB0_,W./7I^59VH77VALCH.G^- %FVU?8 K@G'?O4UUJJH/DY)_*JT>GAHO,.
M0<$_Y_SWJC&F\A1W./SH M1ZJZG).1Z8'^%++JCDDJ<#MP*M:E9C8"H^Y_+_
M #_6LN)@I!/0$9H )I3,=QZG'Z#%+'&).,X/OT/X]O\ /-:5WI.[YDZ^G;\*
MRV0H<'@^] #WB:V/.0?\]ZUM.O3<9#=1CD54L;X8\J3E>V?Y'V_E_+52(1_=
M 'T&* 'T444 7-.3JWX5>J&TCV*/?G\ZFH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN<U#QM%;DI&I<@
MXSD!?P/.?RQ[^J:?XVCN&V2+LR>#G(_$X&/U]\5K]7J6O8CVL;VN=)111618
M445F:SK\>E ;N7(X4=?J?09X_D#@TXQ<G9";25V:=%%%(84444 %%%% !111
M0 4444 %%%% !1110 4444 %%5M0U!+!#+(< ?F3Z#W_ ,]*YM_'P!.(LC/&
M7P?RVG^=:0HSGJD3*<8[G6T52TK5X]37?&>AY!X(],CGKV__ %U=J&G%V8TT
MPHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:K_#^/]*OU
M0U7^'\?Z5?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1KI/$FF17R#S'$94_*Q(QSU&"1G./KQ]<IQ@E3;7>X[R;E8R8Y=0\M;D,&!
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MB0'8_<@9R/<9'/OZ<>F-JBDJLU+FOJ')&UNAQ7B71/L42RN[22%PNYB>F&.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_*I:BMON+_NC^52T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 51U;[@_WOZ&KU4=6^X/][^AH
M LVWW%_W1_*I:BMON+_NC^52T %%%% !1110 4444 %%%% !1110 4444 %%
M%% "$9XJO)8*W(X_E5FB@#.>P8=.:B:V9>Q_#G^5:U% &1Y#>A_(TJVS-V/X
M\?SK6HH SH[!FZ\?K5B*Q5.O)JS10 @&.*6BB@ HHHH **** "BBB@ HHHH
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MJEYH[+YK*P8'' P<=1P%/&0?\FG]5E>UU=B]JO,[.BN4FOKVYC-VFU(P"0N
M6*CG=\P/;Z9QD#D9T?#&N'4T(<?/'C)['.<'Z\<]O3T$RH2C%RTTW&JB;L;5
M%<Y))>WSL8L1(IP X&3CO]UOTX]">34'A_Q#-),;2?DY89P,@KVXP,<'L>?:
MG[!V;NM ]HKV+T\=Y<R/M81(HPG"MN]">I&?TXX/)J;PUJK:E%O?[RL5)'?
M!SCMU_STJIKUZUZXTZ'.XD>8PZ!3U'Y')Y'9><D5M6-DMDBPI]U1WY/J3^)H
MG905TKO;T_X(1^(S_$GW/\^HKEZZCQ)]S_/J*Y>ML+\#]3.KN%%%%;F84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !71Z)HGE8FD'S=@>WN??\ E]>AHFB>5B:0?-V![>Y]_P"7UZ;E
M<M:M?W4;4Z?5A1117,:A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5FZ/_%^']:TJS='_B_#^M &E1110 51
MU;[@_P![^AJ]5'5ON#_>_H: +-M]Q?\ ='\JEJ*V^XO^Z/Y5+0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !5'5ON#_>_H:O51U;[@_P![^AH LVWW%_W1_*I:BMON+_NC^52T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"AJO\/X_TJ_5#5?X?Q_I5^@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH I77^L7\/YU=JE=?ZQ?P_G5V@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "J7_+7_/I5VJ7_+7_ #Z4 7:*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH I:;W_#^M7:I:;W_#^M7: "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "LW1_XOP_K6E6;H_\7X?UH TJ*** "J.K?<'^]_0U
M>JCJWW!_O?T- $EO=JJ@$] .Q]*?]L3U_0U4BM0P!YZ"G_9![T 6/MB>OZ&C
M[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_
MH:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO
M]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>
M]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'
MO0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %
MC[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z
M_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %C[8GK^AH
M^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>O
MZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K
M_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]
M'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9!
M[T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C
M[8GK^AJKJ,PF4!>3G^AIWV0>]'V0>] $L%TJJ 3R .Q]*?\ ;$]?T-5_L@]Z
M/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>
M@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;
M$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#
M1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]
M?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?
M[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH
M^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z
M +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L
M3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-
M'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U
M_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_
ML@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C
M[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH
M L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ
M/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T
M?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7
M]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^
MR#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/
ML@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@
M"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$
M]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1
M]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?
MT-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH 9?RB7&WG&?Z5;^V)Z_
MH:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO
M]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>
M]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'
MO0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %
MC[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z
M_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %C[8GK^AH
M^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>O
MZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] #9Y@SAAT&/YU:^V)Z
M_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_
MV0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K_9![
MT?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>
M] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6
M/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK
M^AH^V)Z_H:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C
M[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_
MH:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO
M]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>
M]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&JOG#S-_;_ .M3OL@]
MZ/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/
M>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?
M;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]
M#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$
M]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5
M?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#W
MH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]
MZ +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]
ML3U_0T?;$]?T-5_L@]Z/L@]Z &V4PBSGOBK7VQ/7]#5?[(/>C[(/>@"Q]L3U
M_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'V
MQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0
MU7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@
M]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(
M/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L
M?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7
M]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;
M$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#
M5?[(/>C[(/>@"Q]L3U_0U4T?^+\/ZT_[(/>F:/\ Q?A_6@#2HHHH *HZM]P?
M[W]#5ZJ.K?<'^]_0T .@^Z/H/Y4^F0?='T'\JK7FJK:'8P.2,\8_QIJ+;LA-
MV+E%9?\ PD,?HWY#_&K-KJ:7/RJ>3V/!_P *ITY+H"DF6Z*;+)Y0+GH 3^59
MO_"0Q^C?D/\ &E&$I; Y)&I167_PD,?HWY#_ !J[9W@NQO7. <<T.$DKM I)
MD]%9TNNI$2A#9!(Z#M^-,_X2&/T;\A_C3]E/L+G1J456L]02[^Z>1V/6I+FX
M%NID/0>GN<5/*[VZCNK7):*I6FK)=-L&0<=\?XU<9MO)Z"AQ:=F":8M%9T6N
MI*0@#9) Z#O^-:-$HN.X)IA15>]OEM "W<]!C-,LM26\R%R"/7'^-/E=K] N
MKV+=%-ED\H%ST )_*LW_ (2&/T;\A_C1&$I; Y)&I167_P )#'Z-^0_QJU9:
M@MYG:#\N.N._XGTH=.25V@4DRU14<]PMN-S' J@WB",<88_@/\:(PE+9 Y)&
MG15>UOTNONGG'0\&II9/*!<] "?RI--.P[CJ*JV6H+>9V@_+CKCO^)]*M4--
M.S!.X4457NK]+7[QYQT')H2;!NQ8HK,7Q!&>,,/P'^-7X+A;@;E.13E"4=T)
M23)***IW6K1V_!.3Z+S_ /6_K246]@;2+E%9J:_&QP<CW(_P)K01PXR#D>HY
MIR@X[@FF.HJA#K*2L(\$$G'S #GTZU?I2BX[@FF%%4KO5DM6V')..V/\:MHV
M\ ],CH>M#BTKA=#J***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *K:/\ Q?A_6K-5M'_B_#^M &E1110 51U;[@_WOZ&KU4=6^X/]
M[^AH =!]T?0?RK!\0_ZP?[H_F:WH/NCZ#^58/B'_ %@_W1_,UKA_C(J?";7V
M&/\ N+_WR*QM8L/LI$J< GMV/7C_ #Q705E^(?\ 5C_>'\C11D^9!-*Q8:?[
M1 7]4.?K@Y_6L[0(%EW[@#C;U /K5FS_ ./8_P"Z_P#6LS3=-^VYYQMQVSUS
M[CTJXI*,E>VI+>J.@^PQ_P!Q?^^14L<0BX4 #V&*Q_\ A&_]O_QW_P"O6G96
MWV9!'G.,\].IS64[6T=RU?L8EN@>X((R-S\'GUK;^PQ_W%_[Y%<^8FEF94.&
M+-@Y(]?2GWL<UIC<QP>X8X^E;SAS-:VT(B[)Z %%M<!4Z!@/7KP1^N*U]9_U
M3?A_,55T6R3_ %P))!(Y&,?AS_/O5K6?]4WX?S%1*2<XKL-+W68UH/LS12]F
MSDGIU*G]*V]6F\J)CZC'/OQ_*LJ6#?;*_=2?R+$?SQ3]1NOMBQQC&7P3UZ_=
M_+.:J2YI)]FQ)V314A@\EXO5MI_-N/TKJ*P]00)/$HZ (!^#&MF>80J7/0"H
MK/FY65!6N8>J.;R80CH#CCGKU/X?TH4_8+CT5CZ8&&_H#_*F:.X,AED(!&>I
MQR>_\ZEUXI+M=2">AP<GU''YUILU#I8CIS&XR[N#T-5+RS148A5R%;^$>E2:
M?<_:$#]\<_4=:6^_U;_[K?RKG5XRL:NS1DZ! LN_< <;>H!]:VHX%B^Z ,^@
M K(\-_Q_\!_K6U5UV^=DTU[J.==O[4FVY.P9QCL!W_&MI-/C08"C\1G]36+X
M?;$A]U/\Q714ZS<6HK85-75SG]4L_L#+)'D9_0CW]_3ZUJR7 N(6D'=&_D<U
M6\0M\@'?=_0T6?\ Q['_ '7_ *TW[T(M[W!:2:(?#?\ '_P'^M;58OAO^/\
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MN7R >"R_KT_+-%.U16?3\@E>+NNI;TBU-VYG?G!]>_\ @/\ "MZF00B%0@Z
M4^LZD^9E1C9!1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV@"W153RYO\ .VCRYO\ .V@"W153RYO\[:/+F_SMH MT54\N;_.VCRYO\[:
M+=%5/+F_SMH\N;_.V@"W153RYO\ .VCRYO\ .V@"W153RYO\[:/+F_SMH MT
M54\N;_.VCRYO\[: +=%5/+F_SMH\N;_.V@"W153RYO\ .VCRYO\ .V@"W153
MRYO\[:/+F_SMH MT54\N;_.VCRYO\[: +=%5/+F_SMH\N;_.V@"W153RYO\
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M?YVT 6Z*J>7-_G;1Y<W^=M %NBJGES?YVT>7-_G;0!;HJIY<W^=M'ES?YVT
M6Z*J>7-_G;1Y<W^=M %NBJGES?YVT>7-_G;0!;HJIY<W^=M'ES?YVT 6Z*J>
M7-_G;1Y<W^=M %NBJGES?YVT>7-_G;0!;HJIY<W^=M'ES?YVT 6Z*J>7-_G;
M1Y<W^=M %NJVC_Q?A_6F^7-_G;3M'_B_#^M &E1110 51U;[@_WOZ&KU4=6^
MX/\ >_H: +-M]Q?]T?RJ6HK;[B_[H_E4M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+]YN6/\ 2M:.,1@*.@H <#CFM.UG\T<]1UK,I\$OE$-0!KT4@.>:6@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"-8WVJ,8 H O6J_:W,QZ+PM,FN%>7YC\J?S_ ,_RJ_:Q>4H7T'_ZZQ;1//D
M;N3G^= &V)U/((_.J>G+YI:<]SQ4C:4A]1]#5B&$1#8.@H SK"Z4%G<X9C[]
M*TDF5^A!^AIC6B-QM'Y52OM/2-2Z\$8[^] &G14-H<HI/H*FH T[.3>H]N*G
MJAIS<D>H_E_^NK] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !169/K7E2_9]O=1G/][';'O6
MG3<6K7$FF%%9FF:U]N8IMQ@9ZY[@>@]:TZ)1<79@FF%%%4]0O6ML;4+YSTSQ
MC'H#0DV[#;L7**9"YD4,1@D X],]J?2 ***S]5U7[!M^7.[/?'3'L?6G&+D[
M(3=C0HJ.WE\Y5?IN /YC-24AA1110 4444 %%%% !1110 45F:GK7V%@FW.1
MGKCN1Z'TJG_PE/\ L?\ CW_UJT5*;5[$N:1OT53L-42]R%R".QZ_6F7VH/;-
MM6,N,9R,^_'0U/([V'S*UR_1114C"BBB@ HHHH **** "BLS4]:^PL$VYR,]
M<=R/0^E:=-Q:2?<2:84444AA1110 4444 4-4Z#\?Z5G5HZIT'X_TK.K:EL1
M/<****LD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EIO?\
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MP*#<R3]"3]/_ *U;JMNY'>H+R[%L,XSF@#($,B<@,/IFDDO'8;">/<5HSZF
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M=_RI044VGN#N[6-+3+B8DQS+T_BX'O\ 0_AT[UI5A:1JCE_L\O)Y&>^1V)_
M^IS6[6=56E_D5!W1S/B;_6#_ '!_,UTK*&&#R#7->)O]8/\ <'\S72LP49/
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MW^L'^X/YFKC"+E%VW0G)I,T--FG<^9+@1E2?X<>HZ'(X]:JIJ4VH.1#\JCU
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MP2>.>HY(]*)N*G:V@1ORW**/=[1,""#SMP,XZ^@Z^QS6O9RM*H9UVMW']?\
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M^8 _*O3JPO!_A9/#D/D*=SL<NW3)_P !V_\ KUNU%22E)M M@HHHJ!A1110
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M %FP7+?05HU3TY>"?4_R_P#UU<H **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *L6MJ9S[#J:+6U,Y]AU-:R($&!T%1.=M"HQN"($&!T%.HHK$L**** "
MBBB@#QGQAITOA&^&HPC]V[EE/;+??0_7)Q['CI7?:)\1K/4U!,@C?NLA"X/U
M/!_/\!717=FEXIBE4,C=0PR*XG4/@]:7!W1L\>>P(9?_ !X9_6M>:,DK[BLT
M=7_PD5K_ ,]HO^_B?XU%<>*[2W&YIX\>SJ3^0)-<9_PI2+_GLW_?(_QIT?P5
MA!^:9R/95!_/FERT^X:F)X[\<?\ "2E=/LP2A89..7/8 =<#KSW],5#\+';3
M=0:U?AF61"/]I#G_ -E->F>'_!EMH/S0I\_]]CN;\^WX 51;X?Q+>C5(W96W
M;BN 5)(P?<9JO:1LX]!69R7Q4\.R6<RZO!G&5W$=59?NM]#@?B/>NC\-?%"V
MU) L["*4#D-PI/J&Z8]CS]>M=D\8D!5AD$8(/(-<9JWPEL[TETW1$]D(V_\
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M/<!L\ ^F/H:[N.,1@*HP , #H .U:2G%+W>HDAU%%%9#/'-#_P"0ZW_7>?\
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MV[YAC' ';Z5NU#M<84444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *6F]_P_K5VJ6F]_P /ZU=H **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH HZD,X_'^E3?8$]/U/\ C46I=OQ_I5VFFT%BO]@3
MT_4_XT?8$]/U/^-6**.9BLBO]@3T_4_XT?8$]/U/^-6**.9A9%?[ GI^I_QH
M^P)Z?J?\:L44<S"R*_V!/3]3_C1]@3T_4_XU8HHYF%D5_L">GZG_ !H^P)Z?
MJ?\ &K%%',PLBO\ 8$]/U/\ C1]@3T_4_P"-6**.9A9%?[ GI^I_QH^P)Z?J
M?\:L44<S"R*_V!/3]3_C1]@3T_4_XU8HHYF%D5_L">GZG_&C[ GI^I_QJQ11
MS,+(K_8$]/U/^-'V!/3]3_C5BBCF8617^P)Z?J?\:/L">GZG_&K%%',PLBO]
M@3T_4_XT?8$]/U/^-6**.9A9%?[ GI^I_P :/L">GZG_ !JQ11S,+(K_ &!/
M3]3_ (T?8$]/U/\ C5BBCF8617^P)Z?J?\:/L">GZG_&K%%',PLBO]@3T_4_
MXT?8$]/U/^-6**.9A9&;/;*KA0.#CU]:M?8$]/U/^-177^L7\/YU=HYF%D5_
ML">GZG_&C[ GI^I_QJQ11S,+(K_8$]/U/^-'V!/3]3_C5BBCF8617^P)Z?J?
M\:/L">GZG_&K%%',PLBO]@3T_4_XT?8$]/U/^-6**.9A9%?[ GI^I_QH^P)Z
M?J?\:L44<S"R*_V!/3]3_C1]@3T_4_XU8HHYF%D5_L">GZG_ !H^P)Z?J?\
M&K%%',PLBO\ 8$]/U/\ C1]@3T_4_P"-6**.9A9%?[ GI^I_QH^P)Z?J?\:L
M44<S"R&H@08'04ZBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "J7_ "U_SZ5=JE_RU_SZ4 7:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH I:;W_  _K5VJ6F]_P_K5V@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K-T?\ B_#^M:59NC_Q?A_6@#2HHHH *K7UN9UVCUSS5FB@#,%C
M*. WZFE^Q2_WO_'C6E10!F_8I?[W_CQH^Q2_WO\ QXUI44 9OV*7^]_X\:/L
M4O\ >_\ 'C6E10!F_8I?[W_CQH^Q2_WO_'C6E10!F_8I?[W_ (\:/L4O][_Q
MXUI44 9OV*7^]_X\:/L4O][_ ,>-:5% &;]BE_O?^/&C[%+_ 'O_ !XUI44
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M8I?[W_CQK2HH S?L4O\ >_\ 'C1]BE_O?^/&M*B@#-^Q2_WO_'C1]BE_O?\
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M\:TJ* ,W[%+_ 'O_ !XT?8I?[W_CQK2HH S?L4O][_QXT?8I?[W_ (\:TJ*
M,W[%+_>_\>--_L^3.=W/KD_X5J44 9OV*7^]_P"/&C[%+_>_\>-:5% &;]BE
M_O?^/&C[%+_>_P#'C6E10!F_8I?[W_CQH^Q2_P![_P >-:5% &;]BE_O?^/&
MC[%+_>_\>-:5% &;]BE_O?\ CQH^Q2_WO_'C6E10!F_8I?[W_CQH^Q2_WO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4C+NX-%% &-1110 4444 %%%%
M!1110 5LJNW@444 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>xcur-20210630_g2.jpg
<TEXT>
begin 644 xcur-20210630_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $_!%,# 2(  A$! Q$!_\0
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M,%RNT$@9R0#^2>D*B_\ !,_PR(XVBC'QCC"QO]Y1]F; /N*^PM8\4:!\*?\
M@JGKOB+XH:G::%H^I>"XX?"NLZ[,D%E R^4)HTFD(1&)%SU(_P!81_RT&0#Z
MJ;]ISX7_ /"EY_BS'XOM+KX?VZ(\^L6D4L_D[W1 CQ(AE5PTB H4#+N^8"N9
M\%_MT? GXA_$#3_!/AWXBZ?J?B34%0VMM'!<+%,6C$BHL[1B(OM.-F_<&RA&
MX%1^>FIB#5_V9/VXO$_A>+R_AAK'B33V\//#$8K::1-0'VF2%<#"$/!TXP ,
M#&*]1_:.T:P\/>$?V QIUG!:?8];T58#'&,H&6Q=\'K\S*&;^\1DY- 'UO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0NX1C^X#M]JZ&B@#DK'X1^!=,\(WWA2S\%^'K3PO?.TEWHD&E0)97#-C<TD
M38Q.U<D@YVCTKH='T;3_  [I-GI>E6-MIFF6<*V]M96<*PPP1J,*B(H"JH
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M?_(U?55% 'RK_P /1OV8O^BF?^4#5/\ Y&H_X>C?LQ?]%,_\H&J?_(U?55%
M'RK_ ,/1OV8O^BF?^4#5/_D:C_AZ-^S%_P!%,_\ *!JG_P C5]544 ?*O_#T
M;]F+_HIG_E U3_Y&H_X>C?LQ?]%,_P#*!JG_ ,C5]544 ?*O_#T;]F+_ **9
M_P"4#5/_ )&H_P"'HW[,7_13/_*!JG_R-7U510!\J_\ #T;]F+_HIG_E U3_
M .1J/^'HW[,7_13/_*!JG_R-7U510!\J_P##T;]F+_HIG_E U3_Y&H_X>C?L
MQ?\ 13/_ "@:I_\ (U?55% 'RK_P]&_9B_Z*9_Y0-4_^1J/^'HW[,7_13/\
MR@:I_P#(U?55% 'RK_P]&_9B_P"BF?\ E U3_P"1J/\ AZ-^S%_T4S_R@:I_
M\C5]544 ?*O_  ]&_9B_Z*9_Y0-4_P#D:C_AZ-^S%_T4S_R@:I_\C5]544 ?
M*O\ P]&_9B_Z*9_Y0-4_^1J/^'HW[,7_ $4S_P H&J?_ "-7U510!\J_\/1O
MV8O^BF?^4#5/_D:C_AZ-^S%_T4S_ ,H&J?\ R-7U510!\J_\/1OV8O\ HIG_
M )0-4_\ D:C_ (>C?LQ?]%,_\H&J?_(U?55% 'RK_P /1OV8O^BF?^4#5/\
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M^UOVC/V6-!?YHIO%5[JA3MNM+0NI_ O7U70!\J_\/1/V9_\ HHLG_A/ZG_\
M(U'_  ]$_9G_ .BBR?\ A/ZG_P#(U?55% 'RK_P]$_9G_P"BBR?^$_J?_P C
M4?\ #T3]F?\ Z*+)_P"$_J?_ ,C5]544 ?*O_#T3]F?_ **+)_X3^I__ "-1
M_P /1/V9_P#HHLG_ (3^I_\ R-7U510!\J_\/1/V9_\ HHLG_A/ZG_\ (U'_
M  ]$_9G_ .BBR?\ A/ZG_P#(U?55% 'RK_P]$_9G_P"BBR?^$_J?_P C4?\
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M .BBR?\ A/ZG_P#(U?55% 'RK_P]$_9G_P"BBR?^$_J?_P C4?\ #T3]F?\
MZ*+)_P"$_J?_ ,C5]544 ?*O_#T3]F?_ **+)_X3^I__ "-1_P /1/V9_P#H
MHLG_ (3^I_\ R-7U510!\J_\/1/V9_\ HHLG_A/ZG_\ (U'_  ]$_9G_ .BB
MR?\ A/ZG_P#(U?55% 'RK_P]$_9G_P"BBR?^$_J?_P C4?\ #T3]F?\ Z*+)
M_P"$_J?_ ,C5]544 ?*O_#T3]F?_ **+)_X3^I__ "-1_P /1/V9_P#HHLG_
M (3^I_\ R-7U510!\J_\/1/V9_\ HHLG_A/ZG_\ (U'_  ]$_9G_ .BBR?\
MA/ZG_P#(U?55% 'RK_P]$_9G_P"BBR?^$_J?_P C4?\ #T3]F?\ Z*+)_P"$
M_J?_ ,C5]544 ?*O_#T3]F?_ **+)_X3^I__ "-1_P /1/V9_P#HHLG_ (3^
MI_\ R-7U510!\J_\/1/V9_\ HHLG_A/ZG_\ (U'_  ]$_9G_ .BBR?\ A/ZG
M_P#(U?55% 'RK_P]$_9G_P"BBR?^$_J?_P C4?\ #T3]F?\ Z*+)_P"$_J?_
M ,C5]544 ?*O_#T3]F?_ **+)_X3^I__ "-1_P /1/V9_P#HHLG_ (3^I_\
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MHEI9Z@9(K\MDW$]S)YAQ(<LV<C)_*@#]DY+B*%L/*B'KAF IJWD#, )XR3T
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M 4444 %%<W\2O'FG_"WX>^)/&.JPW-QIF@Z=/J5S%9JK3/'%&78(&95+$*<
ML!GN*^)/^'U?P0_Z%;X@?^"ZQ_\ DR@#[_HKYZ^"_P"V]X%^.GC[1/".@Z3X
MAM-2U?PY_P )/!+J-M D*VOF^5L8I,Y$FX9P 5Q_%VKZ%H **** "BBB@ HK
M"\<^*O\ A!_!^KZ__8^K>(/[.MVN/[+T.U^TWUSM&?+ABR-[GL,C-.\%>)O^
M$T\(Z/KW]DZIH7]HVL=U_9FM6WV>]M=R@^7-%D[)!G!7)P: -NBBB@ HHHH
M***^8O!GQ6\6:E_P4'^('P_N=9DE\':;X/M=2M-*,482*X>2$-(&"[R2&;@L
M1STH ^G:*** "BBB@ HHHH **Y?XH?$+3OA-\._$?C/5X;JYTO0;";4+F&R1
M6G>.-2S! S*I; XRP'O4'PC^)VE_&?X:^'O&^B6]Y:Z3KEJMW;0Z@B).B$D
M.$9E!X[,: .OHHHH ***YOXE>/-/^%OP]\2>,=5AN;C3-!TZ?4KF*S56F>.*
M,NP0,RJ6(4X!8#/<4 =)17(?"/XG:7\9_AKX>\;Z);WEKI.N6JW=M#J"(DZ(
M20 X1F4'CLQKKZ "BBB@ HHHH ^:OVU?">N>)[SX S:)HVH:Q_9?Q4T2^OO[
M/M9)_LMHHG$D\NP'9$N5W.V%&1DU]*T44 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5&]O%)(DC1HTB?=9E!(^AJ2B@ KXQ_X*,?\AW]G
M#_LI.G_R-?9U?&/_  48_P"0[^SA_P!E)T_^1H ^SJ*** /@GQ7_ &-_P]ST
M+_A-_L_D?\(5'_PBW]I;?+^V><VWR=W'F9^TX[[NG.*^B]>;X&1?M1^'VU<^
M'A\<'TB5-+^T?\?GV3<-VW/R"3&[:3^]*><$^3S*D_:6_9'^'7[5WA^UT[QO
MIUPMY99^P:SIDPAO;/<REPC%65E8+@JZLO.0 P!''_LS?\$]_A/^ROXDN?$?
MAF'5M:\1R1-!#JOB"YCGEM8G WI$L<<:+NV\OM+X+*&"L00#\Y_ O@OXM?M8
M^$_&'Q(TSX1ZUXL^)EYKLO\ 9?Q&MOB#%IDWAR2)XW2TALG=<+&"1S@XE^4J
M0"/>/C1\-=1^.7[:W[,OA7XKVTMMJ6I^ W/BFPL;LP^;.D%T]Q )+=N$>12K
M!&QM8@&OHWQA_P $X?AEXP\6:]J8UWQKH6@>(;^/4M<\&:)KAM=$U699!(QG
M@"%B'89.UU*_P%" 1Z;?_LP^$+SXW>!OB?%+J-AJ_@W2)-%TO3+.2)+ 6S1R
M1X9#&7RJRL!M=0,+P>X!^??Q@\"7?B_]K[6?@QHWP:N/BG\./ASX<LX]#\"Q
M>,CH-M;+)%!(]\9)&WSOOG:(G<3R-Q-9/[0GA'XL^ _^";UKX7^+=G=Z/J&E
M^/+>#16U#58-1N(],,+M"LD\+D,8W:51G;A54!54**_0'XX?L=^$OC=XWTSQ
MH?$'BSP%XSL;5K$>(/!.J_V=>3VQ)/DR/L<%02>@!YP20 !A>(OV /A;K_[.
M^E?!F,ZUI/A:QOX]4DNK&[3[=>W:JRO-/))&X9I-Q+;54#@*$4!0 ?/7Q&^$
M&A_L<_M6_L[:K\,K[5HKWQYJLVC^*8[O5)[QM=1F@\R\F\QVRX:=Y&(&W=M(
M"XR?G70?!_Q1_:RE^)OCNT^$6K>.OB!'XDN+71/'-OX^BTB3PI) R206T%D[
M+D1%MVXXSO\ E*N"Q_17X8_L(_#_ .&/Q.T_QPNL>+?%>HZ/ ]KX?L_%.LM?
MVN@P'($5FK*&5$0[%#L^!S][YJQ_'G_!.OX;^.?&GB+7(]?\:>&-.\37"7?B
M#PQX=UO[)I&L2JY=FN8?+);>2=VUEZDKM8DT >)^,F\7M^UQ^Q./'\ MO&RZ
M+?IK,8DCD_TI;4B0EHR4)+ D[21D\5Y'>(TGP*_X*$!5+'_A.9S@#/ U)R3^
M5?H7K?[*_@O6/B5\+O&4+:AI-S\.;22PT/3-/DC2R$#1>4$D1HV8A4 "[77&
M.<UG^&/V._ /AO3_ (O:?*VJZSIWQ0U&XU+7;34+E-B/,TC.D!B1&109#C)9
MA@?-Q0!\?_M ,O\ PS;^P:N1N.J^%B%SS@6<&?YC\ZP?^%$>%OCE^U]^U_!X
MN2_O=.TK38KNWT^WOYK: W0MPT5PZQLOF-%L;:'W+^\;*GC'T?I'_!,+X;Z;
M)X,DN_&OQ%UV3P?J$%_H@U?7H[B.R6)E;[-'$8/+2%F1"P158[!A@.*]<\.?
MLK^$_#'Q(^*/C:UU#69-5^(ELMKJL,T\1@@58R@, $093@_QL_- 'Y2:CX%C
MTW_@GCX%^/']MZ]<_%'2?$,.GZ/K=QJT[G2[&WDEAAL[>(MY<<2F(. %R&9N
M=IVU^W5G<?:K2"?;M\Q%?;G.,C.*^:[[_@G[\/+_ /9CT_X%R:SXF'A*RU Z
ME'>K=6_V\R&1Y,%_(\O;F1N/+S@#FOI6V@6UMXH4)*QH$!;K@#% $M?GE_P4
MH_Y.F_8\_P"QK/\ Z7:;7Z&U^>7_  4H_P"3IOV//^QK/_I=IM 'Z&T444 %
M%%% !7P1\6_[%_X>R?#+_A./L_\ 97_"(C_A&_[2V_9O[2\^?9LW?+YV[.W/
MS;_*QSLK[WKR#]I#]E/X>?M5>&+;2/'.F323619M/U:PE\F]L6; <QO@@A@!
ME'5E. 2N54@ I^-'^!D7[2W@UO$I\/#XSMITR:%]K_X_/LV\9V_PAL[_ "]W
MSG]\(^/,KXY^%_P5\/\ [<?C/]HGQ;\7+[4;O7/#FOW6@Z!#!J<T">&X(%<1
MRP1JX0-E03N!5GC9BN68GZ2_9K_X)T_"/]E_Q<_BKP]%K&O>)%1H[34O$-U'
M-)8JRE9!"L4<:*64E2Q4M@D @,P,WQ5_X)_?#WXH>-O$/B:#7O&7@:Y\31B+
MQ'9>$-9^Q6>N#&T_:H2CA\J6#!=H;<S$%F9B ? _B[QIXG_:(_94_90_X2W6
M=0EUF[^(!T,Z\)V6\DC$PBCG\WJ954@>9R2T>XDMDUZ%^VM^QC\'OAE\4OV:
M-#\,>"UTO1_$?BV'1-7B34+N3[5:/=0$QL[RE@3Y\WS@A\$ '"KC[<\7?L;?
M#OQ1H/PMT.T@O_#6B?#C5(=6T2PT:9%C,L3!PLQE21I%9AECD.Q9B6R<UJ_M
M%_LQ^%_VF-)\/6NOZEKN@W_A_45U32]9\-WHM;VTG4<,CLC@<A3G;N!12"*
M/SZ^+WA'6?BW^U_XT^&</P>O?B[X)^&^@Z?H_A_P<OC7^P8=(A:W@87FZ1MT
M\K9V[B3\I0/OVH1Z)XD^!_C'4O\ @F]X@TW]H&YF\)>*_ MU/J?AO6M0U.*]
MN8%B53:*\\#ON+M(]N /FQL(7*I7T;\1/V$_"'Q"UGP[X@7QIX^\+^,M)T6/
M0;CQ7X;UP6FIZO;(J@&]E\MA*Y*EF<*I8M\V0J!5\1?L#_#/7O@WX0^%44^O
M:/X$\/7PU&32].O47^UYMQ9C>R/&SR!F9SA&0#=\NT)&$ /GW_@EK<1_'WQ)
M\0/CMXTUZ#Q%\3Y)HM$^RJI7^R;%8D*%4/"^<5897(Q$W.7D%?HG7COAW]EG
MPCX._: U3XM^'KO5M#UC5K!=/U/1K&6%-*O550$D>'RBPD&U,,CK]WI\S[O8
MJ "BBB@ KR/]KS_DU/XQ?]BAJW_I)+7KE>1_M>?\FI_&+_L4-6_])): /*O^
M"6'_ "8S\//^NFI?^G&YKZQKY._X)8?\F,_#S_KIJ7_IQN:^L: "BBB@ KX(
M_P""2W]B_P#"%_%+[?\ 9_\ A:'_  EMW_PD7G[?M^SY?+\S^+R_,^T8[;_,
M[YK[WKY,^/W_  3'^#'[0GCBX\7:G'K?AC7;QFDOYO#=W%"E](0H\R2.6*50
M_P O)0+N+,6W$YH \R_:&^*7PQ^$?[(_QJUC]FN^T73-;_MJ*SUW4/#+LD]I
M<3W 1Y X^95PTJQ,A$:DMY1!4UY]^S5\ OBY\-_C'\+/$O@7X'WWPR\,.D=O
MXPU!_B!:ZS!K]K(B@74L'F JZDO(!&",OPHQS]K_  [_ &._A5\-?@EJ7PIT
M_P -K>>$]6B*:LM],SW&I.553-+*NTB3Y5(,>P(0"@3 KDO@W^P+X$^#_C+P
M]XE?Q-XV\<WWAJV:T\/P>,-9%Y;:,C)L/V6)(XU3Y,+C!48! ! ( /E[]B7]
MEGX??'3XE_';Q'X_T9O$YT3X@7\6E6%U=S+:VLAE9I9?)1U5V?\ <@[PPQ"G
M'%>67'BC6]+^"6J?L6+<RCQ8_P 2(_#=M(QRXT.2?[4+K&.5WJ&.,#9)SCH?
MTX^!O[.OAOX 3^-9?#U[JEXWBS6YM>OO[3ECD$<\IRRQ;(TPGH&W'W-9-U^R
M3X%O/VG+7X[2"_\ ^$SM['[$L >+[&3Y31"<IY>\RB-MF[?C ''% 'SUJWAZ
MQ\(_\%4OA+H6F0_9]-TOX6?8K6'^Y%'+?(B_@J@5XS\ OV?_  W^V+\&/&'Q
MN^(WC*^\)?%"3Q:TEOXQ?4I(3X;CMY8'CMXD,J1I@,50M@H70K]W!_0'5OV=
M?#>L?M&:+\:)KW55\4Z3HC:#!9QRQ"R: O,Y9D,9<OF=^0X' XZY\D\<?\$V
M?A?XX\5:[J+:YXTT+0?$&H1ZGK7@[1=:^SZ)J5PKB0M-!Y9;YF&3M=2O\&P@
M8 /%OVM/"=A\>OVGM)^%&G>$M7^+WBOP_P"%1+/'XF\3_P!D^'](,CQJNH3Q
M6L:3W$Q,D9D6)TRI4(AP=GSO;ZYJ^J_\$AO&=CJVHR:BNB^-X],L]TK2)!;H
M]JRQ1EN?+#.Y4'H&K]$/B5^P;\._B'XUT?Q19ZGXI\!ZEI^E1Z%(/!NK'3TO
MM/0*J6L^$9C&$4)A"I*X!)VKMR;?_@G5\-++X#^)_A!::OXHM?!FO:X->:)+
MR!I[.4>7B*"1X#^[Q$@Q)O;@G=DDD ^D?"O_ "+&C_\ 7G#_ .@"M2J^GV::
M;8VUI$6:.WC6)2W4A0 ,^_%6* "BBB@ KXX\&_\ *5GQ_P#]DWMO_2NWK['K
MXX\&_P#*5GQ__P!DWMO_ $KMZ /L>BBB@ HHHH *^%_%W_*7_P $_P#9/I/_
M $9=U]T5Y1J/[-WAG4_VD-+^-<M]JR^*M.T=M$BLTFB%BT!,AW,GE[R_[UN0
MX' X]0#Y"^*OP=T'XY?\%39_#/BDWTWAQOA^LU]IMG>S6BZ@@D*B&9X71S&'
M=)-H8 M$F<C(/F'PT^*?B;X ?L@?M::-X+O[R&W\$>,)M*T%I9VD?2[:XO%M
MF:)B<@J-SC&,.Q?J6S^B$?[.OAN/]HR7XT"]U3_A*9-$_L$V9EC^Q>1O#[MG
ME[]^1UWX]JQ/A_\ L@> ? -G\4[$KJ'B'3/B1J$^HZY8:U+')#NE+ETB\N-"
MJ?O#C)+# (;(S0!\/?%#X.Z'^R%\+O@1\:_ACJNJQ?$/6]5TRUUV^_M.:=?%
M$5[#]HG6:-V8,K/$" @'WLG+*K+T?@[]G/P9^T1_P45_:)L_'UA-KF@:2--N
MX](^V306\ET;>-8YI!$RERB^:H!.,2OP<U]%_#W_ ()W_#;P%XT\/Z]<:WXR
M\86GAIWE\.>'O%&M&\TO0Y&='5[6'8I4IL 7<S#@$@LJL/3O ?[.OAOX>_&C
MQ_\ $W3KW5)M>\:+;+J%O=2QM:Q"% J>2JQAER!SN9OPH _,/]ICPKIWQ\U#
M]H'QWX5\#WFOVWA&]FMYOB%XR\4NB:?]E #6.F:=:I'@9?,33&1=JDMAWQ7K
M7CSQ'K/QXT/]BSX7>,]:U&Y\(^.M,CU+Q.QNGCDUN2V@BD2&>4$,P+#+<[BS
MJ^0ZJP^AO%__  37^%OC'Q1XRU*76O&FF:/XMGDO-6\*Z7KAM](GNV4D7)@"
M9:1)3YRAF9 X'R[/DKK/%7[$7@+QC\$O!?PWU'4?$(C\&-#)X?\ $]K>QP:S
MISQ,"KQS)$$SM4)S&1A5;&]5< 'A_P 0OV<_#'[.?[+O[3^D>#O&=UJ.@3Z?
M+)'X.-T)X/#I:V1Q'\SO*)) XDW,R[D:/Y3C>WEFM&;XE^"/V'_@KK-W=6OP
M[\6Z1%>:]:VT[P#5/LL$4D5M(ZD'9N R <Y=&&&5"/K3PC^P3\//"?@/XC>'
MFU;Q3KNI>/[<VNN^*M<U-;O5YXL$*HE:/8,9)SY9))&XMM7;J^-/V*O 'CKX
M+^"?AU?7.N6L7@M;;_A'_$FGWBP:QI\D.T++',J;-S! &^3'1@ RHR@#/V7/
MV<_#'[.>N?$/2/!WC.ZU'0)]2BDC\'&Z$\'ATM"CB/YG>422!Q)N9EW(T?RG
M&]OH"O&/V?/V4?!_[.=YXCU32+_7O$WB?Q%*DFJ>)?%6H?;M1N53.Q&DVJ H
M))X4%LC<6VKM]GH **** "OC;X>_\I4?BE_V(-E_Z-MZ^R:^-OA[_P I4?BE
M_P!B#9?^C;>@#[)HHHH **** "BBB@#Q;]M3_DTCXO?]BQ?_ /HEJR_V"?\
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MT6@ HHHH *^-OA[_ ,I4?BE_V(-E_P"C;>OLFOC;X>_\I4?BE_V(-E_Z-MZ
M/LFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **3/;O2T %%%% !7QC_ ,%&
M/^0[^SA_V4G3_P"1K[.KXQ_X*,?\AW]G#_LI.G_R- 'V=1110 4444 %%%%
M!1110 4444 %%%% !1110 445X%\7+CQS;_M#?#+2=$\?WFA^'?$ O/MFE1:
M;:3*?LL2RG$DD9<>9NVGG@#(P: /?:_/+_@I1_R=-^QY_P!C6?\ TNTVOT-K
M\\O^"E'_ "=-^QY_V-9_]+M-H _0VBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\C_:\_Y-3^,7_8H:M_Z22UZY7D?[7G_)J?QB_P"Q0U;_ -))
M: /*O^"6'_)C/P\_ZZ:E_P"G&YKZQKY._P""6'_)C/P\_P"NFI?^G&YKZQH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXX\&_P#*5GQ__P!D
MWMO_ $KMZ^QZ^./!O_*5GQ__ -DWMO\ TKMZ /L>BBB@ HHHH **** "BBB@
M HHHH **** "BBOFOQ!^WEX+T/Q9XBT"W\'?$+Q!<:#J,VE7MUH7AF6\MEN(
MB-Z"1#@D9!['!![U48N3M%7 [7P-_P G,_%3_L$Z)_*[KU^OB'PS^V1HVD_&
M3QOXHG^&?Q6_LW6+#3;:V"^#;@ON@\_S-PSP/WB8]>?2O8?AC^V=X1^*'Q%T
MOP5!X9\;>'-:U."XN+3_ (270)+"*985#2[6<\D!EZ#^(>M4Z<XJ[BQ7/?:*
M**S&%?&WP]_Y2H_%+_L0;+_T;;U]DU\;?#W_ )2H_%+_ +$&R_\ 1MO0!]DT
M444 %%%% !1110 4444 %%%% !1110 4444 %%9-CXMT35-9O-(L]8L+O5;,
M9N;&&Y1YH?\ ?0'*_B*UJ ,?Q1XPT/P1I9U'Q!JUGHUCO$?VB]F6)"QZ*"3R
M?;VK0T_4+75K&"]LKF*\L[A!+#<0.'CD0C(96'!!'<5R'C[PCK&J:SH7B'P]
M-8'6='$\<5KJN_[-,DP4/ED!9'&P88 \%@1\V1H_#GP>_@?PI#I<URMW<M<7
M-Y/)$GEQ"6>>2=UC3)VQJTA55R<*!0!TU%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?"]YH_QK^.WQR^*EG9?':3X7:=X9U5-/L/#ME902R-;&%'2Y8N0
M2'W'!YY!'&,5]8?%SXLZ;\'?#MIK&J:;JFIP7-_!IZPZ1:FXE5Y6VJS*",(.
MY[5^>OQ\TK]F*3XV>,KCQ/\ #KXK:AXFDOW^WWVCV]P;::3C)C*N 4],<4 ?
M?'P$\#^*?A_X+DTWQ=\0;CXDZHUT\HU>Y@2%EC(&(]J''&#^=9/QT^#_ (V^
M+UU8V&B_%#4OA[X96%EOH=!M8_MUU(3QBX?/EJ!V49SSFN8_8;@^'UO\'KA?
MAMH?B70- _M*8M:^*DD6Z,V%W,-Y)VGC'T->Z>*-.NM8\-:M86-T;&]NK2:"
M"Z7K#(R%5?\  D'\* /A^V_8Y^!EUXFU73D^.?C"Y\7:3;M=ZA-'XQS<6J*0
M&DDQ]P D YZ9KZ*^!?P7\9?"/4I(;OXL:M\0?!\EKBVL_$,$<MW!+N!5UNEP
M73;D88'J#FOSS\._"'XM_#F^O_"6F?LXW<FL:AX.OO!NI:Y:W:FQU*YN)PW]
MI23MU 7D@G.?0#%?J3\)?"EYX$^%OA#PWJ-R+R_TC2+6QN+A22))(X51B">V
M5- &IXP.MCPKJ_\ PC2VC>(?LLG]GC4&9;?[1M/E^85!.W=C.!TK\]/AWXZ^
M,7PW_:X^&_@'Q'\99O'OB?6))I/&'A:*R3[#I<!B,D9BE*CL5/R@'U%??7Q1
MM_%5U\._$,?@>[M;'Q>;.0Z7/>Q"2$7 &4#J>,$C&3TSGM7Y_:;_ ,+@_:$^
M)7P9LO$?P:U#P/XZ\)^((]2\2>/VMHX89H(E8,D;+C<)5PI7)'3&1R #]"?$
M7Q$\*>$+N.UU[Q/HVB74B>8D.HW\5N[+DC<%=@2,@C/M7QG^WM\0/"WC#Q)^
MSK!H/B71];GB^(VGO)%IU_%<.B\C<0C$@9(Y]Z^DOBY^R?\ ";X\>(+77/'O
M@RU\1ZK:VPLX;F>>>,I"&9@F$=1C<['IGFOC;]KK]E?X5? 3QK^S]JO@'P=:
M^'-0O?B#I]K<3P3S2&2+.[:0[L.H!X]* /TDHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *\4^*G_ "<I\#/IKO\ Z1I7M=>*?%3_ ).4^!GTUW_TC2@#
MVNOSR_X*4?\ )TW['G_8UG_TNTVOT-K\\O\ @I1_R=-^QY_V-9_]+M-H _0V
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\C_:\_P"34_C%_P!B
MAJW_ *22UZY7D?[7G_)J?QB_[%#5O_226@#RK_@EA_R8S\//^NFI?^G&YKZQ
MKY._X)8?\F,_#S_KIJ7_ *<;FOK&@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH XWXK_ !,M_A'X0N_$M]HNK:SIMFC379TE(7>WB52S2,LDJ948_AR>
M>E;_ (=UB?7M'@O;C2;[0YI-VZQU'RO/CP2/F\IW3G&1ACP1]*\]_:J_Y-M^
M)/\ V KK_P!%FO5: "OCCP;_ ,I6?'__ &3>V_\ 2NWK['KXX\&_\I6?'_\
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MSX__ .R;VW_I7;U]CU\<>#?^4K/C_P#[)O;?^E=O0!]CT444 %%%% !1110
M4444 %%%% !1110 5\+?!/\ Y&_XZ?\ 92M7_P#1=O7W37PM\$_^1O\ CI_V
M4K5__1=O7MY/_O2]&9U/A/4ZX*W_ .3TO@A_V"?$G_HJTKO:X*W_ .3TO@A_
MV"?$G_HJTKZ7-?\ <Y_+\T8P^)'VG1117Y^=05\;?#W_ )2H_%+_ +$&R_\
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M(7 WC#I%'ER0_G97I0![U1110 5\+?!/_D;_ (Z?]E*U?_T7;U]TU\+?!/\
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MW\/7M_\ VG;I<I>2^6/W=F3YLD2M*BM(,8.[ (4F@#Z%HHHH **** "BBB@
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MEY+2)F(/89)X'2O3_#OA^S\+:1!IFGHZ6D.=BR.7/))/)YZFOXKBY:77X_\
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M5V2,H5B0I/"L1D*<?(DG^L;ZU^Z^&_\  Q/K'\F>9C-T8_B[_D5=8_Z])?\
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M_P G3?L>?]C6?_2[3:_(>._^1U/_  Q_([\+_#/T-HHHK\].L**** "BBB@
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M'_D7P^?YL*^%_@W_ ,E ^/G_ &4?4/\ TEM*^Z*^%_@W_P E ^/G_91]0_\
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M%?@7_P C!\;/^RF:Y_Z''7%D_P#O2]&>W4^$]4KXP_;L_P"2T? O_>U;_P!
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MJ"^@DCUFXN+'[+&D7E_,(2X\XM*%(8+P3DU]D6]O%9PI#!$D,*#"QQJ%51Z
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M-7TQ7S/^W1_R!_@Q_P!E/T/^<U73^-$R^%G<5'<?\>\W^XW\JDJ.X_X]YO\
M<;^5?5'SY^:_[&?_ ";_ *+_ -?5W_Z.:O;J\1_8S_Y-_P!%_P"OJ[_]'-7M
MU?K&4_\ (OH?X8_D?G68_P"^5O\ $_S/0_V8?^3CM,_[%C5O_2K3:^VZ^)/V
M8?\ DX[3/^Q8U;_TJTVOMNOR+B;_ )&M7_MW_P!)1^CY#_R+Z?S_ #85\+?!
M/_D;_CI_V4K5_P#T7;U]TU\+?!/_ )&_XZ?]E*U?_P!%V]<63_[TO1GN5/A/
M1K?0]-M-2N-0@T^U@O[@8FNHX%660>C,!D]!U]*^0/V\O^2L? G_ *^=4_\
M0+>OLROC/]O+_DK'P)_Z^=4_] MZ^[II*M1M_/3_ /2XG*]GZ,R/!_C'7/AY
MXHM/$?AJ_73=9M8Y(4FD@69&CD #HR-U!VJ>"""!S6=<7ESJ>J7FH7UPUWJ%
M_=27EU<,JJ99I'+N^%  RQ)P  *AI8_]8OUK]UC@L-#$RQD8+VDE9RZM=OZ\
MCS.9VY;Z'Z=_LI_\FR_"G_L5]-_])HZ\*^'O_*5'XI?]B#9?^C;>O=?V4_\
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M_P#$QTS_ --L->SE-OK2OYF<_A-C^Q]/_P"?"T_[\)_A53X0VL%K^UH1!!%
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MEW(LUYIL-Y(EG=R*% >:$':YPB#D<[5SG%1_M!01P?MA?#,1QK'N\)ZX[;5
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MDVTVTDT_["UK"UEL\K[.8QY>S&-NWICVKYO_ &W(TAL_@7'&JHB_$[1U55&
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MWD,)Z2!0<[#G[W2@#5Z4M96F^+-$UB^EL;#6=/OKV*-9I+:VNDDD1#T8JI)
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M&C_70YL1_"9KU\!?\%%O^3B/V=/^O^3_ -*K:OOVO@+_ (*+?\G$?LZ?]?\
M)_Z56U?0?;A_BC^:/&^S+T?Y,[^LKQ-_R"X_^OVR_P#2J*M6LKQ-_P @N/\
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MF_\ 7K%_Z *NM]TU^XP^%'Y/+XF?2?\ P3P_Y,M^%7_8,?\ ]'RU]%U\Z?\
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M]CH.C7.MM=^&/#\HFTG2_LJH\#!'C0/*#F1421@HP.V2<5\J_MY?\E8^!/\
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M.QF2\6 .P.6C(-L @R  G QQ]A4C*&4@C(/!% 'P/^SS\.]9\8>#_A)<>%O
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M@81)=.?M"*J?NFB'88 P:^RJ6@!**6B@ HHHH **** "BBB@ HHHH *^,?\
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MKX_Q'_WK#_X7^9T83X6?)?[(7_)@/P%_[&^3_P!.%[7T[7S%^R%_R8#\!?\
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M\_-?]C/_ )-_T7_KZN__ $<U>W5XC^QG_P F_P"B_P#7U=_^CFKVZOUC*?\
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MO4Z\L_93_P"37?@__P!B=H__ *10UZG7\7+8^A"BBBF 4444 %%%% !1110
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M^3_TJMJ^@^W#_%'\T>-]F7H_R9W]97B;_D%Q_P#7[9?^E45:M97B;_D%Q_\
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MEOPJ_P"P8_\ Z/EKZ+KYT_X)X?\ )EOPJ_[!C_\ H^6OHNOYG/W8^2OVAO\
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MC["OM^OB#]FG_DY#0_\ L7=6_P#1]A7V_7Y)Q/\ \C6K_P!N_P#I*/T;(?\
MD7P^?YL*^%_@W_R4#X^?]E'U#_TEM*^Z*^%_@W_R4#X^?]E'U#_TEM*X<G_W
MI>C/=J?">I5\;_M[_P#)2/@3_P!A#4O_ $"VK[(KXW_;W_Y*1\"?^PAJ7_H%
MM7W<?XM+_'#_ -+B<O1G&TZ/_6+]13:='_K%^HK^@CRC]-/V2?\ DV'X6?\
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M?PP_[%?2_P#TDBKC9/\ 5M]*[+]G/_DWOX8?]BOI?_I)%0!Z'7S1^W!_Q[_
MW_LJ&D?^B;NOI>OFC]N#_CW^!O\ V5#2/_1-W5P^->I$_A9V]5=4_P"07>_]
M<)/_ $$U:JKJG_(+O?\ KA)_Z":^J/ /SA_8W_Y-[\/?]=KO_P!*'KVJO%?V
M-_\ DWOP]_UVN_\ TH>O:J_6<I_Y%]#_  1_)'YSF/\ OE;_ !/\ST?]EO\
MY.,M/^Q5U3_TKTVOM>OBC]EO_DXRT_[%75/_ $KTVOM>OR'B;_D:U?\ MW_T
ME'Z3D/\ R+Z?S_\ 2F%?"OP+_P"1@^-G_93-<_\ 0XZ^ZJ^%?@7_ ,C!\;/^
MRF:Y_P"AQUQ9/_O2]&>W4^$]4KXP_;L_Y+1\"_\ >U;_ - @K[/KXP_;L_Y+
M1\"_][5O_0(*^]I_QZ'_ %\I_P#I<3EZ/T9RE9?BK_D5=:_Z\;C_ -%M6I67
MXJ_Y%76O^O&X_P#1;5^\8C^#/T?Y'F1W1^J/[*?_ ":[\'_^Q.T?_P!(H:]3
MKRS]E/\ Y-=^#_\ V)VC_P#I%#7J=?Q<MCZ$****8!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!X1^W9K&H:#^R%\5+W2Y'BO%T:2,/'G<$=E1^G
M^PS5\@:AX)\.?#_X#_L8^)/"NE6-EXB;Q/I47VZU@3S[E;E&^TAW W.""2<G
MC;[5^CWC#PGIGCOPKJ_AS6K87FDZK:R6=U W&^-U*L,]C@]>U?*OPG_X)UVG
MPT\?>$]6O/BAXG\4>%_!US)=^&_"VH!?LUA(X(R6R=V-QZ*M 'H?[0?Q=^-O
MP_\ %EA8_#3X,1_$?1I;,33ZD^MPV7DS[V!BV/R<*%;/^U[5\G_M!:A^U1\?
M+WX>7-S^S@NCGP?XBM_$,:Q^)+67[4T6?W1RPV@Y^]S]*_2^B@#X,^)G[5_Q
ML^('PX\5>%T_9/\ &ED^MZ5=::MRU^'$)FA:,.5\@9QNSC(SBLL_M)?&K_HU
M/QI_X'+_ /&*_0>B@#\ZM<_:!^->L:'J>GC]E?QI$;RUFMA(;T';O0KG'D<X
MSFM3X+_M.?&WX3_"/P9X+D_93\9ZE)X?TBUTMKQ;X1B<PQ*A<+Y!V@[<XR<9
MZU^@-% 'QC_PV]\:O^C1?&O_ (,E_P#D>N"U3]H_XV:E\2=1\4G]E7QHB76D
MV>F"U^VC*F":ZD+[O(YS]I QCC9[\?H715PG*G+FCN3**FN5GP#_ ,-/?&K_
M *-0\:_^!Z__ !BOGG]I2U^.?Q\^)'PU\40?LZ^+]$3PA<-.]K(_GFZS+%)@
M,(UV?ZO'0]:_82BNGZW6NG?;7[C#ZO2LU;<_)W_A(/CC_P!&V>,/^_P_^-53
MU34?CEJ5JL(_9O\ &$>V>";=YH/^KE23'^J[[,?C7ZW45[-3B/,ZL'3G4T>C
MTC_D>7#),!3DIQAJM=W_ )GQC_PV]\:O^C1?&O\ X,E_^1Z/^&WOC5_T:+XU
M_P#!DO\ \CU]G45\T>Z?EYX0^(WQO\+^*/B%JS_LQ^,KD>*O$4NNI$MR%^S!
MX(8O*)\D[B/))W<?>Z<5U/\ POOXV?\ 1K'C3_P-'_QBOT:HKTJ>8XFE!0A+
M1>2(Y4]3\9/B=X7^.OQ"^.0^($?[/?BZQA&B)I'V!CYC960OYF_8..<8Q^-1
M_P#"(_'7_HWSQ=_G_@%?L_17LX/BC-LOINEAZMHW;^&+U?JC.5&$G=H_&[PE
MH?QU\,_$SP-XK/[//BZX3PWJO]I-:@[3./)DCV!O+^7_ %F<X/2NW_:;\5?'
M+]H3XL?!CQE#^S5XPT2/X>ZN=3DLY)A,;X>?:R[%81+Y9_T8C)#??'''/ZM4
M5XN89AB<TKO$XN7--V5[);>ED:1@H*T3XQ_X;>^-7_1HOC7_ ,&2_P#R/7AW
MP;^)GQN^%?@5/#\O[,7C+4G74+^]^T)<B,8N+N6X"[?)/W1+MSGG&>,XK]/Z
M*\XL_/?_ (:2^-7_ $:GXT_\#E_^,58^&O[3OQL^'Z>)%;]E+QI>C5M7DU,8
MO@GE!HHH]A_<'/\ JLYXZ]*_0"B@#XQ_X;>^-7_1HOC7_P &2_\ R/7F/Q>^
M//QN^*/BKX<:PG[+7C+3U\):Q+JCPM=B0W(>UF@V ^2-I!E#9P?NXQSFOT<H
MIQ;BTT)I-69\ _\ #3WQJ_Z-0\:_^!Z__&*\P_:6\=?&_P"/_P %?$'@2#]F
M;QEHDNJ&W(OI+@3K'Y5Q'+R@B7.?+QU'7-?J;173+%59)ILP6'IQ=TC\EK#5
MOCE9V%K;G]F[Q@YAB2/=YH&=J@9_U7M4W]O_ !Q_Z-L\8?\ ?X?_ !JOUCHK
MWEQ-FB5E5_\ )8_Y'D?V%E[U]G^+_P S\Z/V<?V@?C=\!_@CX2\ S?LL>,M9
MET.U-LU\EX(1-F1GR$,+;?O8ZGI7I/\ PV]\:O\ HT7QK_X,E_\ D>OLZBOE
MSWS\T_B-\9?C=X\^,WA7QTO[+WC*SCT71[[2FL3=!C*;B2!PX?R1C;Y)&,'.
M[J,5I?\ "^_C9_T:QXT_\#1_\8K]&J*[Z..Q&'CR4Y67HB7%/<_(?]I:3XY_
M'_PIX?T>#]G'QAHC:7K<&KF:203B01I(OEX$:X)\S.<GITKF6\)_'5F)_P"&
M?/%W)_S_  5^SU%>O@N),SR]S>&JVYK7]V+VVW1G*C"6Z/Q5UCP'\=M4TF]L
MQ^S_ .+HS<0O$'(SMW C.-GO7U9\8OVH/C9\5/A+XT\&1_LI>,].D\0Z->:4
MMXU\)! 9H7C#E?(&X#=G&1G'45]_45Q9GG&-SB<9XV?,XZ+1+\DBH4XT](GY
M0_"#XA?%3X)_L\_#SX::_P#LY_$6ZF\-ZV=474=*T][E;E#<3S.I14_=$"=%
M&2=V&/&,5ZK_ ,-A^*?^C:?C%_X3\O\ \17Z$T5XQH?GQ'^V+XH616_X9H^,
M7!S_ ,B_)_\ $5I_"?\ ;<\4?#[X8^$_#%U^S/\ &*YN='TNVL)9H?#TFQVC
MB5"RY4'!(XS7WI10!\:_\/#/$/\ T;!\9O\ PGI/\*\H_:(_:J\8_&72/!5G
MI_[-WQ=L6T+Q;IGB&9KGP[+B2*UD+O&NU3\S \9XK](:*:=G=">JL? '_#:'
MB?\ Z-G^,7_A/R?_ !-'_#9_BC_HV?XQ?^$_)_\ $U]_T5V?7*W<YOJU/L?B
MA\";WXE?"GX=V_AZ_P#@)\3KVYCN9YS-;>'+D(0[[@.8\Y%>@_\ "U/'O_1O
M/Q6_\)V?_P"(K];J*]FAQ'F&'I1HTY+EBK+1=#RZN28*M4E4G%W;ONS\M?A1
M\??&_P /_BGI_BFZ_9T^+-S:VVEWM@T,/AV;>6FDMF5AE , 0-G_ 'A7T!_P
M\,\0_P#1L'QF_P#">D_PK[*HKQ<7BZN.K.O6=Y/]-#U,-AJ>$I*C25HH^-?^
M'AGB'_HV#XS?^$])_A7SUX#^._CCPIXE^)&I7'[.OQ9GC\4>*KG7[=(O#TP,
M,4L,"!'RGW@8B>..17ZGT5G0KSP\^>F]3I:OHS\X?^&K/%W_ $;9\7__  GY
M?_B*\)_:2\5?$7XU>*OAUJNF? #XI:?%X9N;J>XCN_#MP6F$JQ!0FU.H\LYS
MZBOV4HKT%FV+4HRYM4T]NJ=U^*(]G$_$[[5\2O\ H@OQ._\ "<N?_C=*MY\2
ME8'_ (4)\3N#G_D7+G_XW7[845]/_KSG?_/Q?^ HQ^K4^Q\!?!;]M+Q5\,?A
M'X/\)7G[-'QAN[O1-*M["6>#P[+Y<C1QA2RY4'!([UY-X;_:_P!6LOV]/%GC
MM?@?\2+B\O/!D.F-X6BTACJD"K<0M]I>+&1$=H4-ZL/6OU6K/C\/Z7#K<NLI
MIMFFL2PBWDU!8$%P\0((0R8W%<@'&<<5\#)N3;9U'P=\4_VSO%7CZ'PTEM^S
M3\8;?^R]9BU*3S?#TOSHD4J%1A3SF0=?0U7_ .&P_%/_ $;3\8O_  GY?_B*
M_0FBD!^>Z_MB>*0P/_#-'QB_\)^3_P"(K6^%?[;WBCP#\,/"/ABZ_9G^,5S<
MZ+I%IITLT/AV39(\4*1LRY&<$J2,U]Y44 ?&O_#PSQ#_ -&P?&;_ ,)Z3_"O
M)_VAOVJO&/QCLO 4&G_LW?%VQ/AWQ=I_B*<W/AV7][#;^9NC7:I^8[QC/'%?
MI%133L[H3U5CX _X;0\3_P#1L_QB_P#"?D_^)ILO[9GBB2)U'[,_QB!92/\
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M<5\"W=W9U'P;\4OVS?%7CW_A%?LW[-/Q@MQI&LKJ4OF^'I?G06\\6U<*><S
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? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>xcur-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xcur="http://www.exicuretx.com/20210630"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="xcur-20210630.xsd" xlink:type="simple"/>
    <context id="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7e18a0d9b97a4e05b0e2b555178a79c3_I20210809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2021-08-09</instant>
        </period>
    </context>
    <context id="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6d06eb298aa3490d9159416638a3b58f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iacfaf4956355489f844301e39562eb6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i279abc78769c4032be54ddfd0c7ffe6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c766de5b12643f4b84da4a3bfcd49bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a8e31b3400845b785f4078c29ad60c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i149a543a17ce4d93a6385033c1c76dab_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2acf22eafee749ef879e689a5d4b7208_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i07e140d0339e4a2c9fa363c5cc32a6e4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib6ce674313764ae4915943fafa4cb5cd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2bf9870e0c784838b0e84e18c5c665c7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i566e91ad0fa14f2d811d604abd6082cd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if46fbd1f2b5442348f674d9f2a9f0a54_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8bde8e11b76e461896f96c566cc62872_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0d493db55bc244c1818df293641b339b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5a85ec43cc4f4214ba9bfbd44ce67a45_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8b7b77f3ee3b4b51965fe742a7381fbd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i96c703c4ce9440bea4222ca42e9f1f18_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibb34f5fabfa643a7856aef0eb9f11e70_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i165b7f9261d44627b2f958e465d695e5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3e3d4af8ea3748c6a09f9521da9ac2ca_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9a543e3ada2340d0b5c1f3641c1d3468_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5aa243ca27884648b86a0b1eb325cf57_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8dde94d491614ea4bca5ec1bcd8d14b0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5073ecd4f57647949850dc29898c84dd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icddc4f4973ad446fbd01949b82185558_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic0295336b38e40e498f9dd253711b758_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0f137df29abc4c41a4815885b2a3d6b7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib010f58f2ede44548294dae32882407a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibb13b835a182484c8f3fbf8f2b67cc67_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6d226af906d44031be03e8c8a0a7ed41_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifcec14fba6fa467990e368f7ad3ad3d6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6717e4937b164276903f7d7ad12330f9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i27744bcce45d46b1a88c16b8b2198996_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8871fd9e9cd14336b5847fb59ece0447_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic0cc9bb25cb645fbad03da89e50bc2e7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia8cf7cd3ed49446ca5422f8857c95a70_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i91f21e075fbf4956bcf55c01b1894a5c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3530849be0c2436a8869a0a68de58c4e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie0f5631296644c3aa22951553d3ab6cc_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie6f410f5826241079802ef8f86c3de4f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i79a078e9f90449658270fc31aa0b394c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i82a9e001ccee4221ae70569a6c358e78_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5d68452da3a640b7a96348aa84cfe852_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i30e55b2f78ad495ba7a2baa00860f9d1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia77029b06c3e4a209202062d9c9b7340_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if93626e950d1452db9e553b3385f4ace_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6df76506288a4a9cb1f3b1ec2a60be16_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">xcur:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia9df56e3024f4230a66f1aaeeb151149_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-13</startDate>
            <endDate>2019-11-13</endDate>
        </period>
    </context>
    <context id="i323854d9e19745dd9223744aaa4363ae_D20191113-20191113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xcur:DevelopmentandCommercializationLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-13</startDate>
            <endDate>2019-11-13</endDate>
        </period>
    </context>
    <context id="icc5418ff3e7c4d5196e4b2c13c675901_D20191113-20191113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-13</startDate>
            <endDate>2019-11-13</endDate>
        </period>
    </context>
    <context id="iab515d133a4549b18fbb6f4ad02e2cc6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6b844762003d4f3b95be40b6168ead6d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0cbe4aacf45245898bfff13da476b491_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i17febbe492b545c0b97d0ae80370db3f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2dede066e6c145098de6bc8ed6e91eb7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib3b4f20000a14fd2b555bd263b4cb305_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i916551a6aa1f4e67bc25b95d7119fc61_D20190217-20190217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-17</startDate>
            <endDate>2019-02-17</endDate>
        </period>
    </context>
    <context id="iabf8a9f039204f5a9f174a27e912c223_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idf8a680258f340a5b95f6fa0166cc962_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie74bdc37f6204d6dab0e778172766ea3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9a937d2024224f2187dd03316b8a9e85_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia5e3560a2c7c44468ecad7133174a9d2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i073135b508cc4068bc10b72d2b0d3170_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i45e62ef03a17479584641f2e340a929c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00c9b49c74324d46b41817978d7a5a2c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if3b5c379005b46dfbb023e9e0339cb54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09baee4ff554479da4cfb04820c2c407_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i925dc62162064a6e8afe8a1541ec5f89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifed0bbb359d14d848c59c0cae236a4ab_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i31b47b75b7d444be881f797effc35ea5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88343bfea9104524b13b58dd117fa4a0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3fbe3f7a19a3407695cd3173dc3fa872_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf1b0681e7a64826a8f5b37064e1c69f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie654008c14bb45bebaddc4a5e9306fd2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icb46a2e715654544969c6e914b1268af_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9d73b584ce0741a88f6493e030684da2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49032d31daff47918154c5a0df3b9f9e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8ec51807b1e46109dd345b48f722f7d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9577091c72d34a4d87f0ec5ba0d9a62a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i645a0991058845f0b7026139817fe54a_I20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-25</instant>
        </period>
    </context>
    <context id="i41901b1bd0c34219aebdd24b5355e642_D20200925-20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="i436ecc2736cd40ac821c16bdf401d6bc_I20210401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="i7d3967c9df24458ca2996a7076c5be12_D20200925-20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="ia063169c06cb4eb1b3257cbed4a76a5b_I20221001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-01</instant>
        </period>
    </context>
    <context id="iad1abf0184e64b35a21316ccc6ae8ef7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if9d9075e5dfe4e329a0d45099cfb1c9d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i925aaaddcacc4778b5d8b7f62145a333_D20200925-20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="i300147310fb342fa8729d20a235e6672_I20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-25</instant>
        </period>
    </context>
    <context id="i5d311891d17c4c9d82be715743cfa91f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iecb1d260e2dd441b95189e9938852f30_I20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-25</instant>
        </period>
    </context>
    <context id="iead4e91610bb417ba4c9ce8e04fe7b87_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if20db32734cd4856a7b5ebfc55b07f6e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ide2ab8bf32e5471fb89bc743cfb84ebb_D20200302-20200302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-02</startDate>
            <endDate>2020-03-02</endDate>
        </period>
    </context>
    <context id="ic8159ef26edf4cfab622048f57adfe21_D20200701-20200701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xcur:ChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="i54669006cc704c238aa705208cb442e6_I20200701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xcur:ChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="i6ff17028d7f742fc86b80a80958beb1c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7c221311f05b4f77be016eb7ea9c9657_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0645f4970e4a4657940a7c44e95adbf2_I20210327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-27</instant>
        </period>
    </context>
    <context id="i1678fc9eed904b0ea7406fdd2c19c39e_I20210428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-28</instant>
        </period>
    </context>
    <context id="if012e2aa547c4f42b1c5e1a7b5509669_I20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-03</instant>
        </period>
    </context>
    <context id="i03f09592eb17452db7a906b8878473eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0beb38fa0e984be794221ee6085d5212_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i11febcbb571642db9e1cddde4919a982_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i99e8cbf713bb404290e76a87777df0be_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i19701c73d57b47c1b8e1d54bc15798ff_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i647d7754868047e08ca0cedc232ce793_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib87f672fddff47ec9c64d6d8f41b94f9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if36427efb36c41dd9f56f8366f4269ba_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9bd85f97f1394ba795ddb6a54771a121_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4e2f75424b9847e8a73a5ae083e07f16_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id1752c7647ce4804833ba83742c774f7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9193c9218d6942f0a9ab8196225ec04e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3eade0caa9a9429fb165b07368701d49_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="id06b85497bc74266852a0e2b7f0b8df0_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="if4945a8246284e3fba84dfd77ee17303_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia1a36e8396524c158a00a6f20220e59b_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="i7d5200a99a654e799a285ca1f6cfe325_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="ib2b6abdfb80e4807aa0282b97634d068_D20210514-20210514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2021-05-14</startDate>
            <endDate>2021-05-14</endDate>
        </period>
    </context>
    <context id="ia10057774add4610b1347d547800695d_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ib0f12b5a69194c1f8a504c77fc7c66d5_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="i30c821c806ac422d901e22a3a99f78f2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icb72bd4b57dc4ad591c2fe0e40fe9b13_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8428d3250e664f26b96cd9f611b3d8a4_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie7e5df1d06e74bd185e7eb2efc4d0d60_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i30e4b305e726408ea8e78580cff53469_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ieb6d556e4e7c410abd113137b073abea_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0140ea063a1a461d9b7efc35c2a7db94_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib97b67429c7447b8beb926618dc44e33_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2bbc9b612e4f400ea42e7192d40fe224_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i05ee07b9e1c84d11b1a2bce3808048f7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibb18755d773345cab01251ee868b67a2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i80b5550a693944ca96e17fa1695bde69_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i840e5fd58f7b4defa073941d94fdaf68_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2062e93925194437bbd0a3795bd3f03a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibb7aa76093ce43189a28a20fdc93f774_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i536ad3a9715049e6b9540b91aeecaf96_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9fac72b464ac47a9b5b8d5a1d1c209c9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i70f3df893ec74c418b087f907936dff7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i60644eaa534948f49f8d5b8f40af2943_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0a7f1be445ab4577a3269d5dc2dd853c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i18c9158c52b548ed815e6df50eef7fe9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i09b723f0eb514cb19e68b68bef52570d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i203967655c0047368d301fad6b928214_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i862f9b0b1702466189729eff0d9d775a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i75e9456e863e42c28b31cca8610e356b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8e5643a3e14a4b2ca2f6576189dc8cce_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9f67c529634343ec87c7f862a41ec733_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icbfcd4dc60684a77a8e8fff3eb283e9a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i81809ddc049e44b18b81bcffd7f27327_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id968e5bf12ce4186bceeb5caa282ec2b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9a183f19fdd448bdbb48aafc81f24e29_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i24f3a6610c3c4fb7a8f3011378ea9e4a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibd0c5a447ff34bbc8d7908d531b56cff_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7dd5b1839e3a4048b28a43a4c4e685d7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib57710941d894ca1b67a1c5d13d6d090_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifefc3417f0d145cea19c531c9a0c8f9e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5e05ee112bbd483d8bd21004c56c115f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibe496263a9ad417fad626fd81108d45e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ica03537b84e847e99bee1a3a67a888b8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if36f90f4916647c996df4392cf9a2961_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7425a3abf5aa493d95862d239425df58_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia84bea4dabf04dc0b6316097c19d0d55_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i05d4fc50d3924eab98e6d7e3de7886c3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i815c1749dc334f5aa2f2b3d7ce7325b5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iae63ab432b644385ad760c25e7bb81a4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1841aafb4eea4763a606cf71ee256faa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i14e02bfdb4fe4d5c945ef80c6fe4fad3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i42f50fb4ed2946899515880a08b3b57b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1d7ee51b5b4f4652af15034a165fbf74_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib437b59ac25f4bc78adb0e03658f743d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibfb4a947556c46d38903332f34ab5729_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie9ab61d3d42a48659e6eb92b8ae28834_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c3ba902ba2c44f4a67a96f6f613cca1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7875848c586b4375a60e0586a91f2a0e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91a58f1716064afdb7cb38c53987eb36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5292d66c2a14337935384c3078fb0f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15097b5bf7ee4089861f0faff5870a28_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d0d3d621aa248ffb7a89d07e53fb661_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i264f629b27bd4da3a95c37beb796c031_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icfeb9eea9dbf4b46996f9c206cb93ed9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7abd43cf3d894cffa0f7cb487206018b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4e3860c3a63420e9d7641f47962c9cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i21aac650411b42b8a24485f95cec055b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib62061d67fb7462295481dacb0f4878f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bf7aa4a7c3949849940d3879f239db6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b4abd0dd9174b658c26e0a2fb538250_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6dd9add5bb4c45a78909b926908a9321_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1da4f481fa0f4d07a5cf47234b82b9fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12a40373542a452085cc5d600a78424a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icbc3e793a60d4e38acabd4ccbf7e7571_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3949b66929b4496bb22e8f8f15df1a0e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibce5fd94c3494f099a9ee39d5d778059_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13bc69c967ce4483838129c6d0a0b70b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i67b1b75f0b614cad8c61db673b402bc1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib4ad8ee44ca14f698e0bcfb629608444_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89a31a873b4345549a9b1b9489d5fcda_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf6b894493654106958401b815661301_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i075d22f912e34ce8b799f56c4e6c8bff_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9894ed94822f44a1b4e2a85180b8d226_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0304e7ef793b4159a6bfef1cd8f203bf_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i766b5dbdd23d432ebc0191ac53b18fac_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i902680175ed94d4c9937aba91e427308_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ExercisePeriodAxis">xcur:ExercisePeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i3058801971a44b62b1abb284fe077eef_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ExercisePeriodAxis">xcur:ExercisePeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i3c4f363adac940e3bca3d807b358d686_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="agreement">
        <measure>xcur:agreement</measure>
    </unit>
    <unit id="installmentpayment">
        <measure>xcur:installmentPayment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="extensionperiod">
        <measure>xcur:extensionPeriod</measure>
    </unit>
    <unit id="votepershare">
        <measure>xcur:votePerShare</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80L2ZyYWc6NWUxY2E3MDc0YzBjNDg2OGIwYzdmNDZjZmI0MmM2N2IvdGFibGU6ZDEyYjA1ZWY5Y2FkNDFhZWE2Y2M3Y2U3NjgwNWUxNTgvdGFibGVyYW5nZTpkMTJiMDVlZjljYWQ0MWFlYTZjYzdjZTc2ODA1ZTE1OF8zLTEtMS0xLTA_0919ddf7-92fd-4719-9ae7-d9a9f1d70770">0001698530</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80L2ZyYWc6NWUxY2E3MDc0YzBjNDg2OGIwYzdmNDZjZmI0MmM2N2IvdGFibGU6ZDEyYjA1ZWY5Y2FkNDFhZWE2Y2M3Y2U3NjgwNWUxNTgvdGFibGVyYW5nZTpkMTJiMDVlZjljYWQ0MWFlYTZjYzdjZTc2ODA1ZTE1OF80LTEtMS0xLTA_5548950c-36f2-47f9-9695-6f75c0713321">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80L2ZyYWc6NWUxY2E3MDc0YzBjNDg2OGIwYzdmNDZjZmI0MmM2N2IvdGFibGU6ZDEyYjA1ZWY5Y2FkNDFhZWE2Y2M3Y2U3NjgwNWUxNTgvdGFibGVyYW5nZTpkMTJiMDVlZjljYWQ0MWFlYTZjYzdjZTc2ODA1ZTE1OF81LTEtMS0xLTA_0cb68908-e2cd-439b-ad74-4f371cbe18e5">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80L2ZyYWc6NWUxY2E3MDc0YzBjNDg2OGIwYzdmNDZjZmI0MmM2N2IvdGFibGU6ZDEyYjA1ZWY5Y2FkNDFhZWE2Y2M3Y2U3NjgwNWUxNTgvdGFibGVyYW5nZTpkMTJiMDVlZjljYWQ0MWFlYTZjYzdjZTc2ODA1ZTE1OF82LTEtMS0xLTA_57dbc6b2-4689-4f01-a733-fd855e28d566">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80L2ZyYWc6NWUxY2E3MDc0YzBjNDg2OGIwYzdmNDZjZmI0MmM2N2IvdGFibGU6ZDEyYjA1ZWY5Y2FkNDFhZWE2Y2M3Y2U3NjgwNWUxNTgvdGFibGVyYW5nZTpkMTJiMDVlZjljYWQ0MWFlYTZjYzdjZTc2ODA1ZTE1OF83LTEtMS0xLTA_f3efe127-af08-4667-b48a-dd4cfe115596">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDA5_0542ea79-84fd-4e2e-b5e3-925325e87655">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDA1_b3a1ec0f-01b2-4edf-b557-5a18ea39d7dd">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDAw_78703b41-2894-4cfc-bd55-b0d6e6bcfc64">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzk2_76478832-e803-49bf-9251-ffe0f2a34a83">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDA2_80da0118-820a-4b1a-91fc-f6d2e0035ee3">001-39011</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDAx_112c7efc-59af-4210-8013-25cf752c73e6">EXICURE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6MTc1OGNhNTQ4ODA2NDVkYWFjMDU3NjgxZmZhZjI3ZWYvdGFibGVyYW5nZToxNzU4Y2E1NDg4MDY0NWRhYWMwNTc2ODFmZmFmMjdlZl8wLTAtMS0xLTA_bb4a4def-a60a-4fe6-8f62-727f1e7e7486">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6MTc1OGNhNTQ4ODA2NDVkYWFjMDU3NjgxZmZhZjI3ZWYvdGFibGVyYW5nZToxNzU4Y2E1NDg4MDY0NWRhYWMwNTc2ODFmZmFmMjdlZl8wLTItMS0xLTA_f7986bd6-a857-4eb1-909c-43b6c5f69d39">81-5333008</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzk5_debfd99d-87f6-4c15-ba15-a6ef05d30117">2430 N. Halsted St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDA3_33723133-8611-4243-94fa-e7d199f81a3b">Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDAy_0be3d526-fc24-4675-a7fc-149a0dea2479">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzk3_19811ccd-96da-43a0-80eb-d32b9bb4a5d1">60614</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzkx_13513c14-a5fb-4da2-87ac-2f2dfecfb4d8">(847)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzky_38b44512-dd99-4a20-a7e0-2ceda28b117e">673-1700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6NWI2ZmY5NzllOGQwNDQxMDliMzk4NzRiYjI0MzQyZTcvdGFibGVyYW5nZTo1YjZmZjk3OWU4ZDA0NDEwOWIzOTg3NGJiMjQzNDJlN18xLTAtMS0xLTA_f3b8bed3-1694-4ab3-934d-a27bda68c9a7">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6NWI2ZmY5NzllOGQwNDQxMDliMzk4NzRiYjI0MzQyZTcvdGFibGVyYW5nZTo1YjZmZjk3OWU4ZDA0NDEwOWIzOTg3NGJiMjQzNDJlN18xLTItMS0xLTA_0fe41eea-33ed-4948-942c-387907286c9b">XCUR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6NWI2ZmY5NzllOGQwNDQxMDliMzk4NzRiYjI0MzQyZTcvdGFibGVyYW5nZTo1YjZmZjk3OWU4ZDA0NDEwOWIzOTg3NGJiMjQzNDJlN18xLTQtMS0xLTA_2dc5f413-6195-4e4e-bbb1-eec69894ef1d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzkz_6d9ed7cf-f00f-4540-9e23-15e4076aadbc">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzk0_3ffacdb3-429e-44b2-9bb4-e1f2ead54f14">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6M2FhMWUwYTk0MGRlNGE4ZWJkMWMwYzZmYjFjY2JiNGYvdGFibGVyYW5nZTozYWExZTBhOTQwZGU0YThlYmQxYzBjNmZiMWNjYmI0Zl8xLTAtMS0xLTA_9c20590a-949a-4645-a2b3-e2226916a987">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6M2FhMWUwYTk0MGRlNGE4ZWJkMWMwYzZmYjFjY2JiNGYvdGFibGVyYW5nZTozYWExZTBhOTQwZGU0YThlYmQxYzBjNmZiMWNjYmI0Zl8xLTQtMS0xLTA_5756e5d7-5dfe-40b9-827d-7a698e547da9">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGFibGU6M2FhMWUwYTk0MGRlNGE4ZWJkMWMwYzZmYjFjY2JiNGYvdGFibGVyYW5nZTozYWExZTBhOTQwZGU0YThlYmQxYzBjNmZiMWNjYmI0Zl8yLTQtMS0xLTA_5e34f5c4-1dd7-42af-8f3d-64a00c886b41">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yNDA4_b7698d3d-8890-440d-a9cf-c4fec2f281c0">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzk1_5c3dceaa-3ac9-4566-bf85-2e6c25ca90be">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i7e18a0d9b97a4e05b0e2b555178a79c3_I20210809"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xL2ZyYWc6ODQyNzhlMzgyNmUyNGUzYjllMmRkYTlmZjRhNGEyMWYvdGV4dHJlZ2lvbjo4NDI3OGUzODI2ZTI0ZTNiOWUyZGRhOWZmNGE0YTIxZl8yMzA2_e3e3f6dd-a213-4a67-a280-431a3363d18a"
      unitRef="shares">88108543</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfNC0xLTEtMS0w_6daf5c3c-8139-4970-9806-433535195756"
      unitRef="usd">42587000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfNC0zLTEtMS0w_739fbca1-5162-4ea6-bd48-6f630b746cfe"
      unitRef="usd">33262000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfNS0xLTEtMS0w_3d108a5e-7413-4aff-9ffc-ef1fbe8faef6"
      unitRef="usd">13472000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfNS0zLTEtMS0w_58ea21e6-b278-4c71-baa5-245986b97e73"
      unitRef="usd">48818000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfNi0xLTEtMS0w_3f86faed-54dc-4436-be06-4cad329a3a65"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfNi0zLTEtMS0w_4fe4e97e-b52e-46c9-b91b-5d642b25719c"
      unitRef="usd">11000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfOC0xLTEtMS0w_04853c87-f655-4f22-aa35-faeb6c616037"
      unitRef="usd">4588000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfOC0zLTEtMS0w_d67112eb-632e-46bb-bcd2-f4ffa5e1afb6"
      unitRef="usd">4231000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfOS0xLTEtMS0w_b6a02302-198e-4405-8a4e-41d7e4e4d5c3"
      unitRef="usd">60647000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfOS0zLTEtMS0w_b0ff3636-7821-4c2f-834c-734779ff9461"
      unitRef="usd">86322000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTAtMS0xLTEtMA_699b50f7-b37e-489a-abae-411710617f2f"
      unitRef="usd">4102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTAtMy0xLTEtMA_ecd6dd16-1980-4af4-bc38-1a6d57de148e"
      unitRef="usd">4123000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTEtMS0xLTEtMA_1fc16535-0ea8-4020-ba7a-2f732eaab091"
      unitRef="usd">8281000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTEtMy0xLTEtMA_b7898a20-f443-4097-a662-053e1df82083"
      unitRef="usd">8606000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTItMS0xLTEtMA_b58a027e-683d-41d1-8662-97626af6f1ec"
      unitRef="usd">1437000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTItMy0xLTEtMA_82e1e4dd-047d-4c82-ab8c-7f6862d9986b"
      unitRef="usd">1393000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTMtMS0xLTEtMA_738672a4-5d75-4d6e-bf4c-9b33f238677f"
      unitRef="usd">74467000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTMtMy0xLTEtMA_536e2a06-e569-478f-a03b-bcc71257375e"
      unitRef="usd">100444000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTctMS0xLTEtMA_1023b14e-df95-4e4c-8855-a8a1336020c0"
      unitRef="usd">2250000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTctMy0xLTEtMA_31bede6c-b951-4c26-a543-6032407cfb48"
      unitRef="usd">1866000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTgtMS0xLTEtMA_28ac3d89-fec1-4314-94d2-ced57e2d8b36"
      unitRef="usd">3228000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTgtMy0xLTEtMA_572fd635-5925-4963-af12-616663c9ce8f"
      unitRef="usd">3525000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTktMS0xLTEtMA_3b535fd0-2e86-44bd-9716-aca56b54a373"
      unitRef="usd">7267000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMTktMy0xLTEtMA_4380ae22-64c1-4568-9fa8-d763ed964f46"
      unitRef="usd">8343000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjAtMS0xLTEtMA_aaa89be7-4643-4ade-8048-6923d10d7ef5"
      unitRef="usd">12745000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjAtMy0xLTEtMA_998c9d3e-debf-47a5-95f6-95245bb1f866"
      unitRef="usd">13734000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjEtMS0xLTEtMA_e956e6cd-32cd-4f8a-9a83-762ec697b7f0"
      unitRef="usd">16730000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjEtMy0xLTEtMA_8807531e-50a8-4fa6-a84c-f8fbddd48b07"
      unitRef="usd">16589000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjQtMS0xLTEtMA_8d040278-7d4b-42a1-a63e-1a3d62da3ba5"
      unitRef="usd">7696000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjQtMy0xLTEtMA_0c0d21f4-07a9-4f4b-84e8-d4ea2a180597"
      unitRef="usd">7959000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjUtMS0xLTEtMA_6d8c8bc2-53d5-4992-9376-a14254a87479"
      unitRef="usd">656000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjUtMy0xLTEtMA_14be9dc8-e172-47fe-87d4-b134932a556b"
      unitRef="usd">656000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjctMS0xLTEtMA_b252f6f9-7b64-4f1c-99fd-3e6794df582f"
      unitRef="usd">37827000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMjctMy0xLTEtMA_de367b3c-3fb5-48d2-834e-450cc5e29fbd"
      unitRef="usd">38938000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzIx_22b020f6-19da-4595-9b82-fa2d9e4b859b"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzIx_58531308-7b21-4f97-a776-f763333f29dc"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzQ1_2dad900d-dd83-4388-99a8-9e9b9774c5ac"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzQ1_ce09655f-cf24-4559-adea-625950196c7c"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzY3_162f1f8d-6821-45a2-8270-d9c0d0f1652f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzY3_2d852053-2f2a-4edc-9601-348f5601cacf"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzY3_8588ded3-7d9d-4c29-9b48-6c3cfd1050a2"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyNzEwNGE4MTliNzRhZjA5NTQyMzg3MzAyZWViMmVjXzY3_bf2b7b42-b715-46ee-921c-3c1a2e48e77f"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMS0xLTEtMA_a95659cd-7647-4ecc-a5b0-8316f56156d2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzAtMy0xLTEtMA_09ca06ad-af3a-434e-ac00-afefc59bc580"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzE5_74883970-e030-4a1f-ab92-c92cec5b1567"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzE5_b184fba2-e91a-4ed8-8b86-a5b2e98ffdaa"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzQz_523a5beb-491a-4b4a-8b0b-47517a31c766"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzQz_b8e8aba7-4e43-4b6f-96ff-50139f5d30f1"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzY1_3680310d-6d6d-480a-bee8-aef61f3b0bd4"
      unitRef="shares">88096694</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzY1_a09c422e-85ae-46e4-b8c5-3c53882127b5"
      unitRef="shares">88096694</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzk2_00720d85-5264-437e-8063-6a04d2340326"
      unitRef="shares">87651352</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjI4MmQ4YzYzZjk4ZTRkNGI5NDVhNDA5ODI4MzdjMDFhXzk2_11448e58-1a10-4eeb-b81c-237918b721ff"
      unitRef="shares">87651352</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMS0xLTEtMA_31b829a5-ffb4-4b89-bcc0-b6300f898ecc"
      unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzEtMy0xLTEtMA_730211b5-d5f0-46e3-a2f8-da51e731fa79"
      unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzItMS0xLTEtMA_d89ee00d-862a-4403-a72a-a83fcfcf483c"
      unitRef="usd">169337000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzItMy0xLTEtMA_e8ebb0ee-7b32-4543-ab6d-68864090f0aa"
      unitRef="usd">167379000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzMtMS0xLTEtMA_ec35d524-a11e-41cc-adab-5371d860cf28"
      unitRef="usd">5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzMtMy0xLTEtMA_c20c7077-efc4-4bcb-ac06-ec34721d5dd6"
      unitRef="usd">83000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzQtMS0xLTEtMA_815a90bf-f601-47c4-9532-f06834b239a1"
      unitRef="usd">-132711000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzQtMy0xLTEtMA_e41ef82a-f619-431d-bc5b-7aa4ab748d7c"
      unitRef="usd">-105965000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzUtMS0xLTEtMA_a3cb882a-f527-4990-8b11-07397fb80efe"
      unitRef="usd">36640000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzUtMy0xLTEtMA_21a52ee1-a042-4338-ae6b-630c25e62d41"
      unitRef="usd">61506000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzYtMS0xLTEtMA_3d58ed84-e3c4-4b84-89b6-26d3c1ee1cd6"
      unitRef="usd">74467000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xOS9mcmFnOjNmODkzMjQ4Y2JkNTRiOTdhM2NjODM4NWU4ZWI2MGFiL3RhYmxlOjI5MDJkOGRjNGJhMTRlNzY4NGQ5OTVhMTQ1ZTk2OTVkL3RhYmxlcmFuZ2U6MjkwMmQ4ZGM0YmExNGU3Njg0ZDk5NWExNDVlOTY5NWRfMzYtMy0xLTEtMA_2f1442d5-665e-4d17-8d6c-592035f212be"
      unitRef="usd">100444000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMy0xLTEtMS0w_fb32d3fa-6c2c-45fe-9dab-8660408745da"
      unitRef="usd">79000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMy0zLTEtMS0w_e38dd50d-4bca-4bf5-8f25-d2ab22a01cbd"
      unitRef="usd">4847000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMy01LTEtMS0w_00472f65-2e0f-4b2d-ae8c-cb671946797d"
      unitRef="usd">1076000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMy03LTEtMS0w_61e9b4bb-dbc3-4959-b558-1fa34a843f35"
      unitRef="usd">14030000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNC0xLTEtMS0w_7972ee1f-992f-4061-bbf0-50fe8f68e204"
      unitRef="usd">79000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNC0zLTEtMS0w_d4078106-d893-4104-9728-eebae7c27fa4"
      unitRef="usd">4847000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNC01LTEtMS0w_171752ff-dc9d-4cf1-93dd-44754cd3c911"
      unitRef="usd">1076000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNC03LTEtMS0w_050887ef-616a-4933-8d9f-abfffec4c655"
      unitRef="usd">14030000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNi0xLTEtMS0w_43eee5e6-d7d2-4f47-863d-d8612899e50f"
      unitRef="usd">10843000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNi0zLTEtMS0w_26d8160d-d8a9-4fa0-bb76-95b6f21cd0b7"
      unitRef="usd">7008000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNi01LTEtMS0w_0cbb8331-cc34-44f3-89a0-3359ae6b91a2"
      unitRef="usd">21105000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNi03LTEtMS0w_0ddb0f88-c952-457c-a889-3220b6378c22"
      unitRef="usd">13083000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNy0xLTEtMS0w_ca493ff7-fec6-4869-92ad-84c68bcb7ae0"
      unitRef="usd">3098000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNy0zLTEtMS0w_0aed8929-80b8-45a2-a6ac-72d9b15e6723"
      unitRef="usd">2229000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNy01LTEtMS0w_f2e9e71d-3953-476a-baf0-a74aa6a8cf04"
      unitRef="usd">5990000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfNy03LTEtMS0w_17f1584a-0e6e-4771-b08c-5f27d64e06f7"
      unitRef="usd">4803000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOC0xLTEtMS0w_d7b2af60-d26d-49e4-94d6-d743b1ea376c"
      unitRef="usd">13941000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOC0zLTEtMS0w_f484b606-4aa0-4dec-b867-bb9ed333a2c9"
      unitRef="usd">9237000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOC01LTEtMS0w_bee2cf80-36df-4230-a4e0-a7e4775ca090"
      unitRef="usd">27095000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOC03LTEtMS0w_42380232-634c-45e7-8def-5e418ddebdeb"
      unitRef="usd">17886000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOS0xLTEtMS0w_709ffe9d-f751-41e3-9468-7d157a0caa70"
      unitRef="usd">-13862000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOS0zLTEtMS0w_35c97985-9673-4a22-bd58-943129175edf"
      unitRef="usd">-4390000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOS01LTEtMS0w_0154b3a0-f2c3-4c06-b780-855f69758966"
      unitRef="usd">-26019000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfOS03LTEtMS0w_85a1086c-2332-42fa-9d7a-db31c433a7ab"
      unitRef="usd">-3856000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTEtMS0xLTEtMA_dbeccaee-8cbe-4703-83e0-74615df01e18"
      unitRef="usd">2000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTEtMy0xLTEtMA_5af6e15b-fcf7-41ba-bd2b-7f61ad6fc31f"
      unitRef="usd">4000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTEtNS0xLTEtMA_5ce07088-cec9-4e08-864e-a3e133578306"
      unitRef="usd">3000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTEtNy0xLTEtMA_c8b2d234-ae1b-4c98-a431-a98ed8b63ae6"
      unitRef="usd">43000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTItMS0xLTEtMA_5c01632b-d750-4f02-8d6f-b50fb5daa90e"
      unitRef="usd">43000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTItMy0xLTEtMA_d74d94e3-0ae5-4f80-8e7e-8bd94d7c06b6"
      unitRef="usd">267000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTItNS0xLTEtMA_af892e0a-d113-4b4f-8a45-e6f972086615"
      unitRef="usd">131000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTItNy0xLTEtMA_d99bda89-703c-45fb-a477-2041eaeb7eea"
      unitRef="usd">627000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTMtMS0xLTEtMA_ba08e4d0-dc4f-4bb2-a93a-5d29d7875ab8"
      unitRef="usd">450000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTMtMy0xLTEtMA_0c77ea5b-b2f0-49c4-92d5-cdd4109076ea"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTMtNS0xLTEtMA_89df4341-af2e-4be2-b201-fb980f5b6007"
      unitRef="usd">859000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTMtNy0xLTEtMA_df287486-3863-4bc1-9563-eaea32df0190"
      unitRef="usd">128000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTQtMS0xLTEtMA_48778883-20e7-4b4a-8403-78cfdf171ba9"
      unitRef="usd">-2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTQtMy0xLTEtMA_4d05ee9f-edd8-4602-96f9-260feb98a6c0"
      unitRef="usd">-192000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTQtNS0xLTEtMA_db73ad24-52d2-415b-a962-6b0627f38943"
      unitRef="usd">-2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTQtNy0xLTEtMA_edb8b8f6-cb9e-482a-87b4-68ca4ba96916"
      unitRef="usd">153000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTUtMS0xLTEtMA_5ee624c0-4b56-452d-ba99-0f4da56f3bcc"
      unitRef="usd">-407000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTUtMy0xLTEtMA_377cf298-0e12-4bc4-91b0-f8888801def2"
      unitRef="usd">79000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTUtNS0xLTEtMA_6e00ebea-765c-4fbc-9b7d-2bc27a93a16f"
      unitRef="usd">-727000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTUtNy0xLTEtMA_dd298fee-1f2a-40e7-9b5a-561ebb34d199"
      unitRef="usd">695000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTYtMS0xLTEtNjA_08918ac0-bfab-4af2-8fab-e557d855030b"
      unitRef="usd">-14269000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTYtMy0xLTEtNjY_f23b48ea-edcd-4e25-876a-3136bcfdf074"
      unitRef="usd">-4311000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTYtNS0xLTEtMA_fe403e57-48e5-4d2e-80c5-ac6309480203"
      unitRef="usd">-26746000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTYtNy0xLTEtMA_5ab07550-ee33-49bd-97ba-95e96ffc44ac"
      unitRef="usd">-3161000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTctMS0xLTEtNzQ_58288d5c-f1dd-4c82-a978-7c4c5575e210"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTctMy0xLTEtNzg_76110308-4fa3-4a47-b6c8-b6bb22321bba"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTctNS0xLTEtMA_a1eefeda-0cb9-4749-81cd-fe8ddd31d562"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTctNy0xLTEtMA_7a85145b-c0fc-4fc9-aeba-6b22a7825f11"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTgtMS0xLTEtMA_8c2ddffc-4b8b-45d4-93da-313d341d8fb4"
      unitRef="usd">-14269000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTgtMy0xLTEtMA_5dbd4791-4b6a-4036-ad90-e27a0199ea33"
      unitRef="usd">-4311000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTgtNS0xLTEtMA_39a1b8d1-64d1-412e-873a-d8c7e5cdbb59"
      unitRef="usd">-26746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMTgtNy0xLTEtMA_a59b435d-8fcb-4cff-8e0a-929ee5c7bffb"
      unitRef="usd">-3161000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtMS0xLTEtMA_c0d5220b-dd7f-4906-b060-a5ec7e005c07"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtMS0xLTEtMA_e18ff0cb-4647-4acb-9c7b-c2185a2a449e"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtMy0xLTEtMA_d87720f6-a79f-4bea-ad3e-e44ba94da0e9"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtMy0xLTEtMA_eb67c1ac-fb88-433e-baa6-b0594e0eaea7"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtNS0xLTEtMA_82957923-196a-4f72-9290-beefa5bb8215"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtNS0xLTEtMA_ccfd2cfc-6f59-42af-8df3-f08994cf6ddc"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtNy0xLTEtMA_db6e4c83-c068-4252-96e5-7b0d260bb5fc"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjAtNy0xLTEtMA_f8f5df60-81a8-48f0-b060-a4a3379e712d"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtMS0xLTEtMA_2f6db7a2-1507-41df-98f0-a894c549efd7"
      unitRef="shares">88043447</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtMS0xLTEtMA_b629d769-b9e0-4d45-8f7e-19830c791fb7"
      unitRef="shares">88043447</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtMy0xLTEtMA_02c6a5a0-0d6a-46db-82c2-361145b846e9"
      unitRef="shares">87174533</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtMy0xLTEtMA_ccf69255-ef43-4f20-bc1d-fc0926a0c226"
      unitRef="shares">87174533</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtNS0xLTEtMA_39ffb032-32f1-4fea-9780-49d79d966739"
      unitRef="shares">87948440</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtNS0xLTEtMA_8db20d9d-03f8-4013-b238-d1274bb918ba"
      unitRef="shares">87948440</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtNy0xLTEtMA_2d93a7c4-6f50-4728-aed0-63ec3ded246a"
      unitRef="shares">87126847</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yMi9mcmFnOmVjYWE3OTc5Y2MxNDRjMjQ4MTQ2NDA0NGU4YmM3OGE2L3RhYmxlOjZiMmVlM2VhODI0NTQwNDJhNjMzOWM1NWE3MmJlOWFhL3RhYmxlcmFuZ2U6NmIyZWUzZWE4MjQ1NDA0MmE2MzM5YzU1YTcyYmU5YWFfMjMtNy0xLTEtMA_9bbc93a0-8e2b-417f-87bb-d2e55df9e214"
      unitRef="shares">87126847</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfMi0xLTEtMS0w_991d2189-c678-4920-9c20-f4c998ec6379"
      unitRef="usd">-14269000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfMi0zLTEtMS0w_ae678ab1-4da8-4660-9965-37c29323c671"
      unitRef="usd">-4311000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfMi01LTEtMS0w_8c4fb240-385a-49f0-b9a8-2fdd49c9a40c"
      unitRef="usd">-26746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfMi03LTEtMS0w_aa495621-4c3b-443f-89a1-e4d2007d1258"
      unitRef="usd">-3161000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNC0xLTEtMS0w_7efb1152-c35a-4e16-a7a7-73fad736eae4"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNC0zLTEtMS0w_1fe79af9-6aa5-470c-baef-37a45b005c7c"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNC01LTEtMS0w_ae222c5f-a5da-43fb-ac83-31cc3fbe0ef6"
      unitRef="usd">-78000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNC03LTEtMS0w_701c790e-807d-4158-aac6-c7e8393edc13"
      unitRef="usd">365000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNS0xLTEtMS0w_cc954297-3454-4704-bc6d-8d21879d69f5"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNS0zLTEtMS0w_c0d11e66-a619-418f-b61d-e345acf30790"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNS01LTEtMS0w_352ddb87-6738-4763-96da-da852ee91499"
      unitRef="usd">-78000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNS03LTEtMS0w_3625d351-f219-4a69-bc90-ce99e7894c92"
      unitRef="usd">365000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNi0xLTEtMS0w_8542fd36-2096-4426-afcf-eda6e3739c34"
      unitRef="usd">-14296000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNi0zLTEtMS0w_40909898-ee17-44e4-8682-3398a830c6c8"
      unitRef="usd">-3956000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNi01LTEtMS0w_7e6971c3-cec0-49b3-9b5b-59a298fd28f3"
      unitRef="usd">-26824000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yNS9mcmFnOmY4ZmY3YjM0MTdjZjQxYmI4MTVlMDEwMWNhOGM3MjkzL3RhYmxlOjdlZjFjOTU2MTQ3MTQ2MDRhYmVjZGY3YTBhODliZWVmL3RhYmxlcmFuZ2U6N2VmMWM5NTYxNDcxNDYwNGFiZWNkZjdhMGE4OWJlZWZfNi03LTEtMS0w_d3f63256-abbc-4e0f-9e8c-aea0323d891e"
      unitRef="usd">-2796000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="iacfaf4956355489f844301e39562eb6f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMi0xLTEtMS0w_b59753ab-70fa-4f3f-b8e4-88f3f60b117a"
      unitRef="shares">87651352</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iacfaf4956355489f844301e39562eb6f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMi0zLTEtMS0w_0e9b149f-66ca-4c8d-9b25-aac89b91935b"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i279abc78769c4032be54ddfd0c7ffe6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMi01LTEtMS0w_b6fb9925-ac40-45df-b1d7-151c7a9b5e4c"
      unitRef="usd">167379000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c766de5b12643f4b84da4a3bfcd49bc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMi03LTEtMS0w_501fb1ff-8dac-4116-b808-5a0c1df8d754"
      unitRef="usd">-105965000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2a8e31b3400845b785f4078c29ad60c3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMi05LTEtMS0w_06f42acd-a62f-4308-be93-cb9fb72a5499"
      unitRef="usd">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMi0xMS0xLTEtMA_158fd074-8aae-4c5f-b044-cafdcaac853f"
      unitRef="usd">61506000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i149a543a17ce4d93a6385033c1c76dab_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMy0xLTEtMS0w_fc543cb6-8131-41d8-8f92-e19baf5432ca"
      unitRef="shares">342246</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2acf22eafee749ef879e689a5d4b7208_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMy01LTEtMS0w_1d45fc37-9193-48e0-ba45-7c76cfa5a5fa"
      unitRef="usd">546000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i07e140d0339e4a2c9fa363c5cc32a6e4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMy0xMS0xLTEtMA_f84e252a-3ba5-4f4d-bc34-855d574db845"
      unitRef="usd">546000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2acf22eafee749ef879e689a5d4b7208_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfNC01LTEtMS0w_aecb4e37-ca3d-4cc9-8636-bb5df7635b2f"
      unitRef="usd">517000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i07e140d0339e4a2c9fa363c5cc32a6e4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfNC0xMS0xLTEtMA_d505fa28-038b-4de8-8363-aebfea3bc0ea"
      unitRef="usd">517000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib6ce674313764ae4915943fafa4cb5cd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfNi05LTEtMS0w_38740e54-02a4-4ccc-a6f1-46fc99e7379e"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i07e140d0339e4a2c9fa363c5cc32a6e4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfNi0xMS0xLTEtMA_ea47009b-39eb-43e4-ace8-333a053eac4a"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i2bf9870e0c784838b0e84e18c5c665c7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfNy03LTEtMS0w_f42ed82c-ba31-42e4-bd7c-4717b78d250b"
      unitRef="usd">-12477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i07e140d0339e4a2c9fa363c5cc32a6e4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfNy0xMS0xLTEtMA_25a0151c-d314-4524-aed5-1cdd9e359a82"
      unitRef="usd">-12477000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i566e91ad0fa14f2d811d604abd6082cd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfOC0xLTEtMS0w_ffaa233f-9619-4b66-ac6a-57a1cf94ecff"
      unitRef="shares">87993598</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i566e91ad0fa14f2d811d604abd6082cd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfOC0zLTEtMS0w_968e3b38-6868-4f31-84d5-29ecf2ee763b"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if46fbd1f2b5442348f674d9f2a9f0a54_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfOC01LTEtMS0w_dbfed997-810a-4c7c-a617-763a2ea17dde"
      unitRef="usd">168442000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8bde8e11b76e461896f96c566cc62872_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfOC03LTEtMS0w_910c2a7a-96ad-4af9-a586-c4f503d829d4"
      unitRef="usd">-118442000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d493db55bc244c1818df293641b339b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfOC05LTEtMS0w_ec60cc30-bffd-4668-89ad-5ae98e82dd4f"
      unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a85ec43cc4f4214ba9bfbd44ce67a45_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfOC0xMS0xLTEtMA_67062a28-fbd0-4b3f-a0d8-19d09cb615d6"
      unitRef="usd">50041000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8b7b77f3ee3b4b51965fe742a7381fbd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTAtNS0xLTEtMTIz_c58d75c4-df94-4095-8e5f-cf554a8006f4"
      unitRef="usd">764000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTAtMTEtMS0xLTEyMw_9cf89be6-9a2e-431b-9e56-4cd338bbaf1b"
      unitRef="usd">764000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i96c703c4ce9440bea4222ca42e9f1f18_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTEtMS0xLTEtMTIz_a7a9a287-ee28-4937-a571-b9a83e0772ee"
      unitRef="shares">103096</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i8b7b77f3ee3b4b51965fe742a7381fbd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTEtNS0xLTEtMTIz_db45524b-bb3b-4826-b391-a89d06390f03"
      unitRef="usd">131000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTEtMTEtMS0xLTEyMw_c6810d56-6aee-4109-8770-a47fa27aa1a2"
      unitRef="usd">131000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibb34f5fabfa643a7856aef0eb9f11e70_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTItOS0xLTEtMTIz_39acc08f-2871-46a6-b61c-b870a19514c0"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTItMTEtMS0xLTEyMw_8a0186e2-8a4f-4697-9109-5a2f6292068d"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i165b7f9261d44627b2f958e465d695e5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTMtNy0xLTEtMTIz_3d290f81-72ab-4551-94bd-efb6c834c7f1"
      unitRef="usd">-14269000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTMtMTEtMS0xLTEyMw_dd2bc56e-fed9-41d1-9272-e84de8f07fbf"
      unitRef="usd">-14269000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i3e3d4af8ea3748c6a09f9521da9ac2ca_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTQtMS0xLTEtMTI5_12a3a2f7-d494-497b-8969-13fb257863b2"
      unitRef="shares">88096694</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3e3d4af8ea3748c6a09f9521da9ac2ca_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTQtMy0xLTEtMTI5_e0ea1d97-b136-447b-ab8c-08ee575f3b80"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9a543e3ada2340d0b5c1f3641c1d3468_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTQtNS0xLTEtMTI5_0da8cca6-7cd8-4c36-b0b6-560429a5395e"
      unitRef="usd">169337000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5aa243ca27884648b86a0b1eb325cf57_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTQtNy0xLTEtMTI5_a161ed0e-3c82-4c9c-9364-969bd3c9bd36"
      unitRef="usd">-132711000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8dde94d491614ea4bca5ec1bcd8d14b0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTQtOS0xLTEtMTI5_9ff92ac3-5dce-4f33-99ae-3d18320d0022"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmMzYzZkZWJjZjFjNjRiMjVhZTc1MmEyNjZkZWQxYmMzL3RhYmxlcmFuZ2U6YzNjNmRlYmNmMWM2NGIyNWFlNzUyYTI2NmRlZDFiYzNfMTQtMTEtMS0xLTEyOQ_18133df8-8de9-440a-bd7b-4db4ba2505de"
      unitRef="usd">36640000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i5073ecd4f57647949850dc29898c84dd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMi0xLTEtMS0w_942dc7b4-c98c-4024-ad83-cdf13c76e31f"
      unitRef="shares">86069263</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5073ecd4f57647949850dc29898c84dd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMi0zLTEtMS0w_60f29752-55f7-4ef9-ac93-296d68250004"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icddc4f4973ad446fbd01949b82185558_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMi01LTEtMS0w_ba56c8d7-ce78-4114-b52f-bad08c01ef8a"
      unitRef="usd">162062000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0295336b38e40e498f9dd253711b758_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMi03LTEtMS0w_0d6a03d5-8a78-468e-a08f-0f92f79b3456"
      unitRef="usd">-81297000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0f137df29abc4c41a4815885b2a3d6b7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMi05LTEtMS0w_fe019e5e-53db-469f-99e4-05003973d177"
      unitRef="usd">-27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib010f58f2ede44548294dae32882407a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMi0xMS0xLTEtMA_d035b55a-cbed-47b6-b0ae-e7224a5db69c"
      unitRef="usd">80747000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibb13b835a182484c8f3fbf8f2b67cc67_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNC01LTEtMS0w_43d1ba5c-fad8-493f-a36f-3af2bddd659d"
      unitRef="usd">441000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNC0xMS0xLTEtMA_c7687830-e034-4a64-835b-212fbed49184"
      unitRef="usd">441000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6d226af906d44031be03e8c8a0a7ed41_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNS0xLTEtMS0w_c6528691-9692-4775-a610-79a50ec9bb52"
      unitRef="shares">1081184</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibb13b835a182484c8f3fbf8f2b67cc67_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNS01LTEtMS0w_bb1934ef-c65f-4a22-8e75-64457c5266ea"
      unitRef="usd">2766000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNS0xMS0xLTEtMA_76a94969-842e-48e3-8e38-40382c15e701"
      unitRef="usd">2766000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifcec14fba6fa467990e368f7ad3ad3d6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNi05LTEtMS0w_d6b09fb6-3c42-4588-934e-ed75d7d30b08"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNi0xMS0xLTEtMA_2f7faac0-9dd9-481b-a4cc-18e3a81201b3"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i6717e4937b164276903f7d7ad12330f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNy03LTEtMS0w_d9df7393-ae9a-45cb-a634-1cf45562b281"
      unitRef="usd">1150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfNy0xMS0xLTEtMA_68ad7a8d-1514-4a93-a1bb-79ba8e60221e"
      unitRef="usd">1150000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i27744bcce45d46b1a88c16b8b2198996_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOC0xLTEtMS0w_38dc408a-50fb-4799-b73e-e8e5e81c3260"
      unitRef="shares">87150447</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i27744bcce45d46b1a88c16b8b2198996_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOC0zLTEtMS0w_c6565ee2-c749-4dce-acbe-1dd50bad8af6"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8871fd9e9cd14336b5847fb59ece0447_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOC01LTEtMS0w_b715ea15-705a-48db-880d-b1d5c12ea007"
      unitRef="usd">165269000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0cc9bb25cb645fbad03da89e50bc2e7_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOC03LTEtMS0w_64a64a97-aac5-42c7-8f0a-6c2b79a1db55"
      unitRef="usd">-80147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8cf7cd3ed49446ca5422f8857c95a70_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOC05LTEtMS0w_879e04fe-e715-4804-b08c-2da853b31699"
      unitRef="usd">-17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i91f21e075fbf4956bcf55c01b1894a5c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOC0xMS0xLTEtMA_a6c2578c-e649-4c54-910d-36691a6cfdc9"
      unitRef="usd">85114000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3530849be0c2436a8869a0a68de58c4e_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOS0xLTEtMS0xNDg_1291fa77-c19f-4b1f-8f66-971d90f59d45"
      unitRef="shares">55899</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie0f5631296644c3aa22951553d3ab6cc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOS01LTEtMS0xNDg_70b5cb58-4af5-4b59-a440-98f5a2960011"
      unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfOS0xMS0xLTEtMTQ4_caf67701-a408-48a1-ab85-05f47acbaa87"
      unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie0f5631296644c3aa22951553d3ab6cc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTAtNS0xLTEtMTQ4_70d2d5f8-17e9-4d8c-b801-c4b5b08d0d7d"
      unitRef="usd">544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTAtMTEtMS0xLTE0OA_0ea2f0c0-4a9a-4e13-8333-e4ec23258d81"
      unitRef="usd">544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie6f410f5826241079802ef8f86c3de4f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTEtOS0xLTEtMTQ4_65062006-c91d-442a-bdfd-aba2ecdf871f"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTEtMTEtMS0xLTE0OA_0240e613-f2b6-48f0-bc20-97e5bcc422a8"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i79a078e9f90449658270fc31aa0b394c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTItNy0xLTEtMTQ4_0416e73c-8e82-4115-9e53-38c8662e609e"
      unitRef="usd">-4311000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTItMTEtMS0xLTE0OA_d9ac845b-c521-4c37-a4cc-09485058cb05"
      unitRef="usd">-4311000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i82a9e001ccee4221ae70569a6c358e78_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTMtMS0xLTEtMTQ4_3a6f506f-c086-4e6d-8542-7a6900911192"
      unitRef="shares">87206346</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i82a9e001ccee4221ae70569a6c358e78_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTMtMy0xLTEtMTQ4_cda743c7-3abb-42b9-824a-1d9bb46c0cf0"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d68452da3a640b7a96348aa84cfe852_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTMtNS0xLTEtMTQ4_4db9a887-53e7-488e-b6fe-8b50c82d7648"
      unitRef="usd">165863000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i30e55b2f78ad495ba7a2baa00860f9d1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTMtNy0xLTEtMTQ4_dc64c45e-74ea-4de0-8f2b-b47b7ee3f5ce"
      unitRef="usd">-84458000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia77029b06c3e4a209202062d9c9b7340_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTMtOS0xLTEtMTQ4_94bc33fe-f659-4d38-9c79-eb12916f4905"
      unitRef="usd">338000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if93626e950d1452db9e553b3385f4ace_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8yOC9mcmFnOmIwNThmZTU1NGY1NjRiOGY5OTNmNjIzNzIxNzFjYTIzL3RhYmxlOmYyM2Q5YzkxOTViMzRjYzNiOTE2NDdhYTk4OGFkMGRjL3RhYmxlcmFuZ2U6ZjIzZDljOTE5NWIzNGNjM2I5MTY0N2FhOTg4YWQwZGNfMTMtMTEtMS0xLTE0OA_15b357a4-c805-49f2-87d1-2578e24d7dd0"
      unitRef="usd">81752000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMy0xLTEtMS0w_df861657-9c66-468c-bf71-76f9f1670af6"
      unitRef="usd">-26746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMy0zLTEtMS0w_ae715c22-ad3e-4600-8635-ceeeb871b48b"
      unitRef="usd">-3161000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfNS0xLTEtMS0w_9525c243-3d13-4d8b-8112-5346e2a9fbce"
      unitRef="usd">546000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfNS0zLTEtMS0w_a523d5be-9ce4-4017-b854-b984f8d399d7"
      unitRef="usd">335000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfNy0xLTEtMS0w_114d0e22-1839-40b6-8efb-d3c9623787f5"
      unitRef="usd">325000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfNy0zLTEtMS0w_55751224-bc7f-42b5-942f-76d83fe12b8c"
      unitRef="usd">356000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfOC0xLTEtMS0w_d669e074-8e71-46f2-abce-5e754f651e48"
      unitRef="usd">1281000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfOC0zLTEtMS0w_9575c283-ee19-4553-b78a-30d342e06ba7"
      unitRef="usd">985000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfOS0xLTEtMS0w_8da120e8-436b-4ae8-9f90-672da01b247b"
      unitRef="usd">141000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfOS0zLTEtMS0w_3c1560fa-c5a1-4949-8dd2-fe9f7e0edc81"
      unitRef="usd">35000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTAtMS0xLTEtMA_02d3dc75-dc84-49b5-af22-b30ef47c0437"
      unitRef="usd">-171000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTAtMy0xLTEtMA_0d10f635-1b5a-4a55-a65c-a6dbc6e2f2e1"
      unitRef="usd">-95000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTEtMS0xLTEtMA_fd56247c-ba19-4600-b53c-3fd107a0d2ef"
      unitRef="usd">6000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTEtMy0xLTEtMA_056e48a3-6e1e-4b18-acc1-20eab859c539"
      unitRef="usd">0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTItMS0xLTEtMA_fd630bc3-0024-47c0-a756-eb015331516e"
      unitRef="usd">-15000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTItMy0xLTEtMA_9404fa10-6f54-4892-bd37-e7cd5a21c163"
      unitRef="usd">-157000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTQtMS0xLTEtMA_d2afb301-825b-4c83-ae30-34e104604e64"
      unitRef="usd">-11000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTQtMy0xLTEtMA_c267b633-e555-4ae4-8c33-120bb64e5d1a"
      unitRef="usd">-11000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTUtMS0xLTEtMA_7405aeea-20a5-45e1-b709-d91f8952d58e"
      unitRef="usd">357000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTUtMy0xLTEtMA_ebe23dab-f5cb-4f85-ac40-44b7f0916176"
      unitRef="usd">1646000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTYtMS0xLTEtMA_b3d81569-7eca-4817-ae1c-5d9c4036168c"
      unitRef="usd">44000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTYtMy0xLTEtMA_24ef7de0-053a-4f10-86e8-c41380ac0b98"
      unitRef="usd">1034000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTctMS0xLTEtMA_8f555b08-1728-4a1e-8412-d5627510242b"
      unitRef="usd">415000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTctMy0xLTEtMA_a048dba5-0bc1-4579-9a68-6e28ebeeb972"
      unitRef="usd">22000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTgtMS0xLTEtMA_a76c5df7-5a51-4032-8fcc-6738be29d790"
      unitRef="usd">-280000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTgtMy0xLTEtMA_a4706f6e-daa8-437d-8fb6-f97866df342c"
      unitRef="usd">-647000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTktMS0xLTEtMA_5db1bb06-93ad-49ae-a3c9-f11b345e2c71"
      unitRef="usd">-1076000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMTktMy0xLTEtMA_8a2012ce-bddb-40c5-9a95-aa7f944419b1"
      unitRef="usd">-13949000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjAtMS0xLTEtMA_5dd47e65-a53a-427e-a89a-18a0b699ba23"
      unitRef="usd">-263000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjAtMy0xLTEtMA_1b5434fe-b40a-4968-b1f9-959244e9b742"
      unitRef="usd">-59000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjEtMS0xLTEtMA_51bc7937-a144-441a-9753-e7c6d72e46f7"
      unitRef="usd">-25885000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjEtMy0xLTEtMA_582d5730-05bf-4695-9ef4-fafde5c22486"
      unitRef="usd">-18814000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjMtMS0xLTEtMA_0a61c7ab-69dd-4329-ab18-faf58e37e0dd"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjMtMy0xLTEtMA_dbb41a38-ed98-4bac-8299-fdc001817c2f"
      unitRef="usd">38072000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjQtMS0xLTEtMA_77146c78-6262-44c3-8b22-5a4eff282fc6"
      unitRef="usd">37097000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjQtMy0xLTEtMA_1865f845-efce-4f68-8306-d6419d58cb5f"
      unitRef="usd">32103000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjUtMS0xLTEtMA_0ab7e778-de9a-49e5-905b-576fbf57c6ea"
      unitRef="usd">564000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjUtMy0xLTEtMA_67a548c1-2b58-48b5-9aa0-9ad4984b3783"
      unitRef="usd">2996000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjYtMS0xLTEtMA_c3d769f2-f580-4f15-abaa-18450e327eac"
      unitRef="usd">34533000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjYtMy0xLTEtMA_c9896699-dd24-49df-b1be-3d25f64ecc01"
      unitRef="usd">-8965000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjgtMS0xLTEtMA_6e769334-94ff-43b0-8fec-73c032f626dd"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjgtMy0xLTEtMA_bb52fa82-677a-4d52-95a6-773fc3a8159b"
      unitRef="usd">2973000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <xcur:PaymentsOfCommonStockFinancingCosts
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjktMS0xLTEtMA_5d5845fe-0276-4c4e-aa2b-8211084bf6b2"
      unitRef="usd">0</xcur:PaymentsOfCommonStockFinancingCosts>
    <xcur:PaymentsOfCommonStockFinancingCosts
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjktMy0xLTEtMA_bca09185-80c9-4b08-a1dd-061c083eb201"
      unitRef="usd">207000</xcur:PaymentsOfCommonStockFinancingCosts>
    <xcur:PaymentsOfCommonStockFinancingCosts
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMjktMy0xLTEtMA_f0465f00-b857-4c34-9efb-09baf12161a6"
      unitRef="usd">207000</xcur:PaymentsOfCommonStockFinancingCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzEtMS0xLTEtMA_dc527412-76f5-4f77-9535-2fdcdab485a0"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzEtMy0xLTEtMA_f4424801-90d0-4424-a602-a7bb9e79a22e"
      unitRef="usd">100000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzItMS0xLTEtMA_a0042afd-0eb7-45e8-a2e8-8311b95ccd72"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzItMy0xLTEtMA_e6353f11-7df4-4862-bab3-23c8b6627a1d"
      unitRef="usd">4999000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromStockPlans
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzMtMS0xLTEtOTQy_10ed17cc-0bcb-474c-b495-b6c00300be77"
      unitRef="usd">131000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzMtMy0xLTEtOTQ2_979982c6-4587-4835-b7d9-5f7e217133d2"
      unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzMtMS0xLTEtMA_991dd094-0344-4d45-81e5-0a5b88c7c1bc"
      unitRef="usd">546000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzMtMy0xLTEtMA_b8cbe7a3-c1f5-4526-a9af-a7a25ac034b9"
      unitRef="usd">50000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzQtMS0xLTEtMA_ee2afca2-f2ed-45e3-bfec-b722f31ad063"
      unitRef="usd">677000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzQtMy0xLTEtMA_7486ded6-87fa-4f58-bab6-ef4ee6a47997"
      unitRef="usd">-2283000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzYtMS0xLTEtMA_13ef1477-b227-4cf4-8d6c-cd7470cfc1e2"
      unitRef="usd">9325000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzYtMy0xLTEtMA_fbb32296-3ab4-4b1d-9abe-d42b9c4c6ddf"
      unitRef="usd">-30062000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzctMS0xLTEtMA_8fbd472b-ca49-4b46-ba4c-a97418b655a2"
      unitRef="usd">34462000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib010f58f2ede44548294dae32882407a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzctMy0xLTEtMA_61804ba0-8674-4f78-8d80-86206a26a728"
      unitRef="usd">48460000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzgtMS0xLTEtMA_43b19f1d-f636-4a88-9957-566e8c401288"
      unitRef="usd">43787000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if93626e950d1452db9e553b3385f4ace_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOmRkZTU3YjAxMGVjYTQ5M2Y5Nzg1NmJhNGY2NTZiNzlhL3RhYmxlcmFuZ2U6ZGRlNTdiMDEwZWNhNDkzZjk3ODU2YmE0ZjY1NmI3OWFfMzgtMy0xLTEtMA_57c6fca6-be86-4e0b-bdc4-06fbf939551d"
      unitRef="usd">18398000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjQ5ZmNiNGQzOTc5NTRjZjJiMTA5ODhhNGM5MWQ4YmU3L3RhYmxlcmFuZ2U6NDlmY2I0ZDM5Nzk1NGNmMmIxMDk4OGE0YzkxZDhiZTdfNi0xLTEtMS0w_490aa9c9-6bdc-4e87-b791-679f43309949"
      unitRef="usd">11000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjQ5ZmNiNGQzOTc5NTRjZjJiMTA5ODhhNGM5MWQ4YmU3L3RhYmxlcmFuZ2U6NDlmY2I0ZDM5Nzk1NGNmMmIxMDk4OGE0YzkxZDhiZTdfNi0zLTEtMS0w_7cc4a42a-20c2-41ae-80c0-ad1e1aba5c53"
      unitRef="usd">60000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjRkMmQzZjA4MTZmZjRlYTZhMWNmYWY3MzI5OWFjNjQ4L3RhYmxlcmFuZ2U6NGQyZDNmMDgxNmZmNGVhNmExY2ZhZjczMjk5YWM2NDhfMS0xLTEtMS0w_6daf5c3c-8139-4970-9806-433535195756"
      unitRef="usd">42587000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjRkMmQzZjA4MTZmZjRlYTZhMWNmYWY3MzI5OWFjNjQ4L3RhYmxlcmFuZ2U6NGQyZDNmMDgxNmZmNGVhNmExY2ZhZjczMjk5YWM2NDhfMS0zLTEtMS0w_739fbca1-5162-4ea6-bd48-6f630b746cfe"
      unitRef="usd">33262000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjRkMmQzZjA4MTZmZjRlYTZhMWNmYWY3MzI5OWFjNjQ4L3RhYmxlcmFuZ2U6NGQyZDNmMDgxNmZmNGVhNmExY2ZhZjczMjk5YWM2NDhfMi0xLTEtMS0w_8346128d-f34f-4971-8ebe-620fda5b26ca"
      unitRef="usd">1200000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjRkMmQzZjA4MTZmZjRlYTZhMWNmYWY3MzI5OWFjNjQ4L3RhYmxlcmFuZ2U6NGQyZDNmMDgxNmZmNGVhNmExY2ZhZjczMjk5YWM2NDhfMi0zLTEtMS0w_55323044-74d4-44bc-afe4-990cc8f56cd9"
      unitRef="usd">1200000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjRkMmQzZjA4MTZmZjRlYTZhMWNmYWY3MzI5OWFjNjQ4L3RhYmxlcmFuZ2U6NGQyZDNmMDgxNmZmNGVhNmExY2ZhZjczMjk5YWM2NDhfMy0xLTEtMS0w_64e598f3-492a-4ce2-9c24-f6025c74ad0f"
      unitRef="usd">43787000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zMS9mcmFnOjA4NTdkMGZhZWNhMjQyMzhiMjRjOTJkNzc3MzA1ZTUyL3RhYmxlOjRkMmQzZjA4MTZmZjRlYTZhMWNmYWY3MzI5OWFjNjQ4L3RhYmxlcmFuZ2U6NGQyZDNmMDgxNmZmNGVhNmExY2ZhZjczMjk5YWM2NDhfMy0zLTEtMS0w_154570a2-4261-4e6c-9a17-f3e7f14b3679"
      unitRef="usd">34462000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfMTA2Nzg_af756d37-b0e9-4c86-85c7-19a91b02df9b">Description of Business and Basis of Presentation&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exicure, Inc. (the &#x201c;Company&#x201d;) is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases, and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA&#x2122;, technology. The Company believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. The Company is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNA-based therapeutic candidate, for the intrathecal treatment of Friedreich&#x2019;s ataxia (FA).  The Company&#x2019;s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes one of the key strengths of its proprietary SNAs is that they have the potential for increased cellular uptake compared to conventional linear oligonucleotides and as a result the potential to achieve higher efficacy at the same doses of oligonucleotide administered. The Company has shown in clinical and preclinical studies that SNAs may have therapeutic potential in immuno-oncology and dermatology.  In addition, the Company has shown in preclinical studies that SNAs may have therapeutic potential in neurology, ophthalmology, pulmonology, and gastroenterology. Accordingly, the Company has expanded its pipeline into neurology, for which IND-enabling activities are ongoing for XCUR-FXN, and is concluding early stage research activities in ophthalmology, pulmonology, and gastroenterology. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout these unaudited condensed consolidated financial statements, the terms the &#x201c;Company&#x201d; and &#x201c;Exicure&#x201d; refer to Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets and conducts all business activities and operations of Exicure, Inc.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements as of June&#160;30, 2021 and December 31, 2020, and for the six months ended June&#160;30, 2021 and 2020, have been presented in conformity with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Research and License Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, revenue for the three and six months ended June 30, 2021 reflects events and conditions that occurred during that period that increased the number of hours estimated to be required to complete the services under the AbbVie Collaboration Agreement. These increased estimated efforts resulted in less progress occurring relative to the increased estimate of total projected hours to complete the research services (and thus limited revenue recognized) during the three and six months ended June 30, 2021 and compared to the amount of revenue recognized in the comparable periods.  Due to uncertainties inherent in the estimation process, it is at least reasonably possible that estimated efforts required to complete the research services under the AbbVie Collaboration Agreement will be further revised in the near-term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;COVID-19 Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In response to the ongoing COVID-19 pandemic, the Company has taken and continues to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on its business, such as remote working policies, facilitating management&#x2019;s routine communication to address employee and business concerns and providing frequent updates to the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;).  During the second quarter of 2021 and through the date of this report, the Company continues to operate under COVID-19 social distancing guidelines and has generally operated with approximately 100% of its R&amp;amp;D staff on-site.  The Company&#x2019;s office and general and administrative team is also working on-site approximately 50% of the time. The Company&#x2019;s preclinical development program in Friedreich&#x2019;s ataxia (&#x201c;FA&#x201d;) is ongoing and it began IND-enabling studies for XCUR-FXN in late 2020.  The Company also continues to progress its collaborations with AbbVie Inc. (&#x201c;AbbVie&#x201d;).  However, if the COVID-19 pandemic continues to persist for an extended period of time, the Company could experience further significant disruptions to its clinical and preclinical development timelines, which would adversely affect its business, financial condition, results of operations and growth prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company believes that the effects of the COVID-19 pandemic or its impact contributed to delays during the second half of 2020 and the first half of 2021 in its enrollment plans and clinical trial site start-ups for the Phase 2 dose expansion phase of the Phase 1b/2 clinical trial for its cavrotolimod (AST-008) clinical program.  The Company has taken additional measures to increase the enrollment of patients, including frequent interaction with its clinical trial sites currently open as well as increasing the number of clinical trial sites that potentially are activated for this trial so that the Company may continue to enroll patients as initially planned.  However, any additional delays may require the Company to further lengthen its clinical development timeline for cavrotolimod (AST-008).  Pending further enrollment delays or any unanticipated effects of the COVID-19 pandemic on our clinical development plans, the Company expects to report overall response rate, or ORR, results in the first half of 2022. The extent to which the COVID-19 pandemic or its impact or effects may continue to impact the Company&#x2019;s business, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration or spread of the pandemic, its impact and effects, the possibility of additional periods of increases or spikes in the number of COVID-19 cases, travel restrictions, quarantines, social distancing, phased re-openings and business closure requirements in the United States and other countries, and the effectiveness of actions taken globally to contain and treat the disease including, without limitation, the effectiveness and timing of vaccination initiatives in the United States and worldwide.  The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations and growth prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biotechnology industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and the challenges of complying with applicable regulatory requirements.  In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#x2019;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the Company has generated an accumulated deficit of $151,548 since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&#x2019;s current operating plans, it believes that existing working capital at June&#160;30, 2021, including the $20,000 upfront payment received in August 2021 in connection with the Ipsen Collaboration Agreement (see Note 15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Subsequent &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Events&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) and amounts borrowed and available under the MidCap Credit Facility (see Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), is sufficient to fund the Company&#x2019;s current plans for at least the next 12 months from the date these financial statements were issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, such as its &#x201c;at the market offering&#x201d; program pursuant to its equity distribution agreement with BMO Capital Markets Corp., to fund its current operations and business strategy. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company.  The Company has historically principally raised capital through the sale of its securities.  However, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  If the disruption continues to persist and deepens, the Company could experience an inability to access additional capital, which could in the future negatively affect its ability to raise capital and ultimately, its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed consolidated balance sheet as of June&#160;30, 2021, the interim condensed consolidated statements of operations for the three and six months ended June&#160;30, 2021 and 2020, the interim condensed consolidated statements of comprehensive (loss) income for the three and six months ended June&#160;30, 2021 and 2020, the interim condensed consolidated statements of changes in stockholders&#x2019; equity for the three and six months ended June&#160;30, 2021 and 2020, and the interim condensed consolidated statements of cash flows for the six months ended June&#160;30, 2021 and 2020, are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&#x2019;s financial position as of June&#160;30, 2021, the results of its operations for the three and six months ended June&#160;30, 2021 and 2020, and the results of its cash flows for the six months ended June&#160;30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and six months ended June&#160;30, 2021 and 2020 are unaudited. The results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2021, or any other interim periods, or any future year or period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#x2019;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfMTA2Njk_070fc573-cafb-4698-b8b7-82569669ea42">Basis of PresentationThe accompanying unaudited condensed consolidated financial statements as of June&#160;30, 2021 and December 31, 2020, and for the six months ended June&#160;30, 2021 and 2020, have been presented in conformity with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfMTA2Nzk_1e8aef6f-bb9c-4532-a07b-78af443b3f00">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <xcur:ResearchAndDevelopmentStaffOnSitePercentage
      contextRef="i6df76506288a4a9cb1f3b1ec2a60be16_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfMzE2Nw_5cea2abe-eaa5-4cad-ae4e-c38f550a219e"
      unitRef="number">1</xcur:ResearchAndDevelopmentStaffOnSitePercentage>
    <xcur:OfficeAndGeneralAndAdministrativeStaffOnSitePercentage
      contextRef="i6df76506288a4a9cb1f3b1ec2a60be16_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfMzI5Mg_85e197ae-85ab-4e96-9cdf-43cf8c5e8388"
      unitRef="number">0.50</xcur:OfficeAndGeneralAndAdministrativeStaffOnSitePercentage>
    <xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfNzE1Nw_2fa6b475-8ffb-43d7-ada9-4e4bdcb512d0"
      unitRef="usd">-151548000</xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ia9df56e3024f4230a66f1aaeeb151149_D20210801-20210831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfMTA5OTUxMTYzOTU3OQ_9af92333-979d-438f-abde-dbf81e850c63"
      unitRef="usd">20000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:UseOfEstimates
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8zNy9mcmFnOjY1MTdkMzk4N2M5NDQ0MzQ4OWQ4M2Q5NjkxMjI0NDI0L3RleHRyZWdpb246NjUxN2QzOTg3Yzk0NDQzNDg5ZDgzZDk2OTEyMjQ0MjRfMTA2NzQ_bddb9d41-2c40-4f4b-a159-4e3b2c3ff0b9">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#x2019;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80MC9mcmFnOjM1MmY2ZjFkNDI3MTQ1ZjhhNzM2N2I0NzdiMjE4ZDViL3RleHRyZWdpb246MzUyZjZmMWQ0MjcxNDVmOGE3MzY3YjQ3N2IyMThkNWJfMTk3NQ_fd3bfd49-33c1-49d2-878f-5cabf4d1213c">Significant Accounting Policies&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 11, 2021. Since the date of those audited consolidated financial statements, there have been no material changes to the Company&#x2019;s significant accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2016-13&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#x2014;Effective Dates &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#x201c;smaller reporting companies&#x201d; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80MC9mcmFnOjM1MmY2ZjFkNDI3MTQ1ZjhhNzM2N2I0NzdiMjE4ZDViL3RleHRyZWdpb246MzUyZjZmMWQ0MjcxNDVmOGE3MzY3YjQ3N2IyMThkNWJfMTk3MQ_22c745e4-5e4a-4297-9414-92f935d8172b">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2016-13&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#x2014;Effective Dates &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#x201c;smaller reporting companies&#x201d; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTQ2MDY_6dd4f288-3628-471b-98cc-1d9a6dca3c6e">Collaborative Research and License Agreements&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AbbVie Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Agreement&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 13, 2019 (the &#x201c;Effective Date&#x201d;), the Company entered into a Collaboration, Option and License Agreement (the &#x201c;AbbVie Collaboration Agreement&#x201d;), with a wholly-owned subsidiary of Allergan plc, Allergan. On May 8, 2020, Allergan plc, including Allergan was acquired by AbbVie. Pursuant to the AbbVie Collaboration Agreement, the Company granted to AbbVie exclusive access and options to license SNA based therapeutics arising from two collaboration programs related to the treatment of hair loss disorders (each, a &#x201c;Collaboration Program&#x201d;). Under each such license (obtained in connection with the exercise of an Option, as defined and discussed further below), the Company would grant to AbbVie exclusive, royalty-bearing, sublicensable, nontransferable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Under the AbbVie Collaboration Agreement, the Company will use commercially reasonable efforts to conduct two Collaboration Programs, each focused on one or more hair loss disorders to discover one or more SNA products that are directed to, bind to or inhibit one or more specific Collaboration Program targets (each, a &#x201c;Program Target&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the Effective Date, the Company and AbbVie have agreed upon a development plan for each Collaboration Program that describes the development activities and timelines required to advance such Collaboration Program through first IND filing (each, a &#x201c;Development Plan&#x201d;).  The activities described in the Development Plan are conducted under the supervision of the Joint Development Committee (the &#x201c;JDC&#x201d;) consisting of three members from each of the Company and AbbVie. The Company is primarily responsible for performing early stage discovery and preclinical activities (the &#x201c;Initial Development Activities&#x201d;) set forth in the Development Plan for each Collaboration Program and will be solely responsible for all costs and expenses related to the Initial Development Activities. AbbVie may elect, in its sole discretion and at its sole cost and expense, to conduct formulation assessment and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; testing as set forth in a Development Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the completion of all Initial Development Activities, the Company is required to deliver to AbbVie a report that describes the results of the Initial Development Activities and identifies at least one SNA-based compound that satisfies certain criteria for such Collaboration Program as determined by the JDC (the &#x201c;Initial Development Report&#x201d;).  Following the delivery of the Initial Development Report for a Collaboration Program, AbbVie will have the ability for a defined period of time (the &#x201c;Initial Option Exercise Period&#x201d;) to exercise an option (each an &#x201c;Option&#x201d;) to obtain worldwide rights and license to the Company&#x2019;s SNA technology and the Company&#x2019;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any product (each a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Licensed Product&#x201d;) that results from such Collaboration Program during the term of the AbbVie Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At AbbVie&#x2019;s sole option, AbbVie may extend the Initial Option Exercise Period (the &#x201c;Option Extension&#x201d;) and require the Company to perform IND-enabling activities described in the Development Plan (the &#x201c;IND-Enabling Activities&#x201d;), subject to the payment of additional consideration (&#x201c;Extension Exercise&#x201d;). If AbbVie exercises the Option Extension, the Company would be responsible for conducting the IND-Enabling Activities and would be solely responsible for all costs and expenses associated with such activities.  Upon completion of the IND-Enabling Activities, the Company is required to deliver a report that describes the results of the IND-Enabling Activities (the &#x201c;IND-Enabling Activities Data Package&#x201d;) to AbbVie. Following the delivery of IND-Enabling Activities Data Package, AbbVie will have the ability for a defined period of time (the &#x201c;Extended Option Exercise Period&#x201d;) to exercise an Option with respect to such Collaboration Program. After the exercise of an Option with respect to a Collaboration Program, AbbVie will be responsible for all development, manufacturing, and commercialization activities, and costs and expense associated with such activities in connection with Licensed Products arising from such Collaboration Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligation to conduct the activities defined in the Development Plan under the AbbVie Collaboration Agreement commenced on November 13, 2019 and continues until the earlier of (i) the date AbbVie exercises an Option, (ii) the date AbbVie abandons a Collaboration Program and foregoes its Option to that Collaboration Program, or (iii) the fifth anniversary of the Effective Date (the &#x201c;Research Term&#x201d;). If the Initial Option Exercise Period or Extended Option Exercise Period is still in effect for a Collaboration Program or if the Company has not delivered a complete Initial Development Report or, if AbbVie made an Extension Exercise for a Collaboration Program, a complete IND-Enabling Activities Data Package for such Collaboration Program, as determined by the JDC, then the Research Term will automatically extend by one-year increments until such obligation is satisfied, but in no event past the seventh anniversary of the Effective Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the AbbVie Collaboration Agreement, the Company received a $25,000 upfront, non-refundable, non-creditable cash payment (the &#x201c;AbbVie Upfront Payment&#x201d;) related to the Company&#x2019;s research and development costs for conducting the Development Plan for two Collaboration Programs, each focused on one or more targets, and certain options to obtain exclusive, worldwide licenses under certain intellectual property rights owned or controlled by the Company to develop, manufacture and commercialize certain products resulting from each such Collaboration Programs.  The option exercise fee during the Initial Option Exercise Period is $10,000 per Collaboration Program.  If AbbVie elects to extend the Initial Option Exercise Period, AbbVie is required to pay an additional fee of $10,000.  If AbbVie elects to exercise its option during the Extended Option Exercise Period, AbbVie must pay the Company the option exercise fee of $15,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the exercise by AbbVie of an Option with respect to a Collaboration Program, AbbVie would be required to make certain milestone payments to the Company upon the achievement of specified development, product approval and launch, and commercial events, on a Licensed Product by Licensed Product basis. On a Licensed Product by Licensed Product basis, for the first Licensed Product to achieve the associated milestone event, the Company is eligible to receive up to an aggregate of $55,000 for development milestone payments and $132,500 for product approval and launch milestone payments. The Company is also eligible for up to $175,000 in sales milestone payments on a Collaboration Program by Collaboration Program basis, associated with aggregate worldwide sales. Certain product approval milestones are subject to certain reductions under specified circumstances, including for payments required to be made by AbbVie to obtain certain third-party intellectual property rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, to the extent there is any Licensed Product, the Company would be entitled to receive tiered royalty payments of mid-single digits to the mid-teens percentage on future net worldwide product sales of such Licensed Products, subject to certain reductions under specified circumstances. Royalties are due on a Licensed Product by Licensed Product and country by country basis from the date of the first commercial sale of each Licensed Product in a country until the latest to occur of: (i) the expiration date in such country of the last to expire valid claim within the licensed intellectual property covering the manufacture, use or sale of such Licensed Product in such country, (ii) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the tenth anniversary of the first commercial sale of such Licensed Product in such country, and (iii) the expiration of regulatory exclusivity for such Licensed Product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie may terminate the AbbVie Collaboration Agreement for any reason or no reason, either in its entirety or on a Collaboration Program by Collaboration Program basis, at any time on 90 days&#x2019; prior written notice to the Company. Unless earlier terminated, the term of the AbbVie Collaboration Agreement shall continue until (i) if both Option Exercise Periods expire without AbbVie exercising either Option, the expiration of the later to expire Option Exercise Period, and (ii) if either or both Options are exercised on a Licensed Product-by-Licensed Product and country-by-country basis, the expiration of the royalty term for such Licensed Product in such country. Either party may terminate the AbbVie Collaboration Agreement if the other party has materially breached or defaulted in the performance of any of its material obligations and such breach or default continues after the specified cure period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Termination of the AbbVie Collaboration Agreement for any reason will not release either party from any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination. In addition, termination of the AbbVie Collaboration Agreement will not preclude either party from pursuing any rights and remedies it may have under the agreement or at law or in equity with respect to any breach of the AbbVie Collaboration Agreement. If either party terminates the AbbVie Collaboration Agreement, the license and rights granted to AbbVie with respect to the terminated Collaboration Program or License Product shall terminate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Analysis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that AbbVie is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance. Under the AbbVie Collaboration Agreement, the Company has identified a single performance obligation that includes (i) the research and development activities during the Research Term (the &#x201c;AbbVie R&amp;amp;D Services&#x201d;), and (ii) Joint Development Committee services during the Research Term (the &#x201c;AbbVie JDC Services&#x201d;). The Company has concluded that the AbbVie R&amp;amp;D Services is not distinct from the AbbVie JDC Services during the Research Term. The JDC provides oversight and management of the overall AbbVie Collaboration Agreement, and the members of the JDC from the Company have specialized industry knowledge, particularly as it relates to SNA technology. The JDC is meant to facilitate the early stage research being performed and coordinate the activities of both the Company and AbbVie. Further, the JDC services are critical to the ongoing evaluation of a Collaboration Program and the drafting and evaluation of the Initial Development Report and the IND-Enabling Data Package. Accordingly, the Company&#x2019;s participation on the JDC is essential to AbbVie receiving value from the AbbVie R&amp;amp;D Services and as such, the AbbVie JDC Services along with the AbbVie R&amp;amp;D Services are considered one performance obligation (the &#x201c;Collaboration Program Services&#x201d;).  In addition, the Company has concluded that the option to purchase two development and commercialization licenses is considered a marketing offer as the options did not provide any discounts or other rights that would be considered a material right in the arrangement, and thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for these options will be accounted for when they are exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the Effective Date of the AbbVie Collaboration Agreement, the total transaction price was determined to be $25,000, consisting solely of the AbbVie Upfront Payment. The Company also utilized the most likely amount method to estimate any development and regulatory milestone payments to be received. As of the Effective Date of the AbbVie Collaboration Agreement, there were no milestones included in the transaction price.&#160;The milestones were fully constrained due to the significant uncertainties surrounding such payments.&#160;The Company considered the stage of development and the risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or AbbVie.  The Company has determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur.  As of June&#160;30, 2021, the Company determined that any development, regulatory, or commercial milestones continue to be constrained and therefore the related milestone payments continue to be excluded from the transaction price at June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will recognize revenue related to the Collaboration Program Services as the performance obligation is satisfied using an input method to measure progress. The Company believes the input method that most accurately depicts the measure of progress is the actual hours incurred to date relative to projected hours to complete the research service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021, the Company recognized revenue under the AbbVie Collaboration Agreement of approximately $79 and $1,076, respectively.  Revenue for the three and six months ended June 30, 2021 reflects events and conditions that occurred during that period that increased the number of hours estimated to be required to complete the services under the AbbVie Collaboration Agreement. These increased estimated efforts resulted in less progress occurring relative to the increased estimate of total projected hours to complete the research services (and thus limited revenue recognized) during the three and six months ended June 30, 2021 and compared to the amount of revenue recognized in the comparable periods.  During the three and six months ended June&#160;30, 2020, the Company recognized revenue under the AbbVie Collaboration Agreement of approximately $4,833 and $13,949, respectively.  As of June&#160;30, 2021 and December&#160;31, 2020, there was $7,267 and $8,343 of deferred revenue related to the AbbVie Collaboration Agreement, which is classified as current on the unaudited condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dermelix Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2019, Exicure entered into a License and Development Agreement with Dermelix (the &#x201c;Dermelix Collaboration Agreement.&#x201d;)  Under the terms of the Dermelix Collaboration Agreement, Exicure received an upfront payment of $1,000, to be applied against the initial $1,000 of the Company&#x2019;s development expenses.  &lt;/span&gt;&lt;/div&gt;The Company initially recorded the upfront payment of $1,000 as deferred revenue related to its wholly unsatisfied performance obligation and reduced this balance to zero during 2019 by recognizing revenue as services were provided.  The Company recognized no revenue under the Dermelix Collaboration Agreement during the three and six months ended June&#160;30, 2021. The Company recognized $14 and $81 of revenue during the three months ended June&#160;30, 2020 which reflected reimbursement by Dermelix for additional costs incurred by Exicure for early stage development costs beyond the initial $1,000 upfront payment.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <xcur:NumberofCollaborationPrograms
      contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNTQ4_6dd63839-d0d9-440f-8161-f0b968bca80e"
      unitRef="agreement">2</xcur:NumberofCollaborationPrograms>
    <xcur:NumberofCollaborationPrograms
      contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTA2Ng_824ad938-e87c-488f-990e-a1854d7369a7"
      unitRef="agreement">2</xcur:NumberofCollaborationPrograms>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNTQ0Mw_9fbac6b8-607a-48be-85ad-2e02c1fab4ae"
      unitRef="usd">25000000</xcur:CollaborationAgreementUpfrontPayment>
    <xcur:NumberofCollaborationPrograms
      contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTA5OTUxMTY0MjY1Ng_824ad938-e87c-488f-990e-a1854d7369a7"
      unitRef="agreement">2</xcur:NumberofCollaborationPrograms>
    <xcur:CollaborationAgreementOptionExerciseFee
      contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNjAwNw_dce918aa-abde-431f-9dc7-b98288a5841c"
      unitRef="usd">10000000</xcur:CollaborationAgreementOptionExerciseFee>
    <xcur:CollaborationAgreementExtendedOptionAdditionalExerciseFee
      contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNjE0OA_b702da28-3084-4596-97a7-3e90a2987abd"
      unitRef="usd">10000000</xcur:CollaborationAgreementExtendedOptionAdditionalExerciseFee>
    <xcur:CollaborationAgreementOptionExerciseFee
      contextRef="i323854d9e19745dd9223744aaa4363ae_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNjI5Mg_117b2c8a-77a4-44f2-b33d-7879c64037d7"
      unitRef="usd">15000000</xcur:CollaborationAgreementOptionExerciseFee>
    <xcur:RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment
      contextRef="icc5418ff3e7c4d5196e4b2c13c675901_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNjc4Ng_d6953925-01b6-4045-a6bf-ed6a275ef581"
      unitRef="usd">55000000</xcur:RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment>
    <xcur:RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment
      contextRef="icc5418ff3e7c4d5196e4b2c13c675901_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNjgyOA_75f52a2c-e223-4578-97d2-31d8eae7ca5a"
      unitRef="usd">132500000</xcur:RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment>
    <xcur:RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment
      contextRef="icc5418ff3e7c4d5196e4b2c13c675901_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfNjkyMg_035da278-689a-4ac9-b9bd-241b9996b520"
      unitRef="usd">175000000</xcur:RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment>
    <xcur:CollaborationAgreementTerminationPeriodUponWrittenNotice
      contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfODM0MA_095ca829-9e6f-4da8-b5f8-4a3fdc6d3727">P90D</xcur:CollaborationAgreementTerminationPeriodUponWrittenNotice>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTE3NDM_03662a04-5ffc-4e21-9fa1-90a9b5791773"
      unitRef="usd">25000000</xcur:CollaborationAgreementUpfrontPayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab515d133a4549b18fbb6f4ad02e2cc6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMjc0ODc3OTA4NDI3Mg_64dad4a2-ac72-4183-aa74-e69b6059ae9b"
      unitRef="usd">79000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b844762003d4f3b95be40b6168ead6d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMjc0ODc3OTA4NDI4Mg_c8f6983c-743b-4925-9659-bca11e9c6d1e"
      unitRef="usd">1076000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cbe4aacf45245898bfff13da476b491_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMjc0ODc3OTA4NDI4OA_9b6b574d-b72d-49d5-a040-5afab2a74fc5"
      unitRef="usd">4833000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17febbe492b545c0b97d0ae80370db3f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTM0ODY_33462755-5679-4c60-a0f3-356f67460ff8"
      unitRef="usd">13949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2dede066e6c145098de6bc8ed6e91eb7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTM1MzI_b0f1c64b-faea-4788-a93b-78578a272533"
      unitRef="usd">7267000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib3b4f20000a14fd2b555bd263b4cb305_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTM1Mzk_fc9d9d0c-015b-4310-91d1-126d8d71bfde"
      unitRef="usd">8343000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="i916551a6aa1f4e67bc25b95d7119fc61_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTM5NjA_00f9213c-69ea-48b7-99b0-e2f6705e3cbb"
      unitRef="usd">1000000</xcur:CollaborationAgreementUpfrontPayment>
    <xcur:CollaborationDevelopmentExpenses
      contextRef="i916551a6aa1f4e67bc25b95d7119fc61_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTM5OTg_03504f59-7b03-4430-8a06-fdda496b567f"
      unitRef="usd">1000000</xcur:CollaborationDevelopmentExpenses>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="i916551a6aa1f4e67bc25b95d7119fc61_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTQwOTY_de246798-f97c-4289-b2ae-fbeb600fca08"
      unitRef="usd">1000000</xcur:CollaborationAgreementUpfrontPayment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iabf8a9f039204f5a9f174a27e912c223_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTA5OTUxMTY0MjY2NA_1e5d2c63-fdfb-41e9-b1f3-e79d7678fa0b"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf8a680258f340a5b95f6fa0166cc962_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTQyOTU_3406d6ed-64d0-4f69-a2be-be6efc2d09ee"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie74bdc37f6204d6dab0e778172766ea3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTQyOTU_9e2dd762-7ecf-4886-abdf-b0e3d9a8719c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a937d2024224f2187dd03316b8a9e85_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTQ0MDM_43c3b565-fd70-43cb-8a51-c1170c89189d"
      unitRef="usd">14000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5e3560a2c7c44468ecad7133174a9d2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMjc0ODc3OTA4NDMxMA_16ad3666-673d-4b4c-abff-c983ce40ace5"
      unitRef="usd">81000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="i916551a6aa1f4e67bc25b95d7119fc61_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80My9mcmFnOmMxNzZkYzAwYWViZTQ0ZTJiZTRjY2M2ZThhMmI5MzUxL3RleHRyZWdpb246YzE3NmRjMDBhZWJlNDRlMmJlNGNjYzZlOGEyYjkzNTFfMTQ1ODY_39cf702a-375d-4e71-aa40-f80c84f3e6be"
      unitRef="usd">1000000</xcur:CollaborationAgreementUpfrontPayment>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMjg1_770a4753-25ab-4aaa-be1d-5b9d0b7d487a">Supplemental Balance Sheet Information&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.948%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical, contract research and manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.628%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.799%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense was $283 and $187 for the three months ended June 30, 2021 and 2020, respectively, and $546 and $335 for the six months ended June 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.108%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical, contract research and manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMjc5_8c7708b0-280c-4f14-9405-89674484b98a">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.948%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical, contract research and manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfMS0xLTEtMS0w_3675e0c6-bb40-4277-b1d0-093a96c81d7b"
      unitRef="usd">3388000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfMS0zLTEtMS0w_6305e6b8-8914-4efc-a5d6-bcdaac390bb1"
      unitRef="usd">2336000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InterestReceivable
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfMi0xLTEtMS0w_d8d5292c-041b-4e97-9462-729495c0ef5e"
      unitRef="usd">44000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfMi0zLTEtMS0w_c34065e6-3be2-4299-8618-4cb02fa48034"
      unitRef="usd">161000</us-gaap:InterestReceivable>
    <us-gaap:PrepaidInsurance
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfMy0xLTEtMS0w_fbafc8e8-59ea-4cfd-b49e-bdd714ec515a"
      unitRef="usd">254000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfMy0zLTEtMS0w_b719c9fc-3cba-4947-9080-1d15e1bbf3ec"
      unitRef="usd">694000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfNC0xLTEtMS0w_36bdaabe-550e-4b55-adfb-5e3003094241"
      unitRef="usd">902000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfNC0zLTEtMS0w_3e41701c-28e7-410e-8b3c-e74489dcc23e"
      unitRef="usd">1040000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfNS0xLTEtMS0w_f8425284-41b9-480b-98e9-32929c360de9"
      unitRef="usd">4588000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjIwNmIyZGQxMTM3YzQyMThiM2Y4YWY4YjAxYTU2Zjk2L3RhYmxlcmFuZ2U6MjA2YjJkZDExMzdjNDIxOGIzZjhhZjhiMDFhNTZmOTZfNS0zLTEtMS0w_6290b1f5-4a1f-43f5-b747-15f948f85324"
      unitRef="usd">4231000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMjc3_827ba965-d343-43d0-a05d-0ef1d0234c04">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.628%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.799%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i073135b508cc4068bc10b72d2b0d3170_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfMS0xLTEtMS0w_610cdf2e-1504-4f92-a05b-5bcbae8dd0fb"
      unitRef="usd">5966000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i45e62ef03a17479584641f2e340a929c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfMS0zLTEtMS0w_febe4cad-3525-4796-b44c-1e8416b5f9c6"
      unitRef="usd">5476000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i00c9b49c74324d46b41817978d7a5a2c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfMi0xLTEtMS0w_f4ead12e-8ede-41ed-b883-a877f291deed"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if3b5c379005b46dfbb023e9e0339cb54_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfMi0zLTEtMS0w_3c43d155-73fb-4554-8270-c24237b998b9"
      unitRef="usd">192000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i09baee4ff554479da4cfb04820c2c407_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfMy0xLTEtMS0w_e2c04515-a866-480e-8997-d4c3d35834e9"
      unitRef="usd">52000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i925dc62162064a6e8afe8a1541ec5f89_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfMy0zLTEtMS0w_13f9b3c4-1c3e-4234-b6b7-ff079ef1dc75"
      unitRef="usd">46000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifed0bbb359d14d848c59c0cae236a4ab_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNC0xLTEtMS0w_0b82285e-2bdf-4894-a1db-5eec5f975601"
      unitRef="usd">30000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i31b47b75b7d444be881f797effc35ea5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNC0zLTEtMS0w_e422a6df-0268-4a80-bb02-ff5368dcfcb0"
      unitRef="usd">30000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i88343bfea9104524b13b58dd117fa4a0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNS0xLTEtMS0w_d416915c-0963-40a1-814f-601362a8866e"
      unitRef="usd">144000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3fbe3f7a19a3407695cd3173dc3fa872_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNS0zLTEtMS0w_bbc9ac22-9487-496e-bb11-7f60d7596d37"
      unitRef="usd">119000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNi0xLTEtMS0w_e3aa6822-d07d-4da6-90dd-a4bc366242db"
      unitRef="usd">6192000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNi0zLTEtMS0w_4691fd8f-886c-44f4-b1cf-dff208d0e2a4"
      unitRef="usd">5863000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNy0xLTEtMS0w_fc5bf497-2524-4ec4-9b2c-045b46283617"
      unitRef="usd">2090000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfNy0zLTEtMS0w_2a59e6e2-c193-4bb0-aa81-df4717907a0c"
      unitRef="usd">1740000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfOC0xLTEtMS0w_c70aad87-e073-431c-8d7f-a0fa971513bd"
      unitRef="usd">4102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjMzNDZmOWU2YjY0YjRjYTQ4MWE4NzY1YmUzYjM2NDljL3RhYmxlcmFuZ2U6MzM0NmY5ZTZiNjRiNGNhNDgxYTg3NjViZTNiMzY0OWNfOC0zLTEtMS0w_cc612006-5a2c-4af6-9991-6eb38a12ca4b"
      unitRef="usd">4123000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMjE5OTAyMzI1NTk0Nw_da3198a1-9aa5-4604-a6d7-71a0c177bfac"
      unitRef="usd">283000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMjE5OTAyMzI1NTk1Nw_1abf5656-1438-467e-b321-d538f6bdbec6"
      unitRef="usd">187000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMTYz_6597c630-1115-413c-8279-b2c49f07fc88"
      unitRef="usd">546000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMTcw_2a5eca35-8a60-4910-835f-28675eaed21d"
      unitRef="usd">335000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RleHRyZWdpb246MDNhNmQ4OGJkNjk0NGE1OGE4OTAxZDg5ZDk4ZDk3YjJfMjg0_e8c8f742-bdd4-4989-a410-295b78d256a2">&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.108%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical, contract research and manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfMS0xLTEtMS0w_9a9be009-5103-4d01-a819-0860fc97c02f"
      unitRef="usd">1223000</xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent>
    <xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfMS0zLTEtMS0w_2a470152-c665-4cc2-a30b-9c3a99182f98"
      unitRef="usd">1372000</xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfMi0xLTEtMS0w_cd1dab77-62e3-418a-8ca7-14b8b998391f"
      unitRef="usd">1127000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfMi0zLTEtMS0w_c6cd4a58-f9bc-445a-a746-6d971dcbeb08"
      unitRef="usd">1158000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfNS0xLTEtMS0w_a9f97655-0971-40ec-8b95-cafa00288c15"
      unitRef="usd">420000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfNS0zLTEtMS0w_af57d745-d083-4c2d-a20f-38b7aad2b4d3"
      unitRef="usd">223000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfNi0xLTEtMS0w_6a67e001-29b8-4266-8d7e-f5d7b5e54ee5"
      unitRef="usd">458000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfNi0zLTEtMS0w_f10c5cab-cfca-4c82-86b6-400b566d00ee"
      unitRef="usd">772000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfNy0xLTEtMS0w_a12b586f-b4e5-4fb5-bb1c-0402ea17815a"
      unitRef="usd">3228000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80Ni9mcmFnOjAzYTZkODhiZDY5NDRhNThhODkwMWQ4OWQ5OGQ5N2IyL3RhYmxlOjcwZDUxNDk4YTkwNDQ4YzdiZTBkOWE2YzUwMzYxZDljL3RhYmxlcmFuZ2U6NzBkNTE0OThhOTA0NDhjN2JlMGQ5YTZjNTAzNjFkOWNfNy0zLTEtMS0w_071a26e0-1623-4d93-89f1-69e62d11efc7"
      unitRef="usd">3525000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RleHRyZWdpb246NjMxYmIyNjdlNDIzNDBjMThlNTM2MmQ5NjczMDcxZDdfMTIzNw_539dd7b7-f26b-446e-be4e-078f70c038b4">Investments&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021 and December&#160;31, 2020, the Company primarily invested its excess cash in debt instruments of corporations, the U.S. Treasury, financial institutions, and U.S. government agencies with strong credit ratings and an investment grade rating at or above a long-term rating of Aa3/AA- and a short-term rating of P1/A1. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contract maturity of the available-for-sale securities the Company held as of June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:282.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:211.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year but within two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s available-for-sale securities are available to the Company for use in its current operations. As a result, the Company categorizes all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;June&#160;30, 2021&#160;and December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.826%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.025%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:InvestmentTableTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RleHRyZWdpb246NjMxYmIyNjdlNDIzNDBjMThlNTM2MmQ5NjczMDcxZDdfMTIzNQ_d4f78712-71a7-4bf0-af12-3048e4448eed">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contract maturity of the available-for-sale securities the Company held as of June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:282.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:211.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year but within two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentTableTextBlock>
    <xcur:DebtSecuritiesAvailableForSaleCurrentPercent
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjRlNWMzMTFiYTRkNzQ0ZDI5OWY1NDRiMmE2ZGUyZmNkL3RhYmxlcmFuZ2U6NGU1YzMxMWJhNGQ3NDRkMjk5ZjU0NGIyYTZkZTJmY2RfMC0xLTEtMS0w_8489c9df-2b49-4f16-b772-d4abc911a68d"
      unitRef="number">1</xcur:DebtSecuritiesAvailableForSaleCurrentPercent>
    <xcur:DebtSecuritiesAvailableForSaleNoncurrentPercent
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjRlNWMzMTFiYTRkNzQ0ZDI5OWY1NDRiMmE2ZGUyZmNkL3RhYmxlcmFuZ2U6NGU1YzMxMWJhNGQ3NDRkMjk5ZjU0NGIyYTZkZTJmY2RfMS0xLTEtMS0w_a4410834-2885-4e02-8ffb-acccef006d0f"
      unitRef="number">0</xcur:DebtSecuritiesAvailableForSaleNoncurrentPercent>
    <xcur:DebtSecuritiesAvailableforSalePercent
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjRlNWMzMTFiYTRkNzQ0ZDI5OWY1NDRiMmE2ZGUyZmNkL3RhYmxlcmFuZ2U6NGU1YzMxMWJhNGQ3NDRkMjk5ZjU0NGIyYTZkZTJmY2RfMi0xLTEtMS0w_57f5dd66-42e4-467d-9f68-c2a4c24d1692"
      unitRef="number">1</xcur:DebtSecuritiesAvailableforSalePercent>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RleHRyZWdpb246NjMxYmIyNjdlNDIzNDBjMThlNTM2MmQ5NjczMDcxZDdfMTIzNg_0244bbb2-008e-4849-9a01-a5db910bc413">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;June&#160;30, 2021&#160;and December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.826%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.025%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaf1b0681e7a64826a8f5b37064e1c69f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMi0xLTEtMS0w_0d15e265-c6eb-4f87-b34f-ae725b975289"
      unitRef="usd">5999000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaf1b0681e7a64826a8f5b37064e1c69f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMi0zLTEtMS0w_78d0c521-1473-4cba-8e11-d4cf444e434c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaf1b0681e7a64826a8f5b37064e1c69f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMi01LTEtMS0w_3d50bb38-d847-411b-a9c5-90843ea1bcbf"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf1b0681e7a64826a8f5b37064e1c69f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMi03LTEtMS0w_b67036a8-fca3-460a-982f-8add792ae624"
      unitRef="usd">5999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie654008c14bb45bebaddc4a5e9306fd2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMy0xLTEtMS0w_9d56cc81-0257-4011-8398-3bfd9b4f75d4"
      unitRef="usd">6212000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie654008c14bb45bebaddc4a5e9306fd2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMy0zLTEtMS0w_4e8a4eef-e058-4ad9-a981-9fecd39c0da5"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie654008c14bb45bebaddc4a5e9306fd2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMy01LTEtMS0w_0b2f3a67-82fd-49c5-9dac-8de7ffd54ab6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie654008c14bb45bebaddc4a5e9306fd2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfMy03LTEtMS0w_a31669db-b3a5-4e6c-bc93-8e51688a989e"
      unitRef="usd">6213000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icb46a2e715654544969c6e914b1268af_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNS0xLTEtMS0w_5e039f35-ebee-4001-8761-58da51a42072"
      unitRef="usd">1256000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icb46a2e715654544969c6e914b1268af_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNS0zLTEtMS0w_a9f8874a-3179-4c7a-b817-38e3692aeb91"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icb46a2e715654544969c6e914b1268af_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNS01LTEtMS0w_f5dc7ca0-b50e-4ffd-846d-033284e5afd0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icb46a2e715654544969c6e914b1268af_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNS03LTEtMS0w_93611347-8836-4060-ba87-949b34da6159"
      unitRef="usd">1260000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNi0xLTEtMS0w_04d5aca7-52c2-4aa4-af61-c6a1439939eb"
      unitRef="usd">13467000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNi0zLTEtMS0w_d7261bea-0080-44fb-b1ac-058c3cf0ca78"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNi01LTEtMS0w_90dc5eb2-a313-4423-b1f8-2b7eb26f642d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjZiZDNlYjQ2Y2Y0MzQxNzk5MWJkNGM4MDIzOTNlOTAwL3RhYmxlcmFuZ2U6NmJkM2ViNDZjZjQzNDE3OTkxYmQ0YzgwMjM5M2U5MDBfNi03LTEtMS0w_1c991872-68ea-4b4b-9d8f-945e928a4b5d"
      unitRef="usd">13472000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9d73b584ce0741a88f6493e030684da2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMi0xLTEtMS0w_9adc77b1-0972-4534-ae23-10541b4945ae"
      unitRef="usd">15992000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9d73b584ce0741a88f6493e030684da2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMi0zLTEtMS0w_234c7156-0a7b-477d-ad80-ffe9a5a7e84a"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9d73b584ce0741a88f6493e030684da2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMi01LTEtMS0w_ff16e58c-39b7-41a6-9269-94675aa83617"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9d73b584ce0741a88f6493e030684da2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMi03LTEtMS0w_0825a0a8-dd6d-4d86-b6e5-3a8d5bd50db6"
      unitRef="usd">15991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i49032d31daff47918154c5a0df3b9f9e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMy0xLTEtMS0w_e7e3b70d-ffb6-4562-8787-e4e204c2752d"
      unitRef="usd">29227000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i49032d31daff47918154c5a0df3b9f9e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMy0zLTEtMS0w_2e042695-e83d-4ca5-b31e-fecbb63cfd57"
      unitRef="usd">72000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i49032d31daff47918154c5a0df3b9f9e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMy01LTEtMS0w_5361597d-328b-43b6-824a-fcda7e778ea4"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49032d31daff47918154c5a0df3b9f9e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfMy03LTEtMS0w_eaed9a24-c195-4bbe-a6ea-7b48b2f2fe73"
      unitRef="usd">29296000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id8ec51807b1e46109dd345b48f722f7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNC0xLTEtMS0w_ced881e0-d80d-49a5-b7db-d706bc259072"
      unitRef="usd">2251000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id8ec51807b1e46109dd345b48f722f7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNC0zLTEtMS0w_aef6c7e7-97c4-49da-872d-7f323b7b964c"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id8ec51807b1e46109dd345b48f722f7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNC01LTEtMS0w_bd4338ab-b9c1-4eac-8642-164c0fe3f10c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id8ec51807b1e46109dd345b48f722f7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNC03LTEtMS0w_b44adcf7-d9e8-48e8-bc50-ed1c0df330dc"
      unitRef="usd">2253000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9577091c72d34a4d87f0ec5ba0d9a62a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNS0xLTEtMS0w_95b422e6-fbf0-4aab-baa4-2a6c9d18545f"
      unitRef="usd">1265000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9577091c72d34a4d87f0ec5ba0d9a62a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNS0zLTEtMS0w_0fd402b9-5070-4221-9a2c-d24ac1dfcbbc"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9577091c72d34a4d87f0ec5ba0d9a62a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNS01LTEtMS0w_974c9b8a-d764-4f4b-89ee-b4b470480328"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9577091c72d34a4d87f0ec5ba0d9a62a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNS03LTEtMS0w_39331fa5-34b6-4b1b-b034-26fa62a08003"
      unitRef="usd">1278000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNi0xLTEtMS0w_bd697e8a-fdf3-4b92-af3e-fe9a2c075768"
      unitRef="usd">48735000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNi0zLTEtMS0w_9fc226b5-82d1-4d0e-acae-6c997f965ed4"
      unitRef="usd">89000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNi01LTEtMS0w_355d8c82-70a7-439a-91e2-b91386bc41d9"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF80OS9mcmFnOjYzMWJiMjY3ZTQyMzQwYzE4ZTUzNjJkOTY3MzA3MWQ3L3RhYmxlOjNlYjRkNjBmYTg3ZjRiNGNhYjBiOTQ4NWU0OTIwZjY3L3RhYmxlcmFuZ2U6M2ViNGQ2MGZhODdmNGI0Y2FiMGI5NDg1ZTQ5MjBmNjdfNi03LTEtMS0w_a3f8dab6-4458-401a-bb43-eaf26a6cd8de"
      unitRef="usd">48818000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNTI1Nw_8f040513-0278-4632-a0c7-342b812b6da5">Debt&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MidCap Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 25, 2020, the Company entered into a Credit and Security Agreement, as amended on October 21, 2020, (the &#x201c;MidCap Credit Agreement&#x201d;), with MidCap Financial Trust (&#x201c;MidCap&#x201d;), as agent, and the lenders party thereto from time to time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MidCap Credit Agreement provides for a secured term loan facility in an aggregate principal amount of up to $25,000 (the &#x201c;MidCap Credit Facility&#x201d;). The Company borrowed the first advance of $17,500 (&#x201c;Tranche 1&#x201d;) on September 25, 2020 (the &#x201c;Closing Date&#x201d;). Under the terms of the MidCap Credit Agreement, the second advance of $7,500 (&#x201c;Tranche 2&#x201d;) is available to the Company from April 1, 2021 to September 30, 2021, subject to the Company&#x2019;s satisfaction of certain conditions described in the MidCap Credit Agreement. The Company believes the conditions to access the available Tranche 2 amount are satisfied as of June 30, 2021. The proceeds from the MidCap Credit Facility are expected to be used for working capital and general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Tranche 1, and if borrowed Tranche 2, each bear interest at a floating rate equal to 6.25% per annum, plus the greater of (i) 1.50% or (ii) one-month LIBOR. Interest on each loan advance is due and payable monthly in arrears. Principal on each loan advance is payable in 36 equal monthly installments beginning October 1, 2022 until paid in full on October 1, 2025 (the &#x201c;Maturity Date&#x201d;). Prepayments of the loans under the MidCap Credit Agreement, in whole or in part, will be subject to early termination fees in an amount equal to 3.0% of principal prepaid if prepayment occurs on or prior to the first anniversary of the Closing Date and 1.0% of principal prepaid if prepayment occurs after the first anniversary of the Closing Date and prior to the maturity date.  In connection with execution of the Midcap Credit Agreement, the Company paid MidCap a $125 origination fee.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Maturity Date or on any earlier date on which all amounts advanced to the Company become due and payable in full, or are otherwise paid in full, the Company is required to pay an exit fee equal to 3.75% of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;principal amount of all loans advanced to the Company under the MidCap Credit Agreement. Upon the advance of Tranche 1, the Company accrued $656 for the related exit fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligations under the MidCap Credit Agreement are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge). Additionally, the Company&#x2019;s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the MidCap Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MidCap Credit Agreement contains customary affirmative covenants and customary negative covenants limiting the Company&#x2019;s ability and the ability of the Company&#x2019;s subsidiaries, if any, to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MidCap Credit Agreement also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, delisting of the Company&#x2019;s common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, the agent and the lenders may declare all or a portion of the Company&#x2019;s outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the agreement. During the existence of an event of default, interest on the obligations could be increased by 2.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total proceeds, net of fees and issuance costs, borrowed under Tranche 1 were $16,512.  Fees and issuance costs of $332, as well as fees of $656 that are payable to MidCap at maturity of Tranche 1, are recorded as a reduction to the carrying amount of long-term debt on the Company&#x2019;s balance sheet and will be amortized to interest expense through the maturity date of October 1, 2025 using the effective interest method. Fees and issuance costs of $73 attributed to the amount available to be borrowed under Tranche 2 were paid and recorded as deferred financing costs (other assets) and will be (i) recorded as a reduction in the carrying amount of long-term debt in future periods if amounts are borrowed under Tranche 2 or (ii) will be amortized and recorded to interest expense if amounts are not borrowed under Tranche 2. For the three and six months ended June 30, 2021, the Company recognized $37 as interest expense and the remaining balance of the deferred financing costs is $36 as of June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the aggregate carrying value of the Company&#x2019;s long-term debt is $16,730.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the principal maturities of the Company&#x2019;s long-term debt were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal balance outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less: unamortized discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid interest on the MidCap Credit Agreement of $347 and $686 during the three and six months ended June 30, 2021, respectively. The Company paid interest on the Hercules Loan Agreement (as discussed below) of $0 and $142 during the three and six months ended June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hercules Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 2, 2020, pursuant to the terms of the loan agreement with Hercules Technology Growth Capital (&#x201c;Hercules&#x201d;) and subsequent amendments thereto  (the &#x201c;Hercules Loan Agreement&#x201d;), the Company repaid all remaining outstanding obligations under the Hercules Loan Agreement as of the maturity date, including the outstanding principal balance of $4,999 and the end of term fee of $100.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i645a0991058845f0b7026139817fe54a_I20200925"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMzk0_7a905ec5-ab66-47fb-ba98-72c93123d27a"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i41901b1bd0c34219aebdd24b5355e642_D20200925-20200925"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNDcx_7d31e76f-b4da-477d-8851-743a800155e8"
      unitRef="usd">17500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i436ecc2736cd40ac821c16bdf401d6bc_I20210401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNjAy_7c475db9-8688-4218-aa03-c795f31c4fc7"
      unitRef="usd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i645a0991058845f0b7026139817fe54a_I20200925"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTExNQ_3db61533-8f6a-45f7-a7b3-f1ad7f939a74"
      unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7d3967c9df24458ca2996a7076c5be12_D20200925-20200925"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTE1Mw_6bd8507a-83ac-42d1-8980-c13deef7ddea"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <xcur:DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments
      contextRef="ia063169c06cb4eb1b3257cbed4a76a5b_I20221001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTI5NQ_62ab8e5b-ee3a-45eb-8635-db461e01f4de"
      unitRef="installmentpayment">36</xcur:DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments>
    <xcur:DebtInstrumentEarlyTerminationFeePercentageOfPrincipal
      contextRef="iad1abf0184e64b35a21316ccc6ae8ef7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTU1Nw_63e2704a-7ea5-4b03-b0d7-5611113e71ab"
      unitRef="number">0.030</xcur:DebtInstrumentEarlyTerminationFeePercentageOfPrincipal>
    <xcur:DebtInstrumentEarlyTerminationFeePercentageOfPrincipal
      contextRef="if9d9075e5dfe4e329a0d45099cfb1c9d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTY2Mw_4a5a8856-e88a-420b-9687-ab61661da30d"
      unitRef="number">0.010</xcur:DebtInstrumentEarlyTerminationFeePercentageOfPrincipal>
    <us-gaap:LoanProcessingFee
      contextRef="i925aaaddcacc4778b5d8b7f62145a333_D20200925-20200925"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTg3Ng_cd849445-3189-42cf-86b6-894cd1fa2ea2"
      unitRef="usd">125000</us-gaap:LoanProcessingFee>
    <xcur:DebtInstrumentExitFeePercentage
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMjEwMQ_0d52d5e2-7db9-429e-8832-cddb38b393e4"
      unitRef="number">0.0375</xcur:DebtInstrumentExitFeePercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i300147310fb342fa8729d20a235e6672_I20200925"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMjI1MQ_2898bc7c-212e-4f94-934f-f525d923f48c"
      unitRef="usd">656000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="i5d311891d17c4c9d82be715743cfa91f_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMzc2MQ_f5a3aafd-2fcb-4da3-96a3-994e2eccc321"
      unitRef="number">0.020</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i41901b1bd0c34219aebdd24b5355e642_D20200925-20200925"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMzg0Mw_62e7af6b-248c-41ef-bed0-047db4e52a78"
      unitRef="usd">16512000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i300147310fb342fa8729d20a235e6672_I20200925"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMzg3NQ_ab6b9942-c4c6-4db0-8187-f0b4b27cd53b"
      unitRef="usd">332000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i300147310fb342fa8729d20a235e6672_I20200925"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMzg5OA_2898bc7c-212e-4f94-934f-f525d923f48c"
      unitRef="usd">656000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="iecb1d260e2dd441b95189e9938852f30_I20200925"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNDIwNQ_40d2f1b8-3904-4de3-a2e6-f907231260a5"
      unitRef="usd">73000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="iead4e91610bb417ba4c9ce8e04fe7b87_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTA5OTUxMTYzMzc1OA_ed5b57ee-1ff1-49d8-a424-9c74e9e78d89"
      unitRef="usd">37000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="if20db32734cd4856a7b5ebfc55b07f6e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMTA5OTUxMTYzMzc1Mw_c41c3ffe-ea75-45e9-b63b-634a5dd48621"
      unitRef="usd">36000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNDk2NQ_258d639d-db23-4a71-a6a0-a4d7bfe7855b"
      unitRef="usd">16730000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNTI1OA_bb901faf-1987-4b0d-bdf2-37a2c99606bc">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the principal maturities of the Company&#x2019;s long-term debt were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal balance outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less: unamortized discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfMS0yLTEtMS0w_04b651db-4257-4404-b909-ad8f6cfa8667"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfMi0yLTEtMS0w_109c7fc0-474f-4324-9587-5bbfd7f516bb"
      unitRef="usd">1459000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfMy0yLTEtMS0w_403a61f3-75dc-4bda-bdc6-8425b17f9fc8"
      unitRef="usd">5833000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfNC0yLTEtMS0w_ecf4e4e1-8647-4ba4-945c-ef7d186a14f7"
      unitRef="usd">5833000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfNS0yLTEtMS0w_f93d6b8d-e88a-4d3c-8e63-ce07fd9144ce"
      unitRef="usd">4375000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfNi0yLTEtMS0w_5b643af1-ab0a-47bc-abd4-9c90777f397e"
      unitRef="usd">17500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfNy0yLTEtMS0w_59e758bc-a556-47e6-b198-6085364db1ea"
      unitRef="usd">770000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfOC0yLTEtMS0w_980ff173-645a-45ed-b0fa-f01e03c94310"
      unitRef="usd">16730000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfOS0yLTEtMS0w_047bf8c5-a2c0-46e5-b57b-9d13bea9c024"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RhYmxlOmY1NDY4MzZkYzJlMDRjMWVhN2I3OTE3OTg1OTk1MWU4L3RhYmxlcmFuZ2U6ZjU0NjgzNmRjMmUwNGMxZWE3Yjc5MTc5ODU5OTUxZThfMTAtMi0xLTEtMA_64d45799-a6f5-4a62-8503-ab44fae2744e"
      unitRef="usd">16730000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:InterestPaidNet
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNTExNQ_6aac3bc0-4d84-4e41-a125-00a15c251feb"
      unitRef="usd">347000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMjc0ODc3OTA3NDczNA_eccdda8f-94f0-4232-82d8-2f7449828d35"
      unitRef="usd">686000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMjc0ODc3OTA3NDc1Nw_350996fb-8dd8-4fcc-81b9-5a65502b9bb6"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfMjc0ODc3OTA3NDc1MQ_6bf9b4ff-1c7b-4045-a459-32d81c281460"
      unitRef="usd">142000</us-gaap:InterestPaidNet>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ide2ab8bf32e5471fb89bc743cfb84ebb_D20200302-20200302"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNjA0NzMxMzk1OTUzNw_8b010dab-12d6-4bce-8f42-d7163f81b691"
      unitRef="usd">4999000</us-gaap:RepaymentsOfLongTermDebt>
    <xcur:PaymentsForDebtEndTermFees
      contextRef="ide2ab8bf32e5471fb89bc743cfb84ebb_D20200302-20200302"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81Mi9mcmFnOmNlODI0MTc3NjUxODQ5NjI5NDAzOWRjMDAzNGYzYzFjL3RleHRyZWdpb246Y2U4MjQxNzc2NTE4NDk2Mjk0MDM5ZGMwMDM0ZjNjMWNfNjA0NzMxMzk1OTU2OA_c4c1ef0c-95b8-4ced-a085-d10a325a7d6d"
      unitRef="usd">100000</xcur:PaymentsForDebtEndTermFees>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfNDU1Mg_ddc55fcd-1f4d-4752-81bb-7a146987bd8e">Leases&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease arrangements at June 30, 2021 consist of (i) a lease for office and laboratory space at its headquarters in Chicago, Illinois that commenced in July 2020 (the &#x201c;Chicago Lease&#x201d;), (ii) a lease for office space at a multi-tenant facility in Cambridge, MA that commenced in March 2019 and is cancelable at any time (the &#x201c;Cambridge Lease&#x201d;), and (iii) leases for office equipment (the &#x201c;Office Equipment Leases&#x201d;). Each of these leases are classified as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the nature of the Cambridge Lease, the Company determined that this lease represented a short-term lease with an initial term of less than twelve months and, as such, the Cambridge Lease is not recorded on the balance sheet and related lease costs are recognized in the statement of operations as they are incurred. The Company has also elected to not record the Office Equipment Leases on the balance sheet since related payment amounts and lease costs are insignificant. Lease costs for the Office Equipment Leases are recognized in the statement of operations on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease arrangement for office and laboratory space at its former headquarters in Skokie, Illinois ended in February 2021 in accordance with the terms of that lease arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Chicago Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has approximately thirty thousand square feet of office and laboratory space in Chicago, Illinois (the &#x201c;Chicago Lease&#x201d;). The original term (the &#x201c;Original Term&#x201d;) of the Chicago Lease is 10 years, commencing on July 1, 2020 (the &#x201c;Commencement Date&#x201d;), which is the date the premises were ready for occupancy under the terms of the Chicago Lease.  The Company has options to extend the term of the Chicago Lease for&#160;two&#160;additional successive periods of five years each (the &#x201c;Extension Periods&#x201d;) at the then prevailing effective market rental rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial annual base rent during the Original Term is approximately $1,113 for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of 3%, for an aggregate amount of $12,761 over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term.  During the first 12-month period of the Original Term, the base rent and the Company's proportionate share of operating expenses and taxes are subject to certain abatements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Chicago Lease, the Company will maintain a letter of credit for the benefit of the landlord in an initial amount of $1,200, which amount is subject to reduction over time.  Upon execution of the Chicago Lease, the Company paid to the landlord the first installment of base rent and the estimated monthly amount of its pro rata share of taxes and its pro rata share of operating expenses in the aggregate amount of $87 which amount had been adjusted for the abatement as set forth in the lease agreement. The Company also paid the landlord a net amount of $697 toward tenant improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the agreement for the Chicago Lease, the Company is required to maintain a&#160;standby letter of credit during the term of the lease, currently in the amount of $1,200 and subject to reduction over time, which is secured by a restricted certificate of deposit account and presented within other noncurrent assets on the Company&#x2019;s unaudited condensed consolidated balance sheet at June&#160;30, 2021.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized a right of use asset of $8,931 and a lease liability of $8,147 on the Commencement Date. Because the rate implicit in the Chicago Lease is not readily determinable, the Company used its incremental &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;borrowing rate of 8.3% on the Commencement Date to determine the present value of the lease payments over the Original Term. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. As of June&#160;30, 2021, the Company determined it is not reasonably certain that the renewal option would be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information related to the Company&#x2019;s operating lease asset and related operating lease liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes lease costs in the Company&#x2019;s unaudited condensed consolidated statement of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company made cash payments for operating leases of $1,106 and $1,227 during the six months ended June 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the Company&#x2019;s lease liability as of June&#160;30, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <xcur:LesseeOperatingLeaseLeaseArea
      contextRef="ic8159ef26edf4cfab622048f57adfe21_D20200701-20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMTM1NA_41055250-3a29-4406-8d4f-bbf97416284f"
      unitRef="sqft">30000</xcur:LesseeOperatingLeaseLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i54669006cc704c238aa705208cb442e6_I20200701"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMTUwOA_a422e500-9f4f-4230-8ccb-6337e631a3e3">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <xcur:LesseeOperatingLeaseNumberOfExtensions
      contextRef="ic8159ef26edf4cfab622048f57adfe21_D20200701-20200701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMTcyOQ_d3398332-64c8-44c6-83fb-b6a091417a90"
      unitRef="extensionperiod">2</xcur:LesseeOperatingLeaseNumberOfExtensions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i54669006cc704c238aa705208cb442e6_I20200701"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMTc2NQ_71d484cf-ade0-465b-9d33-95d48c9b6e69">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <xcur:LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths
      contextRef="i54669006cc704c238aa705208cb442e6_I20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMTkyMw_4d666c74-e6e4-4c8e-a56a-f5d2a3332fb0"
      unitRef="usd">1113000</xcur:LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths>
    <xcur:LesseeOperatingLeaseBaseRentAnnualPercentageIncrease
      contextRef="i54669006cc704c238aa705208cb442e6_I20200701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMjEwMQ_94c6fb01-a12c-4e9a-93e7-5e61a0f45118"
      unitRef="number">0.03</xcur:LesseeOperatingLeaseBaseRentAnnualPercentageIncrease>
    <xcur:LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm
      contextRef="i54669006cc704c238aa705208cb442e6_I20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMjEzMg_2cc500a1-c687-4b3e-8820-6b2286879a2a"
      unitRef="usd">12761000</xcur:LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i54669006cc704c238aa705208cb442e6_I20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMjYwNA_ae68de9b-699e-4f11-b90f-aee9d7829db0"
      unitRef="usd">1200000</us-gaap:LettersOfCreditOutstandingAmount>
    <xcur:LesseeOperatingLeaseRentalPaymentAdjustedForAbatement
      contextRef="ic8159ef26edf4cfab622048f57adfe21_D20200701-20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMjg5OA_280e02c7-b7f0-491d-a47a-62a90261746a"
      unitRef="usd">87000</xcur:LesseeOperatingLeaseRentalPaymentAdjustedForAbatement>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="ic8159ef26edf4cfab622048f57adfe21_D20200701-20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMzAzOA_8a614518-7b43-4c39-80e1-42a9255b449d"
      unitRef="usd">697000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i54669006cc704c238aa705208cb442e6_I20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMzIzNw_03f1a1d7-9052-4054-a9e3-d235f148eb78"
      unitRef="usd">1200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i54669006cc704c238aa705208cb442e6_I20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMzUwNA_bdf1d694-2da0-47a7-ad8a-4e6f9199b540"
      unitRef="usd">8931000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i54669006cc704c238aa705208cb442e6_I20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMzUzMg_7981e93b-4d91-49bb-b777-2e9064d1babd"
      unitRef="usd">8147000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i54669006cc704c238aa705208cb442e6_I20200701"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfMzY4OA_e90f0f42-7317-4228-ad73-6aaa90ec727e"
      unitRef="number">0.083</us-gaap:LesseeOperatingLeaseDiscountRate>
    <xcur:ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfNDU1OQ_f133d460-980d-4563-ba83-e5670d1aa76c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information related to the Company&#x2019;s operating lease asset and related operating lease liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</xcur:ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjQ2YjYzMTJhMDc4MTQ1NGU5ZGNiNjlkMTI3MGZmOTQ2L3RhYmxlcmFuZ2U6NDZiNjMxMmEwNzgxNDU0ZTlkY2I2OWQxMjcwZmY5NDZfMS0yLTEtMS0w_a5c56e5f-1084-45e1-bace-24018587339b">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjQ2YjYzMTJhMDc4MTQ1NGU5ZGNiNjlkMTI3MGZmOTQ2L3RhYmxlcmFuZ2U6NDZiNjMxMmEwNzgxNDU0ZTlkY2I2OWQxMjcwZmY5NDZfMi0yLTEtMS0w_f9f27bd7-d899-4abe-9970-91a7511fbff2"
      unitRef="number">0.083</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfNDU1Ng_10ac986e-5d90-4d7e-a198-c19f2c5c0804">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes lease costs in the Company&#x2019;s unaudited condensed consolidated statement of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMi0xLTEtMS0w_460e89cd-6dc4-4b31-af5c-9503ee2b678a"
      unitRef="usd">326000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMi0zLTEtMS0w_9c8781dc-28e7-4c49-8d3c-7c0323df552a"
      unitRef="usd">296000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMi01LTEtMS0w_ad7c0c81-f93e-4ff9-9877-35959347de61"
      unitRef="usd">653000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMi03LTEtMS0w_acb9adc3-6e0c-4c04-bdbc-9cfcb5027ed2"
      unitRef="usd">380000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMy0xLTEtMS0w_95166975-30e8-47dd-9459-47c44267c8f5"
      unitRef="usd">31000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMy0zLTEtMS0w_e2d44d27-59d5-425d-b0d1-ed3712c3457f"
      unitRef="usd">29000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMy01LTEtMS0w_66abc61e-a58a-4092-81ba-a021fe5a5b43"
      unitRef="usd">62000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfMy03LTEtMS0w_3af55928-1038-49ef-9f4c-316da90282e4"
      unitRef="usd">67000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNC0xLTEtMS0w_9f349f7a-5b19-4f5d-b549-f02d5b1a94c5"
      unitRef="usd">195000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNC0zLTEtMS0w_e774a3ac-7958-49d7-84b8-f28c0b99863d"
      unitRef="usd">92000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNC01LTEtMS0w_5afec312-cfaf-47d8-b861-610096de5e2c"
      unitRef="usd">572000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNC03LTEtMS0w_3ebaaf49-2467-4ea0-b915-9e5f8fd2f94d"
      unitRef="usd">149000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNS0xLTEtMS0w_7a207632-ab4f-48cb-87ce-f46a24328efd"
      unitRef="usd">552000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNS0zLTEtMS0w_38e4d2d4-fffa-4774-9624-5c5a6bead4d0"
      unitRef="usd">417000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNS01LTEtMS0w_b96e1046-c059-44c0-b4e0-263a0bd31bcb"
      unitRef="usd">1287000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjIxYmEwYzBhODkyMTQyOTI5MzI3ODVlNzlhYjBkZmM2L3RhYmxlcmFuZ2U6MjFiYTBjMGE4OTIxNDI5MjkzMjc4NWU3OWFiMGRmYzZfNS03LTEtMS0w_204f9a5b-8ea2-4c52-ba13-272217c697b1"
      unitRef="usd">596000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfNDQxMg_9d8f72bc-418e-4935-a2fc-18e3818d9cff"
      unitRef="usd">1106000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfNDQxOQ_db14debe-aa77-40db-a2f7-55e85a82bb35"
      unitRef="usd">1227000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RleHRyZWdpb246YjFkNzllZDYzODM2NDJmNjhlMjFhMTAxMzg2YmFkODlfNDU1MQ_f9ffbd50-106b-44de-b1ac-8a20bca67ca2">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the Company&#x2019;s lease liability as of June&#160;30, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfMS0yLTEtMS0w_5e7805da-39a4-4aa1-a593-3a057dee2dd0"
      unitRef="usd">478000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfMi0yLTEtMS0w_0a21f6f6-e5c6-41f8-bdaf-b9cf009ed570"
      unitRef="usd">1163000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfMy0yLTEtMS0w_a5f48a53-f292-4b39-8a44-deafcd8b21ac"
      unitRef="usd">1198000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfNC0yLTEtMS0w_bf47802a-ec47-4bbb-bf36-e25ae65aa5f9"
      unitRef="usd">1235000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfNS0yLTEtMS0w_bb1d4a08-c785-4977-879f-ec58887e7994"
      unitRef="usd">1272000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfNi0yLTEtMS0w_10f91318-075f-4bd6-9fb9-e64e88c17707"
      unitRef="usd">1310000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfNy0yLTEtMS0w_732e547c-f6bf-4dce-b651-720358319c60"
      unitRef="usd">4897000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfOC0yLTEtMS0w_12fd2854-0857-49de-bad2-a061270fd342"
      unitRef="usd">11553000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfOS0yLTEtMS0w_7c48f256-b312-42f6-b0aa-982f17754c42"
      unitRef="usd">3437000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfMTAtMi0xLTEtMA_1328b8d1-0af4-41a3-b87e-6c2ccae56916"
      unitRef="usd">8116000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfMTItMi0xLTEtMA_bf2a8010-aec9-497d-bf71-d5f9fef2c506"
      unitRef="usd">420000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfMTMtMi0xLTEtMA_f47e241c-e521-45f1-a061-5e429f657781"
      unitRef="usd">7696000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81NS9mcmFnOmIxZDc5ZWQ2MzgzNjQyZjY4ZTIxYTEwMTM4NmJhZDg5L3RhYmxlOjc5NzBiZmQ4NTM4NTQxZDg5ZGJjM2QxOTc2ZTJlMDdkL3RhYmxlcmFuZ2U6Nzk3MGJmZDg1Mzg1NDFkODlkYmMzZDE5NzZlMmUwN2RfMTQtMi0xLTEtMA_9cbcec0f-cf58-4bbb-beb0-5d88f7e8e1b4"
      unitRef="usd">8116000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjIyMQ_9733e468-c267-4d17-a8cb-8eeb2433f90c">Stockholders&#x2019; Equity&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021 and December&#160;31, 2020, the Company had 10,000,000 shares of preferred stock, par value $0.0001 authorized and no shares issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021 and December&#160;31, 2020, the Company had authorized 200,000,000 shares of common stock, par value $0.0001.  As of June&#160;30, 2021 and December&#160;31, 2020, the Company had 88,096,694 shares and 87,651,352 shares issued and outstanding, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of shares of the Company&#x2019;s common stock are entitled to one vote per share on all matters to be voted upon by the Company&#x2019;s stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&#x2019;s common stock are entitled to receive ratably any dividends that may be declared from time to time by the Board out of funds legally available for that purpose. In the event of the Company&#x2019;s liquidation, dissolution or winding up, the holders of shares of the Company&#x2019;s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company&#x2019;s common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company&#x2019;s common stock. The outstanding shares of the Company&#x2019;s common stock are fully paid and&#160;non-assessable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of June&#160;30, 2021, no warrants were outstanding. As of December 31, 2020, warrants to purchase 413,320 shares of common stock at a price of&#160;$3.00&#160;per share were outstanding.  The warrants expired unexercised as follows: 163,174 warrants expired on March 27, 2021, 132,884 expired on April 28, 2021, and 117,262 expired on May 3, 2021.  The warrants were classified as a liability which was remeasured each period at fair value. See Note 12,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;for more information on the fair value of the common stock warrant liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net loss reclassified from accumulated other comprehensive loss during the three months ended June 30, 2020 resulted from sales of available-for-sale securities prior to maturity. The gross realized gains and gross realized losses of these sales were $23 and $6, respectively, for the three and six months ended June 30, 2020. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $9,404.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfNzg_b3371a5f-16d9-4de8-a7d8-643547dbed9f"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfNzg_bde8fc37-1fc9-4abd-886a-b0250fa60247"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTE4_09e6849b-ad13-4146-8071-56ada0c2c11d"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTE4_27ae4e9a-13a4-481b-b1c6-a12df02dcec4"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTM2_6a4292ae-8931-41ef-95c7-a9a03cb99a14"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTM2_6d7c7d38-4a77-423a-986d-f7a7457da5c3"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTM2_cbcac11a-1533-43d9-ba28-cb837b59ddc9"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTM2_cd707a5b-bc56-4de6-897f-7a14f12dc6b3"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjI3_bf9d015d-bb8e-41d7-9e86-367112e21eae"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjI3_c2d2d2f1-c58f-461c-b98a-77c2199fe3f9"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjY0_09098f34-096e-4211-9f64-bcdb3c7a221c"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjY0_41536ebb-126c-4c3e-ad01-48cd0854d8a7"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMzAy_8088e5a6-b687-48e7-87e4-4c73793759f2"
      unitRef="shares">88096694</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMzAy_cfdac1c5-a03f-4d2f-80b7-4282668f310c"
      unitRef="shares">88096694</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjE5OTAyMzI1Nzc3OA_00720d85-5264-437e-8063-6a04d2340326"
      unitRef="shares">87651352</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjE5OTAyMzI1Nzc3OA_11448e58-1a10-4eeb-b81c-237918b721ff"
      unitRef="shares">87651352</us-gaap:CommonStockSharesOutstanding>
    <xcur:CommonStockVotingRightsForEachShare
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfNDM1_83d49486-3018-4fff-9c70-75e83f5c6287"
      unitRef="votepershare">1</xcur:CommonStockVotingRightsForEachShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i6ff17028d7f742fc86b80a80958beb1c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjE5OTAyMzI1Nzg0Mw_55b9f407-7da0-40f3-990f-a03fe699245b"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7c221311f05b4f77be016eb7ea9c9657_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTQ4Mg_bfd80c4d-b1a0-4baa-b241-733db4965a92"
      unitRef="shares">413320</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7c221311f05b4f77be016eb7ea9c9657_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTUyMg_9c9596d1-51e6-469f-89b8-2efd8e2b8805"
      unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xcur:ClassofWarrantorRightExpired
      contextRef="i0645f4970e4a4657940a7c44e95adbf2_I20210327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTU5OQ_58bd4d04-618f-4101-824c-a61d755acc2b"
      unitRef="shares">163174</xcur:ClassofWarrantorRightExpired>
    <xcur:ClassofWarrantorRightExpired
      contextRef="i1678fc9eed904b0ea7406fdd2c19c39e_I20210428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTYzOA_d5f581e7-6f2e-4888-983b-92f6f87b51e3"
      unitRef="shares">132884</xcur:ClassofWarrantorRightExpired>
    <xcur:ClassofWarrantorRightExpired
      contextRef="if012e2aa547c4f42b1c5e1a7b5509669_I20210503"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMTY3Mg_f54db714-c65d-4878-82a8-71262adc9702"
      unitRef="shares">117262</xcur:ClassofWarrantorRightExpired>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjIyMw_6a2c7519-f43b-4daa-9e59-46848e300cef">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i03f09592eb17452db7a906b8878473eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfMS0yLTEtMS0w_7693375b-2718-4f08-8784-54a927e12a54"
      unitRef="usd">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2a8e31b3400845b785f4078c29ad60c3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfMS00LTEtMS0w_2a42e341-411d-47b2-9be1-34f4c521e406"
      unitRef="usd">83000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i0beb38fa0e984be794221ee6085d5212_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfMi0yLTEtMS0w_5c7615e4-fc95-4ffc-93b5-35b9d5e64f44"
      unitRef="usd">-51000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i07e140d0339e4a2c9fa363c5cc32a6e4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfMi00LTEtMS0w_2c5d39c9-c5c3-4619-b9c4-387ad543ae4d"
      unitRef="usd">-51000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0beb38fa0e984be794221ee6085d5212_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfMy0yLTEtMS0w_a7f3cb40-5a0c-4eb0-957a-53da823e6fec"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i07e140d0339e4a2c9fa363c5cc32a6e4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfMy00LTEtMS0w_45e9d19b-18ec-4c93-972b-ee66df3f6018"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i11febcbb571642db9e1cddde4919a982_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfNC0yLTEtMS0w_62fe7df5-9935-41bc-82a9-d562e4d11be4"
      unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d493db55bc244c1818df293641b339b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfNC00LTEtMS0w_7aedebda-555e-4a48-8428-75901f976471"
      unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i99e8cbf713bb404290e76a87777df0be_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfNS0yLTEtMS0w_fd1f0956-7be3-4503-88aa-71b48abba274"
      unitRef="usd">-27000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfNS00LTEtMS0w_467f2a6a-3eff-4302-aa9d-893d7584aa49"
      unitRef="usd">-27000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i99e8cbf713bb404290e76a87777df0be_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfNy0yLTEtMS0w_54f081c9-d84a-4a4d-b029-29cbb84ffb58"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfNy00LTEtMS0w_8e564a4a-410e-4cee-a729-3f3c33837a4c"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i19701c73d57b47c1b8e1d54bc15798ff_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfOC0yLTEtMS0w_53d63ac3-536c-43e9-8c81-6850a6d74f72"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8dde94d491614ea4bca5ec1bcd8d14b0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOjY1MjE1Y2Q5OTZhNjQ1MzY5OTZmYWUyMTQ1ZTEwNmM3L3RhYmxlcmFuZ2U6NjUyMTVjZDk5NmE2NDUzNjk5NmZhZTIxNDVlMTA2YzdfOC00LTEtMS0w_05557f1a-f9d9-40a4-b653-762bd868ae55"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i647d7754868047e08ca0cedc232ce793_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfMS0yLTEtMS0w_9bc0fc1d-7d98-4eb2-9ed0-d1c348acfa31"
      unitRef="usd">-27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0f137df29abc4c41a4815885b2a3d6b7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfMS00LTEtMS0w_32955e9c-a6bc-482f-9d00-3aa147f13e44"
      unitRef="usd">-27000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ib87f672fddff47ec9c64d6d8f41b94f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfMi0yLTEtMS0w_ef2c5124-9f0b-4fc4-9515-2ef1a9a7975b"
      unitRef="usd">10000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfMi00LTEtMS0w_b4b703a6-db66-44eb-adcc-8d991ec55dd3"
      unitRef="usd">10000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib87f672fddff47ec9c64d6d8f41b94f9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfMy0yLTEtMS0w_b82386f0-26ba-499b-814f-fdf89104ac98"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfMy00LTEtMS0w_5a601651-66e0-41f1-812a-2bd55694b741"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="if36427efb36c41dd9f56f8366f4269ba_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNC0yLTEtMS0w_196b2c7f-3b66-4b28-8b86-9023150435ec"
      unitRef="usd">-17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8cf7cd3ed49446ca5422f8857c95a70_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNC00LTEtMS0w_e86f150f-6c9e-42d2-a60f-d99f7fcd5d95"
      unitRef="usd">-17000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i9bd85f97f1394ba795ddb6a54771a121_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNS0yLTEtMS0w_ebc14571-71a4-4fcc-a428-466802b8ebfc"
      unitRef="usd">352000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNS00LTEtMS0w_d022b78c-1d24-49ba-98ea-e2bca61a857b"
      unitRef="usd">352000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i9bd85f97f1394ba795ddb6a54771a121_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNi0yLTEtMS0w_34ab6e90-7eb0-4f6b-8045-afefe2bafbb1"
      unitRef="usd">-3000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNi00LTEtMS0w_6dec6f09-8db5-4322-9aff-d3799d1837ca"
      unitRef="usd">-3000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9bd85f97f1394ba795ddb6a54771a121_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNy0yLTEtMS0w_e5289747-e50d-4978-9097-e246c779cfdf"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfNy00LTEtMS0w_66d1d077-b903-47a6-be74-73bb8d443d26"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i4e2f75424b9847e8a73a5ae083e07f16_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfOC0yLTEtMS0w_7eca0d1c-cf28-43d7-935f-4ea8272811f2"
      unitRef="usd">338000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia77029b06c3e4a209202062d9c9b7340_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RhYmxlOmJjMDRkNjBlZjY3NzQ1N2RhZTlmMTVmMzNjYzU4OGNhL3RhYmxlcmFuZ2U6YmMwNGQ2MGVmNjc3NDU3ZGFlOWYxNWYzM2NjNTg4Y2FfOC00LTEtMS0w_2a92859e-a76e-4fcd-9473-20e8b953ce87"
      unitRef="usd">338000</us-gaap:StockholdersEquity>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjE5OTAyMzI1ODI4Mg_b15b6209-70b3-4c27-abba-c38ab64008f8"
      unitRef="usd">23000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjE5OTAyMzI1ODI5OA_487f4493-d37c-41a1-802e-377fdd6c0482"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF81OC9mcmFnOmIwNmQzNGQzYzk1OTQ4NjRhMGE1MDVlNTBhZTM5ZWUyL3RleHRyZWdpb246YjA2ZDM0ZDNjOTU5NDg2NGEwYTUwNWU1MGFlMzllZTJfMjE5OTAyMzI1ODMwNQ_84ce768c-1bb5-43cb-87a2-143c4be21f2c"
      unitRef="usd">9404000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMzEyMQ_a9d2d7fe-1636-46be-b601-a2f5a73aa29e">Equity-Based Compensation&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Awards that may be awarded under the 2017 Equity Incentive Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 4,600,000 shares, (ii) 5% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board. The Compensation Committee made the determination to increase the share reserve for the 2017 Equity Incentive Plan by 4,382,567 shares, effective January 1, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the aggregate number of equity awards available for grant under the 2017 Equity Incentive Plan was 2,831,213.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inducement Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company granted stock options to purchase up to 600,000 shares of common stock as a material inducement to Brian C. Bock, the Company&#x2019;s Chief Financial Officer, to enter into employment with the Company (the &#x201c;Inducement Grant&#x201d;).  The Inducement Grant, which was made pursuant to a stand-alone nonstatutory stock option agreement (the &#x201c;Inducement Award Agreement&#x201d;), was approved by the Compensation Committee of the Board, was awarded in accordance with Nasdaq Listing Rule 5635(c)(4) and outside of the Company&#x2019;s 2017 Equity Incentive Plan and is subject to the terms and conditions of the Inducement Award Agreement.  As such, any shares underlying the Inducement Grant are not, upon forfeiture, cancellation or expiration, returned to a pool of shares reserved for future issuance.  As of June 30, 2021, stock options to purchase up to 600,000 shares of common stock remained outstanding under the Inducement Grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2017 Employee Stock Purchase Plan (the "ESPP") was adopted by the Board in September 2017 and approved by the Company's stockholders in September 2017. Through the ESPP, eligible employees may authorize payroll deductions of up to 15% of their compensation to purchase common stock. The maximum number of shares that an employee may purchase on any exercise date in an offer period will be the smaller of (i) 7,500 shares or (ii) such number of shares as has a fair market value (determined as of the offering date for such offer period) equal to $25,000 within one calendar year minus the fair market value of any other shares of common stock that are attributed to such calendar year. The purchase price per share at each purchase date is equal to 85% of the lower of (i) the closing market price per share of Exicure common stock on the employee&#x2019;s offering date or (ii) the closing market price per share of Exicure common stock on the exercise date. Each offering period is approximately six-months in duration and the first offering period began on November 16, 2020 and ended on May 14, 2021.  In connection with the end of the first offering period on May 14, 2021, the Company issued 103,096 shares of common stock that were purchased under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2018 and each January 1 thereafter through January 1, 2027, by the least of (i) 300,000 shares; (ii) 0.3% of the outstanding shares of common stock on the last day of the immediately preceding calendar year; or (iii) a lesser number of shares determined by the Board. On January 1, 2021 and 2020, the number of shares of common stock available for issuance under the ESPP increased by 258,207 shares and 262,954 shares, respectively. As of June 30, 2021, there were 1,100,791 shares available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity-based compensation expense is classified in the statements of operations as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized equity-based compensation expense at June&#160;30, 2021 was $8,350, which is expected to be amortized over a weighted-average period of 3.2 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 to 6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 to 6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36% to 1.12%; weighted avg. 1.05%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% to 1.68%; weighted avg. 0.67%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.7% to 83.6%; weighted avg. 82.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.0% to 85.8%; weighted avg. 83.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term is based upon the &#x201c;simplified method&#x201d; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#x201c;simplified method&#x201d; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the underlying common stock and the exercise price for the common stock options granted during the six months ended June 30, 2021 and 2020 are summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Options Granted During Period Ended:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value of Underlying Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price of Common Stock Option&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six months ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.54 to $2.57; weighted avg. $1.88&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.54 to $2.57; weighted avg. $1.88&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.19 to $2.80:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;weighted avg. $1.85&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.19 to $2.80:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;weighted avg. $1.85&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of common stock options granted in the six months ended June 30, 2021 and 2020 was $1.31 and $1.29 per common stock option, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of common stock option activity as of the periods indicated is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,227,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,059,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable - June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,580,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and Expected to Vest -&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,559,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of common stock options exercised during the six months ended June 30, 2021 was $77 and $89, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of restricted stock unit activity of the periods indicated is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.512%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance - June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of restricted stock units is based on the Company&#x2019;s closing stock price at the date of grant. At vesting, each outstanding restricted stock unit will be exchanged for one share of the Company&#x2019;s common stock. The restricted stock units granted during the 2021 period generally vest evenly on a quarterly basis over a period of 4 years in exchange for continued service provided by the restricted stock unit recipient during that vesting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares
      contextRef="id1752c7647ce4804833ba83742c774f7_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMjMy_582c6f50-e91a-4c11-a076-24c7dd686192"
      unitRef="shares">4600000</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares>
    <xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding
      contextRef="i9193c9218d6942f0a9ab8196225ec04e_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMjQ4_1b9dba33-7c4e-4683-8979-47ba219543d6"
      unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding>
    <xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant
      contextRef="i3eade0caa9a9429fb165b07368701d49_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfNTc5_a4df7d54-1d8a-4ac4-82fb-b1488b4796c6"
      unitRef="shares">4382567</xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9193c9218d6942f0a9ab8196225ec04e_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfNzMz_7316af51-f784-44af-ad5f-5130fcee7a51"
      unitRef="shares">2831213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id06b85497bc74266852a0e2b7f0b8df0_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0NDcwMg_7004e28c-6589-4438-987f-c8f0a169b814"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if4945a8246284e3fba84dfd77ee17303_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0NDcxMQ_429bb0c9-5184-4240-92e6-738ab9daa86d"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="ia1a36e8396524c158a00a6f20220e59b_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDYzNw_d904e614-4940-432a-90d1-a975ff2f6727"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="i7d5200a99a654e799a285ca1f6cfe325_D20170901-20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDY0Mg_e6f74473-13e5-47f6-a1b4-ce22aa4475dd"
      unitRef="shares">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount
      contextRef="i7d5200a99a654e799a285ca1f6cfe325_D20170901-20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDY0OQ_2a21dec1-c66b-4536-a17b-afef67ca473c"
      unitRef="usd">25000</xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i7d5200a99a654e799a285ca1f6cfe325_D20170901-20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDY1OA_02f75def-729b-44c4-a6f8-0dd0546cf519"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="i7d5200a99a654e799a285ca1f6cfe325_D20170901-20170930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDY3NA_528fcb4d-9254-4f93-984e-5e9728881c9c">P6M</xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ib2b6abdfb80e4807aa0282b97634d068_D20210514-20210514"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0Mjc3Mg_841aadb5-1775-4618-9d88-8b6aba570b13"
      unitRef="shares">103096</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="ia1a36e8396524c158a00a6f20220e59b_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDY3Ng_d233d44d-d8ae-4246-bf75-dc8c222fd799"
      unitRef="shares">300000</xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i7d5200a99a654e799a285ca1f6cfe325_D20170901-20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDY4NQ_622f0f21-7b3a-40c7-8bf0-3a9dfabc1dd5"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant
      contextRef="ia10057774add4610b1347d547800695d_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDY5MQ_41b9377b-570c-4b23-9f7e-8f77392a0a5f"
      unitRef="shares">258207</xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant>
    <xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant
      contextRef="ib0f12b5a69194c1f8a504c77fc7c66d5_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDcwMg_2a44b1c6-19e4-4bc5-9e1a-30a21462dd79"
      unitRef="shares">262954</xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i30c821c806ac422d901e22a3a99f78f2_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDcxMQ_197433cc-18cc-43ef-b954-b2cdfbdebd6b"
      unitRef="shares">1100791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMzExNA_4505f3ae-3ddb-419f-9d9e-900a00da5913">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity-based compensation expense is classified in the statements of operations as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icb72bd4b57dc4ad591c2fe0e40fe9b13_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMi0xLTEtMS0w_2f63c566-0b6e-4782-b640-cd233aaf202f"
      unitRef="usd">361000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8428d3250e664f26b96cd9f611b3d8a4_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMi0zLTEtMS0w_f5f2cdb8-a8f1-4306-89f4-129ea0e5415a"
      unitRef="usd">203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7e5df1d06e74bd185e7eb2efc4d0d60_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMi01LTEtMS0w_d339225b-0181-4c1d-8681-8f507a90df66"
      unitRef="usd">618000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i30e4b305e726408ea8e78580cff53469_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMi03LTEtMS0w_332880cf-1399-4a83-b23b-98ec26778241"
      unitRef="usd">360000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieb6d556e4e7c410abd113137b073abea_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMy0xLTEtMS0w_dc065304-7c53-45d3-9084-608792f963d4"
      unitRef="usd">403000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0140ea063a1a461d9b7efc35c2a7db94_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMy0zLTEtMS0w_7dd48e27-6302-4d0b-8173-c93424067afd"
      unitRef="usd">341000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib97b67429c7447b8beb926618dc44e33_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMy01LTEtMS0w_52a4a9cc-4bd8-4d45-b168-fb8ce615245b"
      unitRef="usd">663000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2bbc9b612e4f400ea42e7192d40fe224_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfMy03LTEtMS0w_0306bab2-746d-4b20-bf0a-6657c154b4a8"
      unitRef="usd">625000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfNC0xLTEtMS0w_56f43608-c2f6-4328-9b8f-f3b7998ec6f6"
      unitRef="usd">764000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfNC0zLTEtMS0w_bc91ba2e-36ee-41d2-a7cf-d382d1c29b00"
      unitRef="usd">544000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfNC01LTEtMS0w_20514040-0b66-41d5-af9f-df2c4b384738"
      unitRef="usd">1281000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmM4NDk5MTMyM2QwNjQ1YTJiZGFiNTY3ZDZiN2QzNTExL3RhYmxlcmFuZ2U6Yzg0OTkxMzIzZDA2NDVhMmJkYWI1NjdkNmI3ZDM1MTFfNC03LTEtMS0w_af7ed6f4-5039-4857-a491-66478e172388"
      unitRef="usd">985000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfODg4_216c035d-2cd1-4522-9881-07f0dd41d98f"
      unitRef="usd">8350000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfOTYw_c93d9ce8-986d-48e3-b499-da7670428921">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMzEyMw_d874e100-01cb-424c-b2de-6822b8867fea">In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 to 6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 to 6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36% to 1.12%; weighted avg. 1.05%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% to 1.68%; weighted avg. 0.67%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.7% to 83.6%; weighted avg. 82.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.0% to 85.8%; weighted avg. 83.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the underlying common stock and the exercise price for the common stock options granted during the six months ended June 30, 2021 and 2020 are summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Options Granted During Period Ended:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value of Underlying Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price of Common Stock Option&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six months ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.54 to $2.57; weighted avg. $1.88&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.54 to $2.57; weighted avg. $1.88&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.19 to $2.80:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;weighted avg. $1.85&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.19 to $2.80:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;weighted avg. $1.85&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i05ee07b9e1c84d11b1a2bce3808048f7_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMi0xLTEtMS0wL3RleHRyZWdpb246OTM4OGQ4MzczNDQ5NDg1Zjk4NzBkOGU1YjU4OTQwMTBfNA_82187e25-9b69-4a4e-9d66-8a545db6772d">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibb18755d773345cab01251ee868b67a2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMi0xLTEtMS0wL3RleHRyZWdpb246OTM4OGQ4MzczNDQ5NDg1Zjk4NzBkOGU1YjU4OTQwMTBfMTA_4677758e-7af9-42e8-b167-9b05f86951ce">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i80b5550a693944ca96e17fa1695bde69_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMi0zLTEtMS0wL3RleHRyZWdpb246YzEzMjllMmNkNGNhNGE5NWFlMTEwMzAyY2RkZGFlNGRfNA_588dedc2-b5c6-49c7-a5a3-46c749de1c88">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i840e5fd58f7b4defa073941d94fdaf68_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMi0zLTEtMS0wL3RleHRyZWdpb246YzEzMjllMmNkNGNhNGE5NWFlMTEwMzAyY2RkZGFlNGRfMTA_bd439953-5e43-4b23-8b66-a0c619dfca2e">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMy0xLTEtMS0wL3RleHRyZWdpb246YTE5MTJmY2FlM2U5NDY4M2FkNDUyM2M3ZjNmYzM0YmNfNA_1f460247-085d-4bfe-bd41-6c5e9aa74063"
      unitRef="number">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMy0xLTEtMS0wL3RleHRyZWdpb246YTE5MTJmY2FlM2U5NDY4M2FkNDUyM2M3ZjNmYzM0YmNfMTA_2b9c845f-0317-4eb2-98d3-31b5bc43e7f6"
      unitRef="number">0.0112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2062e93925194437bbd0a3795bd3f03a_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMy0xLTEtMS0wL3RleHRyZWdpb246YTE5MTJmY2FlM2U5NDY4M2FkNDUyM2M3ZjNmYzM0YmNfMjg_09629459-41fd-4073-9c93-af49947fdf54"
      unitRef="number">0.0105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMy0zLTEtMS0wL3RleHRyZWdpb246YmFmMDk4ZjRlZjg3NDA4MDg4N2U0ZDFjMjg3ZDVkODBfNA_973b4960-435b-4f4b-bfcc-6d0b66ba0eb0"
      unitRef="number">0.0041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMy0zLTEtMS0wL3RleHRyZWdpb246YmFmMDk4ZjRlZjg3NDA4MDg4N2U0ZDFjMjg3ZDVkODBfMTA_96df73ef-4636-4861-9c08-db5e4fcee1c7"
      unitRef="number">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibb7aa76093ce43189a28a20fdc93f774_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfMy0zLTEtMS0wL3RleHRyZWdpb246YmFmMDk4ZjRlZjg3NDA4MDg4N2U0ZDFjMjg3ZDVkODBfMjg_e43386ec-53fc-4346-92c6-ef98092f794c"
      unitRef="number">0.0067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNC0xLTEtMS0wL3RleHRyZWdpb246OTZjYmRiMzA0NzAxNDE0ODhiYzYyNmExY2E0OTExMzNfNA_b1ff64c7-a591-48c6-a2a2-f399f8e9a07f"
      unitRef="number">0.817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNC0xLTEtMS0wL3RleHRyZWdpb246OTZjYmRiMzA0NzAxNDE0ODhiYzYyNmExY2E0OTExMzNfMTA_ccb88e2c-acfd-49f8-bc91-92e62f7504c5"
      unitRef="number">0.836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNC0xLTEtMS0wL3RleHRyZWdpb246OTZjYmRiMzA0NzAxNDE0ODhiYzYyNmExY2E0OTExMzNfMjg_9ef10085-f724-47f9-94f9-a12047b26d3c"
      unitRef="number">0.826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNC0zLTEtMS0wL3RleHRyZWdpb246YzYwOTAxYWU0ZWJiNGU2ZGEyNTIyZGViMTk0MjNlN2ZfNA_50091ec0-d665-4c42-97df-9a0cb4a84039"
      unitRef="number">0.810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNC0zLTEtMS0wL3RleHRyZWdpb246YzYwOTAxYWU0ZWJiNGU2ZGEyNTIyZGViMTk0MjNlN2ZfMTA_9936c3ea-e200-4f8a-b438-ba60c67a332f"
      unitRef="number">0.858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNC0zLTEtMS0wL3RleHRyZWdpb246YzYwOTAxYWU0ZWJiNGU2ZGEyNTIyZGViMTk0MjNlN2ZfMjg_7fc2b12f-4520-465f-ac67-e6e9211a139e"
      unitRef="number">0.838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNS0xLTEtMS0w_c39cf3ea-2370-4823-a11d-4a638e064683"
      unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNS0zLTEtMS0w_59566fd5-5558-46ed-80cd-a275e2e52724"
      unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNi0xLTEtMS0w_0946b66e-62e9-4061-9b50-a15952711fae"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmNlNzcxMDU3YWQxMTQxZDg4MDQ1OWE1NTRjYThiMDkzL3RhYmxlcmFuZ2U6Y2U3NzEwNTdhZDExNDFkODgwNDU5YTU1NGNhOGIwOTNfNi0zLTEtMS0w_8980808d-54f9-47a8-b07a-c7360aae310a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharePrice
      contextRef="i536ad3a9715049e6b9540b91aeecaf96_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMS0xLTEtMS0wL3RleHRyZWdpb246MTZlMmU1Y2I0MmE3NDRkZGI0ZThjZDAwZTc2YjI1ZTZfNA_f21dd200-a020-4a0f-9a23-169c0bfe069b"
      unitRef="usdPerShare">1.54</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i9fac72b464ac47a9b5b8d5a1d1c209c9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMS0xLTEtMS0wL3RleHRyZWdpb246MTZlMmU1Y2I0MmE3NDRkZGI0ZThjZDAwZTc2YjI1ZTZfMTA_01161126-f2b1-471d-8e69-9f3f16e794a5"
      unitRef="usdPerShare">2.57</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i70f3df893ec74c418b087f907936dff7_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMS0xLTEtMS0wL3RleHRyZWdpb246MTZlMmU1Y2I0MmE3NDRkZGI0ZThjZDAwZTc2YjI1ZTZfMjk_f5d9c010-08b6-414e-ac7e-8ebfea04b61a"
      unitRef="usdPerShare">1.88</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i536ad3a9715049e6b9540b91aeecaf96_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMS0zLTEtMS0wL3RleHRyZWdpb246NTdiMzVjZjBlMzJmNDRmMDkwMDIwYjc4MmFjYmMzOGVfNA_268e3aa1-332a-47e8-a220-46f0297435a0"
      unitRef="usdPerShare">1.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i9fac72b464ac47a9b5b8d5a1d1c209c9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMS0zLTEtMS0wL3RleHRyZWdpb246NTdiMzVjZjBlMzJmNDRmMDkwMDIwYjc4MmFjYmMzOGVfMTA_79c73393-c570-411f-8789-5b5f314a2ae5"
      unitRef="usdPerShare">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i70f3df893ec74c418b087f907936dff7_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMS0zLTEtMS0wL3RleHRyZWdpb246NTdiMzVjZjBlMzJmNDRmMDkwMDIwYjc4MmFjYmMzOGVfMjk_225419c0-71e5-42b4-9553-fdf2535b8c2c"
      unitRef="usdPerShare">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharePrice
      contextRef="i60644eaa534948f49f8d5b8f40af2943_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMi0xLTEtMS0wL3RleHRyZWdpb246MzY1ZmQ5NWI4YjY2NDNhOTliYWJjY2VhMGQwOGYyNGVfNA_9770b231-5ce5-47c4-8945-0d2894bd043f"
      unitRef="usdPerShare">1.19</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i0a7f1be445ab4577a3269d5dc2dd853c_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMi0xLTEtMS0wL3RleHRyZWdpb246MzY1ZmQ5NWI4YjY2NDNhOTliYWJjY2VhMGQwOGYyNGVfMTA_23df3b72-99c5-4f8c-94fc-e597850b25f5"
      unitRef="usdPerShare">2.80</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i18c9158c52b548ed815e6df50eef7fe9_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMi0xLTEtMS0wL3RleHRyZWdpb246MzY1ZmQ5NWI4YjY2NDNhOTliYWJjY2VhMGQwOGYyNGVfMjg_ef14b66d-e825-4187-b58a-cb47c1bda590"
      unitRef="usdPerShare">1.85</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i60644eaa534948f49f8d5b8f40af2943_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMi0zLTEtMS0wL3RleHRyZWdpb246OGUzMTVhMjg4NTA0NGNiMGExNDJiODFkMTU3YWUwNzdfNA_0c772b47-86a6-488b-983e-196a7e14c862"
      unitRef="usdPerShare">1.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i0a7f1be445ab4577a3269d5dc2dd853c_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMi0zLTEtMS0wL3RleHRyZWdpb246OGUzMTVhMjg4NTA0NGNiMGExNDJiODFkMTU3YWUwNzdfMTA_85451fa0-fa9d-4b1f-80dd-2a3b18c066df"
      unitRef="usdPerShare">2.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i18c9158c52b548ed815e6df50eef7fe9_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjNlYmJhNGM5OTVkMDRmZGI5YmRjMWE3ZjA4MGExZGI4L3RhYmxlcmFuZ2U6M2ViYmE0Yzk5NWQwNGZkYjliZGMxYTdmMDgwYTFkYjhfMi0zLTEtMS0wL3RleHRyZWdpb246OGUzMTVhMjg4NTA0NGNiMGExNDJiODFkMTU3YWUwNzdfMjg_91faf8a8-9148-4800-96d1-e07d37356171"
      unitRef="usdPerShare">1.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMjc4Mg_8776db63-f930-469d-b8bd-f3e75e2e4ee4"
      unitRef="usdPerShare">1.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMjc4OQ_5b036048-ea30-4bf8-9c33-45fbeea46519"
      unitRef="usdPerShare">1.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMzExOQ_de2403bc-0c7b-4414-ac2c-d61bfed15127">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of common stock option activity as of the periods indicated is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,227,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,059,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable - June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,580,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and Expected to Vest -&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,559,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMS0xLTEtMS0w_c261b086-6cf6-407b-b67a-0da879d986de"
      unitRef="shares">7227296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMS0zLTEtMS0w_6f35b940-9080-4fc5-972f-1e67018353d2"
      unitRef="usdPerShare">2.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i09b723f0eb514cb19e68b68bef52570d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMS01LTEtMS0w_e8f5b22f-68aa-4c4f-b83e-209fca405ab9">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i6d06eb298aa3490d9159416638a3b58f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMS03LTEtMS0w_73c25c5b-ded9-44e1-abe1-d14f444c6662"
      unitRef="usd">1719000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMi0xLTEtMS0w_102d480a-fbfb-4ee3-a2f9-0d311c1dd1b0"
      unitRef="shares">4270086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMi0zLTEtMS0w_436039a4-3424-4cb4-85f6-90803acec3e1"
      unitRef="usdPerShare">1.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMy0xLTEtMS0w_d508c086-98cc-4d29-9514-b2d719a21bd9"
      unitRef="shares">342246</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfMy0zLTEtMS0w_68fef877-6d70-424e-8261-9e72f25addd9"
      unitRef="usdPerShare">1.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNC0xLTEtMS0w_74fde8ed-52f1-4c4f-b13a-1bcdddb0b8a2"
      unitRef="shares">95702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNC0zLTEtMS0w_08e76162-386c-4a62-8add-0fcc6c225f6a"
      unitRef="usdPerShare">2.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNS0xLTEtMS0w_b87e40b3-9eba-42c4-94d1-1b087d037542"
      unitRef="shares">11059434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNS0zLTEtMS0w_461cf2c4-471d-432b-a544-89c141fd2d41"
      unitRef="usdPerShare">2.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNS01LTEtMS0w_ccf655f9-8434-4822-bc3e-ffc2e948c540">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNS03LTEtMS0w_63197066-9dc5-4f83-983d-946e9b7e31de"
      unitRef="usd">1019000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNi0xLTEtMS0w_dfb86d3a-86e3-4b9b-8d56-96fef6163c69"
      unitRef="shares">4580439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNi0zLTEtMS0w_8a33e1fa-25cd-47df-82b5-e94e9b2db5fe"
      unitRef="usdPerShare">2.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNi01LTEtMS0w_baa414d0-4bd4-48f6-8748-3f721d4bcf28">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNi03LTEtMS0w_ad4d90c6-9056-4b3f-8505-e66fc0007d70"
      unitRef="usd">832000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNy0xLTEtMS0w_fb49454d-fe0b-4f20-b08a-8e32271534dd"
      unitRef="shares">10559034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNy0zLTEtMS0w_0979e54c-d2d1-411a-bbaa-fdda0ab80332"
      unitRef="usdPerShare">2.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNy01LTEtMS0w_2ebd4bcb-54bf-4e47-aeff-a7bd31d419aa">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOmQ4Mzk0NTg4ODNiNzQ1ZGJiYjhkNTMzYTg4ZTc5ZDgxL3RhYmxlcmFuZ2U6ZDgzOTQ1ODg4M2I3NDVkYmJiOGQ1MzNhODhlNzlkODFfNy03LTEtMS0w_ac0f0c8a-4f0e-4f78-aa6d-0d457bf37c66"
      unitRef="usd">1007000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMzAyMg_cfb95faf-aed5-4669-bbfc-390a0ad7ccc5"
      unitRef="usd">77000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMzAyOQ_a9257b43-c7cc-4d9e-a55b-9170ef1b620f"
      unitRef="usd">89000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0MDUxNQ_b9adaafa-66d7-455c-8862-348e650b0200">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of restricted stock unit activity of the periods indicated is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.512%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance - June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i203967655c0047368d301fad6b928214_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjY1NWI1ZTUwNDBlYzQ5NzZhOWMyOGRjZGI3OWIwYTk0L3RhYmxlcmFuZ2U6NjU1YjVlNTA0MGVjNDk3NmE5YzI4ZGNkYjc5YjBhOTRfMS0xLTEtMS03NTM_89c69275-c414-415c-a398-8174c55a31b9"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i203967655c0047368d301fad6b928214_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjY1NWI1ZTUwNDBlYzQ5NzZhOWMyOGRjZGI3OWIwYTk0L3RhYmxlcmFuZ2U6NjU1YjVlNTA0MGVjNDk3NmE5YzI4ZGNkYjc5YjBhOTRfMS0zLTEtMS03NTM_99252ad7-3816-442d-b1fa-a4c80ff91346"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i862f9b0b1702466189729eff0d9d775a_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjY1NWI1ZTUwNDBlYzQ5NzZhOWMyOGRjZGI3OWIwYTk0L3RhYmxlcmFuZ2U6NjU1YjVlNTA0MGVjNDk3NmE5YzI4ZGNkYjc5YjBhOTRfMi0xLTEtMS03NTM_901694d5-6e79-4c3a-bef8-efdb4721c57e"
      unitRef="shares">286000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i862f9b0b1702466189729eff0d9d775a_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjY1NWI1ZTUwNDBlYzQ5NzZhOWMyOGRjZGI3OWIwYTk0L3RhYmxlcmFuZ2U6NjU1YjVlNTA0MGVjNDk3NmE5YzI4ZGNkYjc5YjBhOTRfMi0zLTEtMS03NTM_ef5ba06e-032c-42b9-b1f2-5b0e229dac89"
      unitRef="usdPerShare">1.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i75e9456e863e42c28b31cca8610e356b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjY1NWI1ZTUwNDBlYzQ5NzZhOWMyOGRjZGI3OWIwYTk0L3RhYmxlcmFuZ2U6NjU1YjVlNTA0MGVjNDk3NmE5YzI4ZGNkYjc5YjBhOTRfNS0xLTEtMS03NTM_e32ddf48-04fe-41b0-b7f7-af3254e274ad"
      unitRef="shares">286000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i75e9456e863e42c28b31cca8610e356b_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RhYmxlOjY1NWI1ZTUwNDBlYzQ5NzZhOWMyOGRjZGI3OWIwYTk0L3RhYmxlcmFuZ2U6NjU1YjVlNTA0MGVjNDk3NmE5YzI4ZGNkYjc5YjBhOTRfNS0zLTEtMS03NTM_f5e57458-14e0-4f69-97ac-dda482ae35e9"
      unitRef="usdPerShare">1.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting
      contextRef="i75e9456e863e42c28b31cca8610e356b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0NDcyNA_a693a4f9-46e1-4301-b5cb-67e903fe964f"
      unitRef="shares">1</xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i862f9b0b1702466189729eff0d9d775a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82MS9mcmFnOjI3ZDczM2ExNzZmMzQwMGQ4MDk0MjgwYjhiNzQ2ZjU1L3RleHRyZWdpb246MjdkNzMzYTE3NmYzNDAwZDgwOTQyODBiOGI3NDZmNTVfMTA5OTUxMTY0Mjc2Ng_998ad910-0e60-4127-ab96-b7c8e0caad02">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfNjkx_693b64d1-c20e-4fd9-abe3-cad33eef8a4d">Income TaxesThe Company incurred a pretax loss in each of the three and six months ended June 30, 2021 and 2020, which consists entirely of loss in the United States and resulted in no provision for income tax expense during the periods then ended.  The effective tax rate is 0% in each of the three and six months ended June 30, 2021 and 2020 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMTA5OTUxMTYyODgzNQ_14da7ea9-3b78-4e12-889f-936b10a48d37"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMTA5OTUxMTYyODgzNQ_50abfae5-6d7b-49e7-9c73-a81ce1702aa3"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMTA5OTUxMTYyODgzNQ_8bec2b82-294e-4db3-af8f-07c0e8cf0f3a"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMTA5OTUxMTYyODgzNQ_d77575d9-3b4b-4aec-82a3-2b77de84375b"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMjUy_20801442-374c-4019-805d-787a0c0378ee"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMjUy_30acd878-a6e7-4a76-8bc7-5a4019164468"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMjUy_36f805d0-e78d-44eb-83e5-e4a9042bcd04"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82NC9mcmFnOjY4M2U0NDliMmVkNDRjNGJiMzZiOGJiODc2MTAzMDc4L3RleHRyZWdpb246NjgzZTQ0OWIyZWQ0NGM0YmIzNmI4YmI4NzYxMDMwNzhfMjUy_913fdada-889b-40eb-abb8-d1ed6dea86f5"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RleHRyZWdpb246NmMxYTlhMGE5NWI0NDNkZjg0Y2E5OTkwNjBmMThmN2NfMTE4NA_f35b693f-b919-41dc-9799-ecc91217159b">Loss Per Common ShareBasic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options, restricted stock units, and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods.  Therefore, basic and diluted loss per common share is the same for each of the three and six months ended June 30, 2021 and 2020.&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the computation of loss per common share for the three and six months ended June 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and diluted common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,043,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,174,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,948,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,126,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company&#x2019;s loss per share during that period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,059,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,698,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RleHRyZWdpb246NmMxYTlhMGE5NWI0NDNkZjg0Y2E5OTkwNjBmMThmN2NfMTE4Ng_37d18f17-da7d-46d9-bd14-a80197267f70">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options, restricted stock units, and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RleHRyZWdpb246NmMxYTlhMGE5NWI0NDNkZjg0Y2E5OTkwNjBmMThmN2NfMTE5Nw_73899094-b517-4af6-bf2c-d6084e18b526">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the computation of loss per common share for the three and six months ended June 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and diluted common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,043,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,174,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,948,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,126,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfMi0xLTEtMS0w_926d2483-7834-45e6-969c-fc0366fd80cb"
      unitRef="usd">-14269000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfMi0zLTEtMS0w_49729fed-d4ca-45f9-ad2e-1d11464b4967"
      unitRef="usd">-4311000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfMi01LTEtMS0w_4d61a480-03cf-498e-9b8b-ed7ca6549d96"
      unitRef="usd">-26746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfMi03LTEtMS0w_dcc6919a-b911-412b-8fc7-71a4c34da26b"
      unitRef="usd">-3161000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC0xLTEtMS0w_2f6db7a2-1507-41df-98f0-a894c549efd7"
      unitRef="shares">88043447</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC0xLTEtMS0w_b629d769-b9e0-4d45-8f7e-19830c791fb7"
      unitRef="shares">88043447</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC0zLTEtMS0w_02c6a5a0-0d6a-46db-82c2-361145b846e9"
      unitRef="shares">87174533</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC0zLTEtMS0w_ccf69255-ef43-4f20-bc1d-fc0926a0c226"
      unitRef="shares">87174533</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC01LTEtMS0w_39ffb032-32f1-4fea-9780-49d79d966739"
      unitRef="shares">87948440</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC01LTEtMS0w_8db20d9d-03f8-4013-b238-d1274bb918ba"
      unitRef="shares">87948440</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC03LTEtMS0w_2d93a7c4-6f50-4728-aed0-63ec3ded246a"
      unitRef="shares">87126847</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfNC03LTEtMS0w_9bbc93a0-8e2b-417f-87bb-d2e55df9e214"
      unitRef="shares">87126847</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC0xLTEtMS0w_c0d5220b-dd7f-4906-b060-a5ec7e005c07"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2fe60402682e4c08928d8ad923f74049_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC0xLTEtMS0w_e18ff0cb-4647-4acb-9c7b-c2185a2a449e"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC0zLTEtMS0w_d87720f6-a79f-4bea-ad3e-e44ba94da0e9"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6952699fd1e5404d8c4f3954db2417fc_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC0zLTEtMS0w_eb67c1ac-fb88-433e-baa6-b0594e0eaea7"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC01LTEtMS0w_82957923-196a-4f72-9290-beefa5bb8215"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC01LTEtMS0w_ccfd2cfc-6f59-42af-8df3-f08994cf6ddc"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC03LTEtMS0w_db6e4c83-c068-4252-96e5-7b0d260bb5fc"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4f8f7ad0b6c34cb980cf7824f1e17eb1_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOmRkOTRjZjY5YmEwZjRmZTc4YzRlNmNlMDg1MzY3Y2MyL3RhYmxlcmFuZ2U6ZGQ5NGNmNjliYTBmNGZlNzhjNGU2Y2UwODUzNjdjYzJfOC03LTEtMS0w_f8f5df60-81a8-48f0-b060-a4a3379e712d"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RleHRyZWdpb246NmMxYTlhMGE5NWI0NDNkZjg0Y2E5OTkwNjBmMThmN2NfMTE5MQ_b6cc26d9-65ac-4a1f-bdc6-986354a33262">&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company&#x2019;s loss per share during that period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,059,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,698,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8e5643a3e14a4b2ca2f6576189dc8cce_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOjc4MjZlYjA1ZjcxYjQ0NzhiODc4OTNjOGE3MGFjZmJlL3RhYmxlcmFuZ2U6NzgyNmViMDVmNzFiNDQ3OGI4Nzg5M2M4YTcwYWNmYmVfMi0xLTEtMS0w_e220ed72-f6aa-4735-8e9e-fdd113cc3563"
      unitRef="shares">11059434</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9f67c529634343ec87c7f862a41ec733_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOjc4MjZlYjA1ZjcxYjQ0NzhiODc4OTNjOGE3MGFjZmJlL3RhYmxlcmFuZ2U6NzgyNmViMDVmNzFiNDQ3OGI4Nzg5M2M4YTcwYWNmYmVfMi0zLTEtMS0w_a15c43ee-5e5e-41f5-84d3-d838811a6053"
      unitRef="shares">7698313</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icbfcd4dc60684a77a8e8fff3eb283e9a_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOjc4MjZlYjA1ZjcxYjQ0NzhiODc4OTNjOGE3MGFjZmJlL3RhYmxlcmFuZ2U6NzgyNmViMDVmNzFiNDQ3OGI4Nzg5M2M4YTcwYWNmYmVfMy0xLTEtMS0xMzk0_5f32a8ba-c8ac-4c93-b6e9-d00cfa6a3bab"
      unitRef="shares">286000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i81809ddc049e44b18b81bcffd7f27327_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOjc4MjZlYjA1ZjcxYjQ0NzhiODc4OTNjOGE3MGFjZmJlL3RhYmxlcmFuZ2U6NzgyNmViMDVmNzFiNDQ3OGI4Nzg5M2M4YTcwYWNmYmVfMy0zLTEtMS0xNTM1_b8a6392c-81d1-484e-b834-048e7845e93f"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id968e5bf12ce4186bceeb5caa282ec2b_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOjc4MjZlYjA1ZjcxYjQ0NzhiODc4OTNjOGE3MGFjZmJlL3RhYmxlcmFuZ2U6NzgyNmViMDVmNzFiNDQ3OGI4Nzg5M2M4YTcwYWNmYmVfMy0xLTEtMS0w_434edc78-b44c-416c-9a3e-443421b67492"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9a183f19fdd448bdbb48aafc81f24e29_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF82Ny9mcmFnOjZjMWE5YTBhOTViNDQzZGY4NGNhOTk5MDYwZjE4ZjdjL3RhYmxlOjc4MjZlYjA1ZjcxYjQ0NzhiODc4OTNjOGE3MGFjZmJlL3RhYmxlcmFuZ2U6NzgyNmViMDVmNzFiNDQ3OGI4Nzg5M2M4YTcwYWNmYmVfMy0zLTEtMS0w_511c9c92-23c6-4800-8f1a-d8925daa128d"
      unitRef="shares">413320</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RleHRyZWdpb246NTg4NWVkMGI5ZTc0NGNjZmE1Yjc5NmRkYzc3YWJjMDZfMjc2Nw_ba2cf63a-b938-4071-b28b-095cebcb1112">Fair Value Measurements&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets measured at fair value on a recurring basis as of June&#160;30, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments.  The Company&#x2019;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the Company&#x2019;s common stock warrant liability was $0 and no warrants were outstanding  (refer to Note 8, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for more information). The following is a reconciliation of the Company&#x2019;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.237%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain included in other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RleHRyZWdpb246NTg4NWVkMGI5ZTc0NGNjZmE1Yjc5NmRkYzc3YWJjMDZfMjc2Mw_e2bacfe4-247c-4483-9891-72ba0373360d">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets measured at fair value on a recurring basis as of June&#160;30, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i24f3a6610c3c4fb7a8f3011378ea9e4a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMy0xLTEtMS0w_a5def78b-e376-4f94-81d9-0d29fb13cf83"
      unitRef="usd">30101000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibd0c5a447ff34bbc8d7908d531b56cff_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMy0zLTEtMS0w_3c3aec92-b09b-413b-ab59-7a337ea71f89"
      unitRef="usd">30101000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7dd5b1839e3a4048b28a43a4c4e685d7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMy01LTEtMS0w_82a3eaef-fb51-4e5a-ad9f-771c26251350"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib57710941d894ca1b67a1c5d13d6d090_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMy03LTEtMS0w_96f5ae34-291c-451f-95e9-08af0976d3f8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifefc3417f0d145cea19c531c9a0c8f9e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNi0xLTEtMS0w_b8a9b207-9e81-436c-a04e-644492681c75"
      unitRef="usd">5999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e05ee112bbd483d8bd21004c56c115f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNi0zLTEtMS0w_323263df-c0f4-449a-bfd3-f48a655bbb3d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe496263a9ad417fad626fd81108d45e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNi01LTEtMS0w_482bc5e4-bb7f-4374-b83c-5017745f2179"
      unitRef="usd">5999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica03537b84e847e99bee1a3a67a888b8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNi03LTEtMS0w_ad5bb282-5df6-4cb3-aab6-12734402b847"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if36f90f4916647c996df4392cf9a2961_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNy0xLTEtMS0w_5431e7d7-e466-4e03-852d-46137876b18e"
      unitRef="usd">6213000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7425a3abf5aa493d95862d239425df58_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNy0zLTEtMS0w_9f86b45e-c105-42a4-8a8c-551b1f97d266"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia84bea4dabf04dc0b6316097c19d0d55_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNy01LTEtMS0w_91396fef-cf00-4819-9c13-9da67aed0b66"
      unitRef="usd">6213000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i05d4fc50d3924eab98e6d7e3de7886c3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfNy03LTEtMS0w_9868b76c-602a-4192-991d-931730a7eac2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i815c1749dc334f5aa2f2b3d7ce7325b5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfOS0xLTEtMS0w_f23366df-1900-42d1-93ea-99df4842e1f4"
      unitRef="usd">1260000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae63ab432b644385ad760c25e7bb81a4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfOS0zLTEtMS0w_9cfc7d8b-f256-4900-a8f0-edfad04aa3ad"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1841aafb4eea4763a606cf71ee256faa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfOS01LTEtMS0w_4c8ddad3-2fe6-4d7d-8cd2-1978a5182b06"
      unitRef="usd">1260000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i14e02bfdb4fe4d5c945ef80c6fe4fad3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfOS03LTEtMS0w_581db0e7-cc2d-4657-9daf-504813d7359c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i42f50fb4ed2946899515880a08b3b57b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMTAtMS0xLTEtMA_9cd0e9f2-3e10-4f78-adce-33449d9d1fb3"
      unitRef="usd">43573000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1d7ee51b5b4f4652af15034a165fbf74_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMTAtMy0xLTEtMA_87ed3748-56f5-4f76-a860-7434e64738b9"
      unitRef="usd">30101000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib437b59ac25f4bc78adb0e03658f743d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMTAtNS0xLTEtMA_dadef432-92f2-4c8e-a626-76aedfb5d5fe"
      unitRef="usd">13472000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibfb4a947556c46d38903332f34ab5729_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOjUyOGVmNmRhNGRkYzRiZTI4NTQ0NWM1MjdjNmY1NjVhL3RhYmxlcmFuZ2U6NTI4ZWY2ZGE0ZGRjNGJlMjg1NDQ1YzUyN2M2ZjU2NWFfMTAtNy0xLTEtMA_8b7f3f45-9ed3-4be7-955a-aa8ef0ef0584"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie9ab61d3d42a48659e6eb92b8ae28834_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMy0xLTEtMS0w_8a6aba92-ead0-4cd9-ba49-214a6d61ba11"
      unitRef="usd">24586000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1c3ba902ba2c44f4a67a96f6f613cca1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMy0zLTEtMS0w_16dcfb65-08b8-4445-8d69-a547dff6a10b"
      unitRef="usd">24586000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7875848c586b4375a60e0586a91f2a0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMy01LTEtMS0w_de348248-59cc-43ad-974f-8f2af76e9585"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i91a58f1716064afdb7cb38c53987eb36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMy03LTEtMS0w_c42a9cac-4239-416b-a8d7-fb1a3b9bcbef"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if5292d66c2a14337935384c3078fb0f2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNS0xLTEtMS0w_dad6c466-eafa-4ac9-8254-6e817f04135d"
      unitRef="usd">15991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15097b5bf7ee4089861f0faff5870a28_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNS0zLTEtMS0w_fdab328b-aeb5-4b6f-9691-de978b11ae4c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d0d3d621aa248ffb7a89d07e53fb661_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNS01LTEtMS0w_de74149d-1a76-4091-89bb-b3ec6626b18f"
      unitRef="usd">15991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i264f629b27bd4da3a95c37beb796c031_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNS03LTEtMS0w_5d4e6a9c-321d-49e3-98cb-86d3b36a9b2f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfeb9eea9dbf4b46996f9c206cb93ed9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNi0xLTEtMS0w_d088a853-ad02-428c-ba16-b11e76563eb0"
      unitRef="usd">29296000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7abd43cf3d894cffa0f7cb487206018b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNi0zLTEtMS0w_6f1e4c44-8a11-4379-9221-dd55e0d9a240"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic4e3860c3a63420e9d7641f47962c9cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNi01LTEtMS0w_40ad45f3-59c6-46d2-876d-beb9d683b005"
      unitRef="usd">29296000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i21aac650411b42b8a24485f95cec055b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNi03LTEtMS0w_4d15a6fe-ec20-4ac6-b1e6-d49e332a3cb7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib62061d67fb7462295481dacb0f4878f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNy0xLTEtMS0w_4e5eaa40-89c6-4742-b4af-483feb92df5e"
      unitRef="usd">2253000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8bf7aa4a7c3949849940d3879f239db6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNy0zLTEtMS0w_542e2b4a-bce8-458a-9a82-4ea0a630eaac"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b4abd0dd9174b658c26e0a2fb538250_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNy01LTEtMS0w_2b64f407-727e-4c00-a3e7-326f31bc7580"
      unitRef="usd">2253000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6dd9add5bb4c45a78909b926908a9321_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfNy03LTEtMS0w_da9ed9c0-8ea3-41fe-b16e-55ae95b34964"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1da4f481fa0f4d07a5cf47234b82b9fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOC0xLTEtMS0w_5488a9b1-2ff7-4767-874b-06ed161e9bb5"
      unitRef="usd">1278000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i12a40373542a452085cc5d600a78424a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOC0zLTEtMS0w_1f96723a-ca95-4393-b173-ed0718d629b8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icbc3e793a60d4e38acabd4ccbf7e7571_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOC01LTEtMS0w_1ce4515e-ae89-4ba9-b287-853d62e6606a"
      unitRef="usd">1278000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3949b66929b4496bb22e8f8f15df1a0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOC03LTEtMS0w_0f55a004-d050-4923-a50d-bcc9cfcf1534"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibce5fd94c3494f099a9ee39d5d778059_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOS0xLTEtMS0w_70a27d18-fb52-47f9-932d-bb04b2ea9fff"
      unitRef="usd">73404000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i13bc69c967ce4483838129c6d0a0b70b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOS0zLTEtMS0w_1383a220-dbac-4758-adbc-9d002aa9dad1"
      unitRef="usd">24586000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i67b1b75f0b614cad8c61db673b402bc1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOS01LTEtMS0w_3982ed8e-6f37-46aa-a3f6-a601c4ee8130"
      unitRef="usd">48818000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib4ad8ee44ca14f698e0bcfb629608444_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfOS03LTEtMS0w_1c002051-c5e8-4a28-8797-119951dec8d3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="ibce5fd94c3494f099a9ee39d5d778059_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTItMS0xLTEtMA_9ee60193-ff3a-4c87-a128-45e75ff1ee1c"
      unitRef="usd">15000</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="i13bc69c967ce4483838129c6d0a0b70b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTItMy0xLTEtMA_d6b835a6-ba5a-4a99-b992-999a368e3cea"
      unitRef="usd">0</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="i67b1b75f0b614cad8c61db673b402bc1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTItNS0xLTEtMA_a9f26ad2-01db-40ef-bf70-970fddb4af5c"
      unitRef="usd">0</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="ib4ad8ee44ca14f698e0bcfb629608444_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTItNy0xLTEtMA_3dcf27f8-bcee-4e65-aee3-af25da788901"
      unitRef="usd">15000</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ibce5fd94c3494f099a9ee39d5d778059_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTMtMS0xLTEtMA_fd67aec9-1d22-4ffa-b19c-e0bccab7b3d7"
      unitRef="usd">15000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i13bc69c967ce4483838129c6d0a0b70b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTMtMy0xLTEtMA_049c3524-b469-4cee-b617-096c3f3fb53a"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i67b1b75f0b614cad8c61db673b402bc1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTMtNS0xLTEtMA_240d057d-b347-4caf-b29a-86e8e96c6ee4"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ib4ad8ee44ca14f698e0bcfb629608444_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU2ZjRiMzk1NTliMzQyYWViMTU2NGNhMjkyYjFhNGI1L3RhYmxlcmFuZ2U6ZTZmNGIzOTU1OWIzNDJhZWIxNTY0Y2EyOTJiMWE0YjVfMTMtNy0xLTEtMA_fb88e1d9-cab4-4860-b332-82f6a1b3e5e8"
      unitRef="usd">15000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i6ff17028d7f742fc86b80a80958beb1c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RleHRyZWdpb246NTg4NWVkMGI5ZTc0NGNjZmE1Yjc5NmRkYzc3YWJjMDZfMjc0ODc3OTA3MzYxNQ_024b5121-1500-4f7d-8ef0-7adffe7f6171"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i6ff17028d7f742fc86b80a80958beb1c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RleHRyZWdpb246NTg4NWVkMGI5ZTc0NGNjZmE1Yjc5NmRkYzc3YWJjMDZfMjc0ODc3OTA3MzI1OQ_55b9f407-7da0-40f3-990f-a03fe699245b"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RleHRyZWdpb246NTg4NWVkMGI5ZTc0NGNjZmE1Yjc5NmRkYzc3YWJjMDZfMjc3MQ_5d59377d-32b6-4ffa-b191-bef98e79162d">The following is a reconciliation of the Company&#x2019;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended June&#160;30, 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.237%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain included in other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i89a31a873b4345549a9b1b9489d5fcda_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU4ZTczZjgyYmI1ZjRmYmQ5MGZlODU4ZjcwMTA0ZDFhL3RhYmxlcmFuZ2U6ZThlNzNmODJiYjVmNGZiZDkwZmU4NThmNzAxMDRkMWFfMi0xLTEtMS0w_bcee3c76-e557-47f8-8bc1-1dfcdf50cd1d"
      unitRef="usd">15000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="iaf6b894493654106958401b815661301_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU4ZTczZjgyYmI1ZjRmYmQ5MGZlODU4ZjcwMTA0ZDFhL3RhYmxlcmFuZ2U6ZThlNzNmODJiYjVmNGZiZDkwZmU4NThmNzAxMDRkMWFfMy0xLTEtMS0w_d482a326-44b2-4412-8591-abb8fbfdbb7b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iaf6b894493654106958401b815661301_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU4ZTczZjgyYmI1ZjRmYmQ5MGZlODU4ZjcwMTA0ZDFhL3RhYmxlcmFuZ2U6ZThlNzNmODJiYjVmNGZiZDkwZmU4NThmNzAxMDRkMWFfNC0xLTEtMS0w_be5d6382-f9cf-43ac-a4ec-f9934543bef8"
      unitRef="usd">15000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i075d22f912e34ce8b799f56c4e6c8bff_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83MC9mcmFnOjU4ODVlZDBiOWU3NDRjY2ZhNWI3OTZkZGM3N2FiYzA2L3RhYmxlOmU4ZTczZjgyYmI1ZjRmYmQ5MGZlODU4ZjcwMTA0ZDFhL3RhYmxlcmFuZ2U6ZThlNzNmODJiYjVmNGZiZDkwZmU4NThmNzAxMDRkMWFfNS0xLTEtMS0w_dc289c9b-74fe-476e-a9f3-ed7c4cb99d8f"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83My9mcmFnOjE4ODk0YzdiMzA0MDQxYzU4YTAwNjJmZmIxMzhjNjBiL3RleHRyZWdpb246MTg4OTRjN2IzMDQwNDFjNThhMDA2MmZmYjEzOGM2MGJfMjgyNg_030ed432-03c7-496f-a346-04b8602c1e18">Commitments and Contingencies&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 7,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for a discussion of the commitments associated with the Company&#x2019;s lease agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Northwestern University License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 12, 2011, (1) AuraSense, LLC, the Company&#x2019;s former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#x2019;s 2009 license agreement with Northwestern University (&#x201c;NU&#x201d;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs &lt;/span&gt;&lt;/div&gt;as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#x201c;assigned field&#x201d;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#x2019;s sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#x2019;s sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company.  In August 2015, the Company entered into a restated license agreement with NU (the &#x201c;Restated License Agreement&#x201d;). In February 2016, the Company obtained exclusive license as to NU&#x2019;s rights in certain SNA technology it jointly owns with NU (the &#x201c;Co-owned Technology License&#x201d;). The Company&#x2019;s license to NU&#x2019;s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. In June 2016, the Company entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#x201c;Wound Healing License&#x201d;). The Company&#x2019;s rights and obligations in the Co-owned Technology License and the Wound Healing License agreements&#160;are substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as &#x201c;the Northwestern University License Agreements&#x201d;).  All pending patent applications under the Wound Healing License have been abandoned and the Wound Healing License has been terminated.  As of June&#160;30, 2021, the Company has paid to NU an aggregate of $8,361 in consideration of each of the obligations described above.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <xcur:AggregatePaymentsMadeToDateForLicenseAgreements
      contextRef="i9c650a633a1f4de4a05ddb4eab7dad76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83My9mcmFnOjE4ODk0YzdiMzA0MDQxYzU4YTAwNjJmZmIxMzhjNjBiL3RleHRyZWdpb246MTg4OTRjN2IzMDQwNDFjNThhMDA2MmZmYjEzOGM2MGJfMjc2Mw_484c6c95-abc3-4119-920e-8a50b993ec41"
      unitRef="usd">8361000</xcur:AggregatePaymentsMadeToDateForLicenseAgreements>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83Ni9mcmFnOjEyNjBjYjYyMGI0ODRjMTZhMWNmOTRkZmMyMjRjYWNiL3RleHRyZWdpb246MTI2MGNiNjIwYjQ4NGMxNmExY2Y5NGRmYzIyNGNhY2JfNDQz_e0daaa15-052f-46c4-b209-7cedb0e9b47b">Related-Party TransactionsThe Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but, through April 30, 2021, served as a member of the Board. The Company recognized $50 as an expense in each of the six months ended June&#160;30, 2021 and 2020 in connection with these consulting services in the accompanying unaudited condensed consolidated statement of operations.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i9894ed94822f44a1b4e2a85180b8d226_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83Ni9mcmFnOjEyNjBjYjYyMGI0ODRjMTZhMWNmOTRkZmMyMjRjYWNiL3RleHRyZWdpb246MTI2MGNiNjIwYjQ4NGMxNmExY2Y5NGRmYzIyNGNhY2JfMjE5OTAyMzI1NjAxMw_8ed428af-b6ae-425d-823c-63a54e7d21c2"
      unitRef="usd">50000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i0304e7ef793b4159a6bfef1cd8f203bf_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF83Ni9mcmFnOjEyNjBjYjYyMGI0ODRjMTZhMWNmOTRkZmMyMjRjYWNiL3RleHRyZWdpb246MTI2MGNiNjIwYjQ4NGMxNmExY2Y5NGRmYzIyNGNhY2JfMjE5OTAyMzI1NjAxMw_df9442a8-eaab-4cb0-a690-07b79a2663fe"
      unitRef="usd">50000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8xMDk5NTExNjQxNzQw_bf86206c-e2fc-4416-b68c-5d6ac162d393">Subsequent Events&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated subsequent events which may require adjustment to or disclosure in the accompanying unaudited condensed consolidated financial statements and has concluded that there are no subsequent events or transactions that occurred subsequent to the balance sheet date that would require recognition or disclosure in the accompanying unaudited condensed consolidated financial statements, except as noted below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ipsen Collaboration, License, and Option Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30, 2021, the Company entered into a Collaboration, Option and License Agreement (the &#x201c;Ipsen Collaboration Agreement&#x201d;) with IPSEN BIOPHARM LIMITED (&#x201c;Ipsen&#x201d;). Pursuant to the Ipsen Collaboration Agreement, the Company granted to Ipsen exclusive access and options to license SNA based therapeutics arising from two collaboration programs related to the treatment of Huntington&#x2019;s disease and Angelman syndrome, respectively. Each such license would grant to Ipsen exclusive, royalty-bearing, sublicensable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Upon written notice to the Company, Ipsen may exercise its option during the corresponding collaboration program&#x2019;s applicable option exercise period, (each, an &#x201c;Option Exercise Period&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under the terms of the Ipsen Collaboration Agreement, the Company will conduct discovery and development in two collaboration programs for Huntington&#x2019;s disease and Angelman syndrome. The Company shall be solely responsible for all costs and expenses of conducting each collaboration program through the selection of SNA therapeutic candidates for further development (&#x201c;Selection&#x201d;), and Ipsen shall be responsible for all costs and expenses of all additional activities that are necessary to enable the first filing of an investigational new drug application (&#x201c;IND&#x201d;) for each proposed product candidate. In the event that Ipsen exercises an option, Ipsen will be &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;responsible for further development from the license effective date and commercialization of the corresponding licensed product. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Ipsen Collaboration Agreement, the Company will receive an upfront payment of $20,000 (the &#x201c;Ipsen Upfront Payment&#x201d;), and, depending on the timing when Ipsen exercises its option right in a collaboration program, Ipsen will pay to the Company an option exercise fee equal to $10,000 (if exercised within the Option Exercise Period after the Selection) or $25,000 (if exercised within the Option Exercise Period that begins after the first Option Exercise Period and ends after IND filing) for each collaboration program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ipsen will pay a pre-clinical milestone of $5,000 for each collaboration program upon achievement of such milestone regardless of whether an option is exercised.  In addition to the option exercise fees and the pre-clinical milestones described above, if Ipsen exercises an option for a program, development and regulatory milestones will be payable for that program upon the initiation of certain clinical trials, and the filing for processing by the FDA in the United States and by 2 additional regulators outside the United States of a marketing application for review, per program, with an aggregate total of up to $180,000 if both options are exercised. Commercial milestones will be payable for that program upon first commercial sale of a licensed product in certain jurisdictions and the achievement of specified aggregate sales thresholds for all licensed products from that program, with an aggregate total of up to $762,000 if both options are exercised. In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company is eligible to receive tiered royalties at percentages ranging from the mid-single digits to the mid-teens on future net product sales of such commercialized therapeutic candidates. A percentage of the aforementioned payments will be due to NU upon receipt, pursuant to the terms of the Company&#x2019;s existing license agreements with NU (see Note 13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitment and Contingencies,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information on the Northwestern University License Agreements).  In connection with the receipt of the Ipsen Upfront Payment, the Company will incur $3,000 in license fees payable to NU under the terms of the Northwestern License Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Ipsen Collaboration Agreement will remain in effect, unless earlier terminated, until (a) the expiration of the later-to-expire option exercise period, if Ipsen does not exercise either option, or (b) the expiration of the last-to-expire royalty term for any licensed product in such country on a licensed product-by-licensed product and country-by-country basis, if Ipsen exercises one or both options. Upon expiration of the royalty term with respect to a particular licensed product in a country, the license for such product in such country will convert to a fully-paid, irrevocable and perpetual license. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Ipsen Collaboration Agreement also contains customary provisions for termination by either party, including in the event of breach of the Ipsen Collaboration Agreement, subject to cure, and by the Company upon a challenge of the licensed patents, subject, in certain cases, to customary reversion rights. Upon termination of the Ipsen Collaboration Agreement by the Company for Ipsen&#x2019;s breach or bankruptcy, all licenses granted by the Company to Ipsen will terminate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Ipsen Collaboration Agreement includes customary representations and warranties on behalf of both the Company and Ipsen. The Ipsen Collaboration Agreement also provides for customary mutual indemnities.  In addition, the Ipsen Collaboration Agreement imposes certain exclusivity obligations on Ipsen and the Company, respectively, with respect to the development, use, manufacture and commercialization of oligonucleotide-based therapeutic targeting the same targets in the collaboration programs and/or certain other specific targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Either party may assign the Ipsen Collaboration Agreement or delegate its obligations to an affiliate or to a successor to substantially all of the business to which the Ipsen Collaboration Agreement relates without the consent of the other party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the entry into the Ipsen Collaboration Agreement, the Company, Ipsen and NU entered into a side letter to the Northwestern University License Agreements (the &#x201c;Side Letter&#x201d;). Pursuant to the Side Letter, the parties thereto clarified certain provisions of the Northwestern University License Agreements as they apply to the sublicenses granted to Ipsen pursuant to the Ipsen Collaboration Agreement, including providing for the survival of Ipsen&#x2019;s sublicense to the applicable NU intellectual property rights should the Northwestern University License &lt;/span&gt;&lt;/div&gt;Agreements terminate or if the Company&#x2019;s licenses to such intellectual property rights are rendered non-exclusive in accordance with the Northwestern University License Agreements (other than as a result of an act or omission on the part of Ipsen or any of its Affiliates or sublicensees). Additionally, the Side Letter clarified Ipsen&#x2019;s rights to grant further sublicenses under such intellectual property rights granted to the Company pursuant to the Northwestern University License Agreements.</us-gaap:SubsequentEventsTextBlock>
    <xcur:NumberofCollaborationPrograms
      contextRef="i766b5dbdd23d432ebc0191ac53b18fac_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8xMDk5NTExNjQ0MzQz_a3b7fa66-1b07-4223-87a8-14dd041b137d"
      unitRef="agreement">2</xcur:NumberofCollaborationPrograms>
    <xcur:NumberofCollaborationPrograms
      contextRef="i766b5dbdd23d432ebc0191ac53b18fac_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8xMDk5NTExNjQ0MzUx_a3b7fa66-1b07-4223-87a8-14dd041b137d"
      unitRef="agreement">2</xcur:NumberofCollaborationPrograms>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="i766b5dbdd23d432ebc0191ac53b18fac_D20210730-20210730"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8yMTk5MDIzMjY5NDE1_3f9f74ba-46eb-4909-aa4b-e572aac7284d"
      unitRef="usd">20000000</xcur:CollaborationAgreementUpfrontPayment>
    <xcur:CollaborationAgreementOptionExerciseFee
      contextRef="i902680175ed94d4c9937aba91e427308_D20210730-20210730"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8yMTk5MDIzMjY5NDMy_5713e262-13a8-421d-a4d6-8be07e6696d5"
      unitRef="usd">10000000</xcur:CollaborationAgreementOptionExerciseFee>
    <xcur:CollaborationAgreementOptionExerciseFee
      contextRef="i3058801971a44b62b1abb284fe077eef_D20210730-20210730"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8yMTk5MDIzMjY5NDYz_a72d782d-4110-4c24-ab12-210264b5627c"
      unitRef="usd">25000000</xcur:CollaborationAgreementOptionExerciseFee>
    <xcur:RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment
      contextRef="i3c4f363adac940e3bca3d807b358d686_I20210730"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8yMTk5MDIzMjY5NDQ4_10d9a16e-6e62-4192-8df1-8fc29d12d79b"
      unitRef="usd">5000000</xcur:RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment>
    <xcur:RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment
      contextRef="i3c4f363adac940e3bca3d807b358d686_I20210730"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8yMTk5MDIzMjY5NDc5_474795d9-a795-4174-83df-2dcb2ff2db8b"
      unitRef="usd">180000000</xcur:RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment>
    <xcur:RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment
      contextRef="i3c4f363adac940e3bca3d807b358d686_I20210730"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8yMTk5MDIzMjY5NDk2_646fb6e3-b117-4665-a4f1-71a30e02b514"
      unitRef="usd">762000000</xcur:RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment>
    <xcur:CollaborationAgreementLicensingFeesIncurred
      contextRef="i766b5dbdd23d432ebc0191ac53b18fac_D20210730-20210730"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0OTExMmRhZGNlMTRiZTY4MzY5MzdjMWE4Nzc5ZGFkL3NlYzphNDkxMTJkYWRjZTE0YmU2ODM2OTM3YzFhODc3OWRhZF8xMjE0L2ZyYWc6MzI2YjllYTkwZTU1NDVmOWE3YzRiZDBhNTNkMjNmYzQvdGV4dHJlZ2lvbjozMjZiOWVhOTBlNTU0NWY5YTdjNGJkMGE1M2QyM2ZjNF8xNjQ5MjY3NDU2MDEx_e95d0ff6-de12-4210-b012-0191c4d26f8d"
      unitRef="usd">3000000</xcur:CollaborationAgreementLicensingFeesIncurred>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859198551560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXICURE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-5333008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2430 N. Halsted St.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chicago<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(847)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">673-1700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XCUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,108,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001698530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859280905416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 42,587<span></span>
</td>
<td class="nump">$ 33,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">13,472<span></span>
</td>
<td class="nump">48,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">4,588<span></span>
</td>
<td class="nump">4,231<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">60,647<span></span>
</td>
<td class="nump">86,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,102<span></span>
</td>
<td class="nump">4,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">8,281<span></span>
</td>
<td class="nump">8,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">74,467<span></span>
</td>
<td class="nump">100,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">1,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,228<span></span>
</td>
<td class="nump">3,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">7,267<span></span>
</td>
<td class="nump">8,343<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,745<span></span>
</td>
<td class="nump">13,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">16,730<span></span>
</td>
<td class="nump">16,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, noncurrent</a></td>
<td class="nump">7,696<span></span>
</td>
<td class="nump">7,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">37,827<span></span>
</td>
<td class="nump">38,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, June&#160;30, 2021 and December&#160;31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 88,096,694 issued and outstanding, June&#160;30, 2021; 87,651,352 issued and outstanding, December&#160;31, 2020</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">169,337<span></span>
</td>
<td class="nump">167,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(132,711)<span></span>
</td>
<td class="num">(105,965)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">36,640<span></span>
</td>
<td class="nump">61,506<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 74,467<span></span>
</td>
<td class="nump">$ 100,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859204051832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">88,096,694<span></span>
</td>
<td class="nump">87,651,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">88,096,694<span></span>
</td>
<td class="nump">87,651,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859200406712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="nump">$ 4,847,000<span></span>
</td>
<td class="nump">$ 1,076,000<span></span>
</td>
<td class="nump">$ 14,030,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">79,000<span></span>
</td>
<td class="nump">4,847,000<span></span>
</td>
<td class="nump">1,076,000<span></span>
</td>
<td class="nump">14,030,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">10,843,000<span></span>
</td>
<td class="nump">7,008,000<span></span>
</td>
<td class="nump">21,105,000<span></span>
</td>
<td class="nump">13,083,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">3,098,000<span></span>
</td>
<td class="nump">2,229,000<span></span>
</td>
<td class="nump">5,990,000<span></span>
</td>
<td class="nump">4,803,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">13,941,000<span></span>
</td>
<td class="nump">9,237,000<span></span>
</td>
<td class="nump">27,095,000<span></span>
</td>
<td class="nump">17,886,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(13,862,000)<span></span>
</td>
<td class="num">(4,390,000)<span></span>
</td>
<td class="num">(26,019,000)<span></span>
</td>
<td class="num">(3,856,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
<td class="nump">131,000<span></span>
</td>
<td class="nump">627,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(450,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(859,000)<span></span>
</td>
<td class="num">(128,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(192,000)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="nump">153,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(407,000)<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
<td class="num">(727,000)<span></span>
</td>
<td class="nump">695,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before provision for income taxes</a></td>
<td class="num">(14,269,000)<span></span>
</td>
<td class="num">(4,311,000)<span></span>
</td>
<td class="num">(26,746,000)<span></span>
</td>
<td class="num">(3,161,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,269,000)<span></span>
</td>
<td class="num">$ (4,311,000)<span></span>
</td>
<td class="num">$ (26,746,000)<span></span>
</td>
<td class="num">$ (3,161,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (loss) earnings per common share (USD per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (loss) earnings per common share (USD per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic common shares outstanding (in shares)</a></td>
<td class="nump">88,043,447<span></span>
</td>
<td class="nump">87,174,533<span></span>
</td>
<td class="nump">87,948,440<span></span>
</td>
<td class="nump">87,126,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">88,043,447<span></span>
</td>
<td class="nump">87,174,533<span></span>
</td>
<td class="nump">87,948,440<span></span>
</td>
<td class="nump">87,126,847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859204278328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,269)<span></span>
</td>
<td class="num">$ (4,311)<span></span>
</td>
<td class="num">$ (26,746)<span></span>
</td>
<td class="num">$ (3,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income, net of taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (losses) gains on available for sale securities, net of tax</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (14,296)<span></span>
</td>
<td class="num">$ (3,956)<span></span>
</td>
<td class="num">$ (26,824)<span></span>
</td>
<td class="num">$ (2,796)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859204240888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in- Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,069,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 80,747<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 162,062<span></span>
</td>
<td class="num">$ (81,297)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,081,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">2,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,150,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">85,114<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">165,269<span></span>
</td>
<td class="num">(80,147)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,069,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">80,747<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">162,062<span></span>
</td>
<td class="num">(81,297)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,206,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">81,752<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">165,863<span></span>
</td>
<td class="num">(84,458)<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,150,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">85,114<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">165,269<span></span>
</td>
<td class="num">(80,147)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,206,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">81,752<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">165,863<span></span>
</td>
<td class="num">(84,458)<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,651,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">61,506<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">167,379<span></span>
</td>
<td class="num">(105,965)<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,993,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">50,041<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">168,442<span></span>
</td>
<td class="num">(118,442)<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,651,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 61,506<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">167,379<span></span>
</td>
<td class="num">(105,965)<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="nump">342,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">$ (78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,096,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">36,640<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">169,337<span></span>
</td>
<td class="num">(132,711)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,993,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">50,041<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">168,442<span></span>
</td>
<td class="num">(118,442)<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock-ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock-ESPP</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,269)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,269)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,096,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 36,640<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 169,337<span></span>
</td>
<td class="num">$ (132,711)<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859198683544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,746)<span></span>
</td>
<td class="num">$ (3,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">1,281<span></span>
</td>
<td class="nump">985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of long-term debt issuance costs and fees</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of investments</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(357)<span></span>
</td>
<td class="num">(1,646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(1,034)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(280)<span></span>
</td>
<td class="num">(647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,076)<span></span>
</td>
<td class="num">(13,949)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(263)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(25,885)<span></span>
</td>
<td class="num">(18,814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale securities</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(38,072)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sale or maturity of available for sale securities</a></td>
<td class="nump">37,097<span></span>
</td>
<td class="nump">32,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(564)<span></span>
</td>
<td class="num">(2,996)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">34,533<span></span>
</td>
<td class="num">(8,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PaymentsOfCommonStockFinancingCosts', window );">Payment of common stock financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of long-term debt fees and issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,999)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of employee stock purchase plan</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">677<span></span>
</td>
<td class="num">(2,283)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">9,325<span></span>
</td>
<td class="num">(30,062)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash - beginning of period</a></td>
<td class="nump">34,462<span></span>
</td>
<td class="nump">48,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash - end of period</a></td>
<td class="nump">43,787<span></span>
</td>
<td class="nump">18,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures (accounts payable and accrued expenses)</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PaymentsOfCommonStockFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Common Stock Financing Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PaymentsOfCommonStockFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859202772056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 42,587<span></span>
</td>
<td class="nump">$ 33,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash included in other noncurrent assets</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows</a></td>
<td class="nump">$ 43,787<span></span>
</td>
<td class="nump">$ 34,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859196497944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text">Description of Business and Basis of Presentation<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exicure, Inc. (the &#8220;Company&#8221;) is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases, and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA&#8482;, technology. The Company believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. The Company is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNA-based therapeutic candidate, for the intrathecal treatment of Friedreich&#8217;s ataxia (FA).  The Company&#8217;s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes one of the key strengths of its proprietary SNAs is that they have the potential for increased cellular uptake compared to conventional linear oligonucleotides and as a result the potential to achieve higher efficacy at the same doses of oligonucleotide administered. The Company has shown in clinical and preclinical studies that SNAs may have therapeutic potential in immuno-oncology and dermatology.  In addition, the Company has shown in preclinical studies that SNAs may have therapeutic potential in neurology, ophthalmology, pulmonology, and gastroenterology. Accordingly, the Company has expanded its pipeline into neurology, for which IND-enabling activities are ongoing for XCUR-FXN, and is concluding early stage research activities in ophthalmology, pulmonology, and gastroenterology. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout these unaudited condensed consolidated financial statements, the terms the &#8220;Company&#8221; and &#8220;Exicure&#8221; refer to Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets and conducts all business activities and operations of Exicure, Inc.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements as of June&#160;30, 2021 and December 31, 2020, and for the six months ended June&#160;30, 2021 and 2020, have been presented in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, revenue for the three and six months ended June 30, 2021 reflects events and conditions that occurred during that period that increased the number of hours estimated to be required to complete the services under the AbbVie Collaboration Agreement. These increased estimated efforts resulted in less progress occurring relative to the increased estimate of total projected hours to complete the research services (and thus limited revenue recognized) during the three and six months ended June 30, 2021 and compared to the amount of revenue recognized in the comparable periods.  Due to uncertainties inherent in the estimation process, it is at least reasonably possible that estimated efforts required to complete the research services under the AbbVie Collaboration Agreement will be further revised in the near-term.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Risks and Uncertainties</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the ongoing COVID-19 pandemic, the Company has taken and continues to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on its business, such as remote working policies, facilitating management&#8217;s routine communication to address employee and business concerns and providing frequent updates to the Company&#8217;s board of directors (the &#8220;Board&#8221;).  During the second quarter of 2021 and through the date of this report, the Company continues to operate under COVID-19 social distancing guidelines and has generally operated with approximately 100% of its R&amp;D staff on-site.  The Company&#8217;s office and general and administrative team is also working on-site approximately 50% of the time. The Company&#8217;s preclinical development program in Friedreich&#8217;s ataxia (&#8220;FA&#8221;) is ongoing and it began IND-enabling studies for XCUR-FXN in late 2020.  The Company also continues to progress its collaborations with AbbVie Inc. (&#8220;AbbVie&#8221;).  However, if the COVID-19 pandemic continues to persist for an extended period of time, the Company could experience further significant disruptions to its clinical and preclinical development timelines, which would adversely affect its business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company believes that the effects of the COVID-19 pandemic or its impact contributed to delays during the second half of 2020 and the first half of 2021 in its enrollment plans and clinical trial site start-ups for the Phase 2 dose expansion phase of the Phase 1b/2 clinical trial for its cavrotolimod (AST-008) clinical program.  The Company has taken additional measures to increase the enrollment of patients, including frequent interaction with its clinical trial sites currently open as well as increasing the number of clinical trial sites that potentially are activated for this trial so that the Company may continue to enroll patients as initially planned.  However, any additional delays may require the Company to further lengthen its clinical development timeline for cavrotolimod (AST-008).  Pending further enrollment delays or any unanticipated effects of the COVID-19 pandemic on our clinical development plans, the Company expects to report overall response rate, or ORR, results in the first half of 2022. The extent to which the COVID-19 pandemic or its impact or effects may continue to impact the Company&#8217;s business, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration or spread of the pandemic, its impact and effects, the possibility of additional periods of increases or spikes in the number of COVID-19 cases, travel restrictions, quarantines, social distancing, phased re-openings and business closure requirements in the United States and other countries, and the effectiveness of actions taken globally to contain and treat the disease including, without limitation, the effectiveness and timing of vaccination initiatives in the United States and worldwide.  The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biotechnology industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and the challenges of complying with applicable regulatory requirements.  In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company has generated an accumulated deficit of $151,548 since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&#8217;s current operating plans, it believes that existing working capital at June&#160;30, 2021, including the $20,000 upfront payment received in August 2021 in connection with the Ipsen Collaboration Agreement (see Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and amounts borrowed and available under the MidCap Credit Facility (see Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), is sufficient to fund the Company&#8217;s current plans for at least the next 12 months from the date these financial statements were issued.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, such as its &#8220;at the market offering&#8221; program pursuant to its equity distribution agreement with BMO Capital Markets Corp., to fund its current operations and business strategy. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company.  The Company has historically principally raised capital through the sale of its securities.  However, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  If the disruption continues to persist and deepens, the Company could experience an inability to access additional capital, which could in the future negatively affect its ability to raise capital and ultimately, its operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated balance sheet as of June&#160;30, 2021, the interim condensed consolidated statements of operations for the three and six months ended June&#160;30, 2021 and 2020, the interim condensed consolidated statements of comprehensive (loss) income for the three and six months ended June&#160;30, 2021 and 2020, the interim condensed consolidated statements of changes in stockholders&#8217; equity for the three and six months ended June&#160;30, 2021 and 2020, and the interim condensed consolidated statements of cash flows for the six months ended June&#160;30, 2021 and 2020, are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&#8217;s financial position as of June&#160;30, 2021, the results of its operations for the three and six months ended June&#160;30, 2021 and 2020, and the results of its cash flows for the six months ended June&#160;30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and six months ended June&#160;30, 2021 and 2020 are unaudited. The results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2021, or any other interim periods, or any future year or period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859198529528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 11, 2021. Since the date of those audited consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#8212;Effective Dates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#8220;smaller reporting companies&#8221; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859196514872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and License Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Research and License Agreements</a></td>
<td class="text">Collaborative Research and License Agreements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Collaboration Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2019 (the &#8220;Effective Date&#8221;), the Company entered into a Collaboration, Option and License Agreement (the &#8220;AbbVie Collaboration Agreement&#8221;), with a wholly-owned subsidiary of Allergan plc, Allergan. On May 8, 2020, Allergan plc, including Allergan was acquired by AbbVie. Pursuant to the AbbVie Collaboration Agreement, the Company granted to AbbVie exclusive access and options to license SNA based therapeutics arising from two collaboration programs related to the treatment of hair loss disorders (each, a &#8220;Collaboration Program&#8221;). Under each such license (obtained in connection with the exercise of an Option, as defined and discussed further below), the Company would grant to AbbVie exclusive, royalty-bearing, sublicensable, nontransferable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Under the AbbVie Collaboration Agreement, the Company will use commercially reasonable efforts to conduct two Collaboration Programs, each focused on one or more hair loss disorders to discover one or more SNA products that are directed to, bind to or inhibit one or more specific Collaboration Program targets (each, a &#8220;Program Target&#8221;).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Effective Date, the Company and AbbVie have agreed upon a development plan for each Collaboration Program that describes the development activities and timelines required to advance such Collaboration Program through first IND filing (each, a &#8220;Development Plan&#8221;).  The activities described in the Development Plan are conducted under the supervision of the Joint Development Committee (the &#8220;JDC&#8221;) consisting of three members from each of the Company and AbbVie. The Company is primarily responsible for performing early stage discovery and preclinical activities (the &#8220;Initial Development Activities&#8221;) set forth in the Development Plan for each Collaboration Program and will be solely responsible for all costs and expenses related to the Initial Development Activities. AbbVie may elect, in its sole discretion and at its sole cost and expense, to conduct formulation assessment and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing as set forth in a Development Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of all Initial Development Activities, the Company is required to deliver to AbbVie a report that describes the results of the Initial Development Activities and identifies at least one SNA-based compound that satisfies certain criteria for such Collaboration Program as determined by the JDC (the &#8220;Initial Development Report&#8221;).  Following the delivery of the Initial Development Report for a Collaboration Program, AbbVie will have the ability for a defined period of time (the &#8220;Initial Option Exercise Period&#8221;) to exercise an option (each an &#8220;Option&#8221;) to obtain worldwide rights and license to the Company&#8217;s SNA technology and the Company&#8217;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any product (each a </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Licensed Product&#8221;) that results from such Collaboration Program during the term of the AbbVie Collaboration Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At AbbVie&#8217;s sole option, AbbVie may extend the Initial Option Exercise Period (the &#8220;Option Extension&#8221;) and require the Company to perform IND-enabling activities described in the Development Plan (the &#8220;IND-Enabling Activities&#8221;), subject to the payment of additional consideration (&#8220;Extension Exercise&#8221;). If AbbVie exercises the Option Extension, the Company would be responsible for conducting the IND-Enabling Activities and would be solely responsible for all costs and expenses associated with such activities.  Upon completion of the IND-Enabling Activities, the Company is required to deliver a report that describes the results of the IND-Enabling Activities (the &#8220;IND-Enabling Activities Data Package&#8221;) to AbbVie. Following the delivery of IND-Enabling Activities Data Package, AbbVie will have the ability for a defined period of time (the &#8220;Extended Option Exercise Period&#8221;) to exercise an Option with respect to such Collaboration Program. After the exercise of an Option with respect to a Collaboration Program, AbbVie will be responsible for all development, manufacturing, and commercialization activities, and costs and expense associated with such activities in connection with Licensed Products arising from such Collaboration Program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligation to conduct the activities defined in the Development Plan under the AbbVie Collaboration Agreement commenced on November 13, 2019 and continues until the earlier of (i) the date AbbVie exercises an Option, (ii) the date AbbVie abandons a Collaboration Program and foregoes its Option to that Collaboration Program, or (iii) the fifth anniversary of the Effective Date (the &#8220;Research Term&#8221;). If the Initial Option Exercise Period or Extended Option Exercise Period is still in effect for a Collaboration Program or if the Company has not delivered a complete Initial Development Report or, if AbbVie made an Extension Exercise for a Collaboration Program, a complete IND-Enabling Activities Data Package for such Collaboration Program, as determined by the JDC, then the Research Term will automatically extend by one-year increments until such obligation is satisfied, but in no event past the seventh anniversary of the Effective Date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the AbbVie Collaboration Agreement, the Company received a $25,000 upfront, non-refundable, non-creditable cash payment (the &#8220;AbbVie Upfront Payment&#8221;) related to the Company&#8217;s research and development costs for conducting the Development Plan for two Collaboration Programs, each focused on one or more targets, and certain options to obtain exclusive, worldwide licenses under certain intellectual property rights owned or controlled by the Company to develop, manufacture and commercialize certain products resulting from each such Collaboration Programs.  The option exercise fee during the Initial Option Exercise Period is $10,000 per Collaboration Program.  If AbbVie elects to extend the Initial Option Exercise Period, AbbVie is required to pay an additional fee of $10,000.  If AbbVie elects to exercise its option during the Extended Option Exercise Period, AbbVie must pay the Company the option exercise fee of $15,000.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the exercise by AbbVie of an Option with respect to a Collaboration Program, AbbVie would be required to make certain milestone payments to the Company upon the achievement of specified development, product approval and launch, and commercial events, on a Licensed Product by Licensed Product basis. On a Licensed Product by Licensed Product basis, for the first Licensed Product to achieve the associated milestone event, the Company is eligible to receive up to an aggregate of $55,000 for development milestone payments and $132,500 for product approval and launch milestone payments. The Company is also eligible for up to $175,000 in sales milestone payments on a Collaboration Program by Collaboration Program basis, associated with aggregate worldwide sales. Certain product approval milestones are subject to certain reductions under specified circumstances, including for payments required to be made by AbbVie to obtain certain third-party intellectual property rights.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, to the extent there is any Licensed Product, the Company would be entitled to receive tiered royalty payments of mid-single digits to the mid-teens percentage on future net worldwide product sales of such Licensed Products, subject to certain reductions under specified circumstances. Royalties are due on a Licensed Product by Licensed Product and country by country basis from the date of the first commercial sale of each Licensed Product in a country until the latest to occur of: (i) the expiration date in such country of the last to expire valid claim within the licensed intellectual property covering the manufacture, use or sale of such Licensed Product in such country, (ii) </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the tenth anniversary of the first commercial sale of such Licensed Product in such country, and (iii) the expiration of regulatory exclusivity for such Licensed Product in such country.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie may terminate the AbbVie Collaboration Agreement for any reason or no reason, either in its entirety or on a Collaboration Program by Collaboration Program basis, at any time on 90 days&#8217; prior written notice to the Company. Unless earlier terminated, the term of the AbbVie Collaboration Agreement shall continue until (i) if both Option Exercise Periods expire without AbbVie exercising either Option, the expiration of the later to expire Option Exercise Period, and (ii) if either or both Options are exercised on a Licensed Product-by-Licensed Product and country-by-country basis, the expiration of the royalty term for such Licensed Product in such country. Either party may terminate the AbbVie Collaboration Agreement if the other party has materially breached or defaulted in the performance of any of its material obligations and such breach or default continues after the specified cure period. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the AbbVie Collaboration Agreement for any reason will not release either party from any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination. In addition, termination of the AbbVie Collaboration Agreement will not preclude either party from pursuing any rights and remedies it may have under the agreement or at law or in equity with respect to any breach of the AbbVie Collaboration Agreement. If either party terminates the AbbVie Collaboration Agreement, the license and rights granted to AbbVie with respect to the terminated Collaboration Program or License Product shall terminate. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Analysis</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that AbbVie is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance. Under the AbbVie Collaboration Agreement, the Company has identified a single performance obligation that includes (i) the research and development activities during the Research Term (the &#8220;AbbVie R&amp;D Services&#8221;), and (ii) Joint Development Committee services during the Research Term (the &#8220;AbbVie JDC Services&#8221;). The Company has concluded that the AbbVie R&amp;D Services is not distinct from the AbbVie JDC Services during the Research Term. The JDC provides oversight and management of the overall AbbVie Collaboration Agreement, and the members of the JDC from the Company have specialized industry knowledge, particularly as it relates to SNA technology. The JDC is meant to facilitate the early stage research being performed and coordinate the activities of both the Company and AbbVie. Further, the JDC services are critical to the ongoing evaluation of a Collaboration Program and the drafting and evaluation of the Initial Development Report and the IND-Enabling Data Package. Accordingly, the Company&#8217;s participation on the JDC is essential to AbbVie receiving value from the AbbVie R&amp;D Services and as such, the AbbVie JDC Services along with the AbbVie R&amp;D Services are considered one performance obligation (the &#8220;Collaboration Program Services&#8221;).  In addition, the Company has concluded that the option to purchase two development and commercialization licenses is considered a marketing offer as the options did not provide any discounts or other rights that would be considered a material right in the arrangement, and thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for these options will be accounted for when they are exercised.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Effective Date of the AbbVie Collaboration Agreement, the total transaction price was determined to be $25,000, consisting solely of the AbbVie Upfront Payment. The Company also utilized the most likely amount method to estimate any development and regulatory milestone payments to be received. As of the Effective Date of the AbbVie Collaboration Agreement, there were no milestones included in the transaction price.&#160;The milestones were fully constrained due to the significant uncertainties surrounding such payments.&#160;The Company considered the stage of development and the risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or AbbVie.  The Company has determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur.  As of June&#160;30, 2021, the Company determined that any development, regulatory, or commercial milestones continue to be constrained and therefore the related milestone payments continue to be excluded from the transaction price at June 30, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize revenue related to the Collaboration Program Services as the performance obligation is satisfied using an input method to measure progress. The Company believes the input method that most accurately depicts the measure of progress is the actual hours incurred to date relative to projected hours to complete the research service.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021, the Company recognized revenue under the AbbVie Collaboration Agreement of approximately $79 and $1,076, respectively.  Revenue for the three and six months ended June 30, 2021 reflects events and conditions that occurred during that period that increased the number of hours estimated to be required to complete the services under the AbbVie Collaboration Agreement. These increased estimated efforts resulted in less progress occurring relative to the increased estimate of total projected hours to complete the research services (and thus limited revenue recognized) during the three and six months ended June 30, 2021 and compared to the amount of revenue recognized in the comparable periods.  During the three and six months ended June&#160;30, 2020, the Company recognized revenue under the AbbVie Collaboration Agreement of approximately $4,833 and $13,949, respectively.  As of June&#160;30, 2021 and December&#160;31, 2020, there was $7,267 and $8,343 of deferred revenue related to the AbbVie Collaboration Agreement, which is classified as current on the unaudited condensed consolidated balance sheet.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dermelix Collaboration Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2019, Exicure entered into a License and Development Agreement with Dermelix (the &#8220;Dermelix Collaboration Agreement.&#8221;)  Under the terms of the Dermelix Collaboration Agreement, Exicure received an upfront payment of $1,000, to be applied against the initial $1,000 of the Company&#8217;s development expenses.  </span></div>The Company initially recorded the upfront payment of $1,000 as deferred revenue related to its wholly unsatisfied performance obligation and reduced this balance to zero during 2019 by recognizing revenue as services were provided.  The Company recognized no revenue under the Dermelix Collaboration Agreement during the three and six months ended June&#160;30, 2021. The Company recognized $14 and $81 of revenue during the three months ended June&#160;30, 2020 which reflected reimbursement by Dermelix for additional costs incurred by Exicure for early stage development costs beyond the initial $1,000 upfront payment.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859197814152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text">Supplemental Balance Sheet Information<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.948%"><tr><td style="width:1.0%"/><td style="width:73.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical, contract research and manufacturing costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment, net</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.628%"><tr><td style="width:1.0%"/><td style="width:73.813%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.799%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,192&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,740)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,123&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $283 and $187 for the three months ended June 30, 2021 and 2020, respectively, and $546 and $335 for the six months ended June 30, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued expenses and other current liabilities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.108%"><tr><td style="width:1.0%"/><td style="width:73.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.811%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical, contract research and manufacturing costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859196514872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020, the Company primarily invested its excess cash in debt instruments of corporations, the U.S. Treasury, financial institutions, and U.S. government agencies with strong credit ratings and an investment grade rating at or above a long-term rating of Aa3/AA- and a short-term rating of P1/A1. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contract maturity of the available-for-sale securities the Company held as of June&#160;30, 2021:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:282.75pt"><tr><td style="width:1.0pt"/><td style="width:211.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year or less</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year but within two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s available-for-sale securities are available to the Company for use in its current operations. As a result, the Company categorizes all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;June&#160;30, 2021&#160;and December&#160;31, 2020 were as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.826%"><tr><td style="width:1.0%"/><td style="width:45.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,467&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.025%"><tr><td style="width:1.0%"/><td style="width:44.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859197814152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MidCap Credit Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2020, the Company entered into a Credit and Security Agreement, as amended on October 21, 2020, (the &#8220;MidCap Credit Agreement&#8221;), with MidCap Financial Trust (&#8220;MidCap&#8221;), as agent, and the lenders party thereto from time to time.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement provides for a secured term loan facility in an aggregate principal amount of up to $25,000 (the &#8220;MidCap Credit Facility&#8221;). The Company borrowed the first advance of $17,500 (&#8220;Tranche 1&#8221;) on September 25, 2020 (the &#8220;Closing Date&#8221;). Under the terms of the MidCap Credit Agreement, the second advance of $7,500 (&#8220;Tranche 2&#8221;) is available to the Company from April 1, 2021 to September 30, 2021, subject to the Company&#8217;s satisfaction of certain conditions described in the MidCap Credit Agreement. The Company believes the conditions to access the available Tranche 2 amount are satisfied as of June 30, 2021. The proceeds from the MidCap Credit Facility are expected to be used for working capital and general corporate purposes.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tranche 1, and if borrowed Tranche 2, each bear interest at a floating rate equal to 6.25% per annum, plus the greater of (i) 1.50% or (ii) one-month LIBOR. Interest on each loan advance is due and payable monthly in arrears. Principal on each loan advance is payable in 36 equal monthly installments beginning October 1, 2022 until paid in full on October 1, 2025 (the &#8220;Maturity Date&#8221;). Prepayments of the loans under the MidCap Credit Agreement, in whole or in part, will be subject to early termination fees in an amount equal to 3.0% of principal prepaid if prepayment occurs on or prior to the first anniversary of the Closing Date and 1.0% of principal prepaid if prepayment occurs after the first anniversary of the Closing Date and prior to the maturity date.  In connection with execution of the Midcap Credit Agreement, the Company paid MidCap a $125 origination fee.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Maturity Date or on any earlier date on which all amounts advanced to the Company become due and payable in full, or are otherwise paid in full, the Company is required to pay an exit fee equal to 3.75% of the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">principal amount of all loans advanced to the Company under the MidCap Credit Agreement. Upon the advance of Tranche 1, the Company accrued $656 for the related exit fee.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the MidCap Credit Agreement are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge). Additionally, the Company&#8217;s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the MidCap Credit Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement contains customary affirmative covenants and customary negative covenants limiting the Company&#8217;s ability and the ability of the Company&#8217;s subsidiaries, if any, to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, delisting of the Company&#8217;s common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, the agent and the lenders may declare all or a portion of the Company&#8217;s outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the agreement. During the existence of an event of default, interest on the obligations could be increased by 2.0%.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total proceeds, net of fees and issuance costs, borrowed under Tranche 1 were $16,512.  Fees and issuance costs of $332, as well as fees of $656 that are payable to MidCap at maturity of Tranche 1, are recorded as a reduction to the carrying amount of long-term debt on the Company&#8217;s balance sheet and will be amortized to interest expense through the maturity date of October 1, 2025 using the effective interest method. Fees and issuance costs of $73 attributed to the amount available to be borrowed under Tranche 2 were paid and recorded as deferred financing costs (other assets) and will be (i) recorded as a reduction in the carrying amount of long-term debt in future periods if amounts are borrowed under Tranche 2 or (ii) will be amortized and recorded to interest expense if amounts are not borrowed under Tranche 2. For the three and six months ended June 30, 2021, the Company recognized $37 as interest expense and the remaining balance of the deferred financing costs is $36 as of June 30, 2021.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the aggregate carrying value of the Company&#8217;s long-term debt is $16,730.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the principal maturities of the Company&#8217;s long-term debt were as follows:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:76.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining six months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal balance outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less: unamortized discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,730&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid interest on the MidCap Credit Agreement of $347 and $686 during the three and six months ended June 30, 2021, respectively. The Company paid interest on the Hercules Loan Agreement (as discussed below) of $0 and $142 during the three and six months ended June 30, 2020, respectively.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hercules Loan Agreement</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 2, 2020, pursuant to the terms of the loan agreement with Hercules Technology Growth Capital (&#8220;Hercules&#8221;) and subsequent amendments thereto  (the &#8220;Hercules Loan Agreement&#8221;), the Company repaid all remaining outstanding obligations under the Hercules Loan Agreement as of the maturity date, including the outstanding principal balance of $4,999 and the end of term fee of $100.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859196473592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease arrangements at June 30, 2021 consist of (i) a lease for office and laboratory space at its headquarters in Chicago, Illinois that commenced in July 2020 (the &#8220;Chicago Lease&#8221;), (ii) a lease for office space at a multi-tenant facility in Cambridge, MA that commenced in March 2019 and is cancelable at any time (the &#8220;Cambridge Lease&#8221;), and (iii) leases for office equipment (the &#8220;Office Equipment Leases&#8221;). Each of these leases are classified as operating leases.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the Cambridge Lease, the Company determined that this lease represented a short-term lease with an initial term of less than twelve months and, as such, the Cambridge Lease is not recorded on the balance sheet and related lease costs are recognized in the statement of operations as they are incurred. The Company has also elected to not record the Office Equipment Leases on the balance sheet since related payment amounts and lease costs are insignificant. Lease costs for the Office Equipment Leases are recognized in the statement of operations on a straight-line basis over the lease term.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease arrangement for office and laboratory space at its former headquarters in Skokie, Illinois ended in February 2021 in accordance with the terms of that lease arrangement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chicago Lease</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately thirty thousand square feet of office and laboratory space in Chicago, Illinois (the &#8220;Chicago Lease&#8221;). The original term (the &#8220;Original Term&#8221;) of the Chicago Lease is 10 years, commencing on July 1, 2020 (the &#8220;Commencement Date&#8221;), which is the date the premises were ready for occupancy under the terms of the Chicago Lease.  The Company has options to extend the term of the Chicago Lease for&#160;two&#160;additional successive periods of five years each (the &#8220;Extension Periods&#8221;) at the then prevailing effective market rental rate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial annual base rent during the Original Term is approximately $1,113 for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of 3%, for an aggregate amount of $12,761 over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term.  During the first 12-month period of the Original Term, the base rent and the Company's proportionate share of operating expenses and taxes are subject to certain abatements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Chicago Lease, the Company will maintain a letter of credit for the benefit of the landlord in an initial amount of $1,200, which amount is subject to reduction over time.  Upon execution of the Chicago Lease, the Company paid to the landlord the first installment of base rent and the estimated monthly amount of its pro rata share of taxes and its pro rata share of operating expenses in the aggregate amount of $87 which amount had been adjusted for the abatement as set forth in the lease agreement. The Company also paid the landlord a net amount of $697 toward tenant improvements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement for the Chicago Lease, the Company is required to maintain a&#160;standby letter of credit during the term of the lease, currently in the amount of $1,200 and subject to reduction over time, which is secured by a restricted certificate of deposit account and presented within other noncurrent assets on the Company&#8217;s unaudited condensed consolidated balance sheet at June&#160;30, 2021.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a right of use asset of $8,931 and a lease liability of $8,147 on the Commencement Date. Because the rate implicit in the Chicago Lease is not readily determinable, the Company used its incremental </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrowing rate of 8.3% on the Commencement Date to determine the present value of the lease payments over the Original Term. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. As of June&#160;30, 2021, the Company determined it is not reasonably certain that the renewal option would be exercised.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the Company&#8217;s operating lease asset and related operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:76.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes lease costs in the Company&#8217;s unaudited condensed consolidated statement of operations:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made cash payments for operating leases of $1,106 and $1,227 during the six months ended June 30, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the Company&#8217;s lease liability as of June&#160;30, 2021 were as follows:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:76.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining six months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,437)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859197826680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020, the Company had 10,000,000 shares of preferred stock, par value $0.0001 authorized and no shares issued and outstanding.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020, the Company had authorized 200,000,000 shares of common stock, par value $0.0001.  As of June&#160;30, 2021 and December&#160;31, 2020, the Company had 88,096,694 shares and 87,651,352 shares issued and outstanding, respectively.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of shares of the Company&#8217;s common stock are entitled to one vote per share on all matters to be voted upon by the Company&#8217;s stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&#8217;s common stock are entitled to receive ratably any dividends that may be declared from time to time by the Board out of funds legally available for that purpose. In the event of the Company&#8217;s liquidation, dissolution or winding up, the holders of shares of the Company&#8217;s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company&#8217;s common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company&#8217;s common stock. The outstanding shares of the Company&#8217;s common stock are fully paid and&#160;non-assessable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of June&#160;30, 2021, no warrants were outstanding. As of December 31, 2020, warrants to purchase 413,320 shares of common stock at a price of&#160;$3.00&#160;per share were outstanding.  The warrants expired unexercised as follows: 163,174 warrants expired on March 27, 2021, 132,884 expired on April 28, 2021, and 117,262 expired on May 3, 2021.  The warrants were classified as a liability which was remeasured each period at fair value. See Note 12,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for more information on the fair value of the common stock warrant liability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2021:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"/><td style="width:57.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"/><td style="width:57.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net loss reclassified from accumulated other comprehensive loss during the three months ended June 30, 2020 resulted from sales of available-for-sale securities prior to maturity. The gross realized gains and gross realized losses of these sales were $23 and $6, respectively, for the three and six months ended June 30, 2020. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $9,404.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859196215048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text">Equity-Based Compensation<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards that may be awarded under the 2017 Equity Incentive Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 4,600,000 shares, (ii) 5% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board. The Compensation Committee made the determination to increase the share reserve for the 2017 Equity Incentive Plan by 4,382,567 shares, effective January 1, 2021. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the aggregate number of equity awards available for grant under the 2017 Equity Incentive Plan was 2,831,213.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Grant</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company granted stock options to purchase up to 600,000 shares of common stock as a material inducement to Brian C. Bock, the Company&#8217;s Chief Financial Officer, to enter into employment with the Company (the &#8220;Inducement Grant&#8221;).  The Inducement Grant, which was made pursuant to a stand-alone nonstatutory stock option agreement (the &#8220;Inducement Award Agreement&#8221;), was approved by the Compensation Committee of the Board, was awarded in accordance with Nasdaq Listing Rule 5635(c)(4) and outside of the Company&#8217;s 2017 Equity Incentive Plan and is subject to the terms and conditions of the Inducement Award Agreement.  As such, any shares underlying the Inducement Grant are not, upon forfeiture, cancellation or expiration, returned to a pool of shares reserved for future issuance.  As of June 30, 2021, stock options to purchase up to 600,000 shares of common stock remained outstanding under the Inducement Grant.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Employee Stock Purchase Plan (the "ESPP") was adopted by the Board in September 2017 and approved by the Company's stockholders in September 2017. Through the ESPP, eligible employees may authorize payroll deductions of up to 15% of their compensation to purchase common stock. The maximum number of shares that an employee may purchase on any exercise date in an offer period will be the smaller of (i) 7,500 shares or (ii) such number of shares as has a fair market value (determined as of the offering date for such offer period) equal to $25,000 within one calendar year minus the fair market value of any other shares of common stock that are attributed to such calendar year. The purchase price per share at each purchase date is equal to 85% of the lower of (i) the closing market price per share of Exicure common stock on the employee&#8217;s offering date or (ii) the closing market price per share of Exicure common stock on the exercise date. Each offering period is approximately six-months in duration and the first offering period began on November 16, 2020 and ended on May 14, 2021.  In connection with the end of the first offering period on May 14, 2021, the Company issued 103,096 shares of common stock that were purchased under the ESPP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2018 and each January 1 thereafter through January 1, 2027, by the least of (i) 300,000 shares; (ii) 0.3% of the outstanding shares of common stock on the last day of the immediately preceding calendar year; or (iii) a lesser number of shares determined by the Board. On January 1, 2021 and 2020, the number of shares of common stock available for issuance under the ESPP increased by 258,207 shares and 262,954 shares, respectively. As of June 30, 2021, there were 1,100,791 shares available for issuance under the ESPP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-based compensation expense is classified in the statements of operations as follows:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized equity-based compensation expense at June&#160;30, 2021 was $8,350, which is expected to be amortized over a weighted-average period of 3.2 years. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 to 6.1 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 to 6.1 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36% to 1.12%; weighted avg. 1.05%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% to 1.68%; weighted avg. 0.67%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.7% to 83.6%; weighted avg. 82.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.0% to 85.8%; weighted avg. 83.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term is based upon the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#8220;simplified method&#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the underlying common stock and the exercise price for the common stock options granted during the six months ended June 30, 2021 and 2020 are summarized in the table below:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:55.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.250%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Options Granted During Period Ended:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of Underlying Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price of Common Stock Option</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six months ended June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.54 to $2.57; weighted avg. $1.88</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.54 to $2.57; weighted avg. $1.88</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six months ended June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.19 to $2.80:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $1.85</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.19 to $2.80:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $1.85</span></div></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of common stock options granted in the six months ended June 30, 2021 and 2020 was $1.31 and $1.29 per common stock option, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock option activity as of the periods indicated is as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,227,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342,246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,702)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,059,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable - June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580,439&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Expected to Vest -<br/>June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,559,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of common stock options exercised during the six months ended June 30, 2021 was $77 and $89, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit activity of the periods indicated is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.512%"><tr><td style="width:1.0%"/><td style="width:58.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.674%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of restricted stock units is based on the Company&#8217;s closing stock price at the date of grant. At vesting, each outstanding restricted stock unit will be exchanged for one share of the Company&#8217;s common stock. The restricted stock units granted during the 2021 period generally vest evenly on a quarterly basis over a period of 4 years in exchange for continued service provided by the restricted stock unit recipient during that vesting period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859197812184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThe Company incurred a pretax loss in each of the three and six months ended June 30, 2021 and 2020, which consists entirely of loss in the United States and resulted in no provision for income tax expense during the periods then ended.  The effective tax rate is 0% in each of the three and six months ended June 30, 2021 and 2020 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859290056520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Common Share</a></td>
<td class="text">Loss Per Common ShareBasic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options, restricted stock units, and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods.  Therefore, basic and diluted loss per common share is the same for each of the three and six months ended June 30, 2021 and 2020.<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the computation of loss per common share for the three and six months ended June 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"/><td style="width:37.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,269)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,311)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,746)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,161)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,043,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,174,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,948,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,126,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company&#8217;s loss per share during that period:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:69.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,059,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,698,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859196187624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of June&#160;30, 2021 are as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:46.006%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,573&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 are as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"/><td style="width:46.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments.  The Company&#8217;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level 2 of the fair value hierarchy.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company&#8217;s common stock warrant liability was $0 and no warrants were outstanding  (refer to Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information). The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended June&#160;30, 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.237%"><tr><td style="width:1.0%"/><td style="width:72.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain included in other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859197701160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 7,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a discussion of the commitments associated with the Company&#8217;s lease agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Northwestern University License Agreements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2011, (1) AuraSense, LLC, the Company&#8217;s former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#8217;s 2009 license agreement with Northwestern University (&#8220;NU&#8221;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs </span></div>as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;assigned field&#8221;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#8217;s sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company.  In August 2015, the Company entered into a restated license agreement with NU (the &#8220;Restated License Agreement&#8221;). In February 2016, the Company obtained exclusive license as to NU&#8217;s rights in certain SNA technology it jointly owns with NU (the &#8220;Co-owned Technology License&#8221;). The Company&#8217;s license to NU&#8217;s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. In June 2016, the Company entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#8220;Wound Healing License&#8221;). The Company&#8217;s rights and obligations in the Co-owned Technology License and the Wound Healing License agreements&#160;are substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as &#8220;the Northwestern University License Agreements&#8221;).  All pending patent applications under the Wound Healing License have been abandoned and the Wound Healing License has been terminated.  As of June&#160;30, 2021, the Company has paid to NU an aggregate of $8,361 in consideration of each of the obligations described above.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859197842808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party TransactionsThe Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but, through April 30, 2021, served as a member of the Board. The Company recognized $50 as an expense in each of the six months ended June&#160;30, 2021 and 2020 in connection with these consulting services in the accompanying unaudited condensed consolidated statement of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859289941528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events which may require adjustment to or disclosure in the accompanying unaudited condensed consolidated financial statements and has concluded that there are no subsequent events or transactions that occurred subsequent to the balance sheet date that would require recognition or disclosure in the accompanying unaudited condensed consolidated financial statements, except as noted below.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration, License, and Option Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021, the Company entered into a Collaboration, Option and License Agreement (the &#8220;Ipsen Collaboration Agreement&#8221;) with IPSEN BIOPHARM LIMITED (&#8220;Ipsen&#8221;). Pursuant to the Ipsen Collaboration Agreement, the Company granted to Ipsen exclusive access and options to license SNA based therapeutics arising from two collaboration programs related to the treatment of Huntington&#8217;s disease and Angelman syndrome, respectively. Each such license would grant to Ipsen exclusive, royalty-bearing, sublicensable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Upon written notice to the Company, Ipsen may exercise its option during the corresponding collaboration program&#8217;s applicable option exercise period, (each, an &#8220;Option Exercise Period&#8221;).</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Ipsen Collaboration Agreement, the Company will conduct discovery and development in two collaboration programs for Huntington&#8217;s disease and Angelman syndrome. The Company shall be solely responsible for all costs and expenses of conducting each collaboration program through the selection of SNA therapeutic candidates for further development (&#8220;Selection&#8221;), and Ipsen shall be responsible for all costs and expenses of all additional activities that are necessary to enable the first filing of an investigational new drug application (&#8220;IND&#8221;) for each proposed product candidate. In the event that Ipsen exercises an option, Ipsen will be </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">responsible for further development from the license effective date and commercialization of the corresponding licensed product. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Ipsen Collaboration Agreement, the Company will receive an upfront payment of $20,000 (the &#8220;Ipsen Upfront Payment&#8221;), and, depending on the timing when Ipsen exercises its option right in a collaboration program, Ipsen will pay to the Company an option exercise fee equal to $10,000 (if exercised within the Option Exercise Period after the Selection) or $25,000 (if exercised within the Option Exercise Period that begins after the first Option Exercise Period and ends after IND filing) for each collaboration program. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ipsen will pay a pre-clinical milestone of $5,000 for each collaboration program upon achievement of such milestone regardless of whether an option is exercised.  In addition to the option exercise fees and the pre-clinical milestones described above, if Ipsen exercises an option for a program, development and regulatory milestones will be payable for that program upon the initiation of certain clinical trials, and the filing for processing by the FDA in the United States and by 2 additional regulators outside the United States of a marketing application for review, per program, with an aggregate total of up to $180,000 if both options are exercised. Commercial milestones will be payable for that program upon first commercial sale of a licensed product in certain jurisdictions and the achievement of specified aggregate sales thresholds for all licensed products from that program, with an aggregate total of up to $762,000 if both options are exercised. In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company is eligible to receive tiered royalties at percentages ranging from the mid-single digits to the mid-teens on future net product sales of such commercialized therapeutic candidates. A percentage of the aforementioned payments will be due to NU upon receipt, pursuant to the terms of the Company&#8217;s existing license agreements with NU (see Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitment and Contingencies,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on the Northwestern University License Agreements).  In connection with the receipt of the Ipsen Upfront Payment, the Company will incur $3,000 in license fees payable to NU under the terms of the Northwestern License Agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ipsen Collaboration Agreement will remain in effect, unless earlier terminated, until (a) the expiration of the later-to-expire option exercise period, if Ipsen does not exercise either option, or (b) the expiration of the last-to-expire royalty term for any licensed product in such country on a licensed product-by-licensed product and country-by-country basis, if Ipsen exercises one or both options. Upon expiration of the royalty term with respect to a particular licensed product in a country, the license for such product in such country will convert to a fully-paid, irrevocable and perpetual license. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ipsen Collaboration Agreement also contains customary provisions for termination by either party, including in the event of breach of the Ipsen Collaboration Agreement, subject to cure, and by the Company upon a challenge of the licensed patents, subject, in certain cases, to customary reversion rights. Upon termination of the Ipsen Collaboration Agreement by the Company for Ipsen&#8217;s breach or bankruptcy, all licenses granted by the Company to Ipsen will terminate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ipsen Collaboration Agreement includes customary representations and warranties on behalf of both the Company and Ipsen. The Ipsen Collaboration Agreement also provides for customary mutual indemnities.  In addition, the Ipsen Collaboration Agreement imposes certain exclusivity obligations on Ipsen and the Company, respectively, with respect to the development, use, manufacture and commercialization of oligonucleotide-based therapeutic targeting the same targets in the collaboration programs and/or certain other specific targets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either party may assign the Ipsen Collaboration Agreement or delegate its obligations to an affiliate or to a successor to substantially all of the business to which the Ipsen Collaboration Agreement relates without the consent of the other party.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the entry into the Ipsen Collaboration Agreement, the Company, Ipsen and NU entered into a side letter to the Northwestern University License Agreements (the &#8220;Side Letter&#8221;). Pursuant to the Side Letter, the parties thereto clarified certain provisions of the Northwestern University License Agreements as they apply to the sublicenses granted to Ipsen pursuant to the Ipsen Collaboration Agreement, including providing for the survival of Ipsen&#8217;s sublicense to the applicable NU intellectual property rights should the Northwestern University License </span></div>Agreements terminate or if the Company&#8217;s licenses to such intellectual property rights are rendered non-exclusive in accordance with the Northwestern University License Agreements (other than as a result of an act or omission on the part of Ipsen or any of its Affiliates or sublicensees). Additionally, the Side Letter clarified Ipsen&#8217;s rights to grant further sublicenses under such intellectual property rights granted to the Company pursuant to the Northwestern University License Agreements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859195029016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying unaudited condensed consolidated financial statements as of June&#160;30, 2021 and December 31, 2020, and for the six months ended June&#160;30, 2021 and 2020, have been presented in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#8212;Effective Dates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#8220;smaller reporting companies&#8221; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">(Loss) Earnings Per Common Share</a></td>
<td class="text">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options, restricted stock units, and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859287502824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expense and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.948%"><tr><td style="width:1.0%"/><td style="width:73.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical, contract research and manufacturing costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment, net</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.628%"><tr><td style="width:1.0%"/><td style="width:73.813%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.799%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,192&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,740)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,123&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued expenses and other current liabilities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.108%"><tr><td style="width:1.0%"/><td style="width:73.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.811%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical, contract research and manufacturing costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859198021288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contract maturity of the available-for-sale securities the Company held as of June&#160;30, 2021:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:282.75pt"><tr><td style="width:1.0pt"/><td style="width:211.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year or less</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year but within two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities, Available-for-sale</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;June&#160;30, 2021&#160;and December&#160;31, 2020 were as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.826%"><tr><td style="width:1.0%"/><td style="width:45.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,467&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.025%"><tr><td style="width:1.0%"/><td style="width:44.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI http://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI http://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859289941528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Principal Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the principal maturities of the Company&#8217;s long-term debt were as follows:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:76.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining six months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal balance outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less: unamortized discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,730&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859197849976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock', window );">Schedule of Operating Leases, Additional Information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the Company&#8217;s operating lease asset and related operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:76.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes lease costs in the Company&#8217;s unaudited condensed consolidated statement of operations:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the Company&#8217;s lease liability as of June&#160;30, 2021 were as follows:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:76.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining six months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,437)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Operating Leases, Additional Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859198040728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2021:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"/><td style="width:57.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"/><td style="width:57.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859202795768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Equity-Based Compensation Expense Classification in Statement of Operations</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-based compensation expense is classified in the statements of operations as follows:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Determine Fair Value of Common Stock Option Grants</a></td>
<td class="text">In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 to 6.1 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 to 6.1 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36% to 1.12%; weighted avg. 1.05%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% to 1.68%; weighted avg. 0.67%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.7% to 83.6%; weighted avg. 82.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.0% to 85.8%; weighted avg. 83.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the underlying common stock and the exercise price for the common stock options granted during the six months ended June 30, 2021 and 2020 are summarized in the table below:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:55.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.250%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Options Granted During Period Ended:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of Underlying Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price of Common Stock Option</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six months ended June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.54 to $2.57; weighted avg. $1.88</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.54 to $2.57; weighted avg. $1.88</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six months ended June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.19 to $2.80:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $1.85</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.19 to $2.80:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $1.85</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Common Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock option activity as of the periods indicated is as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,227,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342,246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,702)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,059,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable - June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580,439&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Expected to Vest -<br/>June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,559,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Stock Unit Awards Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit activity of the periods indicated is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.512%"><tr><td style="width:1.0%"/><td style="width:58.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.674%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859198000680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of loss per common share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the computation of loss per common share for the three and six months ended June 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"/><td style="width:37.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,269)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,311)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,746)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,161)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,043,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,174,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,948,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,126,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company&#8217;s loss per share during that period:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:69.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,059,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,698,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859198071128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of June&#160;30, 2021 are as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:46.006%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,573&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 are as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"/><td style="width:46.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended June&#160;30, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.237%"><tr><td style="width:1.0%"/><td style="width:72.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain included in other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859280899032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate', window );">Accumulated deficit generated, since inception</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (151,548)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Ipsen Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from Collaborators</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=xcur_COVID19Member', window );">COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ResearchAndDevelopmentStaffOnSitePercentage', window );">Percentage of R&amp;D staff on site</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage', window );">Percentage of time that office and general and administrative staff are on site</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Office And General And Administrative Staff On Site, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ResearchAndDevelopmentStaffOnSitePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Staff on Site, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ResearchAndDevelopmentStaffOnSitePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retained Earnings (Accumulated Deficit), Inception to Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=xcur_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=xcur_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859204294184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and License Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 13, 2019 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Feb. 17, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="nump">$ 4,847,000<span></span>
</td>
<td class="nump">$ 1,076,000<span></span>
</td>
<td class="nump">$ 14,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,267,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,267,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,343,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember', window );">AbbVie Collaboration | Collaboration Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_NumberofCollaborationPrograms', window );">Number of collaboration programs | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementUpfrontPayment', window );">Non-refundable upfront payment received for research agreement</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionExerciseFee', window );">Collaboration option exercise fee</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee', window );">Collaboration option exercise fee</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice', window );">Termination period upon written notice</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
<td class="nump">4,833,000<span></span>
</td>
<td class="nump">1,076,000<span></span>
</td>
<td class="nump">13,949,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,267,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,267,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,343,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_DermelixLicenseAgreementMember', window );">Dermelix License Agreement | Collaboration Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementUpfrontPayment', window );">Non-refundable upfront payment received for research agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 81,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationDevelopmentExpenses', window );">Collaboration development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xcur_DevelopmentandCommercializationLicenseMember', window );">Development and Commercialization License | AbbVie Collaboration | Collaboration Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionExerciseFee', window );">Collaboration option exercise fee</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | AbbVie Collaboration | Collaboration Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment', window );">Development milestone payment</a></td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment', window );">Product approval and launch milestone payment</a></td>
<td class="nump">132,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment', window );">Sales milestone payment</a></td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Extended Option, Additional Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option, Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Termination Period Upon Written Notice</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Development Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_NumberofCollaborationPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Collaboration Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_NumberofCollaborationPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ArrangementNameAxis=xcur_DermelixLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ArrangementNameAxis=xcur_DermelixLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xcur_DevelopmentandCommercializationLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xcur_DevelopmentandCommercializationLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859197819416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid clinical, contract research and manufacturing costs</a></td>
<td class="nump">$ 3,388<span></span>
</td>
<td class="nump">$ 2,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">902<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 4,588<span></span>
</td>
<td class="nump">$ 4,231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859200083288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(2,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,740)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">546<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Scientific equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember', window );">Computers and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859197939464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent', window );">Accrued clinical, contract research and manufacturing costs</a></td>
<td class="nump">$ 1,223<span></span>
</td>
<td class="nump">$ 1,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll-related expenses</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other expenses</a></td>
<td class="nump">458<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 3,228<span></span>
</td>
<td class="nump">$ 3,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical, Contract Research And Manufacturing Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859197726728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtSecuritiesAvailableForSaleCurrentPercent', window );">One year or less</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent', window );">After one year but within two years</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtSecuritiesAvailableforSalePercent', window );">Total</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtSecuritiesAvailableForSaleCurrentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Current, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtSecuritiesAvailableForSaleCurrentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Noncurrent, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtSecuritiesAvailableforSalePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available for Sale, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtSecuritiesAvailableforSalePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859200302776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Available-for-sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="nump">$ 13,467<span></span>
</td>
<td class="nump">$ 48,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">13,472<span></span>
</td>
<td class="nump">48,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="nump">5,999<span></span>
</td>
<td class="nump">15,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">5,999<span></span>
</td>
<td class="nump">15,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="nump">6,212<span></span>
</td>
<td class="nump">29,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">6,213<span></span>
</td>
<td class="nump">29,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 1,260<span></span>
</td>
<td class="nump">$ 1,278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859280614856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 25, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 02, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2022 </div>
<div>installmentPayment</div>
</th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoanProcessingFee', window );">Origination fee</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtInstrumentExitFeePercentage', window );">Exit fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of long-term debt issuance costs and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,730,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,730,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">686,000<span></span>
</td>
<td class="nump">142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,999,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | MidCap Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Floating interest rate</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | MidCap Credit Agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments', window );">Number of monthly installment payments | installmentPayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | MidCap Credit Agreement | Prior to first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal', window );">Early termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | MidCap Credit Agreement | After first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal', window );">Early termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | MidCap Credit Agreement - Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term borrowing</a></td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Fee amount</a></td>
<td class="nump">656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt, net of fees and issuance costs</a></td>
<td class="nump">16,512,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="nump">332,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | MidCap Credit Agreement - Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of long-term debt issuance costs and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans Payable | Secured Debt | Hercules Technology Growth Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,999,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PaymentsForDebtEndTermFees', window );">Payments for debt end term fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanProcessingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses paid for obtaining loans which includes expenses such as application and origination fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanProcessingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Early Termination Fee, Percentage of Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtInstrumentExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exit Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtInstrumentExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Principal Payment, Number of Monthly Installment Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PaymentsForDebtEndTermFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Debt End Term Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PaymentsForDebtEndTermFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xcur_MidCapCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xcur_MidCapCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xcur_MidCapCreditAgreementTranche1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xcur_MidCapCreditAgreementTranche1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xcur_MidCapCreditAgreementTranche2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xcur_MidCapCreditAgreementTranche2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=xcur_HerculesTechnologyGrowthCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=xcur_HerculesTechnologyGrowthCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859280897464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Principal Maturities of Long-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2021 (remaining six months)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">5,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">5,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">4,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal balance outstanding</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">less: unamortized discount and debt issuance costs</a></td>
<td class="num">(770)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">16,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Noncurrent portion</a></td>
<td class="nump">$ 16,730<span></span>
</td>
<td class="nump">$ 16,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859200057704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>extensionPeriod</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,106<span></span>
</td>
<td class="nump">$ 1,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=xcur_ChicagoMember', window );">Chicago</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseLeaseArea', window );">Lease area | ft&#178;</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Contract term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseNumberOfExtensions', window );">Number of extensions | extensionPeriod</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths', window );">Annual rent payment initial twelve months</a></td>
<td class="nump">$ 1,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease', window );">Base rent annual percentage increase</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm', window );">Estimated rental payment over original term</a></td>
<td class="nump">$ 12,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement', window );">Rental payment adjusted for abatement</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Payments for tenant improvements</a></td>
<td class="nump">697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">8,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 8,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Base Rent Annual Percentage Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Estimated Rental Payment Over Original Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseNumberOfExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number of Extensions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseNumberOfExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Rental Payment Adjusted For Abatement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=xcur_ChicagoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=xcur_ChicagoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859197851480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Right of Use Asset Information (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859290908872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 326<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">$ 653<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease costs</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 552<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">$ 1,287<span></span>
</td>
<td class="nump">$ 596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859280838168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Rental Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (remaining six months)</a></td>
<td class="nump">$ 478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">4,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">11,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(3,437)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">8,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">$ 223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liability</a></td>
<td class="nump">$ 7,696<span></span>
</td>
<td class="nump">$ 7,959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859200433224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Current Capitalization (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>votePerShare </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">88,096,694<span></span>
</td>
<td class="nump">87,651,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">88,096,694<span></span>
</td>
<td class="nump">87,651,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockVotingRightsForEachShare', window );">Common stock, voting rights for each share | votePerShare</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CommonStockVotingRightsForEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights For Each Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CommonStockVotingRightsForEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859200038680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock Warrants (Details) - Common Stock - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 03, 2021</div></th>
<th class="th"><div>Apr. 28, 2021</div></th>
<th class="th"><div>Mar. 27, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ClassofWarrantorRightExpired', window );">Warrant expirations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,262<span></span>
</td>
<td class="nump">132,884<span></span>
</td>
<td class="nump">163,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ClassofWarrantorRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ClassofWarrantorRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859203650184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 50,041<span></span>
</td>
<td class="nump">$ 61,506<span></span>
</td>
<td class="nump">$ 85,114<span></span>
</td>
<td class="nump">$ 80,747<span></span>
</td>
<td class="nump">$ 61,506<span></span>
</td>
<td class="nump">$ 80,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">36,640<span></span>
</td>
<td class="nump">50,041<span></span>
</td>
<td class="nump">81,752<span></span>
</td>
<td class="nump">85,114<span></span>
</td>
<td class="nump">36,640<span></span>
</td>
<td class="nump">81,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Gross realized gains, available for sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Gross realized losses, available for sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859280472760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 14, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,270,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,059,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,227,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock-ESPP (in shares)</a></td>
<td class="nump">103,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, stock options, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="nump">$ 89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember', window );">Exicure, Inc. 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares', window );">Number of additional shares authorized, potential maximum additional shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding', window );">Number of additional shares authorized, percentage of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,831,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock | Exicure, Inc. 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant', window );">Increase in number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,382,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant', window );">Increase in number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,207<span></span>
</td>
<td class="nump">262,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum ESPP contribution rate as a percentage of compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares per employee in purchase period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount', window );">Maximum contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">ESPP purchase price as a percentage of market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of additional shares allowable annually under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding shares allowable as annual increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting', window );">Number of shares issued for each vested restricted stock unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859287034200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 764<span></span>
</td>
<td class="nump">$ 544<span></span>
</td>
<td class="nump">$ 1,281<span></span>
</td>
<td class="nump">$ 985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">618<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 403<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859199273224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.36%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.12%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">81.70%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">83.60%<span></span>
</td>
<td class="nump">85.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">82.60%<span></span>
</td>
<td class="nump">83.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.05%<span></span>
</td>
<td class="nump">0.67%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859280450952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of underlying common stock (dollars per share)</a></td>
<td class="nump">$ 1.54<span></span>
</td>
<td class="nump">$ 1.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price of common stock option (dollars per share)</a></td>
<td class="nump">1.54<span></span>
</td>
<td class="nump">1.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of underlying common stock (dollars per share)</a></td>
<td class="nump">2.57<span></span>
</td>
<td class="nump">2.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price of common stock option (dollars per share)</a></td>
<td class="nump">2.57<span></span>
</td>
<td class="nump">2.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of underlying common stock (dollars per share)</a></td>
<td class="nump">1.88<span></span>
</td>
<td class="nump">1.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price of common stock option (dollars per share)</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="nump">$ 1.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859200474760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Stock Options Rollforward (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding beginning balance (in shares)</a></td>
<td class="nump">7,227,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">4,270,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="num">(342,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(95,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding ending balance (in shares)</a></td>
<td class="nump">11,059,434<span></span>
</td>
<td class="nump">7,227,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">4,580,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">10,559,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding beginning balance (in dollars per share)</a></td>
<td class="nump">$ 2.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">2.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding ending balance (in dollars per share)</a></td>
<td class="nump">2.12<span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (years)</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value (thousands)</a></td>
<td class="nump">$ 1,019<span></span>
</td>
<td class="nump">$ 1,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted-average remaining contractual term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value (thousands)</a></td>
<td class="nump">$ 1,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859203713208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - RSU Activity (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance - beginning of period (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">286,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance - end of period (in shares) | shares</a></td>
<td class="nump">286,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance - beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">1.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance - end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859202795208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859280346504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Computation of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,269)<span></span>
</td>
<td class="num">$ (12,477)<span></span>
</td>
<td class="num">$ (4,311)<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="num">$ (26,746)<span></span>
</td>
<td class="num">$ (3,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic common shares outstanding (in shares)</a></td>
<td class="nump">88,043,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,174,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,948,440<span></span>
</td>
<td class="nump">87,126,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">88,043,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,174,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,948,440<span></span>
</td>
<td class="nump">87,126,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">(Loss) earnings per basic common share (USD per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">(Loss) earnings per diluted common share (USD per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859200367800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">11,059,434<span></span>
</td>
<td class="nump">7,698,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">286,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">413,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859280795816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">$ 13,472<span></span>
</td>
<td class="nump">$ 48,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">43,573<span></span>
</td>
<td class="nump">73,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure', window );">Common stock warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">30,101<span></span>
</td>
<td class="nump">24,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure', window );">Common stock warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">13,472<span></span>
</td>
<td class="nump">48,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure', window );">Common stock warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure', window );">Common stock warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">5,999<span></span>
</td>
<td class="nump">15,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">5,999<span></span>
</td>
<td class="nump">15,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">6,213<span></span>
</td>
<td class="nump">29,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">6,213<span></span>
</td>
<td class="nump">29,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">6,213<span></span>
</td>
<td class="nump">29,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">30,101<span></span>
</td>
<td class="nump">24,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">30,101<span></span>
</td>
<td class="nump">24,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrant Liability, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CommonStockWarrantLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859291010920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - Common Stock - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Common stock warrant liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">413,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859198456088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details) - Common Stock - Warrant Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2020</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Gain included in other (expense) income, net</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at June&#160;30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859196582536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_AggregatePaymentsMadeToDateForLicenseAgreements', window );">Aggregate consideration paid to NU for agreement obligations</a></td>
<td class="nump">$ 8,361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_AggregatePaymentsMadeToDateForLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Payments Made To Date For License Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_AggregatePaymentsMadeToDateForLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859198009400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Board of Directors | Consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transactions with related party</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=xcur_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=xcur_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139859301521208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Ipsen Collaboration - Collaboration Arrangement - Subsequent Event<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jul. 30, 2021 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_NumberofCollaborationPrograms', window );">Number of collaboration programs | agreement</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementUpfrontPayment', window );">Non-refundable upfront payment received for research agreement</a></td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment', window );">Pre-clinical milestone payment amount</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment', window );">Development and regulatory milestone payment amount</a></td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment', window );">Commercial milestone payment amount</a></td>
<td class="nump">762,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementLicensingFeesIncurred', window );">Collaboration agreement, licensing fees incurred</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember', window );">Option Exercise Period after the Selection</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionExerciseFee', window );">Collaboration option exercise fee</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember', window );">Option Exercise Period that begins after the first Option Exercise Period</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionExerciseFee', window );">Collaboration option exercise fee</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementLicensingFeesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Licensing Fees Incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementLicensingFeesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option, Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_NumberofCollaborationPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Collaboration Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_NumberofCollaborationPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Collaboration Agreement, Pre-Clinical Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Commercial Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Development And Regulatory Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ExercisePeriodAxis=xcur_ExercisePeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ExercisePeriodAxis=xcur_ExercisePeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ExercisePeriodAxis=xcur_ExercisePeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ExercisePeriodAxis=xcur_ExercisePeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M94][PHA;&H3?L28'R&%M6-]Q/(V=#L.6Y3A.#[]&&O#[M"%-PG62)B*!08'
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M0X<@I&]YEG6XK&!.ZG@[V?>-ZKM':NX>-:/BMJ)^W2J]ZQNR"D .6 4A8:M
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M6^5%NJR#I8-EE*S_!U_KAM@*P+0E@-0!Y*D!M Z@6@#Q6@)8'<#T@+9KX'4
MUP*8: D0=4#5F8-U8U4M/0Z*X.@@2Q]05JIEMO*@ZJXJ6C9PE)0C:UID\M=(
MQA5'UV?'U^/3J\D8C<[/QI.SZ?IH>O[A='Q<?CV]DO\^3LZNINC\!(W>'Y_]
M-IFBTS/YP_GHC_?G'\:3R^DO:/+G]>G5/ZB/KJ=C]/K5&_0*10FZ6J2K/$CF
M^<&@D&;+4PYFM;'AVAAI,7:5%D$,A(WL8:-TN90#=EJDL\] ]-@>?3R?1^6
M#V)T$43S?I3TT2BXBV KDXYDL]EJN8J#(IRC<7@3S:("2'+R]"3GQ2+,D+Q"
M64,6Y>2^#]%I,DN7(7K](<WS-\WT SD4-N.!;,8#J<['6LXW#&^C)(F26SE?
MXR"9R=2R'_-%D(7Y&Q04\DIF;Q'%OR+B8!_JGW5^7N4OZ]K]D2<<X1-!#P;W
M@#.Z<49W=/8$-\-U3K'MQG&9N[&R]FRJ_*9B;"JP((X@3=G$E/4]3'SM?">
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M]EO6WSG\9'2C=VRPF<RE?+.;Q[3C!580Y30QEH'@LJ9]RKDE0AGO%:=7A[3
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M#"9(G7%C4L=%M3 5< @08 *P0@R12@TI6Q"%2YV,8C%W%3,1WI$@5W8YY<T
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ME*9TX[;R_"AX[X*5['0HW";,=A,(?@^WV9K\VQU#/&'4"QNN)^T4.X$ENN6
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MX56Q(/[ 3; !?-_Y=&/0('4C=2"N'"$"XJ/U'OQOC$"3$H*6'$>/>WH]6_.
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M +4<'[C-)M@J/BH7-N")&I<%9@(Y%L#O2XN70;MA ]U_&1?_ %!+ P04
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MC42(_JI=:3 2=$#F8B_8UQ,T\T22!^@"EA+SB\X1_\6<PM'(%+>VJRL1\92
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MH/R=*V#^?H(-Y2T?8L>?EBX-0QH*4XT%2:./;I[.KJZNBFX#,*%QC6W.G5[
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ML!\W;%?&5><;14!^#-Z!.#T>S:)?,=!QM'>,8:2CL4$>J*BIY]?60F@T-J1
M1'HXB,K4MH#HJG.J#[CCNC2]:].#5F-' FGLS$UKJ&_1<6AI=)LI*&I$#(0<
MGT+(7C$R^RNJN2@^,?TF:+GJ] - 05 %>1>2)3Q/'\D(PS%FK 9"DB0PD"$1
M=[CPD&/DW@;</X[+]L4)93*>^;5EV5&1\EVJ4E#GF> 4O#%Y&,DMKA((J94L
MP,-U 8,WX*569LT>$\JN.A(T;6U\UA!#R-X98NS?'=+<F+2L@&H/Y:('Y7?B
M#J2QOFS*9(4E@!#4X[=NE_*LV(,X:?7!X8-D^J2 $VI4+D2:> !*@FML^(*T
MT? I<3C&($]T&F11G_0O &3+&W(?!4^_O8*Q['S(ANG<"<MO'9UV4;& ^F/<
M)Z8RH*8S_E@H)X:KV0,[J85?25M-JO!@YV3/J.+F%H8PG0/Y:+QDL+9K1[4Y
MGXV)[&*!OJ_SZ$TN\X5#&5>P'28K+ PI900*A,14JIH&DO/Y[OP8D-#S 9 <
M(CL"+POZ 4;Z7DB7*/)@4PTUNLW6H#I]K?A,AXK4N2,LD^HBW$GK^SBA/\UG
MPYQ@LF>38<<5LMI5\A&F7A;-ELR:-BIUY#*0IW B_<(++J>)P4QX#W-(+L6I
M%8$B$K_HJ'[AGX&>1M<F]BVW*\-9I]36XF4!H]J>F!F+3M5T@W%'=V9<UQ>H
MN83)&6E%CMIMZPS*>!5R/Q7;HN*TL7N9;3/.!AXLC<0^'RAWU13_&[I)Q(<-
MS2X_9:+F1,5]Q9:-C5N\??-.I4U(XBU\<2LW*PI*C4B2X\*CV25C..V8YL-B
M2&XR=W]RVR(>E3%#PMO^[:<QI1$$!10/=[WB9;+HL(*&:2:B2LF^R\TG5)<[
M2B[R/!N>P%H))ZY]D:K"K4V)'@CJ!%"@>QE8XR-P'^R%E-$_+!8@PN>I@"\1
M]!/V4$W2T?_2+ALVK&+9F8K\^L_>"2)?2*?+U!D*&>0 ,K+6,?$J>36=9(2(
M?K"-D[>6^RI[V'&;Z"9]^IM:;[Y_5WRFZR%E?O25HL&QBR(^3'O0GG3&/=YO
M6%F1J$9:SZ0]IIE,@?NH?#6%VK Q,YW8\""E0@$-I?K(D- I^_/D#BP,:$@M
M4Y'.$(;G9,OW64$\6XY79>(-'.R52.U9OPLXS[TG"BP5C!S!\DMCMRA1Z$R)
M'-V42.;H9HQB[)'V'Q<BPY/MGB^(::W#A3LDLH3D,2CF=VR2B<TU"2J89[C=
M5UKKJCZ89E9G0RZ3,Y-?_?E1;@/.$NO)=OC2$G(QOL<3HT.SM)S@(''O$I8?
M.V+@2L0A5@I(5Z.I>?MKHJ<>5QBTPO/^M\ 4\;ZL=P/'3BU6T8K9A#V;Q"EU
M,[PGSQ<&@[U(H4D;$:5ZSVSW[#S#L]E!^U8U9-=?VCRXEMP4XX-K3N4. E'N
MP=/BWW?F84"^W[-M.A)"G"U7E()0IWD <)/G@:DW;'S.CH*WNB\ZW%2CVQ;*
M9QO15<DJ1'SV=0Z[?+FLXQ+?A?0D7B4E.E.S8+1/2.MX:$P#]\)0N^K\C'=4
MA^0<1='0]:I@L:H/\^3%PYL&H?7F>Z[B6:N2B*KYX VIE9R_[(;I^^'+EP\Y
M\6AM2T9-5W%5&>XQ4S6U'9X'20,HG(7,\HN$X2+"<,O1(<<P.G#3K4,-Q?C(
MP$IWVVKSA192:V(=2(>:B?>E>VND)='QR**RFGBZ83O7Z3#GWR(P*N?H#PK@
MK %GHD<$^]F3IT@@F\&++#HJ2$B8F,!RIOY.@%!$KH9NZA+B=TUH'#%4^\XY
MNL'&XJ?D:+J_F=DYKR?-K,6>##DO,?[+_C41R5CH?27:*I\WN$N;-8@3AWR@
MN*4+4_1_I=D=)YKE@TF$ BB4B6I^$ Y_QC=2X1-3%U)7(Y-=A29"UHW)>Z94
MNE'G+EP+=*G/UM]XX.21C#2Z8#JE"ST_[FX%&3J]D.O<=,&93'RN=3@1(\M(
MT>& ;0RNGCM]'L*?GIX3T89.AF)W3J[;A)A/%5>(-\EXPK$"PPBR!%O?214L
M6 G8!N3)!8N\!2E<1N?YJ8.:XDM%P]@P)?O!"4COK#,YVIO22VJSB//FSC$4
M=*Z."=\?K7."'DBF _8F%1-L(BLQ1N>VQR)L#&,'0DA^%EYT7C(A*&33Y8"(
M)-!S^X 61V(R)'.N:_(OV6<XE93"4*M(HZ"Z)@5MC+Q,H-/"4'-<FT@*B2)U
M5E<6932A'1 HW/8B$V49<,_=TLP_Y&T$&<Q7:,)%A4$%%/+'B^)==KV1KZ2S
M:YJOH)7?AY-SQB.&ESEJU,K)UV\H*Z43E:\<8R"01\^_#<=,LZOGSV:Q8@9W
M-7+Q3V']>&QV*L'T4J8<K48?E'L]DF.%#(4=S7$4"!+!C\&78SE)'9\ Z$W'
M5X7HK2*6= R458I[/48/5) R]U.EQ!9&1\%I_WZO^":,G*E+".3&:S(A88L8
MRNU$S'.\'D,]IR0/M2/4V#%10RJ!^C:SAMY OAE<ICU5>2%W18'0.WK(4[@O
M/]XEI@$RASMAHD;_9ZS]ZC]I[4]F+VYOX[GJ[-LGWXXM?@+VPPN@I5Q5N[W.
MJ'22.3YZ/KMY]ER6?3&[?7(K>0<2>3=0RP Z[\N^4HNQK)&HA"Z,+]AGB#>1
M>=>HKF+MDWM)KYF"B*U-Q;O-52VO_M"+P- '8A8@\^M!F?W:%#_JN>OHE.?Z
MN5S+FQ7OOQKNX8[>R?Q[UHD;O*60-2N16*5-\^+L/DHNTEVA S><[EN@I[J_
MW]3$BTWYY6C"/DKS!4=@,37+>HDP'*YCF5"*R\A1@I8JZCQCC'>1+XJIEX0O
ML]>RD10L^>5S+X<"\H9V^C6]W_Y&7NONA\O+\3\KMP2= *$%IEY=/']Z)L5=
M_-+:#;_D/;=M:]?\<:45)$H#\'QA;1N_T ;IK?_7_P]02P,$%     @ !X$,
M4\GG\HW0 P  0PD  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULK59M
M;]LV$/XK!RT8.D"+).K%<F8;2-(5[;!B08UM'X9]H.6S390B59**G?WZ'2E;
M]8;%;;<!MOBBN^>>>^%1L[TV[^T.T<&AE<K.HYUSW4V2V&:'+;?7ND-%;S;:
MM-S1TFP3VQGDZZ#4RH2E:96T7*AH,0M[#V8QT[V30N&# =NW+3=/=RCU?AYE
MT6GCG=CNG-](%K..;W&)[N?NP= J&5'6HD5EA59@<#./;K.;N\++!X%?!.[M
MV1R\)RNMW_O%F_4\2CTAE-@XC\!I>,1[E-(#$8T/1\QH-.D5S^<G]%?!=_)E
MQ2W>:_FK6+O=/*HC6..&]]*]T_O7>/2G]'B-EC8\83_(EFD$36^=;H_*Q* 5
M:ACYX1B',X7Z.05V5&"!]V HL'S)'5_,C-Z#\=*$YB?!U:!-Y(3R25DZ0V\%
MZ;G%LN\ZB11EQR7<<<E5@[ ,Y?!&#3FGX,T21[:\1M(<<>\&7/8,;@5OM7([
M"]^K-:[_JI\0QY$H.Q&]8Q<!?^C5->1I#"QEV06\?'0\#WCY?W(<?KM=66>H
M=GZ_8+,8;1;!9O&_!_LBKC^X-[;C#<XC.ID6S2-&G^O@@\&.BS7@@<ZY10M<
MK4&['1HJ/V-(';BUZ"Q0!G#, +S$!ML52>59V$E'I(;HB8;+&!HJ 1\[\*2X
M:78!O.6JW]!N;X3:DHPE["O(X[RN:61QGE?$T"$I><T&Q2-?282B@*S*1C-"
MV=X$IUA90#4MX*? >IHRR.*T2+_ M2LHXC*8+V*6>QO4]8Q["AKXH1>=CV,,
MBH+WJ3 L&T&R8B.:CYH$7,;3J@IC,:G@1Z1.LM.2W&@[HQ]#GBQ\_57-,O8=
M9%,&][KM>HK"0-OJC=MS@U R*"IXU1LE*((87F[$P<\MT?*_>ZVH9ONA[0D%
M9*!!:R'S$<RFSWJW-9JDJMA;+^.ZRHFFM3?4.9N^[25WN*:&1Q76B*%V7K X
MG:;?P(LLGA0T7@J;#VU&J0DCRREP9T!>GK?:./''L'%,&>PY)8?5>9"XRNH)
M4.4"I9#^!A':H<F@;S)_RXS7\ F)??5U&+J_?(H'I))B&"9Y7HZ05AR^'/ :
M;IO&]'BQS*3@*R&%$_CI8W2"^W?'*(L9!=>/^82-6!U_,EK*;PT.61RI9I2+
MB7^6]5"3(U6*U(E]0:P\Z@EM\&W$*$AW<F;L,^/@CSQC=1A+5L(_]=?D[&)K
MT6S#]6W)V5ZYX8X;=\<OA-OA8OPH/GQ>O.5F2RT#)&Y(-;V>E!&8X<H>%DYW
MX9I<:4>7;ICNZ"L'C1>@]QNMW6GA#8S?38L_ 5!+ P04    "  '@0Q3E#N/
ML 8%  #_"P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6R]5MMRVS80
M_94=]3+)C&R)E"S)CNT9V6F<=)JI)[<^=/H D2L1$Y!0 % *^_4]"U*RG,9.
MI@]]D$@ NV=WSUZ(\ZUU'WW!'.AS:2I_T2M"6)\-!CXKN%3^V*ZYPLG2NE(%
M+-UJX->.51Z52C-(A\/)H%2ZZEV>Q[U;=WENZV!TQ;>.?%V6RC57;.SVHI?T
M=AMO]*H(LC&X/%^K%;_E\'Y]Z[ :[%%R77+EM:W(\?*B-T_.KL8B'P4^:-[Z
M@W>22!;6?I3%J_RB-Q2'V' 6!$'AL>%K-D: X,:G#K.W-RF*A^\[]!<Q=L2R
M4)ZOK?E#YZ&XZ,UZE/-2U2:\L=N7W,5S(GB9-3[^T[:534<]RFH?;-DIPX-2
M5^U3?>YX.%"8#1]02#N%-/K=&HI>/E=!79X[NR4GTD"3EQAJU(9SNI*DO T.
MIQIZX?)5M6$?P'+PYX, 0-D>9)WR5:N</J \H=>V"H6G7ZJ<\_OZ SBR]R;=
M>7.5/@KX:UT=TVC8IW28)H_@C?;1C2+>Z-O1T9_SA0\.5?#7(\#C/? X H__
M&VV/*DN?G?FUROBBAT;R[#;<N^?JW)-=$LC@/1FDJIR><\;E@AV-DKB+LU P
M7=MRK:J&UDZCL;1I2$<PSDD#C3]G[#UERA<X0,DN I[@HFZMP51FW=HZ)7WB
M6\SWQV^/Z1W:W->NZ=-25ZK*M#)14X>Z$Q6OHNC*;MA5 DCH98BR1R6'@F#'
M5BO*'.<ZD-BH5C[JJ:KS,VJMG,JY.R<5R#I2"X"2(@. H\"NW!W#X[D:#>;S
MHQ:(?&%=^%+D-AG,$P1QP%"A0(</:F$T6B:G5:USEO1X#!BC9$!0L)3CZ;Q>
MZDRUHP-&, !JIX/$%0KX)P,OX$=>+3DT4<;H3P#4H;EO=<U.VQQ@!JEQO)')
MTF)B=]DBH@P.O8$3:')=ZK_AD.,J]Y*Z1K/)6U489]1.9+2C&B,7B2S7SI;:
M"P</>[:T!M-89(0+[D8RC$57@%+%3MD%W0B=<J V2AO1.,+GX,@K4>7LCI<#
MIN$IJ7_7\1G]CE7#RDF&C11F,AS23S1?(B"RN\,%@I&@$'78VKCGZ><?9FF2
M/H/T.QM0BYVF,3O_.NM1;OK,?\-?Y0XB$LH/ X "U4@*') F@I*3,L77L.N3
M8VE3A7QZ? #N-R+*AE>VY5/MO?/WC=]A*N]9^G3#"!9I7!41#74J+7R8 V]+
M\0CUJ?,:!!S@E:JA!=\1"/=+BP 7W%@4@  NE$$3 SA^[7.@M]6@(!C@;([$
M>X2R<A9IJ2MTOXG;A36Y%,L*]>X?.3?8Y[8^ETH[VBA3<YPO,GL8)8B=.'-B
MVSZ:G$5#H5E'[6ZWD;'P'4.1MBR)]5V5^[,OE.;[<*\1KJ>;&,[[NW!>=N'<
M2+@/'__61OM"(OT0(T7^2W9Q3*X5"H5^I)/^Z>DIGKO2/7QKSZZ[V<M46;3R
M8&&EVR=]"%&REY;UJ!VU-U^,VN:0MJ2?GDQHO-?#>C*$K634'T^F8O2>"[(]
M3;_"X?]*4B),I'B1WY/1T]U6\@ YZ6D_3:<$QT585J>3>U\L82(%$PD0=\'*
M^CL9G)R F$,*IS.X-)[UIR.A;R8)?3)YVN[-DAE][48Q.+B4(>!5O'JBZ6U=
MA?9^MM_=WV[G[:7N3KR]&K]6;B4L&UY"=7@\/>F1:Z^;[2+8=;SB+6S A3&^
M%KBALQ,!G"\MV.L68F!_Y[_\!U!+ P04    "  '@0Q3@&W@!F *   1'
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MF:;23/Y@0W-$$EP"ZD+X8Y]'X :B0SR/W;[=6O.@4;856 L983U]F<J1*HZ
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M<=GPL$87'/B\LI;&30@PC?_U#U!+ P04    "  '@0Q3$->B$3\$  "7"@
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M"LLM*P[H0XF6-E)+#<#J0-R-K+U=]C$ZP4R'[W9]L.):SJ>9->05Y9%<2"H
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M1EB6/*+1>@.^+XRAP\8[Z(?^_"=02P,$%     @ !X$,4XOK<]2^"@  -1\
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MDZ1D>8BNX1]&P<)@3?ZX4A+])BW ^X5#EYT?Z(#NE_+7_P902P,$%     @
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M#<&6\;+ <"3'!_!\89'AY@<;Z+XWWOP.4$L#!!0    (  >!#%.MAH_!S@,
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M<N$;0K9Q/^M0KEJ4Z 64!-Y+80H-OXH<\Z?U/G74MQ4=V[J*S@*^:\00XF
M41"%9_#BGF;L\.+OH/GG.M5&T7;XZPSPJ <>.>#1?P,_)]OYXH<"82,Y'8Q2
M;,%8];O34?Z-&@R%,]+5]DIK;AI5F@/(C0NP'2NYK7A%)_.59K84,YM2=J77
MLJJ9.$"!/ >F;2')BKVL<_B=K ,R!5(!+;R&, C@)UAO#)+O&$P;0YO2%*4
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MZ*ITPX*^35#9!(IO)*G7&7:"_FMG]1502P,$%     @ !X$,4YS!/#B] @
MU 4  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL?51M;]HP$/XKIZR:
M6HDU(8%"*2!!NVF;U@FU>_DP[8-)#F+5+YGME':_?F<'4CJU?$G.OGL>/W?V
MW7BCS9TM$1T\2*'L)"J=JT9Q;/,2);.GND)%GI4VDCE:FG5L*X.L"" IXC1)
MSF+)N(JFX["W,-.QKIW@"A<&;"TE,X]S%'HSB;K1;N.&KTOG-^+IN&)KO$7W
MO5H86L4M2\$E*LNU H.K233KCN8]'Q\"?G#<V#T;?"9+K>_\XE,QB1(O" 7F
MSC,P^MWC)0KAB4C&GRUGU![I@?OVCOU#R)UR63*+EUK\Y(4K)]$P@@)7K!;N
M1F\^XC:?ON?+M;#A"YLF-CN/(*^MTW(+)@62J^;/'K9UV ,,DU< Z1:0!MW-
M04'E%7-L.C9Z \9'$YLW0JH!3>*X\I=RZPQY.>'<] J7#HZ_L:5 >S*.'5%Z
M1YQOX?,&GKX"/X-KK5QIX;TJL'B.CTE*JR?=Z9FG!PD_U^H4LJ0#:9)V#_!E
M;7Y9X,L.Y7?%;2ZTK0W"K]G2.D-OX?<!\EY+W@ODO5?(%X:KG%=,P#5SM>&.
MHP6]@B]:K=\Y-!+\\2]5]2"O;\21K5B.DX@ZS:*YQV@Z"]14'VSKTP%7(E2M
M"OE,A?==:EDQ]?CVS3#M#BXLB%99X0NS02H)L[#2@KK3CI[3-Y]C@[ZYN5J#
MY0\@PWV?P!$$TO3"1Z70[?3ZY][,H-\99IDW>T]F'WJ=;-"'IXHMF6 J1Z!!
M81U3A><_@NZ@TT\2H,=(8FK%I#:._\4""KI"72L'%-IHY];6@2'7UEDX'@R2
MD[W*AQ@B/.L,L@0N:V.0T)7GHV&PT_Y5J_P_5XMYZ8'$>YTFT:S#/+$0I#5-
MU^ZV(VO6=.I3>#/OKIE9<T57@BN")J>#?@2FF2'-PNDJ].U2.YH"P2QI[*+Q
M >1?:>UV"W] .\BG_P!02P,$%     @ !X$,4Z#"XW3H P  A D  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&ULC59M;]LV$/XK!ZT;$D"SWBS9SFP#
M2=IB'9HUB+,6P[ /M'2VB$JD1E)QO%^_(^4H=N-X_4(=R;N'=_?<D9INI/JJ
M2T0#CW4E],PKC6DN@D#G)=9,#V2#@G964M7,T%2M ]TH9(4SJJL@#L,LJ!D7
MWGSJUF[5?"I;4W&!MPIT6]=,;:^PDIN9%WE/"W=\71J[$,RG#5OC LT?S:VB
M6="C%+Q&H;D4H' U\RZCBZO,ZCN%SQPW>D\&&\E2RJ]V\J&8>:%U""O,C45@
M]'G :ZPJ"T1N_+/#]/HCK>&^_(3^WL5.L2R9QFM9?>&%*6?>V(,"5ZRMS)W<
M_(J[>%*+E\M*NQ$VG6Z:>)"WVLAZ9TP>U%QT7_:XR\.>P3A\Q2#>&<3.[^X@
MY^5;9MA\JN0&E-4F-"NX4)TU.<>%)65A%.URLC/SCT@A:3B[9\L*]?DT, 1J
MMX)\!W#5 <2O &1P(X4I-;P3!1:']@$YTWL4/WET%9\$_*T5 TA"'^(PCD[@
M)7V$B<-+3D?XU^52&T5%\/<)S&&/.728PU<P%]0;15LAR!5\:E QP\4:NI-\
MN"P*;DN.5?!!='U#LV.I/7W*GC'5?\4,%F DF!+A6M8-$]N??AC'T>@7#;)W
MHK). -.:&IJ)HC?\5J/B;,DK\I-RLT%E36 E*VI2?0'$ ?8<P!=7VEC\S!X(
M8XV$:=O]&<N@JF$R"&&+3.F7^@77N6R% ?( 83Q(X,<3)*0]">EWD^!23UG1
M1A_+\TD@>^]=Z(;E.//H8M.H'M";WU.6NWS8.(UMC]W-Q?^EE'6!Y_9 X.(H
M)ZU@+14"Y3Z7U!M"=Y*6%2\<)=K0ARXX8R/8\4/[%W!?*L2#OH(%?SQ<<,S0
M$.Y)G[[AN'/O#21Q1F,\L6.6)G9E',*BE,ITW.VK)P0V@2R&; 2?*5H7^;Y"
M-$EA$D,ZBB$:3N!>&BKTPP/3-*9Q&(UHC/QX;+\I'7^"]:QG/?MNUM^WIJ7*
MO:%:K-L:[BB5Y,HMV]JD'BV$D]C'"^&&T2%=G]"1QX@^;*BM[232/.RA%RWV
MIVL5XM+2]19SK)>H*/G^BPNE SA[;CI-M5"[6CBW61Z-K0:1X4=98L7$BA.W
M.K3I3U(KIE8DSDC,2$RBD.J,O&(K*@$8^N/):,<E<1;Y*=7)1]3D*:^;UI8K
M%Z2(VL!9X@^3T?D!\\_1OX&Q'T497+=*N=I^Y>*QFD,JVM^ER/]7=>1G5#ZG
M#SQ67,'>RUBC6KOW7X.[C;I'LE_M?S$NNY?U6;W[/[EA:LV%97M%IN%@1)>*
MZM[\;F)DX][9I33T:CNQI-\D5%:!]E=2FJ>)/:#_\9K_!U!+ P04    "  '
M@0Q3<4TC]TD#   #"0  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6S%
M5FUOVS@,_BN$,6 MT-5OS=8528"FVV$;]E*LW=V'PWU09#H6JA=/DIMNOWZ4
M['@ID&2W#X=#8EF2R8</*=+T=&WLG6L0/3PHJ=TL:;QO+]+4\085<Z>F14U/
M:F,5\[2TJ]2U%ED5E91,BRQ[GBHF=#*?QKUK.Y^:SDNA\=J"ZY1B]ML"I5G/
MDCS9;'P6J\:'C70^;=D*;]!_::\MK=(1I1(*M1-&@\5ZEESF%XNS(!\%_A2X
M=EMS")XLC;D+B[?5+,D"(93(?4!@=+O'*Y0R !&-KP-F,IH,BMOS#?H?T7?R
M9<D<7AGYEZA\,TO.$ZBP9IWTG\WZ#0[^3 (>-]+%$=:][(2$>>>\48,R,5!"
M]W?V,,1A2^$\VZ-0# I%Y-T;BBQ?,<_F4VO68(,TH85)=#5J$SFAPZ'<>$M/
M!>GY^8TW_*XQLD+KGL+KKYWPW^#HEBTENN-IZLE$$$SY +?HX8H]<,_A@]&^
M<?!:5U@]UD^)VLBOV/!;% <!WW7Z%,KL!(JLR _@E:._9<0K]^ -'OY]N73>
M4DK\<P#S;,0\BYAG^V)(E5)U$L'4<,EYISK)/%;PR3=HX<HH*I<FY/$]PEO-
MC4(X>F_<[O@>-!5*],*UC.,L(5"']AZ3^6V#4!M)]27T"GPXNZ'(Q'=T0"R
M-TRO:"XT(.,-$(G6:-0^<&9;G$WDS!]Q%@-G&3B?@,:HY=G#"9FU\60NX(NF
M=X(D@Q6LZ%W@>G%*(J#:<XVQ_IE'JPCL'IVGLO8.;HUG$A9,,LT1F(=7R%$M
MB4"9QQ//X F<E_WP:0>S8 *62"R0WA!<,N=$+3@+!4\,)OEQ/WPDRKRS-CC<
MHA5FMZ,1[J?6%K$/S%+4!E8Y$2J+?MC%ZE&\#M K7ASWP[^DM\$=];8(4IW@
M6"=$;1*O_S\SLO\F,_*7Y%^,P7 [< Y[#R#/PO_W@M_K[,N,D*]'><\J/\SJ
M5]E13HIX!7I]O. HAN]X2YA"6ENC?GE.,;%+^OV>L^5D$J\]>1:\+<OS8=SU
M(DVW&I-"NXKMUY&Q3ON^1XV[8X>_[!O;3_'^\X#BO K)([$FU>STQ20!V[?<
M?N%-&]O<TGAJFG':T%<*VB! SVMC_&81#(S?/?,?4$L#!!0    (  >!#%.>
M*%77Z 4  "0/   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;)576T_C
M.!3^*U875B"5-/>D#""5RUQ6&@WB,O.PV@<W<1N+).[83@O[Z_<<.PD42L0^
M-'6<<_E\SG>.[9.-D ^J8$R3QZJLU>FHT'IU/)FHK& 558Y8L1J^+(2LJ(97
MN9RHE60T-TI5.?%=-YY4E->CLQ,S=RW/3D2C2UZS:TE44U54/IVS4FQ.1]ZH
MF[CART+CQ.3L9$67[);I^]6UA+=);R7G%:L5%S61;'$ZFGG'YPG*&X&?G&W4
MBS'!E<R%>,"7;_GIR$5 K&291@L4_M;L@I4E&@(8OUN;H]XE*KX<=]8_F[7#
M6N94L0M1_N*Y+DY'Z8CD;$&;4M^(S5?6KB=">YDHE7F2C95-XA')&J5%U2H#
M@HK7]I\^MG%XH9"Z[RCXK8)O<%M'!N4EU?3L1(H-D2@-UG!@EFJT 1RO,2FW
M6L)7#GKZ[.IWP_73T3DL+"<7HH)D*VKB=7!'YR53AR<3#7Y0>I*U-L^M3?\=
MFS'Y+FI=*')5YRS?UI\ OAZDWX$\]P<-_M74#@G<,?%=WQNP%_2+#HR]X!U[
MMP65[&ANUGQ-GX!CFLRDI/62F?'?L[G2$@CSSX"SL'<6&F?A_X[PU2..&;DH
MJ5)\P3,[S6MRJZFV4,2"_%@Q:;ZH7:D8=(XE?:Q6-&.G(ZA9Q>2:C3I$=OW9
M2T2L1<05R5I0( * =,&(ZD I1"5Z5(0JLA EE+<Z)G>%9&PK_^26/VY/8!;Q
MX;X8W0 X*K."T#J'JEI#MUB9 '20]D@0>_#TW0">L9>:&9=\834 *8T>S:%"
M.*8.2[U7#4$E"#T2QP&)_0@4DSB$9Q3BTQO[*1J>IA$92'?4ISL:3/=,07];
MV<#<8X"U()=,,PG0&/E,N20_:=DPC"&PH1*8;9$]0)I-"KX #?7.3 _[_08=
M+L^YL0$N*;SV2(BP&<2 9!HQ 1P$@)/"BBR-7\QESA4T'H0^QYX])G2U*CMR
MMDKG)<T>CFZS0D"+()7(60DM&G@%).MQ0%9XO6HTTD.23<$AO1M&"@JY,> 0
M"1A;8SS +U.9Y/-GPFEL0!;$\1"+KK:6%3DN!B!V//($E%(PX6]/W'#U<+1
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M12(B8L=3&_'S6\2:4$M'J*\UH6X;0BUXAF0!BN^OG<-1XRJ.!:7+-(SY!6=
M#"W*2O(;UPI#TNP,7G"$-'!._U2.MZ#$3G$6#,[;*(?WS"L-CS'0;\T[V"K6
M;JHS+%*EM-7HTWQM!L>K:EYZW5Y-G7=<KP7&D$&"JMT+FM-T-<E5@E6%FYY6
MRN(LYI8I#K^@:0/^3Q1VG5H@@&:<GO\)4$L#!!0    (  >!#%.8JU:#$P,
M ,<(   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;+56VV[30!#]E9$%
M""1:VTG3"R21F@1$$1512^$!\;"UQ_&J]J[9'3=%XN.97;MN$*X%#[S8>YES
MYLQX=\;3K38W-D<DN"L+96=!3E2]"D.;Y%@*NZ\K5+R3:5,*XJG9A+8R*%(/
M*HMP%$6'82FD"N93O[8V\ZFNJ9 *UP9L79;"_%A@H;>S( [N%R[D)B>W$,ZG
ME=C@)=)5M38\"SN65):HK-0*#&:SX#1^M8P]P%M\EKBU.V-PH5QK?>,F9^DL
MB)PB+# A1R'X=8M++ K'Q#J^MZ1!Y],!=\?W[&]]\!S,M;"XU,47F5(^"XX#
M2#$3=4$7>OL.VX FCB_1A?5/V+:V40!);4F7+9@5E%(U;W'7)F('P#S]@%$+
M&/TM8-P"QC[01ID/:R5(S*=&;\$X:V9S Y\;C^9HI'*?\9(,[TK&T7R%-C&R
M\BG5&2QJRP;6@E I+(25UJVN#5I4)+S5\Q62D(5] 7MP=;F"YT]>P!.0"C[E
MNK:,L].06)GC#Y-6Q:)1,7I$10SG6E%NX8U*,>W!+X?QXP%\R!GITC*Z3\MB
M-$AX6F_V81R_A%$TBOOT#,/?UXKA41_\-SGC[BN-/=_X$;XK5=M:%' A[0UH
M U<J0<-?0=$/^/J!C>&,L+3?!EP==*X.O*N#QR)/DKJL"T&8NNL@$TFP087&
MK;P$/AX)@GOX,].7FH;_T/.[*G([WXLG\>3@>!K>]@B;=,(F@\+XUF(B+,%/
M.*OX. +?W$)<:R/^%/*;@\/.P>'_3O)1Y^IH,):UT0EB:B$SNMP)1)O>RW/T
M1T:Y2D=1?SZ/.PW'@QJ6'S^?K?;BDX%P3CJJD_^=N3AZ*%C1<.[0)*X8;="5
MIHMGHJQ>K\"2R#+@\F0E86\!&6:-HV@_BIX.*=PIJ?$_*"3N>D"Y()[P=4)?
M6IL;5?BQ2+FN2TON(-]B&XDP.!C-L(+)H\&$.ZVB1+/Q'=1"HFM%3=?H5KLN
M?>I[4_A@WK3X<V$V4EDH,&-HM'_$]]<T7;.9D*Y\X[G6Q&W,#W/^TT#C#'@_
MTYKN)\Y!]^\R_P502P,$%     @ !X$,4TG)ND"^!   M!8  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&ULS5A;CZ,V%/XK5M2'76D[8',+JR32S*1S
M6>UN1S/=]J'J@P,G"5K U)@D4^V/KR$$R  .4T75O 1,SOE\;C[?@<F6\>_I
M&D"@713&Z72T%B+YJ&FIMX:(IA<L@5C^LV0\HD(N^4I+$P[4+Y2B4".Z;FL1
M#>+1;%(\>^"S"<M$&,3PP%&:11'ESU<0LNUTA$>'!X_!:BWR!]ILDM 5/('X
MECQPN=(J%#^(($X#%B,.R^GH$G^\)TZN4$C\'L V;=RCW)4%8]_SQ;T_'>FY
M11"")W((*B\;N(8PS)&D'7^7H*-JSURQ>7] ORF<E\XL: K7+/PC\,5Z.AJ/
MD ]+FH7BD6WOH'3(RO$\%J;%+]J6LOH(>5DJ6%0J2PNB(-Y?Z:X,1$/!Z%,@
MI0)YH4!PCX)1*AA#%<Q2P1RJ8)4*UE %NU2PARHXI8(S5&%<*HR'*KBE@EN4
MPSY_1?+G5-#9A+,MXKFT1,MOB@HJM&7.@S@O]B?!Y;^!U!,S620A73!.\YI#
MCY "Y=X:T=A'GP-/%C6@RQ4'D/4M4O1N#H(&8?I^H@FY>0ZA>>5&5_N-2,]&
M7]GF F'C R(Z=K\]S=&[G][3 W('W+4:[@86$LXY@NM F:M1/F7Q!3+T'(7@
M?I1?AJ/H_2@W9['E]BRVW*E1YN!)%'P*Y7XP2D^.-%FM5<F2JF1) 6L,*ME+
MSFF\*JJHJ-KF^E>Q!H[$FL;H6.G/SQ(3W0N(TK\4%AF5149AD7G:HH("-A!G
MT%6->QB[@,EI:#-S7%W7)]JF66UM*7-L.BVYF[8<UAV[)7?;(6?JAMX4/'+;
MK-PVE6[/80F<@W_P^(-L6'+=>9SG>RBKZ3JQ.YP:*'=GMIP:&Z;1ZY-5^60I
M?;I<+"2AHN.,_GBQ;M28HGKL:DO[C=2S4UGD*(/P-8L6<B.V1-Z1WPEG*TZC
M5 9$U;JOG%8.27=6QI5!8[5!+/Y9#D%9[--%""A+EIS)>"3TN8@+!P]D&'PD
MAS^Y.'"8RL1QJWR(I>O]9\*M+'5?T0I84EQ@!]P+))4NH:LM7+FM>&%=90S6
M:W;7SV].B6D/MZ<Q;6"E/;\!ET-,64W  ^;+9,K[+0^$@!C%3,BIH],H-;"K
M(Y\^IXKBQS6_8'*>=E[B6"?Z>8>8.3:,=N_K$.SNZ%V"AFNZ_1FJJ0RKN>Q5
M3;W$.MW5APK>X399*?LZKLD*GV(K'D$8[-IS[7_L[[CF%&R]D0Z/:]+!]O_;
M4J_+#3O:1D_J:CK":CX:?B"=E@FMP]@6D=-0NV!/(MUVB(QQO[<UUV$UV1U[
MZTMO0Y8428%=DE=NVAG]-J.IHU\S&E93VLN.T/DBX"K"=3SEU]Q%U-PU;WB>
MGY-K%D4Y<=$P^&<?F\-)_H'..+:1FLP(?B/'FC3>C5[#70,)O\0\JAWE-$1J
M.B%J.OE"=T&416=.4=WTB?E64E2S 5&_8C3K.@I"2 63&Y2-MS,]5HL\+75Z
M:A8@:A9XX,S//!F-1,[V&QH680EI%LMF/\PVNV,2*4?I'N/JMD_4;?^)2@,&
MFM'1U9WN&&F-CV7Y]]POE*^".$4A+*6N?N%(7_C^$^E^(5A2?#];,"%85-RN
M@?K <P'Y_Y(Q<5CDG^2J#]6S?P%02P,$%     @ !X$,4Q?!#CVS @  7@<
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M2#=7FLL$J@Q$+5)JS]*0HU HK1!+5\9A5<?7KZYQ'Q^N<;XQJL-H<R2"THO
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M<[#Z;*X[@I;Z\-E0(8\RW<SD=08Q!9#O=Y2*8T<9M!>D^ ]02P,$%     @
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MVN%L%9XJ1EX5(\_@^P?PRZC\OEX(R57=_6G!]"M,WV!V#V#.5+6"BG&$A,[
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M.GWES(OFIYA(EIG^8<&DZD;,,%8-(W!MH/:73)$J)[HEJ5K0R3]02P,$%
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MG]83[@JR+9USZ*0&33=H?]V$;?+'5VNF(O3G'Z 2/1B>Z+\<@.@.$,T!]5L
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MD_QRP1D4H%T [V<2SD?EC?TU8?<;V^6_4$L#!!0    (  >!#%.ZVU8'&P,
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M6(V9P#5 /5\P)G<;;: <7/M_ 5!+ P04    "  '@0Q3<VD4ZJ$#  !S#P
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MM5UMM:BH[<-J'TPR@%4[3FV'R]^O[80 ;4AY6%5] 5]FCN?,F=C36W+Q(N<
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MW?'8X5PWI2",@=Z?<JXV$]/VE&WNX!]02P,$%     @ !X$,4P::7-70!
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MW]=)!CG5Y[( @5^64N74X%2M?%THH*ESRKD?!4'/SRD3WF3DUN9J,I*EX4S
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MPY8-E#7 [TN)I:\G-D#3!$[^ E!+ P04    "  '@0Q3V86(:MH&  "Q-@
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MWQ(TWH'>9UJ[C>$3U%^GP6]02P,$%     @ !X$,4ZA*'.,( @  $P0  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C$N>&ULA53=:]LP$/]7A.E#"R-R[#4K
MQ3'D@[$--D*S; ]C#XI]L45EG2>=D^Z_GR0[)H-F>[%TTOT^3CHY.Z%YMC4
ML9=&:3N/:J+VD7-;U- (.\$6M-LYH&D$N=!4W+8&1!E C>))',]X(Z2.\BRL
M;4R>84=*:M@89KNF$>;W$A2>YM$T.B\\R:HFO\#SK!45;(%V[<:XB(\LI6Q
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M?G''_KE\%J:2VC(%!P>+)^_N(V;Z%NP#PC9<^Q[)-5&8UN[5@O$);O^ 2.?
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MJ-T >IXK98\==V3H3GRK?P%02P,$%     @ !X$,4Z8?U?(0 P  ,A$   T
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MVZHHYK[L3MUHGK]]9?CVA>3EWU!+ P04    "  '@0Q3)V75I0P"  "$)0
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MW2&?#?]VFKT!4$L! A0#%     @ !X$,4P=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  '@0Q3ZAQU
MO.\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    "  '@0Q3F5R<(Q &  "<)P  $P              @ '- 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  >!#%-X\*(U4 4  /X5
M   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    "  '@0Q3)[-;DHL%  "'%0  &               @(&4#0
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ !X$,4TXSPS_Q
M @  U0D  !@              ("!51,  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    (  >!#%/QRJTZ=@4  )$8   8              "
M@7P6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  '@0Q3
M,N=&7E$#   N"@  &               @($H'   >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ !X$,4]?!9Y9H!P  %BP  !@
M     ("!KQ\  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M  >!#%/7MJ0:YP8  )8<   8              " @4TG  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    "  '@0Q3"J%L3[@"  !C!@  &
M            @(%J+@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ !X$,4Q+&J\OF$0  :#0  !@              ("!6#$  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  >!#%.V@ZXB0 4  '$,
M   9              " @71#  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ !X$,4RJ"N9+M$@   4   !D              ("!ZT@
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  '@0Q3R>?R
MC= #  !#"0  &0              @($/7   >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    (  >!#%.4.X^P!@4  /\+   9
M  " @19@  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
M!X$,4X!MX 9@"@  $1P  !D              ("!4V4  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    "  '@0Q3>>D!:W$)  !4&0  &0
M            @('J;P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    (  >!#%-SM3B#D@8   43   9              " @9)Y  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ !X$,4YATJ<-*#0
M#B4  !D              ("!6X   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    "  '@0Q3EW,$D*L"   *!@  &0              @('<
MC0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  >!#%,0
MUZ(1/P0  )<*   9              " @;Z0  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ !X$,4]9QC@05!@  "1   !D
M     ("!-)4  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  >!#%.MAH_!S@,  +H)   9              "
M@9^T  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ !X$,
M4T3O6DNL P  ^0@  !D              ("!I+@  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    "  '@0Q3G,$\.+T"  #4!0  &0
M        @(&'O   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   (  >!#%.@PN-TZ ,  (0)   9              " @7N_  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ !X$,4W%-(_=) P   PD
M !D              ("!FL,  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    "  '@0Q3GBA5U^@%   D#P  &0              @($:QP
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  >!#%.A0V/7
MF ,  "\(   9              " @3G-  !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ !X$,4P0K$9H_!   6@L  !D
M ("!"-$  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  '
M@0Q3F*M6@Q,#  #'"   &0              @(%^U0  >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (  >!#%-)R;I O@0  +06   9
M          " @<C8  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#
M%     @ !X$,4Q?!#CVS @  7@<  !D              ("!O=T  'AL+W=O
M<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  '@0Q3"]5W51T$  "H
M$0  &0              @(&GX   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM
M;%!+ 0(4 Q0    (  >!#%-.%) FQP(  (X'   9              " @?OD
M  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ !X$,4S!S
M@LH< @  804  !D              ("!^><  'AL+W=O<FMS:&5E=',O<VAE
M970S."YX;6Q02P$"% ,4    "  '@0Q336<;"S,$  !6$P  &0
M    @(%,Z@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M  >!#%-N$RI4G04  (\:   9              " @;;N  !X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ !X$,4\R_<$?T @  P0@  !D
M             ("!BO0  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    "  '@0Q3.9Q<%R4$  !Z#@  &0              @(&U]P  >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (  >!#%.H.+E.^P$
M 'L$   9              " @1'\  !X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ !X$,4R T4%/4 @  + D  !D              ("!
M0_X  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  '@0Q3
M=*O*2Q(#  # "0  &0              @(%. 0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    (  >!#%/H:Y1Z! ,  (X*   9
M      " @9<$ 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ !X$,4RO4I_6I @  4P<  !D              ("!T@<! 'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  '@0Q3=(UG^#0%   Y&
M&0              @(&R"@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    (  >!#%/[LM%]- 8  &\;   9              " @1T0 0!X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ !X$,4[K;5@<;
M P  Q H  !D              ("!B!8! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    "  '@0Q3<VD4ZJ$#  !S#P  &0
M@(':&0$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (  >!
M#%,#:#8-_0(  /(*   9              " @;(= 0!X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ !X$,4P::7-70!   DQ(  !D
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M=#4W+GAM;%!+ 0(4 Q0    (  >!#%/9A8AJV@8  +$V   9
M  " @78R 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @
M!X$,4T$39)]9 @  4 4  !D              ("!ASD! 'AL+W=O<FMS:&5E
M=',O<VAE970U.2YX;6Q02P$"% ,4    "  '@0Q3<Z6KO\X"  "I!@  &0
M            @($7/ $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4
M Q0    (  >!#%.H2ASC" (  !,$   9              " @1P_ 0!X;"]W
M;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ !X$,4W.RIXIA @
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M96QS+RYR96QS4$L! A0#%     @ !X$,4T\N70,"!0  I2D   \
M     ( !@TL! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  >!#%,G9=6E
M# (  (0E   :              "  ;)0 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    (  >!#%/NU>T8Y@$  /4D   3
M  "  ?92 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !' $< :!,   U5
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>212</ContextCount>
  <ElementCount>382</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>57</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Collaborative Research and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements</Role>
      <ShortName>Collaborative Research and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformation</Role>
      <ShortName>Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2112105 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2120107 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensation</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2141111 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2145112 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2150113 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2152114 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2154115 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables</Role>
      <ShortName>Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/SupplementalBalanceSheetInformation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/Investments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/Debt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/EquityBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2342307 - Disclosure - Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareTables</Role>
      <ShortName>Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/LossPerCommonShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2346308 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Description of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Collaborative Research and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails</Role>
      <ShortName>Collaborative Research and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/InvestmentsDetails</Role>
      <ShortName>Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/InvestmentsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Investments - Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Investments - Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Debt - Principal Maturities of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails</Role>
      <ShortName>Debt - Principal Maturities of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Leases - Right of Use Asset Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LeasesRightofUseAssetInformationDetails</Role>
      <ShortName>Leases - Right of Use Asset Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Leases - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LeasesLeaseCostsDetails</Role>
      <ShortName>Leases - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Leases - Schedule of Future Minimum Rental Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Rental Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Stockholders' Equity - Current Capitalization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails</Role>
      <ShortName>Stockholders' Equity - Current Capitalization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Equity-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails</Role>
      <ShortName>Equity-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Equity-Based Compensation - Schedule of Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails</Role>
      <ShortName>Equity-Based Compensation - Schedule of Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails</Role>
      <ShortName>Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails</Role>
      <ShortName>Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails</Role>
      <ShortName>Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Equity-Based Compensation - RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails</Role>
      <ShortName>Equity-Based Compensation - RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/IncomeTaxes</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Loss Per Common Share - Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails</Role>
      <ShortName>Loss Per Common Share - Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Loss Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2451429 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/CommitmentandContingencies</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2453430 - Disclosure - Related-Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related-Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/RelatedPartyTransactions</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="xcur-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2455431 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/SubsequentEvents</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="xcur-20210630.htm">xcur-20210630.htm</File>
    <File>exicureexhibit103-63021.htm</File>
    <File>exicureexhibit104-63021.htm</File>
    <File>exicureexhibit311-63021.htm</File>
    <File>exicureexhibit312-63021.htm</File>
    <File>exicureexhibit321-63021.htm</File>
    <File>xcur-20210630.xsd</File>
    <File>xcur-20210630_cal.xml</File>
    <File>xcur-20210630_def.xml</File>
    <File>xcur-20210630_lab.xml</File>
    <File>xcur-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>xcur-20210630_g1.jpg</File>
    <File>xcur-20210630_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xcur-20210630.htm": {
   "axisCustom": 2,
   "axisStandard": 27,
   "contextCount": 212,
   "dts": {
    "calculationLink": {
     "local": [
      "xcur-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "xcur-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "xcur-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xcur-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xcur-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "xcur-20210630.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd"
     ]
    }
   },
   "elementCount": 501,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 44,
   "keyStandard": 338,
   "memberCustom": 16,
   "memberStandard": 37,
   "nsprefix": "xcur",
   "nsuri": "http://www.exicuretx.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.exicuretx.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Significant Accounting Policies",
     "role": "http://www.exicuretx.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Collaborative Research and License Agreements",
     "role": "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements",
     "shortName": "Collaborative Research and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - Supplemental Balance Sheet Information",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformation",
     "shortName": "Supplemental Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112105 - Disclosure - Investments",
     "role": "http://www.exicuretx.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - Debt",
     "role": "http://www.exicuretx.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120107 - Disclosure - Leases",
     "role": "http://www.exicuretx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Stockholders' Equity",
     "role": "http://www.exicuretx.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Equity-Based Compensation",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensation",
     "shortName": "Equity-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Income Taxes",
     "role": "http://www.exicuretx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141111 - Disclosure - Loss Per Common Share",
     "role": "http://www.exicuretx.com/role/LossPerCommonShare",
     "shortName": "Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145112 - Disclosure - Fair Value Measurements",
     "role": "http://www.exicuretx.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150113 - Disclosure - Commitment and Contingencies",
     "role": "http://www.exicuretx.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152114 - Disclosure - Related-Party Transactions",
     "role": "http://www.exicuretx.com/role/RelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154115 - Disclosure - Subsequent Events",
     "role": "http://www.exicuretx.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Supplemental Balance Sheet Information (Tables)",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables",
     "shortName": "Supplemental Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Investments (Tables)",
     "role": "http://www.exicuretx.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Debt (Tables)",
     "role": "http://www.exicuretx.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xcur:ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Leases (Tables)",
     "role": "http://www.exicuretx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xcur:ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.exicuretx.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - Equity-Based Compensation (Tables)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationTables",
     "shortName": "Equity-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342307 - Disclosure - Loss Per Common Share (Tables)",
     "role": "http://www.exicuretx.com/role/LossPerCommonShareTables",
     "shortName": "Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2346308 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exicuretx.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business and Basis of Presentation (Details)",
     "role": "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
     "shortName": "Description of Business and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i2fe60402682e4c08928d8ad923f74049_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Collaborative Research and License Agreements (Details)",
     "role": "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
     "shortName": "Collaborative Research and License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i1d59d9f413b24b11bdcaf44ca9c6c94e_D20191113-20191113",
      "decimals": "INF",
      "lang": "en-US",
      "name": "xcur:NumberofCollaborationPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreement",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails",
     "shortName": "Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment, Net (Details)",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails",
     "shortName": "Supplemental Balance Sheet Information - Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i6d06eb298aa3490d9159416638a3b58f_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails",
     "shortName": "Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "xcur:DebtSecuritiesAvailableForSaleCurrentPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Investments (Details)",
     "role": "http://www.exicuretx.com/role/InvestmentsDetails",
     "shortName": "Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "xcur:DebtSecuritiesAvailableForSaleCurrentPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Investments - Available-for-sale Securities (Details)",
     "role": "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails",
     "shortName": "Investments - Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i2fe60402682e4c08928d8ad923f74049_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i2fe60402682e4c08928d8ad923f74049_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i925aaaddcacc4778b5d8b7f62145a333_D20200925-20200925",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoanProcessingFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.exicuretx.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i925aaaddcacc4778b5d8b7f62145a333_D20200925-20200925",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoanProcessingFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Debt - Principal Maturities of Long-Term Debt (Details)",
     "role": "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails",
     "shortName": "Debt - Principal Maturities of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.exicuretx.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xcur:ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Leases - Right of Use Asset Information (Details)",
     "role": "http://www.exicuretx.com/role/LeasesRightofUseAssetInformationDetails",
     "shortName": "Leases - Right of Use Asset Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xcur:ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i2fe60402682e4c08928d8ad923f74049_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Leases - Lease Costs (Details)",
     "role": "http://www.exicuretx.com/role/LeasesLeaseCostsDetails",
     "shortName": "Leases - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i2fe60402682e4c08928d8ad923f74049_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Leases - Schedule of Future Minimum Rental Payments (Details)",
     "role": "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails",
     "shortName": "Leases - Schedule of Future Minimum Rental Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Stockholders' Equity - Current Capitalization (Details)",
     "role": "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
     "shortName": "Stockholders' Equity - Current Capitalization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "xcur:CommonStockVotingRightsForEachShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "votepershare",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i6ff17028d7f742fc86b80a80958beb1c_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)",
     "role": "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails",
     "shortName": "Stockholders' Equity - Common Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i7c221311f05b4f77be016eb7ea9c9657_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i5a85ec43cc4f4214ba9bfbd44ce67a45_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i2fe60402682e4c08928d8ad923f74049_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Equity-Based Compensation - Narrative (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
     "shortName": "Equity-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "ib2b6abdfb80e4807aa0282b97634d068_D20210514-20210514",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i2fe60402682e4c08928d8ad923f74049_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i2fe60402682e4c08928d8ad923f74049_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i2fe60402682e4c08928d8ad923f74049_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Equity-Based Compensation - Schedule of Compensation Expense (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails",
     "shortName": "Equity-Based Compensation - Schedule of Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i2fe60402682e4c08928d8ad923f74049_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
     "shortName": "Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i536ad3a9715049e6b9540b91aeecaf96_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails",
     "shortName": "Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i536ad3a9715049e6b9540b91aeecaf96_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i6d06eb298aa3490d9159416638a3b58f_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails",
     "shortName": "Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i203967655c0047368d301fad6b928214_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Equity-Based Compensation - RSU Activity (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails",
     "shortName": "Equity-Based Compensation - RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i203967655c0047368d301fad6b928214_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i2fe60402682e4c08928d8ad923f74049_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Income Taxes (Details)",
     "role": "http://www.exicuretx.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
       "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
       "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i2fe60402682e4c08928d8ad923f74049_D20210401-20210630",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i2fe60402682e4c08928d8ad923f74049_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Loss Per Common Share - Computation of Earnings Per Share (Details)",
     "role": "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
     "shortName": "Loss Per Common Share - Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i8e5643a3e14a4b2ca2f6576189dc8cce_D20210101-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)",
     "role": "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails",
     "shortName": "Loss Per Common Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i8e5643a3e14a4b2ca2f6576189dc8cce_D20210101-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i42f50fb4ed2946899515880a08b3b57b_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i6ff17028d7f742fc86b80a80958beb1c_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i6ff17028d7f742fc86b80a80958beb1c_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i5073ecd4f57647949850dc29898c84dd_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i838b83569bf54c2e9ddfb7703021db3d_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i89a31a873b4345549a9b1b9489d5fcda_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i89a31a873b4345549a9b1b9489d5fcda_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:AggregatePaymentsMadeToDateForLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451429 - Disclosure - Commitment and Contingencies (Details)",
     "role": "http://www.exicuretx.com/role/CommitmentandContingenciesDetails",
     "shortName": "Commitment and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:AggregatePaymentsMadeToDateForLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i0304e7ef793b4159a6bfef1cd8f203bf_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453430 - Disclosure - Related-Party Transactions (Details)",
     "role": "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related-Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i0304e7ef793b4159a6bfef1cd8f203bf_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i766b5dbdd23d432ebc0191ac53b18fac_D20210730-20210730",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "xcur:NumberofCollaborationPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreement",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455431 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.exicuretx.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i766b5dbdd23d432ebc0191ac53b18fac_D20210730-20210730",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "xcur:NumberofCollaborationPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreement",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "i9c650a633a1f4de4a05ddb4eab7dad76_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business and Basis of Presentation",
     "role": "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation",
     "shortName": "Description of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210630.htm",
      "contextRef": "icfd4383b8f134e10bfaff70102b4b61d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 57,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]",
        "terseLabel": "Chief Financial Officer"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board of Directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r239",
      "r275",
      "r312",
      "r314",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r478",
      "r526",
      "r528",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r239",
      "r275",
      "r312",
      "r314",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r478",
      "r526",
      "r528",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r239",
      "r275",
      "r302",
      "r312",
      "r314",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r478",
      "r526",
      "r528",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r239",
      "r275",
      "r302",
      "r312",
      "r314",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r478",
      "r526",
      "r528",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r124",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails",
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r124",
      "r129",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails",
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r299",
      "r301",
      "r527",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r299",
      "r301",
      "r527",
      "r541",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r124",
      "r129",
      "r220",
      "r313",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails",
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r177",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r454",
      "r456",
      "r459",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r443"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r178",
      "r179"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r213"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r56",
      "r63",
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on short-term investments"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r54",
      "r55",
      "r56",
      "r518",
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r63",
      "r64",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r53",
      "r56",
      "r63",
      "r64",
      "r65",
      "r116",
      "r117",
      "r118",
      "r382",
      "r529",
      "r530",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Investing Activities [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r24",
      "r349",
      "r443"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r346",
      "r347",
      "r348",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in- Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r315",
      "r317",
      "r352",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r317",
      "r342",
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r73",
      "r96",
      "r259",
      "r413"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of long-term debt issuance costs and fees"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r110",
      "r162",
      "r165",
      "r171",
      "r195",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r378",
      "r383",
      "r400",
      "r441",
      "r443",
      "r496",
      "r515"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r48",
      "r110",
      "r195",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r378",
      "r383",
      "r400",
      "r441",
      "r443"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Holding Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r186"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Holding Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r183",
      "r204"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Costs"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r181",
      "r184",
      "r204",
      "r502"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Short-term investments:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r318",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r115",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures (accounts payable and accrued expenses)"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r32",
      "r98"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r91",
      "r98",
      "r103"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash - end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash - beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r91",
      "r401"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r107",
      "r110",
      "r132",
      "r133",
      "r134",
      "r136",
      "r138",
      "r146",
      "r147",
      "r148",
      "r195",
      "r225",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r273",
      "r274",
      "r277",
      "r281",
      "r400",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r294",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r372",
      "r373",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Research and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r221",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r116",
      "r117",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22",
      "r443"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 88,096,694 issued and outstanding, June\u00a030, 2021; 87,651,352 issued and outstanding, December\u00a031, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62",
      "r70",
      "r504",
      "r523"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r296",
      "r297",
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r296",
      "r297",
      "r300"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r303",
      "r311",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes/bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r253",
      "r260",
      "r261",
      "r263",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r18",
      "r19",
      "r109",
      "r114",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r267",
      "r268",
      "r269",
      "r270",
      "r414",
      "r497",
      "r498",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r19",
      "r264",
      "r498",
      "r513"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "totalLabel": "Principal balance outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r236",
      "r267",
      "r268",
      "r412",
      "r414",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Fee amount"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "terseLabel": "Interest rate increase"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Floating interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44",
      "r109",
      "r114",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r267",
      "r268",
      "r269",
      "r270",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Prior to first anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "After first anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r109",
      "r114",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r262",
      "r267",
      "r268",
      "r269",
      "r270",
      "r289",
      "r290",
      "r291",
      "r292",
      "r411",
      "r412",
      "r414",
      "r415",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r249",
      "r265",
      "r267",
      "r268",
      "r413"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "less: unamortized discount and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Gross realized gains, available for sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Gross realized losses, available for sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Debt Securities, Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid Expense and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r35",
      "r249",
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Depreciation, Amortization and Accretion, Net",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAmortizationAndAccretionNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r71",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r130",
      "r132",
      "r136",
      "r137",
      "r138",
      "r142",
      "r143",
      "r387",
      "r388",
      "r505",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (loss) earnings per common share (USD per share)",
        "verboseLabel": "(Loss) earnings per basic common share (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r71",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r132",
      "r136",
      "r137",
      "r138",
      "r142",
      "r143",
      "r387",
      "r388",
      "r505",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (loss) earnings per common share (USD per share)",
        "verboseLabel": "(Loss) earnings per diluted common share (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "(Loss) Earnings Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll-related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Scientific equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r63",
      "r64",
      "r65",
      "r116",
      "r117",
      "r118",
      "r120",
      "r126",
      "r128",
      "r145",
      "r198",
      "r288",
      "r293",
      "r346",
      "r347",
      "r348",
      "r363",
      "r364",
      "r386",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r529",
      "r530",
      "r531",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r96",
      "r272"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r389",
      "r390",
      "r391",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r389",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r251",
      "r267",
      "r268",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r390",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r389",
      "r390",
      "r392",
      "r393",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r251",
      "r303",
      "r304",
      "r309",
      "r311",
      "r390",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r251",
      "r267",
      "r268",
      "r303",
      "r304",
      "r309",
      "r311",
      "r390",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r251",
      "r267",
      "r268",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r390",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r394",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r394",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Gain included in other (expense) income, net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at June\u00a030, 2021",
        "periodStartLabel": "Balance at December 31, 2020"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r251",
      "r267",
      "r268",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r397",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r191",
      "r192",
      "r193",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r262",
      "r286",
      "r385",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r65",
      "r74"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "terseLabel": "Net loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r360",
      "r361",
      "r362",
      "r365",
      "r367",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r127",
      "r128",
      "r161",
      "r358",
      "r366",
      "r368",
      "r525"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/IncomeTaxesDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r95",
      "r479"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r67",
      "r160",
      "r410",
      "r413",
      "r506"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r90",
      "r93",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid on debt"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeDividend": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of dividend income on nonoperating securities.",
        "label": "Investment Income, Dividend",
        "terseLabel": "Dividend income"
       }
      }
     },
     "localname": "InvestmentIncomeDividend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r77",
      "r159"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTableTextBlock": {
     "auth_ref": [
      "r190",
      "r194",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment.",
        "label": "Investment [Table Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]",
        "terseLabel": "Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r190",
      "r494",
      "r509",
      "r540",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r428",
      "r430"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (remaining six months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of credit outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r110",
      "r166",
      "r195",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r379",
      "r383",
      "r384",
      "r400",
      "r441",
      "r442"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r110",
      "r195",
      "r400",
      "r443",
      "r499",
      "r520"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r110",
      "r195",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r379",
      "r383",
      "r384",
      "r400",
      "r441",
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r37",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r37",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoanProcessingFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses paid for obtaining loans which includes expenses such as application and origination fees.",
        "label": "Loan Processing Fee",
        "terseLabel": "Origination fee"
       }
      }
     },
     "localname": "LoanProcessingFee",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loans Payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r19",
      "r250",
      "r266",
      "r267",
      "r268",
      "r498",
      "r516"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails",
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "verboseLabel": "Current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r114",
      "r223",
      "r255"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r114",
      "r223",
      "r255"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r114",
      "r223",
      "r255"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r114",
      "r223",
      "r255"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2021 (remaining six months)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Noncurrent portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r44",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r91",
      "r94",
      "r97"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r57",
      "r60",
      "r65",
      "r69",
      "r97",
      "r110",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r127",
      "r128",
      "r135",
      "r162",
      "r164",
      "r167",
      "r170",
      "r172",
      "r195",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r388",
      "r400",
      "r503",
      "r522"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income, net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r56",
      "r66"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r162",
      "r164",
      "r167",
      "r170",
      "r172"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r422",
      "r430"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liability",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails",
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability, current",
        "verboseLabel": "Current operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails",
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Noncurrent operating lease liability",
        "verboseLabel": "Lease liability, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r418",
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, cash payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r427",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesRightofUseAssetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r426",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesRightofUseAssetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r40"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r58",
      "r61",
      "r376",
      "r377",
      "r381"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive (loss) income",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r50",
      "r54"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (losses) gains on available for sale securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r8",
      "r211"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.",
        "label": "Payments for Tenant Improvements",
        "terseLabel": "Payments for tenant improvements"
       }
      }
     },
     "localname": "PaymentsForTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of long-term debt fees and issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r81",
      "r84",
      "r182"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchase of available for sale securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r318",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r21",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r21",
      "r443"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, June\u00a030, 2021 and December\u00a031, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r8",
      "r210",
      "r211"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid clinical, contract research and manufacturing costs"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r6",
      "r8",
      "r209",
      "r211"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds from Collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from debt, net of fees and issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from common stock offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from long-term borrowing"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "terseLabel": "Proceeds from sale or maturity of available for sale securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r81",
      "r82",
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale of debt securities, available-for-sale"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r86",
      "r345"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r212"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r214",
      "r443",
      "r510",
      "r521"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "negatedTerseLabel": "Net losses (gains) reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r310",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r310",
      "r434",
      "r435",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r310",
      "r434",
      "r438",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r432",
      "r433",
      "r435",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of long-term debt",
        "terseLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r355",
      "r480",
      "r554"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r13",
      "r98",
      "r103",
      "r495",
      "r517"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash included in other noncurrent assets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails",
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r293",
      "r349",
      "r443",
      "r519",
      "r532",
      "r534"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r116",
      "r117",
      "r118",
      "r120",
      "r126",
      "r128",
      "r198",
      "r346",
      "r347",
      "r348",
      "r363",
      "r364",
      "r386",
      "r529",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r157",
      "r158",
      "r163",
      "r168",
      "r169",
      "r173",
      "r174",
      "r176",
      "r298",
      "r299",
      "r481"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r68",
      "r110",
      "r157",
      "r158",
      "r163",
      "r168",
      "r169",
      "r173",
      "r174",
      "r176",
      "r195",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r400",
      "r507"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r56",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Equity-Based Compensation Expense Classification in Statement of Operations"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of loss per common share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Principal Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r436",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r318",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r321",
      "r329",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Common Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used to Determine Fair Value of Common Stock Option Grants"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Restricted Stock Unit Awards Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested balance - end of period (in shares)",
        "periodStartLabel": "Unvested balance - beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested balance - end of period (in dollars per share)",
        "periodStartLabel": "Unvested balance - beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price of common stock option (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum ESPP contribution rate as a percentage of compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum number of shares per employee in purchase period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "verboseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, stock options, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Options granted in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r323",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding ending balance (in shares)",
        "periodStartLabel": "Outstanding beginning balance (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value (thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value (thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding shares allowable as annual increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r316",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of underlying common stock (dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r336",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "ESPP purchase price as a percentage of market price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r17",
      "r500",
      "r501",
      "r514"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r423",
      "r430"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r104",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r107",
      "r110",
      "r132",
      "r133",
      "r134",
      "r136",
      "r138",
      "r146",
      "r147",
      "r148",
      "r195",
      "r225",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r273",
      "r274",
      "r277",
      "r281",
      "r288",
      "r400",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r46",
      "r63",
      "r64",
      "r65",
      "r116",
      "r117",
      "r118",
      "r120",
      "r126",
      "r128",
      "r145",
      "r198",
      "r288",
      "r293",
      "r346",
      "r347",
      "r348",
      "r363",
      "r364",
      "r386",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r529",
      "r530",
      "r531",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r145",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r21",
      "r22",
      "r288",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock-ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r288",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r22",
      "r288",
      "r293",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercise of options (in shares)",
        "terseLabel": "Exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r21",
      "r22",
      "r288",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock-ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r288",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r46",
      "r288",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r27",
      "r28",
      "r110",
      "r180",
      "r195",
      "r400",
      "r443"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r293",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r409",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r409",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r409",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r409",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r444",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r191",
      "r192",
      "r193",
      "r262",
      "r286",
      "r385",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r113",
      "r303",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r113",
      "r303",
      "r311",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual Risk or Uncertainty [Line Items]",
        "terseLabel": "Unusual Risk or Uncertainty [Line Items]"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the unusual risk or uncertainty and its financial impact or potential financial impact.",
        "label": "Unusual Risk or Uncertainty [Table]",
        "terseLabel": "Unusual Risk or Uncertainty [Table]"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r424",
      "r430"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "verboseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Common stock warrant liability"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r131",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average diluted common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r130",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average basic common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_AbbVieCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allergan Collaboration [Member]",
        "label": "AbbVie Collaboration [Member]",
        "terseLabel": "AbbVie Collaboration"
       }
      }
     },
     "localname": "AbbVieCollaborationMember",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical, Contract Research And Manufacturing Costs, Current",
        "label": "Accrued Clinical, Contract Research And Manufacturing Costs, Current",
        "terseLabel": "Accrued clinical, contract research and manufacturing costs"
       }
      }
     },
     "localname": "AccruedClinicalContractResearchAndManufacturingCostsCurrent",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_AggregatePaymentsMadeToDateForLicenseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Payments Made To Date For License Agreements",
        "label": "Aggregate Payments Made To Date For License Agreements",
        "terseLabel": "Aggregate consideration paid to NU for agreement obligations"
       }
      }
     },
     "localname": "AggregatePaymentsMadeToDateForLicenseAgreements",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_ArrangementNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement, Name [Axis]",
        "label": "Arrangement, Name [Axis]",
        "terseLabel": "Arrangement, Name [Axis]"
       }
      }
     },
     "localname": "ArrangementNameAxis",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xcur_ArrangementNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Arrangement, Name [Axis]",
        "label": "Arrangement, Name [Domain]",
        "terseLabel": "Arrangement, Name [Domain]"
       }
      }
     },
     "localname": "ArrangementNameDomain",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ChicagoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chicago",
        "label": "Chicago [Member]",
        "terseLabel": "Chicago"
       }
      }
     },
     "localname": "ChicagoMember",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ClassofWarrantorRightExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Expired",
        "label": "Class of Warrant or Right, Expired",
        "terseLabel": "Warrant expirations (in shares)"
       }
      }
     },
     "localname": "ClassofWarrantorRightExpired",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Extended Option, Additional Exercise Fee",
        "label": "Collaboration Agreement, Extended Option, Additional Exercise Fee",
        "terseLabel": "Collaboration option exercise fee"
       }
      }
     },
     "localname": "CollaborationAgreementExtendedOptionAdditionalExerciseFee",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CollaborationAgreementLicensingFeesIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Licensing Fees Incurred",
        "label": "Collaboration Agreement, Licensing Fees Incurred",
        "terseLabel": "Collaboration agreement, licensing fees incurred"
       }
      }
     },
     "localname": "CollaborationAgreementLicensingFeesIncurred",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CollaborationAgreementOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Option, Exercise Fee",
        "label": "Collaboration Agreement, Option, Exercise Fee",
        "terseLabel": "Collaboration option exercise fee"
       }
      }
     },
     "localname": "CollaborationAgreementOptionExerciseFee",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Termination Period Upon Written Notice",
        "label": "Collaboration Agreement, Termination Period Upon Written Notice",
        "terseLabel": "Termination period upon written notice"
       }
      }
     },
     "localname": "CollaborationAgreementTerminationPeriodUponWrittenNotice",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xcur_CollaborationAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Upfront Payment",
        "label": "Collaboration Agreement, Upfront Payment",
        "terseLabel": "Non-refundable upfront payment received for research agreement"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPayment",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CollaborationDevelopmentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Development Expenses",
        "label": "Collaboration Development Expenses",
        "terseLabel": "Collaboration development expenses"
       }
      }
     },
     "localname": "CollaborationDevelopmentExpenses",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CommonStockVotingRightsForEachShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Voting Rights For Each Share",
        "label": "Common Stock, Voting Rights For Each Share",
        "terseLabel": "Common stock, voting rights for each share"
       }
      }
     },
     "localname": "CommonStockVotingRightsForEachShare",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "xcur_CommonStockWarrantLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrant Liability, Fair Value Disclosure",
        "label": "Common Stock Warrant Liability, Fair Value Disclosure",
        "terseLabel": "Common stock warrant liability"
       }
      }
     },
     "localname": "CommonStockWarrantLiabilityFairValueDisclosure",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_ComputersandSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computers and Software [Member]",
        "label": "Computers and Software [Member]",
        "terseLabel": "Computers and software"
       }
      }
     },
     "localname": "ComputersandSoftwareMember",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ConsultingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Services [Member]",
        "label": "Consulting Services [Member]",
        "terseLabel": "Consulting services"
       }
      }
     },
     "localname": "ConsultingServicesMember",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Early Termination Fee, Percentage of Principal",
        "label": "Debt Instrument, Early Termination Fee, Percentage of Principal",
        "terseLabel": "Early termination fee"
       }
      }
     },
     "localname": "DebtInstrumentEarlyTerminationFeePercentageOfPrincipal",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_DebtInstrumentExitFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Exit Fee, Percentage",
        "label": "Debt Instrument, Exit Fee, Percentage",
        "terseLabel": "Exit fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentExitFeePercentage",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Principal Payment, Number of Monthly Installment Payments",
        "label": "Debt Instrument, Principal Payment, Number of Monthly Installment Payments",
        "terseLabel": "Number of monthly installment payments"
       }
      }
     },
     "localname": "DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xcur_DebtSecuritiesAvailableForSaleCurrentPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsDetails": {
       "order": 1.0,
       "parentTag": "xcur_DebtSecuritiesAvailableforSalePercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available For Sale, Current, Percent",
        "label": "Debt Securities, Available For Sale, Current, Percent",
        "terseLabel": "One year or less"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleCurrentPercent",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsDetails": {
       "order": 2.0,
       "parentTag": "xcur_DebtSecuritiesAvailableforSalePercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available For Sale, Noncurrent, Percent",
        "label": "Debt Securities, Available For Sale, Noncurrent, Percent",
        "terseLabel": "After one year but within two years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleNoncurrentPercent",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_DebtSecuritiesAvailableforSalePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available for Sale, Percent",
        "label": "Debt Securities, Available for Sale, Percent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSalePercent",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_DermelixLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dermelix License Agreement [Member]",
        "label": "Dermelix License Agreement [Member]",
        "terseLabel": "Dermelix License Agreement"
       }
      }
     },
     "localname": "DermelixLicenseAgreementMember",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_DevelopmentandCommercializationLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and Commercialization License [Member]",
        "label": "Development and Commercialization License [Member]",
        "terseLabel": "Development and Commercialization License"
       }
      }
     },
     "localname": "DevelopmentandCommercializationLicenseMember",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ExercisePeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Period",
        "label": "Exercise Period [Axis]",
        "terseLabel": "Exercise Period [Axis]"
       }
      }
     },
     "localname": "ExercisePeriodAxis",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xcur_ExercisePeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Period [Domain]",
        "label": "Exercise Period [Domain]",
        "terseLabel": "Exercise Period [Domain]"
       }
      }
     },
     "localname": "ExercisePeriodDomain",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ExercisePeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Period One",
        "label": "Exercise Period One [Member]",
        "terseLabel": "Option Exercise Period after the Selection"
       }
      }
     },
     "localname": "ExercisePeriodOneMember",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ExercisePeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Period Two",
        "label": "Exercise Period Two [Member]",
        "terseLabel": "Option Exercise Period that begins after the first Option Exercise Period"
       }
      }
     },
     "localname": "ExercisePeriodTwoMember",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ExicureInc.2017EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exicure, Inc. 2017 Equity Incentive Plan [Member]",
        "label": "Exicure, Inc. 2017 Equity Incentive Plan [Member]",
        "terseLabel": "Exicure, Inc. 2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "ExicureInc.2017EquityIncentivePlanMember",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_HerculesTechnologyGrowthCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules Technology Growth Capital [Member]",
        "label": "Hercules Technology Growth Capital [Member]",
        "terseLabel": "Hercules Technology Growth Capital"
       }
      }
     },
     "localname": "HerculesTechnologyGrowthCapitalMember",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_IpsenCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen Collaboration",
        "label": "Ipsen Collaboration [Member]",
        "terseLabel": "Ipsen Collaboration"
       }
      }
     },
     "localname": "IpsenCollaborationMember",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months",
        "label": "Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months",
        "terseLabel": "Annual rent payment initial twelve months"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Base Rent Annual Percentage Increase",
        "label": "Lessee, Operating Lease, Base Rent Annual Percentage Increase",
        "terseLabel": "Base rent annual percentage increase"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBaseRentAnnualPercentageIncrease",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Estimated Rental Payment Over Original Term",
        "label": "Lessee, Operating Lease, Estimated Rental Payment Over Original Term",
        "terseLabel": "Estimated rental payment over original term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_LesseeOperatingLeaseLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Area",
        "label": "Lessee, Operating Lease, Lease Area",
        "terseLabel": "Lease area"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseArea",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "xcur_LesseeOperatingLeaseNumberOfExtensions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number of Extensions",
        "label": "Lessee, Operating Lease, Number of Extensions",
        "terseLabel": "Number of extensions"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfExtensions",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Rental Payment Adjusted For Abatement",
        "label": "Lessee, Operating Lease, Rental Payment Adjusted For Abatement",
        "terseLabel": "Rental payment adjusted for abatement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentalPaymentAdjustedForAbatement",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_MidCapCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MidCap Credit Agreement",
        "label": "MidCap Credit Agreement [Member]",
        "terseLabel": "MidCap Credit Agreement"
       }
      }
     },
     "localname": "MidCapCreditAgreementMember",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_MidCapCreditAgreementTranche1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MidCap Credit Agreement - Tranche 1",
        "label": "MidCap Credit Agreement - Tranche 1 [Member]",
        "terseLabel": "MidCap Credit Agreement - Tranche 1"
       }
      }
     },
     "localname": "MidCapCreditAgreementTranche1Member",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_MidCapCreditAgreementTranche2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MidCap Credit Agreement - Tranche 2",
        "label": "MidCap Credit Agreement - Tranche 2 [Member]",
        "terseLabel": "MidCap Credit Agreement - Tranche 2"
       }
      }
     },
     "localname": "MidCapCreditAgreementTranche2Member",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_NumberofCollaborationPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Collaboration Programs",
        "label": "Number of Collaboration Programs",
        "terseLabel": "Number of collaboration programs"
       }
      }
     },
     "localname": "NumberofCollaborationPrograms",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office And General And Administrative Staff On Site, Percentage",
        "label": "Office And General And Administrative Staff On Site, Percentage",
        "terseLabel": "Percentage of time that office and general and administrative staff are on site"
       }
      }
     },
     "localname": "OfficeAndGeneralAndAdministrativeStaffOnSitePercentage",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_PaymentsForDebtEndTermFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Debt End Term Fees",
        "label": "Payments For Debt End Term Fees",
        "terseLabel": "Payments for debt end term fees"
       }
      }
     },
     "localname": "PaymentsForDebtEndTermFees",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_PaymentsOfCommonStockFinancingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Common Stock Financing Costs",
        "label": "Payments Of Common Stock Financing Costs",
        "negatedLabel": "Payment of common stock financing costs"
       }
      }
     },
     "localname": "PaymentsOfCommonStockFinancingCosts",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_ResearchAndDevelopmentStaffOnSitePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Staff on Site, Percentage",
        "label": "Research and Development Staff on Site, Percentage",
        "terseLabel": "Percentage of R&amp;D staff on site"
       }
      }
     },
     "localname": "ResearchAndDevelopmentStaffOnSitePercentage",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retained Earnings (Accumulated Deficit), Inception to Date",
        "label": "Retained Earnings (Accumulated Deficit), Inception to Date",
        "terseLabel": "Accumulated deficit generated, since inception"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficitInceptiontoDate",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Collaboration Agreement, Pre-Clinical Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Collaboration Agreement, Pre-Clinical Milestone Payment",
        "terseLabel": "Pre-clinical milestone payment amount"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Commercial Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Commercial Milestone Payment",
        "terseLabel": "Commercial milestone payment amount"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Development And Regulatory Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Development And Regulatory Milestone Payment",
        "terseLabel": "Development and regulatory milestone payment amount"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment",
        "terseLabel": "Development milestone payment"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment",
        "terseLabel": "Product approval and launch milestone payment"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment",
        "terseLabel": "Sales milestone payment"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Operating Leases, Additional Information",
        "label": "Schedule of Operating Leases, Additional Information [Table Text Block]",
        "terseLabel": "Schedule of Operating Leases, Additional Information"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant",
        "terseLabel": "Increase in number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "terseLabel": "Maximum contribution amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan",
        "terseLabel": "Number of additional shares allowable annually under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting",
        "terseLabel": "Number of shares issued for each vested restricted stock unit (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "terseLabel": "Offering period duration"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate",
        "terseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding",
        "terseLabel": "Number of additional shares authorized, percentage of common stock outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares",
        "terseLabel": "Number of additional shares authorized, potential maximum additional shares (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_SupplementalBalanceSheetInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Balance Sheet Information [Abstract]",
        "label": "Supplemental Balance Sheet Information [Abstract]",
        "terseLabel": "Supplemental Balance Sheet Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationAbstract",
     "nsuri": "http://www.exicuretx.com/20210630",
     "xbrltype": "stringItemType"
    },
    "xcur_WarrantLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liability [Member]",
        "label": "Warrant Liability [Member]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "WarrantLiabilityMember",
     "nsuri": "http://www.exicuretx.com/20210630",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "http://asc.fasb.org/topic&trid=75115024"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "http://asc.fasb.org/topic&trid=2197064"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r555": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r556": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r557": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r558": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r559": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r560": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r561": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r562": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r563": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r564": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r565": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r566": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r567": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r568": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r569": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001698530-21-000091-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001698530-21-000091-xbrl.zip
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M@,X5S6[<GBA.\%K#\!<X<82"-U0,IHM:G2F<<U'4*&Y^'$=KOZE$\O^!6HK
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M@-Y4H[EO!_VWVR0@^;PLO\#^1FO8-D_,4OG._,][+%L*Q?R=BNCLZ4?OR^_
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ML@<>4!()ZKJ2:4PC],Y,8]QH!@!:X\*UHTN8%D<R$&>8"-"701#!.JS0&4J
MP ^3588;^I4M=VJ3X!G[,,&*E:CW$RCA_+&_\UP_9L&XP<%;X@:IBPX.MY N
M)R"I_B-4L 520+FJL-&@J(8/^.^B79@1>9D!T&X=C6 :YTYXR"ARHG6#FNV:
MT^OC<D%A.-SD >FPQ'J5U$D5 <4Q7TX5.#[8&/%O\PU:HW/47Y-&$ HDXO2.
M5BX+X#TU?R!M A9T0S\ "Z<($62D\SKF7(%Z7#UZV,IRLI$/PN'5UI7.BSVN
M'.":%C._5J7**K3?3U_AP\AW045:>.4G ^_D4;"[<NP&#P"E#H_/$R>/_)0/
M_QPL F?E@D>CEUKP.F[Z^V^G!^?TQT7C1=#Q<1 E\JP".N[7/GRHG1(L8<)J
M]93MLNJ'@^,/1X=/9?@/NW@.'K>V)QSBBZUA69ZS_',<ILZW6[$[# 7_OLM'
MH#"<<?>>SZ*M)R:LKW3//49*K7  %D!(.<414D>5#S4$A"U<(5U6:7@/5+PD
MX!C3#^@0 [YLN1P,";8]W,%OT0<,[/?T22I$@0^G0*=S4#DB'4)^"3KWHX_&
MRA\-JNOOY7B*<S[5T\I1+7,^TFN(.C5^\F!"?1SV#FHW/ A W0H=C)UP-QCS
MH: 4<^:'*B2&CH#UZGAN <<%*Z,@W,3-%C-&1J)(1@,L4)2D9PF(AK,^G(IW
MBZ?6[+*6(SQFWDD?KNNRIA<+UP5;;PI'I15F&5H%'52@*AV!#NG.=)207#4R
M@):-/ZX+JVW/97, MDAS6 ?<P-;T,6B2*'6FMI;9!>#33L;>S@7\7BD>^-#R
M'@FN[0>R2UX1A98;3CDPV( MA41TG9 B>?^FEKBRH&[YHH,79NM/7 [&^\"V
MW&S.<+% ,O;OQ9T(-PL28B2@0B-C\GPF[M+XQ?:/G76\RF#;,\P9GF7R.@(^
MFZ@\FC1W/9.BLI+MA300R'-+"#N2P;L[F82).9 >&PI8T^BI QOX]O9_Y#)!
M%G7U!,H=LL!_C&S4!M[-Q4^&"3-=</@H%B&CE*CTLFF O%R$8);EXJ /@"!A
MZ$F.#&759+DZ*39RZY3?'HHH4 YEVN;\GAX4 Z_%[0<*&L)^B.6_?JHA51 L
M7Z B!Z .U_=N >H9%'D '^84%A#8&146446]3[ED@"S<U2_*.9T)H!XJN!0J
MHSE(WUBW6L S4CJ4AZ_+4;W:SH0/1KZD&7[G.S972IOM3X=:0<O0B;)Z8+%3
ML&8XZ=>NU'MT%,+SX5NA\3?)BY6^_.%,A]/Q1QE2UX]F%TBB5>U]A5/F9Z<5
M;=+L&A;&Z#JH5:K%=:Q?(5%@BF(A@G>OX%E_6\Z#XF"Q=KPM=1V ^97U'@QW
MDH3NQWH0'G#YY-T8AX<;2\;2/H/A>LWM)S/: F-H@5!4>Q]#X4VQZDCCJ?CA
M1.0KSN GCS*NQY^92;+)P["*<Q:98'+*)E+I%^62 VU;:M]/XOE/83!/.N#B
M>RP+H#<0XRN"JH!I9]&*>HY-EW-45HF!$OM^HE>S6*JKQ,=7K6,R,HFE1E(+
M^<Q"5PS[6!9P3[);R?V1)M$I8S5)K)7?+N32E7C_0G@_'[4H*,+/9_(\K9 [
MA_6%<:T]$# JP$GLJ*J@I)3"6"Q9>@YE%C=UNO:64J=[ LL' &(\K=>\X2'Z
MGAT121.X)_AHY(23Q)^=T$J3^C%$KT3QRTE@HQW2EJ22O6:RY))2\%>J<5M1
M-?#\Q+HRG?/=I',6/:6QP+Z2XB7>FQA32B*ORC<"2@<*!*5@8?!(>4;")>+D
M/A$G#[?-( <,EI2IRI@PQ @G:O\PQT1'!53D,V+;.AAE3P/7L1(!A;:U?AKE
MU+^G\/?(H7X.RD3X0=%J"JCE%XTVB5KR;&<ATII6A/(DFIRIXL<XK@B2/"7J
M.A(K*,&:'IA.ECS+-EJ<X9RP:$N.#PN7]:L6!U/IH8&2$KW'PU+NAP86'+@/
M  LG7IW\LOG*H>!7R"YY)FP*D66"^7=<X:R*M2\G2QUJCQ%G>4#$C 7>*K?A
M ;:BN!!(%7M&'$0/3 Z&Q*TPS#.%+"M0+H0*8TOY73)_;FHU\;KL#HP!:CNQ
MBW'[.!.V7Y(L(!-)(MAF-,*=95AKKDS0R,0)?MEFHIK]IM'K]!C9&LW\;:D$
M!<P9,*60X]DZ=,V+51VV@<2,+4!T7;:CVBNIH(HS";A#*2%4S4H'>0<'8%,C
M3^IKAS0*ORL9"H=-?@-21(_/49=01JBCC%!*]Y7^2X%$HC2,),5F@;@S[1]4
M>U"DVPQ5+Y;?K^V!HAR0N5+V3,X0.??%+7<-N5-Z? @8AH/X0T"^1'\A3IGV
M@*6UA5B= ,J3)8@S\EN.73KSCR[SDV)C*_*(&EHY44G2R6@.L4/M156-[EP5
MK #N-^3>]W :Q-8,.3J8HG>RHX;N"QK!HRX/9>1BOFN+FD6G!UH$4C^,U#GJ
M)$(X6CPCE6,$DZHOF/CWU(EIQYA<;CF!*Z+*3R7N#;J*#M^2JZB1*S,WLV7F
M&_7_+"^3>"TAM+0%R!  .!%I*?Z\L>!K99ZTHZ13CHY(9T3]&-X<8GA%ZP2R
M9:4M9(JI)%#I4$4FBRV/?: 5VXF TG"(IR<>/5\6OC2L"V@>2]!GFHXD*<R9
M/B)P1/?ROHD1MXA;BDQ79:R)"7T/#+T8;UN:.!$VR-H!Q='&F .?@HD;8I 8
M&3C>EJ/:B]K"A8FP':Z%_2E%F'9@ 0,1CH_'Z/="CTN2AIJZORC&MM0IG^FU
MF3?^WCCR%%"16HT]7#7*24[<\H/90[GDNBS)3KNR<?VCU$X<:M@C/R=#R]9=
MGFK#07H :@Y/KD8M\-D7+P<)S^D!LQ9..W4WP0EA%'.^T=&37#PO[R[[E9QB
M+X-13VP?4"RG4^F0*QUR/]4AQ[9E'T=8I[IB0MN-2OO1,M$)-=&BNIUH/[HM
M6TK[N;(NU)<Q/00Y"L]ZD':>5>]?8 %H%TD 2N4GN;R U!8J*K]U[E!?5C7;
M2EYD5)@T?I1ZF=B%&/&I2Y5T5&Z.&*&_D\=.J=8JQ9+2+J6(6N+">2?=^X[>
MDE^A!Q80L*,-M^=KKNA?F\$^[8+,=5M>T,OPQU%BW?V<GK69OG.YEK6"Y_R$
M=[X+AB /';S4$)^#8\!_3KW$HY"XV!S0?.Y\9.HSV5DP5:VH'ZEL*ZI:XLOB
M0>K$FRW)!?8IW%%B=J@N^AD^'%!.:(229@B;=F!I HT2V**+R?'P[PE=Q8+_
MX!Y8JO@OF!DP15[;9&2N<#+R=S@E;5,7YY5M*6)]%A-4VQS4]&@4'R%,,P%[
M",78=VWZQ&^5S80#3P+7GPFQ?I[5*T6)E%\P.@2 GSCV-#D#0&]7CH2'4)"4
M0DF.R!6[4N(6(HG0]D5" ](RE@"$8Q)4)AM*+@(@M]!CK(\>52[RAL%)WXKD
M'/.]GO-GO*!-/ ^+\[BU!/W6X=GB&MXMI@'G+'/HLNFC90Y=F4/W!G/H-G2M
M0H&$E,%4$0KYUM'0T)J1[(H 7-K"I W2).57R,H=%"VV&-)?3A1,2:+8? +'
M'%&BAX/!VS1"#!] [E#8E@21Y4<Q17<#] ='*C@ VY(-3W AWQTTT,$JCWR4
MB 86D[G\'FTF= F@Q$0U<"ROSYR0[4RV^M13'W!.>$R61- /Z6<C#9DO: ]L
MV\\:79,="FGIZ'7Z"C;14&_D7V#;>EE2AKHSN6K]"< ^Y*HA^_W8EZ$5O&J$
MHB$>AEP0.J -DTI,+L%$L5Z^Y'M_ZN+U;3P"A1D49'05('0MU8\%QS'2 E[I
M9AP*5#?F?9\*--*'*1-\0DR70"\LK")7_X2.DKPO7KGA3\ZI58^L&,SF!"U+
M0D";&N-("N?(0$$M@PXN5BJ4 K%^!I>AXD[1JG  M=1QU#*X3(A,,G" $V"3
M?3]4\7\89^P$45(<AO-1&0B^G!HL*D?#]P!<\C8^))B%;<YC2/HBX85\-9MX
ML#A$)B22A8ZQ' 29ZTH1&BK5"O:N#S7O1WL8_S+H1Y?1H3\B@S /E/&LSUQ)
M:"^Y:D4KPS+]+/%J \U,528&EC7GLFD2Y5.JQ,GW(%'IOIZ%&]$6+FR05Z,H
MGXUT\5E\"0HF78SD:2<!;E@S^@2I?U(2T\Y:VBOP$H!SDVV,K^OK'W/3S*H4
M'YU\HN&X>$%-,7W,NI7^T49K8E+?L;IU,<EK3'Y038UD>Z",9,O[6#*1Z.2F
MQ\RAF3BZ)-BT)Z7,KUBX4F3^7L?5U:2*83S^0L<WY1G\\)8\@VV?W7#T\B-+
M;?MW], O7&LVH.@I1NU)=4Q"(,2\<]=^+!) 0GO9-,#T\J D?7/)#5S8VHPZ
M6: TN5<',DI; !HL(*E$TG\BY)4^RL/B^6'^0J3\^\E]<*O(SEBGYQ#SD*IA
M*MZS*0Z)7)K+>(!WT^R9194K&R3(W#H'*+@RI=4/5UR+-+_C1&M4(8HHB5M$
MV<!%V@]BH41&M7%;G8::ZL]Y&:]2+>75Q-A@3A KU-4M.M"]=F&+EUYMQ_ZM
MU,]3T.7.9%6BB1;@.PA(*132_."AD+BC^N'%\W#%2U$]Q1'>.<L^?DLLNYZI
M%$9$2].O69V\DZ_7(*"0+/R=%"44+Q$SK4G0<2SI_%8=^.8[B$M=3YMS8EG1
MSY/+ ]) V$K6O*T?L7S@K%S:HS(Y/V.ES(DMU2YJ1S%#X-W8S@)O,9_"1TJO
MSZ@ :;F +E[BL4RW4+80$JADQG(TE>HT3 WS:,'@3):; X0O S SQ?E3:SO9
M4O:M^7O.5@!PA;RG@A*<)XJYI^YQF,E"$<Q_#2/2^G&.*<) "MW(T"9<E";<
M9BQ^F$9_\.:$I1*B<^8P&?72=31!A,QX;Q8:"*]4 \@9DKFQCJ3N R#[N24/
M93U3OIXIA^O:SX-%**K,S]?JK.ZA.P0U>^3HB^-U$#P-)S(@LBA.ZYCH,@1]
M%_-\X1+#1!;T>TC2U1BA%Y37WX!?.+$K5#9O,H!^\S'IP:!T(Y%(% OF6OZF
MG:S3HD<CK7B46*EQ]*'ZQSG..J^)9CI::\I?OS:E#69:EF>H;J$9\]/UO\TK
M>R=O2=F[<B)+@'[G"7^ZV:MXWPEO+)I:M3YM:^ZR8C-WTTK!;E^]#M2Z'O"3
M&/,W,:]J5 &;5BD4<P/HJF[U:^KN7O(#Z)Y+O@5QH+_%]'4_E'$\76;I3 (_
MU X=[',F2R;1N?*("Z0SMST/9WE?=IE^@2699?I%F7Y1IE\\EEQ29QMC#YC@
M='F\L8HMO:SI;+RJ[5R::B]DJJUC,Y>=/\U>N]F^9*WZS8:UC<'79I_5+WNF
M>66V!ZS>OF#U5HM=-/O=ZX'9IR\Z@Z]FCUW5!P.SUV<]LU4?X.+A2W/089T>
M&Z3_K/>:??R1OOK2ZURQ[9NO)@W0[URW+_"W9ILU.NU!K]X8( 0,-NCTZ%\X
M $UVT^R;0 G]K[B6SR:3$#,OV.=O!BTI^04&Z@]ZU_ 3?FVVOW1Z#?@ 4]0;
MC4[OHMYNF.RF.?AJX))PDC[K?*%_]P?U@8D?VN8-^];I_6'0@YWK >SQLMZ[
M@'7A^%]:S<: WJ*WN[UFN]'LM@ XVQ(R@Z_U-NN;C4&STV9'N]7#_:J>X])L
MF[UZBW4^MYJ7=7R@CZ/L5-X+X16M7'4=W=W4FX!&>#3_N.Y]8X->L][:,/FQ
MSYU>KW,#= 5X?:DID##5;%\@N77KO<$W36OXU^=OK-GKF7]V&O7/K6^,-H5T
M^BTAWE[S\NL D9=V"#0C]XLT 4^U +=;0!V$K4!PW5ZG89I$F)IXD00 2O!C
M0NPX6IY52+J'.>KMOARM3V1M7G7A':!!M5A:%;[51T(9T!KZUXVORY>0$#:L
M'>G=!((V61U&ONY)X+0[@_1KW!C*\SJ,IT&9A23]($$)\_W1[MRTS(M+O13:
MD<(*W!OR.)-@UFQ?7#?D/F'G\!<^T89_UMGG:X"1V=>,$+;]%6]EHP%INJ]U
M^@V7#]M#&.DIVG(DR0,7(&JHL]?CW#0!$@C19OO:Q&7 H-_DD)EETPQ-=5(P
MY9?KP36 YL*LMV">_F.!<U/OP4$.),/OF=V>V3?Q(RVG.:!-?:U+U.QTN\"P
MK]M-0$Q $\#%IGDCF3XLC'!-K0[YJ4(X.,!VWVQE-@FCXH' BRV))7]V6M?M
M 2!ABM;-03]#K!*S^^_%AU*X2L=US+/IP;>!GY:<+?@9NCI#8K,.-IE\DJ1K
M9.O>0!DN9C9<<G'+P49COMN-L>_(V_9<?B\+B\&"42T(_IJ&,R8O\) 1(GE!
M8#$AJO,+J[7*AF':A$5-O"3'=&=U2)&2JC65I66:U-5QSEM&UT:K]A1@Q3HC
MBH%@0")]3_H#G1"S89U0/"?*4$R^*8K$-Q]@FU\%Q\<WS1+[22:37,YB\IQ&
M/QF8&LED."!^1U^:GN*@[ZE:O31+-I<XEW9WRDTPRN7!!5/ \TB\%YP<%0<G
MCRK[!^N1LI%VX=HT8LZEZ*F6CIA^I9Q7@##R-CJ9-)$NW$A*4&66PWS?#(ZU
M'.KVLTS=MWSX?HS7%//O^*=."I0#9),C/)%$>XGAI@F;L/*+3%L/F"O3_FJN
MQ5EN@U@4G.VL!I\S;=4FW'%S_4)PX/1GS!-!*MX6E=N*P2J!32D:%: $-H(!
M=^;7DN^M]OMOU0_[YPF<<CW_YB9-(+=T6YGXNQK-T4%Q59<D>YG(9@7JPEU]
MCV\N554Z667@2,65DK3AY,9J]8-$BF7?TA;G?] [T@$J:ORB(U2N\UWH\)3C
MI=5 :5%.DA,J^Z^D&#F?@;NDP(02BU96-J6%3;K&:4G+%WV7LIF>?C]I%9,D
M5*L:-)SONQ !E7@AI[9HGTX.>;"[P$J:T;WX$,NI\VOB9M:M;JG!;;X/*Y<U
M.YXLWEY$.H,%XUE$MPDFZ*7S(]2JIS(9"F5&(,)=69XDUZ\W%,TB@)VA>\%2
M_RS))HRY/EVRL#Q-$!_)\B:J DO[ H%F:["TXR$E<0F;\CZ7 AN'N'3]H6(C
M;2Z;4["&/YD(=,K7+97[C5SQFQ]^9WV\0&S%:#A&3QT0O9F3BCIR2E>0R3:U
M$B8J)GP-BB2<8W;L01;18,2*)'-6CQ"Z:9?C I31+X-( <IAU15<>5X; ;_#
M.^!FDZ'OTBE1CD\$S\4Q$)&0Q4)X>E'D6PZ1-C($@VY-](#^K3A-Y9,X+5'4
M]@/5KYBS+K#TE),(U<6$,JL 0@;UU$3]W>(R6X];%+FBM*M5LV@,*,/EN4Y#
M9;B\#)>_P7!Y84R<V^*8. ^[*TWR>10FJ6NPJM>^;G!/J^4Y+9)VD^:04U'Z
MHHZM6G&!]@3"GO2+M)F#S#F?:ZR;&Q8+U$.Z[9G=AWCEAY<O3R>E<#K\"]/E
M)B#X5,V!/WHO=OOX+2%U'SMB*.V[ $WH4!-?*(U$722](4(7!R[M/ _*#ED7
MH(Z[TNB@;AW9NR,6U?>_IJ$3V8Z5]J1++^.@0<@RP3R9O+&27/N%:36(W9D(
M06[-1!))B6%F;[F-J85)M2N_IFSM.#UT+YT:G"PJ68$I+Q5)VUR\%W)RBD-.
M1Y4/M?7DQ/I)<S)2&F397\$\8JF#Q4A\"ZHH(:U)T-4&J$NB52(Q/6TRF^PS
MUWQ-D41>GA@)OU?L/TLG#Q1#K4R)6XW>1;$.0(VMGO>;E^TZAL_[K-[MFO4>
M1MN_=%HMBE*S;OW2[,.#M=6]YG]%P^I#:5B5AM42PPI1U;'_ON78(R[X8>W0
M&M6&AZ/:Z>FP=F*?CDZK1_QD=#JT_G5P=++UWYMC=.G]\XVQYY?5OS2!-=N8
M2$,Y1S>85-7Y8J@.!$I+'RJG+?;_DFXK\JV2HB_]UG1E1^*AG7=99ZY"D+K3
M3/!0%09*]R%E1*?-A1[%SQ^ XI(SR8R3E^75#W-U;[OTU88:^5$&%34[DXZV
MQ3_95?.B4>^R+\UVO=W S*5![[H_,%9[Y(JQWU6R<?DNG["9#:V<?9[)IG2K
MME /\"HK!H+#B<'^N**>N#+/OU7I5HPWL$6'KA.\$U&L(JC4UO?I"W\J/6[X
M2)]\HNRR"X?::KR5,]6=W5 ]]U[X0&OS_*9ZLD_CR/L,$QTU!(FRBQV:>1")
M,_V/<^P%ZO+9F>/17NBE\[SABO6Y=WA_A<5=)1]H/OFS$MM')Y7#TQI*[AA6
M'MMZ8B74*R34]V)[R6_5RO'QAY4_[U>JS_H-1JT>/_/-U8L].:Q4]Q\W[!X!
M0@(#P!T%W/O[5FUK[A#/#H(?K)KW#."YSD-< OOUD9JT,46W"4*JK:_9U3[N
M:>M1CSX5 #_?2'FT+ 4E6KH;@#=-0TRWK$\BX;IB,J>@OK/S;_.)> $,4$PI
M]H.S*@9&?;RO%G=S_D: (XW75:CPSI!@@!U!"L0'-G'6]>2:3)4%X8>SQ?/>
M(RGZ"@K<V[7#5(E4:8F5EE@AMEA:8J4E5EIBI2568 6DM,1*2ZRTQ$I+K+3$
M?H(EMK*UT7IY_\S7=)3SL'+XRZ06'+_QU(*?DV?\S,!V<8WRE<:ZV;IB!_L'
M^[N'TDS_58WTU9MY8[8A4Z2C<L+ B.J+\ [D:[3,TG_<OL@B*DIN!MFQF$&A
M]K5H'98F8&D"%DGS*4W I2;@!;\#<^5J&@;C66G^_;+FWU(T>&<(4)I^;R0(
MMQD-_JE:^\/:?*W4YDMMOM3F2VV^U.9+;;[4YDMMOM3F2VV^J-K\@R5*9;!F
MQ85@9;#F5PK6])NM9J/39G_66RWS&_M<;__QO@V\4O4O5?\B2;Y2]5^J^O\1
MTK7U L8=3^8M^/=V_*7VOP8K5F'".\.!T@#8^O0GINQU0Q$Y=J;9VVLZ\I_K
MY/T5+873TE+X[_N5Y#5!Q,#URN?NJ_C5E]L9^O:A9QD:YC^;C>N>:;!FN_'<
M/FG4,>M1])@?Y^!P'JY+B/VP<E2J]:5:_V[5^DT 8-&9?^FX?_EC[GGO58\K
M=?DUP/E%<. 7U^4)!HVQ(T:@C]$U('>"=4:C7"C^8:7^&3)\@\K1,_4AUNF:
M/7DY9Z-SU:VWO_T7.DVU5&%*%:9484H5IE1A2A6F5&&*IL*D%P,L\=X]/4NA
M]$LN=PA6]]^18W)OZ-LS^&L<3]Q/_P]02P,$%     @ "($,4^CTK!VQ!P
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M3T "E=N<\C*%DVU["5M_AO?!_LWT^?\ 4$L#!!0    (  B!#%.AH:$<AP<
M ),>   ;    97AI8W5R965X:&EB:70S,3(M-C,P,C$N:'1MW5EM;]LX$OZ^
MOX+K8KL)X'<[3>*D =(DQ078:[LY'XK[=*!%RB9"B5J2LN/[]?=P*#M*[&Q=
M[.ZUO@"Q+7%(SCPS\\Q0.O_Q^N/5^%^?;MC,9YI]^N>[7VZO6*/5Z7P>7'4Z
MU^-K]K?QWW]APW:WQ\:6YTYY97*N.YV;#PW6F'E?C#J=Q6+17@S:QDX[X[M.
M6&K8T<8XV19>-"[.PQU\2BXN?CC_L=5BUR8I,YE[EEC)O12L="J?LL]"NGO6
M:E525Z986C6=>=;O]GOLL['W:L[CN%=>RXO5.N>=>'W>H4W.)T8L+\Z%FC,E
MWC84'PS>\--$B.YQ=_CF]&0RZ Y.WAR?G"1'LM\3_-\]*-F!>)SC_%++MXU,
MY:V9#/N/CH:%/ULHX6>C7K?[4X/D+LY3DWML9C$Y_HQK;*SDY8-O<:VF^8CL
M:<2IJ^'$:&-'K[KT=Q9&6BG/E%Z.?AZK3#KV02[8G<EX_G/3P0<M)ZU*HZ!3
M_Y'0">K1Y2+J>XQUM,KE2O]>/RA]\S!3$^79H-?NLZ<JU\WF=@K+O2DP#>O6
ME$\ M;3?2/NKF[OQ[?O;J\OQ[<</_]A9_[]<V^%6;6^;[)U5/&=7;?;.)/=-
MEDCK5;ID?L;]ZU=')V??NPF]-KME,SZ7S,JYD@NDJ9\IQWXMN448Z"6[DX6Q
MGIF<O3<V8[UNZU=F4G;SH)+2RB:[S9,V3#W][DWMPTG<P4"8DBW9?6X66HHI
M3""+;;13&.R8&[ 6%N0J9SQ?LC+WMI10&#Q&E 8 .,MP!?=KEO($MRPS&1+/
MFRBW(9#+1#K'[3*(9/Q>8M_:F@[W!)3!EIKX$'L$@419\!_$<DR')D):MIBI
M9,9<&3X>YR^DE=4BP8!,.0VB#)R[4'X& UTA$U(PK%M -2-@YAS3!)LLZS#L
MA4,'O^-0R5*5 [* ?@TBGD,:H[8VK/(4@<U#S</O1)<"2\(+-3B:\* *R5
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M#\$6C]&U-9E4H+^ $@5T395I:B=8DP4JL#4>2\]7WL3]GQIH_X#Y"[<$[J.
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MS"NL'0H:LT"<Q!CT2:8-_"D)D._.@@#SI2SG&Z#Y#OTQL"P8AP,QG#%"F0S
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MIH] SIM#OZ>JB(!49TYYK 3CSBE"J&!,:\UH1O42CUX>CQ[]^ /?];JTI^L
M?G_N6\596L/U@^*Y0Z6VO:/B#U_&4UV S2;=M/O;55S[R"Z-3* [+EKKOK2Y
M;N5?THZ]RX%1=Y_9L38="K"6,RQ#H%Y8YF(1NV>&6$QM)KA"> XH($K2@PCT
M:\&ZJR_S=K_]O:BV:+0UEQBJ#<?<84HUXTP90%9C,K#$'"*>6#L/]L,2CV;
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M,K:WI8H@%G@\IEDP302(&V()H;-?$_ZCX]"S5%T[P(I,(L)EH SIR%]"%C3
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M,&K^F93M:R@\5B-[$62: LW$1]9BIMGRH?>:D&0OI'?-.]$^?=VL?GO\VWZ
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M4/!<D I  "=7C6[?GL;WKN'7UE=#<-<_V:+?<C=_O,A;K5N_W36P>WK7KX!
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MN;YZK9:.O#Q8TNT\^8"7R/B"?*0PT3^14*P='15Z7*4'9"F+<X#RO9)BX)N
M':_A7"'PQ6END^<JRJGXI%IVQ,'MU:$42TJ13[(6.)&M-?=D#%\[G\"0[B3*
MJ)\%TM2G)<',U0JCT131K?)8E/KL:HE$S\S1XAP)C"=E<=$[;0Q=Q0-CJ)V:
M55VSL[NTC#P, 3BB<@S,6^=!&4O.Y&HN,$&C/Z82?/>K+M<<L?1YVX!NDK3S
MRG<:74HFJC76YQ%MDK?Q3%\5Y9+O/#?*P(Z"TEM;V2.F.! _P-+&BL4+/70
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M9%(,T28!-*VMZKY2:8V5J[G;+\]];$$Q&G08[%ZZ$19QILL!%QH)8:R./'T
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MWA]LK0+T-Y[<X60&UO]^;_W]YL[1UF9C8W]O<VOOL/ITN/]N9W,]_OS;^CO
M[ZW&X;^WMHX.GUP#- .O^%/2=XL^S.%BB+2J[NJ>ZCJS&/2"^ENL7OO70V\8
MB8[?\WI53NE06I? %ILI:G?6]:\''WYV>1>,VJO7>2<M-MWT\_C^Q0> HM%+
M&=C50]+SJLO7LFH-5?*J5\+_;O#D^O):NO2JYVY?$VB-8';O9;2&[[WVM6DQ
M69.,?-.T7[^6H6^[\\'%TD=-^RKM;[7'\2P50)!?5^C*$-+:?@9K%\1@LT9J
M,&,\2.!:AWV-&CBQZ<&#OF4.<G899[F-=S<1I<*121.;?+!()^[T[_V.;U"T
MF@IP"")X2$W?\>8_S.YM>NO;!M@1Q<,=1&,[6"/B#3,"5_OSV*T)Z9_OV]YZ
MCIK'19Z((U,M6KEK#/9I$@^8SB*_E][OP+9HQKX,KCVBGBYU9SH\!($^*_0Y
M\3F>#,(;"#=;(+QE0B<0;@R.<^IV?:_[^IM@.4$Z>[8Y)D2.C?BW6!-\UL$:
M4ZU2<D+\$#-ESG6KLH_' ?R4]T>-><#H__U=KSCZ:LF-.U/O]DM^^;I3=+;K
M3+A&OY/W#J*WI-]U*X,>$^F'7-F,(YU1JG%@SC.-N'.&>6T$&,DB^WLGZE8H
MHV@EIF[F;=WJ_KK2!)*H&IO %)>]UYU^VQ6]^OI*HZ/;/CZL>:+UV>N(9.L=
M%__:NL:P]=Z&+LOH2_\K%D4"B<'F^41LR7YW]*\KLUF<OR,'Y\=TM^\^;9U_
M?*L^[;>WT/[1UN5N^^#TX]N]UN[10?[QZ)CM?CGFNU_<I]T/6VSOB^4?WVY_
M?D?W6L=?SD[W-C]?[A[]_OGXP\&GCT=;Z+C]GNQO[I+]HUUZ_&7[='_3TOT/
M,-^VO-P_5&W;WN[L?]IK[V]^_K+[Z4]V3'[_O ?/V3]RI[MD[Q/<R_8^O&<?
M/^R0W;?;^3MZ<'K<OFSM?]KANYN_?]Y_>_!I[^WOI["VUMZ78[;W]D^^?_07
M?/__V?O6IK:29-N_HF!NG-L3H737^V%W$,$ ]C"G$;;![<%?'/4TLD'B2L(/
M?OVMV@(D&K 1$F)+JG-ZL$!;6[4K:ZU\5%;F&_SAX$OZWK^^7'XF?=?9!_).
M['[^\FWWY W[\&HWC6_[>^O5.]KZ_ E]V/K"6^_3[UM_'>\='*;7;V-K$WW_
M\V![L+N/OGT4WD3NJ .%J0:F)0*MD !&*:<<:RZY6%MGI,F5_./WZRMC_7_^
M@05Z,0T4+MEN DC,4GL78EI28A(>B6")5L90II'7F&N&A:#*4,M5K(@)84)Q
M(:8Z$=/Y%3%)JJ-U!@/'@D!2*0*L9PI$3-K$2B9<#&OKE#:)(#4BIAF9\XMB
M NX?=7L#R#U5+PY]G-QF_UU-!)EL(FZEW(7FI3D83)5(#I)$=D8"*30T"0WM
MC]E'U&.D# \@&:; 3(R@8W00(HXVJ&A"3/81IDTFIZ:AGU#!8]E']_6(5QZX
M<S H"G"G!^[(?N J&()#LAJ(5,"<Q&"-X4 8UTI8+8.DR;%13855C8"[8B&D
M#>?2PU0=*UQ(-K0]#@\R'N[KKRTT!\W&>#@/O:Y/3LO?Z>=2%&^O)-$*@XO(
M;:&A26BH/6X_1"62D>"!,^^ ,9H(*>3XBC.>$FVH$7R8Q5AU>JJ-'S/K[9&5
M!^_##8@"T\>"Z<A:8#&PD&P"L)P$8,)IL!I;X%XP8@F76+MDYN,:(?07EL)E
M\DX:;/@YJ.=UY8J%1E[GNNCMRS)BU[IB#?=!2Y3D":,D%]+9'@IGH^/WLF0V
M*L$4-IV<3??&-Y404YPZ)2$*SH%%0B!I/9[65;#"B<285";?J\E5G5RO$C.I
MC<E38/QT,!X915Y(C$FP(&AE%%D+UGD"D<5H>, FVKPWW$P"K!&,ERLG[G80
M'G0'N1S,M;2J:>(F]\H\7$Z2FH.M4>CHP70TOA5CA4&$(@)8JT1'#'%0AJ57
MV,ODO3'/'5U;%Z@IV*Q25>Z-BP4*LZPPUN=@D!2L3X'UD>EA48Q44 %2$0S,
MD0B*,@>2,BEUC)H)O+:N1).2665_/#K65R'3^W55).&BAD/."+XH:]8)@Q+N
M>-)PQU NKX]-9Y#<I.U+T;1"8:E)6&KW8",SU- JV?@HM+8<10F6RF2)*&W
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M5'G/D<]G=',U_,A!1<+!$V,),0@[Z]?665.Q)2S54^AJ2>G*1<^HHE9%3%G
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M0J XCT)+KK00:^M$-!&^F1U5\+_B^)]!S*+@_PGP/PI?*&XP4L(!H90 (]&
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ME&HB1IN,W6Q64*.#O^7L_NRUPY0[544[U CU(Q\-$2<,-PB0SQ'DI"I $4>
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M1FG"0<MGCHT83HX5$FAQ64S,6<,&;M_RV@<U&]42A3VXFF#;Q%8J<18#)5I
M3J=FE7N!#',]EW=ZUPKOVG*T.8B(8FJEF76_.*H'>8WW6$DX[C!Q>U"3KE1G
MV4Y3PU^(4A3@;?O=J"FZ?6:=9/:"<>%5M$2-Q60W.L(JHBFE9QFJ%*.LH?+9
M-";8YBF\N43)Y6W8P(SPKBF@?Q,3WI*.?X,+ 3]S(>WZ(K$>@6^N6TR99H%
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MX&Z=UZYE'YLQ?2OOTZ!OM:.94MRSZD%EZLR5ZQO9+L>N#:^8/?I^;[\IXK#
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M,6D^LM[YULC]]NV(>UW6'RU]:W6)T,UR!\-BOV7?QC\UU#4QC@70P=FF&[%
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M/7U=(\6>PWHZ@IY@9^KFOFS9YLOP6DN@6M6(-;+%V7*UMMU@VY9O38E;*.-
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M1F%$?!8D<-RQ(3*@/M%AD*21U-)@/0D_B1>/&Z[1WN38P/^Y,;TS.-GCHF=
M-.G>3"4V2Q=X@/U>;HISH[!>\_"ROS:]W*FP9D<O]Z"7@\.KKU'(8P5;27S?
M!X'@!PISA3F15#&>>L"G2?+J=;@D06CM V9IDL9">S)2 5.2)YY*XX2RU#=^
M;*1?"@2_$P@/=L#*.B*-$D%($A%YA''?(TD0IH0F41P:833UP8P-@G"U""BR
M[^L+@*V%2KP_L*+N)W5L]'1H]E,\^*G1?V="9L-LDIG"UN%^N95UC[RO)E'
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MZW3_ &9UM1V 8 GF4Q$')WO?#\]V+P<G>CC8V;T:[/QQLG=P/!P<[-&],Q!
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M-""5&&5..2-S6]U%I9+4FOQ3:7)]KG])]7L< 7"!,Z:M0\YX@GC,#4TDIXB
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MP>818Z,+@7(GP'N/DM."4!22@QXN0G_WNL V0_\]P,%6OS_, ]Y.?W6/]W=
M4[* O5IA:FWX'WLJ,!*53,CQ8,MRUUH+@A1G5F-,8$GTRENB5L5,8:H$::<'
M\PIR04:RDXW#5<,S)7SO@ WFWC0;@$ECD?N2L;R0L8QD_2Q;@^M1L+1D@'U=
ML 7W%4<FH_=4,7!R.+9>4^*)="&!$Q2D\U5W2/BK!K+%R=[A^MF>\ER)X P"
MQ@A,F!*-K,4,>65$8L3SY',UK+N)'KT0O38PA%&\H##^$RA6L()UL("=1DE9
M2/[&6%(9+M]=;?2'[C#ZP:4+%-EZZO=^HP^TN9\JZ0*)\^!M6K"T61+;^<T^
M"$O?]]JNH%8W"?$EG(V==OP.=CW_8N)JF9R!X]PO/Q@_X,7SCZRY[<5J=&VX
MM2U4Z,_A<;QXMO)^)Q4P5D3IRO!&UJ"X7OQQ G.1P;\+ VP,^_ R\X[3;N];
MUF'P/3*W+B@9D+/8@]?^HFSGR1!>]6/_>@;V_'R+Y-:5%S!6DLMV&EN]BVE>
M;43K#V 6;"]39B";V1+"_V\DH%V#/!O%0\?_#&$28+ZNA2) #!"YQ=&JFR!G
MJQKI)QC:YT'>@/@[]G*S+>#2%R"$Z"M#H28\2^OC'@M.$L$8TDF"#11)(:L<
M0XG8H))AQBJ>PR3T:O+*?S=. #7L,:SE:N.D,RRU$S0;IKB7->^7]J]S2@!8
M9/"YO0F)YEB<M]08:156T@L7R9WHT4VB4.0Z?3Z!(8;MXW]LKYUA),L%>=6"
M0)JG>V#UM<#*(LVL!X,4"-)&8^0)"S$F%4($9DW6Q%5[]-\-@,-?VNW,?"(Z
M@@4]:/RU]<?VI[7&2/<R)RJPHW#/1FP%K%48Q@)O3NQ9 >G%KSNEX]:#=>KU
MUQI_7SAMUUUE]&OXU;4"UP8IL)U.%@/X>O[/)>&S6#(BC<?2.QZ!I#,JE <;
MQJV25K@"?H -S2!#I<S] #?TDL!=#/WO\I:M0NJW4[-\S*WQF*HOC,/X^-7)
M(5SSXYZDUNDH'(J194"*#B@2$R@X+DG$11?SE;?LZCYF977& G0QM7VP6/OM
MX^-LGT91FY(!41"/03NW^&L73"4-.YW)V$[Y+3'M.-I!&1F:)N]_]V(E5A?$
M/4MI'^XP8O77$GFX\^E!%^2WF^UJ$<S) 2(8"Q"."3(&Z@!/EIV#]G$9NDP1
M&$ 5Y"@IT#UMKPW$NH2)YN"&.B8L): ,WGMIHP;UG]TG_F;AW\S#W1F/]GV,
M8\N[G2YTXS5C[Y<<%I<L4H6Y12K:7(L/_ "'@T)"$OA_+"I8&Y#YM9G0FR:"
M6B=9"-L%>SNYD,=&U\/:]+-<@WS!E^'?BME7L0Q0C>^QU[>]LY'H3CJH!3[/
M)TW)!(.5B"*DR".CQN:@.G [GQP!\UY+T^-(TRX%2\ZML%H+B:+6@* 4.V2D
M5CED1J0DP3(<LB5_F#39-*A@[>Y"-"5[1R,<#?#Q6@.H0I:AXUC*5Q$>CS^B
M'XZ\S I!_;6AD)$768RYPEH[5S@$Z*2U-L ]/+CG2CL1M%-)4I)WA!B[A7Y>
M38GZ"RQ $87KYXD B7VU08_FSCYK[>_YH+D!:H\8T09DTR>P[KEZL.$^D&1I
MM!1D<X:W =C5WI\P>U<=ZM)O?OL_KO?;VY>WW[$^*"5\DEUDO.YFXWY6F/XV
M*%PHWLY\H0T\& A.9??[(SH<+H=]7/3=HWB%:%=L9S7?(X<YNGGSZ+3=CU-D
M:%JS@&GW@%^T>^5=X%*9>,0?H(NP(O>E'L9+@:UDS!;DCELL K"]:)T*X(3*
M>QD+&-.4@7C%5N%P\[3Y<0\'08.(%*D<=>341*0UH\C#7#/MF&$QE^Q>4[,<
M_0I^I[5J=I)(I3:5;"L*PG\"9B!_X4TO=N";W^/OI^TP.!AE6TW\JE)+//Z)
M=?UN9SBX_B?7*/1D2_5GTFA*+\W7Q+\'O=%H3D XD0-/]QLJ3.H;VSFU9_V5
MWZ:?$AZQNKC)SWCGV;C^V5-ZM+R:<@E 5W,,-*]BX0/E;\%P[-*,I7'0RP#T
M7[?G-*F5MSL%:H(BO,O8!8#[/[_9N<W,DTKE[/2.S?_;>O?ET^9J8ZOU[I:@
M]!*,M@5(_+FQL]WXTEK_LK&UL[G1>+?=VMAL?2Y??=[^:VMC/;_]?JNUWGJW
MM?Y7X_,.O-'<;.U\?H'+\TNQ7](=PC5"?Q5LJX\Y _ @F^C"? ,'*/\")F!_
M7< 3WH\PW?%"-R1<W9I =3GA"IQ(8C@A^?LRAX6=LIH&G+?1O;?W!L)'-0*S
M$DXR:RMC0]=QMEMC1FN-+R?=<F=M8NMW8@]G\FHP.SV8Q;E<(88QX8H1G!SC
M- $24A,HMI2)**6BL_=BKGI EW9_XVO?_&T>;A%@8U0;$'GE$24T(IX,1X;Q
MA)*@(AC*$M=^Y:T4,\*<>>\QKVY!IF!51_3[A>9X7=Y<[CI %EON^]ZJ!N6&
M;Y7^Y<Y&N6!EYE>U\P" VA^Z_L "F(#FG17J!\K2SCY3OQ\')<QVACFQNOA9
MIQ/]8%@$0+J MW"Q7TIW"_R?B6BL;1SGI#+@LXV33@S[\=>UQGHH]ZSSC59G
M;IZG(3AX152WWPYMFQL\K.8("WQGM7%DL[\VY615[IOOHFH_-D?R>HW]H05E
M'W1[=YBE%RH9UZUYQBG;!O'PPSX,.P><;$KMG(Z2U\)WO\=C6WC$8"_'W[E8
MK/$7.NVC=K%K/6NAK*MR *I4R]'?H^#6Y:2(F0LZZ*YFX(=;%/XU_!)N!Y^'
M=C^G!136H)+!8AGWLUCY WN\7WCH^5%[7?#"C^"C(AP [Q3' 4#UL[A\@W%Y
M$);26\HW/@;Y!T1V@]'K3COF#[*S#BO?AI7-Q*(73X8]N!&, 2;(?RL>L[A>
M^_@[J$VQD5'L3!0;;K[XXECV1RD?)3_)M_[)A S,67>6I,7OHQV>$),==@8E
M#A="=,U:CP*GU0_@G>SN@9TN+G,AC?#C'!.%1\ED(>18:JQ$ >0E=MK]XB[7
MB!^ !-RZ7$NX@3W^UAN>#'PIONTL,]]SX=C5AL^'+R_&4L991ZMY<?N\-@Z,
MRW'.N2G4Z/(W"LD$DP3#/AR&_4I<RIO9'"&VOET^($@:X'".PI2@GK]S:GL9
MO> ;%9')8:3OL:1'U=A*^"SRG:^D.V><!-;1*5AQAO.<!GR2BYJ,8\57#,MP
MD(U @?*31J9,ZVD?'8$$P-.!@;@<*LNOXX_8\SDZ5JYM<<RF?)9>S+^$9ZVR
MDLOLH#$HVS%GVP#35*$-6.T^N)$E;YOY].V)K?/\B\DQ^^ZP$XIA'_O<)ZBT
M?O.%W41@A&A# E&>>Q,T=5$1H3CSR1J29IYMN6?:S58US(U8_O<51^/@.\#_
M4CYA8E- -'F'>+ ,@4<#_Q@>:?3>,TI6WM)9>S0O$6B[@Y)-%5EWJV"*"U$O
M-J\+R*B2DT% ^P4^CC+/2BVZ<&L:P'[B4^9;SW50<S+=.JM"*PZVTRCO.E=:
M6IHCFL\@]?LXYQC1J&R2#E%P;Q G,2$7 T:8JQSP%]2JG' M5P6YVAEFK=%X
M/UM@YLUZ7IQOFV(/B$-Y?*=<8ECTU[S*K/5QSSKI ,<H K,B =L<1IIHA1)V
MW%'E@V YFX%=7>+BA--IS)M:_1(=GFUEZZC%I945V^L/B5H,#FSIK8](%="N
MT1[]8)P+,!W$RM_OY<A]*+.Y+?P5AJ445!$S#TSR+).J<7BM Q0<%6?!,HD=
MT:?+=-#93H$@_8,82X(Y2KBRH^IX^1X7+"RG@1\#_QL<]+K#_8.K*0SYUI?S
MQH;]"[Z74LYL^!['5SR*@X-N6%L4JD7O2* 21QH"Y\09 >PN&L.T%C0Q7*/:
M?8\*;9T"JG$<:").HWP:&% M,F2+?@2Y+R$C,/%6K+Q55TN6@WP/>FTW'(S#
MO*/3"I,G-4#PKJ$]M*0]Q;9\Z7",-2)4B]5(Y1'2?!ZA$)Y?2C^E#"[\.B7?
M.2W[.JVJ3FO<KE5%?D 1R3H!3M@-_2+D,4I%Z-WP,*-<X:OJ-O5PLW3OTBV.
MNX-K;P-J5<5)06%CZ</UVS_*]-!^HSS%.W4T9#IFGL>Q?UP,:RXEM(%'0R3!
MSG&BG 7/RD<=,4]1.:TJIXI?XU3-**I4SD[A]VVG]Z-5?N5T<F==;.]\@?'M
MGH-#1< TQ2"<4#$BDA+)_08ULIR"??(*%B0J';0!TJ%FJ&?_JJ"-X@W@V]MV
MD3<\,A=5<.%:O6OWYY*71'%PC"K&?>!:Y$TM$5WR0CBLDHRS<U]JT)Y70L#Y
M\)QX!E881:M$3BPWR$GFD&3<"C"96F:7>U9B^:QS9',XX1.%3@A='J=\_>*I
MRA(VTS@X/C)_80N^V\XP7A==NVP>YE.#^Z6 S>6=U\>>"R[SC0*7H4('R4Q
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M7?Q,&0[W#^ <KN/6>?-'\_P;V=[Y<@[NF';@ 07K$# -B;CS$>G$*0J*2);
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MYBEM%)V[]F-)?^Q@.@)<M*=K]XOMG5QFWE8_RAVQNBFU?>E:=*S+/G*W=]:
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M'^VCLKGFM3YD_S]I<#E50!-A8J(RAL1]LDZ"H>,Z"65#BG2TW:=&VWWPXH;
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MQ; /08]K)YU:5HY\5A?^A5L-BE3EG-@N7*:?:UW#Z2>]!%H/UGC0M+H<#=B
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MPH$+Y1)37LHB@P@_>??=K#.()GO CT/C72U$;VOSM\@]X>U5>Z#657N@N]O
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M\L9F _[^)NKKN^=[1QM\[R@<3:CC<?W';K-]6-_<$(VO6Z#2C6][1P=XEVX
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M1,X]<5NXNK^+<N2,6F#,-<I?M:(;YC-/9J6.)TSTQK-UJV89=[5;>UK($C_
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MDAI'E0L\6&:-\$RYZ)21'K-[*G-EE5]6C\=JU 8>I34>,4H"XB8R9+1W2,O
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MQ>/EB). )RQQ)_-><:*(06]DQX;PWV&*"_HMC[B0"9;>T4"^&V*_%\GOWIA
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M9YD+>U<Q]=*B-F%AK"*%FSBXD%%[*:=E@Z:T1B$$KD/]NK2N92MY@MP"CN3
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M=8-4QLPQ)ZBV1I3X?"J<L]3I">5.Q/-$=E8,IM,\BKMQY*H/(C]DTZG(1)>
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M#]3#Q7!^,A>*%FC1<.F6V8E$,1=A+JE[>Y9/04#N8I9%A=EE$15N_S<^AXF
MZ+Y$V&4,L2Z? >H!I'!"2UZL\" 2$\Y$PD5K5+#U*2\FGV7L&Q=20K9^H<R6
M2%9SX"3A9PM17<'U5<]'_648OQ(IZ]H$U@?,S'W4!]RY)J8HPKY>+)&)%H8'
MBH*!%Z04#A/<3BL"9?&:LJX*CB W7N4$I!G<S.I4T[[<<C0QBZLN\B0P&2IV
M96NC,CA_O3B7^[Z^(GSCV02>#*?RG[,<_JI:WN*L+AGP04S6DIS:84I93)%
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M=MKX-".B[M925Q_VLJYF;55=(Y>Y28EJI?:T6CYT6P5BH9/7BPX/>_#_5(4
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M0H'@I0H,TDVJ&@R5KH.,$721(_6T$R5]"<F^,J?E'Z_D'_B_*2A1[@1NQ*0
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M,"T,4^$W4UDXQ>5;Q1P+LK2J(U95DQ UDRIJF.Q,O:#-H-*R !>(78!E>\8
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M*JW6P7094-1A+)E6 6K.92[B@['O%QJ%T!9NW8-ZHHN2V1553HC0DE%@XM.
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M8$[JQC,6EH4!;0;$^CO7UML,B#8#XD$R(%K1N+5H1(WWZ'S5/365,&M@!2L
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MR"S&BY9/9V$\5PTDX?L@$1 6 8+=DP833Z=2=:"TUVO,RD,#KJK=K+#V.]5
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MI@I>-*Q7Z, H?LC=#!]@FL?=A+.4:[&O_=WNC=20'2U.M/'H'QW-3^+IZB#
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MDQRVPX,7:?D,% <8>,;FN.5T4YK]GEY<E72G1A%J(O"OZT!>^S=3CNZCZTD
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M0(D-3$HA ?T\R80XH5_08_!6+>/N)(*]OIP7AZ*95*01-P=B_95@A4-:._-
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M&^X^]<[]3P<>F4/7\:W;@%#BAOR("-"SAR?_@UUM:0E*CEY+]J%1?"PL1U'
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MXE,LZ(M!E@/=O1!&'*1SN$M1%$TU)DE(Q<&^3.:6*=)3<PD*>_LG]EK-O/P
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M/P+B]7":A!&O*1\WXVS6#C,ILZ;5R>OX.:T>B%FV[>&P2#EBY:__!%,N ]Z
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M2]L-2_ON"$L[PM)^+RSMC[$1POEN^EP2K/2 0L3.!:GQD-ZJJVWJ)VFT,@L
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M)Q_YFW'DXQ6SZ0@,[-;\Y>UQ_^]R_Z]7CL.BFH"*9GC"A&,MEK<9 W,FVO_
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MRA*2X2%=+3>58@!*IA*][29^&!S5.V8H!=6"\7.9Z)[16-$Q!&+.6X:Y,01
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ME'CQ1P#@\DD0IE$QZX,)[V:-"-;"*GN%%(!B@.@SY<+?5+?SKMEP0C$,B86
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M: /_N0RS6JS.)ZI"-S4CD)Z'Z&93\@&T\5PTO/W"PJDW9!((<"0C+16,3F7
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M+.2R"3FD<NUJ5&_ /I:K!+H['8?UIJ)?$67Q:A8%'P<74?G.R-D."(;5V^2
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M/>Z D=CTT^7@\I$_2>'HIZX+:^2'\"D']\^[85?1'<_7(_;K3S\\/X]#I@?
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MQ%/Y8)KY.N=-<_:*,CFKGW"9OY0W'^ &-K6F1+E[!CJC<)=8JT08ZN7!;GV
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MI\M12"R40G5AP;I;4SL6X<Y$KO?,$)E1LJ+<D<WUL\,8R-OY11=>O2324\%
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M7!3J'<%NJ.BH(]9CJ,*25D:N$DEW@X_<7;P781>^?>:0A6\X9DR=B7 LBCS
M^HIH7]I+=IX6JN>SNQ89N=P'W;!@BVO:=4O#175JJ^)11KUF4J7%H=6*(IT,
M4A&-DMLS7J"DJ):<M\7*Y#]A$;@@P:GZ5'MZZ3'TF&3)ISE0R -.8E>9IJ"\
M8#D7W9&(>H!;X5<J0X2#]%K #*AE,PM:VF-W4)I60',E4DN^0HLZ=KA&/$B%
M82XIOJ0U5"99N:P'SHODW%5AF/?=0/RE*B4K19=\WMWAC>6KPN21%AL_BV1E
MRU+;AQEKQVI]U=)FL55.A\RY ] =>8VP=;%OQ4_Q(L:W PE:>C<X%HMWY=_3
MXKR '5,E.-)UV"C9C*LZ"W7:8?W.92Z=19A$LNH+!L2D .'J >Z%1';/30'^
M\?3QD\=%G)7G71OBW8'JK,.@/CJ1(9>KX::J]B+H)-A/*5[+@BT!"(LD&1$Z
M4>C^80E!IVE\V7<WXU5<VK2+T&=>A-CS"K +*BYNX"P)05@F! 2H!;LCGM,P
MX8K3(-LMLBCLX2 >PL]9"S,=28G@PN5[1<<397GGU[=Q>G)8P3]RX _X>K>"
M!'^(Q%NO5&?)E/3"@J WI'5R_&1>L#-IY5L"9^*;8U8(F@0)?8P]-L&Q.25J
MXTD^Z3Y_HG*5X*^J8<'-2A)*$GY'_:SI>#%(LW@;.<HH4R&JHV(H*)6QFW;
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M[=21X,,-B# ]X2ZJ2^YFM3S5DZ]E'8#_Q8U=MT=AG"]Y/ET2;E6_S.8D?SW
MTZAL2.I/U<;69,*"$QZT7=<*UP69#Q\ VKDOH);J?=@&T(#S *XP$96L-T9L
MY(503@A$@^OU3^A0H'W XQA!C-YTTO+^>Z5XI9N2I(LB>$\FD&MA="YE/9G
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MI"GNBI>VN#M)=Y3/Y OM@$:, A\A'E0H2ACS'&OO85I 9%3Z +8\*K09JF4
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M&,E>W2.&5RO<T:6+2!:E]J9)!51O<\SBE%(14CRDS1,N3_5IG "#[N2EBVW
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M?J7Z3WX:%D87BD%X&?'&"Y7EI#/:PERM15(UP\N5[.N^,?G&=9#\@)C(J-7
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MEZA7,?46=)G:I>+Q!)ZC4E[ R*X, JP95['$*,QD9PE3%K,%/*&8QA*KJ_&
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M>V3)+.FUG0\$:TB=/V?*-5Z3;J69'7L(/MG&6/<Z.S_61VWG=SCKO?9&@3(
M'\)TJ"(>*/3<RS'.K"SBDX]V;^='^[CM?,'4\I656M['<5ZVENV0ZJ7&MKU'
MB6U[_<>(;5<!?%4CAP>JX^!4[RS-)ZI;Y^_V*>8M-""X0WF]=UO_P-T/A!]K
M FS>;O;;SB6-:_7XO-0I63P[.Z[KD3KC2:=FV@(!!\D!(A=G:7 F?[P#FO3(
MFY^%4_P\O*G4/_!&!)<,O8C?BJ^CGWGIG?;;G2X<IO]WEJC_\^7%O##;N# /
M,[_FMUZ[\]9=^'.G_=#?CD_[#[ISV<?VNJJ9^_*Q)^WNZ=&>?*M[U.[W]^9C
M.^V3H^[^?.QQ]V2MQQ[BVJ7UJRP$&*.?7_5>&>^,]4]G'<=%"R//VYU+NV[E
MVN[L#JZNL9DEFT;F[+$]P<E*DC7*[6NB&SS/_!:@9LDP,%F1>XQ/39.A9&UA
M@Q=Z7Q=*W-Y9SJ='T=;&0]&5O8;ND]WFNMS N]V8SW%IU_&X2^8%S(F.-2><
M#T$Z3,(9Q*T;J1@M?TUEK]2AFE50)GGB<=T]\_8Q3B8%0_:RFB]STE[B+Z\7
M/H81'$I^4#[N9?="4)D([-=+2:8>;>-JV\S[.;"_JLD.\ODX\O&;";Z:5[[D
M5SYNZ*E>_/392UQ_O;;[9-9G58"UZ:QC70_L5-;QGA_(6<=QELW.#@]O;V_;
MZC/;-_&/P_-D. : ^V'@WWC)H>]EWJ';/STY[G4.U>>Z[FG/[1Z[;WL=M],_
M.O2/^F[GI.,'=[UN>YRIX;@HJAF> Z!;"A1*OUW92H=07!N) "&+ZP*"GK2]
MM:YWO<@WGG[.,M(PZ/9)0Z%=FQU=DO'<C@^=A+X?!5M:Q"<'_[OE$&*KS>^U
MNUNU8;KQ"S>)_3*34)_A8/QO6%XO_[@\FWW@]HAH9RM=[2K[T3UTW^[ UOP%
M]3IMF]4[#HZ/W_:/:CK__A'S[B<OFTM77/I\8M#MVF]J>1. _I4 -+UG!$I_
M=EWX^)Y[&-R%P#*A M >"SMY4Q^UM2D>/;<DM[^)Y/;R0-1+_V(L^CG^0:&H
M>[PP%'V)X9;;>>GA9J\)-Y^HJP]=][!;YD)\@7-.6<R#WJG:N/_%/.EN!C+-
MI2\RZMNN&6VBOAU*.QXM"?/>SU5,EF) 9RK'@24-JVN;H*Q) 8(Q.6IBLB8%
M6-OKJSK3;7>WUYMK)/7VWM.[G;;[4^/KG[^O-XF=2HZGWSGD1KD=-YC,HGB.
MXDS(^4G._U+_JZ64-PBR6R!0O:0$40NR/&V,#]XGH1K)]\C;XF.@<#Y+PLAQ
M^R3&V@0&36! MF=S[7^[R%WO4A=TC@_=GIU%>8'38&G^Y#DXV&[C8!L'*PZV
M.XV!LS4>(0V_<I;D8('%=$AN]?S62_P'NMG?O;GC]AHGVSA9V_XT3K9QLN)D
M:ZNTFE.*EW3I,PJM>C\Y?W^AP97;W?'@:OD'<G"EP24<'O4.^A U+3ERN&<J
MXC(*O=3YT':^>FIHPXF72JST6SX-')=BI4V'2LVE=1:H<3LOZ=)GY':.7JK3
M>1X[^K+3.:HX'70JG^.VTV5GX2$]Y&]Y-'=Z'?(96&_#\EC*T5P+/_FY$0NT
M[[7*9Q"SV.T0G;8/TH/3FZ+K:LE_.E\TC3 S=1>U &=>@G(501*HSQDE\02U
MP40C#)_/&EU&,N6/)$\S/+3W;H!YN_%^C?=K+FV\WUIH#K?M-M[O^7B_GNO:
MWL_@]H$V'TF/1=OV\DYY.!1#^@(R0\J1?;7D]K[ED=I-];P#]^BU]T:#]PV1
M\N7=<.Q-;P+G?(@*$^YI[Z@%NI/GK,EE/^TZ0&U?Y6N[^E%>,O"F07KPY2X*
MYO*4;J?3;?S7+OBOX\9_/>=+GY'_ZC;^ZSGYK^Z:_LOL?QK_]:(O;?S7"[ST
MV?BOKMI_-0[L&3FP[N(-6+IJ!P;IO74]G'OB_-F^;E^TM7=R>\>=E2[LM--O
M7-BN75KOPOJ-"WO.ESX7%^9VW/;5Y^M=<&+;:/X5RA<X_WK_[9-S-4TST))T
M/L3#' ^=4#/=?<?R\/RK+[_ZL?J.*<G[!%XB*HQ7@#?S4#@=2$L]!ZD[18X5
MA,_Q;9EW0Q+C< [E^\R_H9]A/DO>MYD1:BYM;/E+OQ0'_1 E3'Y9*-WT),JD
MZZG.[(ZD4[D:T_K?1IQIZSNB9RO.U,@:/>"W1M:HD35J9(TV(&NT\YL<V.-=
M7_Q/L\?[Y/SAW<73>#)W+N^4UTHAIW8]' <33V_ZFFU6@[IK+FU29LO-Z<7Y
MI\:<UIK3"R\:YA$=^7\*I]\'7AHTQK4QKLVEC7%=T[A^N/S8&-=:X_HA&(73
ML+&MVUYFC6U]29<^)]OZZ?Q]8UMK;>LG;Q!$C5EMS&IS:6-6[VM6OWZ[;,QJ
MK5G]F@0I$)@V0>NV%UIC75_2I<_'NNX$P<<VFGX1_P#8N'>S"%3X>A0G$R]C
M7@O;$ ,6?:A>X*E_\0&9*%KRREF]:8SNUD%E*S0/2+A@-\0,$.GUDYI=/BK(
MI8[GJ,>I28D@6)AD,#&=.%%_3V;*ZWM9G,R=6>1-V^L#@K;4KK\[#BXEWP'6
M%D#@KOO-NS]F?X?&_3$.G&&A#E/9"V\X)I,A5@$*F9QL[&6.-QPBM0U466;C
M,'7^D7N)LCW1W/D6S.(D \6_C\KL*$MR\ \G) 2T#R0[?D5'\/("#1%?E,7.
M '#4HCZH+AW,G208J9X'8'4X55=XTSD\1O4J@,N*%'((52N7@IH*T!ZQZ!!/
M70LFY%I5H^8>Y_7M. #Z'C7!?8!L*_,:P',0MHA/\UG_,,V'8],-;UI.F*@X
M=Q:0A5870#MN@JDRVI'59.A_M2YN<K#I!?N,#Z2&WV,&OEH,FFL0K&LA6(\7
M(UBA5:'_\ZO5>$BW=_KJE[^.>WW;70)ZW2=\Z]:_9>^@K%M=&G6=^^J7ZZM?
M/Y__\>>WR^O[]D41>+N-96W73H+93H+_Y&&"$4NZ-IT W7@3IAFPPSMCY2A\
MX)S#0AZ?O&-"/I%<6ZK&3/V@;#Q4^0R"L1>-P,7!@W!N\@7($)>#M\/G>7DV
MCA/5.O\>\=*N]+3:C 1GSGE^DZ=J<]$5!M>'+!Y4]MH^=/OHJ'U\[#X(NNVV
MCTY.'Q^WW&_WW/4@M+6;_OY#=[[4+5O:_%[^Z^I"&1\5^GV^:!=VK/7I+'>3
MG!&/FTS9:K^^GY_=8_^_#RTZ3 ]9?>.BC0(<#]&N66-FL.6!JA-UK:,"X=!W
MI'G[U&%/T5G[U!\7XS 850D;7D;/X!//PDR];;A&7[U>1G'Q9AT[?=38Z9=K
MIZL* (VQ7A$'/56/[5.GD,4^'PYCM8V"7&%CLM<SV=4NJ['9:YY:+-F%KDA(
M/M9S[+S91K.:NY"E69# ["].8!X.8G^N_M\XFT2__#]02P,$%     @ "($,
M4^#1M71*$@  )L   !$   !X8W5R+3(P,C$P-C,P+GAS9.U=[7/B.-+_OG^%
MGGRYO:IC@L%YK9VY(H3L4$\2<H',W'W:$K8,>M98K&4GY/[ZIR7;8+ M+ ([
MOC-54YG$5G=+_6NU6JT7__+WQ<Q%K\3GE'F?3XQ/S1-$/(O9U)M\/GD9W34N
M3_[^Y:>??OF?1N.?-\_WZ)99X8QX >KZ! ?$1F\TF*+O-N&_(\=G,_2=^;_3
M5]QH?)%$739_]^ED&J!6LV5LOO6OS\9GIM,D5F/L-,<-\]RX;%Q>M%H-X]*Y
MN#HWFYA<7/UM<GUVU6X[S;/+1O/BK-DP2<MJ7%V>M1I7+0=?G;>-\?F5+9DN
M^#6WIF2&$33,X]<+_OED&@3SZ]/3M[>W3V_M3\R?G+::3>/TGP_W0UGT)"[K
M4N_WM=*+L>\FY=NGXO48<Y(47UBAOU:<+"@\(L'BD\5FIZ*]S?-V<UD<F%$%
M>^KQ 'O6DKT=^(W@?4YX/@V\/A6OA9QFHVDT6D9:DATLR=)BSDZCER<(!X%/
MQV% [I@_NR4.#ET@";T_0NQ2AQ(;#,$E NJU JG7 ?8G)'C$,\+GV")E5/'E
M)X0$1'0V9WZ O RM@_E8UI7[@203+6M#RR)0[YF% VFIHCQ/&I>A.B5NP,5?
MC16/3PMNGYR6KT'(&Q.,YSO4(DT9U21^HE^;E,T:5U=7IPMAA/GUR#4J6;XA
M?FT8+3VQ1=997C;\U4CH]E&'50?4JT-"]\$ZY/:X(HO81BG_YB6KD=^#2RHA
M(1"M/],1R(GU:<)>3VU"I2EO,?_-XN(7:?#K,K'GL4#2BR?QL_F<>@Z+'L C
M =AU@MHS<1*_EG'0.5U#_G>-?<MG[I9^=#KWV9SX 24\[=PE@ZE/G,\GPL4W
M$N_UFXO'GZ F29&,@'73$Z]/@82X]ZN6)+0"_<\G' !P2:2;*C=\[A/=A@,)
MA[%# OT?WWX+N[KM!Q(K=/\[FF\31[?Y0$(]ND/K!?4(WB-J?S[I,HA,G_ $
M:B>>OSSW%4&&E+NB2-@FC%<U^M*$Z _^H<8JFFT@28D$Z2^GFP0;K$).[('W
M1?Z^:><Q<5Q$0;AA(*7IUC6;2Q8_3%2I4/#+8^?EMC_JW78'C[>]QZ'\93BX
M[]]VX.%-Y[[SV.T-O_9ZHV%I"'1X*D R)$@M0&8(VB4Q2DOF:,D=I=FCF#^*
M!!RAS%/[$_:AG5,24*CY(7!=%Z &6?B,CX&,?EZ3]]<CZ+&>AB/X^=![' T'
M=X.GWG-GU(>W>P*\@+D:[':S:>J"O1*$!G=H)>H(<PX2W<'#TW/O*Y3I?^O=
M#X;#_B,\ZAT \R)):@,P80[R,0-8DXM^%I+_BB+91XO(P^EKY_'7'J S' VZ
M__MU<'_;>Q[V_O'2'_WK$%:AD*:VC+-F\_R#EA')!F- :>E_09'\HW7DX=49
M?KV['WP_Q*BPXJU&_KS9O/@@\B )25%'D%5 '"+P*R%(#?]%LWFY+_AK' K>
M$F[Y="ZX,><FY-0CG&//OL&<<N8\I1I7&GD=G@J06T;3,*+Y-N66RSB($7^L
MN"/FH(0_ @%(2A!/TS*.:.9I_I8$F+K\$* FK%78FDWX]W%LT<^QL#KUV2&=
M>-0!3^4%'<MBH1=0;_+$7&I14AY0-1=UOVP;,L6RAEV*'UHQ1 G'(SZ1'O:+
M4RF\6DVSE>UK6_"",3'^K4Y=J\M<%X^9#]5X)<_0$NQ;4_ ^]]0B'B>=B4]D
MM%$>OO(<U5WNS) )KS4(UWBCA+GTEC%[M.)_1#&K<]U!4)NQ>@@\-[-N5 O3
M>@Y_X7P>;3'![@UVQ3:!X920H.\YS)_IA:IE>*G[Y84A<Y/KKC7%%<5LD>2+
M4HR/D*75/,)C5V=4+,U1!5^[>=G.&1E+P8=^C@0<N]Z:UB$ZGV-JD\5<^"HQ
M0V PK_8!/S'#QIP3?;>[9[%JIWQE9@?:DA;10'$U4%(/Z;=E35!<%135Y>BY
MBW"4>PS>06^]/T(Z%X4?27 0BU%*4AH)^/Q=O;XTDDBR-(ZE[+\AD'XTBWRP
M8(+BA\3N1=T*]#80?:H;=:E[BL?4I6)CR@'L1%>TVG ,4ZYD[68X<5507!=I
M/[(V**X.2M6GEJ;4]UX)#_1F:&D:9:QGB&G8)G@IZGKJ63-PRU(J S2CW<[.
MD5(\ZAB%I9JOZ^]R2-7^RC3E^FJQ^NOM9#JOT'AA@."F.7;)D(#&=QJ)M)BJ
M,3LSY<IH(68PD"02&B"B(62@E9!:8GI+QH'&6@@45@\5YT:VWPBRFJE4<W!(
MD:A'A8MV=I(FB.LX'(AV/V(_RACJ+^OE$*O=RZ4I5]ZSNF^@):?:^I GGWH6
MG6/W 0>Q/V7./?,F(R*.PXVU9[):3-7 79G-JP+@EA+02H18:Q5"&D)*W+N.
MJ"H!^,TX"*[ ]HCL_I&])YAK#$YQ<>6XWVH:V=@K(JR=8C7'_C4BY>C?,MK9
M[%M$7L?Q/VKYSA%  ;G2X;1$"K0 @;I' 9$:GL7E!<QYX:0C\OVI/-YN^&SG
MIP:L;1J9=:XE8)*Y&!1>Q.JRX+^^T%5;%.7/+N/ZB98B>C5*IFEDDEU+E.0O
M2'*K,23B[@T[= ES[D*(9\@#")B%LV>9/7_"[SNEQ79@K0;RS#0R\],ED(D<
MT>,B22@6A2)9*!%VQ+D4&!IA]T[,CU@?;.DO8-;O4^;:Q.=B)31X+[]TER55
MA^;G1C9OD6;R%Q2QJ;7Z=;?A%#%0!_ 7[9Q5T!PHZAC.9U4:+^YV\9R"PZ#_
MWBF,U&2K=GF7II'=_I"'7V.Y,KTNYNCL(@C8;,8\^?R[F#3M$+IH,56C>F4:
MY7JEV*4J9$1O42+E"*I43\>RPIFH%XFWBK 9-'%*/ Y3XGO&]P!Q:1%*P-M-
MT\@L4A4 GI*8;#E)RT1":"WQCS1T ^&>+30"ZM#;@5Q$KXQEVH:13?A&G!J2
M%4KS.J*A&=6HN2A#FW:KG5WX+42FCO%-@7)WSE^6Y:=VA6W3R.3MBV&K>XZS
M0.>K:77Z:;Q;<4^XEI*AQMHTC<Q$4(5U>@Z_]BK9AWDT@:5..IR',WF E[_
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M5!X\DZ4>N5>*/#X>6)\<Y";H-DI-LO\#9-I%:AWY=&L#HQ$G;Y %S\$F2;/
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MXOP=1;*AKWGZ>OT2PP+_]I?_!5!+ P04    "  (@0Q3H, *ZR!.  #I9@,
M%0   'AC=7(M,C R,3 V,S!?9&5F+GAM;.V]67=;.;(F^GY^1=[LUQN5F(>S
MNDXOIX<\7NVT?#U4=3]Q80C8[*)('9)RVOWK;X B-5"D1(H;)"TY*\NI@=[[
M0\0'("(0B/CO_^/;Z>"7KSB>]$?#O__*_\9^_06':93[P\]___73QU?@?OT?
M__%O__;?_Q^ __7[^S>_O!BE\U,<3G]Y/L8PQ?S+7_WIEU_^F7'RKU_*>'3Z
MRS]'XW_UOP: _YC]I>>CL^_C_N<OTU\$$WSYM^-_UU&KPC!!+"R",MR!LT(
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M@#[EE+TKUH@F!-L1^..FWCZUNB+PN_,A &&\ MR3,?.$) F76*&55M'NK5D
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MH>!\1"?CU\,RQO\ZIT=6,<V"V2E8RT+0D(32H$0HX+&FI^O@7<Q<E48'_7>
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M$90IJK8.Y36;1ELKN;.-Z-35"!X=\0ZBV@96X%I@M$_TD@F,_A?!>U[+Y9*
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MPP4C&4M%*W"^U,Z5.8%S1H.K[8=LL"R6-JFF1W\2VC$%MA'T7DY"2T)NL]?
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M'<6.WYA2UY4M]PYH>@=#+#%W)D:+0=:I?C/VMC?+ N<:CL[7+K[0UE $*/\
MANUE6UA$EW4KXQ \SSK57[N /<U6EE04/SR8B$[]._V^PE.BN4=M]0AA%@L_
M.D6J>UT=-QBGN)T:N7 J.W/'?820C#M<AW<G# P$C\046:](Y"\)"'<%)=U&
M\.'-AJW#2XK8J5^%+-8IWO<*;"5;*7T^34AUIZ0;$ >86H\'7GRK8'I"5OU4
M4AX,IH]@3X=$'9^!KNI_:W(YH^I>E)$(-4A8W0K7';WQC1(<W4+HXGL&$NY3
M[[\;@M'7+P=EF V6',S87B7&-O,3?Q%H8@T^LH20.MG8_S-5[Q=?L<K0\2VS
M3$I^&G>7HW4[G*N+9A9(B55SD>9.0P-A!;9GG8$;B6A@>E$]89@A7E*"._Y/
M=&SMJ"JO ]X;RN^J_P-3!"R-S^D.![Z@LG0=<5#JC:658&7NJ+[,/*O1_.4^
MWB[3,#^4" B5M*J64V2440!H*%+^'D#_X465N?T:%8&^SQ3_ :@ZC4]O59;%
MH2P2W.P^.A5$Y34A>[ZWV"BFYSCWG6I5N% 6!I&+<U4S+1"J,36FV2SS.0[B
MOEC8N)3A5TPL1U^] &7)P;0=I)^G[TX]PY:AP3D:X.#?WE_P F]8TC;)),G^
MDS[\M=BZ3[O<7L?=*GF>_UJ]$SVP>7.?O7^PP.MA:YP5U[M;"1_>8J&J;B>$
MP,$- SY]EK[8GVVX2?Y<PQ1]O& KG^.468-1P!&ZR5'F]*^16K38KO$"R=QI
MN1W23ZP79;A"#2'75%&"&N&TA#/23:=X[4I.*J)X;+X$S^DI_]2?<$4#OQMD
M^.2^X'BXI:*+K@GY6@GK#2K$! M75/X,CY/0SM!=Y;:BIJO-D2'[>SQQ;Q+#
M%.E8T4!:ASM[L&'#*2^!RIC 95%SC[XJNO:-#W6,QY9C4NJ9WQI'X2:*\A8^
M3W/+KBNP$(;(]LQ+A#;E+1'^O6O/+0H_O])RC#%KBQ@#=1AH 'SY[FC]%I7I
MY?_JQ_9BOW2L;EB/F=,<T)UT#IR ?<S^EWCF_VY .&%^& A;PD0BA8$D,V?<
MOP8B,S)<: "9'SAD@09ZF>HD_GA=G-8:D=R5T#C*2B/BK,RJ4<9XQ!.IW/)V
M6='EFU2?4K SX]=Z2O'Q=->*WA GW$:&$*C4K"DA_EH]+! 99;(I>T;[M<OO
M;K6NU3WHO(X'RTAD4"!CSG9!:$!?B:;! :9CD_.US44)%7MTLMH)#1'1D[V(
M_B*:H'A):GUT%C4S1X[Q7P[7722C.>LEJVSM);ZQTR*L$J.K+UV&..OYB1;S
M/7[3YGRIC&_ANR_9<9H2%SRV+)>URNU)7-*[< IROQ?99P39T:\6S.4N)PZJ
MO(9:$&]WP5&3[[WK=4&TVDAIT+1T@Y!:(&DF7+WIF$D>,+6D15+>/31N:=UZ
MG)N(K*D9OA97]20[P((.M2GH)=WM33"F+T7AD6WB^;$(^:E&N843*M9-4F(^
ME.VG,C*R3Q0W=*KV=;0;N^J:_//H&XLZ\*Z:E4Z6'(U8+U0GJ@%7GJCV%A=/
MC& X6Z,3:$ZN8R:TI]Z;F5#]L,+*0,QRQJ:,<^]3$/P\R/503QFULO>A/"+A
MD$P]6A ?R,F0><[4RK1'<M.FY00N6WPJNC.OO$9WSW"N?I-YO7L.N8C3RR\P
M%"'#MMQCX9 \]<@[@E#;E$ICAUB9A35:T*N#?1"C1-Z[,SV\U%3E+56MVR3?
M+M:.Q\).QUC6A%,JP]'N8%95VZ33B7W'K"E. 8#;V3/O-.4PW9_Q#QYA-X<W
MI1*&<)![:Q@KZSGS[G 0A:1STBY%I5B*+U I3-,\N!A"X8OU &$Q3A/&/.6E
MT<@\\T8R(2%RZ3UC0%5EG& @%A=9N[P<Y2Y[/\MPZ+>R>C:3H@]9UR=]=-6S
MHDX+:5,LT]O%UN%%;)RNITW9'_7ZV!W)K6,HYF;QEW88R#_MP+OA^=L^L:ZI
M.9)3(AGGE0-I<(V80X*4F;-O>,>>18'A(N$$*@NT\4IF,?(/%K:T#N_5O)2[
MRFOR";)J+?" 7NDRG4Z[<QB/+$]PKX[C9S(/1!K9?8E7L[H<+7/XU2R U,.:
M=A_[O=,= S1 83\XVLT1:Z:IK2Z!@CA!A2.F2(4_**]'L&F_#Q+K;/=(7W:N
M<F(I%@F2MDT_+$ #3'EHP @3B<GYB"3>HW_3E49@<VS_X1U;1]1'48<)//.#
M")A(2ZK MUHB;LW^*VQW4'=.O[A4/\C[^&0$DMXND%KQ'+4!-5@6*>WA\7U5
M-;OAW#=,# ;UZBGF'$H,J3I+::RY=Q,?2,M#0UK=A(6<Z[[-1/K8.:51!<XL
MR:Y$HH%%1Z.TTYMH8&D(#5S4H]O2.Y=).*\N.0_?<VT-)%0L#[#/L+3H1-B1
MPT_$P'%+DU52%]XY/YD(*QIY3FE].3_S$[W4'(M98R/0&>/XH1$5#:4M'D)^
M8Y!HI>\_0XA;T++&Q3R78^S&$9.*<HZWI9]*S;)S)95[RN:DJOP-*N7 #JWC
M:'>.:VP^QE91%F:;%2O(^E@^R41_E[JB<V=H+FKGX&[]VCC5+(G:4R#(N6ZS
MIR7\,]'.V=)3?'YY@M3W:, 7B)8 Y&<CY]W/I(ES39&=K'T.=%)'+V^YIFPK
M'WN4&.=HO"Y?R<TL/L,HL4*5'YIL;'(/4^N@<_=L_:J&%:US\.D*1IMMET0V
M;.VF[;4%[HJ6Z)1P?6\=F#(:,-1# PH^@S&MBBK1D_J;>_'7YN_,/,':7HXL
ME,9EMA1?%.^YS3!=71(F2.9Z";'&'Z_DU6'1A*Q4E7E3@G%M,]' &S1P1( &
MRHJ1\INK!A=HIZ#SXO?MJ&6>,Q._>JC6&@]GS?RZX53FL)#BE>:X7[(A4/8Y
MU&/5OGV@V[5=8$AX/+"UY/Q5X#:54SUW.<V+C."R2N6+6M'5%G+.NGY&FYM+
MUON/[W5'RC@-\\B.H@ACC 4EMH4>6PM3^5IQ5[A<@2C1:UR>E+GY7 T2,[%-
M(SZ[K1?:[:1V,Z;-A=4GP]IY+N(B;UQ<.9<E2\K6:.WD0Y\GY5N)P1"7381A
MO*H8(0'YS1/+.?9)]L0MZ=KQY7JMJ()/6'']S/E88AF2GX_Q2MR6T$!5>>!Z
M&QH(6D #CXK\KVB6WT"\K]#9[A5! WS2#U:-AIL(4DD8:U;4,1527XH&4DT.
M3]-.=0QD&*('1^]*6N"RZ2UW*<T;U;#.'@>&W1\W<?EBB8WRYSXGEXS@6X_>
M8L(C.KT]Z<E".PI(.4D0FE^J@Y%Z,1$I72J]!.> <7.MT75(A;6[1B%"HV;Q
MY^HI30HU;SF,7XW,]C%=G8@;*OF<*HGEJ^=?;(OW^OH0.=EV-$AL?'@*#BWI
M#X[WPLG/BD\-B33,)H%::2[&'I%7.SZ+I1$SW ,2.J0#%IO8BVT?'>I@.H,:
MIC/<Q72&F^M^W-/!TQ!+W [U(->/LPM!XY9@R*9 W%XQ_93>J;_LF;/C&1&'
M7OE&M:014X&QYY;GN1$:6"LY[S2.^/V5%GQ&(:W9:F5R&VIR/.-X^J7Z%9/E
MYLK8,L.S>:)8R3"7XNIQH>!PNL9N:>[*H899XH:]]LFC;-W^J[)KK]@NPOP<
M$6C VVA3(KBC8R$X9;\@J@CVG-?H-**>HX.M_,E 2)%@K'P'<Q8J5.UO3SL_
M-3@8N[I7[KK3(CC#'A]FPJC,;CV3#MA3C?RM(-'&QCKS-!_."!N@RY:W^_GX
M<#QYGI0'$=,E4:F2,) +K0T/!!+[2;QX'G^,PN-ODPM\R:.D_XRL1R,JH5N9
MKBEWET#!_?5XYLRE:^/'S$]Z%L4.BF3#:);OQ8\=MFP@&<)!7@M29#T,")_^
MY$C==0(WDRUXT*4!+9&/<1]Q9['RX>*0*^!BUQ O<(Y*"=%2O'4LV_MBQEAW
M8%.V+E[5N9=)K+&Q37$ZD/QR*,V+X?OL^,^;')2\FQ;%V6D7)>*4GDQK#Q1]
M7M*]KG[+@>XDBT=)9I,A:H8UM TQGN(7V2<4N=5?6>'/E%K3;&]2ET+3(N3<
M"7).F:&5ENBWISSTU-UNO^Y2"> #W%>X .FD34'9VH"DGB49EA/&O@%&40%+
M^_PQ)1/Q9?IH-9BJO]%T#SE1@&*:F9+.:(!_8Y RK+EZV76H2O4D]T/MG>Z5
M@)SL4WDT$$,7B((="]A*8GJ(3\.9A^,9B/,;ZT![7C9]JN *DQ,N_8-(6L*=
M%BS9O#>G&!\J!J-VBC^C@70V"UNM@.RSK++,2.Y+W4+3):<^.6<>)F>@936P
M5:SA2!MKG%*7Y^P[3G;BECPJ6)O)X9[:\6K#,7@PIF7C<.OQ.10-9%VH:%@?
MRH-93?MY9S[!FI8L\.-PK9%;L,V H,B"Q"'$WAV-M%0?MBZM&M]ID5BPBU=J
MD7;J*Z7+AU&O4[V@#3Y*,GJT?R\=AK0^S>^)7AL=4ZV*:*>[P,92C!L1S*!3
MY$V;IED55N$O\FV$?%;)@K[*X4'I26O,2[,>V@TCG*0\ZZ?QA4X\ =;BAM>T
MYY160]3-:7L,NC8]0XO<Z>\L)$MWCVU[5B^N0D%!B]R9_:>,MCEBJ1S[M0M0
MW]3TT*9[$A<BJB<VG-ND1<1B(D36<B:0WK2C^CJA[D<STDZNO?9KH4=#GH4K
MW(Y6!X^&<7@[AM=;9L58:EARCP?AK9^E# WHJB<(.*%T8N;E4?O+>'N-IV)K
M"L8[Y1WV[\;>#VHJHQZ=FTILX^PV(C=/",MK9LA$/X[4;*;=!FYY.<=?M^WL
M:*>K7NK68SR4ECRF,COD5J,6B>-H-U*(QQ$TF5\8 H+3Y&22:C0TOMVN+F#^
MA]4 &QSKOXM# ;V$PT@!OF*R(*Y^.5P6YA *YLB]R&T8K?Y9E9:54(S E.&,
MV'BN4+2TK8%DPS7VTN'#'H6RD*\3<2RF,M<BJ1ZCUHRAXNO2@E[M2GK-XG@4
M;U1[S9DMHUZ-B!TT]O1JP)KY<7G%N>-B69J0?HQ(F"$LVZ-6*8XI@;;J@1E<
M:SQU5<TE\+@% "G$:U2LXTF.;Y<\/.XRN+W&LU9Q6U&^22I9*R81IF D&N5G
M;IL[V@G1=/ 8"2Y%PC6]N:#RACTM9Q=X#3PBW<<S+S4BHA4X>C["\XI?MLL0
M5_07(;XWW&K3MX6"7"EJEHR"M"L2WV8+MI,#J *1&(LZ=!\3%Y"7U7.97"TB
MBL12/NH B[,FW?;L^38S[KZ6M5EP+FUR7B=Z'I34LGSA^).?8\=X 8<%O@<"
M'O0PUCD%RVMO:431.,L_?++VB?3]CL.;VWA/);&0\;DX'D_B00DA=PA370C<
M-XQ?%BAM*UQJ2^-OGW)R\J02:YIA."BYO.7X&/GH&@E/EM)=: !*P5S*GBD4
M*O/>QU.&;NO2F]0J'@)O@M('MO$BIL1XL&8%BA3WW3:N. ^5=3*;-0:]H/6B
MBW&#FYP\E!?C/)D74A:8+:-O- +;DGLTWW!"[\0:C725AC6>=1""KXAC&V*+
M(<$K P.5M?8/HY(6KG-,O6TU@Z6]].C55UV-B\>3.M9CFS8A:7A@$6V%D!6X
M]Y#6K#PJ='@37CI+!2XR>6$@R5_Q-&[P%&-X8K0QJN 31A5((P[OZO7;K\7Q
M7;^O4>>Q> OV_L91)<-6])[G--O"F-W%--H=)I%VUR=]I>U>>UE-WX@K!NS-
M4^\<2#IV?IO)>LN  TY_79A1XN0Y?W6WZ-;M]TGFP>8[RA^GR7.X1!'DH;3M
M/D-:=VH#0XO<%BC:F(8,41NN Z1>/'"%NSJ)+QS56BM<*K.%Y"GCE40ELJAH
MV5FQY!IG9X_U$KT*KM5%"P3Z--8)IAOC@0D#'\XQ"@+=+LI-W?XAU3T8QVHY
M;6\D<!>:G\TMB6^K )\Z./7". Q@--#WQ(C*M8&D8:;]RB'L/,IF,=]R2P")
MH-10O-'\7UP(VS:Z/.+@?C]:D?"-]38M%C$X-?R#S7N+W9BU)TJWC,8\/XN*
M33S)?OD&GE-D>ZLD@V+1W83,S??67:?E H:Z\,8@3@<EE!Q#D'CGHG./&/^A
MS+5CHP[6V$PG01\2#@82565936M,&(1'=8?N,IMOF%S.#L_PZ1/W"Q_B]?55
M".6X>,@!Z,G#TX2!5!51-@OZ2?6R#]T$4T./3/M.-Z3W-[:WMLLL'5;/>OT5
M#0^#IU_:&V!'0L>;U5OMS1IUZ8Z"]JC4IH8>I@]*;4B+VFUO[0C.>*R>?9'&
MQA!/V=I?QDZ&C+:KOUXW;](5.XK8I5)[.NI>PW6:H[9Y<BYU#PT$8WSY]F(M
MI.KHUUT?GP6\BH!U)Q/"STA6;(Q?9+J[8B0:7$P]IA:M)Z:M?R>U&C2>T.9=
MGS M6SK!*-_O2NTQ6E1NL9.:43V[M;OP55[&6J!S,:[7@'-SO6@NZM&<'4 )
MZ!IK [[<*$2@VQEWV5:Y(UM*L]3Z6$)H3"*I"1I@[(8[MWE[/I:Z(7Q$[1]&
MIV=]=( %8@W$G\GK,9Z0/'8\9>LD>NT36B!8K?[-8-=!P7^:'TQH*>T\=%7U
MRH3_-5Z;:*%&&EV.(JI>->&7H5PA=7*+! @^8M<42V;$+B-V57"6;]B _7T"
MILTF<SIC,0M"6,8L*0Z.<Y2S8D/8JI0:;6W$;=^7KQYPTGN-ZLUKI)* V4/'
M%V(_5"0TB=KH'/CEC_O5):8(QKI&H8[WI7UD(^HD99K>2:"!O_7.PG\6?574
M_WY6H\!+LFFP]DFAZR>F!?LCR7$W#W!0HQL59XGE?VMDI?P86:[/MI /V8=T
MQ3(L\ OU0V<1,_A*E+N??-PWQNC; F!57]SV=!4I2'APU%U,"DZ'.R$.4EO]
M "EWU8#CD-J38M8I#65IH5TZEH1>GU3NSVMV#E*>HJ-LDKQ]CU"A5;1L<NM(
M%AXE6>8*M[&J^,NZ1Z_86V@G[ 6/1K\(W$XY?0^.47LFRE0CO5*46U0T.*++
M2JNMGN[>" 9<-0==/.T3DV(Q9BO\]W/;5'\_EPK\L'*_[;4M^ K7/0D]VUBT
MPOK\ZZJQ#?>O$W&]_SCI^A/^,\#Y;5/$YT'9AUOG2=ERV)0:<MBNY\*;IR]6
MN2&*"CS!]2YRC;J,P7O%(9'6(^,7:N8'SR$#]HEPQD8=1JQ/'&"I70(#"6A+
MJ"W7Q'CGAZ^/S5R?C'3<PVCP78:]CI5Q#>WESH2.Z,#V>EB"49CIHUR+6-'N
M&[3X+6]ERM=@+0$JL?TY31^KV;QA0M00!T8E>08G14>-6\]'6]Y]Z)%,F/K\
M]3&LM*>"_FNJ""H%_);427)K,ECW*BS\C;A,G]>T0O6K+![:O4]"IJFN<=%>
MG2R7ZCYRGN@3Q)$:C[ M7Q4,ZFB!P':.F-*WN4/^"3/C"$6.SZT.G"E,H9L#
M2/;1*PPW/"G*+4*9:N[;472["/30L2+T;'T13W-[/X)9"$D#>V9]0COR%C.U
M7#PA\5+K)N$)(R(GXOL++/%];^D@1)VOOIT2OY)F?7N(V*E.W3=:\+QX2\ 4
M:#=Z"\]1?86[MDBIXXLI(%&T "EN.K8Z )@"$@!W_%9::/8@6_3\1',M']Y]
M[B<Y+G$5RMW*/3+/BNLC'W6VC=L;SDN13"GU4JOQAVSSG[Q.:HZ6"'*-=SW4
M_B?-Y;?Q8LK"ELG>$:6B-'+=>1Q;HY?G79!0CUR%I\IF:A:DM).M?59/LZ4[
M<18+CY8[-&[%:(Y*M>#>+)QBQ@1;I;BKK+6#RIQ@)QEZ\=F^UHI1!:6VN$C\
MZM5")\]OH!<$&=Z(OLQP0JK''-##IW/0.9GG#.35C<7+@C>P@XB"8XF5?%$H
MRY7@W1P-54V7<?+2UN4 _!?+IS;XG7,1E^S(Q]X&N[:/>\R\6,O-3$CP@!1B
M%,#%,$SWH_N/^9.R_UAF!JA:#X>:M&S+>+8$L>\TG\X%=]R73CP>LE<4ZVR;
MP"O /'?#DB+OD,NV8"N7FSV9->+M+8=F[!YZY[%HV_)X 0Z.1BI3>0B"U">$
M<T#+Q:'Y)A)JCK)]PK0X<?=J@/',@_ON;'</5<%NJ\I20:T>;PX3&CTEGO0;
M7UM,3^1.-FW,S^W!=^Z8>;&1F[__[D-;1XPD&G@@BG&ATM).GUQ! Q1&- _<
M;(M$NTX,Z^^OU05X^IE[!&S2=L/5;B[F9@S8WZ'4%-N@. 1,.O?K[I-]3DG-
MN(7P&V'(6[\!98>&QCM/3GV>.^&H21&,VM:?99$)#EH)3H4O&2<HXA?&BEW6
M_'+UT>ZSMO<L^!*ILP?W?!/0P" M@+\SIA9^,&CIIYDI0/M1^5**#X+7QY\R
M2Z18E++G[\MG(,.QZ7;<JKOUT&@S@]CH9?PU+/E1Y3DU0SU+15FK#6>7K+2!
M4UFVKT'] R7/6")<E,<2N5.=4\>===_S9HLDV"5_(=47113?F'OL"1[Z4I&;
M-^_Q=BUOH9[UT)YM=T.*,!@A^<BE,5S6-]UN=F>L6"#8B#IGZHBO$"<UVZ^)
MX5:\ZGB&X4[4_DSD(D>^.WU5+.9]FWH/9WLSK-BX]%_S;I,KX>>N0[/OK9@0
MW_U\HO+XT;.TNOAT!$.212?=^;I YP(MU82&LDJ.TYQNZ0+9J7#-AUCIV:9$
M4,=]ST99-QHPHYH4:E_XZXH/A;*5'2]6.C/')RJ0:_(B;<JN^$J\\MYXYLO<
MB6!%EK1-D_#H4+(G'Y\S1K#![4P)4RBB/^#@R6K9MEU@W_]:-Q:%(\9U!X%%
M'$BX+2B!Y;-;9,/E_6J=6K>T==1+9EZ2SFT(P=.53;S/A3/':EK"B$?;K2PM
MD5*@!MA0FR.T\CG%FV]=BCI&\?H84=TL#.N()OFG0XU2,S$E/.E/-6/%I[N'
M%!J5&@R>(&TW IYTPIU>7A\5RAF-;#.Q-T['_U3;ELZ8D'06-[^]KBW80;_
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MU2@F2C/:JR7SA7*;2E-0SB'4@6 K]8BEP8=*Y.L^E#5&.;/&$?NPU[:QC9E
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MA78:^&BM!EJ^&=YX@%+,$-!C!T@2D-Z):T]]=,;JTH_(<A0@6 0&74QWR>U
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M4?*IVOH1!>"0.3&3N2 _%H$7PZ_7SO:C2==>GNB(+4><=&H,[Q[YG3LIU\0
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MHGVIE#3/_+G'(2I#&K#%+&[LCD: ?',?Z6EG N3GNPX\>(07&P@PH3=AP,Q
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MJ7;AO)$SNI!C6E7O<<VB[N1EJ>FB(I72.@Z)JR^F&R,XAT(J]N%@MU+"6O-
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M!T+RCBO%3+T:U9Z*W@6=Z90A+=5@,[ZHD=4O!6C@)[^^PLQ2GI#F;):"G[T
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M:L&W*:+]G@CP/TX<_/LJ5?XO(Z?A7TFQH=[(71J'B7'*'04U,="H]7^)N?9
MD3DEZ+V\<HL;=Z7V@M>.2Y?@AAVEIU#_J%CP3 6&\2&HUFM]2"0G/3?X7F/9
M/MR>G21[\\R2S*YX63?-4(8&8#F' ]J3%*/PCQR0Y E57&_Z;C5X/\3_B4M\
MXT>YYB;Q$H/@ADJXR)&-FT($T:/SHO3LYYJINM\N'JDE!7K<NY'=44#7DRJ
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MO.PTR-*0 ?Q[BT%UN#YY*0)7XT?B0WOPM4B4<94'C#:%7IF2OVAHZ]X6]8;
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M+3MW\)G3F,@QNO46X8\J49^A9!'L(U%V4IR!F+6<OB("%%568;?C*YZU.)M
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M)[!"R7 %*!E![^P;^.$\=D)Z#0[6RD:_^M19.4N;BYSQ+T/('6C;5I*=F=!
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M-G8LC0<[CNT+_1G9U]R2KP;(N]"'2'GRU> ^=<4O_L+]N*A(UX^/@3%A+M
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M6".(9;/YKA/J@2]<M+@/^J'H9-)*"#DFPU@EK)-6T(?8F[Z>I"&>QK=W))-
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M>;,<VUO]_EW@JX ]"%T9:)M@![_X>CD2!W!J9<J@M$VIE;%32,6!U4.//AQ
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MWZT9 DEFI][+2]@3BKHQ]#T,<;'71P! II4VKC\*>=&7=W,DO2,D2J%CA/.
MFJ!KEY&40X WE]\4!W QYS4NBI%.E\3;\NQJ??"1FK5^/@U^FALJK23;*;/0
M8('Y;F!8SH=9_KVL%FQBFI6!$U0P36;@/A?6:#BLOW_]N^'KRC$QXBPF)L"J
MHIZ)F/+SYN:!_=C90UJK>E";D0>:J5W]$:%9%WT,V&5!W:J5OX_XD OU3!B/
MI.OF'IMV*I[/B+BZF-LJTA$"6:BM99Q]GSEQ)N?V!1NQ*TZ(PI#0N?'P4A%1
M8RD)E'?3A^BS#A8$-YK)V;!L?&_GNOS81-P:WIK#PCH0+<==I-VA_.0(= \P
M!Z)C>S+7WM2:8RTE"[S%>\N%UXQZ"B8YMA>-FGX[!/V@Z\5]>S35E$UAAI#M
MP"'!H$(6X[ZBOQ?$VU?\SC,#=5B/SQV?ON?O)S1-4$'GOM)?RD#@GD4'R#PB
MU;E;>343N.WYBL[-N<FV<GTA+<+*/D)39FA?,=/O6J% \U7)B>DYXI%M]%DX
M!EE5?NQ9KVQNSOPZX?6DNKW6X<0%03<1L0MX6^>8#'2]I%?,9>#:ND+-"M>$
M5^L>!K"(/*D5=EWQ9MPWUK=@<K?7N3I^H[;9J^H,HP,\, ,%H6:>*NO;?4BU
M&DDUY<26@[+^<-W:;D1F#7'!YV(=FBG=<FD[V$!$A]/A3"LRN52D%UX/W6F4
M(*J<):/2GV>[=7ORW/E3G%=76C.&BSAHM4@A'TWI*X.V;Q&H?Z\6\,CG(9':
M'2!OC#. F91#?/MJE$S*^],5KW' W^%/5MJ7_<?XD_'TYWR?NNSJ:>LEC&Y+
MBWV<3\$!;ETG=O6]S>,QTKR%R]_%%OF-D;\24302*A Y4;]$$G[JP51LKX,-
M]SAKE@Y?W'$,L:[MG9D\?GY5+.!,\+8VN[C^+U*V$FL:+E&M8UU<,_6A.88?
M#W['@/=OD?K_S,(!:L 2O)I2]7HL-27!=OI>*?G6C0FGWFE_!"+<GM70XG)U
M3M(8M+2=>^N[Y$571_$EN(<9#7X57U"WNGDTX<-]Z8_W)+YO:[8 SPR2[D^0
M[M,5CD0TVD.JF#X,\!V&59K62VG'N<[,U^TB")".0IJ)RBII.UL,;%UHT:O[
M'EXF+9L775'<8EQY_#9-8TQ=_3G5X,O!X5H=F^\:J#L)*!\IH[8%A/W$A6=+
M,I+C/]^N:\U[LAJ1NEC.RA=&:-XRV8:?69&I)&-[IN643',SB.76^I[_;>?A
M::1B/-'4)UOP*]B<GQO#:S2STT#0MAQ;5?9 N]Z+K6/##P/\ET,KU=KO:NF>
M5.X-/_@BDL-3(__[HKB%SV:%D9.0S4TJ1(@1M=L5%!@-J5V<3UVA1TJTA@CU
M.U>IUDL8Q0J@Q1O>49L("+"0K"P2@;R]I&6PI,'+C:^U0I,#&4WY[ML2E###
MS(1D:=;T3U$(ADAL)G=NC_*K=T7E/E1W%G,IN4$L,YTWJ]J[S0B#H2/B$_#V
M#?3)M=-L#:DEC=7=I\/B4T,(&,$FSQD'-"5)D\WE^(1Q@,QZ<4=UBAT-)_FK
MQZ-E'AQ>Z< < M[GUH D#M]\F*'S]D)>3W'%.V=&!&P]F1"O43:O,T@DN>IC
ME-;6\7V9WLK[[\]&P:G[2BZ<AH@($AG+$$[8DSE]*I=>/QK6.<MN06*;[5/K
MPB)4&-_@=D%!;4:!LP?D&*1@$_S=A WT_4VEX6?:'+H7A++Y1>K,:'9H?45>
M-.&O^0I?.KQA%?-BB\XU0#44KPXBTBDE,.&!V!CLEN^UT9)C21C?%YR3*>4O
M]S[]N+,]H-;ZE1Y=EFI/J#0U#6U6PZOX+$LJ_"FW37)[OF3\TW6=%V^G')4\
MF#8#2*=.ZDZJYD3/NP[=/<QNO-N*P!\]+?(20 K"J_;GF*Z*"*GW)EWBMH$+
M Y\ND2R7U:D6P]U%_07J;!4\%UG5+VN *!P22"M%1$/FGBR40*-#8G2%W,Q6
M(Q;94_^,O"M-9=;MLH;&7XC+OO(O1U[[1Q*?-.M90!98YXQ8YA*?&_%=4TCR
M$=[[@#P;DT>_B.5E?"Y@G!OM%.Z:I^F+K&JN1<.K%4ETFHE?F]01V@>1B3X#
MI'N==)S5Y6PJ7DHR^:^S!.85048?*8X*HAW?D4>)L;N,PLQ*',(6_%/==54_
M:;7AVQA7R(Z23X0Z;%V<9^_/R-K-6[.1; X1P@$OYPZ.1)R'TGR&5I)T.UW;
MWO/=@DW6'L I?#S"%CJE+<>2(N*/KF0@+2R2+0\%CH0)J>N:ZV#YPH@GKQ^B
MK/$0R /^IYP3LD^[O9[6EX?>?75S.')=NVS!1YQP#H8FI#\,LLVFNBK \*+-
MC> X[9*++Y-2 _,0/Q73ZG/"'3#Z0--+[?:V3-[,_4R\6^>%))@SF/TK[![
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MMN"/T*1R\Q1[J2?U_3-"ASXIZ$NX:"G&I].I.-\\]=:ET\_7;D5.X,LNGB%
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MTD);  \<%T9Z.,".8=8I8\OYYJN?=.GNC63=>:U%6"OTDGHN7022\MO7+1W
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MC:F=5_N04D_>8<'IY"F] ^P]+XP0(\7L%=J+[XQ9B&B&RVN7?*#;>C/G8WT
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MXQ=%^C_,O\\_&;_^6TG7O_ZAPV0T_Y"# HG2B(<Y\_ZGAYIJ G,VS^%PQH3
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M-B5/:[J$O>:_B6(B97^<1+*BGU%ZH9DZE:]I S2C-UEE%%BM)B]V4W.<3$E
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MQN#?*+V6!#8.\Z\J4IG,6M/U<1G.I&H^ XTL-)E36T^KL*:>3K*JZ6=_3F*
MLB3JCV\HUMT8:C*ROTH0=^O=3#PD#IFFU0(VG.;I9Z^2PP/(IMU=EE4LQ+13
MK6!$R8OL<F3//=!6._AH"OHQB3W8D66DNT7QO1V.UC^T927SLS2+KW#XR1%T
MMSU_V#O*QQZLW>%5BQ%#+E/0YTGZE?S*+FS$A.IW<]9BUAM!(6Z&SS7/K1_5
M,HCM-'9ZF37>.>CS]K*#%:V!"Q_";C =GK)R\1<)R>EG?ZE@D 40C$4"M(NX
M"_O6]MDL-OTJ_(SQ]!I^A*FBNY+'LO'T&@U[[?;.]M VES"NJM@J'RX<JQ<9
M??7T60)$' B[43]U^Y#V?3 )9^O>2^C'8DW]\5BOG C_B[=*A.8R5AXV\@2O
M18I'2E"O-L)AI\OK]V\7FK:@4/P!.1Z;K*[(JA;!8]%KO)' R&.\L<N/O]/K
M0F,R-M_8;X+S6V2KT $13HF=\Y\S>9PQ4A\H!'I$U-'=J8I'30='%]$O&&8_
MO+0.FV,D/+E74'QA_[ZD'$%@%:1=)!,:N&"'_,"X'[=S=52IYD"[A C\$0=3
MP/GNW0!_5<!J//)>%1I3.'4N@$1)2C1'+]%7:],&O'FU<FZ"V>KK^QW9-1\<
M477!U 6.^Y7FITSZV397ET8:<5EDY#Z ],[3Y=$-)E7O^9@LQ:Q;%3T4ERFH
MM);4JY?LSC684C,S/YW' R;LIV#J\LQ-NT)] ]K1WM<BHR4=CX<\<ADZY(4'
M=BX4=4P?#YM")74SA&<VES57<^_9WBP50JAE ;K%Y'BX#L8%[5K/F/H.2PD+
M2U?3X^(RE;JD@Q8Z4H%]1\;-PMWA,0MZ;2E BFR7HTC<O+@R33%MM$6X@#]P
M]>+Q]/9R2[ZX*,\?_Z7,ODDNS#P<%R?R9?>[6/4A'0]<O/LB9C^2M0]:<LR/
M4C6/A9M3.-KG,]<I1I!VW&4/LUBM='7(98E8HY9\/(I$5@[Q !PZH?'-<9[;
ME)^U4;,(\0I28IP0=XD,.6O#:3#QFG(>UB@1;YG*ND>3SORIDN@@ ,RUL_1Q
M QH2TQ1Y0.XAP5CKVG9\9!W% \5&Y;1L6>S=UXY7>2[=?T&K1*"BNKX/-:S5
M_B50[&_G3/"'DX-"KI\";QE!UK=+J5_\,1;_<G><=NHOKT7_[@V0?B0\M#+'
M8]Q1<V*)*WI?WSIA!CL&-?R:4:B3J%O-2Q8Y,E*8_UBV 8.LSM=X^$&[_N'X
M>#@_=F4/66?3HZ0*/XB(HS\LBD-CZX6%417>,V/>.G%ES/HAU00RTONT4C0N
M$E>&>8K_7WM7'M5DDL0C*$$4<20X, (1P8$8N40&! (BAE,)$ 2)" )*N!1C
M!.5(@H/@&H& B*@(8;B"'()<X1@N'0&=<(=[D%L0(9R! #DV+,S;G=U]NSN[
M\]:=??[1K][WO9?J^G5W5:JZZZO&2@7KYD<7J"'I-^3;]]]:M2WIW5T2;4ZY
MU2?;_9%<G^YE?;HC=E+EI#LB9:6 DWK#3[M^&3.@3Y\V@9]KKV!0,V>8$JEP
MV3:4=_Z*=<0[V2,Q[TUIP/&5^]Z(J;N%;VIZ(MS8/(!^V?N,E-BGCY327'F
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MTJ,IX+/%[ <VX_[Y4WE7<SCVYFOX@81]V#X8A@&#GB!:Q]XK%WI^@?!2F3O
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M*X1<QY)#Z]Q4+83=)F$N.L32PTBD[[6CPZ_]9IB!6]^L@I6?!\D/Z-S30)\
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MA\![@^<%VVL0'Y=U)@84K<W^])K+(#>Q]^/RNK=T11Q@]<I/4*J@((.[S9^
M3KP?%@XM+ &W9OG%&OCM^$V(YT]UKO/TZY\TDOQ>8I/WWM9:[/HQS%=("J1F
M[@E6%S%WF5Q(YDK4YUPX)V-7(W>8=*6"GO?@?(WBK@:TC]-0^177RX,&@!LB
MD0* 3AC&X)Y]Q_/!AF+0L9=Q_JI%A4P]-70=7Z'R13_=A)!CV=TX;GV&1]C
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M5%K%,H%:KD=(=F_RE>[J0J*L)M&D$%I4?</_:I_BN9*3+D>V%BZ44;N2TKN
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M%*(RE,J1FOLI[$I06HR^\ [F/+T<]V,&I<@$IGA6F8!QSF_'_PIJPHJ#RDQ
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M#.BTS@$9XC,"OPICZF(>X[*N/;X\SB9VO67',55^GF[XANA[*;^6!/QMBM*
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M_-A?/H)T-^@>?@$%XN'3G"Z8](Y3EJM@J+&PMN"IJN8'[O$_^,GYC#GY.#Q
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MZ]],Y$JP>3UI8#[O46JGJW[ I^.'9H>S0LG632F2DJKC/.DO'M_4?O:5<U3
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M+:@]S#S!QL7[W6*4J8C]\??*+VO9&*8\/5WB"0YO:.(!XSO--.FZ0<HM!WB
MH4DB<:1UK5A'PN2QCHO(.8_O-V(3WX@N7CKYXV)6 &"C'.4$#!^WYA_>6X&8
M.,K.&CB5E4X::"0ZX9AZ3[Z3.@+(>7KS6LWX%"F+D=4I"H2Y&H<\$JP=>:>,
MNE1O9=%Y8KOJ\E4'EB6_%*.+U8$SG[>/!Q:^/@(XH,ZO' '.*JLL2-KL?O4
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M9K(-Y!9'1\4F/JMV W&WES]:XL.6%5=(OZY^]HDDN_3ZE<(%[[CZB&KW1*?
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MQ>U]MKH_N#*VPG))<=3JE)WOD\N3O]X]2I8=W[TR>*F1<N1MH52U$?1Z!Y^
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MJ"'-S",4X"@K\SJ_=U P.D;;+1ME,*=*R2"+ @"#YO#?@/])33_SIM#XCX=
MM[@+#H$N1561GM#07=OG$4$$^Z$X,1-LC<%892D)\(N^9+S?/.*-OR<PGE?4
M4&X_]D\N<G9BX1%,75]T6>V_G%!YQ?C;A,I2N5Z-8C$ H*H$RXVSGD%#6\M]
M,3RQ!/A$+$L;7,D F,HKUG8'(P4^8=1#XH<N G;?J=P&]20A)SVZLP;XH?;
M5CEM/"@,_"A/-*-R<C^#4HK6TV(XTTBM3A4#9:15'M56%LV>QM9#G)JL]22[
M&^[Y;9\,_*XO?/Q@P:=[5V1"7!8'?-A6/$ .0E]$S6UQAUI\K><1C9E-!!_/
M>$J:X]N8\OMOO5FONRR/[Y87?>9Q?GR5 _PE_U)R:"*;];FD37G_7KS9U:R/
M*P(.(R_G:B\8-^0Y%3D2J@&CGV"*P!4%1/[6W&<BY\DQ:&>W.25D=B4_E(KF
M7"D@)XWT$]O:X6.!H\QYA)UG+1R[<\02749\J9K&,*H;&^DG"W:U/*DEHKN
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M)C&-E%8,;!Q-P_"#.6YPI(&M.&,6/I7 -(++9%!\&3?;$2Z  E5O>.!O%A9
MA@:'D9)?]-C9+U,J!)Y7RSWJP78#%K>&.'J^%IIG7F,/G7]_6_FQ8578Q=4I
M&_=JG\D;V]Q(H_!#W4%!7S5F?WJEL^+9X-05SZ\B)!$7"E"MM;#QA*"(<+!P
MA+[U%=)P^Y!-].@ \(Y91BGP#A3PCBW/1/3^9$_-=!&^GGL5JJ1\Z.8J21O
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MFQ>6(E@L0)!@VP^ZX VYFZ$JT1"XM&T CG--_['/_A! 7 H2_,#<6KY6I_E
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M1%I[X8H1$E_#ICD'"D*>MC?MB7[>3JW^<5*T*DD6*@+Q-N17Y*?\)^C.C!*
M.H++@?=R_MH&&TF\(B\>*_KOJ/(]Y;?\)56^3 [W*8G?WE_C1%H["?'$KL.&
MWC>!T:]G"?*E>'^#X)06'\Q_\0&!+$BZRLW(R+WNR(N5__VTW9PC?6).W)/(
MF8X&J4J=$\VUA:K2>. QL_0$YZ0:.O?R#$#E A C +8_(DJSKX+>2/ >BWS
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MC'E#(-F)W'SMMTG#Q9 \X?H_-/@,^(^ =_3N0(^:-:&G0=G+':$36]W@$WM
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M55RGNXIS1SW,/VX\^&=[M/[-E]!\Z_\!4$L#!!0    (  B!#%,$OGZ[2.@
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MR,?F33 ;#:?6OYX'0I?)EC:F;U,MZ;6Y[HVI39] )/6 CII&5+4-\.\CPGI
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MC#E&VF7 D*:A5/P(E$HL14H'QSM/[2/=NLI<H1L>R#R+J"(J3!D,\QA#))"
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M#1G\WH"VW*7WW^V6#N,4.G,TMW-0/PYW/'USZ\=]]8;Z99Q@WYUPTI7VWO#
M$VSZX,7F/,QV7-/#WUOE8NK#L?4RY"PA3(>-Z[$#8XA0@"#&"8<D39(X3)*
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ML\?U-SENWC@C\P\RQIG=-71.V*1B?%LLB++AU;):5>_%:I92QH, 2YBA5$T
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MHDX4W. W$V7K[NC779\D^][+><;O]9;?#7"@D8,;O_SRMBI\?>V+\/P,P7?
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M%:G_^]XJ,[=N"E GZNP-/)S5$ -VF $U-6"EN-D>W=K0<^3@5DT1T!R!;4J
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MJG.N[)R8;,.LFD J2QUSW.&&NX@OUHV^]Q];PW0/]03-[?9:U9QW;>/N=MZ
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MGX%RI #I# !+.B_N;?8>!G51OSKY)MZS5FTY[Z #C1W<+>N*O$#!!RU^L#7
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M;H.XNVNP+!3/:$$!X81HRL 9(%F1 "Q$&@N9L ([U09R&'MN/&)$[\EOZ.9
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M32.]@7HO?[\6Y@]S/O*=KHS_ZG[WAFZW/Y?KQZK4W(*E*BZ4MI(*R26 J>"
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M,ZYN7EL'D ;]KS;/F<Z3ZJ#5D4_4Y3XWBBZWN\5O],?RZ>6IB3C,<<80A!G
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M5WVM]J?7NY/>TCST4!5E1Y=K*=[1K:G-7G:R/-Y*M>3+W2(5&<(9%X#H3QA
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M,5,K,#>::\37GZS)H/92FGK*U\'6EIKO) >WTZY'TY=7PND?SN/G2VT3[]/
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MS$[+&37?.R][ :;>B3E#<V%GYOZ,&Q-0WRY+OMJ8I*1R7\)&8H(ECBE@&94
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MI\.M"V/,[2/OB#BZPM4E*.W,H!L!"OQU.V+C;)<,:._5RK@TSJ0VPX"BIQ;
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M;PMN4O'35 $L& 60H PPB2C0VZL4QQ(S%CNY<6T'GMOJ99'/?!O02"E$<%&
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M8CR#&MKOMED_@H_+[]I6^ZI_OZQZ896EML.OH#BB>:4U+IX[5UX?=^*VE=9
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M'\'WP.2594_'F)3J>A0\Y9N^RT9$R<M'0T;_E)O'+7W^MN1TU1:3ICD31$%
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M4K^B\"E]7[M\'%&?E+\Q*\2#^J.L([BU';S=+?^W.B%OJ_!"@0J4FH26A"8
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MN1,Y^11N;D362&>L82V>8XBLSTFS([?7FHK 1.@A$*CZ(VJG\]/P=+I'\ ;
MW6_0KT\!IXT3#@#M66AQB#'<2[2_^;:4:E_3X4&I)9?;IKTMY8E$2)@\A80!
MF"D**(]C0*5B"1.(HLPJ8^[*.'/CWTK4Z%"LI!'6OE3[$*;#G.H1J=#N]LL@
M>6P8;(G%S=7;A\:8K'Z[A:+="NXVEX]L#KS1AJ2F&Q-QU;RR'$J8<$H AH@
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MYP'5P!1RBJ26\?8*[0>,1N?^C<+JE=+_M*Q!,O_.,'!(_CO<^UKY?V?2#Z0
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M_>R(85HU.XZ@,VTY\C8C@T8W&[G=M(W5]V^0C%4N"JF-<\@0@*FVU2D3VN:
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MW%[>!F34HHQJF)'&:5\>\3*1PZ^Q%WH"O\G.S#B51!R4?E0YQ,MWG*P4XJ!
M_3*(PQ>.J'?P!_\BQ6XIWZNV-%GUN=420I1FK3?#J-7ZJ?;F?C*![9_D]^VO
M&OD_]<9!"!,?" 0OJ-XX% 20' I0)!+S6% L<JNE^FXD<U,,G2S&=;>7)FK$
M>8@. D4]B1R2[^^:M&'E,NE4A/:@CIB%Z*]:G,C($]4"N;3[OFMB'"HC3#5!
M$U5'\/JZN)5$\,'D8%F$NP:8KC2"#QZ.RB-XN:&[9?J'U(/K)?+5=_[%'#R^
MTX_=@A59DBK" 1** *@X! 2J#"2\8*DL4IP)J[X3UP:8W?+38HPZD)%!:6^5
M7B3QME%Z+S6AEP,W5IPLTB'11QFD%V\XF3TZ)$[?'!V\;G3IPMW3;FG"WNKN
M.!<.Q7Y?;3:_EY4TW<HWBPRS/(F1!$PF$$"8$4!A+ !*$"L0PP(3YG2*Y0A@
M;B]_#W_;R^OBX?$+(\0OT5]&CJ@6Q-'UY#Q1EL=D >D/?8+FG_DQY0I'T>>[
M4*$;B*E+%(ZBZ$)QPG'W&9^\:8($CG,4+E5 YC#5-@V3("UX#"!)!& F_!8)
MHK5A%J=<N"45V(X\-U7X\B3-R_&TWYYQ.]46A,? .FV?0'6>9A6HN/1HMKPG
M3MF-/GF2E!,IEQ*BW&XP3EM]E'Q)-YM2E;S>X+W6HCRN>-E&.#0GB+]*O0$T
M31(>M]MUR7;;>A>X^D#-)5J-L8S23(&<\0+ A,6 )IG>Q!'%$9<B3F,VHAKU
M_<BL7L_I*U._D]M(SYTY07OQF9:5MC'6>UFU26*>IHCV;)15;:/P(QO%W,!-
M2WJ8:3OU.='$3:-73X5I9N?Q_<LWAPBL1J*'B-4RF?8P#U%?+!.KT@CF3^OZ
M(]FK.O8 :U(][8_&4P7N\<YC ^A7_)^F$J04O^G-?_6Y&;*.[=_4?WS?]>FK
M:R%)L2!,H%QPHF>740 %S0'-: $2(91B N8)DFXQ]*X0YF:9=L",QWO58*T3
M7NLD5^=R?.XS(N,8QH(R(',9F[@_#!A&"#"8R$*1F,HD&;&V!IJ8Z=?2YYX?
MNQ4Q['L0VAWKL4!A)]^F+F4U7'=E1$K$6)8]9T4XPY@X,6(L3>>Y$:/O-&Y)
M.^FV_FYGHAI-FXGE3G_:C/M^M]UL]498PUG$!"N2(3U+L2  \J0 E"<4)) 5
M-$D3Q9!5/]B1X\]M,>O@ ]K@CT0#W&PMZM(.M0#1ZB#!>%WJ.E5VBC3@! 36
MHAWRJ(4>-=C-NM7 CGJX'Z)6(G_*<21S7C6C*X9)U>)(@DYUXMC;C%2(38<R
MTU_GHQGWZ)52 HL$91S(.LR3)Q+@&&8@27F:)41QB9P*.PP--C=5YZ-_I!7)
MEGK+$W6AE50+LZG$50/MJR6/VLB"#[^J9VC :?6,A>AG2L7F.^,TR-ZC_%92
MXTY^:DIO\=W:&'1=XIG@"..4 L)DUYA640I8GK&XR&B:ITZ)9S:#SDVC'$Y1
M3*)4"]5-D5AQ;:=0?#,86+%<)"] 8ID++5[UB]7 D^H9%RI.]8W3=\?IG7W?
M[<-)UB'"MB@R0F.8@[@H)( ((ZUYM.6B-VTR$RR#7"D7?3,TV-STS*''O&O3
MHT%*[=2*+Z("JY,#1[T3[>@OFUAP9Y5B0XE753(XX*0JQ$;T4]5A]9VQ1]7U
M<>@'NM[^^&WU1,MJ47"(&$<0I#2# ,9Y#AB2!<C3@A(D8RERI\H8YT/,33VT
M"*,:8O17 ](Q(O "D;8GN_?0$_RDUHF9$2>NUX3W?()Z-LS$)Z+7Q#P_X;QZ
MY<@$\U7UV30"-.GLG_0M'K^7FX5 J42)9  G+&MS O1^! A!6('2F.72*6SX
MTB!S>\E_W[=$-"@?(H,S^LL@=4T[O\2HW;M^+T^!W_8Q%+DGHP]PX#<E_=)
MTR:F#XAZEIX^=*U[*E ;$?%:&PQT^5^2KE]5XC>M61:"Y42D"3;=+@B !:>
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M2,\'?*YNHU=%'V@M>OT[XQ3)NU6UZJJY-QD9K[Z;<()#5UXB9!KGL  Q3 L
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M_314+ !)\QP(41":%PAAZ%0ZPQW"W)1P?3BMZI2INKI"[\1L;!&B$?-R5P2
M)[:?-Q+@<'H6N/S0>!*G" X8@C&'( $+FBR#!6SN-,*E\%%^D]5.?I1\];FJ
MJQV]W2VWY=>E%')9FJ:M>J7NU6K>_$&7<O.VU#^VJTJVU9P72'*<TT(" E4!
MH(1)4[,-)UBEVK#%E%@I2H^8YJ8Y:Y#14X<R^MK =-A >YHK"W_%]#,06)NV
M D4]B1ZB3B;0$ZI?EUS;MLVD[07KJI=//VD.CI'I)V\BW\E4D^CF9_%+]Z K
MQM-0TWEK_')SY-#Q?.MQ6XK_E)4>:&D.2<53695F/3;EH%H71>?43&6B))>
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MY\-,ZR2Z*N:9:^CZE2/"18RCR1RS59__D.MO)9>;+NV$H$P0K@!*3+U! 0N
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MM4?;AJE[G=JG/(1T:^_'>D[']JG -US;9Y>/4PI[=?.["=LT$34+F"F$),X
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ME]+ 2LL#FYX3+H+YO"R&G5&RQ9 GS.&;XQ21AQJ"OY>5?+.53YM%H4T_R:D
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MBD\0U66\T<QR#:2<+I#V ;]<L?-V,3^AJ.5TDV0*6C+.A0>I3.WT'R-$BH^
ME: 85UESW09FCU'49=S0"F.#J*6?"/96ZFC3Z'S3E)^.=\5#]&"<)5<V.0=1
MN029D9RT"4HW:O#U,#WC5M>,Z'_MJ)+.W/U'AE$IB\@C!U.< A68I7"I>$@E
M,56X-!1*'09C.\UF:E8[,S;<]E)4!\C;7GX31J8Y6I$!HZMRJ[U@HD?PY)>&
MI(16.';>8]R:F0-CL9'J.DC*5;;J_VK&^VN8X>:I#4ELFN@XKS\XFN?;W[CQ
MF^>=]^\7%J7966T6_.I;^ASF)_B!7(-7I2 I0;FBE-$16-BDHK*$4+P$S3")
MK#/3OLTK@</R.:[GV2P9V#%8?O:M- G%:I').>>".6)6& @R9O""E\(\LU&W
M>7RX%]GC.L!] OU9JNQF^NY^+'O:L5DS3:Y_IE,O!^+6) O.87&9(@/%VL3^
M[=';S)_N%+W/464G'?ZOYU9>"O+5;"/9VK_FX]F7+^=_N_[QFWE9+$_/-7U5
MQ5JXP> 8!%>?%=>Q03%F#SH(HWF129DV%^%#4#^N-]X,R0=7; =AXN,\/U5R
MP$V-;CB'E%E]&1 ]>"E(Z,YBL2BL:W13OA.Y8[>(/32JMH;U4"KN ,<7;U<V
M;^&)W3-2\IOS9\CYM[/UN\7ZWW!=QPQ/LA8L>K(-C/E ?*5"1P^C )I))[-,
M1O)6,>%V%/:*UL' <L]_:*"YP1#9P>26\XELGW$]36%VF\%F8UQNKSG:3)<G
M6#_$@!?I<N:Z6 @\"5 "$5R,#K2/1A4F4?$VKUQ;#GBY<,GO..)'ZQ=AN?Q.
MV_M\D#IZIWU]]*1Y(#^*%TXN>0Y@9,G:Y1@"MDN=_9"\CL>X/ <S#X52PZJF
M@Y/Y7C!X-P34IC"BW("QAGP;(SUY.:B 1R=RCI*X; .U'U'6\:NS?5 VJ$(Z
M -A^"0A.WH/6)+K$% /E2)*QA-JKD]P-79)(H<V\[_:YI''J?_<U@(=1Y6 9
M_*$=Q)>X2LOIYO)Y47X[6TWGN%J%>?XMK*:K17E_8YU=?,'G?/PP;M_.# WD
MX5TT!:JCNQ>S:;KUE-RG;%5VX#FGB")I6U]..#!*E2R-]63QVJ0Q'J5I7V-X
M*> ;4C^ZD/7Q+5E_(O'^-MO4,=>X*A:2@M:LCH*I'0XC0G;&9T\_$(W:6#V?
MUI%CXV&0=-?H-599MZ'P,PS#2UR'Z6S5V.!=KG)PN_<@>^W-7U(Z.^<1F ^U
M&;06]?4KJV7G1EDN#8HVUVCMS-\?\[/569A]F*[^_7CYQSSADB0[7W__M.D'
MQWP26A4).AABV(;:$Y.\6\R<,TT.@_5MN@L\25:W1NTY^+AKU(931 <1Q@4S
MQ\LW\[+$_S@CL;XA!_CHVW0U2<%:%H*&))0F=S<4\&AS'5/A7<Q<E4:3XI\@
M:EQ$#:CZAT&UMQ[ZA=3+Q2G)J@J)=EN(8+BM'31\[1[(/90@<K%.86A4>/XD
M65W :G_E;P>J'30Q]B._%\?_^N8E][_C:<3EQ,3 M;4.I*IW,M$(B,P5D$4K
MQI+UDL<?.4_W/[9+#.RBJ\4@@AM1Y:OE^CH1\S'A/"RGB\UNB,9RD3)"*((8
M$-E <)F!S$X:)[ 8N=6U!:UPPW+0W^Y:C4=)&#=S.OP!-(RLQP;+!=U_S%=?
M,$W+%//%QHE9((F Z"^&US]<G5(4 %W26#O%E[!5!F [P#Q&QCBF92#5+H:6
M<R=@>;U88@JK]85MK*.!>>(,N*I3!63D$(6Q8*)#2?]GHMCJKN992+E-PX@P
M&4:Q#T!E#RF/[70<U<E2)YO=\RZ<XF;GY.0PU5>?]#]'@6,PX.GT!&:BS#S(
M'$79RO5XX,/'O?D8_F@91(B=@>!B5V1/YM(S#R+)>A/$ W@1% 0F0C!"H4YA
M%QB,>5P,HZXG=+^#[,;6_ILO)/H7BQE]?['<:.#2DQ;>.B8Y.>2)[%ADM:Z;
M'.LL+>T2R6)A<BL /+9"/QC816V+H6783U[CGH%\.YUC#=56$Z<UBJ #6"P4
MH4O:,E'(!!FU+!1:!5O:7+C_D+1QW]$U3YL-I).QK<T'4@NM7DL!7N)7G"TV
MK1/)A2_E>/YQNL;WN$Q5<2<X04XAOZW5J$*5VEF^7M"QVF@^%8?*.>^V,T#/
M6+2+#,E0NEX<0/!C ^JXE&FJW6+_BG-<AAE]=91/I_-IO0993[_BPRP634>^
M"1P0J\^OO  7/*LI)X96EL#-=M[-;NOWF6(9 &8'4,?8B/M0[WOGF%^%Y7PZ
M/UD=I71V>C:K/6U>(G$_K3-9<7-UO%Z\I&]/:"\)5DB0K,1ZX<\$!*/)V40N
M2@K)H$Q;&K)G+MUGO#6(.6NIA Y<L9LM3:X]R\5R-4F>.^L]0G&R%LH9"5%1
MP$(>:IV,EC3S;68E/TI2GZ[7?B@;5@_=EO%\G)[,I[1?:B_K>[4$NU3L//V!
MPQ3G/(/H]G4XQ2<3 F.T83""8K6@G^L,!"IFA7:R-'J2UJX.YTGY7M>Q:1<C
M*DN'=BFFWMC5;>4DH#;9V1"XU6UBP>WHZ[8RYSF(N6N.&JCFY[1-S6S4(6W5
M6#9+"96"10'9&@15N*=32V6PRFK#=>+\I[-9%Q6W=Q;X?O[G]<;P41;C:$_4
M]ZB@H@C@,XO ,K(H,I/)M2DBW(Z^;FW6<Q!SKT1Z>-5TX*"_6,Q7Q$'>:.<N
M+\7(+"R3%,"*!$HD^LI8!]HE@?19-C6JRG^*JG&3#HW -9@:.H#4'RL\+J]6
MZ^DI!:RKB0G&N-I8O)AZB->D2/3!0@F)Q$+AA\1&N?9;=(R;0V@$FSU$W0%0
MWN&?-^2R7,SIRW3>Z.%AV\H9R\P4 5K5^TW.:EU,R,"4-$&A3UZR)E!Z+J7C
MIA(:@:VINCJ XV42[CTN/WXF0=]E)TC-F=8<@JJR"TR 3\H#PXPV)&0IM\E8
M_8"P<3L2-@+;D,KH-C2\<=?^%2^OML(\OYTFG*_PZ&2)Y_MKE_!P^P\?)D3<
MD9F!PL2'+P:OH*B5%0*9!\,+GKM0P3H#5G.5HW?>8IM7MD_3M;_W?D/F-ZI!
M7DY7:;98D8:N=PRSE@DA/0A'9"JO++B0(J#E)A3+O F-NJEL3^2X@>. &+KO
MW[=1U,]OVO9X5OOL-0YLZ%H^J?T!5F-VRAIEP%'@2,=C*A"TSB DH@A>)[E=
M-7UG]NYC^HSY;+89@O;PAJH-#=\MYNF1'W^BKU9$2!VK<%[4Q)4,SFE'HO&:
MG%3NP!5'CH3!XIDU4L<V7MWPO'1M/9^#R'O7!>.J?>1G$!\J%YOZ7N>S#HX7
M2+P2;6*]JY4*DL=D,K<ZYZV>9&[U\N%JV9$;G8VL^\6^BN@!/1=UO$5$[92V
MD(T*Q'@=7.2C >VX3<Y%5=AP+V=N+#S><YD=5797Z3O(;V2U_QZ^34_/3B\(
M3T$:[0GQ6M3$8.VGX+B*P)+W1H?D)-]JGNM6BK^U],BJWT5QBR&DV$$^ZY$#
M^=HROEC,-V?SI\5[7-9^SZ\7R^/U9R+@M^^?:)'-OE&J'MS603&F%IS)0B>X
MSV"$RU'2IF&NS92.0<@?N7UB'V?7>(#XN7=!9?GB38W/1:%-F8+]F"ZJY+@6
MD,AY)<;1!GG0_-'SR.\R,&@)N^& OR,&QJ[NOL%FF.<Z];F.$ RSZ7]>9#PV
MJ8J+<PUU3EFX #D23\H$56?QDGQSPFR5YN9NB^E'"KN?L^I/B\E=$;$XA'K&
MQMU#KU))-C;;Q$$GHVL5GZF#=@P()<AQ*NA*,%O!J[N7V)V<[X-(OC/D7.PP
M(]&Q1%LJ"ZSMWX2 :((&+$H'$V,VENV"G2Z?;S]+73]^OOT<V8VN_1C_=8H/
MO3T6S@D"?YWCP>JC4Z4@!)DA"J&2*3&XN^]$'D/ 8TOT@X)=%+<87(IC8^$E
M+D]Q-OUV]S[E,I;/: HBQ?*:Y6HA&0012%@J)F]BH&]OZZT\M<XXD6,+5 PH
MSP[BN>I^'9<;(CKODV2+8M9Q\I%T]<0(Y"X7"4Y)*542.O,VP\ >)&?D8;A]
M>"7#*:P#U-T77GA87I?VEC'#LM00@^8D,&,I,H@1M)5,9L?H0&]3J?A,0L>-
MP@: QMTY<PWUU $,']O0%]Q$ARSK5$#6N1,J4<P8 E/D0(;BF"PB-9HE\#1=
M(S\':0F)+<M\=M!/QVA[QO'Q]NKU<N \VWIF2!2ZMJ=#\*4DD#Y8(;(N^FX_
MML;8W(6+D8=_]W6PCP:/L0.4=V=U-R_*K4#K_7)QL@S$B4Q)YBA#'80A:YE@
M@NB9!,VTU9I[A7:[=->3RXQK4\=3_:*)'L9&U"T.K@*T/[Z0Y.?K]^%[_=N$
M)1N<E@JR]1&4WG1J,!%L*%YP=,4;MQ6PMEEMW(O3/O UN%;ZA-GQIK_,JV_U
M"F*%KQ$GUBN3>;'D<D=#?@JY*-$5A&@=LRB#Y7:[ME);+CAN%K]GL.VGFS[Q
M]NJB OJ<M^MASS>Y9$R4P 5M(YD\[2I7(# IH9C 2\@\ZKL-&I^%P"U(&#>'
MTS,FA];?V"C]@%]Q?H8?,"U.YAM>?C^;K:=?9IAQ1O)=5D_YI@YNW-[^/IWA
M:KV8X^5Q0-YSY#8;H BOWN&X##'& BD&F97D5MF\%7"'I&K<L*4/+(^FY9\.
MWN1!Y[.T/OKR9;GX&F;U94LXFZ?/]Z2 .O@0A0!C%(+*/),\7(02?<DQAQR#
M;8/U;4G<"OCF_P*_O?Y_NEWP,1"W]U@NTGGGR.=*J6J!.PV><80@C=.1T]_M
M=@.-AJ%G*WS;_XOO@34[-I@?]LL^X?)T.C]/@N!RNLA_?%G,_[Z<KLE=>[=8
M3Q-.C'>"3JX(V0L+"F.@<ZM6EJ% %'2J:;%=+^I=*=@*L.X?&[ 'T5X'UP<7
M&_.\Y>AY->7?I^O/+\YHWYWB\M6W-#O+T_G)T6J%]/_Y4_@V45ZQ(%@ S(&$
MRJR$R(R'K+41S-&Y(EK563^;V*VP[/]AL7PH-7> Y(?X>CL-<3J;KK^_.%M6
M?4T";<&4'$F.;^IS,(*OPQ)4TDQ9SD/VK2ZX?DS==M<%[!\>K(-KLBM7X$;(
M^NK;EUKLM9I(5"IZQ<$H3TXZHS^B\0FP9&]$]-G%[2IH?[32=A#[![^2&E0=
MO5N^B5>"<:L99.<S*!=*[4@N(40NZ4=9AI .;_*V ^(_[MW5\+KKMLO,Q[,O
M%.=MGM',?JNIBH0?/R.NW\SKDYW-Y]_F8<O.REM\[$!]E9_+P)[M8S9&:HM%
MK]IVR(S*:B5!6"U ^:# 1\Y 2NT\KS.*^7;Y[&<LNG>7F$>6NFZV=*/'.$J.
M*6>R,J@],:@=.$%[C4Y]-%IPI>^6:PS5_^495([X1*$56.[U>&FEM)_9>&V*
MM'9K#K_UAQ_,D#W$S*'-63:>CC8KP-4$GPK!0;2% 4^()LF2W9;%60<T9R\O
M0/MBL5JO7H0OTW5]*(KY_1*_A&DFMV+S,+7&U^O50PWE7#1.YLC!L\WC'QLA
M%E\@"ZE+,1%I@28F;E_*?Q*S]QQ0W35[!U5N!P'%^^7B"R[7W]_/ZBB)>7[U
M'V?3+^?YSROC+F0HKI8-N$+B5$BG"$N)CI)D:IUT3+)-P_ ?TS;BH[!# 7)@
M!74 N>NRZ:.4EF>T_D405&?-U#/IFC.ILQ3,.F(JTF826,M68@19A,R)B6)T
MFX!V>QK'J94[* 0;*>QG=@0OC@.\2".%>5[48R&=9RS#^>FP>R?5@2DXF$NY
MLU@.[7<&'K,I'BDR2I'L)D4MT28+45J"<"Y*^!\JZ=!^YX5P+U*7E\GQI$(*
MP4MP#NN,4R2[G^J0W1221^D$WJT-'NQT?H"<G\1#?([Z[Q_(^ZJA@S/XS9P^
M"U?K#YAP^G7S]$B@UH8["R5F"8J%*I/ZZK.XF)U/+.@V,ZSNT_*3N'7[H&A/
M!70 H8M]\&9.\4\5TR3$R(0B@GVLD8_S!H)G!8I Q9$7)U.;'M=W*?E)7+(!
MC-!NPN\ /)L@^F%+6DQB7,4,7*.@;4!B<5;7Y[DYN"R3#J)- _#':1KG[<%!
M 3600CJ UFTF;B=L+EFRRHIH0X*DB2]EF(&(20 6G@5#G6/<JO_NGD[3@\2-
M\SA@1!=J?Q7MCKH%<3IV)'F>WPDW4COO<-TZ>'QRT0/&B]LS?_ 0T:14E"X@
M#:LU<89#2%R"]X3X@LZ*K'^DBH/?M%YE:AY/&VY\32L<IB0B:,DVEMS4DBH+
MS&5$68H*C88/;4OASQ)(/@,DCZ?5!E16%P?P(]S<Z!Z<7+ >2R"6T))UYPH\
MMY&$YUV*%.@PU:8X<POB>IFO,20JMKU4V%%%/:/N1G]@1"-4%@6R#L22<X)\
M"B]!&!%3J(%2:%/-O@5QXZ)N<$!L?8NUFW8Z -P5"Q?-I'C$$$J=,>YL 65=
M 5>KE$44.:G(A1-M"I?N$-(ID'95]-TYI'M(O0/0O,6PPL^+67YS6E]SGA>B
M7K 2LO!&JP(QIU"+J,B7T(F!U85;4[,XJ8U/]@11X[:=:0VFH;0Q_J.#TR]G
M];,HCOJX*.L_2;H7;)!5YN@5.W_4HP(F<+JF"0,C:\Y1H=SNHNOQ-<;M%M,*
M(T,*M@/#\_IL.9^N*4(G$;V>?JM?72)=V9B\#@E8=N1($E>5$^)).A>%4<S%
M-A.%'J=IW&8OK<W.0+KH %4O%G,*A,\VKR3>G+=ZP]55XTZK4.2B(=M:%)P*
MH\U1ZTY$<D7RC":T2>0_1=6XK5=:(VLP?72 K4=E]?;J-4[Q)3!9/ 3.;-TM
M% )K+H&DE[!HS?C=%%WK>.[MLSJ3'F#0V1A)A-T4U#/D_KI<K%831OX@<R4!
MST[5=Z@:8KV<8"KG'&TD\;4Y*)^FJ]. ;T<4; NRYZND X =I71V>C8+:\PO
MD8A(TXN'J5]FN%'8/!^=+I;KB[E3CS(_"5KJ9&FC1F<C*%,4.$O8B3YJ:R5W
MMA$4A^*@T\!R&-".HN;GP]N?PWN.)Y723^W-Z#M<3Y*A (F%"-YS ZJ07!U'
M!&M3B,6B,*G-)(:GJ.HTA&UL0I^KCL&NV?=Y>W6]G6YNH;JC4EIN=E=EBW:-
M<EC;1=4&:"I(#Y%D5+DLL03Z8-D&95L2V&F .PS@6BAI9^Q]Q65<C/U<X.+=
MQ$7!2[@H>+DH=;GQFJ)MU<=SJ3A8&<A>XCET78AS.?KL:Q%<R9O$#+C@,]A2
M)%G3('GHY@7^^?BR<^F^H!].4YA=MJ&X,7+U]S _*_2ML^5T?G+^\O&R]B\S
MJ3*O":B:ZBR*_&MT$H),%G-4S#*U%;-[$/&3E((\!Q>WIP0>2#\=Q#^OR)(M
MOB-9UXUS?&-K7S+$M+>R^B,2K0;E% >70P(1D@^^\!1=FX/[AZ3])(\2=H%A
M&_5T@+=C<G-(//.3S4W?O<9BKB@TJAB*I["0DQ,+U 8_H$3,6$+4:-O4@SQ-
MUT_R?F$?I VHF!Y@MBE?OO<V]I(;Z946=3I$UAEITZ ^?QNF;6 HK"\VQ#8P
M>Y*NG^15PUXP&TXQ'<#L<4;(_0V\3AUA2CM0EF4(/B8(Q6%6)FB\VT=XN'3@
M'N :_Q7#/N :1AW=OEUX,_^*J_6F)&:7>/3F/Q\FD'R4H#TCP.LGF5>??X4/
MQ4- 1B:!RQ! &:?!>98@RF"BBX2:F)MLK >(V?_-[]5'OIF_Q+C>1!;+?Z>@
M.LZPYH#6WS\B27V#9?KA"UQ2O#W_M R7_8(?;GFCE-$:HZP]- GNN2B(-@B(
MJ<@276 *VYQOK3@:]T9M7QS>?VK<@=Z[;?9Q0SJ[=W>[_R&#F[P&W=J> AS&
MI+)F]=))D0<NBR#72&E($;45Q@=]=[CASV#X[G6K*9D588!($34!'2 JP2#2
M.<T%;;"BVS1B>XRB_@S/<W#PN.'90^X=^-W59MXPD%_#=%;Y>;U8UM$E=WCS
MDJ=8>VZRZ@"J&"(9Q=HF..@<@N8^LS8W\\^A<MS;]Z%QUDP_/\.AM<>5T0.?
M,OBQU>+*YBD<U=Z+,4D++&\2E)Y!(%L#Y#ZIY+)12MC>SZU-%/LTJ"\BS?>X
M3#7@])RIJ$J"8NIC_% "!&TY!,=X=!K3/:X?N:9YSJK]'5;/4?ZM*YAFPA[[
M9<C3C-7V][=Y,S+QR(L#RS6985/'(2CN@*-S07I7K_X' -*]A?L[D!IA:3^1
M=PJG<L[;)4<.;8PQ>-H6QH/"PL$[J2$CUA[D20B_75/GK98;MW;K$-#90[P_
M0W;Q)I\KXO-: L/X-C_^_,&]GF>RU- ?RMH(ATZ 1$FA5K(&O# "A(Y)"Z[C
M3Q3';^'G3U+QRG%%FZ/6R2IG';BL%&1BV.=B*. <+?SJSV%Z#CIVB+J>I8T.
M OW7TWF8IVF8O=D\HZJRVG0^B"(PFUD&;:6JLTAKCM,7L#;HZ IGK3;1(P2-
M"Z3!%7_W>>0 6N@ 3)L!4K1RS:A_Q.77:9K.3X[+ ]RMZNN_U<,_NG@4R&,6
MK 0.W-8^0\8Q<A)#/?AC,-*6D$6;*Y8AN1@7MH/ :M&)CCO ]\?/B^5F2NZ-
M@^6R*0?RS*Q+)$A=;]5%AA!EW/2.%)GD6G2;0_AQFL;%WG@XN=MS;!BE=0"_
M%XOEESJU#V\?1Q?,>%E\HL@:1(J&SI],(9BLP\29,RHG)[)H-0GQ";+&S7)T
M \+A5-<!#O_X^&F)876V_'Z/$^=K<5FTX&LR0!5M2$9.U?%K,A=NLHQMKA<?
MIVG<9$DW"!Q(:5W [Z^+K[B<;]R9$R19U1S# ]LJ,.>UD QT-JD.@ D0G-9@
MO4X^A&Q+HUKG;2D<]TE<1]!LH- .@'ICB-"=B/&:L[=7SP]YX3+6<1H8+,6/
MW 9PS@=@1F- +7WT;9Z!/(O,<<_SUG%X.XUU ,>[+-T1YOFKU?,Q@+^%%86)
MRJ7 O/60'"^TW;2#6(H%2;M/>O0LAS;3+9Y+:2_M:P<'S=WRZY8:[."I^P_X
MNVXQL>F$\L><')K-I,J_T@GT6[UX(!/PC=P9&<ESMH .Z91@D9@.)H*WW.9-
MFC>V.?8'(;^7+DHC8[F!KOLWP8\R_9;^=LUTP>B3I;U<4BU"3O4V5!A7'_)H
MQ:3BJ?0%\%ODCQN/]0_PW76];SN<)A"_>0]\4P 3;P+3%%Y"=D*"LCZ1QY82
MV)A*MB(9V2B_ORV%XT9GXP%U$(UU6T=:>=JENF+S[X:IFKA/PD#5$/6#KU^M
M7%UY%^,5.I$AVCJHT64R']9H8%:Y@,''J-H\E7R8GB%J(AYZFR-=$"KK3;B7
M017/R!?@!DQ"+0B:6J8V S8>(6C\*^L]L?!0^<.^@N_:+NS^&NK&OQ[.1C1\
M__0(.E*TUG!+GC2F^HJW!(A)(D03C')"DY+;I._;6(KK,_3WL+XXQ8[+V\7\
MI-X'7HGX&LF9R>R+TU"$IMT1D9!<>WV@S3*GR*+)K8>O;T=IE[;E.>AY///6
M0%5=&YUW85G[@GS%/4H_'_R<X0S1TR2V-4DL$J:,R9!%'4IAM *'S$$*0EMN
M4''>)MAMY[Q<WYZ<9ZR#BQ3F<:) !T'..RO@?*GS7;)/.1B'I<T8Z@>(Z=*P
M/ <##SDM^PB\@ZQ1M8+K2RMX.9HJ2T81%VK0K*9VM0S@"QE;]":*E J:V.:H
M>HB:\5&SEXKOSLC95]X=8N;BFM9P)9++%DQD%,)[P\ +^BIB"L9$9Z5ODW1Y
MF)YQ<;._GG\ G!V$W@%T-AF?VL8[7DX<DT$GRXH&EQ+Y6H)G^LI+*":KXKA#
MD]HD$.Z1TA=@=M'O7;]W+V%W@):WBS!?O0_?J]6]Y"!IHC]P0%8[="9CP4L=
M@<FB?5$RV$:)F/NTC'N;U@ O>XJ[ \"\H"6GZ]<A;=H?;FPN,PFM$1)"L!:4
MY+4WNXR0K5"6\&X1VQ1/WZ=E_/J6(3V9/67='5HN-I#(&(U1"A@=S10/U#.:
M;08\)19R2"'Z-N?10]2,>R3MJ^$G ;.#N#N S/TCE7DB4ID$.=7FA#H:H,TC
MP9I2K$P.96Q3R-29_[*_=G_HO3Q'U!U@Y>UTCL?E@4UDM3'!FEQG*T6RM746
M:M$D'QZ<1UF<B&UR,H]1-&[9Q. A]A!R[Q0_;VLV='GIZ]7QA9DBR:""K/R0
M<Y81P3 FF#-:EM)HPO$/*!LYDAI$_UN :F=EC-UWY&^X3&<S7'W"]'F^F"U.
MOO]UN?AS_?E%^#)=A]F%N<T&K79<@J\I"R5K>9 2!KC(DMN@0TS;=4'::KG^
M,+.[>A=-9=V!:;IMLC>;BPAE-M+97G2]_$^*8DX72%Y%B5"LUHFWR1G?IV7<
MXJJAC[,]9=T=6MZ%T\MDA:#=PUGM[..BJN,O-#C!+"1;9-:9_M/($7J,HI[N
M&IZOZ2>!LZ/8QSZJ?I]FLI3GAOGH9(F;1O27,^.5L$&P (YAN+BF]UX#%J.M
MK@V_[E:4/') /;%(3XC8586+!O+L$A?UU6'ZC/QR^CN=HYYS"]E8BCD-9^!0
M:S#)%\&M<S;+W?%Q>[$1IVH-IM(?XF0/^?:,%W&97]"&\R($,%9H4TDL$(5F
M(&7B/-,/LMZNT=X6BXTX_NK@>-E%OMVY+1\PX^F7S7QA7$X7>7,\NZ2T#8H!
M.E_CR*0AYN+)B_>9(>T%$P[AP#Q$VS@38P[C!.^MB^[1=7',2Y:4K_/8M2BZ
MOHJ($)PM@"K1,<]\DN$00=7#U/7D&NV/B&<!;@?U= ^YX_GEI:\+DF4N/!T"
MQ1);%&_$D W(J!*J*(37;9I^;TE@S\#;!1G/@MYN:NH>?9_^7%RP9;S3#I.!
MX$VAD#<X</4/&9DWP@BNL-U3FRT([.D6_^#HVTU-(Z)OM5Q//I)Z-O[HQX3S
M0&QL3H=DC"K*"BA:A#H4DYQ>&Q D(B]!2T][:!N<T0HW,$9_NXNO1TG8"DFF
M=Q=M& F/#9$+NO^8K[Y@FI8I7NZE8EQV%)E X61@E<\(3E/D4J)RWCJMMWRV
MM!U,'B-CG"-O(-4NAI9S)V!YO5AB"JO+V-D4RTKM<N:%R2034]])%P>>*ZX8
M.B'O#G<? "FW:1@1)L,H]@&H["'E[KR>MU>/ZFWPVA7:-C(XBDVB4A#1)DB!
MN(LJH&5M)F$^0M!6R+&]GT5#2KT[\+P."8].%V?S]81+R[6T$HPT]8&BSA!4
M9*"+1DLA+I;<[N':0Q3U%)+MJ.XG(;2C[#O T/OE(B'FU6N2VIO5ZJS.;[[]
M^'5BM&5DDB.0'75DH9&LJ3<&B$VI&:_S5]IDF7Y,6T_!UC"X&E@?'2#LMI3>
MS.F3<;7^0&[CQG?,%X-VP@E.M,]!>FW!6FDH:*Q-L3U:H& 1,\_!RMRF6'9[
M&GNJA6QAR0;33W?(V[0E_$BTA'P\_U=R':L;4=GDDU@DSRYFD#*3+Z&XAY E
M^:#22<9<$DH=XKQ\G,*>2I9:H&X@W8Q]BWR;J??+Z3Q-OX39^_!]4Y]Q5B.4
MX_+[8K[^//M>?S',9IO?//^%U<1EFZ,6%I*O):B90F;/R8T0S@5G#4N2W;DP
M?&*6VSZ4]'0]N!_@#J^8OE#X*BQGWZOO,)UO]/<:\=JB'Y<K64PL;2BKE0$3
MK:DM5,BX"^*8_ GI/2HEM=L!>]NNWU.V<W#$-5%"!R=L?1*Z\5A7J^G\A+B:
M4.23)(\*>!(%5%$9HF0.,*DJRR"L:O.>\AXI/:4LACDS]Y-V9V;IVW1]:Q=,
MT.F@HY' 1!T5;HR VF*WOBHN@@)GZWC<Q?[<76@K7+B? 1>#B[4#BW(GKX*7
M:17&R G4D6*-[.-%@Z]8;"UWUD8+J8UM-VGR 8*V0I'_&5 TI.2[ ]#-</;-
M/-4Q-/@2S_\[*='S5%*!S$T=+:X#A"0%<!LUBT&E?)#RJ:=HW"YQRGY>G VF
MH Z@=S-WM^E=A^OC<IG$JY,15A,?M"C"BNK5J6J-$SB6/'#DK+C &"MMS-B/
M:=L.:C]5DGY@A70 L9<7RYZ/0SKG@;B:9*QOY2L;)!<RTG&S4R088Y,J,@7+
M6E5%/4C0=F#ZJ3+S0XB^ P1=C&K9Z.)JK-;\Y'PW1(U>\:*A%N+3;A (@?,
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M;WWLB%H?1D>+003638!TUW"^O7IK)5(.-J($I\B=5YH[")N<9C*:)8=.,W]
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M^.2)0[V4G18[P63>1F;]PF\]U4L5ZUS(!E#ZFIT*&;QS=6]C##8JQ2F:/B8
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MDN+1D0G/=8X2+R5BT2RTB2OO'&/<['13[.S/[BXLT8$^Q/OKV2C,6_3D\4)
M(T&%NK28["\(FX7)"CG9YQZ#E?>]30P^]<AD/TAT8#@/I/O5M_G%['R2@O51
M>B+5KIKI@JQ%0A&**B4)J5UA7>K!Y?%[=!];(V]8^.\!@XX? ZY;PW_#4%MN
M5@WF^Z3\'_^@81+[6QQRH/3]]3<]MCW.,,^,3]5ML+R.CT4(+I.S*+G,0=8
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M(+:/7+H8IC&$8_S^NHD]NV(5KX/]R8K7C9<<8E %4+'HO?+.I<;-.T.0,>X
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MWEERD>M06\=0IVREM:[-+MF-1^H$>\>%R/U978/(JP/@W3[_^CU#6?(J7$;
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M(P\V:Z.V\Q=V^-*M<&9/!V>M^-V^<V?]!_5?,2SQ__F__G]02P$"% ,4
M"  (@0Q3R"N#<RPO  #1=@$ &P              @ $     97AI8W5R965X
M:&EB:70Q,#,M-C,P,C$N:'1M4$L! A0#%     @ "($,4T=*AYTV(@  2R<!
M !L              ( !92\  &5X:6-U<F5E>&AI8FET,3 T+38S,#(Q+FAT
M;5!+ 0(4 Q0    (  B!#%/H]*P=L0<  /0>   ;              "  =11
M  !E>&EC=7)E97AH:6)I=#,Q,2TV,S R,2YH=&U02P$"% ,4    "  (@0Q3
MH:&A'(<'  "3'@  &P              @ &^60  97AI8W5R965X:&EB:70S
M,3(M-C,P,C$N:'1M4$L! A0#%     @ "($,4]8):=D !@  +1T  !L
M         ( !?F$  &5X:6-U<F5E>&AI8FET,S(Q+38S,#(Q+FAT;5!+ 0(4
M Q0    (  B!#%/7F)OS(1<# $?#'  1              "  ;=G  !X8W5R
M+3(P,C$P-C,P+FAT;5!+ 0(4 Q0    (  B!#%/@T;5T2A(  ";    1
M          "  0=_ P!X8W5R+3(P,C$P-C,P+GAS9%!+ 0(4 Q0    (  B!
M#%/'GLD;V1X  *(O 0 5              "  8"1 P!X8W5R+3(P,C$P-C,P
M7V-A;"YX;6Q02P$"% ,4    "  (@0Q3H, *ZR!.  #I9@, %0
M    @ &,L , >&-U<BTR,#(Q,#8S,%]D968N>&UL4$L! A0#%     @ "($,
M4P0]P==T7@$ H- " !0              ( !W_X# 'AC=7(M,C R,3 V,S!?
M9S$N:G!G4$L! A0#%     @ "($,4TN74)DF]0  >QL! !0
M ( !A5T% 'AC=7(M,C R,3 V,S!?9S(N:G!G4$L! A0#%     @ "($,4P2^
M?KM(Z   2?H) !4              ( !W5(& 'AC=7(M,C R,3 V,S!?;&%B
M+GAM;%!+ 0(4 Q0    (  B!#%-U]Z^?"(D  %]=!@ 5              "
M 5@[!P!X8W5R+3(P,C$P-C,P7W!R92YX;6Q02P4&      T #0![ P  D\0'
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
